<SEC-DOCUMENT>0000906709-22-000005.txt : 20220301
<SEC-HEADER>0000906709-22-000005.hdr.sgml : 20220301
<ACCEPTANCE-DATETIME>20220228185226
ACCESSION NUMBER:		0000906709-22-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220301
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		22692729

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nktr-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:b154c77f-11f5-433c-8e4e-b6be98e0afac,g:2cfcd135-9f36-4467-b376-e4c05a9fe6a1,d:1023926dfc3b4cff924b0207eb081f42--><html xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:nktr="http://www.nektar.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nktr-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml80L2ZyYWc6MmRmYzJiZTRkYzZkNGIyZjg4Y2Q3NmRjMDVkZDIwMTUvdGFibGU6YTFiOTcwMWExYzM0NDBhZDkxMWY3NDBjY2Q0NmM1ZTIvdGFibGVyYW5nZTphMWI5NzAxYTFjMzQ0MGFkOTExZjc0MGNjZDQ2YzVlMl8yLTEtMS0xLTExMjk4_dd656d16-3184-44aa-844f-ae10dc5321bc">false</ix:nonNumeric><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml80L2ZyYWc6MmRmYzJiZTRkYzZkNGIyZjg4Y2Q3NmRjMDVkZDIwMTUvdGFibGU6YTFiOTcwMWExYzM0NDBhZDkxMWY3NDBjY2Q0NmM1ZTIvdGFibGVyYW5nZTphMWI5NzAxYTFjMzQ0MGFkOTExZjc0MGNjZDQ2YzVlMl8zLTEtMS0xLTExMjk4_2dbbda4f-382f-4b12-9d56-c2098005b064">2021</ix:nonNumeric><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml80L2ZyYWc6MmRmYzJiZTRkYzZkNGIyZjg4Y2Q3NmRjMDVkZDIwMTUvdGFibGU6YTFiOTcwMWExYzM0NDBhZDkxMWY3NDBjY2Q0NmM1ZTIvdGFibGVyYW5nZTphMWI5NzAxYTFjMzQ0MGFkOTExZjc0MGNjZDQ2YzVlMl80LTEtMS0xLTExMjk4_9b7fb7a4-65f8-459e-8a72-d3854a086f5a">FY</ix:nonNumeric><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml80L2ZyYWc6MmRmYzJiZTRkYzZkNGIyZjg4Y2Q3NmRjMDVkZDIwMTUvdGFibGU6YTFiOTcwMWExYzM0NDBhZDkxMWY3NDBjY2Q0NmM1ZTIvdGFibGVyYW5nZTphMWI5NzAxYTFjMzQ0MGFkOTExZjc0MGNjZDQ2YzVlMl81LTEtMS0xLTExMjk4_88cfb539-7b0e-45f5-982c-78df3add12f5">0000906709</ix:nonNumeric><ix:nonNumeric contextRef="ib53f800cf34743b584b3c807522f25a0_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjA3OTA_047a9ea0-7fde-4ef1-8171-92c0f31dcfa0">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i05da6e7840b44dd9b4425434109ffec4_D20210101-20211231" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTU0_0003ae67-eceb-4b3d-a922-f92cdc2a62bd">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i05da6e7840b44dd9b4425434109ffec4_D20210101-20211231" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTU0_c526c77b-95f7-450d-b638-74b09846bea6">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231" name="nktr:LeaseExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMS0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo1NzBkM2IxNWJkODY0NDhlYTY5MGYyNDhlY2RjM2VmNl8xOQ_aafbf748-eb94-4830-9eeb-f3b77f87a1d3">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i7562d9991df643f7ab9b69837b951eed_D20210101-20211231" name="nktr:LeaseExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMy0xLTEtMTEyOTgvdGV4dHJlZ2lvbjoxZmUzNGY5ZGNjNmE0MzIyYmMyMDNmMGRiNWZiYzJkYV83_acadf74a-e2c3-4130-9183-4f9108ef96cd">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nktr-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12aa694918fb4e37a8989f7f4021c7cc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i000e41e2d6664cc0a62610b6e74c65f6_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib73eda96963641c5adca30248e3b4212_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:CostOfBorrowingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i418e819404874602beccd76277d2832e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:CostOfBorrowingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e8124eb7354356b1cc17142addd673_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48e34961873b4743b7e5dc882aecad66_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i97391b2936f841cc9e4d2b6c592beff9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i385bad4a34ed410299079777e10e8737_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee9f5c266bb64ec48742279a12b86e9f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie556d8a598764c54834d2305fb48307e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a137c1f62e4f37bd438bf66515d037_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0375ded4b7c74c1491fe98ce48a475d8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d34596d03d4f48ad22b490652d61c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie11c771d5728489f9c3498ced689a2e8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f6ca9435254d8598fb70543671cc59_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524617210c1844548d9aaa3cd1afdd18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9dd5c85b0364d75a8dee4e02e0abd75_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87de647067774165be013844df84c1bb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfc39458a49345bdbf9c5f0b59507c25_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb2fa6ca8a0403abea7fdab421e1e5a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic036604bec7a494eb87b4bb2add33694_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc8ae10616f484b97ae80d605c49cd3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e86cae77d44493aad21052dab0a76b8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i875faed795c94a9cbe1dbe5c45959993_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie15c826afa424f9f83b6f1f31eae68e0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c08dcd809044c649a36e6a8870b753f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46aabdbcec054bbc98f62fc64f377f52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dec94ffa8f54d9f8f0e8161b2c81580_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1387c3cbfa6f42a8878e29c7c2e63b8c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i617c9de53110471eb788bd49272cb303_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dc92f30772f4416b1b6a460651e0081_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89a636947a9046a38a2ed739019eb13c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7a330302e89494f86be51dbb5ad4eba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6ab4897a894445fb01edd925a1631d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06602f496e114bfea3a9bdc411724138_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218a36c4ef32491d8ed93aa732435402_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4958a2d31a14357b76df572e493fa94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7070fa33af194d52891eedefe4dfb853_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bcba052d2f340589756a4df2f43f3c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i426f379da93c42a2b87f77f27a1dfc65_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd67d9937f7d47baafb15299a877ed6b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i526f6174d8c74127a9c60db3a5d90b76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aac894909174929a2fae22e8d8a3906_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cb2f5eb7d0d4cd0a19c316ad433666a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2206f8a53bc949e99e036f0c404e52a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd923bc535f4746833b54075312bef7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e0d6be14b9b4e589ab67d81ec71404f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida774e4baed04895887759bea104497e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53f800cf34743b584b3c807522f25a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d4b5ee692844d22bd172e136bf853f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i217337f2d85e411fa6cca2f9cc353fcb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>nktr:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="ia35126ada49c4aa5b6a31fd74e38aa13_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ee5e0af22004d498eafd130a613cee6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib29439b8ce094e458c12e418a5f1055e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57d6518d703e4cdba742d40dbc46673d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d18817442a34679beeb50708361c836_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fd12c28a1fc4527927d94cbb3fecda6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief3930a5607f46ba9969d019065ed3bc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i255350b9923e4b0f90bb25e7e8e6ea4f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05da6e7840b44dd9b4425434109ffec4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76ba7fa3878f41e9baee05ebb5353b2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb1efb0d79f74d20bc94eefb71431fe8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16f975e3020e40db8824c97ec642e248_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb32306fdad746dd9da19728ea7271ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38f44a6188024f06a84a6f4b3d8acfbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a53b7985d374ead811b6e5a7dd2154f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51e7dc8250694c90b0688660e3c7810b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie572f0f09594489993a50e2018463f9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe4e66cfc3c244c896b83266e392cd87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e5ad5ce7ba243e78803676a3ada6929_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbab848955664506b7524f1830aca69c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia01507cb6301463b804b5486907c00f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e094fd9a7d4fc2abfa5a035a57ec8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0eefc7a17f43a49c7d5e3ddf06a052_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72222465a5784d0f8b7df22ece9a04bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f9318818cfa4595b929b1a68fe6e107_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1773cfeb2884095bf5d3d8360db3e44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c7a174caa0406d9fb512ac548781a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69cc5696809542c890b6fc09c58cab17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd78d2a576c437caf2eb6a175e66c00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab142e35c42244cbb7c910e1ada05075_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d44c99d9de54043985c7720d72c53f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4580a99794e6481fb70ca26feccaa301_I20151005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1cba01aa4941709dccf7ddad45a548_D20200413-20200413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-13</xbrli:startDate><xbrli:endDate>2020-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f84d8d2acb4dbabece7f5d1ab1fdeb_I20200413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16608bc88bb04b04bb4edbc265eb647e_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec48343255d40459baca2d723015436_D20210213-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-13</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i493fa2ce12a84012947de2cfdd3a036b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd0edc3092a4746b891c63c927e1490_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ib40b92391c3f4d638cd40df255d8a24f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95ecd88a93ef4d27b3eb882445356c5c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeeda31f60ae46789b8052b8ca1a2041_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7562d9991df643f7ab9b69837b951eed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="term"><xbrli:measure>nktr:term</xbrli:measure></xbrli:unit><xbrli:context id="ic019febd6d76418e963113849a03e38e_D20120224-20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-24</xbrli:startDate><xbrli:endDate>2012-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0419ee4a57947ec9003b707328f0fb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c519c68cc924317ad61bfe414020531_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafb8479bd435454894df0145e038e535_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615094c1dcc2454fba893bc20ef68b47_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1848694a84f244f8b109984fa21ee94e_D20201230-20201230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-30</xbrli:startDate><xbrli:endDate>2020-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15385c8744c4ad794e479a0863b4859_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputInceptionDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fa240bdb2564ada855ed34b4d6af58c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb5f300865a3412b8ef57ad27019eaf6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e574a6749b54555bcb0c1fc438d2730_I20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea8f2c144d74987ad634c719924d556_I20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i859caff83678471fa0131b598ecb3b99_I20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2012-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878fa93fa19746ff958887812ed98a82_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i877ea84e541241f8b6035538b2d966db_D20120225-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-25</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i819532be269b48eaa4fd913474d540a1_D20201217-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-17</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-25</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa71516bf964979bdea09b920eca1e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i431785ba16834d94834f5341637912ac_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e97ae5ba424e32b4c21ebb7a264e1c_D20130301-20130331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-03-01</xbrli:startDate><xbrli:endDate>2013-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26423d2e98f74cab9e74de71740ea6dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nktr:MulquinActionAndDamibaActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>nktr:action</xbrli:measure></xbrli:unit><xbrli:context id="ief3d1876c0504d8894ebee840c0649dc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nktr:DerivativeActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fab95cd4e2f4d70a9bd13e5489022fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7023dcffb6c492e881c7d0fdf2c056c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec07825eabbf46b68172520ab32540ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6b97c8cc6a493d936e8a7260315298_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cfe16cd13d04edfb807fa9cb0df6eee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:MergerAndAcquisitionRelatedClaimsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6394ee3aadea457c813b5c716e2e257a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:SecuritiesRelatedClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad260002e8644641b6913428ec9be8e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:NonSecuritiesRelatedClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id508c66eccd84a1490c07a8346141297_D20180403-20180403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-03</xbrli:startDate><xbrli:endDate>2018-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdcb60f448fd48b6b0f24d116b1058d4_D20180403-20180403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-03</xbrli:startDate><xbrli:endDate>2018-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e56333c0594ef38a927dea5e5be643_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:ShareBasedPaymentArrangementOptionRSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e44fd2a3b7430fb8662bdf1cfee75a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79ae08e8c98b45bba0381fcf4454594a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if63a3ada72f2468d9d15c15cdadb2e60_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia282c760203f4d67bbae06f0bbf2f7ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b027734ada457485944093d8bb55f4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebc2021556634567a9c85d9130eca0e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47aee40635594a2493940a5c79182830_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a0c941d02e442e5830f5ff54b267621_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb01347c4e24ca3bb28d9aab6838bd3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c290b7d2e5c4c6a88d47e27d7256c42_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff6585fd29ca4683aec5e1e6754a8a53_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69b94286514e411f81a8255d0fe0adef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3df606808a1742a88e889573b9cf1eab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4daaf97620504beb90b1882227ff737f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bb556020be549ee87413847caad7cad_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8261a40efe0948f49707ae9d352985c9_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0091cbcb2514452baa6df443b7072779_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie78f916daa434e17a021f7221225eb22_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c31a5edbd5f4e7ba1771e0dd2cfd00f_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a673492af0542c787de8ecf805aa6b6_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0971825b2d534ad7a2466cf3158c182f_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i859a4f864b514e87a0cf719770bf6959_I20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0bd98c891a4594a3a511270a06abda_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdecde4596554cde9aa263b142ab9462_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a15cd1d266049a6b956f4c5cda3ccfe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c265cd979f48f49755e5233054afc9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db809beaa2342b6907e26d5a756ecbc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404b477314254c6c9c18783047bfaddb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fb38abf73194c0185c0ad4dedc15a76_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02fa6a90350c495998c00c9ec2be64b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de3ce10d71c401f8c6b6d9fa8f5d1fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fe08663b69b470d9befa4a3fea814cc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8045653e56804da78b7a3f7548e93f95_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35bc8164332c4f0d942659ecdb9b7c2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6179d6e6ea6445b59e375f1714da51d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id10b0e192e72479c93c3fb96e48815dd_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4cc486142a4e91a1bc4da6d2ef22e4_I20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9610c03746f479f8ed2307f84e94aa8_D20170823-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-23</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94624f38524b41d19de37806eae8205a_D20170823-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-23</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i571d31ed3414457d970b51bd263f4336_D20170823-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-23</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af4611c2c0a47adafeff233ec324125_D20170823-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-23</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e394a6636a846efaeb92892f815f0f7_D20170823-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-23</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf41eee0b3e48dd93b8a4402bac9137_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6e7e8305ef0454abcf6345f4b1ee7d3_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6812a1be21d84f488147e73621f09203_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d391452d324672a836342487419576_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60213b20f36548838d7b341fd83327c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i163fba6573974206a8cbfb1e757d6908_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4620b301e5a3473081e7c8cfc28f8404_D20101001-20101031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-10-01</xbrli:startDate><xbrli:endDate>2010-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib32493f3644b448eb1a1da39e4dbd1cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc31f05452946b7981e6387e3c1acd2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a74676520a541cf835f2a6ff04233d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:TerminatedPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9260c5cf0a145fd9ef016e7007916ce_I20210610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea9636cc4c9d490297fba185f90f9827_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447e3d8d3d6a40ff8c71fa4631994b79_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:RSUsAndPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ef7aa72e7f4284abbf69eb9fcf07de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c98c4e18c764ec4aabcffa64729091b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3636ccf59db74199a476bef6db7fa9b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie278c33e215c4682baa578128551c2d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic55f7a5b573548869eb6b5c0c65a71b4_D20200617-20200617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-17</xbrli:startDate><xbrli:endDate>2020-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0035b332ba9d4aa3ae359c9299758ee5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f052c3b58374798bbb51692c71f38a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie44b9566b75c444fa92e9c77ccb22df0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2401bd6e0c9941d2ac71f0226fb724d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i973a75b3adfc4d628fdc8dbe94b83110_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d494d74848a4be6b679b6d322a4a6ad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f6ea4f6ff6546d4a7b6f841d44f50c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i029b733cde5b4e28800367770689c2a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic276dbba3c744c5dbce8ec6fa2c4d30c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa277296ff1492d902aa6bd17b985a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81a24d5a38eb49e09e58c801f3465307_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a6b923db694bdea933ddef727104ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a941c5289d14ecb98a14b23c2c6474d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i718223867ea449b3bb07403f12f97462_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0779bcc3fd547a7a0d232c80b0cca7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i613d6ffb709a4aceb22ec5c774efb691_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i059dd17f5075463e95e35460261b7a4b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18610030b55b46f09cb8bfa3f26e3ca1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d291eb67ab54f4689d1aac2f2cdcca8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95d9b49258bb447fbbe2d19c4487ee71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13d5a5ae922d40ae88de27a40c5ec05b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nktr:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2ddb03971de844cf8a92d843f8f0c1c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa6e3a9e6e143949bc208e33f67fd4c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00f01d527a214f5cbd961d14f04dc514_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e87ff4a4650460d9333eb26209aaf9e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec3ad0981f8e485fad0d799d0a405dbe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5301b257f77c4c11ae97c725f1ff567b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12bc2ab5a68e4a6b955e5b5866281132_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i642a78ec6bfc491eba5a4895194b3e41_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65153175938b412d9314b0291f9d87ec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4ce7911bf79479fb3e7667b452ea08a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c9bb30fa1f4b63958f70078463ced9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54219086ed7421ab34a8c373a1e98ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147a96a3068f4b9e8496063ad3e68b0c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556b5871a2d143a897968254b351cc82_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie398a4523e0f4e05958bb768906321dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86c78562de248778afb80f62f503bbd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b5f29e74e4445c8bb936628105494a8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cc4668d0303484c94ce77104f692749_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dedd82fa6fc42e28334feede0e3e79a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97b7c38b02314dca802effa14883baf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d3853c1171432d9635c5e80c47d4af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8740f4ce936345f3898f8e6e33e633b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieccfcb48be264718a52f70d827378b42_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f76e5747c79442ca44da532090382c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1f7d11d90fe4876a574e281c5a228d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f5f266f15a24dda8c245439158a48c1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203df220ddd84ea7b49307ff1429d621_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb20ac5be2a460996fe341ee81ca9ec_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33c68986b8dc461c9bc05ee9ec922665_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if45bc2183bdb469d98e2ab68aaa55e0c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic910537dd8174a69bd816bc2d30fd0ac_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae0f8a52f2ff424fb8c210a60b2e720f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b314ab44ce4452395969bc75e04e13e_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f86406928947e18f670fa887c043db_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1023926dfc3b4cff924b0207eb081f42_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">ontents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk5_42447439-035d-49a5-9dee-05d5dc8ada36">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6NTZjYjdlNTFiMTA5NDQyNDkwYTI3N2I3NWQ2ZjQ4NGYvdGFibGVyYW5nZTo1NmNiN2U1MWIxMDk0NDI0OTBhMjc3Yjc1ZDZmNDg0Zl8wLTAtMS0xLTExMjk4_16073e48-e449-4252-92f5-86345fd51dad">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV8yNjk_3798ae49-014d-405b-8594-d654af48a52a"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV8yNjk_0ff961f1-25ad-4224-8781-73a2e4658018">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6MmNkYWVhOTYzYzFhNGZkMTllNWFlNmM0MmZhMjI4MGYvdGFibGVyYW5nZToyY2RhZWE5NjNjMWE0ZmQxOWU1YWU2YzQyZmEyMjgwZl8wLTAtMS0xLTExMjk4_92edc377-f7e9-442c-9b73-346c194560c4">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MTAw_311749c4-153a-407d-a751-79ecf6a2f28f">0-24006</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDky_88775e27-e345-4f56-bfcc-4c184bad9a91">NEKTAR THERAPEUTICS</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6ZjU2ZjIyNWE1ODA5NDkxNWFmN2I2Yzk0N2E2ZTBlMTcvdGFibGVyYW5nZTpmNTZmMjI1YTU4MDk0OTE1YWY3YjZjOTQ3YTZlMGUxN18wLTAtMS0xLTExMjk4_4aebe027-31ef-43bb-9d0b-4a6ab90e13e4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6ZjU2ZjIyNWE1ODA5NDkxNWFmN2I2Yzk0N2E2ZTBlMTcvdGFibGVyYW5nZTpmNTZmMjI1YTU4MDk0OTE1YWY3YjZjOTQ3YTZlMGUxN18wLTItMS0xLTExMjk4_5fb1629c-4d4e-4bda-ad39-9b7a40351bb7">94-3134940</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk0_b8a0844c-d712-4e43-9cac-5cbc8435c312">455 Mission Bay Boulevard South</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDkw_93a67c3a-46da-4039-81fd-19b6c8864cfe">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDkx_fcc06692-d37d-4dc0-84c7-18cb12f85fd4">California</ix:nonNumeric> <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk1_f1ed45d2-170a-41ae-8ff5-0b969f9b1524">94158</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDg1_44fcbd34-4c3f-45ac-885c-26999032fc8d">415</ix:nonNumeric>-<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDg3_e84125e5-a3ac-423c-881f-43f28a62f4e1">482-5300</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:43.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.567%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of Each Class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of Each Exchange on Which Registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6OTEzODRkNzI1MjVlNDhmMmIwMTBkODRmNzZiMmEwZjYvdGFibGVyYW5nZTo5MTM4NGQ3MjUyNWU0OGYyYjAxMGQ4NGY3NmIyYTBmNl8xLTAtMS0xLTExMjk4_5d05f498-efed-4038-8702-1fcb456adf8e">Common Stock, $0.0001 par value</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6OTEzODRkNzI1MjVlNDhmMmIwMTBkODRmNzZiMmEwZjYvdGFibGVyYW5nZTo5MTM4NGQ3MjUyNWU0OGYyYjAxMGQ4NGY3NmIyYTBmNl8xLTEtMS0xLTExMjk4_23ce98ed-9e23-42fc-b70b-8924c3130cec">NKTR</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6OTEzODRkNzI1MjVlNDhmMmIwMTBkODRmNzZiMmEwZjYvdGFibGVyYW5nZTo5MTM4NGQ3MjUyNWU0OGYyYjAxMGQ4NGY3NmIyYTBmNl8xLTItMS0xLTExMjk4_d3e7cbe3-1d69-4afd-9295-4fb291326ea2">NASDAQ Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk2_45be4dd0-d0f3-4d55-9255-3d9109cbe9ec">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDg4_bd181e8a-2a24-4257-bd52-9a8dfa0d6da3">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk3_b229ca81-f602-4b7f-906d-f57ba1232019">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDg5_dfe997a3-b29b-4235-a065-45e2b1f54bc4">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. :</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:20.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6ZWY0OGMyOTcyM2JhNGM1MWJhMTM3ZGJhZDI5ZTgxMjUvdGFibGVyYW5nZTplZjQ4YzI5NzIzYmE0YzUxYmExMzdkYmFkMjllODEyNV8wLTAtMS0xLTExMjk4_09f8aba0-133e-4381-8d98-27de2ef7cbb5">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6ZWY0OGMyOTcyM2JhNGM1MWJhMTM3ZGJhZDI5ZTgxMjUvdGFibGVyYW5nZTplZjQ4YzI5NzIzYmE0YzUxYmExMzdkYmFkMjllODEyNV8xLTQtMS0xLTExMjk4_386958d1-cafe-4db2-92a1-08fee7f09156">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6ZWY0OGMyOTcyM2JhNGM1MWJhMTM3ZGJhZDI5ZTgxMjUvdGFibGVyYW5nZTplZjQ4YzI5NzIzYmE0YzUxYmExMzdkYmFkMjllODEyNV8yLTEtMS0xLTExMjk4_0cf059ab-eba5-4d64-a20d-d4bba0c1414e">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDkz_80a92b89-5932-48b2-9e46-bd2955a31c94">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk4_cd4854b8-0381-40bf-b5d5-93b22cd0b4df">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The approximate aggregate market value of voting stock held by non-affiliates of the registrant, based upon the last sale price of the registrant&#8217;s common stock on the last business day of the registrant&#8217;s most recently completed second fiscal quarter, June&#160;30, 2021, as reported on The NASDAQ Global Select Market, was approximately $<ix:nonFraction unitRef="usd" contextRef="i12aa694918fb4e37a8989f7f4021c7cc_I20210630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV8zMzky_e737bac0-538b-4b94-bf3e-61db8e90d98f">3.1</ix:nonFraction> billion.</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;23, 2022, the number of outstanding shares of the registrant&#8217;s common stock was <ix:nonFraction unitRef="shares" contextRef="i000e41e2d6664cc0a62610b6e74c65f6_I20220223" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV8zNzEy_2a8b132e-487e-4849-9a05-423a2e0c0bd2">186,274,156</ix:nonFraction>. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDg2_51cd2486-f489-4939-8078-5e52c86c0349" escape="true">Portions of registrant&#8217;s definitive Proxy Statement to be filed for its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</ix:nonNumeric> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">ontents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_13">Summary of Risks</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_13">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_22">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_22">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_25">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_25">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_28">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_28">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_31">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_31">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_34">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_34">48</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_37">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_40">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_40">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_43">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_43">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_43">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_46">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_46">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_61">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_61">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_61">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_64">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_64">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_64">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_139">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_139">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_139">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_142">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_142">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_142">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_145">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_145">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_145">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_1727">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_1727">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_148">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_151">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_151">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_151">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_154">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_154">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_154">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_157">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_157">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_157">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_160">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_160">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_160">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_163">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_163">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_163">106</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_166">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_169">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_169">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_169">107</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_172">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_172">112</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">ontents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this annual report on Form&#160;10-K, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation or success of our collaboration arrangements, timing of commercial launches and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part I, Item&#160;1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this annual report on Form 10-K. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this annual report on Form 10-K, the &#8220;Company,&#8221; &#8220;Nektar,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nektar brand and product names, including but not limited to Nektar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">ontents</a></span></div></div><div style="margin-top:6pt;text-indent:63pt"><span><br/></span></div><div id="i1023926dfc3b4cff924b0207eb081f42_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks to our business are more fully described below in Item IA in this Form 10-K, which risks include, among others:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Research and Development Efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on the success of bempegaldesleukin, our lead immuno-oncology (I-O) candidate, and our business will be significantly harmed if we are not successful in developing this drug candidate;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies could have a material and adverse impact on the value of our I-O pipeline;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">significant competition for our polymer conjugate chemistry technology platforms and our products and drug candidates could make our technologies, drug products or drug candidates obsolete or uncompetitive;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">preliminary and interim data from our clinical studies are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">clinical trials for any of our drug candidates could be delayed for a variety of reasons. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Collaboration Partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we are highly dependent on our collaboration partners to initiate, properly conduct and prioritize clinical trials for bempegaldesleukin and NKTR-358, our lead drug candidates, and to perform important additional development and commercialization activities, and our business will be significantly harmed if their actions deprioritize or otherwise harm the prospects of our drug candidates; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the operations of our collaboration partners have been affected by the COVID-19 pandemic in the past, and it is possible that the COVID-19 pandemic will affect the operations of our collaboration partners in the future, which would cause delays in initiating or completing one or more clinical trials involving our drug candidates.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to our Financial Condition and Capital Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if the market size for a new drug that receives approval is significantly smaller than we anticipate, it could negatively impact our revenue, results of operations and financial condition;</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if third-party payers (including government programs) do not provide payment or reimbursement for our products, those products will not be widely accepted, which would negatively impact our business, results of operations and financial condition; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our revenue is exclusively derived from our collaboration agreements. If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt;text-decoration:underline">Risks Related to the COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic. While the COVID-19 pandemic has not had a material adverse effect on our current operations, the ongoing challenges associated with the pandemic, including the emergence of new variants of the coronavirus, such as the Delta and Omicron variants, and resurgences in number and rates of infections, and shortages in raw materials and equipment and other supply chain disruptions, could have a material negative impact on our business and our clinical trial timelines.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">ontents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Supply and Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, our business, financial condition and results of operations could be harmed; and</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause delays, loss of revenue and contract liability.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Business Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if we are unable to create robust sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our drug candidates successfully.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;text-decoration:underline">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to drug candidates granted Breakthrough Therapy designation by the United States Food and Drug Administration (FDA); </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we or our partners may not obtain regulatory approval for our drug candidates on a timely basis, or at all; </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required, which may not be available to us on commercially reasonable terms; and </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">from time to time, we are involved in legal proceedings and may incur substantial litigation costs and liabilities that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above-mentioned risks, our business is subject to a number of additional risks faced by businesses generally. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">ontents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_19"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Nektar Therapeutics is a research-based biopharmaceutical company focused on discovering and developing innovative medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in building and advancing our pipeline of drug candidates as we believe that this is the best strategy to build long-term stockholder value. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Drug Candidates and Technology Platform</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a targeted portfolio of novel drug candidates aimed at selectively modulating pathways within the immune system that play critical roles in a wide range of serious diseases, including oncology, immunology and virology.  In oncology, we are focused on activating the immune system&#8217;s natural tumor-fighting mechanisms, and we are studying several immuno-oncology (I-O) drug candidates in the clinic for a variety of cancer indications.  These proprietary I-O candidates include bempegaldesleukin, NKTR-255 and NKTR-262, each in combination with one or more other therapeutic agents.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In immunology, we are focused on addressing imbalances in the immune system to restore the body&#8217;s self-tolerance mechanisms and achieve immune homeostasis.  In autoimmune disorders, our proprietary IL-2 T-regulatory (Treg) cell stimulator NKTR-358 is currently being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In virology, we believe selective immuno-modulators can be useful in addressing viral infections in people. Our programs in this area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255 with therapies in Gilead&#8217;s antiviral portfolio.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidates are generated from our advanced and proven polymer conjugation technology platform. Polymer conjugation or PEGylation has been a highly effective technology platform for the development of therapeutics with significant commercial success, such as Amgen&#8217;s Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegfilgrastim) and UCB&#8217;s CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (certolizumab pegol). Nearly all of the PEGylated drugs approved over the last fifteen years were enabled with our PEGylation technology through our collaborations and licensing partnerships with a number of well-known biotechnology and pharmaceutical companies. PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that has been shown to safely clear from the body. Its primary use to date has been in currently approved biologic drugs to favorably alter their pharmacokinetic or pharmacodynamic properties. However, in spite of its widespread success in commercial drugs, there are some limitations with the first-generation PEGylation approaches that have been used with biologics. For example, these first generation techniques cannot be used successfully to create small molecule drugs which could potentially benefit from the application of the technology. Other limitations of the early applications of PEGylation technology include sub-optimal bioavailability and bioactivity, and its limited ability to be used to fine-tune properties of the drug.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With our expertise and proprietary technology in polymer conjugation, we have created the next generation of PEGylation technology. Our advanced polymer conjugation technology platform is designed to overcome the limitations of  first generation techniques to allow for the application of technology to a broader range of molecules across many therapeutic areas. We have also developed robust manufacturing processes for generating second generation PEGylation reagents that allow us to utilize the full potential of these newer technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improve efficacy or safety of a drug as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improve targeting or binding affinity of a drug to its target receptors with the potential to improve efficacy and reduce toxicity or drug resistance;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improve solubility of a drug;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">enable oral administration of parenterally-administered drugs, or drugs that must be administered intravenously or subcutaneously, and increase oral bioavailability of small molecules;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">prevent drugs from crossing the blood-brain barrier, or reduce their rate of passage into the brain, thereby limiting undesirable central nervous system effects;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduce first-pass metabolism effects of certain drug classes with the potential to improve efficacy, which could reduce the need for other medicines and reduce toxicity;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduce the rates of drug absorption and of elimination or metabolism by improving stability of the drug in the body and providing it with more time to act on its target;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">differentially alter binding affinity of a drug for multiple receptors, improving its selectivity for one receptor over another; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduce immune response to certain macromolecules with the potential to prolong their effectiveness with repeated doses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a broad range of technologies that we may use when designing our own drug candidates, some of which are further described below.</span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large Molecule Releasable Polymer Conjugates (Cytokines)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customized technologies with large molecule polymer conjugates can be applied to biologics, in particular cytokines, which utilize the polymer as a means to bias action to a certain receptor or receptor sub-type.   In addition, a cytokine&#8217;s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended. An example of this is bempegaldesleukin, which is a CD122-preferential IL-2 pathway agonist designed to stimulate the patient&#8217;s own immune system to fight cancer, without over-activating the immune system, with an every two or every three-week dosing schedule.</span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large Molecule Polymer Conjugates (Proteins and Peptides)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customized technologies with large molecule polymer conjugates have enabled numerous successful PEGylated biologics on the market today. Through rational drug design, a protein&#8217;s or peptide&#8217;s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended. An example of this is Baxalta&#8217;s ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, which was approved by the FDA in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. In December 2016, the FDA expanded the approval of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for use in surgical settings for both adults and pediatric patients, and also for the treatment of Hemophilia A in pediatric patients under 12 years of age.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our scientists have shown that we can also optimize relative receptor binding characteristics of large molecule conjugates. For instance, the cytokine IL-2 has two different receptor complexes in the body that cause opposing effects on the immune system. We have engineered different novel conjugates of IL-2 with optimized differential receptor binding to the IL-2 receptor categories in the immune system. By biasing the receptor binding of these molecules in complementary ways, we have made two different drug candidates: bempegaldesleukin, which selectively activates effector T&#160;cells, which kill tumors; and NKTR-358, which selectively activates regulatory T&#160;cells, which can reduce the pathological immune activation that underlies many autoimmune diseases.  </span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Small Molecule Releasable Polymer Conjugates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our proprietary releasable polymer conjugation technology can be used to optimize the pharmacokinetics and pharmacodynamics of a small molecule drug to substantially increase its efficacy and improve its side effect profile. We are currently using this platform for NKTR-262.  For NKTR-262 and other oncolytics, we believe this platform can improve sub-optimal half-lives that limit therapeutic efficacy. With our releasable polymer conjugate technology platform, we believe that oncolytic drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.</span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Small Molecule Polymer Conjugates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customized technology for small molecule polymer conjugates allows for the fine-tuning of the physicochemical and pharmacological properties of small molecule oral drugs to potentially increase their therapeutic benefit. In addition, this technology can enable oral administration of subcutaneously or intravenously delivered small molecule drugs that have low </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bioavailability when delivered orally. The benefits of this technology can also include: improved potency, modified biodistribution with enhanced pharmacodynamics, and reduced transport across specific membrane barriers in the body, such as the blood-brain barrier. An example of reducing transport across the blood-brain barrier is MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an orally-available peripherally-acting opioid antagonist that is approved in the United States, the EU and other countries. </span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody Fragment Polymer Conjugates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This technology uses a large molecular weight PEG conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody. The specially designed PEG replaces the function of the fragment crystallizable (Fc) domain of full length antibodies with a branched architecture PEG with either stable or degradable linkage. This technology can be used to reduce antigenicity, reduce glomerular filtration rate, enhance uptake by inflamed tissues, and retain antigen-binding affinity and recognition. One approved product on the market that utilizes our technology with an antibody fragment is CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (certoluzimab pegol), which was developed by our partner UCB and is approved for the treatment of Crohn&#8217;s Disease and ankylosing spondylitis in the U.S., axial spondyloarthritis in the EU and psoriatic arthritis and rheumatoid arthritis in the U.S. and EU.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The key elements of our business strategy are described below:</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advance Our Clinical Pipeline of Drug Candidates that Leverages Our Deep Understanding of Immunology and Our Advanced Polymer Conjugate Platform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our objective is to create value by advancing our lead drug candidates through various stages of clinical development. To support this strategy, we leverage the expertise and experience within our internal research, preclinical, clinical development and regulatory departments. A key component of our development strategy is aimed at reducing the risks and time associated with drug development by capitalizing on the known safety and efficacy of existing drugs and drug candidates as well as established pharmacologic targets. For some of our novel drug candidates, we may seek to study the drug candidates in indications for which the parent drugs have not been studied or approved. We believe the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to existing therapies. In addition, in certain instances, we have the opportunity to develop new treatments for patients for which the parent drugs are not currently approved.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ensure Future Growth of our Pipeline through Internal Research Efforts and Advancement of our Preclinical Drug Candidates into Clinical Trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We believe it is important to maintain a diverse pipeline of new drug candidates to continue to build on the value of our business. Our discovery research organization is continuing to identify new drug candidates by applying our technology platform to a wide range of molecule classes, including small molecules and proteins, peptides and antibodies, across multiple therapeutic areas. We continue to advance our most promising research drug candidates into preclinical development with the objective of advancing these early-stage research programs to human clinical studies over the next several years.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transition to a Fully-Integrated Specialty Biotechnology Company with a Commercial Capability in the I-O Therapeutic Area</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we are successful with the development of bempegaldesleukin or one of our I-O drug candidates and one or more of them is approved, we plan to establish a commercial capability in the U.S. and other select major markets to market, sell and distribute these proprietary I-O therapies.&#160;&#160;Under our BMS Collaboration Agreement, we retained significant global commercial rights to bempegaldesleukin including global co-promotion rights for all combinations of bempegaldesleukin with any BMS proprietary therapy, and we lead global commercialization for all other bempegaldesleukin combination regimens. We also have the contractual right under our BMS Collaboration Agreement to record all worldwide sales and revenue&#160;for bempegaldesleukin and we have final decision-making authority regarding the pricing of bempegaldesleukin.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selectively Enter into Strategic Collaboration Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We decide on a drug-candidate-by-drug-candidate basis, how far to advance clinical development (e.g., Phase&#160;1, 2 or 3) and whether to commercialize products on our own, or seek a partner, or pursue a combination of these approaches. When we determine to seek a partner, our strategy is to selectively access a partner&#8217;s development, regulatory, or commercial capabilities with the structure of the collaboration depending on factors such as economic risk sharing, the cost and complexity </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of development, marketing and commercialization needs, therapeutic areas, potential for combination of drug programs, and geographic capabilities.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continue to Build a Leading Intellectual Property Estate across Therapeutic Modalities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are committed to continuing to build on our intellectual property position to protect our scientific and therapeutic advances, whether in the I-O therapeutic area, the field of polymer conjugate chemistry or otherwise. To that end, we have a comprehensive patent strategy with the objective of developing a patent estate covering a wide range of novel inventions, including among others, compositions of matter (such as our drug candidates, formulations, conjugates, and polymeric materials), methods of treatment, and methods of manufacture.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Research and Development Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table summarizes our drug candidates that are being developed by us or in collaboration with other pharmaceutical companies or independent investigators. The table includes the type of molecule or drug, the target indications for the drug candidate, and the status of the clinical development program.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Drug Candidate</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (CD122-preferential IL-2 pathway agonist)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immuno-oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1, Phase 2, and Phase 3 studies ongoing in multiple indications</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358 (cytokine Treg stimulant)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune Disease</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 and Phase 2 studies ongoing in multiple indications</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-255 (IL-15 receptor agonist)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immuno-oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 1 and Phase 1/2 studies ongoing in multiple indications</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research/Preclinical</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-262 (toll-like receptor agonist)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Status definitions are:</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; drug candidate in large-scale clinical trials conducted to obtain regulatory approval to market and sell the drug (these trials are typically initiated following encouraging Phase 2 trial results).</span></div><div style="padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; a drug candidate in clinical trials to establish dosing and efficacy in patients.</span></div><div style="padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; a drug candidate in clinical trials, typically in healthy subjects, to test safety.</span></div><div style="padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research/Preclinical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; a drug candidate is being studied in research by way of in vitro studies and/or animal studies</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Our Pipeline</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immuno-oncology (I-O)</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the area of oncology, we have a particular focus on developing medicines in the area of I-O, which is a therapeutic approach based on targeting biological pathways that stimulate and sustain the body&#8217;s immune response in order to fight cancer. We are developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and natural killer (NK) cells, to increase their numbers and to improve their function to recognize and attack cancer cells.</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bempegaldesleukin (previously known as NKTR-214, cytokine immunostimulatory therapy)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to stimulate the patient&#8217;s own immune system to fight cancer without over-activating the immune system.&#160;&#160;Bempegaldesleukin is designed to grow specific cancer-killing T cells and natural (NK) cell populations in the body, which are known as endogenous tumor-infiltrating lymphocytes (TILs). Bempegaldesleukin stimulates these cancer-killing immune cells in the body by targeting CD122-specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and NK cells. CD122, which is also known as the </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IL-2 receptor beta subunit, is a key signaling receptor that is known to increase proliferation of these CD8+ effector T cells. This receptor selectivity is intended to increase efficacy and improve safety over existing immunostimulatory cytokine drugs. Our strategic objective is to establish bempegaldesleukin as a key component of many I-O combination regimens with the potential to improve the standard of care in multiple oncology settings. To this end, we are executing a comprehensive clinical development program for bempegaldesleukin, including a broad clinical collaboration with the Bristol-Myers Squibb Company (BMS), several clinical collaborations with other third parties with pharmacological agents that have potential complementary mechanisms to bempegaldesleukin, as well as pursuing our own independent clinical studies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The development program for bempegaldesleukin includes combinations with a number of therapeutic approaches where we believe there is a strong biologic rationale for complementary mechanisms of action. On September 21, 2016, we entered into a Clinical Trial Collaboration Agreement with BMS, pursuant to which we and BMS collaborated to conduct Phase&#160;1/2 clinical trials evaluating bempegaldesleukin and BMS&#8217; human monoclonal antibody that binds to PD-1, known as Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as a potential combination treatment regimen in five tumor types and eight potential indications (each, a Combined Therapy Trial). In the first phase of the PIVOT-02 study, we evaluated the clinical benefit, safety, and tolerability of combining bempegaldesleukin with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in thirty-eight patients. Interim data from the dose-escalation phase of the trial was presented at the 2017 SITC meeting in November 2017. We identified the recommended Phase 2 dose for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The second phase of the expansion cohorts, which now falls under the BMS Collaboration Agreement entered into on February 13, 2018, and described below, is evaluating the safety and efficacy of combining bempegaldesleukin with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On August 1, 2019, we and BMS announced that the FDA granted Breakthrough Therapy designation for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with previously untreated unresectable or metastatic melanoma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakthrough Therapy designation is intended to expedite the development and review of medicines aimed at treating serious or life-threatening disease where there is preliminary evidence that the investigational therapy may offer substantial improvement over existing therapies on at least one clinically significant endpoint.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement with BMS (as amended to date, the BMS Collaboration Agreement) that outlined a collaboration for the co-development and co-commercialization of bempegaldesleukin in combination regimens with BMS medicines including Opdivo&#174;.  On April 3, 2018, the closing date of the transaction, BMS paid us a non-refundable upfront cash payment of $1.0 billion and purchased $850.0 million of our common stock at a purchase price of $102.60 per share pursuant to a Share Purchase Agreement (Purchase Agreement). We are eligible to receive additional cash payments up to a total of approximately $1.455 billion (including the milestones which we have already received under the BMS Collaboration Agreement) upon achievement of certain development and regulatory milestones, and up to a total of $350.0 million upon achievement of certain sales milestones. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration development plan (the Collaboration Development Plan) under the BMS Collaboration Agreement is evaluating bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in ongoing registrational trials in first-line metastatic melanoma, adjuvant melanoma, first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer, first-line metastatic renal cell carcinoma (RCC), and muscle-invasive bladder cancer, as well as a Phase 1/2 dose escalation and expansion study to evaluate bempegaldesleukin plus Opdivo&#174; in combination with either axitinib or cabozantinib in first line RCC in order to support a future Phase 3 registrational trial. We and BMS share development costs based on each party&#8217;s relative ownership interest in the compounds included in the regimen. For example, we share clinical development costs for bempegaldesleukin in combination with Opdivo&#174;, BMS 67.5% and Nektar 32.5%. For costs of manufacturing bempegaldesleukin, however, BMS is responsible for 35% and Nektar is responsible for 65% of costs. For indications not included in the Collaboration Development Plan, the parties are free to develop their own medicines in other indications subject to certain cost sharing, premium reimbursement, and timing terms and conditions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the co-commercialization portion of the BMS Collaboration Agreement, we will book all worldwide sales and revenue for bempegaldesleukin.  We and BMS will share global commercialization profits and losses for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses.  Each party bears their own non-product specific core commercialization infrastructure costs.  We retain the final decision-making authority regarding the pricing for bempegaldesleukin.  Bempegaldesleukin will be sold on a stand-alone basis and there will be no fixed-dose combinations or co-packaging without the consent of both parties.  On January 12, 2022, we and BMS entered into an Amendment No. 2 to the BMS Collaboration Agreement pursuant to which we and BMS allocated certain responsibilities related to price negotiations and promotion, market access, patient support and related activities to each party.  The commercial economics under the BMS Collaboration Agreement remain unchanged under this amendment.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the Collaboration Development Plan with BMS, we are also conducting a broad array of development activities evaluating bempegaldesleukin in combination with other agents that have potential complementary mechanisms of action. For example, as specifically allowed under the BMS Collaboration Agreement, we are independently studying </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a PD-1 inhibitor. We are also working with Vaccibody AS to evaluate bempegaldesleukin with Vaccibody's personalized cancer neoantigen vaccine in a Phase 1 proof-of-concept study. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On February 12, 2021, we entered into a financing and co-development collaboration (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ will pay up to $150.0 million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda&#174; (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth. On February 11, 2021, we entered into a collaboration agreement with MSD International GmbH (MSD), an affiliate of Merck, Sharp &amp; Dohme, pursuant to which MSD will provide Keytruda&#174; at no cost for use in the SCCHN Clinical Trial but will not bear any other costs of the trial.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SFJ will have primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we will be the sponsor of the SCCHN Clinical Trial and will also have sole responsibility for regulatory interactions and filings for bempegaldesleukin. The SCCHN Clinical Trial provides for an interim futility analysis, and unless the futility criteria are met, SFJ is required to complete the SCCHN Trial, but if the futility criteria are met, SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. We and BMS, pursuant to the BMS Collaboration Agreement, remain solely responsible for conducting the Phase 3 clinical trials of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the treatment of previously untreated unresectable or metastatic melanoma (the &#8220;Melanoma Indication&#8221; and the &#8220;Melanoma Clinical Trial&#8221;).</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the opportunity to receive Success Payments as outlined below, SFJ has no right to reimbursement of costs incurred by SFJ for the SCCHN Clinical Trial in the event that the Melanoma Clinical Trial and the SCCHN Clinical Trial do not achieve FDA approval. We will pay SFJ a series of success-based annual payments (collectively, the Success Payments) in the event of FDA approval of bempegaldesleukin for the Melanoma Indication, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication. The Success Payments do not begin until the substantial completion of the SCCHN Clinical Trial. The total success-based annual payments for the first indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $450.0 million, paid in annual contractual payments over five years, with the first payment being $30.0 million, with the earliest possible payment expected to occur in late 2024 or early 2025, subject to the substantial completion of the SCCHN Clinical Trial. The total success-based payments for the second indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $150.0 million, paid in annual contractual payments over seven years. Finally, in the event of FDA approval for bempegaldesleukin for any indication other than the Melanoma Indication or the SCCHN Indication, we will make a one-time payment of $37.5 million to SFJ. If the success criterion for the interim futility analysis is not met and SFJ winds down the SCCHN Clinical Trial, then the Success Payments, if any, for the Melanoma Indication and/or the additional bempegaldesleukin indication are reduced pro rata based on the costs incurred by SFJ for the SCCHN Clinical Trial over the aggregate commitment of $150.0 million.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SFJ Agreement provides for certain positive and negative covenants, including restrictions on our ability to incur liens on our intellectual property related to bempegaldesleukin (the bempegaldesleukin IP), or assign or convey any right to receive income with respect to the bempegaldesleukin IP (other than royalty and other license fee obligations to licensors), except for the issuance of senior secured debt secured by all or substantially all of our assets, including the bempegaldesleukin IP. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SFJ Agreement expires upon the payment of all Success Payments to SFJ, unless earlier terminated as provided under the SFJ Agreement. The SFJ Agreement may be terminated by either party for a safety or health concern for the patients, whether by the independent data monitoring company or by mutual agreement of both parties. The SFJ Agreement may also be terminated by either party for material breach or insolvency of the counterparty.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With our non-BMS clinical collaborations for bempegaldesleukin, generally each party supports the collaboration based on its expertise and resources. For example, in February 2021, we entered into a clinical trial collaboration and supply agreement with Merck wherein we will receive supplies of Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at no cost to us. We expect to continue to make significant and increasing investments exploring the potential of bempegaldesleukin with mechanisms of action that we believe are synergistic with bempegaldesleukin based on emerging scientific findings in cancer biology and preclinical development work.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition to these non-BMS clinical collaborations for bempegaldesleukin, we intend to initiate further clinical development programs, on our own or in collaboration with other potential partners, to explore the potential of combining bempegaldesleukin with other therapies such as cancer vaccines (other than Vaccibody&#8217;s personalized cancer neoantigen vaccine), adoptive cell therapy, and other small molecules and biological agents in order to generate novel immuno-oncology approaches.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NKTR-255</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of NK cells and induces survival of both effector and CD8 memory T cells. Recombindant human IL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and the formation of long-term immunological memory, which may lead to sustained anti-tumor immune response. We have initiated a Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. Additionally, we have entered into a separate preclinical research collaboration with Janssen to test the combination of NKTR-255 with therapies in Janssen&#8217;s oncology portfolio. </span></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">NKTR-262</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;NKTR-262 is a small molecule agonist that targets toll-like receptors (TLRs) found on innate immune cells in the body. NKTR-262 is designed to overcome the body&#8217;s dysfunction of antigen-presenting cells (APCs), such as dendritic cells, which are critical to induce the body&#8217;s adaptive immunity and create antigen-specific cytotoxic T&#160;cells. NKTR-262 is being developed as a single intra-tumoral injection to be administered at the start of therapy with bempegaldesleukin in order to induce an abscopal response and achieve the goal of tumor regression in cancer patients treated with both therapies. We have completed the dose-escalation portion of a Phase 1/2 clinical study, which we call the REVEAL study, and the dose-expansion portion of the study is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immunology</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NKTR-358, Agreement with Eli Lilly and Company </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358 is designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease. Current systemic treatments for autoimmune disease, including corticosteroids and anti-TNF agents, suppress the immune system broadly and come with severe side effects. NKTR-358 targets the CD25 sub-receptor in the IL-2 pathway in order to stimulate proliferation and growth of regulatory T cells, which are specific immune cells in the body that modulate the immune system and prevent autoimmune disease by maintaining self-tolerance.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), pursuant to which we and Lilly will co&#8209;develop NKTR-358 (Lilly Agreement). Under the terms of the Lilly Agreement, we received an initial payment of $150.0 million in September 2017 and are eligible for up to $250.0 million in additional development and regulatory milestones. We are responsible for completing Phase 1 clinical development and certain drug product development and drug supply responsibilities assigned to us under the Lilly Agreement. We will share Phase 2 development costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. We will also have the option to contribute funding to Phase 3 development on an indication-by-indication basis, ranging from zero to 25% of the global Phase 3 development costs. We are eligible to receive up to double-digit sales royalty rates that escalate based upon our contribution to Phase 3 development costs and the level of global product annual sales. Lilly will be responsible for all costs of global commercialization and we have an option to co-promote in the U.S. under certain conditions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy patients. We also completed treatment of a Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with systemic lupus erythematosus (SLE). Lilly is conducting two Phase 1b studies in patients with psoriasis and atopic dermatitis, and initiated a Phase 2 study in SLE in October 2020 and a Phase 2 study in ulcerative colitis in March 2021. In addition, Lilly is planning to initiate a Phase 2 study in atopic dermatitis based on positive interim Phase 1b results in that indication and also plans to initiate another Phase 2 study in another immune-mediated disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Virology</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our drug candidates, bempegaldesleukin and NKTR-255, also have potential applications in the area of virology. With regard to bempegaldesleukin, we believe this drug candidate&#8217;s ability to directly increase the numbers of anti-viral CD4+, CD8+ and NK lymphocytes, which are known to be critical for the resolution of many viral infections in people, and specifically infections with respiratory coronaviruses in a variety of animal models, could be useful as a therapeutic in treating individuals affected with COVID-19. We completed a Phase 1b clinical trial of bempegaldesleukin plus standard of care for treatment of adults with mild COVID-19.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With regard to NKTR-255, we believe this drug candidate&#8217;s ability to activate and proliferate NK cells and memory CD8+ T cells to target activated CD4+ T cells can result in killing virus-infected cells.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have entered into a preclinical research collaboration with Gilead to test the combination of NKTR-255 with therapies in Gilead&#8217;s antiviral portfolio. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Partner Programs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of other drug candidates in clinical development and approved products in collaboration with our partners where we invented the drug candidate or where our collaboration partners have licensed our proprietary intellectual property to enable one of their drug candidates. The following table outlines our collaborations with a number of pharmaceutical companies that currently license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products. More than ten products using our PEGylation technology have received regulatory approval in the U.S. or Europe. There are also a number of other candidates that have been filed for approval or are in various stages of clinical development. These collaborations generally contain one or more elements including a license to our intellectual property rights and manufacturing and supply agreements under which we may receive manufacturing revenue, milestone payments, and/or royalties on commercial sales of drug products.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:32.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary or Target<br/>Indications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug<br/>Marketer/Partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Status(1)</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2015*</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxegol tablets) and&#160;&#160;MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opioid-induced constipation in adult patients with chronic non-cancer pain (US); Opioid-induced constipation in adult patients who have and inadequate response to laxatives (EU).</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca AB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2014*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (certolizumab pegol)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn&#8217;s disease, Rheumatoid arthritis, and Psoriasis/ Ankylosing Spondylitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2008**</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (C.E.R.A.) (Continuous Erythropoietin Receptor Activator)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F. Hoffmann-La Roche&#160;Ltd</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved 2007**</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macugen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegaptanib sodium injection)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Age-related macular degeneration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Companies Inc. (formerly, Valeant Pharmaceuticals International, Inc.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved 2004</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Somavert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegvisomant)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved 2003</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dapirolizumab Pegol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic Lupus Erythematosus</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCB Pharma (Biogen)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Status definitions are:</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; regulatory approval to market and sell product obtained in one or more of the U.S., EU or other countries. Year indicates first regulatory approval.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Filed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; an application for approval and marketing has been filed with the applicable government health authority.</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; drug candidate in large-scale clinical trials conducted to obtain regulatory approval to market and sell the drug (these trials are typically initiated following encouraging Phase 2 trial results).</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; a drug candidate in clinical trials to establish dosing and efficacy in patients.</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a drug candidate in clinical trials, typically in healthy subjects, to test safety.</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research/Preclinical &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a drug candidate is being studied in research by way of in vitro studies and/or animal studies.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  *&#160;&#160;&#160;&#160;In December 2020, pursuant to a purchase and sale agreement (the &#8220;2020 Purchase and Sale Agreement&#8221;) we sold our rights to receive royalties on future worldwide new sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MOVANTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (as well as REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and specified licensed products under a Right to Sublicense Agreement, dated October 27, 2017) from and after October 1, 2020 until the purchaser of these rights has received payments equal to $210.0 million (the &#8220;2025 Threshold&#8221;), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0 million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). All rights to receive royalties will return to Nektar once the 2020 Purchase and Sale Agreement expires.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** &#160;&#160;&#160;&#160;In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effective as of January&#160;1, 2012.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With respect to all of our collaboration and license agreements with third parties, please refer to Item&#160;1A. Risk Factors, including without limitation, &#8220;We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition&#8221; and &#8220;We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.&#8221; </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Ongoing Collaboration Partner Programs</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (previously referred to as BAX 855), ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (brand name for ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> in Europe) and Longer-Acting Blood Clotting Proteins for Hemophilia A, Agreement with Subsidiaries of Baxalta Incorporated</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2005, we entered into an exclusive research, development, license, manufacturing and supply agreement (Baxalta License Agreement) with certain subsidiaries of Baxalta (which has been acquired by Takeda), to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation technology. Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. The first product in this collaboration, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (previously referred to as BAX 855), is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein that was developed to increase the half-life of ADVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method). ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was first approved by the FDA on November 30, 2015.&#160;&#160;Since then it has been approved in one or more indications for Hemophilia A in the EU, Japan, and other countries around the world.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, pursuant to the 2020 Purchase and Sale Agreement we sold our rights to receive royalties on future worldwide new sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and from the third party products under a right to sublicense agreement from and after October 1, 2020 until the purchaser of these rights has received payments equal to $210.0 million (the &#8220;2025 Threshold&#8221;), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0 million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). All rights to receive royalties will return to Nektar once the 2020 Purchase and Sale Agreement expires. This 2020 Purchase and Sale Agreement is further discussed in Note 8 of our Consolidated Financial Statements.  </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> and MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (brand name for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> in Europe), Agreement with AstraZeneca AB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was developed using our oral small molecule polymer conjugate technology and we advanced this drug through the completion of Phase 2 clinical studies prior to licensing it to AstraZeneca. MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an orally-available peripherally-acting mu-opioid antagonist which is a medication for the treatment of opioid-induced constipation (OIC), which is a common side effect of prescription opioid medications. Opioids attach to specific proteins called opioid receptors. When the opioids attach to certain opioid receptors in the gastrointestinal tract, constipation may occur. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On September 16, 2014, the FDA approved MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain. On December 9, 2014, the European Commission (EC), granted Marketing Authorisation to MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the naloxegol brand name in the European Union (EU)) as the first once-daily oral PAMORA to be approved in the EU for the treatment of OIC in adult patients who have had an inadequate response to laxative(s). The EC&#8217;s approval applies to all EU member countries plus Iceland and Norway. AstraZeneca launched the commercial sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. in March 2015 and MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Germany, the first EU member country, in August 2015. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, pursuant to the 2020 Purchase and Sale Agreement, we sold our rights to receive royalties on future worldwide new sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MOVANTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from and after October 1, 2020 until the purchaser of these rights has received payments equal to $210.0 million (the &#8220;2025 Threshold&#8221;), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0 million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). All rights to receive royalties will return to Nektar once the 2020 Purchase and Sale Agreement expires. This 2020 Purchase and Sale Agreement is further discussed in Note 7 of our Consolidated Financial Statements. AstraZeneca has agreed to use commercially reasonable efforts to develop one MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> fixed-dose combination product and has the right to develop multiple products which combine MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with opioids. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, Agreement with UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In December 2000, we entered into a license, manufacturing and supply agreement covering our proprietary PEGylation materials for use in CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (certolizumab pegol) with Celltech Chiroscience Ltd., which was acquired by UCB in 2004. Under the terms of the agreement, UCB is responsible for all clinical development, regulatory, and commercialization expenses. We also manufacture and supply UCB with our proprietary PEGylation reagent used in the manufacture of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on a fixed price per gram. We were also entitled to receive royalties on net sales of the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product for the longer of ten years from the first commercial sale of the product anywhere in the world or the expiration of patent rights in a particular country. In February 2012, we sold our rights to receive royalties on all future worldwide net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effective as of January&#160;1, 2012 until the agreement with UCB is terminated or expires. This sale is further discussed in Note&#160;8 of our Consolidated Financial Statements. Our agreement with UCB Pharma expires upon the expiration of all of UCB&#8217;s royalty obligations, provided that the agreement can be extended for successive two year renewal periods upon mutual agreement of the parties. In addition, UCB may terminate the agreement should it cease the development and marketing of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and either party may terminate for cause under certain conditions.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (C.E.R.A.) (Continuous Erythropoietin Receptor Activator), Agreement with F.&#160;Hoffmann-La&#160;Roche Ltd and Hoffmann-La Roche Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In December 2000, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (Roche), which was amended and restated in its entirety in December 2005. Pursuant to the agreement, we license our intellectual property related to our proprietary PEGylation materials for the manufacture and commercialization of Roche&#8217;s MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis. As of the end of 2006, we were no longer required to manufacture and supply our proprietary PEGylation materials for MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under our original agreement. In February 2012, we entered into a toll-manufacturing agreement with Roche under which we manufactured our proprietary PEGylation material for MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2016, we no longer had any continuing manufacturing or supply obligations under this MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement. We were also entitled to receive royalties on net sales of the MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. In February 2012, we sold all of our future rights to receive royalties on future worldwide net sales of MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effective as of January&#160;1, 2012. This sale is further discussed in Note&#160;8 of our Consolidated Financial Statements. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Macugen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, Agreement with Bausch Health Companies Inc., formerly Valeant Pharmaceuticals International, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2002, we entered into a license, manufacturing and supply agreement with Eyetech, Inc. (subsequently acquired by Valeant Pharmaceuticals International, Inc. or Valeant), pursuant to which we license certain intellectual property related to our proprietary PEGylation technology for the development and commercialization of Macugen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a PEGylated anti-vascular endothelial growth factor aptamer currently approved in the U.S. and EU for age-related macular degeneration. Under the terms of the agreement, we will receive royalties on net product sales in any particular country for the longer of ten years from the date of the first commercial sale of the product in that country or the duration of patent coverage. Our agreement with Valeant expires upon the expiration of our last relevant patent containing a valid claim. In addition, Valeant may terminate the </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement if marketing authorization is withdrawn or marketing is no longer feasible due to certain circumstances, and either party may terminate for cause if certain conditions are met.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Somavert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, Agreement with Pfizer, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In January 2000, we entered into a license, manufacturing and supply agreement (LMS Agreement) with Sensus Drug Development Corporation (subsequently acquired by Pharmacia Corp. in 2001 and then acquired by Pfizer in 2003), for the PEGylation of Somavert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pegvisomant), a human growth hormone receptor antagonist for the treatment of acromegaly. In January 2017, we entered into a master material supply agreement (Supply Agreement) with Pfizer, in which the LMS Agreement was terminated.  We currently manufacture our proprietary PEGylation reagent for Pfizer on a price per gram basis under the Supply Agreement.  Our obligation under the Supply Agreement to supply our proprietary PEGylation reagent to Pfizer continues until December 31, 2023.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dapirolizumab Pegol, Agreement with UCB Pharma S.A.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2010, we entered into a license, manufacturing and supply agreement with UCB Pharma S.A., (UCB) under which we granted UCB a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize an anti-CD40L PEGylated Fab being developed by UCB and their partner Biogen Idec, for the treatment of autoimmune disorders, including systemic lupus erythemastosus (SLE). Most recently, in July 2019, Biogen announced a plan to initiate with UCB a Phase 3 study of dapriolizumab pegol in patients with active SLE, which clinical study is currently ongoing. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Development and Approval Process</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The research and development, clinical testing, manufacture and marketing of products using our technologies are subject to regulation by the FDA and by comparable regulatory agencies in other countries. These national agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing (in&#160;vitro, in animals, and in human clinical trials), manufacture, labeling, storage, recordkeeping, approval, marketing, advertising and promotion of our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The approval process required by the FDA before a product using any of our technologies may be marketed in the U.S.&#160;depends on whether the chemical composition of the product has previously been approved for use in other dosage forms. If the product is a new chemical entity that has not been previously approved, the process includes the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">extensive preclinical laboratory and animal testing;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission of an Investigational New Drug (IND) prior to commencing clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for the intended indication;&#160;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">extensive pharmaceutical development for the characterization of the chemistry, manufacturing process and controls for the active ingredient and drug product; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission to the FDA of a New Drug Application (NDA) for approval of a drug or a Biological License Application (BLA) for approval of a biological product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If the active chemical ingredient has been previously approved by the FDA, the approval process is similar, except that certain preclinical tests, including those relating to systemic toxicity normally required for the IND and NDA or BLA, and clinical trials, may not be necessary if the company has a right of reference to existing preclinical or clinical data under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) or is eligible for approval under Section&#160;505(b)(2) of the FDCA or the biosimilars provisions of the Public Health Services Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Preclinical tests include laboratory evaluation of product chemistry and animal studies to assess the safety and efficacy of the product and its chosen formulation. Preclinical safety tests must be conducted by laboratories that comply with FDA good laboratory practices (GLP) regulations. The results of the preclinical tests for drugs, biological products and combination products subject to the primary jurisdiction of the FDA&#8217;s Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) are submitted to the FDA as part of the IND and are reviewed by the FDA before clinical trials can begin. Clinical trials may begin 30&#160;days after receipt of the IND by the FDA, unless the FDA raises objections or requires clarification within that period. Clinical trials involve the administration of the drug to healthy volunteers or patients </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the supervision of a qualified, identified medical investigator according to a protocol submitted in the IND for FDA review. Drug products to be used in clinical trials must be manufactured according to current good manufacturing practices (cGMP). Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to monitor participant safety and product efficacy as well as other criteria to be evaluated in the study. Each protocol is submitted to the FDA in the IND.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Apart from the IND process described above, each clinical study must be reviewed by an independent Institutional Review Board (IRB), and the IRB must be kept current with respect to the status of the clinical study. The IRB considers, among other things, ethical factors, the potential risks to subjects participating in the trial and the possible liability to the institution where the trial is conducted. The IRB also reviews and approves the informed consent form to be signed by the trial participants and any significant changes in the clinical trial.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Clinical trials are typically conducted in three sequential phases. Phase 1 involves the initial introduction of the drug into healthy human subjects (in most cases) and the product generally is tested for tolerability, pharmacokinetics, absorption, metabolism and excretion. Phase 2 involves studies in a limited patient population to:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">determine the preliminary efficacy of the product for specific targeted indications;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">determine dosage and regimen of administration;&#160;and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">identify possible adverse effects and safety risks.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If Phase 2 trials demonstrate that a product appears to be effective and to have an acceptable safety profile, Phase 3 trials are typically undertaken to evaluate the further clinical efficacy and safety of the drug and formulation within an expanded patient population at geographically dispersed clinical study sites and in large enough trials to provide statistical proof of efficacy and tolerability. The FDA, the clinical trial sponsor, the investigators or the IRB may suspend clinical trials at any time if any one of them believes that study participants are being subjected to an unacceptable health risk. In some cases, the FDA and the drug sponsor may determine that Phase 2 trials are not needed prior to entering Phase 3 trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Following a series of formal meetings and communications between the drug sponsor and the regulatory agencies, the results of product development, preclinical studies and clinical studies are submitted to the FDA as an NDA or BLA for approval of the marketing and commercial shipment of the drug product. The FDA may deny approval if applicable regulatory criteria are not satisfied or may require additional clinical or pharmaceutical testing or requirements. Even if such data are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy all of the criteria for approval. Additionally, the approved labeling may narrowly limit the conditions of use of the product, including the intended uses, or impose warnings, precautions or contraindications which could significantly limit the potential market for the product. Further, as a condition of approval, the FDA may impose post-market surveillance, or Phase 4, studies or risk evaluation and mitigation strategies. Product approvals, once obtained, may be withdrawn if compliance with regulatory standards is not maintained or if safety concerns arise after the product reaches the market. The FDA may require additional post-marketing clinical testing and pharmacovigilance programs to monitor the effect of drug products that have been commercialized and has the power to prevent or limit future marketing of the product based on the results of such programs. After approval, there are ongoing reporting obligations concerning adverse reactions associated with the product, including expedited reports for serious and unexpected adverse events.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Each manufacturing establishment producing the active pharmaceutical ingredient and finished drug product for the U.S.&#160;market must be registered with the FDA and typically is inspected by the FDA prior to NDA or BLA approval of a drug product manufactured by such establishment. Such inspections are also held periodically after commercialization. Manufacturing establishments of U.S.&#160;marketed products are subject to inspections by the FDA for compliance with cGMP and other U.S.&#160;regulatory requirements. They are also subject to U.S.&#160;federal, state, and local regulations regarding workplace safety, environmental protection and hazardous controls, among others.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In situations where our partners are responsible for clinical and regulatory approval procedures, we may still participate in this process by submitting to the FDA a drug master file developed and maintained by us which contains data concerning the manufacturing processes for polymer conjugation materials or drug product. For those products for which we have development responsibility, we prepare and submit an IND and are responsible for additional clinical and regulatory procedures for drug candidates being developed under an IND. The clinical and manufacturing, development and regulatory review and approval process generally takes a number of years and requires the expenditure of substantial resources. Our ability to manufacture and market products, whether developed by us or under collaboration agreements, ultimately depends upon the completion of satisfactory clinical trials and success in obtaining marketing approvals from the FDA and equivalent foreign health authorities.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sales of our products outside the U.S.&#160;are subject to local regulatory requirements governing clinical trials and marketing approval for drugs. Such requirements vary widely from country to country.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA may grant Fast Track or Breakthrough Therapy designation to a drug candidate, which allows the FDA to expedite the review of new drugs that are intended for serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Important features of Fast Track or Breakthrough Therapy designation include a potentially reduced clinical program and close, early communication between the FDA and the sponsor company to improve the efficiency of product development.  On August 1, 2019, we and BMS announced that the FDA granted Breakthrough Therapy designation for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with previously untreated unresectable or metastatic melanoma.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S.&#160;The company that obtains the first FDA approval for a designated orphan drug for a rare disease receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. In addition, the Orphan Drug Act provides for protocol assistance, tax credits, research grants, and exclusions from user fees for sponsors of orphan products. Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication generally may be approved during the exclusivity period only if the second product is shown to be &#8220;clinically superior&#8221; to the original orphan drug in that it is more effective, safer or otherwise makes a &#8220;major contribution to patient care&#8221; or the holder of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Similar incentives also are available for orphan drugs in the EU.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage, Reimbursement, and Pricing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sales of any products for which we may obtain regulatory approval depend, in part, on the coverage and reimbursement status of those products. In the U.S., sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payers. Third-party payers include government programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care providers, private health insurers and other organizations. Other countries and jurisdictions will also have their own unique mechanisms for approval and reimbursement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The process for determining whether a payer will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payer will pay for the product. Third-party payers may limit coverage to specific products on an approved list or formulary which might not include all of the FDA-approved products for a particular indication. Third-party payers may also refuse to include a particular branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. Further, private payers often follow the coverage and payment policies established by certain government programs, such as Medicare and Medicaid, which require manufacturers to comply with certain rebate, price reporting, and other obligations. For example, the Medicaid Drug Rebate Program, which is part of the Medicaid program (a program for financially needy patients, among others), requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services under which the manufacturer agrees to report certain prices to the government and pay rebates to state Medicaid programs on outpatient drugs furnished to Medicaid patients, as a condition for receiving federal reimbursement for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Further, in order for a pharmaceutical product to receive federal reimbursement under Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the Public Health Service&#8217;s 340B drug pricing program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Third-party payers are increasingly challenging the prices charged for medical products and services, and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the price of therapeutics have been a focus in this effort. The U.S. government and state legislatures have shown significant interest in implementing cost-containment programs, including price controls and restrictions on reimbursement, among other controls. Adoption of price controls or other cost-containment measures could limit coverage for or the amounts that federal and state governments or private payers will pay for health care products and services, which could also result in reduced demand for our drug candidates or additional pricing pressures and affect our ultimate profitability, if approved. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover an approved product or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Healthcare Laws and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we obtain regulatory approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes, referred to as the &#8220;HIPAA All-payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website.  Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If our drug candidates become commercialized, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, integrity and oversight agreements to resolve allegations of non-compliance, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.  Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.  Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act (collectively, the Affordable Care Act), enacted in 2010, expanded the reach of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the applicable criminal fraud statutes </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contained within 42 U.S.C. &#167;&#160;1320a-7b. Pursuant to the Affordable Care Act, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act or the civil monetary penalties statute. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The federal False Claims Act prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent. Although we would not submit claims directly to payers, manufacturers can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been prosecuted under the federal False Claims Act in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $11,463 and $23,331 for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. In addition, private individuals have the ability to bring actions under the federal False Claims Act and certain states have enacted laws modeled after the federal False Claims Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In each country or jurisdiction outside of the U.S. in which we seek and receive regulatory approval to commercialize our products, we will be subject to additional laws and regulations specific to those locations. These regulations and laws will also impact, among other things, our proposed sales and marketing programs in those jurisdictions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legislative and Regulatory Landscape</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing, marketing, coverage and reimbursement of products regulated by the FDA or other government agencies. In addition to new legislation, FDA and healthcare fraud and abuse and coverage and reimbursement regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. While specific changes and their timing are not yet apparent, there may be significant changes to the healthcare environment in the future that could have an adverse effect on anticipated revenues from therapeutic candidates that we may successfully develop and for which we may obtain regulatory approval. Furthermore, federal agencies, Congress, state legislatures, and the private sector have shown significant interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit coverage for or the amounts that federal and state governments will pay for health care products and services, which could also result in reduced demand for our products or additional pricing pressures and affect our ultimate profitability.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We own more than 310 U.S. and 1,200 foreign patents and a number of pending patent applications that cover various aspects of our technologies. We have filed patent applications, and plan to file additional patent applications, covering various aspects of our advanced polymer conjugate technologies and our drug candidates. More specifically, our patents and patent applications cover polymer architecture, drug conjugates, formulations, methods of making polymers and polymer conjugates, methods of administering polymer conjugates, and methods of manufacturing polymers and polymer conjugates. Our patent portfolio contains patents and patent applications that encompass our advanced polymer conjugate technology platforms. Our patent strategy is to file patent applications on innovations and improvements to cover a significant majority of the major pharmaceutical markets in the world. Generally, patents have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid). In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully protect our trade secrets. Others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to, or disclose, our trade secrets. Please refer to Item&#160;1A. Risk Factors, </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including but not limited to &#8220;We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.&#8221; In certain situations in which we work with drugs covered by one or more patents, our ability to develop and commercialize our technologies may be affected by limitations in our access to these proprietary drugs. Even if we believe we are free to work with a proprietary drug, we cannot guarantee that we will not be accused of, or determined to be, infringing a third party&#8217;s rights and be prohibited from working with the drug or found liable for damages. Any such restriction on access or liability for damages would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, opposition, reexamination or other proceedings that can result in the revocation of the patent or maintenance of the patent but in an amended form (and potentially in a form that renders the patent without commercially relevant or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a short period of protection, if any, following the commercialization of products encompassed by our patent.&#160;We may have to participate in post-grant proceedings before the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us. Please refer to Item&#160;1A. Risk Factors, including without limitation, &#8220;If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;U.S.&#160;and foreign patent rights and other proprietary rights exist that are owned by third parties and relate to pharmaceutical compositions and reagents, and equipment and methods for preparation, packaging and delivery of pharmaceutical compositions. We cannot predict with any certainty which, if any, of these rights will be considered relevant to our technology by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. We could incur substantial costs in defending ourselves and our partners against any such claims. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S.&#160;and abroad and could result in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from third parties. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternative technology. The failure to obtain licenses if needed may have a material adverse effect on our business, results of operations and financial condition. Please refer to Item&#160;1A. Risk Factors, including without limitation, &#8220;We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. The agreements provide that all inventions conceived by an employee shall be our property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenue is derived from our collaboration agreements with partners, under which we may receive a combination of revenue elements including up-front payments for licensing agreements, clinical research reimbursement or co-funding, milestone payments based on clinical progress, regulatory progress or net sales achievements, royalties and/or product sales revenue. Our revenues are concentrated among a limited number of collaboration partners under long-term arrangements. We derive the substantial majority of our product sales from UCB and Pfizer. Following the 2020 Purchase and Sale Agreement (wherein under a capped return sale arrangement we sold our rights to receive royalties on future worldwide new sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/MOVANTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and specified licensed products), other than our product sales, substantially all of our revenues are non-cash royalty revenues. However, our collaborations with BMS and Lilly for the development of bempegaldesleukin and NKTR-358, respectively, provide for the most significant portion of our potential future development and regulatory milestone payments, as well as royalties from net sales of NKTR-358, if approved. Additionally, these collaboration partners provide significant financial support for the development and commercialization of these programs. BMS bears 67.5% of the costs of developing bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 35% of the costs of manufacturing bempegaldesleukin and 35% of the costs of joint commercialization. Lilly bears </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75% of the costs of Phase 2 development of NKTR-358, will bear 100% of the costs of Phase 3 development, subject to our right to contribute up to 25% of Phase 3 development costs on an indication-by-indication basis in exchange for higher royalties, if approved, and will be responsible for all costs of global commercialization, subject to our option to co-promote in the U.S. under certain conditions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Competition in the pharmaceutical and biotechnology industry is intense and characterized by aggressive research and development and rapidly-evolving science, technology, and standards of medical care throughout the world. We frequently compete with pharmaceutical companies and other institutions with greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Science and Technology Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We face intense science and technology competition from a multitude of technologies seeking to enhance the efficacy, safety and ease of use of approved drugs and new drug molecule candidates. A number of the drug candidates in our pipeline have direct and indirect competition from large pharmaceutical and biopharmaceutical companies. With our advanced polymer conjugate technologies, we believe we have competitive advantages relating to factors such as efficacy, safety, ease of use and cost for certain applications and molecules. We constantly monitor scientific and medical developments in order to improve our current technologies, seek licensing opportunities where appropriate, and determine the best applications for our technology platforms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the fields of advanced polymer conjugate technologies, our competitors include Biogen Idec Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories, Ltd., Mountain View Pharmaceuticals, Inc., SunBio Corporation, NOF Corporation, and Novo Nordisk A/S (assets formerly held by Neose Technologies, Inc.). Several other chemical, biotechnology and pharmaceutical companies may also be developing advanced polymer conjugate technology or technologies intended to deliver similar scientific and medical benefits. Some of these companies license intellectual property or PEGylation materials to other companies, while others apply the technology to create their own drug candidates.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product and Program Specific Competition</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bempegaldesleukin</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous companies engaged in developing immunotherapies to be used alone, or in combination, to treat a wide range of oncology indications targeting both solid and liquid tumors. In particular, we expect to compete in the cytokine-based therapies space with potential competitors including Alkermes PLC, Asher Biotherapeutics, Aulos Bioscience, Bright Peak Therapeutics, Cue Biopharma, Neoleukin, Sanofi SA (through its acquisition of Synthorx, Inc.), Synthekine, Inc., Werewolf Therapeutics, and Xilio Therapeutics.  We may also face competition from other therapeutic approaches including tumor infiltrating lymphocytes, or TILs, and chimeric antigen receptor-expressing T cells, or CAR-Ts. Potential competitors in the TIL and CAR-T space include Gilead (through its acquisition of Kite Pharma)/NCI, Apeiron Biologics, Philogen S.p.A., Brooklyn ImmunoTherapeutics LLC, Anaveon AG, Adaptimmune LLC, and Iovance Biotherapeutics, Inc. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NKTR-358</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;There are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease.&#160;In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC, Jassen Pharmaceuticals, AstraZeneca and Tizona Therapeutics), regulatory T cell therapies (Targazyme, Inc., Caladrius BioSciences, Inc., and Tract Therapeutics, Inc.), or IL-2 based therapies (Amgen, Inc., BMS (through its acquisition of Delnia, Inc.), GentiBio, Inc., ILTOO Pharma, Kyverna Therapeutics, Merck &amp; Co, through its acquisition of Pandion Therapeutics, and Sanofi SA, through its acquisition of Synthorx, Inc.).</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NKTR-255</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous companies engaged in developing immunotherapies with different approaches to enhancing NK cell populations which are a key component of the innate immune system. The approaches include engineered biologics </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">targeting the IL-15 pathway as well as autologous and allogenic cell therapy approaches. For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., nkarta therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.).</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our total research and development expenditures can be disaggregated into the following significant types of expenses (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third party and direct materials costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel, overhead and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation and depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a manufacturing facility located in Huntsville, Alabama that manufactures our proprietary PEG reagents for subsequent conjugation to active pharmaceutical ingredients (APIs). The facility is also used to produce APIs themselves, as well as PEG conjugates of those APIs, to support the early phases of clinical development of our drug candidates. The facility and associated equipment are designed and operated to be consistent with all applicable laws and regulations. As we do not maintain the capability to manufacture biologics nor finished drug products for our development programs, we primarily utilize contract manufacturers to manufacture biologics and finished drug product for us. We also utilize the services of contract manufacturers to manufacture APIs and finished drug products required for later phases of clinical development and eventual commercialization.  Our contract manufacturers have contractual obligations to comply with all applicable laws and regulations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We source drug starting materials for our manufacturing activities from one or more suppliers. For the drug starting materials necessary for our drug candidate development, we have agreements for the supply of such drug components with drug manufacturers or suppliers that we believe have sufficient capacity to meet our demands. However, from time to time, we source critical raw materials and services from one or a limited number of suppliers and there is a risk that if such supply or services were interrupted, it could materially harm our business. In addition, we typically order raw materials and services on a purchase order basis for early phase clinical development products and enter into long-term supply arrangements only for late stage products nearing regulatory approval for marketing authorization.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As a manufacturer of PEG reagents for the U.S.&#160;market, we are subject to inspections by the FDA and the U.S. Environmental Protection Agency for compliance with cGMP and other U.S.&#160;regulatory requirements, including U.S.&#160;federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We have incurred, and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. To our knowledge, we comply with all material governmental regulations applicable to our business.  We would be subject to significant penalties for failure to comply with these laws and regulations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2021, we had 740&#160;employees, of which 577&#160;employees were engaged in research and development, manufacturing, and quality activities and 163&#160;employees in general administrative and commercial operations function. Of the 740&#160;employees, 661 were located in the U.S. We have a number of employees who hold advanced degrees, such as a Ph.D. None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages. We are committed to attracting, developing, advancing and retaining a diverse and talented workforce. As part of our measures to attract and retain personnel, we offer a total rewards package to our full-time employees consisting of base salary, cash bonuses based on individual and company performance, equity compensation and comprehensive benefits, including health insurance, life insurance, retirement plans, and paid holiday and vacation time. We support our employee&#8217;s further development by providing professional development opportunities. We believe that we maintain good relations with our employees.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To complement our own expert professional staff, we utilize specialists in clinical development, regulatory affairs, pharmacovigilance, process engineering, manufacturing and quality assurance. These individuals include scientific advisors as well as independent consultants.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.nektar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information in, or that can be accessed through, our website is not part of this annual report on Form&#160;10-K. Our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q and current reports on Form&#160;8-K and amendments to those reports are available, free of charge, on or through our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities Exchange Commission (SEC). The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding our filings at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov.</span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION ABOUT OUR EXECUTIVE OFFICERS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table sets forth the names, ages and positions of our executive officers as of February&#160;28, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Age</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Position</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Howard W. Robin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, President and Chief Executive Officer</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gil M. Labrucherie, J.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Operating Officer and Chief Financial Officer </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Northcott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Commercial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jillian B. Thomsen</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Finance and Chief Accounting Officer</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark A. Wilson, J.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and General Counsel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan Zalevsky, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Research and Development Officer</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Howard W. Robin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our President and Chief Executive Officer since January 2007 and has served as a member of our board of directors since February 2007. Mr.&#160;Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr.&#160;Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (Berlex), a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer of Berlex. From 1984 to 1987, Mr.&#160;Robin was Director</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen&#160;&amp; Co. prior to joining Berlex. Mr.&#160;Robin serves as a director of the Biotechnology Industry Organization, the world&#8217;s largest biotechnology industry trade organization, and also serves as a director of BayBio, a non-profit trade association serving the Northern California life sciences community. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Gil M. Labrucherie </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Senior Vice President, Chief Financial Officer since June 2016, and added the role of Chief Operating Officer in October 2019. Mr.&#160;Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007 and served as our Senior Vice President, General Counsel and Secretary from April 2007 through June 2016 when he was promoted to Senior Vice President and Chief Financial Officer. From October 2000 to September 2005, Mr.&#160;Labrucherie was Vice President of Corporate Development at E2open, a platform enterprise software as a service company. While at E2open, Mr.&#160;Labrucherie was responsible for global corporate alliances and merger and acquisitions. Mr.&#160;Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. Mr.&#160;Labrucherie received his J.D. from the Berkeley Law School and his B.A. from the University of California Davis.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">John Northcott</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Senior Vice President and Chief Commercial Officer since December 2019. From 2015 to 2019, Mr. Northcott served as the Chief Commercial Officer of Pharmacyclics. From 2013 to 2015, Mr. Northcott was Chief Commercial Officer at Lexicon Pharmaceuticals. He has held commercial roles from 2007 to 2013 in both U.S. and Global marketing with Genentech and the Roche Group, including the role of International Business Leader. Prior to Roche/Genentech, Mr. Northcott held management positions in sales and marketing in a variety of therapeutic areas at other pharmaceutical companies including Merck and Pfizer. Mr. Northcott received a bachelor&#8217;s degree in Business Administration from St. Francis Xavier University.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Jillian B. Thomsen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Senior Vice President, Finance and Chief Accounting Officer since February 2010. From March 2006 through March 2008, Ms.&#160;Thomsen served as our Vice President Finance and Corporate Controller and from April 2008 through January 2010 she served as our Vice President Finance and Chief Accounting Officer. Before joining Nektar, Ms.&#160;Thomsen was Vice President Finance and Deputy Corporate Controller of Calpine Corporation from September </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2002 to February 2006. Ms.&#160;Thomsen began her career as a certified public accountant at Arthur Andersen LLP, where she worked from 1990 to 2002, and specialized in audits of multinational consumer products, life sciences, manufacturing and energy companies. Ms.&#160;Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mark A. Wilson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Senior Vice President and General Counsel since June 2016. Mr. Wilson joined Nektar in May 2002 and initially served as Patent Counsel and then as Senior Patent Counsel to the company prior to 2008 when he was promoted to Vice President, Intellectual Property. Before joining Nektar in 2002, Mr. Wilson was an associate at Reed &amp; Associates, a patent law firm in Menlo Park, California, where he represented both start-up and Fortune 500 companies. Mr. Wilson received his J.D. from Seton Hall University, School of Law, and his B.S. in Pharmacy from Rutgers University, College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the California Bar.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jonathan Zalevsky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Chief Research &amp; Development Officer since October 2019. Dr. Zalevsky served as our Senior Vice President, Biology and Preclinical Development from April 2017 through November 2017 and served as our Senior Vice President, Research and Chief Science Officer from November 2017 to October 2019. From July 2015 through April 2017, Dr. Zalevsky served as our Vice President, Biology and Preclinical Development. Prior to joining Nektar, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. Prior to working at Takeda, Dr. Zalevsky held a number of research and development positions at Xencor, Inc. Dr. Zalevsky received his Ph.D. in Biochemistry from the Tetrad Program at the University of California, San Francisco. He received dual bachelor degrees in Biochemistry and Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the success of bempegaldesleukin, our lead I-O candidate.&#160;We are executing a clinical development program for bempegaldesleukin and clinical and regulatory outcomes for bempegaldesleukin, if not successful, will significantly harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is highly dependent on our ability to successfully develop, obtain regulatory approval for, and commercialize bempegaldesleukin. In general, most investigational drugs, including I-O drug candidates such as bempegaldesleukin, do not become approved drugs. Accordingly, there is a very meaningful risk that bempegaldesleukin will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals.&#160;To date, reported clinical outcomes from bempegaldesleukin have had a significant impact on our market valuation, and business prospects and we expect this to continue in future periods.&#160;If one or more clinical studies of bempegaldesleukin are delayed (as a result of, for example, our collaboration partner causing a delay of the initiation or completion of one or more clinical trials for reasons outside of our control) or not successful, it would materially harm our market valuation, prospects, financial condition and results of operations.&#160;For example, under the BMS Collaboration Agreement, we are entitled to up to approximately $1.455 billion in development milestone payments (of which we have received $50.0 million) that are based upon clinical and regulatory successes from the bempegaldesleukin development program. One or more failures in bempegaldesleukin studies could jeopardize such milestone payments, and any product sales or royalty revenue or commercial milestone payments that we would otherwise be entitled to receive could be reduced, delayed or eliminated.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, promising results from earlier trials may not predict similarly favorable outcomes in subsequent trials. For example, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational drug candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational drug candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our drug candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may experience delays in clinical trials of drug candidates. We have ongoing trials evaluating bempegaldesleukin, including trials evaluating bempegaldesleukin as a potential combination treatment with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as other ongoing and planned combination trials. Our partner Lilly is conducting two Phase 2 studies of NKTR-358 in patients with SLE and ulcerative colitis as well as two Phase 1b studies in patients with psoriasis and atopic dermatitis. We also continue to conduct a Phase 1/2 study evaluating bempegaldesleukin in combination with NKTR-262 in patients with solid tumors.&#160;&#160;In addition, we have initiated a Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. These and other clinical studies may not begin on time, enroll a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our drug candidates could be delayed for a variety of reasons, including:</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in obtaining regulatory authorization to commence a clinical study;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching agreement with applicable regulatory authorities on a clinical study design;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">for drug candidates (such as bempegaldesleukin and NKTR-358) partnered with other companies, delays caused by our partner; </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by the COVID-19 pandemic (see also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in recruiting suitable patients to participate in a trial;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites dropping out of a trial due to the detriment of enrollment rates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in manufacturing and delivery of sufficient supply of clinical trial materials;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory authorities policies or guidance applicable to our drug candidates; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays caused by changing standards of care or new treatment options.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, results for the studies would be delayed, and consequently the regulatory approval process would be delayed which would also delay our ability to commercialize these drug candidates, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies, could have a material and adverse impact on the value of our I-O research and development pipeline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development of I-O therapies is a very competitive global segment in the biopharmaceutical industry attracting tens of billions of dollars of investment each year.&#160; Our clinical trial plans for bempegaldesleukin, NKTR-262, and NKTR-255 face substantial competition from other I-O combination regimens already approved, and many more combination therapies that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As I-O combination therapies are relatively new approaches in cancer treatment and few have successfully completed late stage development, I-O drug development entails substantial risks and uncertainties that include rapidly changing standards of care, identifying contribution of component therapies, patient enrollment competition, evolving regulatory frameworks to evaluate combination regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of I-O drug candidates.&#160;</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The risk of clinical failure for any drug candidate remains high prior to regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a drug candidate may not predict the results that will be obtained in later phase clinical trials of the drug candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a drug candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary drugs and drug candidates could make our technologies, drugs or drug candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and drug candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories Ltd., SunBio Corporation, Laysan Bio, Inc., Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many competitors for our drug candidates currently in development. For bempegaldesleukin, there are numerous companies engaged in developing immunotherapies to be used alone, or in combination, to treat a wide range of oncology indications targeting both solid and liquid tumors. In particular, we expect to compete with therapies with tumor infiltrating lymphocytes, or TILS, chimeric antigen receptor-expressing T cells, or CAR-T, cytokine-based therapies, and checkpoint inhibitors. Potential competitors in the TIL and CAR-T space include Gilead Sciences, Inc. (through its acquisition of Kite Pharma, Inc.)/NCI, Apeiron Biologics, Philogen S.p.A., Brooklyn ImmunoTherapeutics LLC, Anaveon AG, Adaptimmune LLC, and Novartis AG; potential competitors in the cytokine-based therapies space include Alkermes PLC, Asher Biotherapeutics, Aulos Bioscience, Bright Peak Therapeutics, Cue Biopharma, ImmunityBio, Inc., Neoleukin Therapeutics, Inc., Philogen S.p.A., Roche, Sanofi SA (through its acquisition of Synthorx, Inc.), Synthekine, Inc., Werewolf Therapeutics, and Xilio Therapeutics, and Eli Lilly &amp; Co. (through its acquisition of Armo BioSciences); and potential competitors in the checkpoint inhibitor space include GlaxoSmithKline plc (through its acquisition of Tesaro, Inc.), Macrogenics, Inc., Merck, Bristol-Myers Squibb Company, and Roche. For NKTR-358, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC, Janssen, AstraZeneca, and Tizona Therapeutics), regulatory T cell therapies (Targazyme, Inc., Caladrius BioSciences, Inc., and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc., Celgene Corporation, GentiBio, Inc., ILTOO Pharma, Kyverna Therapeutics, Merck &amp; Co, through its acquisition of Pandion Therapeutics, and Roche). For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., nkarta therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.). There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies uncompetitive or obsolete.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Collaboration Partners </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our collaboration partners to initiate, properly conduct and prioritize clinical trials for bempegaldesleukin and NKTR-358 and to perform important additional development and commercialization activities, and our business will be significantly harmed if their actions deprioritize or otherwise harm the prospects of our drug candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on BMS (through the BMS Collaboration Agreement) and Lilly (through the Lilly Agreement) to initiate, properly conduct, and prioritize clinical trials and other development-related activities for bempegaldesleukin and NKTR-358, respectively.  Furthermore, we will rely on BMS and Lilly to perform specified commercialization activities for bempegaldesleukin and NKTR-358, respectively, pursuant to the applicable agreement. In the event BMS or Lilly fails to initiate, properly conduct and prioritize their obligations under their applicable agreement with us, our business will be significantly harmed.  Even if the applicable agreement provides us with enforcement or other curative rights to address the harm caused by BMS&#8217;s or Lilly&#8217;s action (or failure to act), our efforts in pursuing a remedy would be costly and there is no guarantee that efforts would succeed or be sufficient to fully address the harm.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for reasons outside of our control, the operations of our collaboration partners may be affected by the COVID-19 pandemic, or they may adopt more restrictive procedures for addressing the COVID-19 pandemic, either of which would delay initiating or completing one or more clinical trials involving our drug candidates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirement</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreements with various pharmaceutical or biotechnology companies (other than Nektar-run trials under the BMS Collaboration Agreement), our collaboration partner is generally solely responsible for:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">designing and conducting large scale clinical studies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">marketing and selling the drugs when and if they are approved.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaboration partners with commercial rights may choose to devote fewer resources to the marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of drug candidates or to litigation or arbitration proceedings;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may be unable to pay us as expected;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners may respond to natural disasters or health epidemics, such as the COVID-19 pandemic, by ceasing all or some of their development responsibilities (including the responsibility to clinical develop our drug candidates).</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly impair our access to capital necessary to fund our research and development efforts for our drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantial future capital requirements and there is a risk that we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had cash and investments in marketable securities valued at approximately $798.8 million. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, timing and outcomes of clinical studies and regulatory reviews of our drug candidates, particularly bempegaldesleukin and NKTR-358;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing, cost and results of our clinical development programs;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our general and administrative expenses, capital expenditures and other uses of cash; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes concerning patents, proprietary rights, or license and collaboration agreements that could negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue to advance our drug candidates to later stage research and development, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is very difficult to estimate the commercial potential of drug candidates due to important factors such as safety and efficacy compared to other available treatments, including changing standards of care, third party payer reimbursement standards, patient and physician preferences, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic and biosimilar versions of our drug candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We also depend on our relationships with other companies for sales and marketing performance and the commercialization of drug candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If government and private insurance programs do not provide payment or reimbursement for our partnered drug or proprietary drugs, those drugs will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and markets in other countries, patients generally rely on third-party payers to reimburse all or part of the costs associated with their treatment. In both domestic and foreign markets, sales of our partnered and proprietary products that receive regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid in the U.S., managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a biologic candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. Further, due to the COVID-19 pandemic, millions of individuals have lost or will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our biologic candidates even if there is adequate coverage and reimbursement from third-party payers. It is unclear what effect, if any, the American Rescue Plan Act will have on the number of covered individuals. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payers tend to follow CMS to a substantial degree. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors payers consider in determining reimbursement are based on whether the product is (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational. In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent federal legislation and actions by federal, state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face competition in the United States for our development candidates and investigational medicines, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act (MMA) contains provisions that call for the promulgation of regulations that expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these changes to U.S. importation laws will not take effect, unless and until the U.S. Secretary of Health and Human Services (HHS) certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September 23, 2020, the U.S. Secretary of HHS made such certification to Congress, and on October 1, 2020, FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the issuance of the final rule, several industry groups have filed federal lawsuits challenging multiple aspects of the final rule, and authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. On September 25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future biologic candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is exclusively derived from our collaboration agreements, from which we receive upfront fees, research and development reimbursement and funding, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any biologic candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, we reported a net loss of $523.8 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestones and other contingent payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our biologic candidates and the regulatory approval and market success of our biologic candidates. We may not be able to achieve and sustain profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for bempegaldesleukin, NKTR-358, NKTR-262, and NKTR-255;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive necessary regulatory and marketing approvals;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain or expand manufacturing at necessary levels;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achieve market acceptance of our partnered products;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receive revenue or royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain sufficient funds to finance our activities.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-top:18pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business could be adversely affected, directly or indirectly, by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, including both our own manufacturing operations as well as the manufacturing operations of third parties upon whom we rely. With respect to the ongoing COVID-19 pandemic, national, state and local governments in regions affected by the COVID-19 pandemic have implemented, and may continue to implement or reinstate safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter-in-place orders and shutdowns, business closures and other measures.  These measures may disrupt normal business operations both in and outside areas affected by COVID-19, and may have significant negative impacts on our business. Even as these safety precautions are eased or reduced over time, there may be long lasting effects of these precautions on our business that may only be fully realized in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Throughout the pandemic we have modified our office policies to maintain productivity and safety of our employees. Although we believe these and the other safety measures we have taken in response to the COVID-19 pandemic have not substantially impacted our productivity, it is not certain that this will continue to be the case. Operating requirements may continually change due to the COVID-19 pandemic and we may experience unpredictability in our expenses, employee productivity and availability and employee work culture. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Certain of our clinical trials have been and may continue to be affected by the COVID-19 pandemic. Investigator recruitment, clinical site initiation, patient screening and patient enrollment may be delayed due to, for example, prioritization of hospital resources toward the COVID-19 pandemic. Some patients who are successfully enrolled in clinical trials involving our biologic candidates may not be able to comply with clinical trial protocols due to, for example, shelter-in-place orders impeding movement, disrupted healthcare services, or health issues for suspected or confirmed COVID-19 status. Similarly, our ability to recruit and retain patients and principal investigators and site staff, all of whom may have heightened risk for COVID-19, could adversely impact our clinical trial operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Delays and disruptions experienced by our collaborators or other third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect clinical development or regulatory approvals of our biologic candidates. For example, due to recent supply chain disruptions, we have been monitoring our supply chains for any disruptions or constraints caused by the COVID-19 pandemic. To date, we have not experienced any supply impact. However, if we, our collaborators or any third parties which we rely on are adversely effected by any supply disruptions or shortages in raw materials and equipment caused by the COVID-19 pandemic, our ability to manufacture our products and to supply drug candidates for our clinical trials could be negatively impacted, which could harm our business prospects, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Although we are implementing measures to maintain the integrity of our clinical trials, there is no guarantee that we will prevent all study protocol violations, missed study treatment visits, and other influences that jeopardize reliability and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">validity of our clinical trial data. If a regulatory authority determines our clinical trial data lacks integrity, there is no guarantee that we will have a remedy to correct or otherwise address the deficiency. Even if such a remedy is identified, the cost for implementing the remedy could be prohibitively expensive, time consuming, or both. As a consequence, a clinical study of our biologic candidate in which the integrity of the clinical study is questioned or doubted may require lengthy and costly remediation measures (such as, for example, over-enrolling patients into the study or repeating the study), thereby causing substantial harm to our business.  </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also, the COVID-19 pandemic could postpone necessary interactions with regulators regarding our drug candidates in development and could delay review or approval of our regulatory submissions. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The rapid development and fluidity of the COVID-19 pandemic results in a substantial number of individual variables that could cause a significant negative impact on our operations and our business, thereby precluding useful predictions as to how this pandemic will ultimately affect us. In particular, it is unclear how our business may be affected by the emergence of new variants of the coronavirus, such as the Delta and Omicron variants, and recent resurgences in number and rates of COVID-19 infections. Thus, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our clinical trial timelines, is subject to change. We do not yet know the full extent of potential impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material negative impact on our operations and our business. Furthermore, to the extent the ongoing COVID-19 pandemic adversely affects our operations and business, it may also heighten the other risks described in this &#8220;Risk Factors&#8221; section. </span></div><div style="margin-top:10pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Supply and Manufacturing</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our contract manufacturers are not able to manufacture biologic substance or substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our contract manufacturing organizations (CMOs) are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#8217; clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#8217; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on CMOs to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of biologics involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. These risks and uncertainties are compounded by the COVID-19 pandemic wherein the facilities and employees responsible for manufacturing biologics for use in clinical trials may be negatively impacted such that there is an insufficient supply of study biologic drugs. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party CMOs required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our CMOs to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act)  in response to the COVID-19 pandemic. Throughout the COVID-19 outbreak, there has been public concern over the availability and accessibility of critical medical products, and the CARES Act enhances FDA&#8217;s existing authority with respect to drug shortage measures. Under the CARES Act, we must have in place a risk management plan that identifies and evaluates the risks to the supply of approved drugs for certain serious diseases or conditions for each establishment where the drug or API is manufactured. The risk management plan will be subject to FDA review during an inspection. If we experience shortages in the supply of our marketed products, our results could be materially impacted.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or biologic candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product according to the specifications previously submitted to or approved by the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop biologic candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our biologic candidate that such CMO owns independently. This would increase our reliance on such a CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our products or biologic candidates. In addition, in the case of the CMOs that supply our biologic candidates, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We purchase some of the starting material for biologics and biologic candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply, diminution in quality of raw materials supplied to us or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CMOs are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our CMOs for compliance with applicable regulatory requirements. Any failure to follow and document our or our CMOs&#8217; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our CMOs, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Business Operations</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to create robust sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our biologic candidates successfully.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are in the very early stages of building commercialization and distribution capabilities for bempegaldesleukin in the United States and Europe. To commercialize any of our biologic candidates that receive regulatory approval for commercialization, we must develop robust internal sales, marketing and distribution capabilities, and manage inventory, supply, labeling, storage, record keeping, and advertising and promotion capabilities, which is both</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expensive and time consuming, or enter into arrangements with third parties to perform these services. For example, we have committed to co-commercialize bempegaldesleukin with BMS and establish global distribution and infrastructure for us to be able to book global revenue for bempegaldesleukin if it achieves regulatory approval. Establishing this commercialization capability requires a significant commitment of financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution, administration and compliance capabilities. Factors that may inhibit our efforts to commercialize our products directly or through partnerships include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our inability to recruit and retain management talent to lead key marketing and distribution roles;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inability of sales personnel and medical science liaisons to obtain access to or successfully educate adequate numbers of physicians about the potential benefits associated with the use of, and to subsequently prescribe, our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the lack of complementary products or multiple product pricing arrangements may put us at a competitive disadvantage relative to companies with more extensive product lines; and unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third parties to conduct the clinical trials for our biologic candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our biologic candidates. We rely heavily on these parties for the successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our biologic candidates to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical trials could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to manage our growth effectively, which could adversely affect our operations and financial performance.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability to manage and operate our business as we execute our development and growth strategy will require effective planning and execution. Significant rapid growth could strain our management and internal resources, and other problems may arise that could adversely affect our financial performance. We expect that our efforts to grow will place a significant strain on personnel, management systems, infrastructure and other resources. Our ability to effectively manage future growth will also require us to successfully attract, train, motivate, retain and manage new employees and continue to update and improve our operational, financial and management controls and procedures. If we do not manage our growth effectively, our operations and financial performance could be adversely affected.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future depends on the proper management of our current and future business operations and their associated expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy requires us to manage our business to provide for the continued development and potential commercialization of our proprietary and partnered biologic candidates. Our strategy also calls for us to undertake increased research and development activities and establish a commercial organization in collaboration with our partners, while simultaneously managing the capital necessary to support this strategy. If we are unable to manage effectively our current operations and any growth we may experience, our business, financial condition and results of operations may be adversely </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other dilutive financing arrangements on unfavorable terms.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we rely on other pharmaceutical or biotechnology companies with established sales, marketing and distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenue we receive will depend upon the efforts of third parties, which may not be successful and over which we have little or no control. In the event that we market our products without a partner, we would be required to build, either internally or through third-party contracts, a sales and marketing organization and infrastructure, which would require a significant investment, and we may not be successful in building this organization and infrastructure in a timely or efficient manner. We would also incur substantial costs in building such capabilities before receiving regulatory approval of our products, which would have an adverse effect on our financial condition if our products are not ultimately approved.  </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must attract and retain experts in the areas of research, development (including clinical testing), manufacturing, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Intellectual Property, Litigation and Regulatory Concerns</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to biologic candidates granted Breakthrough Therapy designation by the FDA.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to evaluate and continue ongoing discussions with the FDA on regulatory strategies that could enable us to take advantage of expedited development pathways for certain of our biologic candidates, although we cannot be certain that our biologic candidates will qualify for any expedited development pathways or that regulatory authorities will grant, or allow us to maintain, the relevant qualifying designations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakthrough Therapy designation is intended to expedite the development and review of biologic candidates that are designed to treat serious or life-threatening diseases when preliminary clinical evidence indicates that the biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a biologic candidate as a Breakthrough Therapy provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the biologic candidate and ensure collection of appropriate data needed to support approval; more frequent written correspondence from FDA about such things as the design of the proposed clinical trials and use of biomarkers; intensive guidance on an efficient drug development program, beginning as early as Phase 1; organizational commitment involving senior managers; and eligibility for rolling review and priority review.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received Breakthrough Therapy designation for the treatment of patients with previously untreated unresectable or metastatic melanoma, we may elect not to pursue Breakthrough Therapy designation for our other biologic candidates, and the FDA has broad discretion whether or not to grant these designations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, even if we believe a particular biologic candidate is eligible for Breakthrough Therapy, we cannot be assured that the FDA would decide to grant it. Breakthrough Therapy designation does not change the standards for biologic approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the Breakthrough Therapy designation. Thus, even though we have received Breakthrough Therapy designation for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we may not experience a faster development process or review, and, upon any filing seeking regulatory approval, we may not obtain an approval from the FDA for bempegaldesleukin or any of our other biologic candidates.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners do not obtain regulatory approval for our biologic candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may not obtain regulatory approval for biologic candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Biologic candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. For example, although the FDA granted a Breakthrough Therapy designation to bempegaldesleukin in combination with Opdivo&#174; for the treatment of patients with previously untreated unresectable or metastatic melanoma, there is no guarantee regulatory approval will follow, if at all, for this or any indication of bempegaldesleukin on a timely basis. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a biologic candidate. In addition, undesirable side effects caused by our biologic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. For example, AstraZeneca is&#160;conducting a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to other treatments of opioid-induced constipation in patients with chronic, non-cancer pain and the results of this study could at some point in the future negatively impact the labeling, regulatory status, and commercial potential of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which could reduce our future royalties from sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of drug candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partner&#8217;s performance;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered biologic candidate development programs;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">indemnity obligations for intellectual property infringement, product liability and certain other claims.</span></div><div style="margin-top:19pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g., financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, we could be subject to substantial liabilities, which would harm our financial condition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property licenses related to the development of our biologic candidates on a commercially reasonable basis, if at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent rights will be considered relevant to our or our collaboration partners&#8217; technology or biologic candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the sufficiency of the scope and adequacy of these licenses is very uncertain in view of the long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology to avoid a need to secure a license. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the biologic, which could significantly harm our business, results of operations, and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 310 U.S. and 1,200 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to opposition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, re-examinations or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expire prior to the commercialization of the biologic. Moreover, even if a patent encompassing a biologic has not expired prior to the biologic's commercialization, the patent may only provide a short period of protection following the commercialization of products.&#160; In addition, our patents may be subject to post grant proceedings, such as or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examinations, before the U.S. Patent and Trademark Office (or equivalent proceedings in other jurisdictions), which could result in a loss of the patent and/or substantial cost to us.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our biologic candidates.&#160;There can be no assurance that the patent applications for which we apply will actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&#160;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.&#160;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&#160;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secret protection and other unpatented proprietary rights for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our biologic candidates, if approved, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any biologic candidates for which we obtain marketing approval. Our future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. On December 2, 2020, the Office of Inspector General, or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OIG, published further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. This rule (with exceptions) became effective January 19, 2021. Implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and pharmacy benefit manager service fees are currently under review by the Biden administration and may be amended or repealed. We continue to evaluate what effect, if any, the rule will have on our business;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the U.S. federal False Claims Act (FCA), which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payers if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery; </span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provisions of the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes, referred to as the &#8220;HIPAA All-Payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website, effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician assistants and nurse practitioners;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information, and also includes the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there  may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">additionally, state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts. These state-equivalent laws may also apply to our business practices, including, but not limited to, research, distribution, and sales or marketing arrangements. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to penalties, including administrative, civil or criminal penalties, imprisonment, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions to the normal functioning of the FDA and other government agencies could hinder their ability to perform and carry out important roles and activities on which the operation of our business relies, which could negatively impact our business. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable.  Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold due to the COVID-19 pandemic, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. In April 2021, the FDA issued guidance for industry formally announcing plans to employ remote interactive evaluations, suing risk management methods, to meet user fee commitments and goal dates.  Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be appropriate,</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> FDA has stated that it generally intends to issue a complete response letter.  Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. Additionally, as of June 23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals. On July 16, 2020, the FDA noted that it is continuing to expedite oncology product development with its staff teleworking full-time. However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions the FDA is unable to complete such required inspections during the review period. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future shutdowns of other government agencies, such as the SEC, may also impact our business through review of our public filings and our ability to access the public markets.</span></div><div style="padding-left:36pt;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;affect our business, financial condition and results of operations.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies. Third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or biologic candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. For example, we are involved in ongoing litigation with Aether Therapeutics Inc., who in March 2020 filed a complaint against AstraZeneca, Nektar and Daiichi-Sanko, Inc. alleging that MOVANTIK&#174; infringes U.S. Patent Nos. 6,713,488, 8,748,448, 8,883,817 and 9,061,024. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. We are also regularly involved in opposition proceedings at the European Patent Office and in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and re-examination proceedings at the U.S. Patent and Trademark Office where third parties </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our biologic candidates and platform technologies.  If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain biologics or biologic candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, we are involved in legal proceedings other than those related to intellectual property.  In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018,  about clinical trials of bempegaldesleukin.  In December 2020, the court dismissed the action with prejudice.  The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument was held on December 10, 2021. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, a derivative action was filed against certain of the Company's current and former officers and directors in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF) alleging that the Company's officers and directors breached their fiduciary duties by exposing the Company to securities actions. The parties agreed to stay further proceedings in this action until thirty days after the U.S. Court of Appeal for the Ninth Circuit&#8217;s final resolution of the appeal in the Mulquin action.  </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties. There is no guarantee that our insurance coverage for damages resulting from a litigation or the settlement thereof (including the Mulquin action and related shareholder derivative lawsuit) is sufficient, thereby resulting in substantial financial risk to the Company.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of lawsuits and complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses for any of the legal proceedings we are currently involved in. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at December&#160;31, 2021.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found in violation of privacy and data protection laws, we may be required to pay penalties, be subjected to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to many laws and regulations intended to protect the privacy and data of individuals participating in our clinical trials and our employees, among others. For example, with regard to individuals participating in our clinical trials, these laws and regulations govern the safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. In addition to federal laws and regulations in the United States, such as the HIPAA requirements relating to the privacy, security and transmission of individually identifiable health information, many state and foreign laws also govern the privacy and security of health information. These laws often differ from each other in significant ways, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has increased our compliance costs and may increase our potential liability. The CCPA has prompted a number of proposals for new federal and state privacy legislation. If passed, these proposals could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), and the implementing legislation of EU Member States, which became effective on May 25, 2018, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU. The GDPR is wide-ranging in scope and imposes strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to, for example, (i) </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, and (iii) ensuring the security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20 million or 4% of annual global revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are found liable for the inappropriate collection, storage, use or disclosure of protected information of individuals (such as employees and or clinical patients protected by any privacy or data protection law), we could be subject to reputational harm, monetary fines (such as those imposed by the GDPR and CCPA), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and the development of our biologic candidates could be delayed. In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-top:18pt;padding-left:18pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a research-based biopharmaceutical company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations (including, but not limited to, the handling and disposal of both our hazardous and non-hazardous waste)</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Investment and Securities</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;losses for investors and securities class action and shareholder derivative litigation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. During the year ended December 31, 2021, based on closing prices on the NASDAQ Global Select Market, the closing price of our common stock ranged from $10.83 to $25.46 per share. In response to volatility in the price of our common stock in the past, plaintiffs&#8217; securities litigation firms have sought information from us and/or shareholders as part of their investigation into alleged securities violations and breaches of duties (among other corporate misconduct allegations). Following their investigations, plaintiffs&#8217; securities litigation firms have often initiated legal action, including the filing of class action lawsuits, derivative lawsuits, and other forms of redress. We expect our stock price to remain volatile and we continue to expect the initiation of legal actions by plaintiffs&#8217; securities litigation firms following share price fluctuations. A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch &#8211; in particular, data from clinical studies of bempegaldesleukin has had a significant impact on our stock price;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of outcomes from our clinical trials which can be difficult to predict particularly for clinical studies that have event-driven end points such as progression-free survival and overall survival;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by collaboration partners as to their plans or expectations related to biologic candidates and approved biologics in which we have a substantial economic interest;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding terminations or disputes under our collaboration agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our results of operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products that may compete with our approved partnered products or products under development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of changes in governmental regulation affecting us or our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation brought against us or third parties to whom we have indemnification obligations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of drug formulations developed by us or others;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financing needs and activities; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a classified board of directors such that not all members of the board may be elected at one time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board to authorize the issuance of &#8220;blank check&#8221; preferred stock to increase the number of outstanding shares and thwart a takeover attempt;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on who may call a special meeting of stockholders.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We significantly rely on information technology systems, and any failure, inadequacy, interruption, breach, or security lapse of that technology within our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may result in a material disruption of our development programs and our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our business, we collect, store and transmit large amounts of confidential information, proprietary data, intellectual property and personal data. Despite the implementation of security measures, our internal computer systems and those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to loss, damage, denial-of-service, unauthorized access, or misappropriation. Such cybersecurity breaches may be the result of unauthorized activity by our employees and contractors, as well as by third parties who use cyberattack techniques involving malware, hacking and phishing, among others. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of an increase in the number of employees adopting a remote working environment during the COVID-19 pandemic, which may be less secure and more susceptible to hacking attacks. Our information technology systems, and those of our partners, vendors, CROs, CMOs or other contractors or consultants are also vulnerable to natural disasters, terrorism, war and telecommunication and electrical failures. Any such compromise or disruption, no matter the origin, may cause an interruption of our operations. For instance, the loss of preclinical data or data from any clinical trial involving our biologic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, the loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information could compromise the commercial viability of one or more of our programs, which would negatively affect our business. Also, the costs to us to investigate and mitigate cybersecurity incidents could be significant.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. In the U.S., the rules dealing with federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retroactive application) could adversely affect us or holders of our common stock. In recent years, such changes have been made and changes are likely to continue to occur in the future. For example, on March 27, 2020, the CARES Act was signed into law and included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 pandemic, including temporary changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the EU may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 31, 2020, the U.K. ceased to be a member state of the EU, a process known as Brexit, and began a transition period, which expired on December 31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the U.K. and the EU agreed on a trade and cooperation agreement, under which the EU and the U.K. will now form two separate markets governed by two distinct regulatory and legal regimes. The trade and cooperation agreement covers the general objectives and framework of the relationship between the U.K. and the EU, including as it relates to trade, transport and visas. Under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the EU. Depending on the application of the terms of the trade and cooperation agreement, we, our collaboration partners and others could face new regulatory costs and challenges.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global economic and political conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance have been, and may continue to be, affected by global economic conditions, including, for example, adverse global economic conditions resulting from the COVID-19 pandemic. See also the risk factor in this Item 1A titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; In addition, our operations and performance may be affected by political or civil unrest or military action, including the current conflict between Russia and Ukraine, terrorist activity, unstable governments and legal systems. As a result of global economic conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. Our ability to conduct clinical trials in regions experiencing political or civil unrest could negatively affect clinical trial enrollment or the timely completion of a clinical trial. We believe the aforementioned economic conditions have led and could continue to lead to reduced demand for our and our collaboration partners&#8217; drug products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with rising international trade tensions or sanctions, our business may be adversely affected following new or increased tariffs that result in increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partners&#8217; drug products, affect our and our collaboration partners&#8217; ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by corporate citizenship and&#160;sustainability&#160;matters.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increased focus from certain investors, employees, and other stakeholders concerning corporate citizenship and&#160;sustainability&#160;matters, which include environmental concerns and social investments. We could fail to meet, or be perceived to fail to meet, the expectations of these certain investors, employees and other stakeholders concerning corporate citizenship and sustainability matters, thereby resulting in a negative impact to our business. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If earthquakes or other catastrophic events strike, our business may be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama and own and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, or terrorist event in any of these locations, our ability to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture and supply materials for biologic candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaboration partners and important vendors and suppliers to us or our collaboration partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes, tornadoes and pandemics any of which could harm our business (including, for example, by disrupting supply chains important to the success of our business), results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_25"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.  Unresolved Staff Comments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_28"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.  Properties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">California</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We lease a 155,215 square foot facility in the Mission Bay Area of San&#160;Francisco, California (Mission Bay Facility), under an operating lease which expires in 2030. The Mission Bay Facility is our corporate headquarters and also includes our research and development operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We also lease 135,936 square feet of office space in San Francisco (the Third Street Facility), under an operating lease which expires in 2030. The Third Street Facility provides additional space to support our research and development activities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alabama</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We currently own a facility consisting of approximately 124,000 square feet in Huntsville, Alabama, which houses laboratories as well as administrative, clinical and commercial manufacturing facilities for our PEGylation and advanced polymer conjugate technology operations as well as manufacturing of APIs for early clinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">India</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We own a research and development facility consisting of approximately 88,000&#160;square feet, near Hyderabad, India. In addition, we lease approximately 1,600&#160;square feet of office space in Hyderabad, India, under a three-year operating lease that will expire in 2024.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_31"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.  Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, we are subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. With respect to ongoing securities class action and shareholder derivative litigation, please refer to Note 9 to our Consolidated Financial Statements and Item 1A. Risk Factors, including without limitation, &#8220;We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.&#8221;</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_34"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.  Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_40"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.  Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our common stock trades on The NASDAQ Global Select Market under the symbol &#8220;NKTR.&#8221; </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of February&#160;23, 2022, there were approximately 153 holders of record of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have never declared or paid any cash dividends on our common stock. We currently expect to retain any future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There were no sales of unregistered securities and there were no common stock repurchases made during the year ended December&#160;31, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding our equity compensation plans as of December&#160;31, 2021 is disclosed in Item&#160;12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; of this Annual Report on Form&#160;10-K and is incorporated herein by reference from our proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC pursuant to Regulation&#160;14A not later than 120&#160;days after the end of the fiscal year covered by this Annual Report on Form&#160;10-K.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Measurement Comparison</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The material in this section is being furnished and shall not be deemed &#8220;filed&#8221; with the SEC for purposes of Section&#160;18 of the Exchange Act or otherwise subject to the liability of that section, nor shall the material in this section be deemed to be incorporated by reference in any registration statement or other document filed with the SEC under the Securities Act or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following graph compares, for the five year period ended December&#160;31, 2021, the cumulative total stockholder return (change in stock price plus reinvested dividends) of our common stock with (i)&#160;the NASDAQ Composite Index, (ii)&#160;the NASDAQ Pharmaceutical Index, (iii)&#160;the RDG SmallCap Pharmaceutical Index, (iv)&#160;the NASDAQ Biotechnology Index and (v)&#160;the RDG SmallCap Biotechnology Index. Measurement points are the last trading day of each of our fiscal years ended December&#160;31, 2017, December&#160;31, 2018, December&#160;31, 2019, December&#160;31, 2020 and December&#160;31, 2021. The graph assumes that $100 was invested on December&#160;31, 2016 in the common stock of the Company, the NASDAQ Composite Index, the Nasdaq Pharmaceutical Index, the RDG SmallCap Pharmaceutical Index, the NASDAQ Biotechnology Index and the RDG SmallCap Biotechnology Index and assumes reinvestment of any dividends. The stock price performance in the graph is not intended to forecast or indicate future stock price performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><img src="nktr-20211231_g1.jpg" alt="nktr-20211231_g1.jpg" style="height:568px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div id="i1023926dfc3b4cff924b0207eb081f42_43"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.  Reserved</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_46"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8.8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this section as well as factors described in &#8220;Part&#160;I, Item&#160;1A&#160;&#8212; Risk Factors.&#8221;</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Direction of Our Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative new medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in new drug discovery and advancing our pipeline of drug candidates as we believe that this is the best strategy to build long-term stockholder value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we focus on developing medicines in immuno-oncology (I-O), which is a therapeutic approach based on targeting biological pathways that stimulate and sustain the body&#8217;s immune response in order to fight cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the I-O area, we are executing a broad clinical development program evaluating bempegaldesleukin (previously referred to as NKTR-214). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in collaboration with Bristol-Myers Squibb Company (BMS) as well as other independent development work evaluating bempegaldesleukin in combination with other checkpoint inhibitors and agents with potential complementary mechanisms of action. In August of 2019, the FDA granted a Breakthrough Therapy designation for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with untreated unresectable or metastatic melanoma. We expect to continue to make substantial research and development investments as we execute our broad clinical development program for bempegaldesleukin. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2018, we entered into a Strategic Collaboration Agreement with BMS (as amended to date, the BMS Collaboration Agreement) that outlined a collaboration for the development and co-commercialization of bempegaldesleukin in combination regimens with BMS medicines including Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the joint development portion of the arrangement, we and BMS share development costs based on each party&#8217;s relative ownership interest in the compounds included in the regimen. For example, we share clinical development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with 67.5% to BMS and 32.5% to Nektar. For costs of manufacturing bempegaldesleukin, however, BMS is responsible for 35% and Nektar is responsible for 65% of costs. BMS supplies Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> free of charge.   </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Collaboration Development Plan is evaluating bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in ongoing registrational trials in first-line metastatic melanoma, adjuvant melanoma, first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer, first-line metastatic renal cell carcinoma (RCC), and muscle-invasive bladder cancer, as well as a Phase 1/2 dose escalation and expansion study to evaluate bempegaldesleukin plus Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with either axitinib or cabozantinib in first line RCC in order to support a future Phase 3 registrational trial. Several other registrational-supporting pediatric and safety studies for the combination of bempegaldesleukin and Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are currently ongoing. For indications not included in the Collaboration Development Plan, the parties are free to develop their own medicines in other indications subject to certain cost sharing, premium reimbursement, and timing terms and conditions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration, we have received $1.9 billion from BMS, including a $1.0 billion upfront payment and an $850.0 million equity investment upon the effective date of the arrangement in 2018 and $50.0 million in milestones for the initiation of two registrational trials in 2020. The BMS Collaboration Agreement entitles Nektar to receive up to $1.4 billion of potential future milestones for the acceptance of our regulatory submissions and commercial launch of bempegaldesleukin in the US, EU and Japan in up to four indications. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the results of one or more of our registrational trials in bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> meet their primary endpoints, we are entitled to milestones of $35.0 million and $25.0 million for the acceptance of our Biologics License Application (BLA) with the US Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA), respectively, for bempegaldesleukin in the first indication and $30.0 million in aggregate per indication for the acceptance of our BLA and MAA in up to three additional indications. If approved, we are entitled to milestones of $250.0 million in the US and $250.0 million in the European Union (EU) for the first commercial sale of bempegaldesleukin in the first indication and $100.0 million in each of the US and EU for the first commercial sale of bempegaldesleukin in up to three additional indications. As a result, whether and when bempegaldesleukin is approved in any indication will have a significant impact on our future results of operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2022, we and BMS entered into an Amendment No. 2 to the BMS Collaboration Agreement pursuant to which we and BMS allocated certain responsibilities related to price negotiations and promotion, market access, patient support and related activities to each party.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retain the final decision-making authority regarding the pricing for bempegaldesleukin.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin will be sold on a stand-alone basis and there will be no fixed-dose combinations or co-packaging without the consent of both parties. We and BMS will share global commercialization profits and losses for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each party bears their own non-product specific core commercialization infrastructure costs.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the Collaboration Development Plan with BMS, we are conducting and pursuing additional I-O research and development activities evaluating bempegaldesleukin in combination with other agents that have potential complementary mechanisms of action. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic objective is to establish bempegaldesleukin as a key component of many I-O combination regimens with the potential to enhance the standard of care in multiple oncology settings. For example, we are independently studying bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a non-small cell lung cancer (NSCLC) Phase 1/2 trial. In addition, on February 12, 2021, we entered into a financing and co-development collaboration with SFJ Pharmaceuticals to support a Phase 2/3 registrational clinical study of bempegaldesleukin plus Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with head and neck cancer whose tumors express PD-L1. We expect to continue to make significant and increasing investments exploring the potential of bempegaldesleukin with mechanisms of action that we believe are synergistic with bempegaldesleukin based on emerging clinical development outcomes, scientific findings in cancer biology and preclinical development work.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our non-BMS clinical collaborations for bempegaldesleukin, generally each party supports the collaboration based on its expertise and resources. For example, our co-development collaboration agreement with SFJ includes both </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial support from SFJ in the form of up to $150.0 million to fund the Phase 2/3 registrational clinical study of bempegaldesleukin plus Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in head and neck cancer, as well as operational support from SFJ in managing the clinical trial. In addition, we announced on February 17, 2021, that we had entered into a clinical trial collaboration and supply agreement with Merck wherein we will receive supplies of Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at no cost to us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next most advanced I-O program is NKTR-255. NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of natural killer (NK) cells and induces survival of both effector and CD8+ memory T cells. Recombinant human IL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular toxicity molecules as well as to enhance CAR-T therapies. We have initiated a Phase 1 dose escalation and expansion clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, as well as a Phase 1/2 clinical study of NKTR-255 in patients with relapsed or refractory head and neck squamous cell carcinoma or colorectal cancer. In addition, we announced on September 21, 2021, that we had entered into a new oncology clinical collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255 in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in the Phase II JAVELIN Bladder Medley study.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also conducting studies of bempegaldesleukin in combination with NKTR-262. NKTR-262 is a small molecule agonist that targets toll-like receptors found on innate immune cells in the body. NKTR-262 is designed to stimulate the innate immune system and promote maturation and activation of antigen-presenting cells, such as dendritic cells, which are critical to induce the body&#8217;s adaptive immunity and create antigen-specific cytotoxic T cells. NKTR-262 is being developed as an intra-tumoral injection in combination with systemic bempegaldesleukin to induce an abscopal response and achieve the goal of tumor regression in cancer patients treated with both therapies. The Phase 1/2 dose-escalation and expansion trial in patients with solid tumors is currently ongoing.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In immunology, NKTR-358 targets the underlying immune system imbalance in the body that occurs in patients with autoimmune disease. NKTR-358 is designed to optimally target the IL-2 receptor complex in order to stimulate proliferation and growth of regulatory T cells. NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of autoimmune diseases. In 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to develop and commercialize NKTR-358, pursuant to which we received an initial payment of $150.0 million and are eligible for up to an additional $250.0 million for development and regulatory milestones. We have completed our responsibilities for Phase 1 clinical development and certain drug product development and supply activities. We also share Phase 2 development costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. We will have the option to contribute funding to Phase 3 development on an indication-by-indication basis, ranging from zero to 25% of the Phase 3 development costs and receive a royalty rate on global NKTR-358 sales up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization and we will have an option to co-promote in the U.S. under certain conditions. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy patients. We also completed treatment of a Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with systemic lupus erythematosus (SLE). Lilly is conducting two Phase 1b studies in patients with psoriasis and atopic dermatitis, and initiated a Phase 2 study in SLE in October 2020 and a Phase 2 study in ulcerative colitis in March 2021. In addition, based on positive interim Phase 1b results in atopic dermatitis announced in December 2021, Lilly is planning to initiate a Phase 2 study in that indication and also plans to initiate another Phase 2 study in another immune-mediated disease.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In virology, we have studied bempegaldesleukin in a Phase 1b clinical study in adult patients who had been diagnosed with mild COVID-19 infection to evaluate whether bempegaldesleukin&#8217;s adaptive immune-stimulating mechanism to promote priming and proliferation of T cells and NK cells could be useful in the emerging treatment options for COVID-19. We also have a preclinical research collaboration with Gilead to test the combination of NKTR-255 with therapies in Gilead&#8217;s antiviral portfolio.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The level of our future research and development investment will depend on a number of trends and uncertainties including clinical study outcomes, future studies required to advance programs to regulatory approval, and the economics related to potential future collaborations that may include up-front payments, development funding, milestones, and royalties. Over the next several years, we plan to continue to make significant investments to advance our early drug candidate pipeline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically derived all of our revenue and substantial amounts of operating capital from our collaboration agreements. In addition to our collaborations with BMS and Lilly, we have received upfront and milestone payments under a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of other previous collaboration agreements, several of which have resulted in approved drugs, for which we may continue to manufacture the polymer reagents used in the production of the drug products and may be entitled to royalties for net sales of these approved drugs. As of December 31, 2020, however, we have sold the majority of our rights to receive royalties under these arrangements, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">2012 Purchase and Sale Agreement: In 2012, we sold all of our rights to receive royalties from CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of Chron&#8217;s disease and other autoimmune indications) and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of anemia associated with chronic kidney disease) under our collaborations with UCB Pharma and F. Hoffmann-La Roche&#160;Ltd, respectively, to RPI Finance Trust (RPI), an affiliate of Royalty Pharma for $124.0 million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2020 Purchase and Sale Agreement: In December 2020, we sold our rights, subject to a cap, to receive royalties from MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / MOEVNTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (for the treatment of opioid-induced constipation), ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/ ADYNOVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a half-life extension product of Factor VIII) and other hemophilia products, under our arrangements with AstraZeneca AB, Baxalta, Inc. (a wholly owned-subsidiary of Takeda Pharmaceutical Company Ltd.), and Novo Nordisk A/S, respectively, for $150.0 million to entities managed by HealthCare Royalty Management (HCR) under a capped sale arrangement, such that all future royalties return to Nektar if HCR receives $210.0&#160;million in royalties by December 31, 2025 (the 2025 Threshold) or $240.0&#160;million if the 2025 Threshold is not met. See Note 8 to our Consolidated Financial Statements for a further description of the capped nature of this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While in the near-term we continue to expect to generate substantially all of our revenue from collaboration arrangements, including the potential remaining $1.4 billion in regulatory and commercial launch milestones under the BMS collaboration, our plan is to generate significant commercial revenue from proprietary products, the first of which being bempegaldesleukin, if approved. Since we do not have experience commercializing products or an established commercial organization, there will be substantial risks and uncertainties in future years as we build commercial, organizational, and operational capabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the marketing efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Item 1A "Risk Factors".</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the approved drugs and clinical development programs described above are key elements of our future success, we believe it is critically important that we continue to make substantial investments in our earlier-stage drug candidate pipeline. We have several drug candidates in earlier stage clinical development or being explored in research that we are preparing to advance into the clinical trials in future years. We are also advancing several other drug candidates in preclinical development in the areas of I-O, immunology, and other therapeutic indications. We believe that our substantial investment in research and development has the potential to create significant value if one or more of our drug candidates demonstrates positive clinical results, receives regulatory approval in one or more major markets and achieves commercial success. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market value.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of the COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, COVID-19, the disease resulting from a novel strain of coronavirus infection, was declared a global pandemic. Many countries, including the United States and India, initially took steps such as restricting travel, closing schools, and issuing shelter-in-place orders to slow or moderate the spread of the virus. More recently, states and countries have adopted individualized approaches to respond to the COVID-19 pandemic. In particular, the emergence of new variants of the coronavirus, such as the Delta and Omicron variants, and local resurgences in number and rates of infections, and the further spread of the virus may result in the return of prior restrictions or the institution of restrictions in the affected areas, which could have an adverse effect on our business, including our clinical trial timelines. We have been monitoring our supply chains for any disruptions or constraints caused by the COVID-19 pandemic. To date, we have not experienced any significant impacts on our supply, but ongoing global shortages in labor, raw materials and equipment could limit our ability to manufacture our products or to supply drug candidates for our clinical trials, or delay our research and development efforts. It remains unclear how long the negative impacts caused by the coronavirus will continue into the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our operations in research, manufacturing and maintenance that occur within our facilities are continuing in accordance with applicable guidelines and orders. Across all our locations, we have instituted a temporary work from home policy for office personnel who do not need to work on site to maintain productivity and we allow employees to voluntarily return to work on site with appropriate health and safety measures. The safety and well-being of our employees, and the patients </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and healthcare providers in our clinical trial programs, are of first and foremost importance to us. We believe that the safety measures we are taking and instructing our contractors to take in response to the COVID-19 pandemic meet or exceed the guidance and requirements issued from government and public health officials. We continue to monitor our operations and applicable government recommendations in light of new developments in the ongoing COVID-19 pandemic. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are currently engaged in the clinical testing of our drug candidates and the COVID-19 pandemic introduces significant challenges to our clinical development programs which are central to our business. The evolving situation around the COVID-19 pandemic, along with the resulting public health guidance measures that have been put into place, have thus far had varying impacts on the clinical testing of our drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the COVID-19 pandemic. Any current assessments of the effects of the COVID-19 pandemic on our clinical programs, including the specific clinical programs discussed below, are difficult to predict and subject to change and, with regard to individual clinical trial sites within these studies, will likely vary by the geographic region in which they are located.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has not had a significant impact on timelines for the ongoing registrational clinical trials studying the combination of bempegaldesleukin and Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cancer indications being led by Nektar (such as adjuvant melanoma, RCC and first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer). We currently expect to have topline data readouts for our RCC and urothelial cancer trials in the first half of 2022. For Nektar&#8217;s Phase 1/2 trial studying the combination of bempegaldesleukin and Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in NSCLC, although the COVID-19 pandemic delayed the initiation of certain investigator sites in Europe earlier in the trial, we presented initial safety as well as preliminary overall response rate data for the dose-escalation and 0.006 mg/kg NSCLC expansion cohorts of this study in the second half of 2021. We are closely monitoring the impact of the COVID-19 pandemic on the European and other ex-U.S. sites for any impact on timelines for the ongoing study. With regard to Nektar&#8217;s ongoing Phase 1/2 clinical study of NKTR-262 in patients with solid tumors, this study largely remains on schedule although we experienced some initial challenges with new investigator site initiations. Nektar&#8217;s Phase 1 clinical study of NKTR-255 in patients with relapsed/refractory hematologic malignancies has enrolled slower than anticipated due to ongoing challenges caused by the COVID-19 pandemic, and the dose-escalation monotherapy portion of the study is currently expected to be completed in the first half of 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For clinical studies of our drug candidates being run by our partners, BMS is enrolling patients in each of the BMS-led registration studies and re-started initiation of new investigator sites in the third quarter of 2020 following a pause in the initiation of new investigator sites it instituted for all of its studies as a result of the COVID-19 pandemic. In the summer of 2020, BMS extended its timeline estimates by approximately six months for the first data read-outs for the first-line melanoma trial, which we currently expect to occur in the first half of 2022.  The overall supply chain impact stemming from the COVID-19 pandemic delayed the start of the Phase 2b study of NKTR-358 in ulcerative colitis (UC), which is run by our partner Lilly and which Lilly is currently enrolling along with a Phase 2 study in moderate to severe lupus patients. Resource constraints at contract research organizations also caused some delays in data availability. While BMS and Lilly are not currently projecting any delays related to the COVID-19 pandemic, the rapid development and fluidity of the COVID-19 pandemic preclude any firm estimates as to the ultimate effect this disease will have on our collaborators&#8217; clinical trials. As a result, there remains substantial uncertainty as to potential impacts on our collaboration partner studies. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to mitigate the negative effects of the COVID-19 pandemic on our clinical trials (both in terms of clinical trial timelines and integrity of clinical study data), we have taken steps to help our clinical trial investigators and their teams continue to provide care and uninterrupted access to their patients. Particularly, in the context of our clinical trials directed to investigational cancer treatments, for example, we are actively working with our study sites to implement measures to prevent study protocol violations, to minimize any disruption of treatment visits, to accommodate for patient visit delays caused by limited access to healthcare facilities, to leverage alternative methods for maintaining clinical trial integrity, and to properly record patient event data that may be influenced by the COVID-19 pandemic. In addition, to the extent that the integrity of individual patient data is negatively affected by the COVID-19 pandemic, we will consider measures to maintain the integrity of the clinical study overall (such as over-enrolling patients into the study and removing all patients originating from an affected study site when performing statistical analyses of study endpoints). Although these measures may have the benefit of preserving the overall integrity of a clinical study, implementing these measures could result in a delay in completing the study.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to financing our near-term business needs, as set forth below in &#8220;Key Developments and Trends in Liquidity and Capital Resources,&#8221; we estimate we have working capital to fund our current business plans through at least the next twelve months.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Developments and Trends in Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing. At December&#160;31, 2021, we had approximately $798.8 million in cash and investments in marketable securities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the years ended December&#160;31, 2021 and 2020 is presented below. Additional information required by Item 7 for the year ended December 31, 2019 can be found in Item 7 in our Annual Report on Form 10-K for the year December 31, 2020, filed with the SEC on February 26, 2021 and is incorporated herein by reference.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue (in thousands, except percentages)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Decrease)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Decrease)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,008)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as development or manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of products and services expected to be required to fulfill our performance obligations. Given the uncertainties in research and development collaborations, significant judgment is required to make these estimates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, dependent on whether one of more of our registrational studies in bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> meet their primary endpoints, we may file a BLA and/or MAA for bempegaldesleukin in one or more indications. We are entitled to milestones of $35.0 million and $25.0 million for the acceptance of our BLA and MAA filings, respectively, for bempegaldesleukin in the first indication and $30.0 million in aggregate per indication for the acceptance of our BLA and MAA for up to three additional indications. If approved, we are entitled to milestones of $250.0 million in the US and $250.0 million in the EU for the first commercial sale of bempegaldesleukin in the first indication and $100.0 million in each of the US and EU for the first commercial sale of bempegaldesleukin in up to three additional indications. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the recognition of these milestones, if any, and product sales for bempegaldesleukin, if approved, is dependent upon the timing of the readouts of our registrational trials and, if the results are positive, the timelines for regulatory filing submissions and reviews.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales increased for the year ended December&#160;31, 2021, as compared to the year ended December&#160;31, 2020, due to increased demand from our collaboration partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other than the potential for sales of bempegaldesleukin, if approved and as described above, we expect product sales in 2022 to decrease compared to 2021 due to decreased demand from our collaboration partners.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On December 16, 2020, we entered into the 2020 Purchase and Sale Agreement with HCR, under which we sold to HCR certain of our rights to receive royalty payments arising on worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beginning October 1, 2020. As a result, we recognized royalty revenue for these products for the nine months ended September 30, 2020, and recognized these royalties as non-cash royalty revenue for the three months ended December </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31, 2020 and for the year ended December 31, 2021. Please see Note 8 to our Consolidated Financial Statements for additional information on the 2020 Purchase and Sale Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not recognize any royalty revenue during 2021 because we recognized all such royalties as non-cash royalty revenue as a result of the 2020 Purchase and Sale Agreement, and we expect this presentation to continue through the end of the HCR royalty sale arrangement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash Royalty Revenue Related to Sales of Future Royalties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For a discussion of our Non-cash royalty revenue, please see our discussion below &#8220;Non-Cash Royalty Revenue and Non-Cash Interest Expense.&#8221;</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and Other Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements and certain research and development activities. The level of license, collaboration and other revenue depends in part upon the estimated recognition period of the upfront payments allocated to continuing performance obligations, the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of research and development work, and entering into new collaboration agreements, if any.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2020, pursuant to the BMS Collaboration Agreement, we recognized $25.0&#160;million for the achievement of the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and $25.0 million for the achievement of the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. We did not achieve any additional milestones during the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other than the potential for the recognition of milestones under our BMS Collaboration Agreement, we expect license, collaboration and other revenue for 2022 to be consistent with 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties. See Item&#160;1A.&#160;Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by geography (in thousands)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. The following table sets forth revenue by geographic area:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,114&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,966&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,907&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,915&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue attributable to the U.S. for the year ended December&#160;31, 2021 was lower than for the year ended December&#160;31, 2020 primarily due to the recognition of $50.0 million of milestones during the year ended December 31, 2020, from the BMS Collaboration Agreement as described above.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of goods sold (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,897&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,477&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,420&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross profit (loss) (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,973)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product gross margin</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Percentage change represents an improvement since the negative gross margin has decreased.</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our strategy is to manufacture and supply polymer reagents to support our drug candidates or our third-party collaborators where we have a strategic development and commercialization relationship or where we derive substantial economic benefit. Typically, we have elected to enter into and maintain those manufacturing relationships associated with long-term collaboration agreements which include multiple sources of revenue, which we view holistically and in aggregate. We have a predominantly fixed cost base associated with our manufacturing activities. As a result, our product gross profit and margin are significantly impacted by the mix and volume of products sold in each period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product gross margin improved for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020 primarily due to a more favorable product mix in 2021 compared to 2020. We have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the polymer reagent, and we expect this arrangement to continue with this partner in future years. We also receive royalty revenue from this collaboration. In each of the years ended December&#160;31, 2021 and 2020, the royalty revenue from this collaboration exceeded the related negative gross profit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expect product gross margin to continue to fluctuate in future periods depending on the level and mix of manufacturing orders from our customers. Other than the potential for sales of bempegaldesleukin, which, if approved and as described above, would improve our product gross margin, we expect product gross margin to remain negative in 2022 and to be approximately consistent with 2021 as a result of the collaborative arrangement described above.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expense (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,269&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,678&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,409)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Where we perform research and development activities under a  joint development collaboration, such as our collaboration with BMS, we record the expense reimbursement from our partners as a reduction to research and development expense, and we record our share of our partners&#8217; expenses as an increase to research and development expense. Under the BMS Collaboration Agreement, BMS generally bears 67.5% of development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 35% of costs for manufacturing bempegaldesleukin. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize our employee and infrastructure resources across multiple development and research programs. The following table presents expenses incurred for clinical and regulatory services, clinical supplies, and preclinical study support provided by third parties as well as contract manufacturing costs for each of our drug candidates. The table also presents other costs and overhead consisting of personnel, facilities and other indirect costs (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Clinical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Study</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Status</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (CD122-preferential IL-2 pathway agonist)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2/3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-358 (cytokine Treg stimulant)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-255 (IL-15 receptor agonist)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKTR-262 (toll-like receptor agonist)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery research, manufacturing and other costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total clinical development, contract manufacturing and other third party costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,894&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel, overhead and other costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation and depreciation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Clinical Study Status definitions are provided in the chart found in Part&#160;I, Item&#160;1. Business.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Development expenses for bempegaldesleukin include expenses under the BMS Collaboration Agreement, other collaboration agreements and our own independent studies. The amounts for the years ended December&#160;31, 2021 and 2020 include net reductions of $64.3 million and $90.4 million, respectively, of development cost reimbursements from BMS under our collaboration, net of our share of BMS&#8217;s costs. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The amounts for the year ended December&#160;31, 2021 and 2020 include reductions of $37.2 million and $37.8 million of employee cost reimbursements from BMS under our collaboration.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was consistent between the year ended December&#160;31, 2021 and December&#160;31, 2020. Research and development expense increased for our independent development of bempegaldesleukin outside of the BMS Collaboration Agreement, including our registrational Phase 2/3 trial in head and neck cancer under our co-development agreement with SFJ and our Phase 1b trial in COVID-19. Research and development expense decreased under our BMS Collaboration Agreement because we have fully enrolled our registrational trials in first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer and first-line metastatic renal cell carcinoma and because we completed certain manufacturing activities for bempegaldesleukin in 2020. These decreases were partially offset by an increase in expense for our Phase 3 adjuvant melanoma trial under the BMS Collaboration Agreement. As a result of the decrease in expense under the BMS Collaboration Agreement, the net reductions recorded to research and development expense for BMS&#8217;s reimbursements of our costs decreased from $128.2 million for the year ended December 31, 2020 to $101.5 million for the year ended December 31, 2021. Please see Note 11 to our Consolidated Financial Statements for additional information regarding our BMS Collaboration Agreement..</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, research and development expense increased for our development of NKTR-255 in our Phase 1/2 studies in liquid and solid tumors, partially offset by a decrease in development costs for NKTR-358. We completed certain Phase 1 clinical development and drug product development deliverables for NKTR-358 in 2020, for which we were responsible for 100% of costs. Phase 1B and Phase 2 development continues, for which we are responsible for 25% of costs and Lilly is responsible for 75% of costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development expense to increase for 2022 compared to 2021. We expect our development expense for bempegaldesleukin to increase as we continue our registrational trial in adjuvant melanoma and our Phase 2/3 study in head and neck cancer under our co-development agreement with SFJ. We expect research and development expense to increase for our continued development of Phase 1/2 dose-escalation and expansion studies for NKTR-255 in multiple myeloma, non-Hodgkin lymphoma, relapsed or refractory head and neck squamous cell carcinoma, and colorectal cancer. In addition, we are collaborating with Lilly to develop NKTR-358, and Lilly will be conducting the recently started Phase 2 studies and other ongoing studies in 2022, for which we are responsible for 25% of costs. The timing and amount of our future clinical investments will vary significantly based upon our evaluation of ongoing clinical results and the structure, timing, and scope of additional clinical development programs and potential clinical collaboration partnerships (if any) for these programs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition to our drug candidates that we plan to evaluate in clinical development during 2022 and beyond, we believe it is vitally important to continue our substantial investment in a pipeline of new drug candidates to continue to build the value </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our drug candidate pipeline and our business. Our discovery research organization is identifying new drug candidates across a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We also plan from time to time to evaluate opportunities to in-license potential drug candidates from third parties to add to our drug discovery and development pipeline. We plan to continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for a given clinical study design;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of time required to enroll clinical study participants;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and location of sites included in the clinical studies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes);</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential for changing standards of care for the target patient population;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of producing supplies of the drug candidates needed for clinical trials and regulatory submissions;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety and efficacy profile of the drug candidate;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the use of clinical research organizations to assist with the management of the trials;&#160;and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and timing of, and the ability to secure, approvals from government health authorities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as those collaborations that we have already completed for bempegaldesleukin, NKTR-358, or clinical collaborations where we would share costs and operational responsibility with a partner such as we have done with NKTR-255. In certain situations, the clinical development program and process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and outcomes of our clinical studies could be impacted by the uncertainties of the COVID-19 pandemic.  Please see discussion above on effects of the COVID-19 pandemic.  The risks and uncertainties associated with our research and development projects are discussed more fully in Item&#160;1A. Risk Factors. As a result of the uncertainties discussed above, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, anticipated completion dates or when and to what extent we will receive cash inflows from a collaboration arrangement or the commercialization of a drug candidate.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expense (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,844&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,682&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,162&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;General and administrative expense includes the cost of administrative staffing, business development, sales and marketing, finance, and legal activities as well as certain overhead allocations consisting of support and facilities-related costs. General and administrative expense increased for the year ended December&#160;31, 2021 compared with the year ended December&#160;31, 2020 primarily due to increased personnel costs as we begin a stage appropriate build of our commercial capability to co-commercialize bempegaldesleukin with BMS. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect general and administrative expense to increase for 2022 compared to 2021, as we continue to build our commercial capabilities. However, we will only incur our most significant commercialization expenditures, if the results of at </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">least one of our registrational studies in bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> meets its primary endpoints. BMS and we share commercial costs, using a ratio of 35% to BMS and 65% to Nektar, and each party bears its own costs for non-product specific core commercialization infrastructure.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of the NKTR-181 program.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, in the three months ended March 31, 2020, we wrote off $19.7 million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5 million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and severance costs. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Development Derivative Liability</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 6 to our Consolidated Financial Statements, we remeasure the development derivative liability under our co-development agreement with SFJ to fair value at each reporting date. The change in fair value recorded for the year ended December&#160;31, 2021 primarily reflects the accretion of the scenario-based probability-adjusted discounted cash flows of our obligation to potentially pay Success Payments to SFJ using our imputed borrowing rate of 12.7%, net of the accretion of SFJ&#8217;s obligation to fund the SCCHN Clinical Trial, using SFJ&#8217;s estimated borrowing rate of 1.5%. We review our estimates at each reporting period, and, in particular, in future periods, as information becomes available, such as the applicable clinical trial results and FDA approval decisions, we will re-evaluate our probability of success estimates related to achieving FDA approval for bempegaldesleukin in the Melanoma Indication, the SCCHN Indication and one additional indication, and will record a corresponding increase or decrease in the fair value of the development derivative liability. Additionally, in future periods, we may adjust our estimate of the probability of a successful interim futility analysis and we will record a corresponding increase or decrease to the fair value of the development derivative liability, reflecting the decrease or increase (as applicable) in the likelihood of SFJ&#8217;s resulting obligation to complete the full SCCHN Clinical Trial. Such changes in the probabilities of success may result in a material expense or benefit in the period when the information is received. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022, we expect that we will record a significant remeasurement adjustment when we receive the results of our registrational study in the Melanoma Indication. If the Melanoma Clinical Trial meets its primary endpoints, our probability of paying Success Payments to SFJ will significantly increase, which will significantly increase the fair value of the development derivative liability. Conversely, if the Melanoma Clinical Trial does not meet its primary endpoints, our probability of paying Success Payments to SFJ will significantly decrease, which will significantly decrease the fair value of the development derivative instrument.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Cash Royalty Revenue, Non-Cash Interest Expense and Loss on Revaluation of Liability (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to the sales of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Increase)/<br/>Decrease<br/>2021 vs.<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense on liabilities related to the sales of future royalties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,046)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 8 to our Consolidated Financial Statements, we continue to recognize non-cash royalty revenue for the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2012 Purchase and Sale Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue for the 2012 Purchase and Sale Agreement resulting from net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2021 was consistent with the year ended December 31, 2020. Non-cash interest expense for the 2012 Purchase and Sales Agreement decreased for the&#160;year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020&#160;due to the lower interest rate used in the three months ended December 31, 2021 as a result of the revaluation of the liability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 8 to our Consolidated Financial Statements, to resolve UCB's challenges to our patents and their resulting obligation to pay us the royalties on net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;which we had sold to RPI, RPI and UCB negotiated a reduction in the royalty term and decreased royalty rates over the remaining term, which was implemented through the Settlement Agreement between UCB and us. As a result of accounting for the Settlement Agreement as a debt modification, we remeasured the liability to fair value based on the present value of the royalty payments to RPI after the modification, discounted at a rate of 16%. The recognition of the loss on the revaluation has no effect on our cash flows, and the net income statement effect over the term of 2012 Purchase and Sale Agreement remains unchanged. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the term of this arrangement, the net proceeds of the transaction of $114.0 million, consisting of the original proceeds of $124.0 million, net of $10.0 million in payments from us to RPI, is amortized as the difference between the non-cash royalty revenue and the sum of the non-cash interest expense and the loss on the revaluation of the liability. To date, we have amortized $35.7 million of the net proceeds. There are a number of factors that could materially affect our estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, future interest rates could differ significantly. After the modification, we will continue to periodically assess future non-cash royalty revenues, and we will adjust any such change in our estimated interest rate prospectively based on our best estimates of future non-cash royalty revenue such that future non-cash interest expense will amortize the remaining $78.3 million of the net proceeds, since all changes in the royalties are absorbed by RPI. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before the modification, we had increased our forecasts of future non-cash royalties at various intervals, primarily due to sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> exceeding previous expectations. Due to these increases in estimated future royalties, we increased the prospective effective interest rate from 17% at inception to 48% as of the modification date. In connection with the modification and the reduction in the royalty rate and the royalty term, the net present value of the modified royalty stream, discounted at the current fair market value discount rate of 16%, is higher than the prior liability balance. The difference of $23.5 million was reported as a loss on the revaluation of the liability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Purchase and Sale Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 8 to the Consolidated Finance Statements and above under Royalty Revenue, we began recognizing non-cash royalty revenue for the 2020 Purchase and Sale Agreement in the three months ended December 31, 2020. Non-cash royalty revenue and non-cash interest expense increased for 2021 as we recognized them for the full year. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Purchase and Sale Agreement provides for a capped return sale arrangement under which the 2020 Purchase and Sale Agreement will automatically expire, and HCR&#8217;s right to receive the sold royalties will cease when HCR has received payments equaling $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025. Our estimate of the imputed interest rate reflects that our estimates for sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are sufficient to achieve the 2025 Threshold. As a result, we expect the interest rate to remain consistent between 2021 and 2022. However, if sales estimates decline and we conclude that the 2025 Threshold will not be achieved, we expect that the interest rate would increase modestly.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Other Income (Expense), net (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net decreased for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020, primarily due to decreases in market interest rates and lower investment balances which have been utilized to fund our operations and the repayment of our senior notes on April 13, 2020. The effective interest rate earned on investments which we purchased after the COVID-19 pandemic began has been significantly lower than historical interest rates. We expect that our interest income and other income (expense), net will decrease for 2022 compared to 2021 due to lower investments balances as we fund our operations and continued low interest rates.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense (in thousands, except percentages)</span></div><div style="margin-top:18pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Increase)/<br/>Decrease<br/>2021 vs.<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,851)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,851&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Interest expense during the year ended December&#160;31, 2020 consisted of interest from our senior secured notes. In October 2015, we issued $250.0 million in aggregate principal amount of 7.75% senior secured notes, which we repaid on April 13, 2020. As a result, we incurred no interest expense after the repayment date.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense (in thousands, except percentages)</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage Increase/<br/>(Decrease)<br/>2021 vs.<br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the years ended December&#160;31, 2021 and 2020, our income tax expense primarily results from our foreign operations. Due to our expected net loss in 2022, we expect income tax expense to be consistent with 2021 and reflect taxable income for our foreign operations.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have financed our operations primarily through revenue from upfront and milestone payments under our strategic collaboration agreements, royalties and product sales, as well as public and private placements of debt and equity securities. At December&#160;31, 2021, we had approximately $798.8 million in cash and investments in marketable securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing. We expect the clinical development of our drug candidates including bempegaldesleukin, NKTR-358, and NKTR-255 will continue to require significant investment to continue to advance in clinical development with the objective of obtaining regulatory approval or entering into one or more collaboration partnerships. Additionally, we have begun to invest in a stage appropriate build for commercialization of bempegaldesleukin. If the results of one or more of our registrational trials in bempegaldesleukin meet their primary endpoints to support health authority filings, we expect to increase our commercialization investment significantly to prepare for the commercial launch of bempegaldesleukin. The preparation for our potential first commercial drug launch requires a significant investment in building a commercial infrastructure, hiring a commercial sales force and incurring other third-party costs, which we will incur before we begin to receive any revenues from the sale of bempegaldesleukin, if approved. Even if our BLA or MAA for bempegaldesleukin is approved, we cannot be assured that the gross margin from sales of bempegaldesleukin will be sufficient to recover the costs of these investments in the near-term period following commercial launch. Under our BMS Collaboration Agreement, we share commercialization costs, using a ratio of 35% to BMS, 65% to Nektar, but each parties bears its own costs for non-product specific core commercialization infrastructure. If bempegaldesleukin is approved, we will share the net commercial profits and losses in the same manner of 35% to BMS and 65% to Nektar.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS and a $150.0 million upfront payment from Lilly for our collaboration agreement for NKTR-358. In the future, we expect to receive substantial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments from our collaboration agreements with BMS and Lilly. In particular, under the BMS Collaboration Agreement, as discussed above, we are entitled to approximately $1.4 billion of potential future milestones for the acceptance of our regulatory submissions and commercial launch of bempegaldesleukin in the US, EU and Japan in up to four indications. Of these milestones, $560.0 million are associated with the acceptance of our regulatory submissions and commercial launches of bempegaldesleukin in its first indication in the U.S. and EU, subject to regulatory approval. As a result, whether and when bempegaldesleukin is approved in any indication will have a significant impact on our future liquidity and capital resources. We have no credit facility or any other sources of committed capital.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 12, 2021, we entered into a co-development agreement with SFJ Pharmaceuticals (SFJ), pursuant to which SFJ will pay up to $150.0 million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with pembrolizumab (Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). In exchange for funding the SCCHN Clinical Trial, SFJ is entitled to a series of contingent success-based payments with the first payment due after substantial completion of the SCCHN Clinical Trial which we currently expect to occur in late 2024 or early 2025 as follows: (i) if bempegaldesleukin receives FDA approval for first line metastatic melanoma or the SCCHN Indication, we would pay SFJ $450.0 million over a series of five annual payments with the first annual payment being $30.0 million; (ii) if bempegaldesleukin receives FDA approval in both the Melanoma Indication and the SCCHN Indication, we would pay SFJ an additional $150.0 million paid over a series of seven annual payments; and (iii) if bempegaldesleukin receives FDA approval in an indication other than the Melanoma Indication or the SCCHN Indication, we would pay SFJ a one-time payment of $37.5 million. See Note 6 to our Consolidated Financial Statements for additional information.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the short term, we do not anticipate that the effects of the COVID-19 pandemic will have a material effect on our results of operations or financial position since we do not generate significant cash flows from recurring revenues and our revenues are generally less affected by shelter-in place or similar orders. However, if delays caused by the COVID-19 pandemic in commencing and enrolling patients in our clinical trials or those run by our partners result in a delay in completing these trials, our ability to file for regulatory approval and commercialize these products (if approved) and receive associated milestone payments may also be delayed.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. To date we have not experienced any liquidity issues with respect to these securities. We believe that, even allowing for potential liquidity issues with respect to these securities and the effect of the COVID-19 pandemic on the financial markets, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our current business plan is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for bempegaldesleukin, the sales levels of our products, if and when they are approved, the sales levels for those products for which we are entitled to royalties, if and when they are approved, clinical program outcomes, whether, when and on what terms we are able to enter into new collaboration transactions, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions. We may pursue various financing alternatives to fund the expansion of our business as appropriate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the Securities and Exchange Commission, which expires in March 2024. The 2021 Shelf Registration Statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $300.0 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which may be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities have been sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our only significant noncancellable contractual commitments relate to our leases. Please see Note 7 to our Consolidated Financial Statements for additional information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from operating activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash flows used in operating activities for the year ended December&#160;31, 2021 totaled $412.7 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; Cash flows used in operating activities for the year ended December 31, 2020 totaled $313.3 million, which includes $353.6 million of net operating cash uses and $9.7 million for interest payments on our senior secured notes, partially offset by $50.0 million in milestones under the BMS Collaboration Agreement.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, if any, will increase in 2022 compared to 2021 primarily as a result of increased research and development expenses. If the results of one or more of our registrational trials for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meets their primary endpoints, we expect our cash flows used in preparing for the commercial launch of bempegaldesleukin will significantly increase. However, we are entitled to milestones for the acceptance of our BLA or MAA filing by the FDA and EMA, respectively, and the commercial launch of bempegaldesleukin, the receipt of which is dependent upon if and when our BLA or MAA is accepted, our filings are approved and we are able to complete a first commercial sale of bempegaldesleukin. A substantial portion of these milestones are based on the first commercial sale of bempegaldesleukin in the U.S. and EU and there is therefore uncertainty regarding the timing of achievement of this portion of the milestones depending on health authority review timelines.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from investing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We paid $15.0 million and $7.3 million to purchase or construct property, plant and equipment in the years ended December&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As described in Note 5 to our Consolidated Financial Statements, in the second quarter of 2020, we redeemed the senior secured notes at par and therefore repaid the principal of $250.0 million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC, pursuant to which we sold our rights to receive royalty payments arising from the worldwide net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, beginning on October 1, 2020. We received proceeds of $146.3&#160;million, representing the selling price of $150.0 million, net of transaction costs. See Note 8 for additional details on the 2020 Purchase and Sale Agreement, including the capped nature of the arrangement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We received proceeds from issuance of common stock related to our employee option and stock purchase plans of $33.2 million and $23.4 million in the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation and presentation of financial statements in conformity with U.S.&#160;generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources and evaluate our estimates on an ongoing basis. Actual results may differ materially from those estimates under different assumptions or conditions. We have determined that, for the periods in this report, the following accounting policies and estimates are critical in understanding our financial condition and the results of our operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development Derivative Liability</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above and in Note 6 to our Consolidated Financial Statements, in February 2021, we entered into a co-development agreement with SFJ (the SFJ Agreement), pursuant to which SFJ will provide up to $150.0 million in committed funding for a Phase 2/3 registrational clinical study of bempegaldesleukin plus Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with head and neck cancer whose tumors express PD-L1 (the SCCHN Indication). In exchange for funding the SCCHN Clinical Trial, SFJ is entitled to a series of contingent success-based payments as follows: (i) if bempegaldesleukin receives FDA approval for first line metastatic melanoma (the Melanoma Indication) or the SCCHN Indication, we would pay SFJ $450.0 million over a series of five annual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments with the first payment due after substantial completion of the SCCHN Clinical Trial which we currently expect to occur in late 2024 or early 2025; (ii) if bempegaldesleukin receives FDA approval in both the Melanoma Indication and the SCCHN Indication, we would pay SFJ an additional $150.0 million paid over a series of seven annual payments; and (iii) if bempegaldesleukin receives FDA approval in an indication other than first line metastatic melanoma or the SCCHN Indication, would pay SFJ a one-time payment of $37.5 million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SCCHN Clinical Trial provides for an interim futility analysis, and unless the futility criteria are met, SFJ is required to complete the SCCHN Clinical Trial. However, if the futility criteria are met, SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. and the Success Payments, if any, for the Melanoma Indication and/or the additional bempegaldesleukin indication are reduced pro rata based on the costs incurred by SFJ for the SCCHN Clinical Trial over the aggregate commitment of $<ix:nonFraction unitRef="usd" contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementCommittedFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml81OC9mcmFnOmQ1MzcxMTE1NDdjYTQ1MzZiOTA2ZmM1YTRiMDZiM2Y0L3RleHRyZWdpb246ZDUzNzExMTU0N2NhNDUzNmI5MDZmYzVhNGIwNmIzZjRfMTY0OTI2NzQ0MzIwNzg_0b016bce-c9e8-427f-aa65-fc3a2a2aae5f">150.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the SFJ Agreement as a derivative instrument, which we measure based on the scenario-based discounted cash flows of our obligation to pay the Success Payments to SFJ, net of the scenario-based discounted cash flows of SFJ&#8217;s obligation to fund the SCCHN Clinical Trial. Accordingly, we record increases to the derivative liability as SFJ funds the SCCHN Clinical Trial as non-cash research and development expense or as we receive cash payments from SFJ, and we record adjustments to the derivative as the net present value of these two scenario-based discounted cash flows changes over time as the Change in fair value of development derivative liability line in our Consolidated Financial Statements. Our discounted cash flow methodology makes a number of complex assumptions requiring significant management judgment about the probability and timing of cash flows and the risk-adjusted rate we use to discount such cash flows to present value. The key inputs to the valuation include our estimates of the following: (i) the probability and timing of achieving FDA approval in the Melanoma Indication, the SCCHN Indication and any other bempegaldesleukin indication, (ii) the timing of the substantial completion of the SCCHN Clinical Trial that SFJ must achieve before receiving a Success Payment, (iii) the probability of termination of the study due to meeting the interim futility criteria, (iv) the amount of costs incurred by SFJ if the success criterion for the interim futility analysis is not met, (v) SFJ&#8217;s cost of borrowing (<ix:nonFraction unitRef="number" contextRef="ib73eda96963641c5adca30248e3b4212_I20211231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml81OC9mcmFnOmQ1MzcxMTE1NDdjYTQ1MzZiOTA2ZmM1YTRiMDZiM2Y0L3RleHRyZWdpb246ZDUzNzExMTU0N2NhNDUzNmI5MDZmYzVhNGIwNmIzZjRfMTY0OTI2NzQ0MzI5MTU_0c2550ad-29b7-4bd4-9e27-653a30bc1fa5">1.5</ix:nonFraction>% as of December 31, 2021), and (vi) the Company&#8217;s imputed cost of borrowing for debt with similar terms (<ix:nonFraction unitRef="number" contextRef="i418e819404874602beccd76277d2832e_I20211231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml81OC9mcmFnOmQ1MzcxMTE1NDdjYTQ1MzZiOTA2ZmM1YTRiMDZiM2Y0L3RleHRyZWdpb246ZDUzNzExMTU0N2NhNDUzNmI5MDZmYzVhNGIwNmIzZjRfMTY0OTI2NzQ0MzI5OTk_fa8c9cfb-41c9-40df-9d30-d48aac16b0be">12.7</ix:nonFraction>% as of December 31, 2021). </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of these inputs are considered Level 3 inputs in the fair value hierarchy because no market data exists which we can directly or indirectly observe to assist us in developing these estimates. Additionally, the inputs which have the most significant effect on the valuation of this derivative instrument are our estimates related to the probability and timing of the SCCHN Clinical Trial meeting the futility criteria, the results of the registrational trials in the Melanoma Indication, the SCCHN Indication and another bempegaldesleukin indication meeting their primary endpoints, and the FDA approval of bempegaldesleukin in one or more indications. We generally do not believe we will have information to adjust these probabilities until these clinical results are released to us, and therefore when we adjust these assumptions in the period when the information becomes available to us, we expect that such adjustment will have a material effect on our financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Modification</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 8 to our Consolidated Financial Statements, to resolve UCB&#8217;s challenges to our patents and their resulting obligation to pay us the royalties on net sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;which we had sold to RPI, RPI and UCB negotiated a reduction in the royalty term and decreased royalty rates over the remaining term. This negotiation was implemented through the Letter Agreement between RPI and us, which permitted us to enter into the Settlement Agreement with UCB. When we initially sold our rights to receive royalties to RPI, we concluded that we should account for the transaction as debt under ASC 450-10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 450-10) due to our continuing involvement in the generation of the royalties due to our obligation to manufacture the polymer reagent purchased by UCB for the production of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since this obligation remained unchanged as a result of the Settlement Agreement, we concluded that we should account for the Letter Agreement within the scope of ASC 450-10. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our assessment, we concluded that the Letter Agreement represented a modification of the 2012 Purchase and Sale Agreement, since RPI had agreed to reduced royalty payments. Since our estimates of the present value of the reduction in the future royalties exceeded 10% of our estimates of the present value of the royalties before the modification (including the royalties from MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which remain unchanged as a result of these agreements), we concluded that we should treat the modification as an extinguishment of the prior liability and recognize a new liability based on the revised royalty payments and term, discounted to fair value. The estimation of the fair value required us to develop estimates of the future sales of CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over the remaining royalty terms, as well as estimate an appropriate discount rate. Since no active, traded markets exist for arrangements of this nature, we concluded that the 2020 Purchase and Sale Arrangement was economically similar enough to the modified 2012 Purchase and Sale Agreement to use as a basis for the discount rate because the products under both arrangements are well established drugs and the duration of the arrangements are similar. Accordingly, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we utilized our estimated imputed interest rate of 16% from the inception of the 2020 Purchase and Sale Agreement as the discount rate to estimate the fair value of the modified 2012 Purchase and Sale Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our estimates of the future royalties to be received by RPI under the modified 2012 Purchase and Sale Agreement had been higher or lower, our estimated fair value of the new liability would have been higher or lower as well, resulting in a larger or smaller loss on the revaluation. Similarly, if our estimated discount rate had been lower or higher, the estimated fair value of the liability would have been higher or lower, resulting in a larger or smaller loss on revaluation.</span></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements with pharmaceutical and biotechnology partners, we assess whether the arrangements fall within the scope of Accounting Standards Codification (ASC) 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we record such payments as a reduction of research and development expense or general and administrative expense, based on where we record the underlying expense.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that our collaboration agreements with BMS and Lilly fall within the scope of ASC 808. We concluded that the upfront and milestone payments under these arrangements fall within the scope of ASC 606 and therefore recognize these payments as revenue in License, collaboration and other revenue. However, due to the collaborative nature of our joint development and commercialization of bempegaldesleukin, we recognize the reimbursements we receive from BMS for their share of the costs that we incur for the development, manufacturing and commercialization of bempegaldesleukin as a reduction of research and development expense or general and administrative expense, as applicable.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We recognize license, collaboration and other research revenue, including the upfront fees and milestone payments based on the facts and circumstances of each contractual agreement. At the inception of each agreement, we determine which promises represent distinct performance obligations, for which management must use significant judgment. Additionally, at inception and at each reporting date thereafter, we must determine and update, as appropriate, the transaction price, which includes variable consideration such as development and commercial launch milestones. These milestones include the $1.7 billion clinical, regulatory and commercial launch milestones under our collaboration agreements with BMS and Lilly. We must use judgment to determine when to include the variable consideration for these milestones in the transaction price such that inclusion of such variable consideration will not result in a significant reversal of revenue recognized when the contingency surrounding the variable consideration is resolved. To date, we have not included these remaining milestones from BMS and Lilly in the respective transaction prices due to the significant uncertainties involved with clinical development and regulatory approval. We generally do not believe that we would update the transaction price before events that are outside of our control occur, such as the release of clinical trial results, regulatory acceptance of a BLA or similar filing or regulatory approval. However, if these results are positive, we may conclude that certain milestones meet the recognition requirements for inclusion in the transaction price and therefore we would recognize them as revenue before the milestone event occurs and the payment becomes due to us, provided that the achievement of the milestone is within our control.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_61"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate and Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A hypothetical 50&#160;basis point increase in interest rates would result in an approximate $1.8 million decrease, less than 1%, in the fair value of our available-for-sale securities at December&#160;31, 2021. This potential change is based on sensitivity analyses performed on our investment securities at December&#160;31, 2021. Actual results may differ materially. The same hypothetical 50&#160;basis point increase in interest rates would have resulted in an approximate $2.5 million decrease, less than 1%, in the fair value of our available-for-sale securities at December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2021, we held $762.6&#160;million of available-for-sale investments, excluding money market funds, with an average time to maturity of six months. To date we have not experienced any liquidity issues with respect to these securities, but should such issues arise, we may be required to hold some, or all, of these securities until maturity. We believe that, even allowing for potential liquidity issues with respect to these securities, our remaining cash, cash equivalents, and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months. Based on our available cash, the timing of the maturities of our investments and our expected operating cash requirements, we currently do not intend to sell these securities prior to maturity and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The majority of our revenue, expense, and capital purchasing activities are transacted in U.S.&#160;dollars. However, we have contracts with contract manufacturing organizations in Europe, transacted in the British pound sterling or Euros, and incur costs from sites in a variety of international locations which are compensated in their respective local currencies. Additionally, a portion of our operations consists of research and development activities outside the United States, with transactions in the Indian Rupee. Accordingly, we are subject to foreign currency exchange risk for these transactions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our international operations are subject to risks typical of international operations, including, but not limited to, differing economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility. We do not utilize derivative financial instruments to manage our exchange rate risks. We do not believe that inflation has had a material adverse impact on our revenues or operations in any of the past three years.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.  Financial Statements and Supplementary Data</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_67">Reports of Independent Registered Public Accounting Firm (PCAOB ID:</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_67"> </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml82NC9mcmFnOmY3ZmY5MTJiNjAzMTQwYWNiOGJjYzQ0MzBmMGFiYzY3L3RhYmxlOjQ2MjJjNTE4NDhkZjQ0MGFiZDM3YTVhM2ZmM2JiNmMxL3RhYmxlcmFuZ2U6NDYyMmM1MTg0OGRmNDQwYWJkMzdhNWEzZmYzYmI2YzFfMS0wLTEtMS0yMzA5MC90ZXh0cmVnaW9uOjI4MTJiZjhkZWNhNjRiMzliZTg2NDExNDEzYWFmMzgwXzE2NDkyNjc0NDE4Njk_7e9ec53d-de8b-4cb8-8dee-4b118494551f">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_67">)</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_67">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_70">Consolidated Balance Sheets at December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_70">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_70"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_70">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_70">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_73">Consolidated Statements of Operations for each of the three years in the period ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_73">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_73">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_76">Consolidated Statements of Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_76">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_76"> for each of the three years in the period ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_76">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_76">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_79">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_79">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_79">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_82">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_82">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_82">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_85">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_85">79</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Nektar Therapeutics</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Nektar Therapeutics (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:13pt"><span><br/></span></div><div style="margin-bottom:13pt"><span><br/></span></div><div style="margin-bottom:13pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accounting for accrued research and development expenses</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">As more fully described in Note 1 to the consolidated financial statements, the Company records expenses and accruals for estimated costs of research and development activities, including third party contract services costs for clinical research and contract manufacturing. Clinical trial and contract manufacturing activities performed by third parties are expensed based upon estimates of work completed in accordance with agreements with the respective Clinical Research Organization (&#8220;CRO&#8221;) or Contract Manufacturing Organization (&#8220;CMO&#8221;). Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial and contract manufacturing activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements. During 2021, the Company incurred $400.3 million of research and development expenses. The Company recorded an accrued liability of $26.8 million and $4.6 million for clinical trial and contract manufacturing expenses, respectively, as of December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing the accounting for accrued clinical trial and contract manufacturing expenses is complex because of the high volume of data used in management&#8217;s estimates, the assumptions used by management to develop their estimates and verifying the cost and extent of unbilled work performed during the reporting period.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the accounting for accrued research and development expenses, including the Company&#8217;s assessment and estimation of accrued costs for clinical trial and contract manufacturing activities performed by third parties. This assessment was done with the Company&#8217;s financial and operational personnel to determine the appropriate project status and estimated accrual of costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To test the Company&#8217;s accounting for accrued clinical trial and contract manufacturing expenses, our audit procedures included, among others, obtaining supporting evidence from third parties of the research and development activities performed for significant clinical trials and contract manufacturing services. We agreed, on a sample basis, the Company schedules to key milestones and completion terms, activities, timing, and costs to signed CMO and CRO contracts in order to evaluate the status of completion and accuracy of invoices received from the vendors. We met with clinical and manufacturing personnel to understand the status of significant research and development activities. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements.</span></div><div><span><br/></span></div></td></tr><tr style="height:260pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accounting for cost-sharing under the Bristol-Myers Squibb (BMS) Collaboration Agreement</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">The Company and Bristol-Myers Squibb Company (BMS) both conduct research and development activities under a Strategic Collaboration Agreement for bempegaldesleukin (NKTR-214). As more fully explained in note 11 to the consolidated financial statements, the Company and BMS share certain internal and external development costs under the collaboration agreement. The Company&#8217;s research and development costs include external actual and estimated Clinical Research Organizations (&#8220;CRO&#8221;) and Contract Manufacturing Organization (&#8220;CMO&#8221;) costs in addition to internal employee costs. BMS provides reports to support their research and development activities performed and costs incurred in the relevant period under the terms of the agreement. Estimates included in each party&#8217;s research and development costs are trued up to actuals by each party when known. Eligible costs incurred by each party during the reporting period are offset and the net amount is owed to the party with the excess costs. The Company has a net receivable of $21.4 million from BMS under the collaboration as of December 31, 2021. During a reporting period in which there is a net receivable to the Company, the net amount of BMS&#8217; reimbursement of collaboration expense is recorded as a reduction of research and development expense. For the year ended December 31, 2021, the Company recorded $101.5 million as a reduction of research and development expenses for BMS&#8217; share of the Company&#8217;s research and development expenses, net of the Company&#8217;s share of BMS&#8217; research and development expenses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">Auditing the cost-sharing under the collaboration agreement was especially challenging because of the complexity of the data used by the Company for determining the actual and estimated research and development activities that are eligible for reimbursement under the collaboration agreement. The research and development expenses include management&#8217;s judgment regarding the estimated third party contract service costs for clinical research and contract manufacturing incurred during the reporting period. Additionally, the Company evaluates the costs incurred and activities performed by BMS to assess their eligibility for reimbursement under the agreement.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">We evaluated the design and tested the operating effectiveness of controls over the accounting for the cost-sharing conducted under the collaboration agreement, including the Company&#8217;s assessment and measurement of its and BMS&#8217;s activities performed and costs incurred that are eligible for reimbursement. This includes conducting meetings with program management, clinical operations and manufacturing personnel to determine the progress to date under the collaboration and substantiating the calculation of eligible costs and activities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit procedures included, among others, testing the eligibility of the Company&#8217;s research and development costs against the terms of the agreement. We met with Company personnel and reviewed meeting minutes to understand discussions held with BMS during various committee meetings to corroborate our knowledge of the collaboration activities that have occurred to date. We tested the activities reported by the Company and BMS for appropriate classification and disclosure under the collaboration agreement. We obtained an external confirmation from BMS for the net amount owed to the Company.</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Accounting for the Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As discussed in note 6 to the consolidated financial statements, on February 12, 2021, the Company entered into a co-development funding agreement (&#8220;SFJ Arrangement&#8221;) with SFJ Pharmaceuticals Group company (&#8220;SFJ&#8221;) under which SFJ agreed to pay up to $150 million in committed funding to support a phase 2/3 study of bempegaldesleukin in combination with Keytruda in squamous cell cancer of the head and the neck (&#8220;SCCHN&#8221;). In return the Company will pay SFJ a series of success-based annual payments in the event of FDA approval of bempegaldesleukin for the Melanoma indication, the SCCHN indication, or both, and in the event of one additional bempegaldesleukin indication. The SFJ Agreement is presented as a development derivative liability whose fair value is based on unobservable inputs and is remeasured at each reporting date. As SFJ conducts the SCCHN clinical trial, the Company records non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remits funding to support the Company&#8217;s internal cost of conducting the trial, the Company also records a corresponding increase to the development derivative liability. The change in the fair value between reporting periods is recorded as a gain or loss in the Company&#8217;s Consolidated Statement of Operations. For the year ended December 31, 2021, the Company recorded $16.7 million of non-cash research and development expense and a loss of $8.0 million reflecting the change in the fair value of the development derivative liability. The fair value of the development derivative liability as of December 31, 2021 was $27.7 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We identified the a) initial accounting, and b) valuation of the development derivative liability as a critical audit matter. The development derivative liability is valued using several unobservable inputs in a scenario-based discounted cash flow method, whereby each scenario makes assumptions about the probability and timing of cash flows, and such cash flows are present valued using risk-adjusted discount rates. Auditing this model required a high degree of auditor judgment as well as analysis by our fair value specialists.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We evaluated the design and tested the operating effectiveness of controls over management&#8217;s initial accounting and valuation of the development derivative liability. This included conducting meetings with the Company&#8217;s financial and operational personnel to determine the progress to date of the ongoing clinical studies and their process and procedures around the development of the unobservable inputs utilized in the estimation of the fair value of the development derivative liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our audit procedures included, among others, testing and evaluating the reasonableness of management&#8217;s assumptions by comparing the assumptions within the model to internal communications among management and the Company&#8217;s Board of Directors, information included in the Company&#8217;s earnings releases, analyst reports for the Company and life science industry third-party research reports. We also conducted inquiries with those responsible for clinical trials regarding the progress of ongoing trials.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With the assistance of our fair value specialists, we evaluated the reasonableness of the valuation methodology including the discount rates used by testing the source information and the mathematical accuracy of the calculation.</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml82Ny9mcmFnOmRjOTFjMGNjZTc3ODRiMTRhMDFiM2QwYmZhNjI0NjAzL3RleHRyZWdpb246ZGM5MWMwY2NlNzc4NGIxNGEwMWIzZDBiZmE2MjQ2MDNfMTQyOTM2NTExNjg5MjY_d6ad7d4e-5362-4e46-b177-ac881a7aee64">Ernst &amp; Young LLP</ix:nonNumeric>  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1993.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml82Ny9mcmFnOmRjOTFjMGNjZTc3ODRiMTRhMDFiM2QwYmZhNjI0NjAzL3RleHRyZWdpb246ZGM5MWMwY2NlNzc4NGIxNGEwMWIzZDBiZmE2MjQ2MDNfMTQyOTM2NTExNjg5Mjc_5d553094-83ca-43ee-a274-d26275f7db40">Redwood City, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the Stockholders and the Board of Directors of Nektar Therapeutics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opinion on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have audited Nektar Therapeutics&#8217; internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Nektar Therapeutics (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ernst &amp; Young LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redwood City, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except par&#160;value&#160;information)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNC0xLTEtMS0xMTI5OA_dc513e74-9bc4-4f52-9753-86cdd697371f">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNC0zLTEtMS0xMTI5OA_fff9b0ae-ca3a-4df3-869f-ca77b25e9bbb">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNS0xLTEtMS0xMTI5OA_c8d45786-ca28-46d9-8cda-9b6852b2bc24">708,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNS0zLTEtMS0xMTI5OA_580d2afc-817b-4845-b9c8-b2251f0d003c">862,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNi0xLTEtMS0xMTI5OA_6f5dec94-a1db-4ec6-807f-aeae57ef6287">22,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNi0zLTEtMS0xMTI5OA_45e1d2a7-fe57-42eb-adc1-e0ef523d7b45">38,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNy0xLTEtMS0xMTI5OA_dd7d3bde-04a4-4d0f-8b4a-e71fff8873fe">15,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNy0zLTEtMS0xMTI5OA_109acf31-ec2d-48a9-afcc-7993d877f697">15,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfOS0xLTEtMS0xMTI5OA_3c17f497-13b2-48fa-a239-1e39c4b5dc0f">23,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfOS0zLTEtMS0xMTI5OA_88a55ada-a6e8-4b72-8762-e4365ae16e40">21,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTAtMS0xLTEtMTEyOTg_d2f8eced-4004-4fb8-bd04-e88267ee5aec">795,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTAtMy0xLTEtMTEyOTg_8cc3619c-db9a-4c26-ad04-e8285281919e">1,138,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTEtMS0xLTEtMTEyOTg_7cd8637a-6841-473b-97be-d3629d6d5c0d">64,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTEtMy0xLTEtMTEyOTg_a09392b5-64a2-4778-af4a-5f56cb4fe169">136,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTItMS0xLTEtMTEyOTg_77f62c26-94da-414c-870b-9e39adf8724d">60,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTItMy0xLTEtMTEyOTg_82befe2b-ed67-41ff-badc-b5bfce58d33e">59,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTMtMS0xLTEtMTEyOTg_f8862e50-cd3a-44a0-9be0-0bc8abbb1ae3">117,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTMtMy0xLTEtMTEyOTg_9ecc2ac7-64b2-4b6f-99b1-a71871faa61f">126,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTQtMS0xLTEtMTEyOTg_c0c322ee-d8b5-46ac-b521-88e0d8a8ff12">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTQtMy0xLTEtMTEyOTg_ce7631e4-ca61-45f7-b845-6f9fca1ae4f9">76,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTUtMS0xLTEtMTEyOTg_0faa186a-cb87-41fe-a6d5-05bcdebbd129">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTUtMy0xLTEtMTEyOTg_ab8610e5-74f8-4bb9-9553-2aacc03a0e7d">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTYtMS0xLTEtMTEyOTg_6cc7caa0-3619-4c8b-a732-fee5749fc598">1,117,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTYtMy0xLTEtMTEyOTg_374599e8-acb3-43d4-8ecb-161564d607d4">1,538,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjAtMS0xLTEtMTEyOTg_db2ddfa9-118b-4f0a-870a-5518138098d3">9,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjAtMy0xLTEtMTEyOTg_c80c600f-0677-4ba8-9045-bbd12a8e2682">22,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjEtMS0xLTEtMTEyOTg_7c8bf5d7-e7c7-4615-aab1-44e02f19c20f">15,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjEtMy0xLTEtMTEyOTg_fbd1344a-9d74-4423-be59-48e8983284f7">14,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:AccruedClinicalTrialExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjItMS0xLTEtMTEyOTg_49e817fc-8dbe-4742-a58d-64a0d4abc283">26,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="nktr:AccruedClinicalTrialExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjItMy0xLTEtMTEyOTg_6f96aa49-c05c-4193-9172-eef578c83c46">44,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjQtMS0xLTEtMTEyOTg_27aa9ed5-a337-47bb-9ce5-e8e2fa7f5710">15,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjQtMy0xLTEtMTEyOTg_8b328b4a-de7f-4777-a818-3339b5c45cec">20,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjUtMS0xLTEtMTEyOTg_66d512d5-9874-4d29-bc17-9d5ef3f0fd0e">17,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjUtMy0xLTEtMTEyOTg_f610b78c-f7d6-422f-9923-726bb2433721">13,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjctMS0xLTEtMTEyOTg_2a119f9b-dd7d-4159-8a2e-532f640ce824">85,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjctMy0xLTEtMTEyOTg_77a0bea9-cc8b-46c9-a433-8f60ca975395">115,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjgtMS0xLTEtMTEyOTg_e58738d2-0049-4a76-97d3-e84ff220a0f1">125,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjgtMy0xLTEtMTEyOTg_0ce6db69-322e-49b2-811e-bed098e8d767">136,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjYtMS0xLTEtMTMxMDM_30a23f51-00aa-42c9-bd6b-b8d3a880323d">27,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjYtMy0xLTEtMTMxMTc_75d31081-1001-426a-89f0-d98a1d06bb4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjktMS0xLTEtMTEyOTg_1933e1a0-43f9-4d09-b0f1-edc598fa8549">195,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjktMy0xLTEtMTEyOTg_890d277a-2fcd-4404-8e8d-51fd7d8a5b00">200,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzEtMS0xLTEtMTEyOTg_79f65ada-3ad8-4bdb-8a79-d73aa1ba8f46">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzEtMy0xLTEtMTEyOTg_672d4da7-ee1c-4c7b-b62d-6f5cfb893ff9">8,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzItMS0xLTEtMTEyOTg_235c4054-07d8-43a4-84a8-f5731e6ffe7f">437,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzItMy0xLTEtMTEyOTg_9bea22ef-0819-4875-8fa3-d825f9eb0f48">461,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzMtMS0xLTEtMTEyOTg_88c6eddf-2b08-4ae3-be72-926f3e47635c"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzMtMy0xLTEtMTEyOTg_d35eeeaa-9aae-4b92-a979-636972a669e2"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV8yMQ_26ff4440-462b-401b-9868-e57e8e861dde"><ix:nonFraction unitRef="usdPerShare" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV8yMQ_43e5d71b-4b6a-4ca0-ad22-d5389ee5e29e">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV8zNQ_83b660a1-148b-4b68-a47f-9fa9b8430cee"><ix:nonFraction unitRef="shares" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV8zNQ_c25c5bf7-4be2-4340-96ec-80ba78898406">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_0883444e-0270-44b4-aa56-2857dfd3c028"><ix:nonFraction unitRef="shares" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_241f3d23-510e-4e8f-8c0b-20e9d474cc32"><ix:nonFraction unitRef="shares" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="INF" name="nktr:PreferredStockShareDesignated" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_64090482-e09a-4689-96a7-b218cd7265f3"><ix:nonFraction unitRef="shares" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_d2748ced-5d29-48f3-9239-12c9aa06470f"><ix:nonFraction unitRef="shares" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="INF" name="nktr:PreferredStockShareDesignated" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_d79e82f3-6c6c-47a6-99b2-052d7ff19809"><ix:nonFraction unitRef="shares" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_f159bb67-772e-49f3-9be9-add941593037">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares designated, issued or outstanding at December 31, 2021 or 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMS0xLTEtMTEyOTg_0f50fce2-0106-4184-9288-9e8211444b39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMy0xLTEtMTEyOTg_0bf9111c-b4dc-482a-b675-0818137b8ca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF8xOA_8ce5475e-5fac-4b60-a8e8-d437f591dd35"><ix:nonFraction unitRef="usdPerShare" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF8xOA_fdc66911-dc3b-4da9-82d0-7b13bd9cfd5c">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF8zMg_1be04ced-cd02-4ada-9ec3-1386ed9665e9"><ix:nonFraction unitRef="shares" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF8zMg_7cbd56c2-6895-43ca-94fb-2b0ce9b71b6a">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF81NA_154e7e2b-d40e-4062-9adf-496dcc4d1d18"><ix:nonFraction unitRef="shares" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF81NA_d87f0c32-a1f1-4c9f-8260-f829dd55789f">185,468</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF82OA_2a07a5ae-7fef-40a7-84bc-396757de7409"><ix:nonFraction unitRef="shares" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF82OA_f27899d6-7c11-40aa-a3ca-0c32761a3fd8">180,091</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMS0xLTEtMTEyOTg_c50bd5a8-9ad6-40b3-9a09-d6e03d50f75f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMy0xLTEtMTEyOTg_0dd2a4e3-ac40-4fff-920e-6157ff979f8e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in excess of par value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzctMS0xLTEtMTEyOTg_39ae51d7-7486-43ff-9efa-50514d542645">3,516,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzctMy0xLTEtMTEyOTg_71c292e8-b5c1-4d52-b738-ec7f7fda8a34">3,388,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzgtMS0xLTEtMTEyOTg_5ff49d1d-f9cc-445b-bc32-6742bf423b90">4,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzgtMy0xLTEtMTEyOTg_319cd2af-1fa1-4864-9afd-8d211cab6bf9">2,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzktMS0xLTEtMTEyOTg_3041b845-5f61-46ba-a762-c8dcbe4c1290">2,832,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzktMy0xLTEtMTEyOTg_b4ac66a4-0c80-4230-b248-1b0dc38df49b">2,309,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNDAtMS0xLTEtMTEyOTg_07bc894e-8af7-43cc-90df-cb38d3d009de">679,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNDAtMy0xLTEtMTEyOTg_86b3f435-5c29-431a-be01-3bac25b9888c">1,077,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNDEtMS0xLTEtMTEyOTg_0c5c43cf-ed09-474d-8182-29888cf21a06">1,117,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNDEtMy0xLTEtMTEyOTg_f58a3d27-cd3f-4349-bb68-6f0f1a9c751a">1,538,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;per&#160;share&#160;information)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97391b2936f841cc9e4d2b6c592beff9_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMy0xLTEtMS0xMTI5OA_b4ecb503-365f-475e-a2af-f689be2205ac">23,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385bad4a34ed410299079777e10e8737_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMy0zLTEtMS0xMTI5OA_9d5efb4b-12f0-4e63-aa46-e4bb044ed8f3">17,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee9f5c266bb64ec48742279a12b86e9f_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMy01LTEtMS0xMTI5OA_197e3070-4208-4333-b0f2-01de0901ba63">20,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie556d8a598764c54834d2305fb48307e_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNC0xLTEtMS0xMTI5OA_9a2b6b2a-8d29-468f-acca-e093ec5d2da3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62a137c1f62e4f37bd438bf66515d037_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNC0zLTEtMS0xMTI5OA_8346a722-d13b-42ef-bcf4-223fe7283e39">30,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0375ded4b7c74c1491fe98ce48a475d8_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNC01LTEtMS0xMTI5OA_5b690ba7-cfcb-404c-837d-597a01abe1f5">41,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d34596d03d4f48ad22b490652d61c2_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNS0xLTEtMS0xMTI5OA_81d1e213-22ea-400f-9fae-8efcfadb5d3f">77,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11c771d5728489f9c3498ced689a2e8_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNS0zLTEtMS0xMTI5OA_dbeb7368-fdb1-4156-a2a7-1efa9571bea2">48,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f6ca9435254d8598fb70543671cc59_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNS01LTEtMS0xMTI5OA_35a28b03-d4e1-402c-acda-0c0f718f1743">36,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524617210c1844548d9aaa3cd1afdd18_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNi0xLTEtMS0xMTI5OA_b4e74109-d371-4dd5-a216-69d602d0f8ff">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9dd5c85b0364d75a8dee4e02e0abd75_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNi0zLTEtMS0xMTI5OA_9804daa5-d722-46ea-8444-8ae66150e57b">55,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87de647067774165be013844df84c1bb_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNi01LTEtMS0xMTI5OA_fd3d4c31-baef-4d08-853a-d158db8167b3">16,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNy0xLTEtMS0xMTI5OA_168102cc-aa5e-4458-b8c6-f2d40de3482d">101,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNy0zLTEtMS0xMTI5OA_a58216c5-64de-45ca-9399-eae00685a046">152,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNy01LTEtMS0xMTI5OA_30d49b83-bdbe-4897-9a25-915e4deebda1">114,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating costs and expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfOS0xLTEtMS0xMTI5OA_d6e0e43a-cf82-40a0-99f1-0d06d585d28b">24,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfOS0zLTEtMS0xMTI5OA_9ea1d736-ef6c-4d0a-89ba-840d35d642b1">19,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfOS01LTEtMS0xMTI5OA_76f68591-42d4-48ab-8831-a746a0393f33">21,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTAtMS0xLTEtMTEyOTg_19ea17e3-84a2-47a0-bac0-ddc74a2293c8">400,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTAtMy0xLTEtMTEyOTg_dc79fbf4-93da-40ce-8dbe-2b76d516e650">408,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTAtNS0xLTEtMTEyOTg_ecf7babb-fb77-4e6a-8e3d-91b371e53639">434,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTEtMS0xLTEtMTEyOTg_4682c30e-bea1-4e32-a234-270ab4aa8614">122,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTEtMy0xLTEtMTEyOTg_2449c209-2167-4484-a0f2-5f103915c08c">104,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTEtNS0xLTEtMTEyOTg_cc3badd7-f45d-4808-bd96-7f1c14dcc285">98,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTItMS0xLTEtMTEyOTg_50214c2a-082b-4088-9646-872ab804c9da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTItMy0xLTEtMTEyOTg_44d457c8-8407-4533-a197-f0c1ab814006">45,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTItNS0xLTEtMTEyOTg_9c2ab5f9-bc84-415c-9c22-01f1f3068cc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTMtMS0xLTEtMTEyOTg_da2f45f0-12f3-4ca0-a151-3d0f340bfef8">548,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTMtMy0xLTEtMTEyOTg_c519b605-5a8b-4348-94f1-978b4314866e">578,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTMtNS0xLTEtMTEyOTg_2a466a9f-78d0-4906-bdfe-d09852af3631">554,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTQtMS0xLTEtMTEyOTg_b37c216a-df66-438c-bd57-5233c9f5d99d">446,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTQtMy0xLTEtMTEyOTg_747fc9e0-34ac-4ba8-b8a0-61288d1d08a4">425,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTQtNS0xLTEtMTEyOTg_51c45e74-989f-478c-910f-cf6bd7ec82ac">440,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income (expense):</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTYtMS0xLTEtMjA4NTc_8e96ec95-0538-4d56-89b6-42f4e0e09556">8,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTYtMy0xLTEtMjI5OTg_30903be2-1f6c-4456-b00c-b4bf9e087cfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTYtNS0xLTEtMjI5OTg_cc0a9630-2774-4c13-89f6-fccf602f1c4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liabilities related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTctMS0xLTEtMTEyOTg_95e36d59-f3ed-4ffd-bd58-233f9d5ef9c9">47,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTctMy0xLTEtMTEyOTg_b60d35d1-da15-4ca2-8f58-ea55b639d8ef">30,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTctNS0xLTEtMTEyOTg_5cb9a8a6-5700-46c5-ae27-a5dfe4de3c20">25,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtMS0xLTEtMTM5Mjk_808cf332-41ec-4e3d-b9f4-66468f50fca6">24,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtMy0xLTEtMTM5OTA_9dde7904-930e-4d2b-98dd-c696926f9223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtNS0xLTEtMTM5OTA_a7f1279a-8114-498a-941b-0e5a2733f309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtMS0xLTEtMTEyOTg_42107f15-2daf-491d-bca1-cafc36921976">2,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtMy0xLTEtMTEyOTg_74319ac7-a2c7-40a9-ba9e-61fdb1dfaa80">18,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtNS0xLTEtMTEyOTg_b35c5fd5-b518-4d42-84f5-6079dd1598ba">46,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtMS0xLTEtMTYzNDU_c6d49e7b-5f4a-4c96-bda5-d3ff07d6b892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtMy0xLTEtMTYzNDU_97e25835-48c6-4c94-b2ec-aea83ff5c9c9">6,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtNS0xLTEtMTYzNDU_f58d3bd2-e5d1-44ec-baf2-a3c110980b23">21,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-operating expense, net</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTktMS0xLTEtMTEyOTg_de2384ce-0eef-4c07-a701-fc22048265d5">77,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTktMy0xLTEtMTEyOTg_24f4a1da-45d8-4b5c-bbaa-25d804469acb">18,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTktNS0xLTEtMTEyOTg_0807c467-8e05-4cbc-b4c3-0c924fb07afc">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjAtMS0xLTEtMTEyOTg_d0f3c153-2bbf-4b0b-8f69-f07162228abe">523,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjAtMy0xLTEtMTEyOTg_7dfada6b-4071-4b6e-8f2e-bfe292f9a97b">443,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjAtNS0xLTEtMTEyOTg_6ab2136c-2090-4f52-bf2d-cdfaf17d6aff">440,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtMS0xLTEtMTEyOTg_82462a48-cb24-462e-85f2-cb79b1f3ee22">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtMy0xLTEtMTEyOTg_3402ab4f-ad65-423e-b6ef-053e7993d0f8">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtNS0xLTEtMTEyOTg_ccc1fbd3-8bb9-42b5-a35c-4e8e1b094423">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjItMS0xLTEtMTEyOTg_eee0cea3-c3df-4d1d-8224-71d18f30fec1">523,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjItMy0xLTEtMTEyOTg_599ee55a-d8e8-45b3-97ef-3e6333a649c0">444,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjItNS0xLTEtMTEyOTg_ecda7f48-d6a2-4b30-914a-04911a5187e6">440,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtMS0xLTEtMjA5MTE_0d95e51d-12a5-42a9-a318-1424998ef631"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtMS0xLTEtMjA5MTE_cc51a471-97a7-45e3-a6c6-d32354e17714">2.86</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtMy0xLTEtMjA5MTE_7e6ab542-01f4-4337-81b8-29fe4fd14a4b"><ix:nonFraction unitRef="usdPerShare" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtMy0xLTEtMjA5MTE_fc1092f0-176a-406a-ae9f-a3dfb89b7708">2.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtNS0xLTEtMjA5MTE_2546ffc0-c075-43a6-9283-d71d22ee5a70"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtNS0xLTEtMjA5MTE_7be8e084-92bc-4665-aa62-f4382ae50ae8">2.52</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in computing basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctMS0xLTEtMjA5MDQ_179be33e-6f1b-4897-8cec-c86d6e0288ea"><ix:nonFraction unitRef="shares" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctMS0xLTEtMjA5MDQ_3acf3b77-1493-4e4c-b238-d97a47388d8a">183,298</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctMy0xLTEtMjA5MDQ_1dd6db55-57e9-4e66-bf35-adca953c5070"><ix:nonFraction unitRef="shares" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctMy0xLTEtMjA5MDQ_bda172d5-b93d-4d66-a320-501de64a3e25">178,581</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctNS0xLTEtMjA5MDQ_03150b26-e82f-4f1f-a884-5b0be103f36a"><ix:nonFraction unitRef="shares" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctNS0xLTEtMjA5MDQ_96744acb-e085-4b77-a515-39a1c68592c8">174,993</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfMi0xLTEtMS0xMTI5OA_1fa00922-0128-400e-8c13-bd35ebd933d3">523,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfMi0zLTEtMS0xMTI5OA_917a061b-89e0-4447-8826-7d2a9902d9ad">444,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfMi01LTEtMS0xMTI5OA_9d6fffae-3273-4246-938f-d6f45724065a">440,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNC0xLTEtMS0xMTI5OA_5b9fdbcc-4be4-47f4-a75d-ff8d89bf79b1">1,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNC0zLTEtMS0xMTI5OA_4af918b0-4b80-4777-baa2-0863eef34fdd">927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNC01LTEtMS0xMTI5OA_86b01ad0-ef17-4280-8560-5ea2865e65ac">5,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNS0xLTEtMS0xMTI5OA_f81a1565-cc5f-4912-b7dc-06b67a6a661a">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNS0zLTEtMS0xMTI5OA_a97006dc-6b16-4e65-98d8-7f945f267de6">363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNS01LTEtMS0xMTI5OA_8768ad66-0c4f-4513-be4b-7c9821df23af">382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNi0xLTEtMS0xMTI5OA_7f8fc6da-62a5-45a9-9e8e-24982672da80">1,862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNi0zLTEtMS0xMTI5OA_325bb386-695a-4a23-92d6-2fd5d6ffd22e">1,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNi01LTEtMS0xMTI5OA_e826c2b5-eb0d-4d5f-bcdf-e5be9704d54f">5,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNy0xLTEtMS0xMTI5OA_5a21a8cd-d1d3-4ee1-ab87-d81a94331166">525,699</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNy0zLTEtMS0xMTI5OA_5c0849ba-801f-412b-85e8-16da41018fc1">445,730</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNy01LTEtMS0xMTI5OA_62ab51f2-205e-4f94-b033-0557392fc844">435,356</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Capital in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Excess of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfc39458a49345bdbf9c5f0b59507c25_I20181231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS0xLTEtMS0xMTI5OA_9ebd9e9c-78b6-4921-b58e-c45a69c47a8f">173,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc39458a49345bdbf9c5f0b59507c25_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS0zLTEtMS0xMTI5OA_5e19a671-693c-4680-be54-9aea29a2c124">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb2fa6ca8a0403abea7fdab421e1e5a_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS01LTEtMS0xMTI5OA_6a7efba7-f24b-4257-b2a6-818c8287b065">3,147,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic036604bec7a494eb87b4bb2add33694_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS03LTEtMS0xMTI5OA_a6e6e9f5-3307-4b8d-b748-b29ce2a186f2">6,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdc8ae10616f484b97ae80d605c49cd3_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS05LTEtMS0xMTI5OA_4c5916e9-b1d0-4740-9646-a5c675556dc1">1,424,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e86cae77d44493aad21052dab0a76b8_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS0xMS0xLTEtMTEyOTg_6a711624-aa76-4d5c-baac-decaa6fa004f">1,717,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i875faed795c94a9cbe1dbe5c45959993_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMi0xLTEtMS0xMTI5OA_f5bf99c1-b139-4901-9b21-1b23beeb3c31">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875faed795c94a9cbe1dbe5c45959993_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMi0zLTEtMS0xMTI5OA_0a37187b-4a24-41f0-b7f4-fe273056bf1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15c826afa424f9f83b6f1f31eae68e0_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMi01LTEtMS0xMTI5OA_fafbf0be-30e3-46a9-aab0-9a868cc33321">23,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMi0xMS0xLTEtMTEyOTg_af5b5ab0-0049-40a7-9832-303104f679cd">23,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15c826afa424f9f83b6f1f31eae68e0_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMy01LTEtMS0xMTI5OA_c369df01-bdde-4d01-94f4-af2309dae374">99,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMy0xMS0xLTEtMTEyOTg_91c8c936-ee62-4497-b7ba-e319183cb236">99,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c08dcd809044c649a36e6a8870b753f_D20190101-20191231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNi03LTEtMS0xMTI5OA_ccdd25df-d531-422d-b195-488661fcf0d7">5,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aabdbcec054bbc98f62fc64f377f52_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNi05LTEtMS0xMTI5OA_1f035804-6af5-4220-a42f-d035be90ff2a">440,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNi0xMS0xLTEtMTEyOTg_dad04754-8d58-4cc6-90df-f573e60bf2f3">435,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2dec94ffa8f54d9f8f0e8161b2c81580_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy0xLTEtMS0xMTI5OA_edf40442-1008-47c5-8b3b-bc5aceadd13b">176,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dec94ffa8f54d9f8f0e8161b2c81580_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy0zLTEtMS0xMTI5OA_7aee2c2c-aa80-4f3c-a480-973922a4afe1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1387c3cbfa6f42a8878e29c7c2e63b8c_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy01LTEtMS0xMTI5OA_849e1677-849e-4a1a-afa1-5fab55e87e07">3,271,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i617c9de53110471eb788bd49272cb303_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy03LTEtMS0xMTI5OA_34c25c60-76ca-423b-933c-41566cc13662">1,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dc92f30772f4416b1b6a460651e0081_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy05LTEtMS0xMTI5OA_9f05ceb3-6bec-4d0c-b2b2-c5be16559db2">1,864,718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a636947a9046a38a2ed739019eb13c_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy0xMS0xLTEtMTEyOTg_678cd4be-69cd-408b-9e62-cf1e63e7e7df">1,405,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7a330302e89494f86be51dbb5ad4eba_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOC0xLTEtMS0xMTI5OA_9e617f26-2185-4474-be55-a2cf67e16095">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a330302e89494f86be51dbb5ad4eba_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOC0zLTEtMS0xMTI5OA_a9c9a09c-e73d-4c7f-9408-00554898226f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ab4897a894445fb01edd925a1631d2_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOC01LTEtMS0xMTI5OA_02664b4c-a2d8-4800-a239-ed0cd1d09f2d">23,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOC0xMS0xLTEtMTEyOTg_88a4ca7d-4949-482f-a327-5ab6d3fe2bd9">23,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ab4897a894445fb01edd925a1631d2_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOS01LTEtMS0xMTI5OA_a5e24de8-8eba-46fd-9610-bc682bef2723">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOS0xMS0xLTEtMTEyOTg_fe649b0a-8b2b-4f88-9050-77c597ea0979">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06602f496e114bfea3a9bdc411724138_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTAtNy0xLTEtMTEyOTg_8ae194ff-66f5-4510-bc7c-7a5147dbe6f8">1,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i218a36c4ef32491d8ed93aa732435402_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTAtOS0xLTEtMTEyOTg_97216144-a0a5-47f5-8263-87b1aecd8f10">444,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTAtMTEtMS0xLTExMjk4_cb7f7908-d476-4ebe-bc73-235c849d279e">445,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4958a2d31a14357b76df572e493fa94_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtMS0xLTEtMTEyOTg_d12b247f-8d38-48b6-924a-c93297298338">180,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4958a2d31a14357b76df572e493fa94_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtMy0xLTEtMTEyOTg_7122c8f5-b774-415c-84c3-f002a0355ace">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7070fa33af194d52891eedefe4dfb853_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtNS0xLTEtMTEyOTg_1ea3f2ee-2433-4fc8-83f9-47936c427cfa">3,388,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bcba052d2f340589756a4df2f43f3c8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtNy0xLTEtMTEyOTg_23bb13f0-910d-4b25-b76a-a9c2bc3a9f32">2,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i426f379da93c42a2b87f77f27a1dfc65_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtOS0xLTEtMTEyOTg_4546717f-4f50-40cc-a8a1-8946a53c7fbd">2,309,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtMTEtMS0xLTExMjk4_df69fe49-5bfc-4fcb-a467-97fb0a4db097">1,077,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd67d9937f7d47baafb15299a877ed6b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTItMS0xLTEtMTEyOTg_37735157-3876-4347-9040-2fa8980fe00d">5,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd67d9937f7d47baafb15299a877ed6b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTItMy0xLTEtMTEyOTg_2788d14e-c0db-4b22-a6c4-0b3c4089760d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526f6174d8c74127a9c60db3a5d90b76_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTItNS0xLTEtMTEyOTg_1ec3f8f6-6616-4089-a312-2bc8706a6a64">33,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTItMTEtMS0xLTExMjk4_a61a8375-8d18-4abd-9736-96cdf51890bf">33,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526f6174d8c74127a9c60db3a5d90b76_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTMtNS0xLTEtMTEyOTg_13d57d28-50a5-4884-bc95-37701cdbb0b8">94,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTMtMTEtMS0xLTExMjk4_aa4c419e-efb9-4a94-b6c4-4c61e04d8653">94,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7aac894909174929a2fae22e8d8a3906_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTQtNy0xLTEtMTEyOTg_92621598-c9a2-44d0-bc3e-e783489d3b18">1,862</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cb2f5eb7d0d4cd0a19c316ad433666a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTQtOS0xLTEtMTEyOTg_5930acc2-45c7-4c5a-915f-1483ea43171d">523,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTQtMTEtMS0xLTExMjk4_26ea8808-bc0d-46a4-9085-d9e19cc051cd">525,699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2206f8a53bc949e99e036f0c404e52a5_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtMS0xLTEtMTEyOTg_15afee35-032a-4158-9980-1c83aa844c04">185,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2206f8a53bc949e99e036f0c404e52a5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtMy0xLTEtMTEyOTg_9fec5269-d3fe-4174-bf12-d51f4966f38c">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd923bc535f4746833b54075312bef7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtNS0xLTEtMTEyOTg_d690813f-4a85-4028-b0a1-a61af9ad3999">3,516,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e0d6be14b9b4e589ab67d81ec71404f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtNy0xLTEtMTEyOTg_0d9db531-3133-49a8-ae29-27420162105f">4,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida774e4baed04895887759bea104497e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtOS0xLTEtMTEyOTg_87fb1d15-15c9-4fc4-80c3-9df41a9b157e">2,832,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtMTEtMS0xLTExMjk4_dd8807f0-df84-431b-8c6a-3c4754c690dd">679,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMy0xLTEtMS0xMTI5OA_84b242ad-a860-4f8a-9f9d-c8f02ca324f7">523,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMy0zLTEtMS0xMTI5OA_61d698f6-d03e-43ff-bb1b-add153054df0">444,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMy01LTEtMS0xMTI5OA_cc22e81b-076b-4658-9137-0cb9c24bee34">440,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to the sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNS0xLTEtMS0xMTI5OA_4dc797b9-5fce-4e00-a7f5-b3f907f18b6c">77,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNS0zLTEtMS0xMTI5OA_d4ae87b4-cf9b-4aa8-add7-79be305a3c92">48,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNS01LTEtMS0xMTI5OA_7c88818a-b341-4cc4-9c29-e720d3e57b89">36,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense on liabilities related to sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNi0xLTEtMS0xMTI5OA_51de2009-6b02-43da-a850-67a25403e0a2">47,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNi0zLTEtMS0xMTI5OA_57988cbc-534a-41d0-ab64-8b2890b6cf63">30,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNi01LTEtMS0xMTI5OA_ef6d62c8-b159-4168-b067-84b3d9741aec">25,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0xLTEtMS0xNTUwNg_b1e87c18-1747-4cf7-ab27-1ec9c586b642">24,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0zLTEtMS0xNTUwNg_4b28b2f6-f4d0-4c97-9df4-d55eb3ccbb7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy01LTEtMS0xNTUwNg_c9eb67f8-bcbf-4158-90ae-45d014337381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0xLTEtMS0xMzE2MA_e9a94fb5-a10e-4f88-bd61-e10814c59215">8,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0zLTEtMS0xMzE2Nw_b37ba5c5-035f-4245-870d-ad55cf379a0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy01LTEtMS0xMzE3NA_428fe477-4290-43d5-8790-786394c99bdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS0xLTEtMS0xNTUxMw_d612dd6a-6d14-41ef-bdaa-cf223a0f6f2b">16,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS0zLTEtMS0xNTUxMw_ba504876-131b-4a48-b7e0-68cc252c0eed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS01LTEtMS0xNTUxMw_96cbd83d-6d06-4e8d-9d06-c7f82b84732f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0xLTEtMS0xMTI5OA_9578e354-e236-4cf1-920d-9c9aa23ce776">94,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0zLTEtMS0xMTI5OA_bb8990b9-7222-41c9-b0ce-da9c5ebd0c3f">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy01LTEtMS0xMTI5OA_cd9e4131-f3fc-4456-aed5-e02baffe05c2">99,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOC0xLTEtMS0xMTI5OA_96a6848f-1b99-44f1-b621-408d68c52322">14,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOC0zLTEtMS0xMTI5OA_7071fcd4-85c6-462c-a651-c9c770cc8b92">14,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOC01LTEtMS0xMTI5OA_f9a55592-8969-4d62-b0f6-346a76955738">13,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of advance payments to contract manufacturers and equipment for terminated program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS0xLTEtMS0xMTI5OA_38975538-0ecd-42d3-b706-3c8bd5d83de6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS0zLTEtMS0xMTI5OA_1675b268-3285-4e99-97d8-5d57f74462c8">20,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS01LTEtMS0xMTI5OA_253c8b07-dee0-478d-bcac-4a5ba5db7f4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of premiums (discounts), net and other non-cash transactions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTAtMS0xLTEtMTEyOTg_0497e470-2968-4e16-9deb-ac3da7d7dca6">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTAtMy0xLTEtMTEyOTg_07cbddd4-68ec-4e50-ae91-ea089baf3832">3,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTAtNS0xLTEtMTEyOTg_399e94f0-abc4-45f3-816f-58c6fd97d6f3">11,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTItMS0xLTEtMTEyOTg_e5dc9ddf-706a-4cab-b6d9-db7400216311">12,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTItMy0xLTEtMTEyOTg_8ab15f3a-53ce-482a-9991-6ff9c4406289">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTItNS0xLTEtMTEyOTg_5d9d8530-a04b-4fd2-b17c-309d63544eba">6,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTMtMS0xLTEtMTEyOTg_deebbc35-17b6-4a63-a682-9ae561bac1d7">509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTMtMy0xLTEtMTEyOTg_a8362f0d-4054-4556-928c-cae3d51545e8">2,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTMtNS0xLTEtMTEyOTg_9b48a314-29a1-4d9d-8496-541ad73a5428">1,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTQtMS0xLTEtMTEyOTg_d182bdfc-983a-418f-aa83-d097a19a1ef3">2,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTQtMy0xLTEtMTEyOTg_3ead489b-c576-4ca8-b6be-4f9b4cff96c8">2,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTQtNS0xLTEtMTEyOTg_db2c2b47-8ddf-48d7-b01d-ba9eea803286">13,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTUtMS0xLTEtMTEyOTg_569dc6e3-bae8-43e6-8610-d6369df33ea0">2,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTUtMy0xLTEtMTEyOTg_6514e487-096e-4eda-8015-51d7b806ec78">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTUtNS0xLTEtMTEyOTg_08b3ae13-8ce3-4c47-b6db-5479fb3f9182">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTYtMS0xLTEtMTEyOTg_591b947a-5828-49c7-ae68-cc2a8a3fd3d0">11,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTYtMy0xLTEtMTEyOTg_71c33919-a896-4f16-86a7-769d5cbea5f2">2,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTYtNS0xLTEtMTEyOTg_65dc6bff-4c1b-4534-9833-9b7cb308d666">12,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTctMS0xLTEtMTEyOTg_233445d9-1731-4174-ba9a-e399bcdcaaa7">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTctMy0xLTEtMTEyOTg_49bdfd26-2252-4a5e-b54e-e510470287b2">4,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTctNS0xLTEtMTEyOTg_ae752d6c-4e33-46a3-8542-f9759dcc18bb">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTgtMS0xLTEtMTEyOTg_f957424f-39ed-4abb-8f81-5225fc23a5b9">23,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTgtMy0xLTEtMTEyOTg_dfb5350b-5fe7-4005-b397-805d0881650d">8,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTgtNS0xLTEtMTEyOTg_35b39636-118f-4825-83ae-9091e867d181">4,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTktMS0xLTEtMTEyOTg_6ec0a31c-4582-4463-8aeb-7c9ef0315330">605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTktMy0xLTEtMTEyOTg_a2fdaa3d-4bb5-4c78-9445-d27e9cc09f9d">5,516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTktNS0xLTEtMTEyOTg_c1499095-ceda-4e68-87c9-2def842b8cff">16,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjAtMS0xLTEtMTEyOTg_7f600b86-b16d-48bb-b467-d92213010448">412,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjAtMy0xLTEtMTEyOTg_81eccb73-d549-4ded-8ea9-7812d52ae57d">313,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjAtNS0xLTEtMTEyOTg_dd8ab7f7-563e-43b7-9a1d-831474060a17">328,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjItMS0xLTEtMTEyOTg_75bfcf66-68a0-4b75-bbeb-84e0f3be2a32">960,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjItMy0xLTEtMTEyOTg_5a20c8ef-2e6f-4646-b83b-ee3c8d198e9a">987,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjItNS0xLTEtMTEyOTg_c064afd4-d9e9-4611-8b2f-ee9aa960aa36">1,380,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjMtMS0xLTEtMTEyOTg_92b90b97-026f-406e-83c4-09583f780c8a">1,166,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjMtMy0xLTEtMTEyOTg_2a4260db-d1cb-4580-ba37-5317de5d1a41">1,449,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjMtNS0xLTEtMTEyOTg_79acefa1-4fbb-48b3-ba74-6bfc2a9c3e93">1,614,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjQtMS0xLTEtMTEyOTg_439f05fe-62c9-473c-92af-3467f9c9960d">11,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjQtMy0xLTEtMTEyOTg_1b030a74-a7da-4f26-b0c7-08e5e42b2b29">41,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjQtNS0xLTEtMTEyOTg_f80a2cfd-edc0-4f1c-ac84-2c1b461bec49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjUtMS0xLTEtMTEyOTg_d75745ab-7626-4d48-8776-baebec93083b">14,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjUtMy0xLTEtMTEyOTg_ae0fe13b-3544-487b-87ac-e058f7281a01">7,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjUtNS0xLTEtMTEyOTg_933c04cb-3777-4475-858a-95a0f713f6b3">26,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjctMS0xLTEtMTEyOTg_a891af03-3405-442e-af5e-ad500b7a812d">202,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjctMy0xLTEtMTEyOTg_71f766ee-bfaf-4262-a21c-ce21db03a96f">496,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjctNS0xLTEtMTEyOTg_1670f85f-fcbb-46b1-b2c1-f7b5368cf9f6">206,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties, net of $<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-5" name="nktr:SaleOfFutureRoyaltiesTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzAtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4YjhhZTE5YjgyYTI0ZTVjYjYyNjRkMmQzMzczMmZlNV81MQ_fe2231ad-e724-47c2-b114-3830d8e9f96b">3.8</ix:nonFraction> million of transaction costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:ProceedsFromSaleOfFutureRoyaltiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzAtMS0xLTEtMTEyOTg_156a1537-92c5-48ed-9f0f-6b8d264dbaa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:ProceedsFromSaleOfFutureRoyaltiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzAtMy0xLTEtMTEyOTg_a6680598-92c2-4845-818f-508ed8c602f6">146,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:ProceedsFromSaleOfFutureRoyaltiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzAtNS0xLTEtMTEyOTg_004b167d-ea5c-4931-98fe-b0c7fe49d61b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzEtMS0xLTEtMTEyOTg_908e546b-4cff-4eed-95ff-23414a799a47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzEtMy0xLTEtMTEyOTg_f26694b2-16a7-4fc4-8b97-f84ed93390cf">250,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzEtNS0xLTEtMTEyOTg_5dc918ae-05a7-4672-9ed3-f4e0fdb036b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash receipts from development derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItMS0xLTEtMTMyMzI_ddb69855-da34-4b46-b71f-868e31ec1c0e">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItMy0xLTEtMTMyMzk_67549080-51fd-4202-89c6-8a4b2d19c711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItNS0xLTEtMTMyNDY_546fae13-d985-485e-b0e4-fdadf525b676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from shares issued under equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItMS0xLTEtMTEyOTg_976ecad4-2c47-428f-aa14-75cf1c505bf5">33,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItMy0xLTEtMTEyOTg_2c925ba1-98e0-43b6-8446-21ff16a4bc3e">23,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItNS0xLTEtMTEyOTg_0d7a2f08-03da-4bb4-94e9-f709d170d9e6">23,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzMtMS0xLTEtMTEyOTg_3652e645-c043-4ec3-8570-65e6d7be8559">36,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzMtMy0xLTEtMTEyOTg_8346e957-05bc-4dc0-9df2-2f451391341e">80,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzMtNS0xLTEtMTEyOTg_60a47580-4a3e-4149-94b6-4ac66debe91c">23,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzQtMS0xLTEtMTEyOTg_03613112-695c-4b4a-a7e4-ff823132e2d6">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzQtMy0xLTEtMTEyOTg_171a8bf1-fc4b-42b5-bf59-22bcd31607b3">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzQtNS0xLTEtMTEyOTg_ea5c04e7-e8f1-4a50-abb3-f95036972ea4">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzUtMS0xLTEtMTEyOTg_1535c3b1-0fa7-47b2-82a5-fc656c733dcb">173,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzUtMy0xLTEtMTEyOTg_0bfd1194-6c4e-47bb-9aff-3547256c366a">102,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzUtNS0xLTEtMTEyOTg_93b5f0d8-ec5e-49f5-9351-af4c67852fdd">98,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzYtMS0xLTEtMTEyOTg_bc0e0971-e1ac-4fe5-9a52-c0d20738f789">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a636947a9046a38a2ed739019eb13c_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzYtMy0xLTEtMTEyOTg_11e9f675-c691-4d35-9297-8311121edccc">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e86cae77d44493aad21052dab0a76b8_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzYtNS0xLTEtMTEyOTg_971c9d69-48fc-452a-a657-538d14fc0d5c">194,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzctMS0xLTEtMTEyOTg_795a40e5-8fc1-4565-90aa-448c2be25349">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzctMy0xLTEtMTEyOTg_3ac6388e-cbca-4ef2-9ec1-9126859140cd">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a636947a9046a38a2ed739019eb13c_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzctNS0xLTEtMTEyOTg_b120133e-1c1b-4535-8aa0-1d6c0369518d">96,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzktMS0xLTEtMTEyOTg_ad798c3b-1e35-4040-8de1-f021c7653d5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzktMy0xLTEtMTEyOTg_958ef441-81a7-49a8-8a90-7b000fcec3c4">9,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzktNS0xLTEtMTEyOTg_c39396f4-0aa5-4faa-b787-f2192c95c85b">19,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDAtMS0xLTEtMTEyOTg_a814bea9-865d-4110-bf75-faf59cf2e129">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDAtMy0xLTEtMTEyOTg_7c7f2554-4295-4161-8c68-c08b104f7ade">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDAtNS0xLTEtMTEyOTg_010e43df-8df9-4e2c-8044-0205b392d2a1">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets recognized in exchange for lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDEtMS0xLTEtMTEyOTg_c0bbb956-284e-43c8-a863-4d7c3661b846">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDEtMy0xLTEtMTEyOTg_cd9899f6-b415-4da9-9a72-7645aeed7c38">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDEtNS0xLTEtMTEyOTg_15e8ecd4-f2ca-4585-8c78-ba1736c65ff0">57,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable recognized in exchange for long-term liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDQtMS0xLTEtMjI1ODA_b8eb7205-8521-4190-b75c-2b094186d6f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDQtMy0xLTEtMjI1ODA_6aa383ea-b9c3-4914-a067-ad1b1bb5faf8">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDQtNS0xLTEtMjI1ODA_3e3a07d5-e09e-4303-8806-0eaf280dd716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEKTAR THERAPEUTICS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2021</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ote&#160;1&#160;&#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwNDM_5beb9637-e82d-4045-af44-23a6c1876b53" continuedAt="i0a52e90aca99480fa3d8d3c651e5a54b" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i0a52e90aca99480fa3d8d3c651e5a54b" continuedAt="if9fccdc727c64d6f9d775887a2ffc659"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:OrganizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzY_e917d6b8-c582-48a6-a9d8-1c8cdfe84aee" continuedAt="i849861c8109b4baa9b7443cb12be8b7b" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i849861c8109b4baa9b7443cb12be8b7b">&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</ix:continuation> At December&#160;31, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-5" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTA0OA_d3fa843a-88f4-468f-b27e-58f8c12b1081">798.8</ix:nonFraction> million in cash and investments in marketable securities.</span></div><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzc_a6dcdec0-2c55-4777-be40-0fd85d1c536d" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation, Principles of Consolidation and Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Nektar Therapeutics Europe GmbH, Nektar Therapeutics (India) Private Limited (Nektar India),  Inheris Biopharma, Inc. (Inheris) and certain other entities in Europe. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in the valuation of our development derivative liability as further described in Note 6; our assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="if9fccdc727c64d6f9d775887a2ffc659" continuedAt="i7870304deb3a4bc2830099544369f471"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwNDQ_5d9b596c-8c00-47fb-9550-1587c610b5b6" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzA_1335c46d-6762-40f1-816a-033a1e25fdae" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at estimated fair value. The disclosed fair value related to our cash equivalents and investments is based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. Development derivative liability is recorded at its estimated fair value based on management&#8242;s estimates of several unobservable inputs, including the probabilities of success of ongoing clinical trials and various other inputs described above and in Note 6.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the years ended December&#160;31, 2021 and 2020, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzE_8d4afa71-decd-4676-abaa-412987c8e77d" continuedAt="i1a2256de3b174ea89ef861bea57154c8" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments in Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and investments are held or issued by financial institutions that management believes are of high credit quality. However, they are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have seen credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#8217; equity as accumulated other comprehensive income (loss). We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i7870304deb3a4bc2830099544369f471" continuedAt="i819f7505f8cc468da9ca272aa4239582"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1a2256de3b174ea89ef861bea57154c8">&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.</ix:continuation></span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzI_9ca4770a-1299-4ac0-898e-9d3ad72a8c96" continuedAt="i9e96503f46db437caf8dc395bf197431" escape="true">Accounts Receivable and Significant Customer Concentrations</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9e96503f46db437caf8dc395bf197431" continuedAt="ib9585a73e95747a7bfb309764351dc5d">&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments, as well as reimbursable costs from collaborative research and development agreements.</ix:continuation> Our accounts receivable included $<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-5" name="nktr:NetExpenseReimbursementsFromCollaborationPartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfODg1Mw_46678e18-bacc-4c8c-ad39-fe836d627347">21.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-5" name="nktr:NetExpenseReimbursementsFromCollaborationPartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTY0OTI2NzQ0ODIyNDU_98109d9d-23d2-4a0f-8e5f-e82ab5050d10">38.7</ix:nonFraction> million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) as of December&#160;31, 2021 and December&#160;31, 2020, respectively. The remaining accounts receivable related primarily to product sales. <ix:continuation id="ib9585a73e95747a7bfb309764351dc5d">We perform a regular review of our partners&#8217; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.</ix:continuation></span></div><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMjI_532975cc-c4fe-4398-981f-0d7deb322c53" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Significant Supplier Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTA5OTUxMTYzNTk5Nzc_e91ef43d-9aba-4c03-a53b-990148512d31" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We state property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjA3OTA_047a9ea0-7fde-4ef1-8171-92c0f31dcfa0">three</span> to <ix:nonNumeric contextRef="i8d4b5ee692844d22bd172e136bf853f3_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTA5OTUxMTYzNTk5Nzg_fd27603a-5e84-4941-a21f-bf46385f70fb">ten years</ix:nonNumeric>, depreciate buildings over the estimated useful life of generally <ix:nonNumeric contextRef="i217337f2d85e411fa6cca2f9cc353fcb_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjA4NzM_3a20333a-2099-4eae-91a1-bb274c2d6118">twenty years</ix:nonNumeric> and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in <ix:nonFraction unitRef="reporting_unit" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="INF" name="nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjExODc_056b89af-e433-49ca-8bae-6bf7f5dd96e0">one</ix:nonFraction> reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting units equals its fair value.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i819f7505f8cc468da9ca272aa4239582" continuedAt="i593ea6f25ad842988fa24fe0754b7ee8"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMjE_de4e98d5-40fa-4106-bad4-2d3fb0cc564a" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 7 for additional information regarding our leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMjY_99f37107-550b-4757-8549-f4191f4b82be" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwNDc_fa0763c4-d124-419f-9332-464005aabf2b" continuedAt="ia1a2de6070b34f1bae094d8f67f16a96" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i593ea6f25ad842988fa24fe0754b7ee8" continuedAt="i4a9e79bf3f694f7dbe0e87e84afa0018"><ix:continuation id="ia1a2de6070b34f1bae094d8f67f16a96"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue, including Non-cash royalty revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2021, we have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 8. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our aggregate royalty and non-cash royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="ia35126ada49c4aa5b6a31fd74e38aa13_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTY0OTI2NzQ0NzI5OTE_a9c5f31c-652a-41c5-bd47-080c1cab7d34">77.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i9ee5e0af22004d498eafd130a613cee6_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTY0OTI2NzQ0NzMxMTA_54b2fdf3-d491-4ef8-8bea-b8ca1ef3bae6">79.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib29439b8ce094e458c12e418a5f1055e_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTY0OTI2NzQ0NzMxMjU_4c3953be-643a-4c80-bf61-bc1bf4add9ca">77.5</ix:nonFraction>&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively, represents revenue for granting licenses for which we had satisfied in prior periods. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. As described further in Note 11, we recognized $<ix:nonFraction unitRef="usd" contextRef="i57d6518d703e4cdba742d40dbc46673d_D20200101-20201231" decimals="INF" name="nktr:SalesMilestoneRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfODI0NjMzNzI2NTI5NQ_8d70991b-958a-416c-ac04-d4d6b3646e20">50.0</ix:nonFraction>&#160;million of milestones in the year ended December 31, 2020 because we had previously satisfied the performance obligation. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div></ix:continuation><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzQ_3b678c19-6f5a-411e-b3fa-45a03686e69f" continuedAt="i99892b6279874079bbe600ad64ce5d1e" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i4a9e79bf3f694f7dbe0e87e84afa0018" continuedAt="ie44294d0c4e0436e8402617305b6830e"><ix:continuation id="i99892b6279874079bbe600ad64ce5d1e"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMjc_67d61304-6318-4b32-997c-5c6c24c6d246" continuedAt="i3c66b7eb899a408984b35f057ccd0c34" escape="true">Impairment of Assets and Other Costs for Terminated Program</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3c66b7eb899a408984b35f057ccd0c34">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</ix:continuation> As a result, in the three months ended March 31, 2020, we wrote off $<ix:nonFraction unitRef="usd" contextRef="i8d18817442a34679beeb50708361c836_I20200331" decimals="-5" name="nktr:WriteOffOfPrepayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMjk0NTA_95a1a7b2-f6dd-4283-a141-cb73e248bace">19.7</ix:nonFraction>&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $<ix:nonFraction unitRef="usd" contextRef="i8d18817442a34679beeb50708361c836_I20200331" decimals="-5" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMjk1NTI_314ade53-eab0-45b4-a485-ccbada8b7592">25.5</ix:nonFraction>&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. </span></div><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMTU_eedaf040-d26d-4158-a086-791abaa1898b" continuedAt="i3d571f078c2043b1a9fb2b71a7fc5acc" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs), performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs, PSUs and ESPP shares on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For options and RSUs that vest upon the achievement of performance milestones, we recognize expense provided that we believe that the performance milestones are probable of achievement, and we estimate the vesting period based on our evaluation of the  estimated date of achievement of these milestones. For PSUs, we recognize expense based on the grant date fair value regardless of whether the market condition is met. Additionally, we do not adjust the expense based on the number of shares ultimately issued, which may be higher or lower than the grant amount. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="ie44294d0c4e0436e8402617305b6830e"><ix:continuation id="i3d571f078c2043b1a9fb2b71a7fc5acc" continuedAt="i63914e6e0f0a494b93510749dde2c9dc"><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#8217; stock to the index. </span></div></ix:continuation><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i63914e6e0f0a494b93510749dde2c9dc" continuedAt="i8fcbbe47956a4ecab3613491a75de4db">&#8226;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:continuation id="i8fcbbe47956a4ecab3613491a75de4db">The fair value of an RSU is equal to the closing price of our common stock on the grant date.</ix:continuation> </span></div><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTA5OTUxMTYzNTk5ODA_af317193-4262-433d-8dbf-070a1813ac38" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.</span></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMTY_538b9753-fd3d-4815-ac34-9e95edb55d65" continuedAt="i6fa6070e0b694f1ab16a5b17562ccbbc" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6fa6070e0b694f1ab16a5b17562ccbbc">&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented.</ix:continuation> For the years ended December 31, 2021,  2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded weighted average outstanding stock options, RSUs and PSUs totaling <ix:nonFraction unitRef="shares" contextRef="i8fd12c28a1fc4527927d94cbb3fecda6_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzQxNzU_87812c34-dd98-404c-8c7a-cb3a6e4f11f8">18.4</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="ief3930a5607f46ba9969d019065ed3bc_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTY0OTI2NzQ0NzE4Mjc_8fcd695d-3789-400f-bc25-a29c5722b36e">17.4</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i255350b9923e4b0f90bb25e7e8e6ea4f_D20190101-20191231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzQxODI_48b45b65-5ad2-449d-97d0-16cfcb85e317">17.9</ix:nonFraction> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzU_c4573a0c-5a15-4011-914e-b3fa7d2e5ffc" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our comprehensive loss includes our net loss, gains and losses from the foreign currency translation of the assets and liabilities of our foreign subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwNDI_194b8a15-e590-464b-bd1c-7e4f6be9c14f" escape="true"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjU1OA_cfcea5a8-b1ce-4888-b235-1f1240873e1f" continuedAt="icfb3ad86fe6a41a09f5e3ac45a45c7d6" escape="true">Cash and Investments in Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="icfb3ad86fe6a41a09f5e3ac45a45c7d6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjU1Mw_01876556-f6f6-4080-b05b-3585b677f5dc" continuedAt="i22961b7310384b39bf07a0fafbae6468" escape="true">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i22961b7310384b39bf07a0fafbae6468"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfMi0xLTEtMS0xMTI5OA_c7114042-5315-4626-a732-7a8f2dff350a">25,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfMi0zLTEtMS0xMTI5OA_e200782b-17f8-47da-9505-d519aa76d664">198,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfMy0xLTEtMS0xMTI5OA_718b6149-d770-48f0-9217-6235d5417607">708,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfMy0zLTEtMS0xMTI5OA_3be10219-b233-4659-8bf6-bb2f3186eefe">862,941</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfNC0xLTEtMS0xMTI5OA_20889c9d-c41c-450d-b354-ba42e0d83e6a">64,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfNC0zLTEtMS0xMTI5OA_1b748d46-a94a-4447-8e63-acbe94decca1">136,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfNS0xLTEtMS0xMTI5OA_9252ad8a-03d0-4c33-8e2f-56bf672340c3">798,783</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfNS0zLTEtMS0xMTI5OA_0be2731f-da81-4c4c-a212-de40485b52a2">1,198,558</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. All of our long-term investments as of December&#160;31, 2021 and 2020 had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTU0_0003ae67-eceb-4b3d-a922-f92cdc2a62bd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTU0_c526c77b-95f7-450d-b638-74b09846bea6">one</span></span> and <ix:nonNumeric contextRef="i76ba7fa3878f41e9baee05ebb5353b2b_D20200101-20201231" name="nktr:LongTermInvestmentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTYx_85cf2432-13ef-4855-9943-767b29077267"><ix:nonNumeric contextRef="idb1efb0d79f74d20bc94eefb71431fe8_D20210101-20211231" name="nktr:LongTermInvestmentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTYx_b86c9272-6077-4444-82bf-de2bbed4300f">two years</ix:nonNumeric></ix:nonNumeric>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2021 and 2020, we sold available-for-sale securities totaling $<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMzI5ODUzNDg4ODA4NQ_5419bec3-0f40-4bd9-abb6-fa3850afe7d7">11.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMzI5ODUzNDg4ODA5NQ_0e198e32-2fe6-42b3-83af-2c85c1ec4869">41.7</ix:nonFraction>&#160;millions, respectively. We did <ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="INF" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMzg0ODI5MDcwMTQ4NA_7e6572a8-471c-482b-b36f-9fb2e980ed8c">no</ix:nonFraction>t sell any available-for-sale securities in the year ended December 31, 2019. Gross realized gains and losses on those sales were not significant. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our accrued interest receivable, which totaled $<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfOTU5_8a63bd09-e29a-4927-afd6-bef2329265a4">1.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfOTY2_d561be33-a0bc-4938-b78b-b91c5d1b43ff">5.1</ix:nonFraction>&#160;million at December&#160;31, 2021 and December&#160;31, 2020, respectively, in other current assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjU1NQ_cab7de91-6cdf-461b-8feb-6077dd9e3f78" continuedAt="i2677adacec624514b0311e219c9b72b9" escape="true">Our portfolio of cash and investments in marketable securities includes (in thousands):</ix:nonNumeric></span><ix:continuation id="i2677adacec624514b0311e219c9b72b9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f975e3020e40db8824c97ec642e248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMi0zLTEtMS0xMTI5OA_d4637de1-8b29-4823-8abf-28b6189d413f">278,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f975e3020e40db8824c97ec642e248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMi01LTEtMS0xMTI5OA_67bdc7b1-ab5b-4abc-9659-7a519e907b54">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f975e3020e40db8824c97ec642e248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMi03LTEtMS0xMTI5OA_daae9b9a-f232-4123-92ee-27e6ed49c10a">361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f975e3020e40db8824c97ec642e248_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMi05LTEtMS0xMTI5OA_cdbbd8be-ee60-4d66-ad2c-c85e0a219ec0">278,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb32306fdad746dd9da19728ea7271ef_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMi0xMS0xLTEtMTEyOTg_220f1962-0a79-4852-918e-c6813d902625">687,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f44a6188024f06a84a6f4b3d8acfbb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMy0zLTEtMS0xMTI5OA_3df67151-2759-4021-9d98-46ce94199309">478,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f44a6188024f06a84a6f4b3d8acfbb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMy01LTEtMS0xMTI5OA_0490281b-0432-4f0d-aa86-9fe76d44ac52">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38f44a6188024f06a84a6f4b3d8acfbb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMy03LTEtMS0xMTI5OA_19300527-af8e-41c8-a7d8-2c656120bdd6">308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f44a6188024f06a84a6f4b3d8acfbb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMy05LTEtMS0xMTI5OA_db9a35f7-4461-4cda-acad-4a77e0b0aa6d">478,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a53b7985d374ead811b6e5a7dd2154f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMy0xMS0xLTEtMTEyOTg_c38eb8f6-7b6d-4c97-a054-e067786a3ae0">313,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e7dc8250694c90b0688660e3c7810b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNC0zLTEtMS0xMTI5OA_79a50f3b-ecae-4732-b223-70c56fbc064d">5,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e7dc8250694c90b0688660e3c7810b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNC01LTEtMS0xMTI5OA_7fd1502c-3b10-4cd4-a1fa-4eb3317c8078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51e7dc8250694c90b0688660e3c7810b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNC03LTEtMS0xMTI5OA_5d34b33a-52ce-4e3a-8c70-a7e082a04b50">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e7dc8250694c90b0688660e3c7810b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNC05LTEtMS0xMTI5OA_21f95854-7ef8-40f0-8ec1-a5bb2b69d899">5,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie572f0f09594489993a50e2018463f9e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNC0xMS0xLTEtMTEyOTg_186a24ef-fdb0-4fb5-977e-7e4166929b56">2,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNS0zLTEtMS0xMTI5OA_a9dcbb7c-b384-4404-8cb8-081ade9c882b">763,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNS01LTEtMS0xMTI5OA_b975a3e0-6f12-463c-822d-616061d10669">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNS03LTEtMS0xMTI5OA_f06e6e64-b6ac-4f1e-8212-116c0e099f96">674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNS05LTEtMS0xMTI5OA_6999760c-65a6-4630-8aeb-4406b4c3af00">762,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNS0xMS0xLTEtMTEyOTg_e2c7f180-e732-47fb-9cb7-58e7af4930be">1,003,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe4e66cfc3c244c896b83266e392cd87_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNi05LTEtMS0xMTI5OA_3abe657c-beee-46f1-8f58-e52a743a54a8">23,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5ad5ce7ba243e78803676a3ada6929_I20201231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNi0xMS0xLTEtMTEyOTg_c76d32b2-8621-4895-b320-a0bc758f353a">179,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbab848955664506b7524f1830aca69c_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNy05LTEtMS0xMTI5OA_10f30504-4fe6-4288-bd2e-02a6d077c4fc">10,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia01507cb6301463b804b5486907c00f4_I20201231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNy0xMS0xLTEtMTEyOTg_014d3f53-4abb-40f2-8646-14b4d2b93a7b">9,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfOC05LTEtMS0xMTI5OA_5d9ccc23-586e-473d-b212-bbca0d3828a3">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfOC0xMS0xLTEtMTEyOTg_71d8fada-aac0-4f89-b0fd-aa99b15a125b">6,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfOS05LTEtMS0xMTI5OA_1b156f5a-ad84-479a-bff1-0b99cec1d2be">798,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfOS0xMS0xLTEtMTEyOTg_8cadea41-ad46-48bc-82e1-b7b99843f0eb">1,198,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December&#160;31, 2020, our gross unrealized gains and losses totaled $<ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjMyOA_dcf3bf92-10b2-403b-b267-4e7853da83e2">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjMzNQ_2fea6ddb-595e-4f68-ac5f-d074199649bd">0.2</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both December&#160;31, 2021 and 2020, we had letter of credit arrangements in favor of our landlords and certain vendors totaling $<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjQ1OQ_8f0cc5aa-0d58-4191-88d0-fda23fb148b8"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjQ1OQ_a83a0b03-0079-41c6-a2f8-0c961c115264">8.1</ix:nonFraction></ix:nonFraction> million. These letters of credit are secured by investments of similar amounts.</span></div></ix:continuation><div id="i1023926dfc3b4cff924b0207eb081f42_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RleHRyZWdpb246ZjY1ZjlhZTI5ZGYwNDU2OWJjYjZjN2M1OGYxYWM3ZDFfNzk_9578d656-c35e-4889-9b20-fe25980fa5ab" continuedAt="i2e6d18cdc20f4e28bde9ff61fd3a4e80" escape="true">Inventory</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i2e6d18cdc20f4e28bde9ff61fd3a4e80"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RleHRyZWdpb246ZjY1ZjlhZTI5ZGYwNDU2OWJjYjZjN2M1OGYxYWM3ZDFfODA_f820c9d4-252b-4497-a63a-577a710352ba" continuedAt="i9473be09b8204ccbb4f04c0bfc0af17f" escape="true">Inventory consists of the following (in thousands):</ix:nonNumeric></span><ix:continuation id="i9473be09b8204ccbb4f04c0bfc0af17f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfMi0xLTEtMS0xMTI5OA_5580a0b8-b326-43cd-8c34-ef2b502c68a0">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfMi0zLTEtMS0xMTI5OA_d970d167-5b24-4694-b2e3-699bd1c2e240">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfMy0xLTEtMS0xMTI5OA_8828fd80-d493-4b60-be8e-b984cb9b432e">9,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfMy0zLTEtMS0xMTI5OA_24d0d78a-2e20-4ae5-a139-1070f813538d">10,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfNC0xLTEtMS0xMTI5OA_54d0017d-a12d-4373-90fa-f0380f034423">3,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfNC0zLTEtMS0xMTI5OA_5c94d2b4-524c-46c6-8073-541d81bbf9cd">2,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfNS0xLTEtMS0xMTI5OA_25b63123-406c-4f2b-8060-afe9581e16a2">15,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfNS0zLTEtMS0xMTI5OA_cd6d87e2-1d00-4a08-b3a6-79764bba81e1">15,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;4&#160;&#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RleHRyZWdpb246ZjZhNTYwNmM1ZTY0NGY2MmEzYmMzNTg0NTNmZmZkMTlfNjc2_03e7a2f3-78a6-4e1f-b301-7f7b75b688f9" continuedAt="if12b713a080b449ab4faeeecaa811ab6" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="if12b713a080b449ab4faeeecaa811ab6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RleHRyZWdpb246ZjZhNTYwNmM1ZTY0NGY2MmEzYmMzNTg0NTNmZmZkMTlfNjc3_42b9b59e-b4a6-4c25-b059-e12c28daade2" continuedAt="i3ccb8918ee7c47b9aa1eab0bd271f429" escape="true">Property, plant and equipment consists of the following (in thousands):</ix:nonNumeric></span><ix:continuation id="i3ccb8918ee7c47b9aa1eab0bd271f429"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e094fd9a7d4fc2abfa5a035a57ec8f_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMi0xLTEtMS0xMTI5OA_ad567efe-79d8-46ea-81db-9fd58b52c93e">97,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0eefc7a17f43a49c7d5e3ddf06a052_I20201231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMi0zLTEtMS0xMTI5OA_ced0b81c-1718-497a-b152-aad106a30694">92,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72222465a5784d0f8b7df22ece9a04bb_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMy0xLTEtMS0xMTI5OA_4223e2f1-bf4a-44f1-a86a-0d294f825b78">42,704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f9318818cfa4595b929b1a68fe6e107_I20201231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMy0zLTEtMS0xMTI5OA_e673c7ef-7dc2-4ba2-a325-776f4a383fa1">40,121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1773cfeb2884095bf5d3d8360db3e44_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNC0xLTEtMS0xMTI5OA_dbd57fc6-3c17-499b-843c-12b3aaeed433">28,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c7a174caa0406d9fb512ac548781a1_I20201231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNC0zLTEtMS0xMTI5OA_99eb91fd-909d-4358-9a66-236e0f8ffe61">28,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69cc5696809542c890b6fc09c58cab17_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNS0xLTEtMS0xMTI5OA_381a62e6-448b-40a1-8267-08b88809038d">22,374</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbd78d2a576c437caf2eb6a175e66c00_I20201231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNS0zLTEtMS0xMTI5OA_27cbc066-8ab6-4702-bf46-bfebd6aa64ab">21,796</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab142e35c42244cbb7c910e1ada05075_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNi0xLTEtMS0xMTI5OA_d3ffe330-30fa-4844-87b0-db27c1acbe15">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d44c99d9de54043985c7720d72c53f7_I20201231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNi0zLTEtMS0xMTI5OA_741adb2c-0659-4f7c-8f97-1313568c1523">9,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNy0xLTEtMS0xMTI5OA_de076e28-4ebc-44af-a764-2a44e42a6bae">201,386</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNy0zLTEtMS0xMTI5OA_c9fb028b-d7bc-4413-9f6e-521c336726a3">193,450</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfOC0xLTEtMS0xMTI5OA_30b755b8-0cf0-4518-bfb7-e408853c5645">148,039</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfOC0zLTEtMS0xMTI5OA_7bed803d-7ed8-467f-b325-8a82b57a5ded">138,488</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfOS0xLTEtMS0xMTI5OA_9410946c-e9cc-425d-bf14-4b6298eb9554">53,347</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="nktr:DepreciablePropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfOS0zLTEtMS0xMTI5OA_26ca192e-aca4-4f86-948b-466b899090db">54,962</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMTAtMS0xLTEtMTEyOTg_4a4f4d6d-cff4-4068-b727-475f787473ba">7,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMTAtMy0xLTEtMTEyOTg_e1c62d2e-8728-474d-bc19-2805862995b6">4,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMTEtMS0xLTEtMTEyOTg_7a00f9c5-c53e-440e-af87-35d05b9e4a7f">60,510</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMTEtMy0xLTEtMTEyOTg_6c7730a6-8e2a-455a-9ba3-026897597b14">59,662</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Building and leasehold improvements include our manufacturing, research and development and administrative facilities and the related improvements to these facilities. Laboratory and manufacturing equipment include assets that support both our manufacturing and research and development efforts. Construction-in-progress includes assets being built to enhance our manufacturing and research and development efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense for property, plant and equipment for the years ended December&#160;31, 2021, 2020, and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RleHRyZWdpb246ZjZhNTYwNmM1ZTY0NGY2MmEzYmMzNTg0NTNmZmZkMTlfNjQ3_8474d6b2-f6f8-498c-b305-695ab24aae52">13.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RleHRyZWdpb246ZjZhNTYwNmM1ZTY0NGY2MmEzYmMzNTg0NTNmZmZkMTlfNjUx_2d8840f7-ab37-4774-a85e-85a0f0117bb0">12.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RleHRyZWdpb246ZjZhNTYwNmM1ZTY0NGY2MmEzYmMzNTg0NTNmZmZkMTlfNjU5_652d98f7-3f84-43d1-b55e-eac4235579c2">11.0</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i1023926dfc3b4cff924b0207eb081f42_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;5&#160;&#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzExNTI_09e15b18-28eb-44c5-b216-c77a5ea5c30b" continuedAt="ic2143b41716e496f987f3ad27f09eba9" escape="true">Senior Secured Notes</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic2143b41716e496f987f3ad27f09eba9">&#160;&#160;&#160;&#160;On October 5, 2015, we completed the sale and issuance of $<ix:nonFraction unitRef="usd" contextRef="i4580a99794e6481fb70ca26feccaa301_I20151005" decimals="-5" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzk0_618ad44b-6626-4e36-bccc-1a43673a773c">250.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i4580a99794e6481fb70ca26feccaa301_I20151005" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzEzMA_ee1014f1-569c-438d-a469-a3ee333182a4">7.75</ix:nonFraction>% senior secured notes due 2020 (the Notes). The Notes bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="i4580a99794e6481fb70ca26feccaa301_I20151005" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzMyMw_08c99bfc-dfe9-4a93-89b5-15aaefddbaf3">7.75</ix:nonFraction>% per annum and were to mature on October 5, 2020. On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $<ix:nonFraction unitRef="usd" contextRef="i3a1cba01aa4941709dccf7ddad45a548_D20200413-20200413" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzEwMzQ_26896866-870d-44d2-b6bc-5d9826c0fb07">250.0</ix:nonFraction>&#160;million and accrued interest of $<ix:nonFraction unitRef="usd" contextRef="i69f84d8d2acb4dbabece7f5d1ab1fdeb_I20200413" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzEwNjE_a0e55484-8440-4ffc-97fe-f5c11bb96812">4.8</ix:nonFraction>&#160;million.</ix:continuation></span></div><div id="i1023926dfc3b4cff924b0207eb081f42_1653"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:DevelopmentDerivativeLiabilityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNDUz_d93ee9d1-cff5-434e-8d49-e6b9c368c596" continuedAt="i55afce7ce6544c2a946e3b7516dde87f" escape="true">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</ix:nonNumeric></span></div><ix:continuation id="i55afce7ce6544c2a946e3b7516dde87f" continuedAt="iedca2de273594de49b15ebf75fc70c95"><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a co-development agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ will pay up to $<ix:nonFraction unitRef="usd" contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementCommittedFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNDU2_363db331-2bf6-4f70-b158-ed5287fbff7f">150.0</ix:nonFraction>&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth. On February 11, 2021, we entered into a collaboration agreement with MSD International GmbH (MSD), an affiliate of Merck, Sharp &amp; Dohme, pursuant to which MSD will provide Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at no cost for use in the SCCHN Clinical Trial but will not bear any other costs of the trial.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SFJ will have primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we will be the sponsor of the SCCHN Clinical Trial and will also have sole responsibility for regulatory interactions and filings for bempegaldesleukin. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the opportunity to receive Success Payments as outlined below, SFJ has no right to reimbursement of costs incurred by SFJ for the SCCHN Clinical Trial in the event that the Melanoma Clinical Trial and the SCCHN Clinical Trial do not achieve FDA approval. We will pay SFJ a series of success-based annual payments (collectively, the Success Payments) in the event of FDA approval of bempegaldesleukin for the Melanoma Indication, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication. The Success Payments do not begin until the substantial completion of the SCCHN Clinical Trial. The total success-based annual payments for the first indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndication" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNDcy_ad9bb2ba-5fe4-4276-9142-71c9397f622a">450.0</ix:nonFraction>&#160;million, paid in annual contractual payments over <ix:nonNumeric contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212" name="nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTUw_44bbccee-7d57-4978-97ee-72671c995db3">five years</ix:nonNumeric>, with the first payment being $<ix:nonFraction unitRef="usd" contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementSuccessBasedPaymentsFirstPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNDg4_86fe9564-437b-4627-9c7a-c1406d7b4110">30.0</ix:nonFraction>&#160;million, with the earliest possible payment expected to occur in late 2024 or early 2025, subject to the substantial completion of the SCCHN Clinical Trial. The total success-based payments for the second indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndication" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTAz_79348d19-0725-48bf-adc4-0cec8966cc30">150.0</ix:nonFraction>&#160;million, paid in annual contractual payments over <ix:nonNumeric contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212" name="nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTQ5_65f46f4d-4346-4597-903f-525fae8f475c">seven years</ix:nonNumeric>. Finally, in the event of FDA approval for </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="iedca2de273594de49b15ebf75fc70c95"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bempegaldesleukin for any indication other than the Melanoma Indication or the SCCHN Indication, we will make a one-time payment of $<ix:nonFraction unitRef="usd" contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementAdditionalIndicationPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTE5_066fcc6b-cba4-4574-b43a-34f9397d8cf9">37.5</ix:nonFraction>&#160;million to SFJ. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SCCHN Clinical Trial provides for an interim futility analysis, and unless the futility criteria are met, SFJ is required to complete the SCCHN Trial, but if the futility criteria are met, SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. We and BMS, pursuant to the BMS Collaboration Agreement, remain solely responsible for conducting the Phase 3 clinical trials of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the treatment of previously untreated unresectable or metastatic melanoma (the &#8220;Melanoma Indication&#8221; and the &#8220;Melanoma Clinical Trial&#8221;). If the success criterion for the interim futility analysis is not met and SFJ winds down the SCCHN Clinical Trial, then the Success Payments, if any, for the Melanoma Indication and/or the additional bempegaldesleukin indication are reduced pro rata based on the costs incurred by SFJ for the SCCHN Clinical Trial over the aggregate commitment of $<ix:nonFraction unitRef="usd" contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212" decimals="INF" name="nktr:CollaborativeArrangementCommittedFunding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTM0_0b016bce-c9e8-427f-aa65-fc3a2a2aae5f">150.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SFJ Agreement provides for certain positive and negative covenants, including restrictions on our ability to incur liens on our intellectual property related to bempegaldesleukin (the bempegaldesleukin IP), or assign or convey any right to receive income with respect to the bempegaldesleukin IP (other than royalty and other license fee obligations to licensors), except for the issuance of senior secured debt secured by all or substantially all of our assets, including the bempegaldesleukin IP. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SFJ Agreement expires upon the payment of all Success Payments to SFJ, unless earlier terminated as provided under the SFJ Agreement. The SFJ Agreement may be terminated by either party for a safety or health concern for the patients, whether by the independent data monitoring committee or by mutual agreement of both parties. The SFJ Agreement may also be terminated by either party for material breach or insolvency of the counterparty.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present the SFJ Agreement as a Development derivative liability in our Consolidated Balance Sheets, which we remeasure to fair value at each reporting date. As SFJ conducts the SCCHN Clinical Trial, we record non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remits funding to us to support our internal costs of conducting the trial, we also record a corresponding increase to the development derivative liability. We present the gain (loss) from the remeasurement as Change in fair value of development derivative liability in our Consolidated Statements of Operations. <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNDU0_d72c3109-a5e1-487a-87fc-b9356102886c" continuedAt="i7cca49f9d37746ff8e03cfdfba823255" escape="true">The following table presents the changes in the development derivative liability for the year ended December&#160;31, 2021:</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center;text-indent:31.5pt"><ix:continuation id="i7cca49f9d37746ff8e03cfdfba823255"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at inception on February 12, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16608bc88bb04b04bb4edbc265eb647e_I20210212" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGFibGU6MWUzYTgxNmQxNWRjNGFlOWE2NjY5MDZkNDk5YWRjNDUvdGFibGVyYW5nZToxZTNhODE2ZDE1ZGM0YWU5YTY2NjkwNmQ0OTlhZGM0NV8xLTItMS0xLTE3OTA5_314f99d6-f538-4a5a-a9a1-e3db970a076a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec48343255d40459baca2d723015436_D20210213-20211231" decimals="-3" name="nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGFibGU6MWUzYTgxNmQxNWRjNGFlOWE2NjY5MDZkNDk5YWRjNDUvdGFibGVyYW5nZToxZTNhODE2ZDE1ZGM0YWU5YTY2NjkwNmQ0OTlhZGM0NV8yLTItMS0xLTE3OTA5_63a9603a-95e4-4f5b-9250-ec0ac60f6246">16,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec48343255d40459baca2d723015436_D20210213-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGFibGU6MWUzYTgxNmQxNWRjNGFlOWE2NjY5MDZkNDk5YWRjNDUvdGFibGVyYW5nZToxZTNhODE2ZDE1ZGM0YWU5YTY2NjkwNmQ0OTlhZGM0NV8zLTItMS0xLTE3OTA5_bc3cccf1-15c5-4df3-94f4-24f51531a8e2">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec48343255d40459baca2d723015436_D20210213-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGFibGU6MWUzYTgxNmQxNWRjNGFlOWE2NjY5MDZkNDk5YWRjNDUvdGFibGVyYW5nZToxZTNhODE2ZDE1ZGM0YWU5YTY2NjkwNmQ0OTlhZGM0NV80LTItMS0xLTE3OTA5_1ce2b489-d24b-4c10-8a40-fda05902023f">8,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493fa2ce12a84012947de2cfdd3a036b_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGFibGU6MWUzYTgxNmQxNWRjNGFlOWE2NjY5MDZkNDk5YWRjNDUvdGFibGVyYW5nZToxZTNhODE2ZDE1ZGM0YWU5YTY2NjkwNmQ0OTlhZGM0NV81LTItMS0xLTE3OTA5_4efe193f-5f05-4f4b-aa53-ba4717e6db7f">27,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We valued the derivative using a scenario-based discounted cash flow method, whereby each scenario makes assumptions about the probability and timing of cash flows, and we discount such cash flows to present value using a risk-adjusted rate. The key inputs to the valuation include our estimates of the following: (i) the probability of the Melanoma Clinical Trial, the SCCHN Clinical Trial and another bempegaldesleukin trial meeting their primary endpoints, (ii) the probability and timing of achieving FDA approval in the Melanoma Indication, the SCCHN Indication and any other bempegaldesleukin indication, (iii) the timing of the substantial completion of the SCCHN Clinical Trial that SFJ must achieve before receiving a Success Payment, (iv) the probability of termination of the study due to meeting the interim futility criteria, (v) the amount of costs incurred by SFJ if the success criterion for the interim futility analysis is not met, (vi) SFJ&#8217;s cost of borrowing, currently estimated at <ix:nonFraction unitRef="number" contextRef="ib73eda96963641c5adca30248e3b4212_I20211231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTU5_0c2550ad-29b7-4bd4-9e27-653a30bc1fa5">1.5</ix:nonFraction>%, and (vii) the Company&#8217;s imputed cost of borrowing for debt with similar terms, currently estimated at <ix:nonFraction unitRef="number" contextRef="i418e819404874602beccd76277d2832e_I20211231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTUy_fa8c9cfb-41c9-40df-9d30-d48aac16b0be">12.7</ix:nonFraction>%.</span></div></ix:continuation><div id="i1023926dfc3b4cff924b0207eb081f42_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;7&#160;&#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIyMTQ_8510b3fb-26b0-4261-9466-0f4ddfb73caa" continuedAt="i2a3778f4b5024cbfaf123ce00398a946" escape="true">Operating Leases</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2a3778f4b5024cbfaf123ce00398a946" continuedAt="i69347e4cad15458dbe0c334cb25b55cf">&#160;&#160;&#160;&#160;Our leases consist of a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. 19, LLC (ARE) for our <ix:nonFraction unitRef="sqft" contextRef="i9fd0edc3092a4746b891c63c927e1490_I20211231" decimals="0" name="nktr:AreaOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzE1Mg_0fff6f53-aefe-4ad4-bf42-2e84d49efc04">155,215</ix:nonFraction> square foot corporate office and R&amp;D facility located at 455 Mission Bay Boulevard, San Francisco, California (the Mission Bay Facility) and a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) for an additional <ix:nonFraction unitRef="sqft" contextRef="ib40b92391c3f4d638cd40df255d8a24f_I20211231" decimals="0" name="nktr:AreaOfLeasedSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzQxMQ_15b1ad44-c68d-45af-8a7e-be174da2b7fa">135,936</ix:nonFraction> square foot facility to support our R&amp;D operations at 360 Third Street, San Francisco, </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i69347e4cad15458dbe0c334cb25b55cf" continuedAt="i7e7633a6d4b04785bb867145d6cabfd5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California (the Third Street Facility). <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:LesseeOperatingLeaseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIyMTU_acca60b4-9214-4280-a903-f7d9f3e5bfe7" continuedAt="ie8f6671f4a14483f8df9913e8ff7f10b" escape="true">The following table presents key information regarding these leases (dollars in thousands):</ix:nonNumeric></span><ix:continuation id="ie8f6671f4a14483f8df9913e8ff7f10b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mission Bay Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Street Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commencement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="i95ecd88a93ef4d27b3eb882445356c5c_D20200101-20201231" decimals="0" name="nktr:AreaOfLeasedSpaceDelivered" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzQtMS0xLTEtMTEyOTg_153374b2-7c1c-48fe-afe6-4355eafe34e1">4,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="iaeeda31f60ae46789b8052b8ca1a2041_D20200101-20201231" decimals="0" name="nktr:AreaOfLeasedSpaceDelivered" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzQtMy0xLTEtMTEyOTg_95e1b483-fad1-474d-b8ca-44483f034c7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ecd88a93ef4d27b3eb882445356c5c_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzUtMS0xLTEtMTEyOTg_dcee13a6-5f0c-4770-a6e0-b863aa3b8ef8">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeeda31f60ae46789b8052b8ca1a2041_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzUtMy0xLTEtMTEyOTg_f294ac18-4a60-4c59-8b19-75ce97c3dfa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231" decimals="0" name="nktr:AreaOfLeasedSpaceDelivered" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzctMS0xLTEtMTEyOTg_bec3d44c-1735-4b14-b077-6bf1df948aed">2,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="i7562d9991df643f7ab9b69837b951eed_D20210101-20211231" decimals="0" name="nktr:AreaOfLeasedSpaceDelivered" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzctMy0xLTEtMTEyOTg_a6b3f0e8-134d-4036-9209-6262c791b64c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzgtMS0xLTEtMTEyOTg_9aed2a57-268a-4d7e-b697-7842cf5747bd">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7562d9991df643f7ab9b69837b951eed_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzgtMy0xLTEtMTEyOTg_40394114-13de-406a-bddb-f6f04185c1cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renewal terms</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="term" contextRef="idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231" decimals="INF" name="nktr:NumberOfConsecutiveTermsToExtendLease" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMS0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo1NzBkM2IxNWJkODY0NDhlYTY5MGYyNDhlY2RjM2VmNl80_2bf00cb7-5eec-4141-876f-86a4819db2c1">Two</ix:nonFraction> consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMS0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo1NzBkM2IxNWJkODY0NDhlYTY5MGYyNDhlY2RjM2VmNl8xOQ_aafbf748-eb94-4830-9eeb-f3b77f87a1d3">five</span>-year terms</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="term" contextRef="i7562d9991df643f7ab9b69837b951eed_D20210101-20211231" decimals="INF" name="nktr:NumberOfConsecutiveTermsToExtendLease" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMy0xLTEtMTEyOTgvdGV4dHJlZ2lvbjoxZmUzNGY5ZGNjNmE0MzIyYmMyMDNmMGRiNWZiYzJkYV80_26a7ee75-5736-4030-8150-bf3fd5f22e39">One</ix:nonFraction> <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMy0xLTEtMTEyOTgvdGV4dHJlZ2lvbjoxZmUzNGY5ZGNjNmE0MzIyYmMyMDNmMGRiNWZiYzJkYV83_acadf74a-e2c3-4130-9183-4f9108ef96cd">five</span>-year term</span></div></td></tr></table></ix:continuation></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The monthly base rent for both facilities will escalate over the term of the lease at various intervals. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Both leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance costs and taxes. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the Third Street Lease, our fixed annual base rent on an&#160;industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize rent expense for these operating leases on a straight-line basis over the lease period. <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIyMTE_9bab286a-f8f0-464b-b4ec-f13306de6536" continuedAt="ideeb1118a8894bcbaba84fc6ec6fd036" escape="true">The components of lease expense, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="ideeb1118a8894bcbaba84fc6ec6fd036"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzItMS0xLTEtMTEyOTg_001e9244-3d2e-42db-b308-ce9417b9b7c8">19,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzItMy0xLTEtMTEyOTg_9cb6684e-c99d-448e-a067-0c83d3f237bc">18,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzItNS0xLTEtMTEyOTg_1d8ca285-b4d1-41ce-85e1-2006225d4162">14,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzMtMS0xLTEtMTEyOTg_b51460a8-4ac9-4279-a435-ea2be1fb1945">8,974</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzMtMy0xLTEtMTEyOTg_26d31982-1124-4dcd-93ba-31390b57d427">8,179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzMtNS0xLTEtMTEyOTg_53fdd521-8b0a-44c1-84d0-49a172769905">6,408</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzQtMS0xLTEtMTEyOTg_1ccb3072-bf06-4c47-87cf-6ec0415c26b2">28,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzQtMy0xLTEtMTEyOTg_a9a3a4be-2f00-46d7-ab4b-72747a158da0">27,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzQtNS0xLTEtMTEyOTg_7b4d01c4-cd01-4691-9a8c-31bd24feb900">21,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the years ended December&#160;31, 2021, 2020 and 2019, we  paid $<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzE3NTk_cfe7ac70-44f1-4e66-9fc6-7e8c7d4d283b">16.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzE3NjY_e8aad39f-1bd5-48b8-ac17-59de78109e31">16.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzM4NDgyOTA3MTIyOTM_c0b7dad2-22a1-42c3-bd39-8e47cfedb4b1">8.4</ix:nonFraction>&#160;million, respectively, of operating lease payments related to our lease liabilities, which we include in net cash used in operating activities in our Consolidated Statements of Cash Flows.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i7e7633a6d4b04785bb867145d6cabfd5"><div style="margin-top:10pt;text-indent:31.5pt"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIyMTI_68b70490-23d3-4e06-b28c-594284740601" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the maturities of our operating lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzEtMS0xLTEtMTEyOTg_9733a0a9-eba4-4eef-a36d-2dbf93383d43">18,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzItMS0xLTEtMTEyOTg_6e386cc6-a200-4182-bc38-c201b6581a7f">20,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzMtMS0xLTEtMTEyOTg_3b6de05c-b2cb-4c4f-aaa3-7b25460fbeb9">21,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzQtMS0xLTEtMTEyOTg_1d6d9b93-47ce-4f2a-87cb-7130d55ab779">22,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzUtMS0xLTEtMTEyOTg_36c74cbc-722b-4dad-8c2b-0dc3b6f03e56">22,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzYtMS0xLTEtMTEyOTg_541051c0-2f50-48a8-aaac-d79e40c20069">75,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzctMS0xLTEtMTEyOTg_b6ec2b35-8549-4ec0-80e0-df12eb2fefbc">181,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: portion representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzgtMS0xLTEtMTEyOTg_4615f19e-70da-4f23-85ef-7dd9baa67f02">37,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: lease incentives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzktMS0xLTEtMTEyOTg_818bdd41-5ff5-463c-b08d-1c8e73b3f4cc">653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzEwLTEtMS0xLTExMjk4_1b07773c-c04f-4e4e-8390-837a69a1ad7a">143,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzExLTEtMS0xLTExMjk4_bc71d796-ded5-42ef-8f44-83b26b9fe904">17,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzEyLTEtMS0xLTExMjk4_1ae67e49-ef12-4541-80d2-a0b494494902">125,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2021, the weighted-average remaining lease term is <ix:nonNumeric contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIxMTQ_5c008641-38c9-4afe-b483-c7ce70976144">8.1</ix:nonNumeric> years and the weighted-average discount rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIyMDg_ba2d0e98-db3d-413d-9647-5300189b4c9e">5.8</ix:nonFraction>%.</span></div></ix:continuation><div id="i1023926dfc3b4cff924b0207eb081f42_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 &#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzg2MTE_158e5c94-1fb9-4df3-92e4-46099fe8cfdd" continuedAt="ibbcdcaaedc9a42598d0a60f6b4047193" escape="true">Liabilities Related to the Sales of Future Royalties</ix:nonNumeric></span></div><ix:continuation id="ibbcdcaaedc9a42598d0a60f6b4047193" continuedAt="i6ef3e2515e1b45db9f3fae146fa66e1c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic019febd6d76418e963113849a03e38e_D20120224-20120224" decimals="-5" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzcxOA_33f67797-3a39-4817-855d-b5694b057d29">124.0</ix:nonFraction> million for the 2012 Transaction Royalties.&#160;Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $<ix:nonFraction unitRef="usd" contextRef="ic019febd6d76418e963113849a03e38e_D20120224-20120224" decimals="-5" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzEyMTU_d595b9f5-9e91-4d60-a90b-b5ec7309ebb3">124.0</ix:nonFraction> million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the effective interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are remitted directly to RPI. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2020, UCB served notice of a Declaratory Judgment of Patent Invalidity, filed in the United States District Court for the District of Delaware, seeking a declaration of invalidity of certain of our patents that we had licensed to UCB and pursued similar actions in other jurisdictions. On October 14, 2021, RPI and we entered into a Letter Agreement which permitted us to enter into a Settlement Agreement, effective October 13, 2021, with UCB to effect the negotiation between RPI and UCB in which UCB and RPI agreed to a reduction in the royalty term and annual decreases in the royalty rate over the remaining royalty term in exchange for UCB&#8217;s withdrawal of all of UCB&#8217;s litigation and challenges. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded that we should account for the decrease in royalty payments to RPI as a result of these agreements as a modification of our liability. Due to the significance of the change in the estimated royalty payments, we concluded that we should treat the modification as an extinguishment of the prior liability and recognize a new liability based on the revised royalty payments and term, discounted to fair value. Accordingly, we estimated the fair value to be approximately $<ix:nonFraction unitRef="usd" contextRef="ib0419ee4a57947ec9003b707328f0fb9_I20211231" decimals="-5" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM4NDgyOTA3MTEzMzA_ef667043-198e-4746-b6ac-e3405ea6089d">84.7</ix:nonFraction>&#160;million, reflecting a discount rate of <ix:nonFraction unitRef="number" contextRef="i7c519c68cc924317ad61bfe414020531_I20211231" decimals="3" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM4NDgyOTA3MTEzNDU_71125cda-e245-4dd2-a1fc-587ea5894133">16.0</ix:nonFraction>%, and we began amortizing the liability prospectively at this rate commencing in the three months ended December 31, 2021. As a result, we recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="iafb8479bd435454894df0145e038e535_D20211001-20211231" decimals="-5" sign="-" name="nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzE2NDkyNjc0NDM0ODY3_d9e4395f-a757-4391-babe-000d3cd4c045">23.5</ix:nonFraction>&#160;million on the revaluation of the prior liability in the three months ended December 31, 2021, and we wrote off of the remaining $<ix:nonFraction unitRef="usd" contextRef="iafb8479bd435454894df0145e038e535_D20211001-20211231" decimals="-5" name="nktr:TransactionCostsRelatedToRevisedRoyaltyPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM4NDgyOTA3MTEzNTI_7670af4c-baa3-4ecb-a5af-a782594f5394">0.9</ix:nonFraction>&#160;million of unamortized transaction costs. We present these charges in Loss on revaluation of liability related to the sale of future royalties line in our Consolidated Statement of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time that certain return thresholds are met as described below, of (a) MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB, as amended, (b) ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i6ef3e2515e1b45db9f3fae146fa66e1c" continuedAt="i3282e8cac51c4ae9a21a29e7c7f4d6ca"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as amended, (c) REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $<ix:nonFraction unitRef="usd" contextRef="i615094c1dcc2454fba893bc20ef68b47_D20201216-20201216" decimals="-5" name="nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzI4Njg_736bee69-9fe6-4414-b91a-d52b10e0659e">210.0</ix:nonFraction>&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $<ix:nonFraction unitRef="usd" contextRef="i615094c1dcc2454fba893bc20ef68b47_D20201216-20201216" decimals="-5" name="nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzI5NjQ_85f9d51f-b0fb-42ea-bd04-cd95c6ad061f">240.0</ix:nonFraction>&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $<ix:nonFraction unitRef="usd" contextRef="i615094c1dcc2454fba893bc20ef68b47_D20201216-20201216" decimals="-5" name="nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzMyMjg_e8325800-08ba-4258-8e6f-b363163900d5">208.0</ix:nonFraction>&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2020, we received aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1848694a84f244f8b109984fa21ee94e_D20201230-20201230" decimals="-5" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM2NDQ_192cf146-4f85-4d54-8b60-37f3fce90ff6">150.0</ix:nonFraction>&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i1848694a84f244f8b109984fa21ee94e_D20201230-20201230" decimals="-5" name="nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM3MzA_a35d2037-2c66-4034-abd8-d9af97a00e11">3.8</ix:nonFraction>&#160;million in transaction costs, which will be amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these products, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, to be received by HCR in the first quarter of 2021. We recorded the $<ix:nonFraction unitRef="usd" contextRef="i1848694a84f244f8b109984fa21ee94e_D20201230-20201230" decimals="-5" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzQzMzE_fe1ac853-c05b-4738-a6b3-2e14d9238817">150.0</ix:nonFraction>&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. As of December 31, 2021, our prospective effective interest rate used to amortize the liability is <ix:nonFraction unitRef="number" contextRef="id15385c8744c4ad794e479a0863b4859_I20211231" decimals="2" name="nktr:RoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM4NDgyOTA3MTU2NjA_513ad7ef-a140-4887-a1b4-5970cedd2417">15</ix:nonFraction>%.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzg2MTI_84bd8064-568a-4900-897c-69b9bb7a3389" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account of each arrangement (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties&#8212;beginning<br/>balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa240bdb2564ada855ed34b4d6af58c_I20201231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItMS0xLTEtMTEyOTg_78dc06a1-c471-4ecf-a751-945112a5537d">65,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb5f300865a3412b8ef57ad27019eaf6_I20201231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItMy0xLTEtMTEyOTg_48c6076a-b1b6-4784-8dda-2f85936a2ed4">139,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItNS0xLTEtMTEyOTg_a6f3671b-1ce9-4687-bbd6-8753817acd10">205,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e574a6749b54555bcb0c1fc438d2730_I20120224" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItNy0xLTEtMTEyOTg_75761ba9-b843-463d-9464-787d56781798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea8f2c144d74987ad634c719924d556_I20201216" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItOS0xLTEtMTEyOTg_d2d19180-aca6-40f7-9978-cbb912956b14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859caff83678471fa0131b598ecb3b99_I20120224" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItMTEtMS0xLTExMjk4_70c37eba-cf47-4f89-be32-2ac0bc5e69f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878fa93fa19746ff958887812ed98a82_D20210101-20211231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtMS0xLTEtMTEyOTg_dc94702b-d662-4b7c-be3f-f1faadea0a42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtMy0xLTEtMTEyOTg_c5eed882-4863-4b47-9b84-4df668aad76c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtNS0xLTEtMTEyOTg_725445b1-b34c-413b-8e45-573175a83942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877ea84e541241f8b6035538b2d966db_D20120225-20211231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtNy0xLTEtMTEyOTg_448a2ce3-2618-4e5e-88e2-c8b376dc6072">124,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819532be269b48eaa4fd913474d540a1_D20201217-20211231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtOS0xLTEtMTEyOTg_83a93bdb-d191-4de5-9ac1-957315a28cbb">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231" decimals="-3" name="nktr:RoyaltyMonetizationProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtMTEtMS0xLTExMjk4_36d0e077-f0ee-4eb3-b0fd-11d2bacb0de5">274,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i878fa93fa19746ff958887812ed98a82_D20210101-20211231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtMS0xLTEtMTEyOTg_89721545-d20e-4103-aa3c-cfe4d9c0587d">37,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtMy0xLTEtMTEyOTg_a1db148a-5c17-4916-a15f-ff2f3b0abf24">40,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtNS0xLTEtMTEyOTg_a7c04246-ae24-4b6d-9d81-35f46111422c">77,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i877ea84e541241f8b6035538b2d966db_D20120225-20211231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtNy0xLTEtMTEyOTg_a662cf65-4451-46e0-b367-547f2895d890">282,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i819532be269b48eaa4fd913474d540a1_D20201217-20211231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtOS0xLTEtMTEyOTg_bf9ce76a-674a-4c7c-bc6c-2c6f1b0a69ce">50,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231" decimals="-3" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtMTEtMS0xLTExMjk4_91de4b11-338d-4e41-8425-23f6c43bddf6">333,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878fa93fa19746ff958887812ed98a82_D20210101-20211231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtMS0xLTEtMTEyOTg_853fdc60-dc32-41f4-a7b3-7b2231a927ec">26,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtMy0xLTEtMTEyOTg_fe836f52-9d5f-4aee-9b20-6593f59e2ed8">20,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtNS0xLTEtMTEyOTg_4d7a251e-6cd1-4955-b6c9-17b485f65b73">47,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877ea84e541241f8b6035538b2d966db_D20120225-20211231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtNy0xLTEtMTEyOTg_17ae864a-9662-4c33-82e8-05732eda9676">223,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819532be269b48eaa4fd913474d540a1_D20201217-20211231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtOS0xLTEtMTEyOTg_d3ceaba9-988a-4b2c-bdd9-74858d79b9c9">20,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231" decimals="-3" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtMTEtMS0xLTExMjk4_7cc4affc-13be-4997-8d4b-7d2e2b774f48">244,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878fa93fa19746ff958887812ed98a82_D20210101-20211231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtMS0xLTEtMTEyOTg_3270bdb6-1e2c-412c-8f3b-c9eef9f0b524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtMy0xLTEtMTEyOTg_c03ad4c4-f429-4371-a4f8-fac2c6bc7d86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtNS0xLTEtMTEyOTg_303a5b4d-6f73-40df-9996-f4b70405058a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i877ea84e541241f8b6035538b2d966db_D20120225-20211231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtNy0xLTEtMTEyOTg_6669d6c1-4a44-41e0-aad1-1598b46a2f75">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819532be269b48eaa4fd913474d540a1_D20201217-20211231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtOS0xLTEtMTEyOTg_d1f09425-331d-4c33-93db-6cc02d212d08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231" decimals="-3" name="nktr:PartialRepaymentOfRoyaltySaleProceeds" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtMTEtMS0xLTExMjk4_91ca03ce-3ee5-4852-b523-b0c57030bd38">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878fa93fa19746ff958887812ed98a82_D20210101-20211231" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMS0xLTEtMTQ2MDU_b64d8854-8802-47be-947c-5f6b4aeacaca">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231" xsi:nil="true" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMy0xLTEtMTQ2MDU_820a2bb9-0e2b-4e9e-9790-38177a63ba61"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctNS0xLTEtMTQ2MDU_e39a7759-0264-4808-a349-4bcb34550739">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877ea84e541241f8b6035538b2d966db_D20120225-20211231" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctNy0xLTEtMTQ1OTE_55178002-e5c9-4f96-ae2c-2bfacb440582">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819532be269b48eaa4fd913474d540a1_D20201217-20211231" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctOS0xLTEtMTQ1OTE_9bbc2fee-bb28-4ddd-baf4-696104db8b23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231" decimals="-3" name="nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMTEtMS0xLTE0NTkx_56c25cba-8b73-4c52-b843-3eecab6986af">23,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMS0xLTEtMTEyOTg_7287224f-16cf-47a3-b184-d535a8c0b272">78,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMy0xLTEtMTEyOTg_78afca95-4e9d-403e-8d48-6cec35c38f8d">120,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctNS0xLTEtMTEyOTg_11647d84-0177-45d6-ad9d-ee180d3a64b2">198,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctNy0xLTEtMTEyOTg_3d331b2e-2541-48d6-af0b-fdcd0e9939f9">78,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctOS0xLTEtMTEyOTg_18396234-bacc-42e1-9b2f-cecaa4e1c3c2">120,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMTEtMS0xLTExMjk4_4aa66d4b-5bd3-4ac1-a1bc-632c04877489">198,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtMS0xLTEtMTEyOTg_b390683d-fdea-4d13-925a-8d8a2134cf9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtMy0xLTEtMTEyOTg_f085c4f2-4323-4aa0-be14-da66cdcfadcc">2,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtNS0xLTEtMTEyOTg_b589d544-d438-4c13-bbbb-f622421c449a">2,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtNy0xLTEtMTEyOTg_626785d0-a09b-4729-8aec-8887582e2a73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtOS0xLTEtMTEyOTg_7b20c5b7-4633-4798-9c67-ad6817c71cb8">2,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtMTEtMS0xLTExMjk4_32376e3a-9925-45a7-978c-e8218d3e10f4">2,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktMS0xLTEtMTEyOTg_feb88c0b-27f0-4b05-8310-75ea0cea8311">78,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktMy0xLTEtMTEyOTg_d561ced9-128b-4ec7-ac63-8012b6d6d402">117,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktNS0xLTEtMTEyOTg_83a5974b-74d8-4145-add5-3bdd96527eda">195,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktNy0xLTEtMTEyOTg_cfe61588-97e2-4ce0-98f3-f731efdab833">78,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktOS0xLTEtMTEyOTg_ae2e3193-3f9e-48ac-aa59-0f2afa792881">117,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktMTEtMS0xLTExMjk4_aac49e51-afac-45e4-9edf-18a47f9d0267">195,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the 2012 Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $<ix:nonFraction unitRef="usd" contextRef="i431785ba16834d94834f5341637912ac_D20140301-20140331" decimals="-5" name="nktr:PaymentMadeForMilestoneNotAchievedYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzUwODI_fccc4a0e-f896-4cfd-a34b-2bcfaf3db304">7.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i10e97ae5ba424e32b4c21ebb7a264e1c_D20130301-20130331" decimals="-5" name="nktr:PaymentMadeForMilestoneNotAchievedYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzUwODk_c12683c1-1fa1-462a-b5a7-65edc492acce">3.0</ix:nonFraction> million, respectively, as a result of worldwide net sales of MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the 12 month periods ended December&#160;31, 2013 and 2012 not reaching certain minimum thresholds. The 2012 Purchase and Sale Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense, as well as the loss on the revaluation described above, over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i3282e8cac51c4ae9a21a29e7c7f4d6ca"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the appropriate Royalty Obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are a number of factors that could materially affect the amount and timing of royalty payments from our licensees, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI or HCR are made in U.S. dollars (USD) while significant portions of the underlying sales of the products of our licensees are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from our licensees, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the respective Royalty Obligation. Conversely, for the 2012 Purchase and Sale Agreement, if sales of these products are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the 2012 Royalty Obligation.</span></div></ix:continuation><div id="i1023926dfc3b4cff924b0207eb081f42_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;9&#160;&#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzk0Nzg_e31a4238-8900-49e7-bf49-2823c342a937" continuedAt="i5c16c66ab6a9444eb2295a42393b929d" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i5c16c66ab6a9444eb2295a42393b929d" continuedAt="i1fc8297f363547c9ac0b83cf3630d950"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the normal course of business, we enter into various firm purchase commitments related to contract manufacturing, clinical development and certain other items. As of December&#160;31, 2021, these commitments were approximately $<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-5" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzI3Ng_75cd393c-73a2-4e5b-9d5e-e0e76bc71f47">8.2</ix:nonFraction> million, all of which we expect to pay in 2022.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018, about the clinical trials of bempegaldesleukin. The Mulquin complaint was amended in May 2019. The defendants moved to dismiss and the court granted the motion without prejudice in July 2020. The Mulquin plaintiffs again amended their complaint and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice. The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument occurred on December 10, 2021, and the matter remains pending with the court. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second putative securities class action was filed against the Company and certain of our executives in the U.S. District Court for the Northern District of California in August 2019 (Case No. 4-19-cv-05173, which we refer to as the Damiba action).  The Damiba plaintiffs challenged public statements Nektar made, between February 2019 and May 2019, about its bempegaldesleukin clinical trials and collaboration with Bristol-Myers Squibb. After the Damiba plaintiffs filed an amended complaint and the defendants moved to dismiss, the court dismissed the action without prejudice in January 2021. The Damiba plaintiffs subsequently voluntarily dismissed the action, with prejudice, in March 2021.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the <ix:nonFraction unitRef="action" contextRef="i26423d2e98f74cab9e74de71740ea6dd_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzE2NDkyNjc0NjcxMDU_f7de4db7-b0c0-4c8e-8fda-657c68b85865">two</ix:nonFraction> securities actions (the Mulquin action and the Damiba action), <ix:nonFraction unitRef="action" contextRef="ief3d1876c0504d8894ebee840c0649dc_D20210101-20211231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzE2NDkyNjc0NjcwOTU_7d51a6c7-98f7-42d1-b002-af91592bf38a">three</ix:nonFraction> additional sets of derivative actions have been filed against certain of the Company&#8217;s current and former officers and directors, purportedly on the Company&#8217;s behalf. These derivative actions are based on the allegations in the securities actions and on the premise that the Company&#8217;s officers and directors breached their fiduciary duties by exposing the Company to one or both of the securities actions. The first derivative action was filed in the U.S. District Court for the District of Delaware in February 2019 (Case No. 1:19-cv-00322-MN-JLH). After amending their complaint several times, the plaintiffs in that action voluntarily dismissed their claims without prejudice in April 2021.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second set of derivative actions was filed in February 2020 in the U.S. District Court for the Northern District of California (Case No. 4:20-cv-01088-JSW). The derivative actions in California were consolidated and the Company moved to dismiss on the basis that the plaintiffs had neither made a demand on the Company&#8217;s board of directors nor shown that a demand would be futile. On September 1, 2021, the court dismissed the action with prejudice.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i1fc8297f363547c9ac0b83cf3630d950" continuedAt="i4182a1ba567b4e08ba132e732f0fdd4e"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third derivative complaint was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF). The parties agreed to stay further proceedings in this action until thirty days after the U.S. Court of Appeals for the Ninth Circuit&#8217;s final resolution of the appeal in the Mulquin action.  </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature and status of these securities class action lawsuits and derivative complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded <ix:nonFraction unitRef="usd" contextRef="i3fab95cd4e2f4d70a9bd13e5489022fd_I20191231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzQ1MTQ_5c6381ab-746e-4ba7-8e3b-c6af11bac62b"><ix:nonFraction unitRef="usd" contextRef="if7023dcffb6c492e881c7d0fdf2c056c_I20211231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzQ1MTQ_d8ed32d3-ba61-484f-b134-6c301e0f1978">no</ix:nonFraction></ix:nonFraction> liability for these matters in our Consolidated Balance Sheets at either December&#160;31, 2021 or December 31, 2020. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We operate in a number of foreign countries. As a result, we are subject to numerous local laws and regulations that can result in claims made by foreign government agencies or other third parties that are often difficult to predict even after the application of good faith compliance efforts.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the course of our normal operating activities, we have agreed to certain contingent indemnification obligations as further described below. The term of our indemnification obligations is generally perpetual. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. To date, we have not incurred significant costs to defend lawsuits or settle claims based on our indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded <ix:nonFraction unitRef="usd" contextRef="iec07825eabbf46b68172520ab32540ae_I20211231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzU3MzY_9367375d-4207-45b0-8675-dd1d2a7190e7"><ix:nonFraction unitRef="usd" contextRef="iad6b97c8cc6a493d936e8a7260315298_I20201231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzU3MzY_f12ddfef-749d-4e36-a334-0952883b8c21">no</ix:nonFraction></ix:nonFraction> liabilities for these obligations in our Consolidated Balance Sheets at either December&#160;31, 2021 or December 31, 2020.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification of Underwriters and Initial Purchasers of our Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with our sale of equity we have agreed to defend, indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director and Officer Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential amount of future payments we could be required to make under this </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4182a1ba567b4e08ba132e732f0fdd4e">indemnification is unlimited; however, we have insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe any obligations under this indemnification would not be material, other than retention of up to $<ix:nonFraction unitRef="usd" contextRef="i8cfe16cd13d04edfb807fa9cb0df6eee_I20211231" decimals="INF" name="nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzg5OTg_5aa27454-82ec-4fcf-bf13-614277631691">10.0</ix:nonFraction> million per incident for merger and acquisition related claims, $<ix:nonFraction unitRef="usd" contextRef="i6394ee3aadea457c813b5c716e2e257a_I20211231" decimals="-5" name="nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzkwNTc_0def215c-bf03-4e3d-b3d5-b134781d0770">10.0</ix:nonFraction> million per incident for securities related claims and $<ix:nonFraction unitRef="usd" contextRef="iad260002e8644641b6913428ec9be8e8_I20211231" decimals="-5" name="nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzkxMDc_98e43a62-4083-4fb7-9328-863c4c7af836">10.0</ix:nonFraction> million per incident for non-securities related claims per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.</ix:continuation></span></div><div id="i1023926dfc3b4cff924b0207eb081f42_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;10&#160;&#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90ZXh0cmVnaW9uOmE0MmE3MGVjYjA0NTRiNjdiNWFkYWI2ZjZhNzg1NzE5Xzg4ODU_200cff5e-9e0d-4031-a81e-757c7d819e8d" continuedAt="i58985c0c1ece4f4784ff66811769d43b" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="i58985c0c1ece4f4784ff66811769d43b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 11, on April 3, 2018, we completed the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="id508c66eccd84a1490c07a8346141297_D20180403-20180403" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90ZXh0cmVnaW9uOmE0MmE3MGVjYjA0NTRiNjdiNWFkYWI2ZjZhNzg1NzE5XzEzMQ_247c1882-2fcb-4eea-874b-de0d335d2002">8,284,600</ix:nonFraction> shares of our common stock under a Share Purchase Agreement with BMS. These shares are unregistered and subject to certain lock-up and stand-still provisions for a <ix:nonNumeric contextRef="icdcb60f448fd48b6b0f24d116b1058d4_D20180403-20180403" name="nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90ZXh0cmVnaW9uOmE0MmE3MGVjYjA0NTRiNjdiNWFkYWI2ZjZhNzg1NzE5Xzg4ODY_9730197a-6bcf-4e64-b0ad-79f5c143aeec">five-year</ix:nonNumeric> period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the SEC, which expires in March 2024. The 2021 Shelf Registration Statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="INF" name="nktr:SaleOfStockValueAuthorizedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90ZXh0cmVnaW9uOmE0MmE3MGVjYjA0NTRiNjdiNWFkYWI2ZjZhNzg1NzE5XzM4NDgyOTA3MTYxNDI_79140d18-6e7e-4445-9753-562beeab0059">300.0</ix:nonFraction>&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which may be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities have been sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.</span></div><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90ZXh0cmVnaW9uOmE0MmE3MGVjYjA0NTRiNjdiNWFkYWI2ZjZhNzg1NzE5Xzk4OTU2MDQ2NjgxNTE_2e123217-4f49-4e71-b14b-2995f6fcc5d5" continuedAt="idbccb1a242d94e50b480060b4252e6f4" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, shares of common stock reserved for future issuance are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and PSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08e56333c0594ef38a927dea5e5be643_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90YWJsZTpiOGZiMDJmNWJlNTY0M2U0ODZjYTgwYTQ5ZGViOWEzOS90YWJsZXJhbmdlOmI4ZmIwMmY1YmU1NjQzZTQ4NmNhODBhNDlkZWI5YTM5XzAtMS0xLTEtMjIxNjQ_08f10518-b9f9-41f5-9fef-6d30178830a9">23,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2017 Performance Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85e44fd2a3b7430fb8662bdf1cfee75a_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90YWJsZTpiOGZiMDJmNWJlNTY0M2U0ODZjYTgwYTQ5ZGViOWEzOS90YWJsZXJhbmdlOmI4ZmIwMmY1YmU1NjQzZTQ4NmNhODBhNDlkZWI5YTM5XzEtMS0xLTEtMjIxNjQ_3a86d01f-c524-4343-9ec8-87facd414e2b">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79ae08e8c98b45bba0381fcf4454594a_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90YWJsZTpiOGZiMDJmNWJlNTY0M2U0ODZjYTgwYTQ5ZGViOWEzOS90YWJsZXJhbmdlOmI4ZmIwMmY1YmU1NjQzZTQ4NmNhODBhNDlkZWI5YTM5XzItMS0xLTEtMjIxNjQ_952c3a28-324e-4673-a17d-ded0994fd483">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90YWJsZTpiOGZiMDJmNWJlNTY0M2U0ODZjYTgwYTQ5ZGViOWEzOS90YWJsZXJhbmdlOmI4ZmIwMmY1YmU1NjQzZTQ4NmNhODBhNDlkZWI5YTM5XzMtMS0xLTEtMjIxNjQ_ae3da3f7-2ec1-4e78-831a-03870d398537">26,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1023926dfc3b4cff924b0207eb081f42_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;11&#160;&#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzIxMDc4_d289009c-f634-44ad-a48d-76aa8b3b09ef" continuedAt="i9249ba5ca43e429694d37aa9917c7729" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i9249ba5ca43e429694d37aa9917c7729" continuedAt="i1ae9d35cee9648a2a2b4304b0f02c084"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzIxMDc5_d58212ae-35a0-404b-ae8f-649c14ceea8d" continuedAt="i291a705622a245519a68091057c7694e" escape="true">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i291a705622a245519a68091057c7694e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:32.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63a3ada72f2468d9d15c15cdadb2e60_D20210101-20211231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzItNC0xLTEtMTEyOTg_06a557db-d9e6-4e2b-8ff7-089a975c6eb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282c760203f4d67bbae06f0bbf2f7ca_D20200101-20201231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzItNi0xLTEtMTEyOTg_497dba3e-2566-4e8e-bc5d-641df16c97e4">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b027734ada457485944093d8bb55f4_D20190101-20191231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzItOC0xLTEtMTEyOTg_0728977d-25d7-49b1-b2b8-3e69f1f11db3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NKTR-358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc2021556634567a9c85d9130eca0e8_D20210101-20211231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzMtNC0xLTEtMTEyOTg_4b1bfaec-ec34-46d4-bfb9-cc1b00d58c3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47aee40635594a2493940a5c79182830_D20200101-20201231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzMtNi0xLTEtMTEyOTg_9c62359c-0648-48ff-a0a7-39605e8e0048">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0c941d02e442e5830f5ff54b267621_D20190101-20191231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzMtOC0xLTEtMTEyOTg_dbe66bb9-28e1-4344-907d-b639b5ca8752">7,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bb01347c4e24ca3bb28d9aab6838bd3_D20210101-20211231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzQtNC0xLTEtMTEyOTg_f30ea82c-c702-4353-b088-9ac2923b4d12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c290b7d2e5c4c6a88d47e27d7256c42_D20200101-20201231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzQtNi0xLTEtMTEyOTg_0e500ac4-f922-4b40-8d1b-cdace08fcf03">4,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6585fd29ca4683aec5e1e6754a8a53_D20190101-20191231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzQtOC0xLTEtMTEyOTg_ed489c84-6b5d-43a8-b557-4b14c4d79334">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69b94286514e411f81a8255d0fe0adef_D20210101-20211231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzYtNC0xLTEtMTEyOTg_562897a2-c564-4e24-8e10-029953c54205">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df606808a1742a88e889573b9cf1eab_D20200101-20201231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzYtNi0xLTEtMTEyOTg_999e76a1-8b7a-4877-aebd-6233891d99ff">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4daaf97620504beb90b1882227ff737f_D20190101-20191231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzYtOC0xLTEtMTEyOTg_3416f5bb-f180-40ea-b5b8-6af0c9848880">4,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzctNC0xLTEtMTEyOTg_c3e5eb9c-acea-417d-8a41-b09bba01c863">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzctNi0xLTEtMTEyOTg_440726ff-7a21-425b-91e9-ca36b2b48567">55,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzctOC0xLTEtMTEyOTg_8e6c374d-a56a-4fb0-87f8-633917f710e1">16,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2021, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-8" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE5MzE_0dd1bd97-2f09-4e07-8421-eba68f17bedd">1.7</ix:nonFraction>&#160;billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive other contingent payments, including contingent sales milestones and royalty payments, as described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There have been no material changes to our collaboration agreements for the year ended December&#160;31, 2021, except as </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i1ae9d35cee9648a2a2b4304b0f02c084" continuedAt="i6a13248e2ee64f809804379370232c36"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">described below.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb (BMS): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (previously referred to as NKTR-214)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing <ix:nonFraction unitRef="number" contextRef="i3bb556020be549ee87413847caad7cad_D20180212-20180213" decimals="INF" name="nktr:ProfitsAndLossesSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzMwOTc_89ddbd80-86a1-48d6-adf9-7770813024ec">65</ix:nonFraction>% and BMS sharing <ix:nonFraction unitRef="number" contextRef="i8261a40efe0948f49707ae9d352985c9_D20180212-20180213" decimals="INF" name="nktr:ProfitsAndLossesSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzMxMTY_dd174715-0367-41f3-81e6-9e7ae8968a5a">35</ix:nonFraction>% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="number" contextRef="i0091cbcb2514452baa6df443b7072779_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzM0NzI_de8c8037-200b-4100-b975-85964a1b5ca3">67.5</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="ie78f916daa434e17a021f7221225eb22_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzM0OTU_add1c346-abac-4951-987e-c6834242624a">32.5</ix:nonFraction>% to Nektar. The parties share costs for the manufacturing and joint commercialization of bempegaldesleukin, <ix:nonFraction unitRef="number" contextRef="i8261a40efe0948f49707ae9d352985c9_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzM1Nzc_5ee74dd2-79d2-41c8-8d3b-8c12c421d640">35</ix:nonFraction>% of the costs to BMS and <ix:nonFraction unitRef="number" contextRef="i3bb556020be549ee87413847caad7cad_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzM2MDA_cc2015a3-d38c-40d3-a8cc-05065b5188d2">65</ix:nonFraction>% to Nektar. On January 9, 2020, we and BMS entered into Amendment No. 1 (the First Amendment) to the BMS Collaboration Agreement, pursuant to which, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. BMS has the right, at its sole discretion, to terminate co-funding its share of the development costs for the adjuvant melanoma collaboration study if the metastatic melanoma collaboration study fails to meet the primary endpoint of progression free survival. If BMS exercises such right, we have the right, in our sole discretion, to continue the adjuvant melanoma study. On January 12, 2022, we and BMS entered into an Amendment No. 2 to the BMS Collaboration Agreement, pursuant to which we and BMS allocated certain responsibilities for price negotiations and promotion, market access, patient support and related activities to each party. The cost sharing for the development, manufacturing and commercialization under our collaboration remains unchanged as a result of these amendments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i6c31a5edbd5f4e7ba1771e0dd2cfd00f_D20180401-20180430" decimals="-8" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzQ0OTU_01b3d545-7e90-4c9b-92a2-b6de01dab3e1">1.0</ix:nonFraction>&#160;billion and purchased <ix:nonFraction unitRef="shares" contextRef="i3a673492af0542c787de8ecf805aa6b6_I20180430" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzQ4NTE_2fba0e33-929d-4bae-8215-2db3312be250">8,284,600</ix:nonFraction> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i0971825b2d534ad7a2466cf3158c182f_D20180401-20180430" decimals="-5" name="nktr:SaleOfStockConsiderationReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzQ5NjU_ecc820af-5b26-4731-b1d3-873d59c19761">850.0</ix:nonFraction>&#160;million. Pursuant to Amendment No. 1 described below, we received a non-refundable, creditable milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i859a4f864b514e87a0cf719770bf6959_I20200109" decimals="INF" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE3NTkyMTg2MTA3OTg1_baafe73d-7ea6-4dcb-8e0d-365c29f74539">25.0</ix:nonFraction>&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i859a4f864b514e87a0cf719770bf6959_I20200109" decimals="INF" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE3NTkyMTg2MTA4MTk2_b32b8497-3492-4ec6-8796-70c59a62dce4">25.0</ix:nonFraction>&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. We are eligible to receive potential future payments for development and regulatory milestones of approximately $<ix:nonFraction unitRef="usd" contextRef="i8f0bd98c891a4594a3a511270a06abda_D20210101-20211231" decimals="-6" name="nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE3NTkyMTg2MTA4OTE0_1efbc2bf-7929-46eb-b5c9-d2bc11fcf470">1.4</ix:nonFraction>&#160;billion (which reflects the reduction for the creditable milestone for the muscle-invasive bladder cancer trial) and up to a total of $<ix:nonFraction unitRef="usd" contextRef="icdecde4596554cde9aa263b142ab9462_D20180401-20180430" decimals="INF" name="nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE3NTkyMTg2MTA5MDk3_08e67d19-2623-40c6-b9d9-0d89bc48d0fb">350.0</ix:nonFraction>&#160;million upon the achievement of certain sales milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. For the years ended December&#160;31, 2021, 2020 and 2019, we recorded $<ix:nonFraction unitRef="usd" contextRef="i7a15cd1d266049a6b956f4c5cda3ccfe_D20210101-20211231" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzY4NjE_c791a206-3b49-429a-9775-862a0f128c48">101.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie2c265cd979f48f49755e5233054afc9_D20200101-20201231" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzY4Njg_89c06efc-9afa-47f4-afd3-0b75f0382f46">128.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8db809beaa2342b6907e26d5a756ecbc_D20180101-20181231" decimals="-5" name="nktr:ReimbursementOfExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzY4NzY_2d69b25c-0fa0-4845-917a-1a9aa65952a9">105.4</ix:nonFraction> million, respectively, as a reduction of research and development expenses for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses.  As of December&#160;31, 2021 and 2020, we have recorded an unbilled receivable of $<ix:nonFraction unitRef="usd" contextRef="i404b477314254c6c9c18783047bfaddb_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzcwNzQ_900113af-deb8-424c-b80d-bd586f1802e1">21.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8fb38abf73194c0185c0ad4dedc15a76_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzcwODI_cd9bfe0e-99b8-416f-97fb-4e01b56bc9d5">38.7</ix:nonFraction> million, respectively, from BMS in accounts receivable in our Consolidated Balance Sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our share of development costs is limited to an annual cap of $<ix:nonFraction unitRef="usd" contextRef="i02fa6a90350c495998c00c9ec2be64b1_D20210101-20211231" decimals="INF" name="nktr:CompanyShareOfDevelopmentCostsAnnualCap" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzcyMzA_be7f676b-013e-4535-92cd-25d7b1127f33">125.0</ix:nonFraction>&#160;million. To the extent this annual cap is exceeded, BMS reimburses us for the excess, which we must repay to the extent that our share of development costs are less than the annual cap in a future year. For the year-ended December 31, 2020, our share of the development costs exceeded the annual cap and therefore we included the $<ix:nonFraction unitRef="usd" contextRef="i7de3ce10d71c401f8c6b6d9fa8f5d1fc_D20200101-20201231" decimals="INF" name="nktr:CompanyShareOfDevelopmentCostsAnnualCap" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzM4NDgyOTA3NTU2OTY_9bce6f8a-aee6-4292-8c2c-189e89a419fe">4.0</ix:nonFraction>&#160;million reimbursement in our accounts receivable as of December 31, 2020 and recorded an off-setting liability in Other long-term liabilities. For the year-ended December 31, 2021, our share of the development costs was sufficiently lower than the cap such that we are required to repay the $<ix:nonFraction unitRef="usd" contextRef="i7de3ce10d71c401f8c6b6d9fa8f5d1fc_D20200101-20201231" decimals="INF" name="nktr:CompanyShareOfDevelopmentCostsAnnualCap" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzMyOTg1MzQ5NDYwMTE_9bce6f8a-aee6-4292-8c2c-189e89a419fe">4.0</ix:nonFraction>&#160;million and therefore have reclassified the liability as a reduction of our accounts receivable as of December 31, 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analogized to ASC 606 for the accounting for our two performance obligations, consisting of the delivery of the licenses to develop and commercialize bempegaldesleukin and our participation on joint steering and other collaboration committees. We determined that our committee participation is not material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During 2018, we aggregated the total consideration of $<ix:nonFraction unitRef="usd" contextRef="i6fe08663b69b470d9befa4a3fea814cc_D20180101-20181231" decimals="-7" name="nktr:AggregateConsiderationReceivedFromAgreements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzg0MDU_dea4291f-d78d-49c4-a21a-ad58ad848da5">1.85</ix:nonFraction>&#160;billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i6a13248e2ee64f809804379370232c36" continuedAt="i00ef1694d84846dabd56c7355bc97f4d"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $<ix:nonFraction unitRef="usd" contextRef="i8045653e56804da78b7a3f7548e93f95_I20181231" decimals="-5" name="nktr:EstimatedFairValueOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzg3NTY_fa40fddf-8c00-4b92-a16a-2579e70ebb03">790.2</ix:nonFraction>&#160;million in stockholders&#8217; equity. We allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="i6fe08663b69b470d9befa4a3fea814cc_D20180101-20181231" decimals="-5" name="nktr:RemainingAmountAllocatedToTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzg4MTE_968ee0f0-e629-4307-b532-a071dbc0fd77">1,059.8</ix:nonFraction>&#160;million to the transaction price of the collaboration agreement, which we recognized in 2018. During the year ended December 31, 2020, we received $<ix:nonFraction unitRef="usd" contextRef="i35bc8164332c4f0d942659ecdb9b7c2a_D20200101-20201231" decimals="-5" name="nktr:RemainingAmountAllocatedToTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzgyNDYzMzcyNzA5NzI_f642e23b-3eab-4e09-bf82-c1beee10b4db">50.0</ix:nonFraction>&#160;million in aggregate for the achievements of the first patient, first visit in the registrational muscle-invasive bladder cancer trial and the registrational adjuvant melanoma trial, which we recognized as revenue in 2020 because we had previously satisfied our performance obligation of granting the licenses. We continue to exclude the variable consideration of the potential future development, regulatory and sales milestones of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i6179d6e6ea6445b59e375f1714da51d8_I20211231" decimals="-8" name="nktr:PotentialDevelopmentRegulatoryAndSalesMilestones" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzkwMDE_d232865e-f850-4fb3-b25b-9faaa0fc6e2b">1.8</ix:nonFraction>&#160;billion from the transaction price as of December&#160;31, 2021 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NKTR-358 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $<ix:nonFraction unitRef="usd" contextRef="id10b0e192e72479c93c3fb96e48815dd_D20170901-20170930" decimals="-5" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzk5Njc_b7e807e9-a258-44d6-a85e-d20161e6a7c1">150.0</ix:nonFraction>&#160;million in September 2017 and are eligible for up to $<ix:nonFraction unitRef="usd" contextRef="ide4cc486142a4e91a1bc4da6d2ef22e4_I20170823" decimals="INF" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwMDE1_0134fbcd-c6a5-4bf1-8bb6-3f4a5c072e01">250.0</ix:nonFraction>&#160;million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and certain drug product development and supply activities, (iii) will share with Lilly Phase 1B and 2 development costs with <ix:nonFraction unitRef="number" contextRef="ie9610c03746f479f8ed2307f84e94aa8_D20170823-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwMjk4_3e273014-766a-4e61-b14b-201558d3a626">75</ix:nonFraction>% of those costs borne by Lilly and <ix:nonFraction unitRef="number" contextRef="i94624f38524b41d19de37806eae8205a_D20170823-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwMzM1_c512f23b-6aa9-4037-a1c8-35ae53b6d5cd">25</ix:nonFraction>% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from <ix:nonFraction unitRef="number" contextRef="i571d31ed3414457d970b51bd263f4336_D20170823-20170823" decimals="INF" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwNDg1_541c17e4-9ea6-4cc6-9855-810adb173ec4">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i4af4611c2c0a47adafeff233ec324125_D20170823-20170823" decimals="INF" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwNDkx_1c4dff30-6214-4983-a161-fd69f5b4b9d8">25</ix:nonFraction>% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by <ix:nonFraction unitRef="number" contextRef="i2e394a6636a846efaeb92892f815f0f7_D20170823-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwOTA0_a62f2fde-6bab-46e0-9d74-9ae5a1beaff7">50</ix:nonFraction>% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by <ix:nonFraction unitRef="number" contextRef="i2e394a6636a846efaeb92892f815f0f7_D20170823-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzExMTM5_c612f492-0b97-4313-b1a5-f0878d6ef1e5">75</ix:nonFraction>% if both conditions occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $<ix:nonFraction unitRef="usd" contextRef="id10b0e192e72479c93c3fb96e48815dd_D20170901-20170930" decimals="-5" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY2ODM3_a22bab55-15fa-4400-8eb5-4923fcc2d7d8">150.0</ix:nonFraction>&#160;million upfront payment as $<ix:nonFraction unitRef="usd" contextRef="ifdf41eee0b3e48dd93b8a4402bac9137_D20170901-20170930" decimals="-5" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY2ODYw_8abf7805-105c-4d53-815b-93aa6b927b08">125.9</ix:nonFraction>&#160;million to the license, $<ix:nonFraction unitRef="usd" contextRef="ib6e7e8305ef0454abcf6345f4b1ee7d3_D20170901-20170930" decimals="-5" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY2ODgw_2554deac-dc32-41f4-b83a-9fdd4423789b">17.6</ix:nonFraction>&#160;million to our portion of the Phase 1 clinical development and $<ix:nonFraction unitRef="usd" contextRef="i6812a1be21d84f488147e73621f09203_D20170901-20170930" decimals="-5" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY2OTM5_82b34425-f11d-4ef0-ab5b-db6460b4f42a">6.5</ix:nonFraction>&#160;million to the drug product development. We recognized the $<ix:nonFraction unitRef="usd" contextRef="i45d391452d324672a836342487419576_D20170801-20170831" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY3NTU5_4c5b4796-40ff-4ee5-b1ef-53046f602cdf">125.9</ix:nonFraction>&#160;million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development through the three months ended March 31, 2020. As of December&#160;31, 2021, we have <ix:nonFraction unitRef="usd" contextRef="i60213b20f36548838d7b341fd83327c8_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY4MDY0_ff058a85-6c3c-4c37-ae65-301c355e4568">no</ix:nonFraction> deferred revenue related to this agreement.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to exclude the other milestones from the transaction price as of December&#160;31, 2021 due to the significant uncertainties involved with clinical development. </span></div><div style="margin-top:18pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Baxalta Incorporated/Takeda: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Hemophilia A program includes ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was approved by the FDA in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. We are entitled to royalties based on worldwide net sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and an  sales milestone upon achievement of an annual worldwide net sales target.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i00ef1694d84846dabd56c7355bc97f4d"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, we are entitled to single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement. As described in Note 8, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (naloxegol oxalate), previously referred to as naloxegol and NKTR-118,</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2014 and December 2014, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> /MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the US and EU, respectively. In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, excluding Europe, Canada and Israel, to RedHill Biopharma. These sublicenses did not change our rights under the agreement with AstraZeneca, and our royalty rate, royalty term and future potential sales milestones remain unchanged. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from AstraZeneca and RedHill Biopharma, we are entitled to significant and escalating double-digit royalty payments and sales milestones. For the net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the sublicense to Kirin, we are entitled to <ix:nonFraction unitRef="number" contextRef="i163fba6573974206a8cbfb1e757d6908_D20160301-20160331" decimals="INF" name="nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE4NjUw_f8d84318-cbf6-451e-85a0-fb8503759394">40</ix:nonFraction>% of the royalties and sales milestones received by AstraZeneca. AstraZeneca is entitled to deduct a portion of its costs for a post-marketing study required by the FDA, subject to certain limits, only through a reduction of the royalties due to us. As of December 31, 2021, our cumulative share of these costs was not significant.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 8, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement, and HCR will bear the cost of any reductions for the post-marketing study.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the 2010 Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the 2010 Agreement, we received a $<ix:nonFraction unitRef="usd" contextRef="i4620b301e5a3473081e7c8cfc28f8404_D20101001-20101031" decimals="-5" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDc0ODEz_0c2f0640-bf3e-489d-adbe-51b47349ccb1">50.0</ix:nonFraction> million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen. We recognized this revenue on a straight-line basis over the <ix:nonNumeric contextRef="ib32493f3644b448eb1a1da39e4dbd1cf_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE0MjkzNjUxMjE5NjM4_b781ab90-02bd-42d9-88b1-a2e924f2b747">ten-year</ix:nonNumeric> term of the 2010 Agreement through September 2021.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, as of December&#160;31, 2021, we have other collaboration agreements, including with our collaboration partner UCB Pharma, under which we are entitled to up to a total of $<ix:nonFraction unitRef="usd" contextRef="icbc31f05452946b7981e6387e3c1acd2_I20211231" decimals="-5" name="nktr:PotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzIwNDQy_a29d1584-26a0-460d-9bce-de139e353d31">40.0</ix:nonFraction> million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of December&#160;31, 2021, we have deferred revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i2a74676520a541cf835f2a6ff04233d4_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzIxMDI2_1872d2c8-feac-42a1-82d0-64e8ce481e8f">2.0</ix:nonFraction> million related to these other collaboration agreements.</span></div></ix:continuation><div id="i1023926dfc3b4cff924b0207eb081f42_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;12 &#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMjg_d8b5a27b-0c31-472b-95ab-88b38480e917" continuedAt="i6450d60c4cbb4b5a9ef527da9fcc3260" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i6450d60c4cbb4b5a9ef527da9fcc3260" continuedAt="i215e4f520eac4f338b128622855d74ca"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> 2017 Performance Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our 2017 Performance Incentive Plan (2017 Plan) provides for the issuance of our common stock to members of the Board of Directors, officers or employees, certain consultants and advisors and our subsidiaries. Our 2017 Plan has been amended and restated such that an aggregate <ix:nonFraction unitRef="shares" contextRef="i85e44fd2a3b7430fb8662bdf1cfee75a_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NTU2Njk_05b27207-9167-4161-ade3-3e586d2c0c58">34,200,000</ix:nonFraction> shares have been authorized for issuance as of December&#160;31, 2021, including <ix:nonFraction unitRef="shares" contextRef="ib9260c5cf0a145fd9ef016e7007916ce_I20210610" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIxMzg5_631503c6-d66a-48a9-a68b-1ddde21668e1">5,000,000</ix:nonFraction> shares that were approved on June 10, 2021. Under the 2017 Plan, we may issue stock options, restricted stock, performance stock, stock units, stock appreciation rights and other similar types of awards. When the 2017 Plan was approved on June&#160;14, 2017, any shares of our common stock that were available for issuance under our 2012 Performance Incentive Plan (the 2012 Plan) ceased to be available for future grants. However, options and RSUs granted under the 2012 Plan </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i215e4f520eac4f338b128622855d74ca" continuedAt="i65c38bb063034db8ad35daa2cf4e4ca5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remained outstanding, and any options or RSUs that were cancelled or forfeited became available for issuance under the 2017 Plan. Shares issued for RSUs, PSUs or any other &#8220;full-value award&#8221; will be counted against the share limit as <ix:nonFraction unitRef="number" contextRef="i85e44fd2a3b7430fb8662bdf1cfee75a_I20211231" decimals="INF" name="nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIzMTI5_550ddb1d-a284-4a0d-891f-5b3a96576dcf">1.5</ix:nonFraction> shares for every one share actually issued in connection with the award. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted or issued non-qualified stock options, RSUs and PSUs to employees, officers, and non-employee directors. For our employees, the requisite service period is generally <ix:nonNumeric contextRef="iea9636cc4c9d490297fba185f90f9827_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIxNzQ4_43eec72a-a9df-4f81-945f-05686d9947e6">four years</ix:nonNumeric> for stock options, and <ix:nonNumeric contextRef="i447e3d8d3d6a40ff8c71fa4631994b79_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDI0MzUy_9c0e2ddf-490f-408c-a4ed-ccaceadd1ea3">three years</ix:nonNumeric> for RSUs and PSUs. For our directors, the requisite service is generally <ix:nonNumeric contextRef="i37ef7aa72e7f4284abbf69eb9fcf07de_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIxODM4_f1fd37c2-9e3f-4e2c-bc90-e204e33e4c0c">one year</ix:nonNumeric> for stock options and RSUs. The maximum term of a stock option or stock appreciation right is <ix:nonNumeric contextRef="i0c98c4e18c764ec4aabcffa64729091b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIyMTk0_2daf90a0-1378-411b-8e55-2bcb71b10438">eight years</ix:nonNumeric> from the date of grant. The per share exercise price of an option generally may not be less than the fair market value of a share of our common stock on the NASDAQ Stock Market on the date of grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Change in Control Plan (the CIC Plan), in the event of a change of control of Nektar and a subsequent termination of employment initiated by us or a successor company other than for Cause (as defined in the CIC Plan) within <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:ChangeInControlSeverancePaymentPeriodForExecutives" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDI4NDU2_42688a39-ea2f-43c0-82c7-224d5bdc7d20">twelve months</ix:nonNumeric> following a change of control, our employees are entitled to full acceleration of their unvested equity awards. Our Chief Executive Officer, Senior Vice Presidents and Vice Presidents (including Principal Fellows) are also entitled to full acceleration of unvested equity awards if the termination is initiated by the employee for a Good Reason Resignation (as defined in the CIC Plan) within <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:ChangeInControlSeverancePaymentPeriodForExecutives" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDI4ODMy_42688a39-ea2f-43c0-82c7-224d5bdc7d20">twelve months</ix:nonNumeric> following a change of control. Additionally, non-employee directors would also be entitled to full acceleration of vesting of all outstanding stock awards in the event of a change of control transaction.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the terms of our the Employee Stock Purchase Plan (ESPP), employees may purchase shares of our common stock based on a percentage of their compensation subject to certain limits. Shares are purchased at <ix:nonFraction unitRef="number" contextRef="i3636ccf59db74199a476bef6db7fa9b5_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDI1Mjgy_e60b145e-5c46-43c4-a0fe-1df2f81ec7e9">85</ix:nonFraction>% of the lower of the closing price on either the first day or last day of each six-month offering period. An aggregate <ix:nonFraction unitRef="shares" contextRef="ie278c33e215c4682baa578128551c2d8_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NTU2ODE_7f0ad506-4d11-4408-9d23-8758d47fcf43">3,500,000</ix:nonFraction> shares have been authorized for issuance under our ESPP, including <ix:nonFraction unitRef="shares" contextRef="ic55f7a5b573548869eb6b5c0c65a71b4_D20200617-20200617" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIzNzEx_3bc48911-d974-4aa1-ae08-b304afeed7ba">1,000,000</ix:nonFraction> shares approved on June 17, 2020.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMzM_cc20908d-07bb-4856-8482-0c61b71ddec9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0035b332ba9d4aa3ae359c9299758ee5_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzItMS0xLTEtMTEyOTg_8410c5e5-2a04-4c8c-8343-0744e7333b82">2,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f052c3b58374798bbb51692c71f38a3_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzItMy0xLTEtMTEyOTg_ba7c80d8-2826-49a1-a73b-40043b229158">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44b9566b75c444fa92e9c77ccb22df0_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzItNS0xLTEtMTEyOTg_d2c7f3bb-ab82-4421-9295-2d13d542b85b">4,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2401bd6e0c9941d2ac71f0226fb724d4_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzMtMS0xLTEtMTEyOTg_e44d2db0-dbfd-4950-a6e0-a1f8ca59d2ef">54,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973a75b3adfc4d628fdc8dbe94b83110_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzMtMy0xLTEtMTEyOTg_bc9fdff8-9873-42ed-9f23-ac17f22c4e26">57,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d494d74848a4be6b679b6d322a4a6ad_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzMtNS0xLTEtMTEyOTg_f847d6e9-15a3-461f-9948-ef7fa2a20669">63,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6ea4f6ff6546d4a7b6f841d44f50c2_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzQtMS0xLTEtMTEyOTg_307a184b-3e88-44da-8b29-5ae6de5b9e5c">37,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029b733cde5b4e28800367770689c2a5_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzQtMy0xLTEtMTEyOTg_b2ad349b-1f90-473f-bd0d-b4cb241038d6">33,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic276dbba3c744c5dbce8ec6fa2c4d30c_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzQtNS0xLTEtMTEyOTg_766a131f-5c31-4e17-bc9b-8ac552f4ba52">32,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaa277296ff1492d902aa6bd17b985a1_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzUtMS0xLTEtMTEyOTg_d9026eac-bfb3-42da-8946-fda1a95b8719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a24d5a38eb49e09e58c801f3465307_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzUtMy0xLTEtMTEyOTg_fe7b5329-366b-42a1-96ec-09406058a4a4">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a6b923db694bdea933ddef727104ed_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzUtNS0xLTEtMTEyOTg_6e969084-3919-4df0-bb57-6aa1f51b18f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzYtMS0xLTEtMTEyOTg_d10d0dd8-eb66-4912-8564-88fddbed6ad4">94,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzYtMy0xLTEtMTEyOTg_63cabd6b-31bf-4584-b236-5855cbc97384">94,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzYtNS0xLTEtMTEyOTg_652e0742-6980-4529-a9b5-b04d67037b40">99,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance. Stock-based compensation expense resulting from PSUs and our ESPP was not significant in the years ended December&#160;31, 2021, 2020, and 2019.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, total unrecognized compensation costs of $<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzM2Mg_3fad7141-72e5-4541-985b-c9af69d1c198">187.4</ix:nonFraction> million related to unvested stock-based compensation arrangements are expected to be recognized as expense over a weighted-average period of <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMjk_9d4f9e83-f52e-4205-a170-de744b527738">2.6</ix:nonNumeric> years.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Black-Scholes Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:continuation id="idbccb1a242d94e50b480060b4252e6f4" continuedAt="i75e9a3e70cc645dfbddad77bba175682">The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:</ix:continuation></span><ix:continuation id="i75e9a3e70cc645dfbddad77bba175682"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzItMS0xLTEtMTEyOTg_e556e83b-ae71-4998-be0f-f1a2d9d90000">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzItMy0xLTEtMTEyOTg_6ade4514-026e-4bec-aee8-c28ee8a61b8d">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzItNS0xLTEtMTEyOTg_3fdbcd11-ec38-43ac-86ce-6bfdb3cac2bc">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzMtMS0xLTEtMTEyOTg_c7795fd5-82dd-44ba-a390-f83c85c4c188">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzMtMy0xLTEtMTEyOTg_634c6af3-25f3-485f-8f45-073a438e5e80">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzMtNS0xLTEtMTEyOTg_2219e1d9-a5fb-4093-9079-a94d356de0cd">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzQtMS0xLTEtMTEyOTg_5bca2561-1f1a-4042-a024-66c847841baa">63.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzQtMy0xLTEtMTEyOTg_f125c71b-d0c4-4e05-b205-0910986f191a">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzQtNS0xLTEtMTEyOTg_09eec4e5-8cd2-4e76-bc72-eb0e2321ed8a">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzUtMS0xLTEtMTEyOTg_298f45d4-0168-49b1-bd3f-368f15a31019">5.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzUtMy0xLTEtMTEyOTg_ba23a3d3-c8f5-4186-b85c-238f193fb8e8">5.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzUtNS0xLTEtMTEyOTg_bb76a933-bbef-4792-988b-cb623a277c3e">5.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzYtMS0xLTEtMTEyOTg_65a06501-e1bb-410f-b0a8-efff72bdf511">8.07</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzYtMy0xLTEtMTEyOTg_d1f54af8-6e7e-473c-94a2-44c1ab7c6115">10.70</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzYtNS0xLTEtMTEyOTg_f41b519f-31c5-4ea4-b099-2a17c0ec4ab1">12.25</ix:nonFraction></span></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i65c38bb063034db8ad35daa2cf4e4ca5"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The average risk-free interest rate is based on the U.S.&#160;treasury yield curve in effect at the time of grant for periods commensurate with the expected life of the stock-based award. We have never paid dividends, nor do we expect to pay dividends in the foreseeable future; therefore, we used a dividend yield of <ix:nonFraction unitRef="number" contextRef="i7a941c5289d14ecb98a14b23c2c6474d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzExNzE_fccf7b10-c450-4fa4-95bf-be6d86f13edb">zero</ix:nonFraction>. Our estimate of expected volatility is based on the daily historical trading data of our common stock at the time of grant over a historical period commensurate with the expected life of the stock-based award. We estimated the weighted-average expected life based on the contractual and vesting terms of the stock options, as well as historical cancellation and exercise data.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMzc_4bfde961-cc7b-4bfd-9873-509fc24ce802" continuedAt="i80f003345123435c8eab6d4bb2dc5250" escape="true">The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):</ix:nonNumeric></span><ix:continuation id="i80f003345123435c8eab6d4bb2dc5250" continuedAt="i0957a2ddc195486fa70fff66cb547a87"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:51.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzEtMS0xLTEtMTEyOTg_65231f30-9734-4178-9e84-77154bb2dc49">13,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzEtMy0xLTEtMTEyOTg_7de07f15-3116-416b-8169-da02f1153935">24.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzItMS0xLTEtMTEyOTg_85463d3c-becd-4bb9-94f3-526b8463565d">2,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzItMy0xLTEtMTEyOTg_8aa4ae37-db72-4b97-8f87-2523c76ff5b4">14.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzMtMS0xLTEtMTEyOTg_e4954bc1-feea-4f60-a6a6-84d91646fe69">2,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzMtMy0xLTEtMTEyOTg_e39ad9cf-37ea-458e-97f1-cc40a02ab624">12.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited &amp; canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzQtMS0xLTEtMTEyOTg_fd64b4cf-2e81-4abc-adf0-8343d2c2c774">504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzQtMy0xLTEtMTEyOTg_b7106a6d-9491-4515-9a7a-68c82a0e664a">46.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzUtMS0xLTEtMTEyOTg_17039465-c9e3-4e71-8b48-fd27e96d862e">13,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzUtMy0xLTEtMTEyOTg_7380af15-93ba-455f-bf0d-069743187776">23.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzUtNS0xLTEtMTEyOTg_bf5ec6ec-9dd8-445a-8611-136210fad4bf">4.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzUtNy0xLTEtMTEyOTg_f217ab66-2217-4adc-b5ed-ec7756a0dbd6">2,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzctMS0xLTEtMTEyOTg_083bfe61-d178-4003-bea9-e5fb9bedec01">8,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzctMy0xLTEtMTEyOTg_a5c40468-ff6a-474a-8de5-032b7b58c870">26.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzctNS0xLTEtMTEyOTg_0b8ec953-8e03-4949-ad0a-6e55931330f2">3.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzctNy0xLTEtMTEyOTg_159d3842-09e3-4d28-8678-c6488f9af5cd">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="i0957a2ddc195486fa70fff66cb547a87" continuedAt="i280adc9ae12c4d08ab9c630242b93830">_______________________________________________________________</ix:continuation></span></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i280adc9ae12c4d08ab9c630242b93830" continuedAt="i94962869100a40ed91772fc19953961b">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"><ix:continuation id="i94962869100a40ed91772fc19953961b">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2021.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The intrinsic value of options exercised during the years ended December&#160;31, 2021, 2020 and 2019 totaled $<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIwNjQ_30df7ceb-2935-43a7-87ea-c5250f2a22d0">17.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIwNjg_1eebdcfe-3aea-4727-9e74-a674a68dbdfe">15.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIwNzU_11661f9b-aeb6-43e7-8240-c604ff890bc8">30.6</ix:nonFraction> million, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of RSU Activity</span></div><div style="margin-top:12pt;text-indent:36pt"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMzE_69a78c70-6c46-4d8d-819c-52891de0873b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU award activity is as follows (in thousands except for per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i718223867ea449b3bb07403f12f97462_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzEtMS0xLTEtMTEyOTg_ef8e8f89-fafd-42c8-9ee7-27f5fa9c0df0">7,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i718223867ea449b3bb07403f12f97462_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzEtMy0xLTEtMTEyOTg_f5c4514a-8ce9-4e7b-bf9e-478b15eb3cc9">22.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzItMS0xLTEtMTEyOTg_22ae8b9c-3a5c-48e4-90c8-b13e98d41341">6,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzItMy0xLTEtMTEyOTg_8a90d4ae-f191-4025-ac72-ca81b0bc300d">14.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzMtMS0xLTEtMTEyOTg_fa189e50-115f-4303-b99b-cc80260d3291">2,617</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzMtMy0xLTEtMTEyOTg_779cdf16-24ed-4acc-810a-f0f334344f66">25.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzQtMS0xLTEtMTEyOTg_195e9932-f2d9-4ad4-8e63-7805e0db0cf1">1,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzQtMy0xLTEtMTEyOTg_318990fe-060c-4cf6-9fe2-324a61a8bf51">21.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0779bcc3fd547a7a0d232c80b0cca7d_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzUtMS0xLTEtMTEyOTg_5f59320b-9973-4252-8077-362bf5364b1f">9,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0779bcc3fd547a7a0d232c80b0cca7d_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzUtMy0xLTEtMTEyOTg_7a01d0c5-8740-4a94-a39d-e43c4ff91d08">16.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair values of RSUs granted during the years ended December&#160;31, 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzM4NDgyOTA3MTE4MjI_bdc7319b-90aa-4dd3-85b9-3089a55daa38">14.68</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i613d6ffb709a4aceb22ec5c774efb691_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzM4NDgyOTA3MTE4MzA_a3d5d2d1-6514-4425-8d6e-b0d7aca198c5">19.24</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i059dd17f5075463e95e35460261b7a4b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzM4NDgyOTA3MTE4Mzg_a7c8a142-4faa-4f5d-8c11-fab02a6ceb55">23.32</ix:nonFraction>, respectively. The fair value of restricted stock that vested in the years ended December&#160;31, 2021, 2020 and 2019 totaled $<ix:nonFraction unitRef="usd" contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMDA_1cbebaa2-fdc0-45bb-ae35-738c1a4e05cd">45.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i613d6ffb709a4aceb22ec5c774efb691_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMDQ_09305eb7-ad44-4a85-b454-0d5b630118fa">33.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i059dd17f5075463e95e35460261b7a4b_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMTE_87b0ff36-bd52-45fd-bd6f-87480317d846">32.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Retirement Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of <ix:nonFraction unitRef="number" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE3NTkyMTg2MDU3OTQ0_3b2fa454-1cae-497b-bd1e-a7ea04d3e039">60</ix:nonFraction>% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="INF" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE3NTkyMTg2MDU4MTgy_7eb7f825-f70b-4aaa-b1fa-dad2632e4330">6,000</ix:nonFraction> per participant. For the years ended December&#160;31, 2021, 2020, and 2019, we recognized $<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE3NTkyMTg2MDU4MjU2_53dd7f6f-4cda-4727-a802-aafdecf63255">3.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE3NTkyMTg2MDU4MjYx_33b397d6-9833-471d-87ab-be2c010ca65a">3.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE3NTkyMTg2MDU4Mjcw_49980921-e55f-4a2a-91f6-867f9c977d2f">3.5</ix:nonFraction> million, respectively, of compensation expense in connection with our 401(k) retirement plan.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="i1023926dfc3b4cff924b0207eb081f42_127"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;13&#160;&#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNzM_32d2032e-aae1-42c0-a3b3-5b26f6c870f3" continuedAt="i9f88d507f3cb4af3b8b6a2d73a434b7e" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i9f88d507f3cb4af3b8b6a2d73a434b7e" continuedAt="i0884ff1b0d3341beb8818f54e461bb74"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNjc_93283c18-d9c9-4014-a795-ba3a95da5251" continuedAt="i99d7f198d42b47cab4fc549bfc7632e0" escape="true">Income (loss) before provision for income taxes includes the following components (in thousands):</ix:nonNumeric></span><ix:continuation id="i99d7f198d42b47cab4fc549bfc7632e0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzItMS0xLTEtMTEyOTg_c911626c-055d-4a39-9d7a-31f1d5b3fcb3">524,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzItMy0xLTEtMTEyOTg_2c93685a-70e7-488c-ac00-eb3365229f28">445,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzItNS0xLTEtMTEyOTg_bd070876-e8b1-4aff-b28d-1aace17b5c65">441,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzMtMS0xLTEtMTEyOTg_ca3608d9-2b7a-43fa-a0da-e2c19777cae1">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzMtMy0xLTEtMTEyOTg_0592b8b9-e6fc-474d-b80a-9ec71b7ea33b">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzMtNS0xLTEtMTEyOTg_28a82e8a-23e9-473f-accb-89d4fa8e9214">1,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzQtMS0xLTEtMTEyOTg_c3d2bb37-cacb-469f-85d2-0a474e9047e3">523,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzQtMy0xLTEtMTEyOTg_c3c22425-dd5c-4ae4-b05b-4e05459d4766">443,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzQtNS0xLTEtMTEyOTg_a61f9db5-3be5-4735-8b1a-f7a9884c719c">440,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNzU_d5bfc599-a7e9-4c1d-9c6c-9b45299de08e" continuedAt="i2b566eb052c3412680a98c4a22857e80" escape="true">The provision for income taxes consists of the following (in thousands):</ix:nonNumeric></span><ix:continuation id="i2b566eb052c3412680a98c4a22857e80"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzMtMS0xLTEtMTEyOTg_a44c351c-8833-4d7e-8cda-2d123549b260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzMtMy0xLTEtMTEyOTg_8ff4d8e2-b05b-4cf4-8b47-db1f43cfdce2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzMtNS0xLTEtMTEyOTg_172c6bbe-c640-4f7d-9607-8c7b62994e87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzQtMS0xLTEtMTEyOTg_6d8ab60a-8058-408c-a45c-d80ca953f484">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzQtMy0xLTEtMTEyOTg_8985e59a-b147-4da5-acdb-bcd75a7005ce">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzQtNS0xLTEtMTEyOTg_bc001a88-ca6a-4b41-8792-bd0cf1bf392b">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzUtMS0xLTEtMTEyOTg_e70f2b9e-eaba-4eb3-9e5d-2e6bcd353c55">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzUtMy0xLTEtMTEyOTg_cae47cd5-74f7-435d-a17b-4ed0c5cc22f4">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzUtNS0xLTEtMTEyOTg_ad44f8c8-9a0b-4e4e-84c9-7c8fe0f8875b">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzYtMS0xLTEtMTEyOTg_7375ae29-5b8f-431a-9e08-25d6ce410b3c">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzYtMy0xLTEtMTEyOTg_d2388ee1-28cb-445b-b7d5-7926e98fd86f">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzYtNS0xLTEtMTEyOTg_a71f991b-72f3-46ff-b03b-3d72d9665f2c">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzgtMS0xLTEtMTEyOTg_be14d625-8f13-4991-9a0e-464fb986bf5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzgtMy0xLTEtMTEyOTg_868e2f5c-e052-49bf-8dac-be95a81f1478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzgtNS0xLTEtMTEyOTg_676af439-7cfa-47cb-a430-ab39260936d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzktMS0xLTEtMTEyOTg_23cc9eb5-d5f8-4d0a-a500-a708c36745c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzktMy0xLTEtMTEyOTg_784db96b-1643-41e7-b912-1f1788b4977f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzktNS0xLTEtMTEyOTg_d41d00c1-7818-4cd7-a50f-64bfae507608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEwLTEtMS0xLTExMjk4_0f219243-90ff-48b5-b144-f3fd034ffdae">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEwLTMtMS0xLTExMjk4_a479fe3f-80a7-4b0e-bb66-0d75d1db38c4">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEwLTUtMS0xLTExMjk4_4d8006b2-e006-40fc-9425-4b479ef2d50c">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzExLTEtMS0xLTExMjk4_04af13a6-66c4-4b60-a860-141a042487bf">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzExLTMtMS0xLTExMjk4_aaa231fa-ae97-4a55-ad06-394d5f5809c4">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzExLTUtMS0xLTExMjk4_20cd8ff5-97f0-49c6-b0d4-1809f8fd9578">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEyLTEtMS0xLTExMjk4_f45aa302-6425-4774-a550-e312613e5f03">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEyLTMtMS0xLTExMjk4_261e7d9b-487c-4154-81b3-6416a8d17ca3">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEyLTUtMS0xLTExMjk4_35886f8c-d58f-47fc-bc31-94e4b75ed0dd">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="i0884ff1b0d3341beb8818f54e461bb74" continuedAt="ibebf46873ebc4c158948001897ff3d8c"><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNjk_2494d964-3173-4e2a-9862-a9208d59ed98" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzItMS0xLTEtMTEyOTg_e85537d4-72ae-4596-99f6-446fd295c354">109,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzItMy0xLTEtMTEyOTg_f408643f-28b6-4215-bb60-59245cb8493d">93,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzItNS0xLTEtMTEyOTg_7c86764b-8646-436d-a0c9-8c23b097159e">92,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzMtMS0xLTEtMTEyOTg_fb7529fb-47fb-439e-8197-926de7b2dccc">4,727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzMtMy0xLTEtMTEyOTg_e1771577-4714-45bb-91c1-a3e4b1c61d3d">3,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzMtNS0xLTEtMTEyOTg_8f4b5d46-b1a4-4850-a487-ae535da7f27b">10,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzUtMS0xLTEtMTEyOTg_f6cf5e72-0ebe-4601-9ba6-1dcb045182fd">97,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzUtMy0xLTEtMTEyOTg_21eae999-59f7-43cc-b9bc-36da5a6b63e8">87,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzUtNS0xLTEtMTEyOTg_90abd1d9-dc65-44ff-baaa-f40a3d485471">104,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtMS0xLTEtMTgyMTI_12cfe79f-97a6-42ea-875d-6914498bb6ed">9,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtMy0xLTEtMTgyMTI_14795ae9-9dbc-48f6-84ac-a2b74ce982ed">6,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtNS0xLTEtMTgyMTI_9731d1f1-03b2-4778-97d2-e3b878db4a15">5,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" sign="-" name="nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzctMS0xLTEtMTkwNTc_d8ec3150-9f14-4b72-8b60-bdec810e02b5">7,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" sign="-" name="nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzctMy0xLTEtMTkwNTc_727930a9-9434-432a-8bb6-51e6fb22f0f8">7,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzctNS0xLTEtMTkwNTc_9432dda4-4387-406c-a7f3-55c089cac9df">7,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzgtMS0xLTEtMTkwNjc_09c18455-5912-4045-995a-d8bf7251bae1">4,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzctMy0xLTEtMTkxNjg_0ce87c34-ec5f-4878-8968-4bf7fe413da0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationDispositionOfAssets" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzctNS0xLTEtMTkxNjg_46fa1bed-fd2e-4a45-820a-801c4dc84b37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtMS0xLTEtMTEyOTg_16240ea8-2980-4367-99ce-cb9c63b0b468">6,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtMy0xLTEtMTEyOTg_a33a3c3e-3c0a-4f2a-ae9f-85e457d5dc64">7,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtNS0xLTEtMTEyOTg_d0805ee5-b7cd-462f-b89b-f20fa5ea6da9">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzktMS0xLTEtMTEyOTg_da7649e3-8f9b-49ff-85b9-484d756e383b">3,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzktMy0xLTEtMTEyOTg_841ed5c5-7691-4aad-b1a2-a0d74d0438c6">3,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzktNS0xLTEtMTEyOTg_58128f2b-0359-4f78-8901-71e1228f2f67">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzEwLTEtMS0xLTExMjk4_41e0ab63-fb62-445b-8982-7c7d480dbe45">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzEwLTMtMS0xLTExMjk4_f95a7f23-2ca8-442e-8e51-4b06d400e5d4">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzEwLTUtMS0xLTExMjk4_e2fdd3db-cdd0-4d00-b2ec-807f84ebb809">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets and Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNjQ_5120d869-2e32-4b43-b906-f7723fc360ff" continuedAt="i77628a82565d4598849cb72dde36e7f4" escape="true">We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i77628a82565d4598849cb72dde36e7f4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzMtMS0xLTEtMTEyOTg_780cd222-af15-496b-8dc3-c124ff617810">564,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzMtMy0xLTEtMTEyOTg_2e016e37-04d2-4d1f-8ca9-f523d879d395">456,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzQtMS0xLTEtMTEyOTg_e0527f2d-a0b2-4b51-988b-bae47add0199">139,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzQtMy0xLTEtMTEyOTg_dd221d7c-6833-4ab9-a96a-4cc1269887c7">132,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzUtMS0xLTEtMTEyOTg_b55229ab-ee2c-4b4b-8708-85c3377eabff">34,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="nktr:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzUtMy0xLTEtMTEyOTg_812db9df-68fe-43b7-99c0-26dd97f9a1d3">35,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzYtMS0xLTEtMTgyNzI_5ca59609-e06e-4529-9e3e-460d65b327a8">33,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzYtMy0xLTEtMTgyNzI_2e08db5b-7587-40dd-a7eb-389d763c2ba8">32,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzYtMS0xLTEtMTEyOTg_ef968d6a-7878-4a99-b8e1-e191407aee62">23,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzYtMy0xLTEtMTEyOTg_627e0c31-1afc-4a0d-8391-6f43bbda87b3">32,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzctMS0xLTEtMTEyOTg_eda728d0-84af-4056-aaf7-84fefd3a49e1">6,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzctMy0xLTEtMTEyOTg_0b973e1e-99ae-441b-9ec7-49ce59344544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzgtMS0xLTEtMTEyOTg_f776626a-74ee-46a2-b1ab-f06f655abb0c">10,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzgtMy0xLTEtMTEyOTg_c1385dfe-df42-45c3-bce9-7f8eaf546860">11,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzktMS0xLTEtMTEyOTg_a442cb4e-6026-4715-b861-e9bb4a1f1e8b">813,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzktMy0xLTEtMTEyOTg_30f7ec8e-73c9-4cdc-aa61-ac77f5a14467">701,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzEwLTEtMS0xLTExMjk4_9833086e-3b68-48be-8502-98ad10cbb62a">785,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzEwLTMtMS0xLTExMjk4_d79bc1c1-f98e-42b9-ba4a-ab6947c4ed80">670,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzExLTEtMS0xLTExMjk4_1608aebe-60b4-4921-8e22-d45f0744bcad">28,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzExLTMtMS0xLTExMjk4_d5870720-e25d-493f-b46f-79f255b42ca6">31,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzEzLTEtMS0xLTExMjk4_1de19005-34a1-40a4-85b0-173e10e568d1">27,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzEzLTMtMS0xLTExMjk4_12254c18-7194-4a52-bddb-29662df5792d">29,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE0LTEtMS0xLTExMjk4_3e00aa88-4306-421f-b4cc-118050a40cc9">564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE0LTMtMS0xLTExMjk4_26f045b3-9acc-44c2-a87f-11f76fc670a6">1,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE1LTEtMS0xLTExMjk4_64a569c8-2810-4c35-9192-03567be45332">27,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE1LTMtMS0xLTExMjk4_fea74daf-a1d9-404e-8f88-5a016d792a45">31,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE2LTEtMS0xLTExMjk4_06c432b4-3776-4c59-b9b9-edb7b465a8e9">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE2LTMtMS0xLTExMjk4_f7c93b33-2025-423b-b467-34f7e95e6a1e">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Because of our lack of U.S.&#160;earnings history, other than income resulting from revenue recognized from the BMS Collaboration Agreement, and projected future losses, we have fully reserved our net U.S.&#160;deferred tax assets with a valuation allowance. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzEzOTE_e590de1e-14f8-4635-865b-43d636a9b679">115.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzEzOTg_ce61f70a-8f0e-497a-8ce5-f2179b15fbca">95.0</ix:nonFraction> million during the years ended December&#160;31, 2021 and 2020, respectively. The increase in the valuation allowance is consistent with the increase in net operating loss carryforwards in the respective periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Operating Loss and Tax Credit Carryforwards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2021, we had a net operating loss carryforward for federal income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="i18610030b55b46f09cb8bfa3f26e3ca1_I20211231" decimals="-8" name="nktr:NetOperatingLossCarryforwardForIncomeTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzE3NTY_4ce80f67-6b71-4cb0-89a9-08b13c92beb9">2.4</ix:nonFraction> billion, portions of which will begin to expire in 2022 and a total state net operating loss carryforward of approximately $<ix:nonFraction unitRef="usd" contextRef="i0d291eb67ab54f4689d1aac2f2cdcca8_I20211231" decimals="-8" name="nktr:NetOperatingLossCarryforwardForIncomeTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzE4ODg_32c70c13-ef33-4877-8c19-82f4864bfb49">1.5</ix:nonFraction> billion, portions of which will begin to expire in 2026. We have federal research credits of approximately $<ix:nonFraction unitRef="usd" contextRef="i95d9b49258bb447fbbe2d19c4487ee71_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzIyMjU_649b90c2-7bef-4a52-aa96-7cd4cfa11095">103.3</ix:nonFraction>&#160;million, which will begin to expire in 2023 and state research credits of approximately $<ix:nonFraction unitRef="usd" contextRef="i13d5a5ae922d40ae88de27a40c5ec05b_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzIzMDg_7b46d13d-b02c-4a0c-a331-16d7c1df30e9">47.0</ix:nonFraction>&#160;million which have no expiration date. We have federal orphan drug credits of $<ix:nonFraction unitRef="usd" contextRef="i95d9b49258bb447fbbe2d19c4487ee71_D20210101-20211231" decimals="-5" name="nktr:FederalOrphanDrugCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzIzODE_43a1f0d3-0615-406c-a171-03ea7fe24a95">19.4</ix:nonFraction>&#160;million which will begin to expire in 2026. Utilization of some of the federal and state </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="ibebf46873ebc4c158948001897ff3d8c" continuedAt="i348b3135b4964cdaa74bcd25d8b934e7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized tax benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNjU_ebbd8fe8-451f-47b5-8970-0463ce8fc11d" continuedAt="i223ada4cba6a4740baa91360724dd027" escape="true">We have the following activity relating to unrecognized tax benefits (in thousands):</ix:nonNumeric></span><ix:continuation id="i223ada4cba6a4740baa91360724dd027"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzItMS0xLTEtMTEyOTg_a17dad01-7581-43a5-aeda-0361631c43a2">78,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a636947a9046a38a2ed739019eb13c_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzItMy0xLTEtMTEyOTg_ab321c82-5f44-4e80-94b9-9b6fb3543adf">77,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e86cae77d44493aad21052dab0a76b8_I20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzItNS0xLTEtMTEyOTg_980fd6c3-dc12-4436-bb85-2e75673ea6ad">27,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzQtMS0xLTEtMTEyOTg_c77b5d29-633d-44d3-ad30-81bf37d83c11">2,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzQtMy0xLTEtMTEyOTg_f24c9e6c-47e2-4d77-98b2-3cfffdcc31a2">2,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzQtNS0xLTEtMTEyOTg_c1a8267f-559c-4d04-aa61-b55548a1450e">49,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzUtMS0xLTEtMTEyOTg_3d523ba1-a2c4-4232-9cb9-0157307139a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzUtMy0xLTEtMTEyOTg_8b6f520e-8c87-4845-8ce0-b78daff695a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzUtNS0xLTEtMTEyOTg_14379a4a-a4be-4ee9-baa6-0b82967e10d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzctMS0xLTEtMTEyOTg_f0407761-a99f-4628-9eee-33a51045d1f3">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzctMy0xLTEtMTEyOTg_bbfbbceb-0867-43d7-bd4c-55fb91073331">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzctNS0xLTEtMTEyOTg_81779632-65c1-46b9-8960-5a51e045a6ce">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzgtMS0xLTEtMTEyOTg_ba3614bd-3a90-4a11-8bdf-e323bfc509d5">490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzgtMy0xLTEtMTEyOTg_16b057d0-cd4f-49c1-bdcc-e7499c57f834">1,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzgtNS0xLTEtMTEyOTg_09e16ce9-83c0-420e-81ad-f8878acc4d30">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzktMS0xLTEtMTEyOTg_fd3d0537-5f45-4c47-bacd-cf2d88ac80d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzktMy0xLTEtMTEyOTg_8359b8e2-b3b5-4bcd-b9fd-5bb886c4d3fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzktNS0xLTEtMTEyOTg_928233cb-3491-4ec9-9664-1d696f79bc0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzEwLTEtMS0xLTExMjk4_a4c78143-67c9-4b17-8fcd-2d705cb949b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzEwLTMtMS0xLTExMjk4_eab19d92-7403-49e9-ad32-7604afcbaeaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzEwLTUtMS0xLTExMjk4_7717ea05-48a8-4eda-ad6c-396d697c36aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzExLTEtMS0xLTExMjk4_d46c9b09-303e-43ef-b87f-8960c71277b5">80,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzExLTMtMS0xLTExMjk4_b030fe84-5d25-42b8-9f98-30762af36ae9">78,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a636947a9046a38a2ed739019eb13c_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzExLTUtMS0xLTExMjk4_9f2a5483-7884-46b3-8290-84a87b91264d">77,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we are eventually able to recognize our uncertain tax positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Adjustments to the substantial majority of our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carryforwards rather than resulting in a cash outlay.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We file income tax returns in the U.S., California, Alabama, certain other states and India. As a result of our net operating loss and research credit carryforwards, substantially all of our domestic tax years remain open and subject to examination. We may be subject to examination in India from time to time, but we do not believe that any liability resulting from such an examination would have a material effect on our financial position or results of operations.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i348b3135b4964cdaa74bcd25d8b934e7">Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. During the years ended December&#160;31, 2021, 2020 and 2019, <ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_06265ed0-9962-4bc4-ab0d-89ac6720dc11"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_27470754-3312-4667-828d-68fdedd99b0c"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_64d96f32-be31-438a-9150-7248e08b6397"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_697e0fbe-20d6-4903-b8dc-8a443a3de7c9"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_d321b5ba-87ea-4b35-9201-278930b5c6b5"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_e81e6a1b-52de-4bc5-8f47-947232083077">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> significant interest or penalties were recognized relating to unrecognized tax benefits. Although it is reasonably possible that certain unrecognized tax benefits could change in the future, we do not anticipate any significant changes over the next <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNjE_a679261a-fe22-4504-9862-4dfa44a57bcd">twelve months</ix:nonNumeric>.</ix:continuation> </span></div><div id="i1023926dfc3b4cff924b0207eb081f42_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;14&#160;&#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzE0Mzg_b6271651-4fc0-47b0-924b-1972fac370b8" continuedAt="ie8ad155de1204ddca9a757134360ff22" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="ie8ad155de1204ddca9a757134360ff22" continuedAt="ib04be77e4dbd411ab4f9f826a9f83bfb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We operate in <ix:nonFraction unitRef="segment" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="INF" name="nktr:NumberOfOperatingBusinessSegment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzQ4_6bf06281-5f91-49d4-9ab4-9058209ebe2b">one</ix:nonFraction> business segment which focuses on applying our technology platforms to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as <ix:nonFraction unitRef="segment" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="INF" name="nktr:NumberOfOperatingBusinessSegment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzM5MQ_6bf06281-5f91-49d4-9ab4-9058209ebe2b">one</ix:nonFraction> business segment by our Chief Executive Officer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenue is derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from UCB Pharma, Baxalta / Takeda, AstraZeneca and Pfizer  represented <ix:nonFraction unitRef="number" contextRef="i2ddb03971de844cf8a92d843f8f0c1c8_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzYyMA_6dce37a6-4a86-4b26-a2e0-cbb353752b73">36</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ifaa6e3a9e6e143949bc208e33f67fd4c_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzYyNA_2855bc24-14d9-45d4-a7b1-521d310220cf">23</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i00f01d527a214f5cbd961d14f04dc514_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzYyOA_1af18536-1eac-4cab-8d3b-4c9fae847a6b">16</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6e87ff4a4650460d9333eb26209aaf9e_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzYzNQ_ec49d6cf-1569-456e-99db-c30d38dc9692">13</ix:nonFraction>% of our revenue, respectively, for the year ended December&#160;31, 2021. Revenue from BMS, UCB Pharma, Baxalta / Takeda, and AstraZeneca represented <ix:nonFraction unitRef="number" contextRef="iec3ad0981f8e485fad0d799d0a405dbe_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5Xzc2Mg_95a55f6b-c21b-4956-8bd8-915c0c15fed4">33</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i5301b257f77c4c11ae97c725f1ff567b_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5Xzc2Ng_e85a701b-3a78-4428-8a69-06d42ad42799">23</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i12bc2ab5a68e4a6b955e5b5866281132_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5Xzc3NA_bc1e35f3-573a-4b81-a52c-1c17bd7b7707">14</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i642a78ec6bfc491eba5a4895194b3e41_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzM4NDgyOTA2OTk4MDU_dbd8a610-6551-4e0a-8cfb-9b7e32c9588d">13</ix:nonFraction>% of our revenue for the year-ended December&#160;31, 2020. Revenue from UCB Pharma, Baxalta / Takeda, and AstraZeneca represented <ix:nonFraction unitRef="number" contextRef="i65153175938b412d9314b0291f9d87ec_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzM4NDgyOTA2OTk4MTA_0603042c-36fe-4e3b-858b-cdab369e37b2">28</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ic4ce7911bf79479fb3e7667b452ea08a_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzM4NDgyOTA2OTk4MTU_abe9165c-c622-43af-962b-02c64c1d74f2">19</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="ia9c9bb30fa1f4b63958f70078463ced9_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzM4NDgyOTA2OTk4MjA_f292d03d-de3e-4403-ae0b-79912eece923">17</ix:nonFraction>% of our revenue for the year-ended December 31, 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><ix:continuation id="ib04be77e4dbd411ab4f9f826a9f83bfb"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzE0NDA_863d4d7d-92cc-44b1-9028-75f37ad47f31" continuedAt="id513fa9a820b456cbd933c72803fb95a" escape="true">The following table sets forth revenue by geographic area (in thousands):</ix:nonNumeric></span><ix:continuation id="id513fa9a820b456cbd933c72803fb95a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie54219086ed7421ab34a8c373a1e98ba_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzItMS0xLTEtMTEyOTg_71a99938-6a49-447d-a87e-b9697f43a523">10,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147a96a3068f4b9e8496063ad3e68b0c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzItMy0xLTEtMTEyOTg_da29bff3-a8f3-4917-8694-47a1acaaffd8">64,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i556b5871a2d143a897968254b351cc82_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzItNS0xLTEtMTEyOTg_a3510c35-c7fc-4a5c-bb78-86cadc1a1e4b">27,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of World</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie398a4523e0f4e05958bb768906321dd_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzMtMS0xLTEtMTEyOTg_dc29947d-19b7-410c-a2ee-3f9e0af465f8">91,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86c78562de248778afb80f62f503bbd_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzMtMy0xLTEtMTEyOTg_69e43db3-1c30-4b10-842e-26f94dbf338d">87,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5f29e74e4445c8bb936628105494a8_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzMtNS0xLTEtMTEyOTg_053e7a7d-d3f3-4dae-a7d0-bb9535cf62f7">87,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzQtMS0xLTEtMTEyOTg_7919af32-d4a1-42f1-8028-87dea65ec411">101,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzQtMy0xLTEtMTEyOTg_b222d92c-b9c7-4f5a-8c54-a29652994abb">152,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzQtNS0xLTEtMTEyOTg_c39763a7-5c9b-41bf-aba2-e1f004c6f0a3">114,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i9cc4668d0303484c94ce77104f692749_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEwOTY_f67eebc2-7c3a-483f-bfec-f35201fc4684">56.1</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="i7dedd82fa6fc42e28334feede0e3e79a_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzExMTc_5f41d5be-a737-4349-a832-89a81b18abd7">93</ix:nonFraction>%, of the net book value of our property, plant and equipment was located in the United States and $<ix:nonFraction unitRef="usd" contextRef="i97b7c38b02314dca802effa14883baf0_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEyMTc_fe91bfa6-779d-4912-9489-630edda7cf20">4.4</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="i18d3853c1171432d9635c5e80c47d4af_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEyMzg_b4ae67e9-7002-4251-8b8e-e2730787fd6c">7</ix:nonFraction>%, was located in India.&#160;At December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i8740f4ce936345f3898f8e6e33e633b2_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEyNzE_4b774fce-7f47-4a66-9ec6-61f0f88df5de">54.5</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="ieccfcb48be264718a52f70d827378b42_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEyOTI_bd81eb21-4224-4509-b0bf-68915db131d4">91</ix:nonFraction>%, of the net book value of our property, plant and equipment was located in the United States&#160;and $<ix:nonFraction unitRef="usd" contextRef="i3f76e5747c79442ca44da532090382c2_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEzOTI_4adf516b-d2ac-44c7-a291-c893e8c1904b">5.1</ix:nonFraction> million, or approximately <ix:nonFraction unitRef="number" contextRef="id1f7d11d90fe4876a574e281c5a228d8_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzE0MTM_72b0a9f9-6f39-4c5e-9e20-278ce66082f2">9</ix:nonFraction>%, was located in India.</span></div></ix:continuation><div id="i1023926dfc3b4cff924b0207eb081f42_136"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;15&#160;&#8212; <ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90ZXh0cmVnaW9uOjk2NmQwM2ZhZjlhMzRlNzliYjI2MjI1M2M4MTgzZjRlXzkxNQ_6f8d78e5-a7a3-4de0-990d-cac3858acded" continuedAt="ibcb95d01604e41b6935079a93af87e26" escape="true">Selected Quarterly Financial Data (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="ibcb95d01604e41b6935079a93af87e26"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90ZXh0cmVnaW9uOjk2NmQwM2ZhZjlhMzRlNzliYjI2MjI1M2M4MTgzZjRlXzkxNg_81474454-ee53-47d1-ae1d-e1210a161151" continuedAt="i96401349995b4872b5b91ab94dad8159" escape="true">The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as our audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and the results for any one quarter may not be indicative of our future performance. All data is in thousands except per share information.</ix:nonNumeric></span><ix:continuation id="i96401349995b4872b5b91ab94dad8159" continuedAt="i924d3ad18e9f4b54a61539b7b279c697"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5f266f15a24dda8c245439158a48c1_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItMS0xLTEtMTEyOTg_42828279-379b-4be2-8a5b-0bc4f92e442e">4,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203df220ddd84ea7b49307ff1429d621_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItMy0xLTEtMTEyOTg_fa3651ab-1acf-42df-8ad6-4efc6ffb8ca5">7,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb20ac5be2a460996fe341ee81ca9ec_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItNS0xLTEtMTEyOTg_51b183e4-1abb-4d61-a8e2-22e7c1c17d96">5,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c68986b8dc461c9bc05ee9ec922665_D20211001-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItNy0xLTEtMTEyOTg_ffe8879b-e3e5-4ac5-9a81-25eff994a699">5,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if45bc2183bdb469d98e2ab68aaa55e0c_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItOS0xLTEtMTEyOTg_b01cd864-008f-4c2d-b890-c5f934aefcb6">3,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic910537dd8174a69bd816bc2d30fd0ac_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItMTEtMS0xLTExMjk4_d1261334-d8d1-401a-9843-5a20d6bd1edf">5,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae0f8a52f2ff424fb8c210a60b2e720f_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItMTMtMS0xLTExMjk4_8ec221c7-87ca-40d1-93c6-fdcbc169f151">5,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b314ab44ce4452395969bc75e04e13e_D20201001-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItMTUtMS0xLTExMjk4_83c194c2-2dd6-4a35-a22c-42395a4b6e82">2,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtMS0xLTEtMTEyOTg_8cf8f8ef-8137-4f81-88e8-d67b50895b22">23,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtMy0xLTEtMTEyOTg_bf2b6f5b-324a-4235-9b19-fc792e55493c">28,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtNS0xLTEtMTEyOTg_fd73e35f-d1ae-489e-b114-d853bc13178d">24,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtNy0xLTEtMTEyOTg_48a4c3ba-7d0a-43d9-a943-e832f7d0116a">25,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtOS0xLTEtMTEyOTg_7c3fd665-f182-423f-a8c6-ea0b1dc4159f">50,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtMTEtMS0xLTExMjk4_0fb19239-99c6-4782-b1c1-61872e0d19d3">48,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtMTMtMS0xLTExMjk4_fdd10f4d-b057-4c6d-91a1-78187f99684e">30,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtMTUtMS0xLTExMjk4_dba90637-6533-415f-98cb-ef8268992f00">23,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtMS0xLTEtMTEyOTg_66c7b642-d67a-466e-8c1b-8987ab430142">5,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtMy0xLTEtMTEyOTg_3b8910a2-7735-4adb-9d01-7a387c2bb4b1">7,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtNS0xLTEtMTEyOTg_fae9bd48-e6ed-4914-adf1-269ef0f0d17f">5,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtNy0xLTEtMTEyOTg_a571e47e-3aef-4ffa-ac65-64864528f050">6,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtOS0xLTEtMTEyOTg_9d9f326f-05cc-4870-a408-1ca2a684533b">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtMTEtMS0xLTExMjk4_d5aeb51a-f959-4aa3-86aa-3d22dadafaf4">5,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtMTMtMS0xLTExMjk4_94145f1d-0da9-4b66-a73c-8ff63f852fa9">5,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtMTUtMS0xLTExMjk4_234ff348-3ff1-4e29-90cf-1d05ce2904d0">4,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtMS0xLTEtMTEyOTg_30b60c89-5baa-4cee-9752-6c49f9f250e5">95,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtMy0xLTEtMTEyOTg_f16547f4-81d1-4633-a076-d17e2c9ea975">101,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtNS0xLTEtMTEyOTg_6ef9a1a0-6c6d-41e2-b210-7265e5db57ba">103,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtNy0xLTEtMTEyOTg_ca18ef3b-d9f5-452a-a263-fcfbe9a7b977">99,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtOS0xLTEtMTEyOTg_9905e0c1-ff8f-4718-996d-ab4fc90e6206">108,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtMTEtMS0xLTExMjk4_92faf230-e6c5-4158-916a-60d52ec0ccb5">96,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtMTMtMS0xLTExMjk4_3b3407cd-2543-4ffa-95fb-bba56e291ad0">100,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtMTUtMS0xLTExMjk4_84313116-e7e2-4ca3-99bb-3ea939e164c8">102,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtMS0xLTEtMTEyOTg_8689f98d-1ca2-44ee-b0a2-d2143c529422">109,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtMy0xLTEtMTEyOTg_11806283-4b4f-411d-9b3b-10eed9c6b40e">110,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtNS0xLTEtMTEyOTg_a38d1212-e063-4512-a47e-9d141ce73396">113,596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtNy0xLTEtMTEyOTg_1479f561-c0e8-4e6e-9bd0-17f724a315a1">112,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtOS0xLTEtMTEyOTg_a76c8123-adfc-4fbc-b37a-4d4060f082ad">133,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtMTEtMS0xLTExMjk4_a2e4eade-a0d8-40a4-9cc5-a734e8d92d33">77,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtMTMtMS0xLTExMjk4_6e3cc735-ba84-4780-beae-3bc2b58d1044">103,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtMTUtMS0xLTExMjk4_2d59ff3a-ad08-4b59-950a-524151d8e1e8">110,721</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctMS0xLTEtMTEyOTg_7fe46a07-3bc7-4a6a-aec8-29768a123b1a">122,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctMy0xLTEtMTEyOTg_407df18c-7363-4b9c-a1c3-ecbcc6ce669f">125,519</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctNS0xLTEtMTEyOTg_8cf9dd32-7411-4705-889f-8386a1127d9e">129,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctNy0xLTEtMTEyOTg_62bdfd23-a7a3-447e-9481-5bc28f35faff">145,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctOS0xLTEtMTEyOTg_9d2cc85c-174a-4936-acb9-cd95da56b9ba">138,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctMTEtMS0xLTExMjk4_6e05cd72-674d-45c9-a6d5-b43fb8fc29dc">80,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctMTMtMS0xLTExMjk4_4845c4b6-2a61-4828-a301-f6025b2c9f66">108,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctMTUtMS0xLTExMjk4_ea066ad7-c0d6-4220-b864-9570aac29d41">117,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted(1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMS0xLTEtMjE5MDc_4fc8a287-b170-41fa-b2bc-e364a5276661"><ix:nonFraction unitRef="usdPerShare" contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMS0xLTEtMjE5MDc_b96d22e8-30f2-4603-875c-8da9a167e4da">0.68</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMy0xLTEtMjE5MDc_5bd07dc2-7a33-4536-b26c-54babc9735ba"><ix:nonFraction unitRef="usdPerShare" contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMy0xLTEtMjE5MDc_9be4df16-e19a-4ce2-a3ee-3363989ef87b">0.69</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtNS0xLTEtMjE5MDc_43038e49-8c04-4400-bbf0-cd74aac510f6"><ix:nonFraction unitRef="usdPerShare" contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtNS0xLTEtMjE5MDc_c61aa13a-1afb-447c-8274-abc9cafa2bd4">0.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtNy0xLTEtMjE5MDc_4e3974ac-23e6-4e26-a2ff-d9484f9589d0"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtNy0xLTEtMjE5MDc_6091c83e-b56b-4d16-9d9f-7d2d839414eb">0.79</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtOS0xLTEtMjE5MDc_103a1a95-fc65-4e74-b6cc-dfa1ec50e473"><ix:nonFraction unitRef="usdPerShare" contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtOS0xLTEtMjE5MDc_b34554bd-c674-4d57-86a1-8c50e3a76c00">0.78</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTEtMS0xLTIxOTA3_bcfb21f7-5a1c-467b-ba72-d270e0a8c89b"><ix:nonFraction unitRef="usdPerShare" contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTEtMS0xLTIxOTA3_deb2cf50-620b-488e-a96e-5821242f095b">0.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTMtMS0xLTIxOTA3_23eff66a-c66f-46da-87c5-52cf934d90b7"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTMtMS0xLTIxOTA3_9e8bf4ee-3eba-45cd-bb85-04924e1f6361">0.61</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTUtMS0xLTIxOTA3_6c7a4082-b524-491b-8bda-783e8cc1c210"><ix:nonFraction unitRef="usdPerShare" contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTUtMS0xLTIxOTA3_8cbc105f-1eaf-409f-8419-fc189d4b200c">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:continuation id="i924d3ad18e9f4b54a61539b7b279c697"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Quarterly loss per share amounts may not total to the year-to-date loss per share due to rounding.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_142"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule&#160;13a-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our management has assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2021. In making its assessment of internal control over financial reporting, management used the criteria described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212; Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Based on our evaluation under the framework described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8212; Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The effectiveness of our internal control over financial reporting as of December&#160;31, 2021 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report, which is included herein.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. There was no change in our internal control over financial reporting during the quarter ended December&#160;31, 2021, which was identified in connection with our management&#8217;s evaluation required by Exchange Act Rules&#160;13a-15(f) and 15d-15(f) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Specifically, despite the fact that most of our employees are working remotely due to the COVID-19 pandemic, we do not believe that our adjustments to how we work have materially impacted our internal controls over financial reporting. We continue to monitor and assess the potential impact of the COVID-19 pandemic, and the related shelter-in-place requirements, on our internal controls and strive to minimize the impact on our internal control design and operating effectiveness.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on the Effectiveness of Controls</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_145"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_1727"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_151"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Officers and Corporate Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information relating to our executive officers required by this item is set forth in Part&#160;I&#160;&#8212; Item&#160;1 of this report under the caption &#8220;Information about our Executive Officers&#8221; and is incorporated herein by reference. The other information required by this Item is incorporated by reference from the definitive proxy statement for our 2020 Annual Meeting of Stockholders to be filed with the SEC pursuant to Regulation&#160;14A (Proxy Statement) not later than 120&#160;days after the end of the fiscal year covered by this Form&#160;10-K under the captions &#8220;Corporate Governance and Board of Directors,&#8221; &#8220;Proposal&#160;1&#160;&#8212; Election of Directors&#8221; and &#8220;Section&#160;16(a) Beneficial Ownership Reporting Compliance.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information regarding our audit committee financial expert will be set forth in the Proxy Statement under the caption &#8220;Audit Committee,&#8221; which information is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have a Code of Business Conduct and Ethics applicable to all employees, including the principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Business Conduct and Ethics is posted on our website at www.nektar.com. Amendments to, and waivers from, the Code of Business Conduct and Ethics that apply to any of these officers, or persons performing similar functions, and that relate to any element of the code of ethics definition enumerated in Item&#160;406(b) of Regulation&#160;S-K will be disclosed at the website address provided above and, to the extent required by applicable regulations, on a current report on Form&#160;8-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As permitted by SEC Rule&#160;10b5-1, certain of our executive officers, directors and other employees have or may set up a predefined, structured stock trading program with their broker to sell our stock. The stock trading program allows a broker acting on behalf of the executive officer, director or other employee to trade our stock during blackout periods or while such executive officer, director or other employee may be aware of material, nonpublic information, if the trade is performed according to a pre-existing contract, instruction or plan that was established with the broker when such executive officer, director or employee was not aware of any material, nonpublic information.  Executive officers and directors can only sell our stock in accordance with our securities trading policy and pursuant to a stock trading program set up under Rule 10b5-1 (wherein &#8220;exercise and hold&#8221; and stock purchases are exempted, and sales outside such a program can proceed upon approval of the Nominating and Corporate Governance Committee of our Board of Directors.  Employees who are not executive officers may trade our stock outside of the stock trading programs set up under Rule&#160;10b5-1 subject to our securities trading policy.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_154"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_157"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_160"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Relationships and Related Transactions and Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_163"></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principal Accountant Fees and Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our independent public accounting firm is Ernst &amp; Young LLP, Redwood City, California, PCAOB Auditor ID 42.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is included in the Proxy Statement and incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i1023926dfc3b4cff924b0207eb081f42_169"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;15.  Exhibits and Financial Statement Schedules</span></div><div style="padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.91pt">The following documents are filed as part of this report:</span></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Consolidated Financial Statements:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following financial statements are filed as part of this Annual Report on Form&#160;10-K under Item&#160;8 &#8220;Financial Statements and Supplementary Data.&#8221;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reports of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_67">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets at December 31, 2021 and 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_70">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations for each of the three years in the period ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_73">75</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income (Loss) for each of the three years in the period ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_76">76</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_79">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_82">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1023926dfc3b4cff924b0207eb081f42_85">79</a></span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:51.34pt">Financial Statement Schedules:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;All financial statement schedules have been omitted because they are not applicable, or the information required is presented in our consolidated financial statements and notes thereto under Item&#160;8 of this Annual Report on Form&#160;10-K.</span></div><div style="padding-left:126pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:51.34pt">Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Except as so indicated in Exhibit&#160;32.1, the following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form&#160;10-K.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">Certificate of Ownership and Merger of Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000121390020043821/ea132008ex3-1_nektartherap.htm">Amended and Restated Bylaws of Nektar Therapeutics.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to Exhibits&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">3.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">3.4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000121390020043821/ea132008ex3-1_nektartherap.htm">3.5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-4_1.htm">Specimen Common Stock certificate.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415002842/s101972_ex10-2.htm">Indenture dated October 5, 2015 by and between Nektar Therapeutics and Wilmington Trust, National Association, and TC Lending, LLC including the form of 7.75% Senior Secured Note due 2020.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4(28)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191231ex44.htm">Description of Securities. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex103.htm">2000 Equity Incentive Plan, as amended and restated.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex102.htm">2000 Non-Officer Equity Incentive Plan, as amended and restated.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex104.htm">2008 Equity Incentive Plan, as amended and restated.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex107.htm">Discretionary Incentive Compensation Policy++</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512089389/d262604dex108.htm">Amended and Restated Change of Control Severance Benefit Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6(9)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415001516/s101346_ex10-1.htm">2012 Performance Incentive Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7(10)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415003667/s102370_ex10-1.htm">Forms of Stock Option Agreement, Performance Stock Option Agreement, Restricted Stock Unit Agreement and Performance Restricted Stock Unit Agreement under the 2012 Performance Incentive Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8(11)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670921000014/nktr2021-06x30xexx101.htm">Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9(12)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459019005639/nktr-ex109_7.htm">Forms of Stock Option Agreement, Performance Stock Option Agreement, Non-Employee Director Stock Option Agreement, Restricted Stock Unit Agreement, Performance Restricted Stock Unit Agreement, and Non-Employee Director Restricted Stock Unit Agreement under the Amended and Restated 2017 Performance Incentive Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10(13)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000014/nktr-2020x06x30xexx102.htm">Employee Stock Purchase Plan, as amended and restated.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11(14)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000906709/000090670920000009/nktr2020-03x31ex101.htm">Amended and Restated Compensation Plan for Non-Employee Directors.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12(15)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000110465904022735/a04-8706_1ex10d4.htm">401(k) Retirement Plan.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13(16)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312507240872/dex104.htm">Form of Severance Letter for executive officers of the company.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w26.htm">Amended and Restated Letter Agreement, executed effective on December&#160;1, 2008, with Howard W. Robin.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w27.htm">Amended and Restated Letter Agreement, executed effective on December&#160;1, 2008, with John Nicholson.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16(17)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000095012311020657/f57959exv10w22.htm">Letter Agreement, executed effective on December&#160;10, 2009, with Stephen K. Doberstein,&#160;Ph.D.++</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17(28)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191231ex1017.htm">Transition, Separation and General Release Agreement, dated as of January 9, 2020, by and between Stephen K. Doberstein and Nektar Therapeutics.  ++</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18(19)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000090670919000010/nktr2019-09x30xexx101.htm">Separation, Consulting and General Release Agreement effective as of October 15, 2019, by and between Nektar Therapeutics and John Nicholson.++</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19(28)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191231ex1019.htm">Employment Agreement effective as of December 4, 2019, by and between Nektar Therapeutics and John Northcott.++</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20(16)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312507240872/dex108.htm">Amended and Restated Built-to-Suit&#160;Lease between Nektar Therapeutics and BMR-201 Industrial Road LLC, dated August&#160;17, 2004, as amended on January&#160;11, 2005 and July&#160;19, 2007.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21(18)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459017022445/nktr-ex102_237.htm">Lease Agreement dated August 4, 2017, as amended by the First Amendment to Lease dated as of August 29, 2017, by and between ARE-San Francisco No. 19, LLC and Nektar Therapeutics.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22(20)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312506167850/dex102.htm">Settlement Agreement and General Release, dated June&#160;30, 2006, by and between The Board of Trustees of the University of Alabama, The University of Alabama in Huntsville, Nektar Therapeutics AL, Corporation (a wholly-owned subsidiary of Nektar Therapeutics), Nektar Therapeutics and J. Milton Harris.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.23(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w34.htm">Exclusive Research, Development, License and Manufacturing and Supply Agreement, by and among Nektar AL Corporation, Baxter Healthcare SA, and Baxter Healthcare Corporation, dated September&#160;26, 2005, as amended.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000136231009003350/c82049exv10w35.htm">Exclusive License Agreement, dated December&#160;31, 2008, between Nektar Therapeutics, a Delaware corporation, and Novartis Pharma AG, a Swiss corporation.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.25(17)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000095012311020657/f57959exv10w31.htm">Supply, Dedicated Suite and Manufacturing Guarantee Agreement, dated October&#160;29, 2010, by and among Nektar Therapeutics, Amgen Inc. and Amgen Manufacturing, Limited.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.26(21)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000114420409056637/v164533_ex10-1.htm">License Agreement by and between AstraZeneca AB and Nektar Therapeutics, dated September&#160;20, 2009.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.27(22)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459016022647/nktr-ex101_193.htm">Collaboration and License Agreement dated as of May 30, 2016, by and between Daiichi Sankyo Europe GmbH and Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.28(18)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459017022445/nktr-ex101_179.htm">License Agreement effective as of August 23, 2017, by and between Eli Lilly and Company and Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.29(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415002842/s101972_ex10-1.htm">Purchase Agreement dated September 30, 2015 by and among Nektar Therapeutics and TC Lending, LLC and TAO Fund, LLC.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.30(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000161577415002842/s101972_ex10-3.htm">Pledge and Security Agreement dated October 5, 2015 by and among Nektar Therapeutics and TC Lending, LLC.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.31(23)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312512209441/d311622dex101.htm">Purchase and Sale Agreement, dated as of February 24, 2012, between Nektar Therapeutics and RPI Finance Trust.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.32(24)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312513433110/d594595dex101.htm">Amendment No. 1 to License Agreement dated effective as of August 8, 2013, by and between Nektar Therapeutics and AstraZeneca AB.+</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.33(25)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459018012975/nktr-ex41_103.htm">Investor Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.34(25)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459018012975/nktr-ex101_104.htm">Strategic Collaboration Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000906709/000090670921000005/nktr20201231-exx1035.htm">Co-Development Agreement, dated as of February 12, 2021, by and between SFJ Pharmaceuticals XII, L.P. and Nektar Therapeutics.+</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.36(28)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670920000004/nktr20191213ex1035.htm">Amendment No. 1 to Strategic Collaboration Agreement dated as of January 9, 2020, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.37(26)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000119312518044320/d499642dex101.htm">Share Purchase Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.38(27)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/906709/000156459018020709/nktr-ex101_86.htm">Office Lease, effective as of May 31, 2018, by and between Kilroy Realty Finance Partnership, L.P., and Nektar Therapeutics.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Documents</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39(29)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/906709/000090670921000005/nktr20201231-exx1039.htm">Purchase and Sale Agreement, dated December 16, 2020, by and between entities managed by Healthcare Royalty Management, LLC and Nektar Therapeutics.+</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40(30)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr20211231-exx1040.htm">Amendment No. 2 to Strategic Collaboration Agreement dated as of January 12, 2022, by and between Bristol-M</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nktr20211231-exx1040.htm">yers Squibb and Company and Nektar Therapeutics.+</a></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1(30)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr20211231-exx211.htm">Subsidiaries of Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1(30)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr20211231-exx231.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_175">Power of Attorney (reference is made to the signature page).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1(30)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr-20211231xexx311.htm">Certification of Nektar Therapeutics&#8217; principal executive officer required by Rule&#160;13a-14(a) or Rule&#160;15d-14(a).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2(30)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr-20211231xexx312.htm">Certification of Nektar Therapeutics&#8217; principal financial officer required by Rule&#160;13a-14(a) or Rule&#160;15d-14(a).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nktr-20211231xexx321.htm">Section&#160;1350 Certifications.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Label Linkbase Document. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document. </span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101). </span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Exhibit&#160;32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Inline XBRL information is filed herewith.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2008.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 1998.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2000.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;8-K, filed on January&#160;23, 2003.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2009.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;8-K, filed on December 21, 2020.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;8-K, filed on October&#160;6, 2015.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2011.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:51.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form 8-K, filed on June&#160;17, 2015.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form 8-K filed on December&#160;17, 2015.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form&#160;10-Q for the quarter ended June 30, 2021.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form 10-K for the year ended December 31, 2018.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2020.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the Quarter ended March 31, 2020.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30, 2007.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Annual Report on Form&#160;10-K for the year ended December 31, 2010.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2006.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2009.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2012.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Current Report on Form 8-K filed on February 14, 2018.&#160;&#160;</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.</span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2019.  </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(29)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:46.34pt">Incorporated by reference to the indicated exhibit in Nektar Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2020. </span></div><div style="padding-left:63pt;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(30)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:46.34pt">Filed herewith.</span></div><div style="padding-left:27pt;text-indent:-45pt"><span><br/></span></div><div style="margin-top:18pt;padding-left:126pt;text-indent:-126pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;16. Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City and County of San&#160;Francisco, State of California on February&#160;28, 2022.</span></div><div style="margin-top:12pt;text-indent:63pt"><span><br/></span></div><div style="margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.233%"><tr><td style="width:1.0%"></td><td style="width:10.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABRUCHERIE</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Senior Vice President, Chief Operating Officer, and Chief Financial Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.233%"><tr><td style="width:1.0%"></td><td style="width:10.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ILLIAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HOMSEN</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jillian B. Thomsen</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Senior Vice President, Finance and Chief Accounting Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:63pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:63pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:63pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:63pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="i1023926dfc3b4cff924b0207eb081f42_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1023926dfc3b4cff924b0207eb081f42_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;KNOW ALL PERSON BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gil M. Labrucherie and Jillian B. Thomsen and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratify and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Signature</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/   H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBIN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer, President and Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Howard W. Robin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/   G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> M. L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ABRUCHERIE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Chief Operating Officer, and Chief Financial Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gil M. Labrucherie</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ILLIAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> B. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">HOMSEN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Finance and Chief Accounting Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jillian B. Thomsen</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OBERT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> B. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">HESS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, Chairman of the Board of Directors</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Robert B. Chess</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EFFREY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">JER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jeffrey R. Ajer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> M. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">RAINARD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diana M. Brainard </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">YRIAM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> J. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">URET</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Myriam J. Curet</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ARIN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ASTHAM</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Karin Eastham</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  R. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">REER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R. Scott Greer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/  R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A. W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">HITFIELD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Roy A. Whitfield</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>2
<FILENAME>nktr20211231-exx1040.htm
<DESCRIPTION>EX-10.40
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icc2ad263f3ae440eb270d0000d2f9734_1"></div><div style="min-height:118.08pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.40</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. </font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT NO. 2 TO<br>STRATEGIC COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment No. 2 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Amendment No. 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to the Agreement (as defined below) is entered into as of January 12, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Amendment No. 2 Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between Nektar Therapeutics, a Delaware corporation, headquartered at 455 Mission Bay Boulevard South, Suite 100, San Francisco, California 94158 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Nektar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York, 10154 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">BMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Nektar and BMS may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have entered into a Strategic Collaboration Agreement dated as of February 13, 2018 and effective as of April 3, 2018, as subsequently amended by Amendment No. 1 to Strategic Collaboration Agreement, dated January 9, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have agreed to further amend the Agreement with respect to certain provisions relating to responsibility for price negotiations and certain promotional responsibilities, market access, patient support, and related activities as set forth in this Amendment No. 2&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing premises and the mutual promises and covenants contained herein, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">New Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties shall reasonably discuss and mutually agree upon the scope and parameters of certain activities, which shall be consistent with standard industry practices, including definitions, if necessary and appropriate, relating to market access, reimbursement and patient support, as further described herein, in the Global Pricing and Reimbursement Plan and Budget.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18pt">Amended and Restated Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The definitions set forth below are amended and restated in their entirety and incorporated into the Agreement by this reference.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Allowable Commercialization Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean those expenses (a)&#160;incurred in connection with the Commercialization of the Products pursuant to the Commercialization Plan and Budget and the Global Pricing and Reimbursement Plan and Budget, each as mutually agreed by the Parties and approved by the JCC in accordance with Section 8.3 and (b)&#160;that are consistent with the approved budget set forth in the Commercialization Plan and Budget and the Global Pricing and Reimbursement Plan and Budget, as relevant, and are specifically attributable to Products, and shall consist of (i)&#160;Cost of Goods Sold, (ii)&#160;the market access and reimbursement and patient support costs mutually agreed by the Parties and approved by the JCC under the Global Pricing </font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:118.08pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Reimbursement Plan and Budget, in accordance with Section 8.3, (iii)&#160;Marketing Expenses, (iv)&#160;Distribution Expenses, and (v)&#160;Post-Approval Regulatory Expenses. The JFC shall establish procedures for the calculation of Allowable Commercialization Expenses, including proper allocation of FTE costs to the extent that such FTEs promote other products (including the allocation of sales force effort between first, second and third position detail) or otherwise engage in activities not solely related to the Commercialization of the Product.  For clarity, subject to Section&#160;9.5, each Party shall be responsible for and solely bear any Commercialization expenses not contemplated in, or in excess of the agreed amounts set forth in, the approved budget set forth in the Commercialization Plan and Budget or the Global Pricing and Reimbursement Plan and Budget, as applicable.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Global Pricing and Reimbursement Plan and Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean the strategy, plan and budget setting forth the pricing, market access, and reimbursement and patient support plan for each Product in the Field in the Territory on a global basis during a given Calendar Year and the &#91;***&#93; succeeding Calendar Years, as developed by Nektar and approved by the JCC in accordance with Section 8.3 (subject to Nektar final decision-making authority with respect to Pricing Decisions under Section 8.6(a)), as amended from time to time in accordance with the procedures set forth in this Agreement.  The Global Pricing and Reimbursement Plan and Budget shall be developed by Nektar with reasonable support and input by BMS, which Nektar shall consider in good faith, with respect to market access&#47;reimbursement and patient support and advocacy activities. Upon adoption of the Global Pricing and Reimbursement Plan in accordance with this Agreement, such plan shall become incorporated into this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article&#160;2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMENDMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">Section 8.3 of the Agreement is amended and restated in its entirety and incorporated into the Agreement by this reference&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.3&#160;&#160;&#160;&#160;Responsibilities of the Joint Commercialization Committee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party shall use Commercially Reasonable Efforts to keep the JCC informed about activities performed by that Party hereunder.  The JCC will be responsible for the overall oversight of the global Commercialization of the Product.  Commercialization of each Product shall be pursuant to the Commercialization Plan and Budget and the Global Pricing and Reimbursement Plan and Budget, provided that Commercialization in the countries other than Major Markets shall be conducted in a manner consistent with the Commercialization Plan and Budget and the Global Pricing and Reimbursement Plan and Budget.  The JCC (or in the absence of a formal JCC meeting, the JCC Co-Chairs) shall be responsible for the following, to the extent consistent with Applicable Law (including Applicable Law, antitrust, anti-monopoly or competition law or regulation, whether or not statutory) and Section 8.9(h)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;reviewing and providing timely comments to the initial Commercialization Plan and Budget proposed by BMS and the Global Pricing and Reimbursement Plan and Budget proposed by Nektar&#59;</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:118.08pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;updating and amending each of the Commercialization Plan and Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the Global Pricing and Reimbursement Plan and Budget as Regulatory Approvals for the Product are obtained (whether as a result of Collaboration Studies or Independent Studies)&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;overseeing the Commercialization Plan and Budget and Global Pricing and Reimbursement Plan and Budget, including approving each of the Commercialization Plan and Budget and the Global Pricing and Reimbursement Plan and Budget, and any material amendments thereto&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;reviewing and providing timely comments to proposals from Nektar with respect to the initial post-approval Product price, any price increase&#47;decrease ranges, annual price discounting&#47;rebate ranges, and purchase, access and coverage conditions for Third Party payors and other purchasers  (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pricing Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the period for which the applicable Pricing Decisions shall apply (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pricing Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) including approving any amendments thereto&#59; provided that all Pricing Decisions shall be subject to both Parties&#8217; legal and compliance guidelines, good faith consideration of comments and input from BMS, and Nektar final decision-making authority under Section 8.6(a)&#59;  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e)&#160;&#160;&#160;&#160;overseeing the activities of the Parties with respect to the global Commercialization and pricing of the Product under each of the Commercialization Plan and Budget and the Global Pricing and Reimbursement Plan and Budget, and providing a forum for the Parties to discuss, monitor and coordinate all activities and communications regarding the global Commercialization and pricing of the Products, including payor interactions and discount&#47;rebate range negotiations with respect to Products&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Intentionally Blank</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;reviewing and providing timely comments to proposed communication strategies and communications with any Regulatory Authority regarding the global Commercialization of the Product and, if applicable, approving such proposed communications and communication strategies&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;appointing working teams, to be made up of an equal number of representatives from each Party, that will hold telephone discussions at a mutually agreed-upon frequency to review global Commercialization of the Product issues that arise in the course of a study under the Commercialization Plan and Budget set forth therein, and delegating certain decision-making authority to such working teams&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;reviewing each Party&#8217;s &#91;***&#93; forecast provided to the JCC for quantities of Product necessary for global Commercialization of the Products, which shall be reviewed &#91;***&#93;, and for which &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;determining the quantities of Product, necessary for global Commercialization of the Products within a sufficient minimum lead time and </font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:118.08pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">coordinating the supply of such quantities by the respective Party in accordance with Article 5 and the Supply Agreements or other arrangements&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;reviewing each Party&#8217;s Commercialization forecast for the BMS Assets and other Nektar Assets used in Combined Therapies and advising each Party with respect to allocation of applicable available inventory&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;discussing any other topics or issues relating to the global Commercialization of the Product that either Party requests that cannot be resolved at the working team level.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">Section 8.5 of the Agreement is amended and restated in its entirety and incorporated into the Agreement by this reference&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.5&#160;&#160;&#160;&#160;Dispute Resolution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The representatives of the JCC shall attempt in good faith to reach consensus on all matters properly brought before the JCC.  Except as otherwise provided in this Agreement, if, after a good faith, reasonable and open discussion among the members of the JCC, the JCC is unable to agree on a matter that has been properly before it for a period of &#91;***&#93; and that calls for a decision, either Party may refer the dispute (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JCC Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to the JEC for resolution.  If the JEC is unable to reach a resolution within &#91;***&#93; of the referral of the JCC Dispute to the JEC, either Party may refer such JCC Dispute to the Executive Officers for resolution.  Subject to the following sentence, if the Executive Officers are unable to reach a resolution within &#91;***&#93; of such referral and such JCC Dispute is not otherwise addressed by Section 8.6 (Final Decision-Making Authority of the Parties), the dispute shall be resolved through arbitration as provided for in Article 15, whether as a Commercial&#47;Financial Dispute or as an Arbitration Matter.  If the JCC Dispute regards the Commercialization Plan and Budget and its contents for any </font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product or the Global Pricing and Reimbursement Plan and Budget and its contents for any Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, then such JCC Dispute shall not be subject to arbitration hereunder, no Party shall have final decision-making authority unless otherwise specified herein and the Parties shall not be deemed to be in breach of their Commercially Reasonable Efforts to Commercialize the Product, and the previous year&#8217;s Commercialization Plan and Budget and Global Pricing and Reimbursement Plan and Budget shall apply until the Parties align and agree on a revised Commercialization Plan and Budget and Global Pricing and Reimbursement Plan and Budget.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">Section 8.6 of the Agreement is amended and restated in its entirety and incorporated into the Agreement by this reference&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.6&#160;&#160;&#160;&#160;Final Decision-Making Authority of the Parties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event a JCC Dispute is unresolved pursuant to Section 8.5 as set forth above&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Nektar shall have final decision-making authority regarding (i) Pricing Decisions for the Product in (x) Nektar Combinations and (y) BMS Combinations, in each of (x) and (y), on a continuing, global basis, provided that the Pricing Decisions, once established for any given Pricing Period, shall not be changed during the applicable Pricing Period except as jointly agreed by the Parties through the JCC, and (ii) the Commercialization of Nektar Combinations </font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:118.08pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and any Monotherapy, and (iii) the market access, reimbursement and patient support and advocacy activities for the Product in (x) Nektar Combinations and (y) BMS Combinations, in each of (x) and (y) on a continuing, global basis, provided that the market access, reimbursement and patient support and advocacy activities, once established for any given period under the Global Pricing and Reimbursement Plan and Budget, shall not be changed during the applicable period except as jointly agreed by the Parties through the JCC.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Subject to Nektar&#8217;s final decision-making authority with respect to Price for the Product as set forth in Section 8.6(a), BMS shall reasonably cooperate in good faith with Nektar regarding the Commercialization (but not Pricing Decisions) of the BMS Combinations, to the extent not otherwise explicitly set forth or in conflict with any other provision in this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided, that the Parties expressly acknowledge and agree that nothing contained in this Section 8.6 grants any decision-making authority to Nektar with respect to any pricing decisions or activities relating to any BMS Asset&#8221;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">Section 8.7 of the Agreement is amended and restated in its entirety and incorporated into the Agreement by this reference&#58;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.7&#160;&#160;&#160;&#160;Pricing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As a general matter and subject to the oversight of the JCC under Section 8.3, Nektar shall be responsible for price negotiations, Pricing Decisions and other industry-standard market access activities (including interactions with Third Party payors and&#47;or purchasers regarding the purchase, coverage, and&#47;or reimbursement of the Product), in (a) Nektar Combinations and (b) BMS Combinations, in each of (a) and (b) in all countries in the Territory, whether developed under the Joint Development Plan or an Independent Study, provided, however, that Nektar shall not engage in any price negotiations or other interactions or make any Pricing Decisions with respect to BMS Assets, which negotiations and other interactions and decisions shall be the responsibility of and controlled by BMS.  For clarity, (x) Nektar will not discuss any pricing or other contracting terms that solely relate to BMS Assets as these discussions are the sole responsibility of and controlled by BMS, and further, if Nektar were to receive a question from a Third Party regarding the price or coverage terms of a BMS Asset, Nektar will direct such question to BMS, and (y) BMS will not discuss any pricing or other contracting terms that solely relate to Nektar Assets, as these discussions are the sole responsibility of and controlled by Nektar, and further, if BMS were to receive a question from a Third Party regarding the price or coverage terms of a Nektar Asset, BMS will direct such question to Nektar.</font><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> BMS shall have the right to jointly participate in any such interactions led by Nektar solely for purposes of participating in discussions relating to the clinical profile, including safety and efficacy, of the Product in BMS Combinations&#59; provided, however, that BMS may not participate in discussions specific to and negotiations of price.  With respect to the foregoing, any deviation from the Pricing Decisions requires a disclosure to and approval of the JCC, subject to Nektar&#8217;s final decision making authority under Section 8.6, as limited by such Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">Section 8.9 of the Agreement is amended and restated in its entirety and incorporated into the Agreement by this reference&#58;</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5-</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:118.08pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.9&#160;&#160;&#160;&#160;Commercialization.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Parties shall be responsible for paying all Commercialization costs incurred by such Party set forth in the Commercialization Plan and Budget and Global Pricing and Reimbursement Plan approved by the JCC, and subject further to the Revenue Reporting and Reconciliation Procedures and Section 9.5.  Each Party shall use Commercially Reasonable Efforts to Commercialize Products in the Field in the Territory in accordance with the Commercialization Plan and Budget and the terms of this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The JCC may establish standards applicable to the Parties&#8217; performance of Commercialization activities in accordance with the Commercialization Plan and Budget, the Global Pricing and Reimbursement Plan and Budget and this Agreement, which may include standards for sales representatives promoting Products in the Field.  The Parties may review and discuss each Party&#8217;s (and its Affiliates&#8217;) performance against such standards at each meeting of the JCC.  If the JCC determines that a Party or its Affiliate has failed to comply with such standards and such failure could adversely affect the Development or Commercialization of any Product in the Field, or if the JCC does not agree and one Party believes such is the case, the JCC shall (or such Party may) escalate the issue to the JEC for review and resolution.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Each Party shall be responsible for day-to-day implementation of the Commercialization activities with respect to the Product for which it has or otherwise is assigned responsibility under this Agreement, the Commercialization Plan and Budget, and the Global Pricing and Reimbursement Plan and Budget and shall keep the other Party reasonably informed as to the progress of such activities, as determined by the JCC.  The Commercialization Plan and Budget and the Global Pricing and Reimbursement Plan and Budget shall include a description of the respective Commercialization efforts on a country-by-country basis delegated to a Party for the Product, the Nektar Combinations and BMS Combinations. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;BMS shall have certain responsibility for the promotion</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> marketing in the Territory for BMS Combinations Developed under the Joint Development Plan or under an Independent Study as set forth in the Commercialization Plan and Budget, and BMS shall provide reasonable support and input to Nektar, which Nektar shall consider in good faith, with respect to medical support, market access&#47;reimbursement and patient support and advocacy activities to maximize the efficiency and effectiveness of such activities.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Subject to Section 8.9(c)(i) above and the standards established by the JCC set forth in Section 8.9(b) above with respect to the performance of Commercialization activities, Nektar shall </font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have primary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsibility for the promotion, marketing, medical support, market access&#47;reimbursement and patient support and advocacy activities in the Territory for each of (x) the Nektar Combinations and (y) the BMS Combinations, </font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:118.08pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in each of (x) and (y) Developed under the Joint Development Plan or under an Independent Study, in accordance with the Commercialization Plan and Budget and Global Pricing and Reimbursement Plan approved by the JCC.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;For clarity, nothing in Section 8.9(c) shall limit either Party from promoting the Product to the extent permitted by Applicable Law outside of the scope of the Commercialization Plan and Budget, provided that (A) such promotion shall be consistent with the other provisions of this Article 8&#59; (B) such promotion shall be consistent with the Product Brand Strategy in order to prevent counter-detailing of BMS Combinations or Nektar Combinations&#59; (C) the Parties will not be permitted to create, disseminate or otherwise use or employ negative messaging regarding the BMS Assets and BMS Combinations, in the case of Nektar, and the Nektar Assets and Nektar Combinations, in the case of BMS&#59; and (D) the Parties shall limit claims of efficacy and safety for any Product to those that are consistent with Applicable Laws.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Unless otherwise approved by the JCC, in the performance of Commercialization (including promotion) of the Nektar Compound and Product pursuant to this Agreement, neither Party (nor any Nektar Successor or BMS Successor) shall use, other than promotional materials approved in accordance this Agreement, the trademarks, logos, promotional materials, trade dress, copyrights, corporate logos, corporate names, visual identity and branding elements of the other Party (or the other Party&#8217;s other products) without the prior written consent of such other Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;The Parties shall use Commercially Reasonable Efforts to ensure commercial availability of the Nektar Assets (other than the Product) or BMS Assets, as applicable, that are used in Combined Therapies, at a level and volume of supply necessary to support achievement of the forecasted sales of the Product. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Product Brand Strategy and Promotional Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The JCC shall appoint a joint Product brand strategy working team (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product Brand Strategy Working Team</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  As set forth in the Commercialization Plan and Budget, Nektar and BMS shall develop the global brand strategy for the Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product Brand Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), including positioning, branding, and global messaging, that will guide the development of the relevant sales, promotion and advertising materials (x) by Nektar (for the Nektar Combinations pursuant to Section 8.9(g)(ii)) and (y) by BMS (for the BMS Combinations pursuant to Section 8.9(g)(iii)).  The Product Brand Strategy must comply with each Party&#8217;s applicable SOPs, the Commercialization Plan and Budget, Applicable Laws and Regulatory Approvals.  If the Product Brand Strategy Working Team cannot agree upon certain matters relating to the Product Brand Strategy, the matter may be referred to (A) the JCC or (B) for legal and compliance matters, the legal or compliance departments of the Parties, and then to the JCC for resolution, subject in this case to the final approval of the Parties&#8217; respective compliance officers and legal departments, provided that if the Parties&#8217; </font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-7-</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:118.08pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compliance officers or legal departments are unable to reach an agreement on the matter referred to them in accordance with the immediately preceding sentence, then the Parties shall adopt the approach of the Party with the more conservative compliance or legal position regarding such matter.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Nektar shall develop the relevant sales, promotion, market access and advertising materials relating to the Nektar Combinations for use in the Territory by Nektar and its Affiliates, provided that such materials, to the extent that they relate to the Product, shall be consistent with the Product Brand Strategy.  Nektar shall be responsible for compliance for such materials, including with Applicable Law and the applicable Regulatory Approvals.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;BMS shall develop the relevant sales, promotion and advertising materials relating to the BMS Combinations for use in the Territory by BMS and its Affiliates, provided that such materials, to the extent that they relate to the Product, shall be consistent with the Product Brand Strategy.  </font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nektar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be responsible, and shall indemnify BMS, for compliance for market access materials, including with Applicable Law and the applicable Regulatory Approvals, developed by or on behalf of Nektar.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;Copies of all promotional materials relating to the Nektar Combinations and BMS Combinations as set forth in Sections 8.9(g)(ii) and 8.9(g)(iii), used by Nektar and BMS and their Affiliates in the Territory will be archived by Nektar and BMS, as applicable, in accordance with Applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;The JCC shall develop and approve Product packaging for use in the Territory by both Parties and their Affiliates, which shall be consistent with the Commercialization Plan and Budget and compliant with the Product Brand Strategy, each Party&#8217;s applicable SOPs, Applicable Laws and Regulatory Approvals. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;The Parties shall establish reasonable procedures to protect the secrecy of Nektar&#8217;s and BMS&#8217;s competitively sensitive Confidential Information with respect to the Commercialization of Combined Therapies, including limiting access to such information to ensure that employees performing activities in connection with a Party&#8217;s assets or combination of assets outside the Joint Development Plan that compete with a Product in the Field do not receive competitively sensitive Confidential Information with respect to the Commercialization of Combined Therapies.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article&#160;3</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BMS COMBINATION COMMERCIALIZATION OPTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">The Parties acknowledge and agree that the pricing and promotional and related activities undertaken by Nektar herein shall not amend or supersede, or be deemed an exercise of, the BMS Combination Commercialization Option set forth in Section 8.12 of the Agreement.</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8-</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:118.08pt;width:100%"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. </font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article&#160;4</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">Except as amended by this Amendment No. 2, all the terms and conditions of the Agreement shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">In the event of a conflict between the terms of this Amendment No. 2 and the terms of the Agreement, the terms of this Amendment No. 2 shall prevail.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">The headings used in this Amendment No. 2 have been inserted for convenience of reference only and do not define or limit the provisions hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">This Amendment No. 2 may be signed in any number of counterparts (facsimile and electronic transmission included), each of which shall be deemed an original, but all of which shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">This Amendment No. 2 and all claims relating to or arising out of this Amendment No. 2 or the breach thereof shall be governed and construed in accordance with the internal laws of the State of New York, USA, excluding any choice of law rules that may direct the application of the laws of another jurisdiction. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.  No part of this Amendment No. 2 changes the rights and obligations of the Parties under Article 15 of the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">This Amendment No. 2 and the Agreement (as amended by this Amendment No. 2) constitute the entire understanding between the Parties with respect to the subject matter hereof, and supersede all prior agreements whether oral or written.  No amendment, modification, waiver, release or discharge to this Amendment No. 2 or the Agreement shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">This Amendment No. 2 has been prepared jointly and shall not be strictly construed against either Party. No presumption as to construction of this Amendment shall apply against either Party with respect to any ambiguity in the wording of any provision(s) of this Amendment No. 2 irrespective of which Party may be deemed to have authored the ambiguous provision(s).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;signature page follows&#93;</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-9-</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="icc2ad263f3ae440eb270d0000d2f9734_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties hereto, intending to be legally bound hereby, have caused this Amendment No. 2 to be executed by their duly authorized representatives as of the Amendment No. 2 Effective Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nektar Therapeutics</font></div><div style="margin-bottom:12pt;margin-top:36pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Gil M. Labrucherie</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Gil M. Labrucherie </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; COO and CFO</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; January 12, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bristol-Myers Squibb Company</font></div><div style="margin-bottom:12pt;margin-top:36pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Elizabeth Mily</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Elizabeth Mily</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; EVP, Strategy &#38; Business Development</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; January 12, 2022 </font></div></td></tr></table></div><div><font><br></font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Amendment No. 2 to</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Strategic Collaboration Agreement</font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>nktr20211231-exx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic1fc457cf2444b8c9709e39a8c65c6b4_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 21.1</font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Subsidiaries of Nektar Therapeutics</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Jurisdiction of Incorporation or Organization</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Inheris Biopharma, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">United States</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>nktr20211231-exx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ieb91db7d978f463cb3827c68be871d5e_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.05pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Consent of Independent Registered Public Accounting Firm </font></div><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Registration Statement (Form S-8 No. 333-145259) pertaining to the 401(k) Retirement Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Registration Statement (Form S-8 No. 333-153106) pertaining to the 2008 Equity Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) Registration Statement (Form S-8 No. 333-170371) pertaining to the Employee Stock Purchase Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4) Registration Statement (Form S-8 No. 333-183193) pertaining to the 2012 Performance Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5) Registration Statement (Form S-8 No. 333-197781) pertaining to the Employee Stock Purchase Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6) Registration Statement (Form S-8 No. 333-206136) pertaining to the 2012 Performance Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7) Registration Statement (Form S-8 No. 333-218777) pertaining to the 2017 Performance Incentive Plan of Nektar Therapeutics,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8) Registration Statement (Form S-8 No. 333-226004) pertaining to the Amended and Restated 2017 Performance Incentive Plan of Nektar Therapeutics, </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9) Registration Statement (Form S-8 No. 333-242327) pertaining to the Amended and Restated 2017 Performance Incentive Plan and Amended and Restated Employee Stock Purchase Plan of Nektar Therapeutics, </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10) Registration Statement (Form S-3 No. 333-254237) of Nektar Therapeutics, and</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11) Registration Statement (Form S-8 No. 333-258900) pertaining to the Amended and Restated 2017 Performance Incentive Plan of Nektar Therapeutics&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of our reports dated February 28, 2022, with respect to the consolidated financial statements of Nektar Therapeutics and the effectiveness of internal control over financial reporting of Nektar Therapeutics included in this Annual Report (Form 10-K) of Nektar Therapeutics for the year ended December 31, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">Redwood City, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">February 28, 2022 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>nktr-20211231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3233e6db2f8148708beb8cb54c97f0ad_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Howard W. Robin, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Nektar Therapeutics for the year ended December&#160;31, 2021&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;28, 2022</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBIN</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></td></tr></table></div><div style="margin-top:6pt;text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>nktr-20211231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i78cd85d9da6e4846af055490dc12ab59_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Gil M. Labrucherie, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Nektar Therapeutics for the year ended December&#160;31, 2021&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;28, 2022</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABRUCHERIE</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President, Chief Operating Officer, and Chief Financial Officer</font></td></tr></table></div><div style="margin-top:6pt;text-align:right;text-indent:45pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>nktr-20211231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6d60bb4c3cb7484e857dfce74d11307e_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATIONS*</font></div><div style="margin-top:12pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#8220;Company&#8221;), and Gil M. Labrucherie, Senior Vice President, Chief Operating Officer, and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:10pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Annual Report on Form 10-K, for the year ended December&#160;31, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Annual Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;28, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBIN</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABRUCHERIE</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Howard W. Robin</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gil M. Labrucherie</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President, Chief Operating Officer, and Chief Financial Officer</font></td></tr></table></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification accompanies the Annual Report on Form 10-K, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>nktr-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b154c77f-11f5-433c-8e4e-b6be98e0afac,g:2cfcd135-9f36-4467-b376-e4c05a9fe6a1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nktr="http://www.nektar.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nektar.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.nektar.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.nektar.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.nektar.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>1007009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecurities" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities">
        <link:definition>2104102 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesTables" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails">
        <link:definition>2406402 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails">
        <link:definition>2408404 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.nektar.com/role/Inventory">
        <link:definition>2109103 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.nektar.com/role/InventoryTables">
        <link:definition>2310302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoriesDetails" roleURI="http://www.nektar.com/role/InventoryScheduleofInventoriesDetails">
        <link:definition>2411405 - Disclosure - Inventory - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.nektar.com/role/PropertyPlantandEquipment">
        <link:definition>2112104 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentTables">
        <link:definition>2313303 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>2414406 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentAdditionalInformationDetails" roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails">
        <link:definition>2415407 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeniorSecuredNotes" roleURI="http://www.nektar.com/role/SeniorSecuredNotes">
        <link:definition>2116105 - Disclosure - Senior Secured Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeniorSecuredNotesDetails" roleURI="http://www.nektar.com/role/SeniorSecuredNotesDetails">
        <link:definition>2417408 - Disclosure - Senior Secured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability">
        <link:definition>2118106 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables">
        <link:definition>2319304 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails">
        <link:definition>2420409 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails" roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails">
        <link:definition>2421410 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.nektar.com/role/OperatingLeases">
        <link:definition>2122107 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.nektar.com/role/OperatingLeasesTables">
        <link:definition>2323305 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesAdditionalInformationDetails" roleURI="http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails">
        <link:definition>2424411 - Disclosure - Operating Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofOperatingLeaseInformationDetails" roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails">
        <link:definition>2425412 - Disclosure - Operating Leases - Schedule of Operating Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofLeaseExpenseDetails" roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails">
        <link:definition>2426413 - Disclosure - Operating Leases - Schedule of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails" roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails">
        <link:definition>2427414 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1">
        <link:definition>2427414 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyalties" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties">
        <link:definition>2128108 - Disclosure - Liabilities Related to the Sales of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables">
        <link:definition>2329306 - Disclosure - Liabilities Related to the Sales of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails">
        <link:definition>2430415 - Disclosure - Liabilities Related to the Sales of Future Royalties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail">
        <link:definition>2431416 - Disclosure - Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.nektar.com/role/CommitmentsandContingencies">
        <link:definition>2132109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2433417 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.nektar.com/role/StockholdersEquity">
        <link:definition>2134110 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.nektar.com/role/StockholdersEquityTables">
        <link:definition>2335307 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>2436418 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails" roleURI="http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails">
        <link:definition>2437419 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements">
        <link:definition>2138111 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsTables" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables">
        <link:definition>2339308 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails">
        <link:definition>2440420 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetails" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>2441421 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetails_1" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails_1">
        <link:definition>2441421 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.nektar.com/role/StockBasedCompensation">
        <link:definition>2142112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.nektar.com/role/StockBasedCompensationTables">
        <link:definition>2343309 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2444422 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>2445423 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails" roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails">
        <link:definition>2446424 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails" roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails">
        <link:definition>2447425 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails" roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails">
        <link:definition>2448426 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.nektar.com/role/IncomeTaxes">
        <link:definition>2149113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.nektar.com/role/IncomeTaxesTables">
        <link:definition>2350310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails" roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails">
        <link:definition>2451427 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails">
        <link:definition>2452428 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2453429 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails" roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails">
        <link:definition>2454430 - Disclosure - Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2455431 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>2456432 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.nektar.com/role/SegmentReporting">
        <link:definition>2157114 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.nektar.com/role/SegmentReportingTables">
        <link:definition>2358311 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>2459433 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuebyGeographicAreaDetail" roleURI="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail">
        <link:definition>2460434 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialData" roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialData">
        <link:definition>2161115 - Disclosure - Selected Quarterly Financial Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataTables" roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables">
        <link:definition>2362312 - Disclosure - Selected Quarterly Financial Data (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataDetails" roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails">
        <link:definition>2463435 - Disclosure - Selected Quarterly Financial Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nktr_BristolMyersSquibbCollaborationAgreementMember" abstract="true" name="BristolMyersSquibbCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SelectedQuarterlyFinancialDataLineItems" abstract="true" name="SelectedQuarterlyFinancialDataLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" abstract="false" name="GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LeaseExtensionTerm" abstract="false" name="LeaseExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInProductionCosts" abstract="false" name="PercentageOfSharingInProductionCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_BempegaldesleukinMember" abstract="true" name="BempegaldesleukinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_AggregateConsiderationReceivedFromAgreements" abstract="false" name="AggregateConsiderationReceivedFromAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PartialRepaymentOfRoyaltySaleProceeds" abstract="false" name="PartialRepaymentOfRoyaltySaleProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsTable" abstract="true" name="LicenseAndCollaborationAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_SaleOfStockConsiderationReceived" abstract="false" name="SaleOfStockConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ProceedsFromSaleOfFutureRoyaltiesNet" abstract="false" name="ProceedsFromSaleOfFutureRoyaltiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PotentialDevelopmentAndRegulatoryMilestones" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SelectedQuarterlyFinancialDataTable" abstract="true" name="SelectedQuarterlyFinancialDataTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" abstract="false" name="AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AccruedClinicalTrialExpensesCurrent" abstract="false" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" abstract="false" name="PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AmgenIncMember" abstract="true" name="AmgenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MergerAndAcquisitionRelatedClaimsMember" abstract="true" name="MergerAndAcquisitionRelatedClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" abstract="false" name="ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_StockOptionsRSUsAndPSUsMember" abstract="true" name="StockOptionsRSUsAndPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_IncomeTaxesDisclosureTable" abstract="true" name="IncomeTaxesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LesseeOperatingLeaseTableTextBlock" abstract="false" name="LesseeOperatingLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" abstract="false" name="TransactionCostsRelatedToRevisedRoyaltyPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" abstract="true" name="TwoThousandSeventeenPerformanceIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" abstract="false" name="LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" abstract="false" name="MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" abstract="false" name="ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_IncomeTaxesDisclosureLineItems" abstract="true" name="IncomeTaxesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_Nektar358Member" abstract="true" name="Nektar358Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OpdivoMember" abstract="true" name="OpdivoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SaleOfStockValueAuthorizedInTransaction" abstract="false" name="SaleOfStockValueAuthorizedInTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NKTR181Member" abstract="true" name="NKTR181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_Nektar214Member" abstract="true" name="Nektar214Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ImpairmentOfEquipmentFromTerminatedProgram" abstract="false" name="ImpairmentOfEquipmentFromTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" abstract="false" name="UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LegalMattersMember" abstract="true" name="LegalMattersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CompanyShareOfDevelopmentCostsAnnualCap" abstract="false" name="CompanyShareOfDevelopmentCostsAnnualCap" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" abstract="true" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_ScheduleOfLeasesTable" abstract="true" name="ScheduleOfLeasesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_EstimatedFairValueOfShares" abstract="false" name="EstimatedFairValueOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DepreciablePropertyPlantAndEquipmentGross" abstract="false" name="DepreciablePropertyPlantAndEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" abstract="false" name="ProceedsFromSaleOfPotentialFutureRoyaltiesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementCommittedFunding" abstract="false" name="CollaborativeArrangementCommittedFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" abstract="true" name="ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" abstract="false" name="NumberOfReportingUnitsToEvaluateGoodwillForImpairment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" abstract="false" name="DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NeulastaMember" abstract="true" name="NeulastaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PotentialDevelopmentMilestones" abstract="false" name="PotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreementMember" abstract="true" name="PurchaseAndSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_BMSCollaborationAgreementMember" abstract="true" name="BMSCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_RoyaltiesLiabilityMeasurementInput" abstract="false" name="RoyaltiesLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nktr_DevelopmentDerivativeLiabilityTextBlock" abstract="false" name="DevelopmentDerivativeLiabilityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_OrganizationPolicyTextBlock" abstract="false" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" abstract="false" name="AmountOfTransactionPriceAllocatedToPerformanceObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_FutureRoyaltiesMember" abstract="true" name="FutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" abstract="true" name="ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" abstract="false" name="TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsLineItems" abstract="true" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_WriteOffOfPrepayment" abstract="false" name="WriteOffOfPrepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_RSUsAndPSUsMember" abstract="true" name="RSUsAndPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CollaborativeArrangementAdditionalIndicationPayment" abstract="false" name="CollaborativeArrangementAdditionalIndicationPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AreaOfLeasedSpace" abstract="false" name="AreaOfLeasedSpace" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="nktr_NonSecuritiesRelatedClaimsMember" abstract="true" name="NonSecuritiesRelatedClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NumberOfOperatingBusinessSegment" abstract="false" name="NumberOfOperatingBusinessSegment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nktr_MulquinActionAndDamibaActionMember" abstract="true" name="MulquinActionAndDamibaActionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" abstract="false" name="UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_TaxPositionsRelatedToCurrentYearAbstract" abstract="true" name="TaxPositionsRelatedToCurrentYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsFirstPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LongTermInvestmentMaturityPeriod" abstract="false" name="LongTermInvestmentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" abstract="false" name="PercentageOfSharingInPhaseTwoDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" abstract="false" name="PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" abstract="false" name="PaymentMadeForMilestoneNotAchievedYearTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AreaOfLeasedSpaceDelivered" abstract="false" name="AreaOfLeasedSpaceDelivered" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="nktr_TaxPositionsRelatedToPriorYearsAbstract" abstract="true" name="TaxPositionsRelatedToPriorYearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_BaxaltaIncorporatedOrTakedaPLCMember" abstract="true" name="BaxaltaIncorporatedOrTakedaPLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LicenseCollaborationAndOtherRevenueMember" abstract="true" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_RoyaltyMonetizationProceeds" abstract="false" name="RoyaltyMonetizationProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NektarMember" abstract="true" name="NektarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2020Member" abstract="true" name="PurchaseAndSaleAgreement2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ComputerFurnitureAndOtherMember" abstract="true" name="ComputerFurnitureAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsFirstIndication" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreement2012Member" abstract="true" name="PurchaseAndSaleAgreement2012Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_DepreciablePropertyPlantAndEquipmentNet" abstract="false" name="DepreciablePropertyPlantAndEquipmentNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NektarThreeFiveEightMember" abstract="true" name="NektarThreeFiveEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInDevelopmentCosts" abstract="false" name="PercentageOfSharingInDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LeasesLineItems" abstract="true" name="LeasesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_ProfitsAndLossesSharingPercentage" abstract="false" name="ProfitsAndLossesSharingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_RemainingAmountAllocatedToTransactionPrice" abstract="false" name="RemainingAmountAllocatedToTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_DrugProductDevelopmentMember" abstract="true" name="DrugProductDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NetOperatingLossCarryforwardForIncomeTax" abstract="false" name="NetOperatingLossCarryforwardForIncomeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PhaseOneClinicalDevelopmentMember" abstract="true" name="PhaseOneClinicalDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" abstract="false" name="StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_ManufacturingLaboratoryAndOtherEquipmentMember" abstract="true" name="ManufacturingLaboratoryAndOtherEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" abstract="false" name="CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashAndNonCashRoyaltiesMember" abstract="true" name="CashAndNonCashRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SecuritiesRelatedClaimsMember" abstract="true" name="SecuritiesRelatedClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_UCBPharmaMember" abstract="true" name="UCBPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ReimbursementOfExpenses" abstract="false" name="ReimbursementOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PaymentMadeForMilestoneNotAchievedYearOne" abstract="false" name="PaymentMadeForMilestoneNotAchievedYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" abstract="false" name="InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nktr_OtherPartnerMember" abstract="true" name="OtherPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" abstract="false" name="NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SFJPharmaceuticalsMember" abstract="true" name="SFJPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SalesMilestoneRevenue" abstract="false" name="SalesMilestoneRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_TerminatedPartnershipMember" abstract="true" name="TerminatedPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" abstract="false" name="PotentialDevelopmentRegulatoryAndSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AstraZenecaAbMember" abstract="true" name="AstraZenecaAbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NetExpenseReimbursementsFromCollaborationPartner" abstract="false" name="NetExpenseReimbursementsFromCollaborationPartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LicenseCollaborationOtherRevenue" abstract="false" name="LicenseCollaborationOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" abstract="false" name="CollaborativeArrangementSuccessBasedPaymentsSecondIndication" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" abstract="false" name="PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_NumberOfConsecutiveTermsToExtendLease" abstract="false" name="NumberOfConsecutiveTermsToExtendLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" abstract="true" name="SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" abstract="false" name="PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nktr_ThirdStreetLeaseMember" abstract="true" name="ThirdStreetLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" abstract="true" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" abstract="false" name="GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_SaleOfFutureRoyaltiesTransactionCosts" abstract="false" name="SaleOfFutureRoyaltiesTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" abstract="false" name="EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_DerivativeActionMember" abstract="true" name="DerivativeActionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_MissionBayLeaseMember" abstract="true" name="MissionBayLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" abstract="false" name="ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ChangeInControlSeverancePaymentPeriodForExecutives" abstract="false" name="ChangeInControlSeverancePaymentPeriodForExecutives" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_FederalOrphanDrugCredits" abstract="false" name="FederalOrphanDrugCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCompanyMember" abstract="true" name="BristolMyersSquibbCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" abstract="false" name="ShareBasedCompensationPlansShareLimitForEveryOneShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="nktr_BuildingAndLeaseholdImprovementsMember" abstract="true" name="BuildingAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_CostOfBorrowingMember" abstract="true" name="CostOfBorrowingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" abstract="false" name="AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>nktr-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b154c77f-11f5-433c-8e4e-b6be98e0afac,g:2cfcd135-9f36-4467-b376-e4c05a9fe6a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_020aef89-1f5c-49f0-9416-815d84186460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_21071761-a909-4b4e-a860-16aa5c439f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_020aef89-1f5c-49f0-9416-815d84186460" xlink:to="loc_us-gaap_AssetsCurrent_21071761-a909-4b4e-a860-16aa5c439f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ba89ca89-0831-473a-929d-eea3efaa8292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_020aef89-1f5c-49f0-9416-815d84186460" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ba89ca89-0831-473a-929d-eea3efaa8292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2262da51-15a3-457b-97f1-91c1ca563e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_020aef89-1f5c-49f0-9416-815d84186460" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2262da51-15a3-457b-97f1-91c1ca563e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8ec13560-e85a-4bf1-9919-3670e25acbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_020aef89-1f5c-49f0-9416-815d84186460" xlink:to="loc_us-gaap_Goodwill_8ec13560-e85a-4bf1-9919-3670e25acbb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_27a2542b-e69d-407f-8e40-f3940be8ab77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_020aef89-1f5c-49f0-9416-815d84186460" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_27a2542b-e69d-407f-8e40-f3940be8ab77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_066ba4aa-83ff-4b53-b5ff-89f8648dfc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_020aef89-1f5c-49f0-9416-815d84186460" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_066ba4aa-83ff-4b53-b5ff-89f8648dfc43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3403a030-5d7b-4868-8d3c-91f88ab2b186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_1a8615fd-428f-4cfe-bd03-807671516b81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3403a030-5d7b-4868-8d3c-91f88ab2b186" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_1a8615fd-428f-4cfe-bd03-807671516b81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d944074c-94d7-40cb-93dc-07fba80193c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3403a030-5d7b-4868-8d3c-91f88ab2b186" xlink:to="loc_us-gaap_LiabilitiesCurrent_d944074c-94d7-40cb-93dc-07fba80193c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_714af8da-9576-4287-a17b-d8816d0a7d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3403a030-5d7b-4868-8d3c-91f88ab2b186" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_714af8da-9576-4287-a17b-d8816d0a7d87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_211b4f7e-57b7-4f94-9a36-a997e9822402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3403a030-5d7b-4868-8d3c-91f88ab2b186" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_211b4f7e-57b7-4f94-9a36-a997e9822402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_a3acde1f-9ae2-446f-82cb-b1fbca666d39" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3403a030-5d7b-4868-8d3c-91f88ab2b186" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_a3acde1f-9ae2-446f-82cb-b1fbca666d39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b371f599-4c8a-42d5-b811-9a64a0cb53ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb17de60-5643-4cae-acea-0bf63eeee4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b371f599-4c8a-42d5-b811-9a64a0cb53ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb17de60-5643-4cae-acea-0bf63eeee4cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_df546245-6b4a-4fb0-ac65-10d38580d4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b371f599-4c8a-42d5-b811-9a64a0cb53ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_df546245-6b4a-4fb0-ac65-10d38580d4fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_df564939-ba6c-412a-9b41-edd0c9bbf5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b371f599-4c8a-42d5-b811-9a64a0cb53ac" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_df564939-ba6c-412a-9b41-edd0c9bbf5dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e2b0b63c-64e9-4025-9ce8-218d09b61a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b371f599-4c8a-42d5-b811-9a64a0cb53ac" xlink:to="loc_us-gaap_InventoryNet_e2b0b63c-64e9-4025-9ce8-218d09b61a26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0cb542a5-72b0-465c-8fb5-1f1a8fdbb019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b371f599-4c8a-42d5-b811-9a64a0cb53ac" xlink:to="loc_us-gaap_OtherAssetsCurrent_0cb542a5-72b0-465c-8fb5-1f1a8fdbb019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5bd377a6-ad79-4117-a2d7-b866bbf3755d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0ffc7788-405f-46b5-be0c-7f4f226d449f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5bd377a6-ad79-4117-a2d7-b866bbf3755d" xlink:to="loc_us-gaap_Liabilities_0ffc7788-405f-46b5-be0c-7f4f226d449f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1e91f249-0bca-4c6f-9e82-b14f5622b257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5bd377a6-ad79-4117-a2d7-b866bbf3755d" xlink:to="loc_us-gaap_StockholdersEquity_1e91f249-0bca-4c6f-9e82-b14f5622b257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_137d1278-888a-4f67-83d6-c33b2059dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5bd377a6-ad79-4117-a2d7-b866bbf3755d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_137d1278-888a-4f67-83d6-c33b2059dbc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2b66fc2f-87c4-4f5e-bd4d-a44acbedeb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a3c2a115-7cef-42e0-bbc2-07611eb41c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b66fc2f-87c4-4f5e-bd4d-a44acbedeb1f" xlink:to="loc_us-gaap_AccountsPayableCurrent_a3c2a115-7cef-42e0-bbc2-07611eb41c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1fc66649-eca4-4a59-b983-4a677657e6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b66fc2f-87c4-4f5e-bd4d-a44acbedeb1f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1fc66649-eca4-4a59-b983-4a677657e6ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_b54eb081-7b3a-41dc-a2f4-5a78d788bb96" xlink:href="nktr-20211231.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b66fc2f-87c4-4f5e-bd4d-a44acbedeb1f" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_b54eb081-7b3a-41dc-a2f4-5a78d788bb96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6174414f-a240-4097-b9d1-b853fbc5c613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b66fc2f-87c4-4f5e-bd4d-a44acbedeb1f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6174414f-a240-4097-b9d1-b853fbc5c613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6d4a5a13-d822-4306-9b8e-b0489241e346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b66fc2f-87c4-4f5e-bd4d-a44acbedeb1f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6d4a5a13-d822-4306-9b8e-b0489241e346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b21247a-0b3a-4223-92fa-ddb748df3206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_75efc232-56bf-41aa-84d7-213a23dc4dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b21247a-0b3a-4223-92fa-ddb748df3206" xlink:to="loc_us-gaap_PreferredStockValue_75efc232-56bf-41aa-84d7-213a23dc4dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9ed62f23-2513-4185-9fc7-af9136395fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b21247a-0b3a-4223-92fa-ddb748df3206" xlink:to="loc_us-gaap_CommonStockValue_9ed62f23-2513-4185-9fc7-af9136395fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c6902dd3-327d-417b-a315-7fdfc331ac14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b21247a-0b3a-4223-92fa-ddb748df3206" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c6902dd3-327d-417b-a315-7fdfc331ac14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1cbcaed5-3aad-43e3-b793-ccfaa096250d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b21247a-0b3a-4223-92fa-ddb748df3206" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1cbcaed5-3aad-43e3-b793-ccfaa096250d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d735044c-0f45-4419-8220-a7132c855855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b21247a-0b3a-4223-92fa-ddb748df3206" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d735044c-0f45-4419-8220-a7132c855855" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4bb1eb98-c683-4f94-83aa-5e8e4d544921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b103863c-0d9a-4406-b45e-1f004a7f1000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4bb1eb98-c683-4f94-83aa-5e8e4d544921" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b103863c-0d9a-4406-b45e-1f004a7f1000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_de90c2cd-39dc-4ab2-b8d8-11e317626331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4bb1eb98-c683-4f94-83aa-5e8e4d544921" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_de90c2cd-39dc-4ab2-b8d8-11e317626331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1685ef03-599f-4797-a182-cf0eb69274fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_421fc314-396a-44e4-88a4-40f9b97c5aee" xlink:href="nktr-20211231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1685ef03-599f-4797-a182-cf0eb69274fc" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_421fc314-396a-44e4-88a4-40f9b97c5aee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6dffa0b8-d8c4-4cfd-80fc-91632cc26862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1685ef03-599f-4797-a182-cf0eb69274fc" xlink:to="loc_us-gaap_InterestExpense_6dffa0b8-d8c4-4cfd-80fc-91632cc26862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_cef55659-30ad-456e-b95a-0ed1f07be4a7" xlink:href="nktr-20211231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1685ef03-599f-4797-a182-cf0eb69274fc" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_cef55659-30ad-456e-b95a-0ed1f07be4a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9e0c2a41-9f34-4045-9c83-e1123bdf7937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1685ef03-599f-4797-a182-cf0eb69274fc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9e0c2a41-9f34-4045-9c83-e1123bdf7937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_cb58ab7a-3e9e-4fea-9eb5-c617e22921f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1685ef03-599f-4797-a182-cf0eb69274fc" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_cb58ab7a-3e9e-4fea-9eb5-c617e22921f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3aec0ea0-3d62-412f-bea1-7c70d60d6a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_615714c9-9775-4736-8843-c79381db9a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3aec0ea0-3d62-412f-bea1-7c70d60d6a78" xlink:to="loc_us-gaap_OperatingIncomeLoss_615714c9-9775-4736-8843-c79381db9a7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4cbaffa1-a5b1-4ef4-8cff-38714750246f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3aec0ea0-3d62-412f-bea1-7c70d60d6a78" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4cbaffa1-a5b1-4ef4-8cff-38714750246f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c7329dac-b1e3-41af-8bac-224ccc6586bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a235876a-69e5-4464-baf8-e76a7f5a4094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c7329dac-b1e3-41af-8bac-224ccc6586bd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a235876a-69e5-4464-baf8-e76a7f5a4094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e65bb115-769c-443e-983d-95cac5e27b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c7329dac-b1e3-41af-8bac-224ccc6586bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e65bb115-769c-443e-983d-95cac5e27b72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_70e92b6b-a9d9-4ea6-8395-a851e2c6eb51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c7329dac-b1e3-41af-8bac-224ccc6586bd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_70e92b6b-a9d9-4ea6-8395-a851e2c6eb51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_a2012316-6a76-4414-9db6-8d8d74e78056" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c7329dac-b1e3-41af-8bac-224ccc6586bd" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_a2012316-6a76-4414-9db6-8d8d74e78056" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_993c3264-46d3-4ee1-aa74-6b18638cc76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_98785ddb-ebb3-4954-b490-bd6089742cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_993c3264-46d3-4ee1-aa74-6b18638cc76b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_98785ddb-ebb3-4954-b490-bd6089742cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6b612a4e-5d6d-46e9-9ce3-aa444474c03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_993c3264-46d3-4ee1-aa74-6b18638cc76b" xlink:to="loc_us-gaap_CostsAndExpenses_6b612a4e-5d6d-46e9-9ce3-aa444474c03d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0613ce99-756b-42a9-9a85-4343e8e5070f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_46d16d77-9eb7-42bf-a157-ee76e39f9e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0613ce99-756b-42a9-9a85-4343e8e5070f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_46d16d77-9eb7-42bf-a157-ee76e39f9e70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b6e04e96-9307-44f4-bc1c-bc5529501768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0613ce99-756b-42a9-9a85-4343e8e5070f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b6e04e96-9307-44f4-bc1c-bc5529501768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f6f97993-6cdc-4a8f-8173-cd17c4f78752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c6351507-313a-471a-a7d0-d65028c5c763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f6f97993-6cdc-4a8f-8173-cd17c4f78752" xlink:to="loc_us-gaap_NetIncomeLoss_c6351507-313a-471a-a7d0-d65028c5c763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5a71c8e0-e60a-4a4d-9c28-c9febb8b40ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f6f97993-6cdc-4a8f-8173-cd17c4f78752" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5a71c8e0-e60a-4a4d-9c28-c9febb8b40ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f83eebd7-2af4-45d3-b9e9-537a0d6938bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fc00cc7e-e3f9-4242-96f0-1902ae446546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f83eebd7-2af4-45d3-b9e9-537a0d6938bb" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fc00cc7e-e3f9-4242-96f0-1902ae446546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6a00ffdb-e70f-49fa-8cee-ecb0102ba8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f83eebd7-2af4-45d3-b9e9-537a0d6938bb" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6a00ffdb-e70f-49fa-8cee-ecb0102ba8c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6e04e8de-3e23-430d-925a-3dd3005d3a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f83eebd7-2af4-45d3-b9e9-537a0d6938bb" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6e04e8de-3e23-430d-925a-3dd3005d3a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e077c256-a825-4910-92a7-096a5b4d7be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f83eebd7-2af4-45d3-b9e9-537a0d6938bb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e077c256-a825-4910-92a7-096a5b4d7be8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c23affb6-32bb-4376-9f57-fb85b9522457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_990238f2-3071-4738-a512-a268886c1df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c23affb6-32bb-4376-9f57-fb85b9522457" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_990238f2-3071-4738-a512-a268886c1df7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bccb3c96-ed34-4cc6-bf0c-45053c0014c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c23affb6-32bb-4376-9f57-fb85b9522457" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bccb3c96-ed34-4cc6-bf0c-45053c0014c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0169ccb4-8dd1-4752-bd2b-ae4945b5d36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c23affb6-32bb-4376-9f57-fb85b9522457" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0169ccb4-8dd1-4752-bd2b-ae4945b5d36a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e9b2251-42a0-4bd9-b330-26fb1668bd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c23affb6-32bb-4376-9f57-fb85b9522457" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e9b2251-42a0-4bd9-b330-26fb1668bd56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c96b5190-6833-493f-837e-d7441c5bbd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_ProfitLoss_c96b5190-6833-493f-837e-d7441c5bbd1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f6d7ece1-72d6-459c-ad2f-e1f2c369b810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f6d7ece1-72d6-459c-ad2f-e1f2c369b810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_c5da1192-be27-4b4f-a7de-f89f655068d0" xlink:href="nktr-20211231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_c5da1192-be27-4b4f-a7de-f89f655068d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_890e49a9-ca97-4b36-90ec-228e247af46b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_890e49a9-ca97-4b36-90ec-228e247af46b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_bfe1a666-43ed-4e34-aec2-f3c22923d8d9" xlink:href="nktr-20211231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_bfe1a666-43ed-4e34-aec2-f3c22923d8d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d4e9b079-569f-42c1-90c6-ba841ca9526d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d4e9b079-569f-42c1-90c6-ba841ca9526d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_813a68f0-3cd8-4a56-917b-ae61fbc4f852" xlink:href="nktr-20211231.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_813a68f0-3cd8-4a56-917b-ae61fbc4f852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_5f81edf8-ad6d-41f6-b6f2-030d7f118cc5" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_5f81edf8-ad6d-41f6-b6f2-030d7f118cc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_351cfc73-98cf-4409-9a71-d6f64493059e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_351cfc73-98cf-4409-9a71-d6f64493059e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_806d38b5-8e76-4374-9563-0627b5bcbde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_806d38b5-8e76-4374-9563-0627b5bcbde5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_87934c98-90b5-423b-ba33-f601ce60956f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_87934c98-90b5-423b-ba33-f601ce60956f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_981802d4-c7d9-426d-88f0-b3d3765178bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_981802d4-c7d9-426d-88f0-b3d3765178bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_7a0eee41-1eb7-47e3-908e-f8a8d40f3778" xlink:href="nktr-20211231.xsd#nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_7a0eee41-1eb7-47e3-908e-f8a8d40f3778" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_748bfe57-c0dd-4186-a195-3953715ded55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_DepreciationAndAmortization_748bfe57-c0dd-4186-a195-3953715ded55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2c6d42d9-2cf5-4208-850b-005ccc130aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2c6d42d9-2cf5-4208-850b-005ccc130aa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_99d9bd4d-1cc0-4686-a906-61b1ad0186f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_99d9bd4d-1cc0-4686-a906-61b1ad0186f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_d3df2619-7c92-43b0-8a3b-359574b6619c" xlink:href="nktr-20211231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_d3df2619-7c92-43b0-8a3b-359574b6619c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_82bd640d-a74c-4017-87b9-0141faa30388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6829bf41-0a8d-4a41-b895-ceddbc90d6db" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_82bd640d-a74c-4017-87b9-0141faa30388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4473ecf0-c102-4584-8256-6ba63905b00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_d4606911-faa2-4c14-9136-10ee72c62767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4473ecf0-c102-4584-8256-6ba63905b00b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_d4606911-faa2-4c14-9136-10ee72c62767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_ea142c7d-06bc-4c1d-83ae-33d5d4ac112e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4473ecf0-c102-4584-8256-6ba63905b00b" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_ea142c7d-06bc-4c1d-83ae-33d5d4ac112e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_27c633d6-623d-4914-b557-efdc925af486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4473ecf0-c102-4584-8256-6ba63905b00b" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_27c633d6-623d-4914-b557-efdc925af486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_836f3735-7ce2-4b3d-945f-53087e63de31" xlink:href="nktr-20211231.xsd#nktr_ProceedsFromSaleOfFutureRoyaltiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4473ecf0-c102-4584-8256-6ba63905b00b" xlink:to="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_836f3735-7ce2-4b3d-945f-53087e63de31" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_fe9f0813-1939-4a0d-be86-c25ec2a77f0c" xlink:href="nktr-20211231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c1784a7-cc61-4fb3-aab7-3ce38265f718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_fe9f0813-1939-4a0d-be86-c25ec2a77f0c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c1784a7-cc61-4fb3-aab7-3ce38265f718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9d0946ef-8018-4cd9-809d-22926b78c52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_fe9f0813-1939-4a0d-be86-c25ec2a77f0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9d0946ef-8018-4cd9-809d-22926b78c52f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_15390b79-83f6-4b3d-8ff4-6c2b941b7e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_fe9f0813-1939-4a0d-be86-c25ec2a77f0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_15390b79-83f6-4b3d-8ff4-6c2b941b7e9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_128c0911-a35b-4123-a93a-e0d2f49ba982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ca769460-f40e-44e4-a774-d96ad5c13167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_128c0911-a35b-4123-a93a-e0d2f49ba982" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ca769460-f40e-44e4-a774-d96ad5c13167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0c14ce0-17fd-4574-bc19-e02cdad97805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_128c0911-a35b-4123-a93a-e0d2f49ba982" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b0c14ce0-17fd-4574-bc19-e02cdad97805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8ac8049-10b7-4494-ad51-a3e7aa457027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_128c0911-a35b-4123-a93a-e0d2f49ba982" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8ac8049-10b7-4494-ad51-a3e7aa457027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_dd8330a7-cf96-4438-97dc-ea1bc2878442" xlink:href="nktr-20211231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1d28df9e-9404-48c3-814b-e74984d00bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_dd8330a7-cf96-4438-97dc-ea1bc2878442" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1d28df9e-9404-48c3-814b-e74984d00bfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_71eae13e-7f8b-459f-ac59-e773de3081c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_dd8330a7-cf96-4438-97dc-ea1bc2878442" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_71eae13e-7f8b-459f-ac59-e773de3081c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_1f1c229a-1360-4377-80e7-8fe369f6b26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_dd8330a7-cf96-4438-97dc-ea1bc2878442" xlink:to="loc_us-gaap_Cash_1f1c229a-1360-4377-80e7-8fe369f6b26f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryScheduleofInventoriesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#InventoryScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ad902501-0163-4f4b-bf29-f77132436d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9750d40c-f8fb-42f2-8635-9868765bed02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ad902501-0163-4f4b-bf29-f77132436d26" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9750d40c-f8fb-42f2-8635-9868765bed02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d392f2e3-8d33-45a1-a413-c12dd9d23124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ad902501-0163-4f4b-bf29-f77132436d26" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d392f2e3-8d33-45a1-a413-c12dd9d23124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_36a38ff6-eac7-4a8e-ad31-fa730aeebb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ad902501-0163-4f4b-bf29-f77132436d26" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_36a38ff6-eac7-4a8e-ad31-fa730aeebb8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bed3aa32-a835-4a2e-a74a-ffe8dbb03d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_ee410f19-08c8-4b6b-b7e2-b64388be095d" xlink:href="nktr-20211231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_bed3aa32-a835-4a2e-a74a-ffe8dbb03d2d" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_ee410f19-08c8-4b6b-b7e2-b64388be095d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_2f07e45b-c71e-4227-8dfd-b70f1a9b60e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_bed3aa32-a835-4a2e-a74a-ffe8dbb03d2d" xlink:to="loc_us-gaap_ConstructionInProgressGross_2f07e45b-c71e-4227-8dfd-b70f1a9b60e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_94b759ea-0723-4b4b-9b6d-89d28d4467a8" xlink:href="nktr-20211231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_598cc1e7-9f51-436e-93b1-f338cc3dd95d" xlink:href="nktr-20211231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_94b759ea-0723-4b4b-9b6d-89d28d4467a8" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_598cc1e7-9f51-436e-93b1-f338cc3dd95d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a246bb8f-d256-4df5-b94b-ce87a3236179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_94b759ea-0723-4b4b-9b6d-89d28d4467a8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a246bb8f-d256-4df5-b94b-ce87a3236179" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesScheduleofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_45064150-e49c-444c-9901-d6003399aa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ba406fea-633b-4e3b-9f73-66fc3a44398c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_45064150-e49c-444c-9901-d6003399aa2e" xlink:to="loc_us-gaap_OperatingLeaseCost_ba406fea-633b-4e3b-9f73-66fc3a44398c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_fd2bbf33-4e86-4495-a747-9b3f54e6410a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_45064150-e49c-444c-9901-d6003399aa2e" xlink:to="loc_us-gaap_VariableLeaseCost_fd2bbf33-4e86-4495-a747-9b3f54e6410a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ec1dfe3d-b2b9-4f25-8863-2bf815891006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b2a2ec63-4e7e-40f3-9448-9b85b6cb4c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ec1dfe3d-b2b9-4f25-8863-2bf815891006" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b2a2ec63-4e7e-40f3-9448-9b85b6cb4c83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2165911-aee1-45d9-9640-179e765e24d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ec1dfe3d-b2b9-4f25-8863-2bf815891006" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2165911-aee1-45d9-9640-179e765e24d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a33cb504-1850-45e1-afbb-3d60ada91a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_95a8e385-e55f-48db-951d-f700a52deea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a33cb504-1850-45e1-afbb-3d60ada91a33" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_95a8e385-e55f-48db-951d-f700a52deea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_26c56f2c-d194-4745-aeb7-1534dbdbcc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a33cb504-1850-45e1-afbb-3d60ada91a33" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_26c56f2c-d194-4745-aeb7-1534dbdbcc99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc7534f8-5b85-452e-840e-151ed5a96ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a33cb504-1850-45e1-afbb-3d60ada91a33" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc7534f8-5b85-452e-840e-151ed5a96ded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3d00e1c3-8900-4e7b-a1d9-b633d1f1052f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a33cb504-1850-45e1-afbb-3d60ada91a33" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3d00e1c3-8900-4e7b-a1d9-b633d1f1052f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_deb13f5a-baa4-4b39-88cf-34f0ba9236a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a33cb504-1850-45e1-afbb-3d60ada91a33" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_deb13f5a-baa4-4b39-88cf-34f0ba9236a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_edd2e25a-b0d6-4170-b351-038654a7742a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a33cb504-1850-45e1-afbb-3d60ada91a33" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_edd2e25a-b0d6-4170-b351-038654a7742a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d17dbd42-b6ca-4b75-863b-313d4f3a96b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0525d0e7-bd47-4b36-bff7-2d4e05ad92c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d17dbd42-b6ca-4b75-863b-313d4f3a96b8" xlink:to="loc_us-gaap_OperatingLeaseLiability_0525d0e7-bd47-4b36-bff7-2d4e05ad92c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_794dc52f-fd5b-41b5-93e7-1f2f47c9ba64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d17dbd42-b6ca-4b75-863b-313d4f3a96b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_794dc52f-fd5b-41b5-93e7-1f2f47c9ba64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_b831612a-bac7-4dde-a1ed-ccbbf108e05a" xlink:href="nktr-20211231.xsd#nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d17dbd42-b6ca-4b75-863b-313d4f3a96b8" xlink:to="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_b831612a-bac7-4dde-a1ed-ccbbf108e05a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20211231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_3cd1668d-d6d5-4928-ac09-37d15f3f7215" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_046694c2-cf3a-455b-a3a8-4295e39bff84" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_3cd1668d-d6d5-4928-ac09-37d15f3f7215" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_046694c2-cf3a-455b-a3a8-4295e39bff84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_5c51799f-7592-4023-a4b5-5bfea7cd29d5" xlink:href="nktr-20211231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_3cd1668d-d6d5-4928-ac09-37d15f3f7215" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_5c51799f-7592-4023-a4b5-5bfea7cd29d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b697015-c3c5-4b6f-9b52-550f37baa886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_76bb6ad5-5b39-4e57-992d-5315ca70ca4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b697015-c3c5-4b6f-9b52-550f37baa886" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_76bb6ad5-5b39-4e57-992d-5315ca70ca4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_70999663-9c53-411b-8688-4a85869e6ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b697015-c3c5-4b6f-9b52-550f37baa886" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_70999663-9c53-411b-8688-4a85869e6ef6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e9fb8e42-e66f-4626-b29e-a7216c04b201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ddd746f4-7faa-4880-b45f-e795b3672766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e9fb8e42-e66f-4626-b29e-a7216c04b201" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ddd746f4-7faa-4880-b45f-e795b3672766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eff61b58-95ed-4ce3-b491-e0e90a0f2da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e9fb8e42-e66f-4626-b29e-a7216c04b201" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eff61b58-95ed-4ce3-b491-e0e90a0f2da2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_63a2ffd8-cee1-49fb-8f11-9f90f17ca210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d3c5df63-61af-4fcb-83be-afc85ce3cc88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_63a2ffd8-cee1-49fb-8f11-9f90f17ca210" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d3c5df63-61af-4fcb-83be-afc85ce3cc88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_650895bd-50f3-48f7-be03-7884c713ddbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_63a2ffd8-cee1-49fb-8f11-9f90f17ca210" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_650895bd-50f3-48f7-be03-7884c713ddbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f2483953-a927-42fa-8453-2a6ede5af294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_63a2ffd8-cee1-49fb-8f11-9f90f17ca210" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f2483953-a927-42fa-8453-2a6ede5af294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1e1b2a0f-8859-4ca5-9103-ce8c410124f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a240b8c7-796b-4755-8e3f-0415c773eed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1e1b2a0f-8859-4ca5-9103-ce8c410124f7" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a240b8c7-796b-4755-8e3f-0415c773eed7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c70b29e3-a53d-4821-b45e-6c57c00fbf16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1e1b2a0f-8859-4ca5-9103-ce8c410124f7" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c70b29e3-a53d-4821-b45e-6c57c00fbf16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_703f13ae-beb8-401b-a11c-de2767460c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1e1b2a0f-8859-4ca5-9103-ce8c410124f7" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_703f13ae-beb8-401b-a11c-de2767460c9d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_436af4b7-75f5-4824-9e7d-30df688d43bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_e2febb84-4345-4088-907a-2a14c24a28e4" xlink:href="nktr-20211231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_436af4b7-75f5-4824-9e7d-30df688d43bb" xlink:to="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_e2febb84-4345-4088-907a-2a14c24a28e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_39190766-a0b6-49de-ab17-1f59908f7ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_436af4b7-75f5-4824-9e7d-30df688d43bb" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_39190766-a0b6-49de-ab17-1f59908f7ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_87abd1c6-f489-4047-b6d1-c2f56f5eadda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_436af4b7-75f5-4824-9e7d-30df688d43bb" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_87abd1c6-f489-4047-b6d1-c2f56f5eadda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ba1e1c0a-0a47-4865-a212-46859f5ab654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_436af4b7-75f5-4824-9e7d-30df688d43bb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ba1e1c0a-0a47-4865-a212-46859f5ab654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_7069c325-32e6-4bcb-a33b-24942fcc413c" xlink:href="nktr-20211231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_436af4b7-75f5-4824-9e7d-30df688d43bb" xlink:to="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_7069c325-32e6-4bcb-a33b-24942fcc413c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_1e348a03-0781-4121-a7e9-fa1aa2664eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_436af4b7-75f5-4824-9e7d-30df688d43bb" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_1e348a03-0781-4121-a7e9-fa1aa2664eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f2ae4f64-4df2-4cb4-a562-f45133244ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_436af4b7-75f5-4824-9e7d-30df688d43bb" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f2ae4f64-4df2-4cb4-a562-f45133244ada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_c3eee7ce-af5f-47e9-a410-0276b029f405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_436af4b7-75f5-4824-9e7d-30df688d43bb" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_c3eee7ce-af5f-47e9-a410-0276b029f405" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_a7a5f200-5162-4cc6-a199-6630d47bdcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_321568f9-c0bd-4f2a-a45f-f98dbcce322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_a7a5f200-5162-4cc6-a199-6630d47bdcc7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_321568f9-c0bd-4f2a-a45f-f98dbcce322e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_9af163ff-7cf3-4144-be8f-458fe2bee38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_a7a5f200-5162-4cc6-a199-6630d47bdcc7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_9af163ff-7cf3-4144-be8f-458fe2bee38d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a34223bb-7c5c-42e0-8dc4-fdb7edf930f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_82e56582-0b1e-40b7-b3de-10bbd5b4ccac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a34223bb-7c5c-42e0-8dc4-fdb7edf930f9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_82e56582-0b1e-40b7-b3de-10bbd5b4ccac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_8fa0ddcd-5bf6-4773-8aba-428d2f7cce30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a34223bb-7c5c-42e0-8dc4-fdb7edf930f9" xlink:to="loc_us-gaap_DeferredTaxLiabilities_8fa0ddcd-5bf6-4773-8aba-428d2f7cce30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6f249e1d-f320-4910-a733-48d85faad71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_24039c20-a6e6-4250-99dd-ab5dc264b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f249e1d-f320-4910-a733-48d85faad71f" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_24039c20-a6e6-4250-99dd-ab5dc264b7a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a9ff85cd-dbad-4da1-bf3a-1a15601f2351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f249e1d-f320-4910-a733-48d85faad71f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a9ff85cd-dbad-4da1-bf3a-1a15601f2351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_31effa08-e08c-4777-ba36-9e8224f2ed9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f249e1d-f320-4910-a733-48d85faad71f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_31effa08-e08c-4777-ba36-9e8224f2ed9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_8d9d0930-28b8-4418-91e5-04376ff6b012" xlink:href="nktr-20211231.xsd#nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f249e1d-f320-4910-a733-48d85faad71f" xlink:to="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_8d9d0930-28b8-4418-91e5-04376ff6b012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLeaseLiability_30595db4-6873-47f7-bf35-5b135db846f9" xlink:href="nktr-20211231.xsd#nktr_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f249e1d-f320-4910-a733-48d85faad71f" xlink:to="loc_nktr_DeferredTaxAssetsLeaseLiability_30595db4-6873-47f7-bf35-5b135db846f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8ee26c32-fa84-491f-a6f6-859f97012c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f249e1d-f320-4910-a733-48d85faad71f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8ee26c32-fa84-491f-a6f6-859f97012c4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_818c90df-3c7e-4dd5-a6d4-6de6121d2926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6f249e1d-f320-4910-a733-48d85faad71f" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_818c90df-3c7e-4dd5-a6d4-6de6121d2926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_cef35dd6-8e35-4c2c-ba87-f0597c7d5f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_17a3d528-e888-4c79-a726-452ff01bd34b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_cef35dd6-8e35-4c2c-ba87-f0597c7d5f22" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_17a3d528-e888-4c79-a726-452ff01bd34b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fa131464-fc8d-42d9-a610-b511e2319b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_cef35dd6-8e35-4c2c-ba87-f0597c7d5f22" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fa131464-fc8d-42d9-a610-b511e2319b12" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>nktr-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b154c77f-11f5-433c-8e4e-b6be98e0afac,g:2cfcd135-9f36-4467-b376-e4c05a9fe6a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="if608c04ac7164bbeb5e1a25bf12d68fd_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_cbc37273-122b-4809-9585-1fbb73ddce38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_RevenuesAbstract_cbc37273-122b-4809-9585-1fbb73ddce38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37f82e3b-4904-40ba-9474-18055cf140b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_cbc37273-122b-4809-9585-1fbb73ddce38" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37f82e3b-4904-40ba-9474-18055cf140b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ed599bf1-a9b9-4ff3-872f-e9b50a71d9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ed599bf1-a9b9-4ff3-872f-e9b50a71d9c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_817d6ef4-82c6-47c5-abf3-217e73627379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_817d6ef4-82c6-47c5-abf3-217e73627379" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b37c87be-2bde-4404-9066-6c8c48c54ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b37c87be-2bde-4404-9066-6c8c48c54ed6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_509d3bf8-9fdd-46e6-92f4-2ef589815d63" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_509d3bf8-9fdd-46e6-92f4-2ef589815d63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d6234d75-95f1-4e38-8b51-e054b23e21d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:to="loc_us-gaap_CostsAndExpenses_d6234d75-95f1-4e38-8b51-e054b23e21d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_34e7456a-501c-4817-9a51-ee6d002008e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_OperatingIncomeLoss_34e7456a-501c-4817-9a51-ee6d002008e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_25cff60c-665e-4c00-ae23-ffcdf7674385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_25cff60c-665e-4c00-ae23-ffcdf7674385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a03ac9d5-032e-44b7-9a09-a25eba5d451c" xlink:href="nktr-20211231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a03ac9d5-032e-44b7-9a09-a25eba5d451c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_a5316795-d504-441a-b6cd-ca42381260e8" xlink:href="nktr-20211231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_a5316795-d504-441a-b6cd-ca42381260e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bf2b8641-ac5c-4f20-adc5-698fd0bdf972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bf2b8641-ac5c-4f20-adc5-698fd0bdf972" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_197db2af-5812-490c-babf-6f578cc7a698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_us-gaap_InterestExpense_197db2af-5812-490c-babf-6f578cc7a698" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d6ca9d03-2c0f-4252-8006-1e2a19a283fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d6ca9d03-2c0f-4252-8006-1e2a19a283fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d7c4456-6998-4ebc-b18d-0fe26afa56c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d7c4456-6998-4ebc-b18d-0fe26afa56c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2af272de-9e5e-4eff-8951-18e6089f3cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2af272de-9e5e-4eff-8951-18e6089f3cf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_05b385d0-d331-4ff8-8fba-553e85510010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_NetIncomeLoss_05b385d0-d331-4ff8-8fba-553e85510010" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7d1e690d-552b-4b0a-a7a7-6988dd80afd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_7d1e690d-552b-4b0a-a7a7-6988dd80afd4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ef3fd452-5aee-473f-b0d4-909f2115ac5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7d1e690d-552b-4b0a-a7a7-6988dd80afd4" xlink:to="loc_us-gaap_EarningsPerShareBasic_ef3fd452-5aee-473f-b0d4-909f2115ac5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d2a61f49-9554-45be-b1ee-c8f779f6f4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7d1e690d-552b-4b0a-a7a7-6988dd80afd4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d2a61f49-9554-45be-b1ee-c8f779f6f4f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3208f566-43b0-4bab-892a-35fab1a00e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3208f566-43b0-4bab-892a-35fab1a00e0d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_30fb4459-1a61-436f-8b27-20c9307f2124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3208f566-43b0-4bab-892a-35fab1a00e0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_30fb4459-1a61-436f-8b27-20c9307f2124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f965c9c-9a29-4d03-8f32-11653adaf041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3208f566-43b0-4bab-892a-35fab1a00e0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f965c9c-9a29-4d03-8f32-11653adaf041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_668c3e63-bb92-4d79-8ea3-cb479af3ed80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_StatementTable_668c3e63-bb92-4d79-8ea3-cb479af3ed80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_61c74750-2518-4c28-a167-a4f2218df167" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_668c3e63-bb92-4d79-8ea3-cb479af3ed80" xlink:to="loc_srt_ProductOrServiceAxis_61c74750-2518-4c28-a167-a4f2218df167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_61c74750-2518-4c28-a167-a4f2218df167_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_61c74750-2518-4c28-a167-a4f2218df167" xlink:to="loc_srt_ProductsAndServicesDomain_61c74750-2518-4c28-a167-a4f2218df167_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_61c74750-2518-4c28-a167-a4f2218df167" xlink:to="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6e14e423-b005-4a57-a60d-1f13fc6d4bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:to="loc_us-gaap_ProductMember_6e14e423-b005-4a57-a60d-1f13fc6d4bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c72a306d-814b-4776-8fcc-db427c4d9021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:to="loc_us-gaap_RoyaltyMember_c72a306d-814b-4776-8fcc-db427c4d9021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_c4d3020e-eabc-4b21-bfcb-5bb6880089a6" xlink:href="nktr-20211231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_c4d3020e-eabc-4b21-bfcb-5bb6880089a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_b2503d9f-9611-41a5-8dc6-bba075888119" xlink:href="nktr-20211231.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_b2503d9f-9611-41a5-8dc6-bba075888119" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i420426b0b2ec48018320e56fdc4267ec_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c1bd2e2-9d27-452d-98be-1d75ee29a61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c1bd2e2-9d27-452d-98be-1d75ee29a61e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3478f963-ea12-4272-b4ac-ed7f774aa756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_SharesOutstanding_3478f963-ea12-4272-b4ac-ed7f774aa756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b0377f2-630f-4165-b064-b594624bbd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_StockholdersEquity_6b0377f2-630f-4165-b064-b594624bbd8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bf82a8af-2fcf-48da-9042-c35eba00261e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bf82a8af-2fcf-48da-9042-c35eba00261e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_83fea252-cdcf-4b64-b3a4-a85a86392d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_83fea252-cdcf-4b64-b3a4-a85a86392d70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32a6f998-2170-4ee0-87e6-7dc6f6126a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32a6f998-2170-4ee0-87e6-7dc6f6126a0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f287012b-ad7e-4fac-8ce6-0df5a4d7923a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f287012b-ad7e-4fac-8ce6-0df5a4d7923a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_fb0f2700-c0a2-4119-9287-34f615d42a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4198d7ab-ffc6-4ad3-a02b-060512568af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ea24f2c-53ca-4e58-91b9-9aea42604466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0c1bd2e2-9d27-452d-98be-1d75ee29a61e" xlink:to="loc_us-gaap_StatementTable_1ea24f2c-53ca-4e58-91b9-9aea42604466" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1fbe31c0-5826-4f03-97a5-a03cb7f6f65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1ea24f2c-53ca-4e58-91b9-9aea42604466" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1fbe31c0-5826-4f03-97a5-a03cb7f6f65b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1fbe31c0-5826-4f03-97a5-a03cb7f6f65b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1fbe31c0-5826-4f03-97a5-a03cb7f6f65b" xlink:to="loc_us-gaap_EquityComponentDomain_1fbe31c0-5826-4f03-97a5-a03cb7f6f65b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1fbe31c0-5826-4f03-97a5-a03cb7f6f65b" xlink:to="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9419422c-885d-49c1-b7a4-4974fc5b2a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:to="loc_us-gaap_CommonStockMember_9419422c-885d-49c1-b7a4-4974fc5b2a0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_52b84b74-d0b3-4fe9-8fe5-33587f02e481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_52b84b74-d0b3-4fe9-8fe5-33587f02e481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9182f806-8672-42e4-b4c7-8dc48a833ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9182f806-8672-42e4-b4c7-8dc48a833ec7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f46a22f1-c743-47e8-8b28-d86c0ae5bf80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:to="loc_us-gaap_RetainedEarningsMember_f46a22f1-c743-47e8-8b28-d86c0ae5bf80" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i29a32b16c9704f608744e6009d540fec_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:href="nktr-20211231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_e17917a1-b950-44f9-ac91-5bfa45aac5ac" xlink:href="nktr-20211231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_e17917a1-b950-44f9-ac91-5bfa45aac5ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_3661668c-f137-4426-b3e4-1ae8e84c9e39" xlink:href="nktr-20211231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_3661668c-f137-4426-b3e4-1ae8e84c9e39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_194df37d-56f6-47d4-8f64-143292a55316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_194df37d-56f6-47d4-8f64-143292a55316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_2d07bd10-bf44-4b87-94a2-a6765b02838c" xlink:href="nktr-20211231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_2d07bd10-bf44-4b87-94a2-a6765b02838c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e56e5e4-81b1-4f13-aefe-dc31bace93a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e56e5e4-81b1-4f13-aefe-dc31bace93a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_29348e5d-4fda-4002-8d9b-cabd460784f7" xlink:href="nktr-20211231.xsd#nktr_SalesMilestoneRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_SalesMilestoneRevenue_29348e5d-4fda-4002-8d9b-cabd460784f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment_5a41fede-5b46-40e4-aabc-3c33f0d1ee20" xlink:href="nktr-20211231.xsd#nktr_WriteOffOfPrepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_WriteOffOfPrepayment_5a41fede-5b46-40e4-aabc-3c33f0d1ee20" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_c38676fe-f830-471e-8313-6dc49848160b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_c38676fe-f830-471e-8313-6dc49848160b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6a589015-ac1a-4669-a669-0cba600b7e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6a589015-ac1a-4669-a669-0cba600b7e24" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:href="nktr-20211231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7747156e-8812-4ee0-bd52-f67540d79a69" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_srt_RangeAxis_7747156e-8812-4ee0-bd52-f67540d79a69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7747156e-8812-4ee0-bd52-f67540d79a69_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7747156e-8812-4ee0-bd52-f67540d79a69" xlink:to="loc_srt_RangeMember_7747156e-8812-4ee0-bd52-f67540d79a69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2e325f9c-20e3-4c0c-bd4a-aab93aa08aaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7747156e-8812-4ee0-bd52-f67540d79a69" xlink:to="loc_srt_RangeMember_2e325f9c-20e3-4c0c-bd4a-aab93aa08aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b529b7f4-df57-47c7-95e7-2cf7dfdf214c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2e325f9c-20e3-4c0c-bd4a-aab93aa08aaf" xlink:to="loc_srt_MinimumMember_b529b7f4-df57-47c7-95e7-2cf7dfdf214c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fdc34467-518e-404e-ab7c-7fafd5dc06d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2e325f9c-20e3-4c0c-bd4a-aab93aa08aaf" xlink:to="loc_srt_MaximumMember_fdc34467-518e-404e-ab7c-7fafd5dc06d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_010ccb26-a705-488b-9e73-ac2b20f723ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_010ccb26-a705-488b-9e73-ac2b20f723ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_010ccb26-a705-488b-9e73-ac2b20f723ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_010ccb26-a705-488b-9e73-ac2b20f723ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_010ccb26-a705-488b-9e73-ac2b20f723ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_117407c2-a8d1-49d9-b975-97317715188b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_010ccb26-a705-488b-9e73-ac2b20f723ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_117407c2-a8d1-49d9-b975-97317715188b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_7331f5d4-3851-4d34-b3ca-e2479ee215b8" xlink:href="nktr-20211231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_117407c2-a8d1-49d9-b975-97317715188b" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_7331f5d4-3851-4d34-b3ca-e2479ee215b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_0c897598-9b25-4dc7-bb5e-e1c977ea77eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_117407c2-a8d1-49d9-b975-97317715188b" xlink:to="loc_us-gaap_BuildingMember_0c897598-9b25-4dc7-bb5e-e1c977ea77eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aac728f9-9aee-4562-97b0-82900cf7891c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_srt_ProductOrServiceAxis_aac728f9-9aee-4562-97b0-82900cf7891c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aac728f9-9aee-4562-97b0-82900cf7891c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_aac728f9-9aee-4562-97b0-82900cf7891c" xlink:to="loc_srt_ProductsAndServicesDomain_aac728f9-9aee-4562-97b0-82900cf7891c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d341c727-5fc1-4a02-8d8d-3fa2961acc4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_aac728f9-9aee-4562-97b0-82900cf7891c" xlink:to="loc_srt_ProductsAndServicesDomain_d341c727-5fc1-4a02-8d8d-3fa2961acc4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_028719a0-975a-4313-b4a2-f5280e6e84a1" xlink:href="nktr-20211231.xsd#nktr_NKTR181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d341c727-5fc1-4a02-8d8d-3fa2961acc4a" xlink:to="loc_nktr_NKTR181Member_028719a0-975a-4313-b4a2-f5280e6e84a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_7be8545f-a28b-4a68-aa35-1aeee3111ac9" xlink:href="nktr-20211231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d341c727-5fc1-4a02-8d8d-3fa2961acc4a" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_7be8545f-a28b-4a68-aa35-1aeee3111ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndNonCashRoyaltiesMember_d3027dc6-8712-485a-bda7-894f72b7306b" xlink:href="nktr-20211231.xsd#nktr_CashAndNonCashRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d341c727-5fc1-4a02-8d8d-3fa2961acc4a" xlink:to="loc_nktr_CashAndNonCashRoyaltiesMember_d3027dc6-8712-485a-bda7-894f72b7306b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_248f78b0-c575-44e0-b276-ba8858c5906f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_248f78b0-c575-44e0-b276-ba8858c5906f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_248f78b0-c575-44e0-b276-ba8858c5906f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_248f78b0-c575-44e0-b276-ba8858c5906f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_248f78b0-c575-44e0-b276-ba8858c5906f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_515a7626-0c76-45e1-8aac-c91b3e537865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_248f78b0-c575-44e0-b276-ba8858c5906f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_515a7626-0c76-45e1-8aac-c91b3e537865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsRSUsAndPSUsMember_ce283d17-3332-4186-8c6b-f0b3cab4f4ad" xlink:href="nktr-20211231.xsd#nktr_StockOptionsRSUsAndPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_515a7626-0c76-45e1-8aac-c91b3e537865" xlink:to="loc_nktr_StockOptionsRSUsAndPSUsMember_ce283d17-3332-4186-8c6b-f0b3cab4f4ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4346becd-8117-4d06-bd47-18eb1b4572fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4346becd-8117-4d06-bd47-18eb1b4572fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4346becd-8117-4d06-bd47-18eb1b4572fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4346becd-8117-4d06-bd47-18eb1b4572fc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4346becd-8117-4d06-bd47-18eb1b4572fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3dbe196-13a3-47e9-abec-5561c4c28802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4346becd-8117-4d06-bd47-18eb1b4572fc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3dbe196-13a3-47e9-abec-5561c4c28802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_84feb216-48f7-471f-a789-3b96048bbef1" xlink:href="nktr-20211231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3dbe196-13a3-47e9-abec-5561c4c28802" xlink:to="loc_nktr_BMSCollaborationAgreementMember_84feb216-48f7-471f-a789-3b96048bbef1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails" xlink:type="extended" id="ie4047c3cad2e4e88951d756dab884bfb_CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:href="nktr-20211231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_81b212f0-ca45-40ef-be94-45bb66fe5163" xlink:href="nktr-20211231.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_81b212f0-ca45-40ef-be94-45bb66fe5163" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_17f09dc9-f0dc-49b7-b587-16c79247ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_17f09dc9-f0dc-49b7-b587-16c79247ae24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_c3da947e-eeec-4844-9918-1fcd7dd7d47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_us-gaap_InterestReceivableCurrent_c3da947e-eeec-4844-9918-1fcd7dd7d47b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_983d00e6-abda-4d72-89b1-48081102596b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_983d00e6-abda-4d72-89b1-48081102596b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da407772-a153-433a-8902-37e72c85e47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da407772-a153-433a-8902-37e72c85e47e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_d38f31a4-b798-4958-bd95-fbe14f723750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_d38f31a4-b798-4958-bd95-fbe14f723750" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_0e48631e-ca5d-477a-9a02-5466a7c39a5c" xlink:href="nktr-20211231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_0e48631e-ca5d-477a-9a02-5466a7c39a5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5c123be8-ad26-473c-aad8-ebc8c83775b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_0e48631e-ca5d-477a-9a02-5466a7c39a5c" xlink:to="loc_srt_RangeAxis_5c123be8-ad26-473c-aad8-ebc8c83775b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5c123be8-ad26-473c-aad8-ebc8c83775b7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5c123be8-ad26-473c-aad8-ebc8c83775b7" xlink:to="loc_srt_RangeMember_5c123be8-ad26-473c-aad8-ebc8c83775b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9410c84e-e5f8-401c-919b-ee1768d9b82d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5c123be8-ad26-473c-aad8-ebc8c83775b7" xlink:to="loc_srt_RangeMember_9410c84e-e5f8-401c-919b-ee1768d9b82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aa93622c-2c0e-46de-9f24-4301073aa6d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9410c84e-e5f8-401c-919b-ee1768d9b82d" xlink:to="loc_srt_MinimumMember_aa93622c-2c0e-46de-9f24-4301073aa6d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b71fbfe5-0d15-477d-a959-bba78b749706" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9410c84e-e5f8-401c-919b-ee1768d9b82d" xlink:to="loc_srt_MaximumMember_b71fbfe5-0d15-477d-a959-bba78b749706" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="extended" id="ie2e77fdc77a0440abc09af46af22a9f2_CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f805489c-b94b-4058-a337-823e90705193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f805489c-b94b-4058-a337-823e90705193" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f4462c9c-d189-4f40-8a19-0ec740fa8db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f4462c9c-d189-4f40-8a19-0ec740fa8db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9bc62439-3b41-4af0-95d4-d66152327efb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9bc62439-3b41-4af0-95d4-d66152327efb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a62958d1-94bf-44b1-bd24-54065d552307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a62958d1-94bf-44b1-bd24-54065d552307" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_bbc5a727-27b7-467a-81ac-2e9b0fce39e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_bbc5a727-27b7-467a-81ac-2e9b0fce39e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_a0572bea-c232-4557-936d-89cfb7c8d56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_Cash_a0572bea-c232-4557-936d-89cfb7c8d56e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ba47fefe-9d5d-4467-adc8-c08be53b11c0" xlink:href="nktr-20211231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ba47fefe-9d5d-4467-adc8-c08be53b11c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76726c36-859f-4ca2-861a-8c3460abec9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76726c36-859f-4ca2-861a-8c3460abec9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_aa532de2-58ba-45e4-9448-b90df6716351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76726c36-859f-4ca2-861a-8c3460abec9f" xlink:to="loc_us-gaap_InvestmentTypeAxis_aa532de2-58ba-45e4-9448-b90df6716351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_aa532de2-58ba-45e4-9448-b90df6716351_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_aa532de2-58ba-45e4-9448-b90df6716351" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_aa532de2-58ba-45e4-9448-b90df6716351_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_aa532de2-58ba-45e4-9448-b90df6716351" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_98db5883-de6a-478d-9059-317090296f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_98db5883-de6a-478d-9059-317090296f75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_464ae642-85fa-4a01-8fde-9df57347bde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:to="loc_us-gaap_CommercialPaperMember_464ae642-85fa-4a01-8fde-9df57347bde5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fd6ac170-e458-4708-8650-18cb84bfb71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fd6ac170-e458-4708-8650-18cb84bfb71d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f62824c5-d658-4993-97f1-56fded722935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f62824c5-d658-4993-97f1-56fded722935" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4833659c-f2de-49d8-a4dc-7b37d43f0017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4833659c-f2de-49d8-a4dc-7b37d43f0017" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9529d222-03c9-498e-aca0-c844dabe9aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76726c36-859f-4ca2-861a-8c3460abec9f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9529d222-03c9-498e-aca0-c844dabe9aea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9529d222-03c9-498e-aca0-c844dabe9aea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9529d222-03c9-498e-aca0-c844dabe9aea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9529d222-03c9-498e-aca0-c844dabe9aea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37f695bc-51e3-4a9b-8dae-da76b5e47a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9529d222-03c9-498e-aca0-c844dabe9aea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37f695bc-51e3-4a9b-8dae-da76b5e47a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_85bf03ef-76aa-4059-98fc-d1cd85db73b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37f695bc-51e3-4a9b-8dae-da76b5e47a5d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_85bf03ef-76aa-4059-98fc-d1cd85db73b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7fd32eac-4093-4a83-8595-33f56018431b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37f695bc-51e3-4a9b-8dae-da76b5e47a5d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7fd32eac-4093-4a83-8595-33f56018431b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="id6133df02b204253b586643e8af292f5_PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_141bf550-944c-420e-8f1a-6fdf8706716c" xlink:href="nktr-20211231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_141bf550-944c-420e-8f1a-6fdf8706716c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c19d0f99-7e78-4e77-b91b-89895fb22a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c19d0f99-7e78-4e77-b91b-89895fb22a21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_eb6d3f6b-5d49-4ca4-9af1-380c0270e1c0" xlink:href="nktr-20211231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_eb6d3f6b-5d49-4ca4-9af1-380c0270e1c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_ec747558-74dc-400d-8ba2-fa7858d79418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_us-gaap_ConstructionInProgressGross_ec747558-74dc-400d-8ba2-fa7858d79418" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ef3d36ff-fe1b-413e-b831-435008e35dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ef3d36ff-fe1b-413e-b831-435008e35dd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f014048-e29e-483e-8959-cdefdde7a199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f014048-e29e-483e-8959-cdefdde7a199" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0133434-70a2-4bdd-8af6-ce3ca68a772b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f014048-e29e-483e-8959-cdefdde7a199" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0133434-70a2-4bdd-8af6-ce3ca68a772b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b0133434-70a2-4bdd-8af6-ce3ca68a772b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0133434-70a2-4bdd-8af6-ce3ca68a772b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b0133434-70a2-4bdd-8af6-ce3ca68a772b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0133434-70a2-4bdd-8af6-ce3ca68a772b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember_eefd3e43-febe-4cdb-a2c5-6ca00f29e73c" xlink:href="nktr-20211231.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:to="loc_nktr_BuildingAndLeaseholdImprovementsMember_eefd3e43-febe-4cdb-a2c5-6ca00f29e73c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember_bec3aaeb-db16-442f-aa14-b053747fad7c" xlink:href="nktr-20211231.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:to="loc_nktr_LaboratoryEquipmentMember_bec3aaeb-db16-442f-aa14-b053747fad7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember_38c472f6-4a34-4a22-a9c7-e8d2929f04ed" xlink:href="nktr-20211231.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:to="loc_nktr_ComputerFurnitureAndOtherMember_38c472f6-4a34-4a22-a9c7-e8d2929f04ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_6efecc3f-f6f2-43d9-858b-870a4d395aeb" xlink:href="nktr-20211231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_6efecc3f-f6f2-43d9-858b-870a4d395aeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_34748a3b-3a24-4508-b503-f262d1fbee0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_34748a3b-3a24-4508-b503-f262d1fbee0f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SeniorSecuredNotesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#SeniorSecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SeniorSecuredNotesDetails" xlink:type="extended" id="i99d889eed0cb4e89b625f9a61051c158_SeniorSecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_f2bb6bda-c575-4ac0-985d-680663ebe2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:to="loc_us-gaap_SeniorNotes_f2bb6bda-c575-4ac0-985d-680663ebe2cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eb3fd085-cc75-430c-91f6-be11cd585943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eb3fd085-cc75-430c-91f6-be11cd585943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_afe3d190-4c4d-4598-8f2f-09cb192f5640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_afe3d190-4c4d-4598-8f2f-09cb192f5640" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_33cf2013-c5e6-4599-aa86-bac6db79f290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:to="loc_us-gaap_InterestReceivable_33cf2013-c5e6-4599-aa86-bac6db79f290" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_abbb83eb-6a7c-45b8-b55a-1e1fa32ef8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:to="loc_us-gaap_DebtInstrumentTable_abbb83eb-6a7c-45b8-b55a-1e1fa32ef8c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfba12d1-b695-4bfa-ac2b-bce29fb6f6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_abbb83eb-6a7c-45b8-b55a-1e1fa32ef8c4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfba12d1-b695-4bfa-ac2b-bce29fb6f6d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bfba12d1-b695-4bfa-ac2b-bce29fb6f6d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfba12d1-b695-4bfa-ac2b-bce29fb6f6d5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bfba12d1-b695-4bfa-ac2b-bce29fb6f6d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_48cf6d43-8e1b-4aa7-b472-df74682192b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfba12d1-b695-4bfa-ac2b-bce29fb6f6d5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_48cf6d43-8e1b-4aa7-b472-df74682192b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1cda6da4-d035-480b-ad9b-74276cf47985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_48cf6d43-8e1b-4aa7-b472-df74682192b7" xlink:to="loc_us-gaap_SeniorNotesMember_1cda6da4-d035-480b-ad9b-74276cf47985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8eb021a1-357a-4a82-99b2-f6e058dd2446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_abbb83eb-6a7c-45b8-b55a-1e1fa32ef8c4" xlink:to="loc_us-gaap_DebtInstrumentAxis_8eb021a1-357a-4a82-99b2-f6e058dd2446" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8eb021a1-357a-4a82-99b2-f6e058dd2446_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8eb021a1-357a-4a82-99b2-f6e058dd2446" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8eb021a1-357a-4a82-99b2-f6e058dd2446_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e8d572f-61f6-45fd-852c-a227ecfbb252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8eb021a1-357a-4a82-99b2-f6e058dd2446" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e8d572f-61f6-45fd-852c-a227ecfbb252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_3d8d72f0-f2ec-4f36-8bc1-b4a403f05487" xlink:href="nktr-20211231.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e8d572f-61f6-45fd-852c-a227ecfbb252" xlink:to="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_3d8d72f0-f2ec-4f36-8bc1-b4a403f05487" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="extended" id="i7e1ec9f6e11a40498c631fd30d1f32ed_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_6feb9e90-3ad8-44b0-8a92-8214717cc58e" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_6feb9e90-3ad8-44b0-8a92-8214717cc58e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_f217540f-679e-471a-927f-cf965b70dd36" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_f217540f-679e-471a-927f-cf965b70dd36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_e2c4411d-49eb-4612-a58c-c77216cd6af4" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_e2c4411d-49eb-4612-a58c-c77216cd6af4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_7d84661a-f766-4aae-909a-94262ea1b4d9" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_7d84661a-f766-4aae-909a-94262ea1b4d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_c9b46afb-153f-4cb8-ac5e-1f17263fd279" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_c9b46afb-153f-4cb8-ac5e-1f17263fd279" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_bbc719bf-e923-4b04-a7f2-e1e716d62682" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_bbc719bf-e923-4b04-a7f2-e1e716d62682" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_21b8b9b3-ae06-4080-8f79-fa4944eb8b90" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementAdditionalIndicationPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_21b8b9b3-ae06-4080-8f79-fa4944eb8b90" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_76d765a8-bbfb-4caa-af7c-0e6b569451ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_76d765a8-bbfb-4caa-af7c-0e6b569451ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f317e6b-b2f4-45ce-aef3-d496b5933c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f317e6b-b2f4-45ce-aef3-d496b5933c00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b9d68d09-f0c4-4c10-b4b4-7e32c31d799c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f317e6b-b2f4-45ce-aef3-d496b5933c00" xlink:to="loc_srt_CounterpartyNameAxis_b9d68d09-f0c4-4c10-b4b4-7e32c31d799c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9d68d09-f0c4-4c10-b4b4-7e32c31d799c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b9d68d09-f0c4-4c10-b4b4-7e32c31d799c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b9d68d09-f0c4-4c10-b4b4-7e32c31d799c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1d2dbd9b-ef49-4d2a-adba-7f5a07d228bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b9d68d09-f0c4-4c10-b4b4-7e32c31d799c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1d2dbd9b-ef49-4d2a-adba-7f5a07d228bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_a144262c-e6d3-4eb8-a0d1-1078a23e91b9" xlink:href="nktr-20211231.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1d2dbd9b-ef49-4d2a-adba-7f5a07d228bf" xlink:to="loc_nktr_SFJPharmaceuticalsMember_a144262c-e6d3-4eb8-a0d1-1078a23e91b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2f10b84c-cc7c-48b9-b4b8-5b499832bc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f317e6b-b2f4-45ce-aef3-d496b5933c00" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2f10b84c-cc7c-48b9-b4b8-5b499832bc5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2f10b84c-cc7c-48b9-b4b8-5b499832bc5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2f10b84c-cc7c-48b9-b4b8-5b499832bc5e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2f10b84c-cc7c-48b9-b4b8-5b499832bc5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d58a4982-2e18-4cae-8424-bb47630fe67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2f10b84c-cc7c-48b9-b4b8-5b499832bc5e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d58a4982-2e18-4cae-8424-bb47630fe67d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CostOfBorrowingMember_9b08d053-4deb-479c-b517-1d6588290522" xlink:href="nktr-20211231.xsd#nktr_CostOfBorrowingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d58a4982-2e18-4cae-8424-bb47630fe67d" xlink:to="loc_nktr_CostOfBorrowingMember_9b08d053-4deb-479c-b517-1d6588290522" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails" xlink:type="extended" id="ie624deee32c8423fb4bcd1d0200ea269_CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76259ea1-3c92-41a3-8311-a2a8f0c5aa80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76259ea1-3c92-41a3-8311-a2a8f0c5aa80" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3bcc8b75-a788-49a4-a6e1-1a714a0cb95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3bcc8b75-a788-49a4-a6e1-1a714a0cb95a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_86ec7554-a5e3-4eb3-8a75-353053e600e4" xlink:href="nktr-20211231.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_86ec7554-a5e3-4eb3-8a75-353053e600e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b2fa699f-6ba0-4ef8-a162-6df28d4951d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b2fa699f-6ba0-4ef8-a162-6df28d4951d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_f715dfb4-d707-4806-b3fc-1b100ee90aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_f715dfb4-d707-4806-b3fc-1b100ee90aa8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a614ca37-5ecd-4de4-8a92-1bdba35d45dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f22837cf-fc22-4cef-af25-6b25ab5da124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76259ea1-3c92-41a3-8311-a2a8f0c5aa80" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f22837cf-fc22-4cef-af25-6b25ab5da124" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_00bb9e83-fb79-4b58-8389-9cbf9316ec30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f22837cf-fc22-4cef-af25-6b25ab5da124" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_00bb9e83-fb79-4b58-8389-9cbf9316ec30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_00bb9e83-fb79-4b58-8389-9cbf9316ec30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_00bb9e83-fb79-4b58-8389-9cbf9316ec30" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_00bb9e83-fb79-4b58-8389-9cbf9316ec30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d7516dd0-7a3f-4450-8d61-51c9f4654cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_00bb9e83-fb79-4b58-8389-9cbf9316ec30" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d7516dd0-7a3f-4450-8d61-51c9f4654cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_dcad0751-6a9c-4114-bf22-bc66e7427c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d7516dd0-7a3f-4450-8d61-51c9f4654cd4" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_dcad0751-6a9c-4114-bf22-bc66e7427c9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9ff49c0-2c96-4a52-9c0f-55f1b182de20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f22837cf-fc22-4cef-af25-6b25ab5da124" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9ff49c0-2c96-4a52-9c0f-55f1b182de20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9ff49c0-2c96-4a52-9c0f-55f1b182de20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9ff49c0-2c96-4a52-9c0f-55f1b182de20" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9ff49c0-2c96-4a52-9c0f-55f1b182de20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e04f9ea3-e214-4836-8b73-517b55619ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9ff49c0-2c96-4a52-9c0f-55f1b182de20" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e04f9ea3-e214-4836-8b73-517b55619ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8dedf5c7-10ee-43cb-9d65-be2c879a6113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e04f9ea3-e214-4836-8b73-517b55619ab6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8dedf5c7-10ee-43cb-9d65-be2c879a6113" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="extended" id="ic16ee88e824f4d6297a02b136e78f99c_OperatingLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:href="nktr-20211231.xsd#nktr_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpace_bd320543-9421-4c31-8f6a-cf41a0f43835" xlink:href="nktr-20211231.xsd#nktr_AreaOfLeasedSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_nktr_AreaOfLeasedSpace_bd320543-9421-4c31-8f6a-cf41a0f43835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1e9f7b0b-925a-40ac-bccf-aeefc7c3dcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_us-gaap_OperatingLeaseCost_1e9f7b0b-925a-40ac-bccf-aeefc7c3dcf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_d2d69409-a574-4d08-bd29-8fd2db85e871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_us-gaap_OperatingLeasePayments_d2d69409-a574-4d08-bd29-8fd2db85e871" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b50ce741-801c-4ab6-8c38-62a469be8ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b50ce741-801c-4ab6-8c38-62a469be8ee7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b96159a0-08cb-46e6-a7e1-04709f67b534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b96159a0-08cb-46e6-a7e1-04709f67b534" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_066f36aa-0c87-4da6-bdfb-7f8ea39c9b9d" xlink:href="nktr-20211231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_nktr_ScheduleOfLeasesTable_066f36aa-0c87-4da6-bdfb-7f8ea39c9b9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_ac14218e-875d-4985-be9f-fa1486ab92ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_ScheduleOfLeasesTable_066f36aa-0c87-4da6-bdfb-7f8ea39c9b9d" xlink:to="loc_us-gaap_LeaseContractualTermAxis_ac14218e-875d-4985-be9f-fa1486ab92ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ac14218e-875d-4985-be9f-fa1486ab92ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ac14218e-875d-4985-be9f-fa1486ab92ba" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ac14218e-875d-4985-be9f-fa1486ab92ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_7bd49bab-0a9d-4248-8686-dc26259c33f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ac14218e-875d-4985-be9f-fa1486ab92ba" xlink:to="loc_us-gaap_LeaseContractualTermDomain_7bd49bab-0a9d-4248-8686-dc26259c33f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_b50315d8-2b20-46e0-9c42-76764a91aae8" xlink:href="nktr-20211231.xsd#nktr_MissionBayLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_7bd49bab-0a9d-4248-8686-dc26259c33f8" xlink:to="loc_nktr_MissionBayLeaseMember_b50315d8-2b20-46e0-9c42-76764a91aae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_27ce8b59-6629-4784-9ffd-2f6600053026" xlink:href="nktr-20211231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_7bd49bab-0a9d-4248-8686-dc26259c33f8" xlink:to="loc_nktr_ThirdStreetLeaseMember_27ce8b59-6629-4784-9ffd-2f6600053026" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesScheduleofOperatingLeaseInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails" xlink:type="extended" id="ib2e4129ebf184084949eab5161066aa7_OperatingLeasesScheduleofOperatingLeaseInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:href="nktr-20211231.xsd#nktr_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpaceDelivered_d702eaaf-636c-4cbb-91f0-0688c432268e" xlink:href="nktr-20211231.xsd#nktr_AreaOfLeasedSpaceDelivered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:to="loc_nktr_AreaOfLeasedSpaceDelivered_d702eaaf-636c-4cbb-91f0-0688c432268e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ab8c6a2b-73c0-4a3e-9cff-9c90e9f74861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ab8c6a2b-73c0-4a3e-9cff-9c90e9f74861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfConsecutiveTermsToExtendLease_f427fb30-f546-4874-8b9d-80cfd6b954a2" xlink:href="nktr-20211231.xsd#nktr_NumberOfConsecutiveTermsToExtendLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:to="loc_nktr_NumberOfConsecutiveTermsToExtendLease_f427fb30-f546-4874-8b9d-80cfd6b954a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeaseExtensionTerm_0d58deb9-dbc5-46e7-9c1b-742641dc0959" xlink:href="nktr-20211231.xsd#nktr_LeaseExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:to="loc_nktr_LeaseExtensionTerm_0d58deb9-dbc5-46e7-9c1b-742641dc0959" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_f25eec48-6648-4b89-9a3b-56123ff2765d" xlink:href="nktr-20211231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:to="loc_nktr_ScheduleOfLeasesTable_f25eec48-6648-4b89-9a3b-56123ff2765d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_ad6cd46b-f4c7-43d3-ae57-21655b75ab29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_ScheduleOfLeasesTable_f25eec48-6648-4b89-9a3b-56123ff2765d" xlink:to="loc_us-gaap_LeaseContractualTermAxis_ad6cd46b-f4c7-43d3-ae57-21655b75ab29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ad6cd46b-f4c7-43d3-ae57-21655b75ab29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ad6cd46b-f4c7-43d3-ae57-21655b75ab29" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ad6cd46b-f4c7-43d3-ae57-21655b75ab29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_9f45eeaf-bd60-4d31-821f-c41122295e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ad6cd46b-f4c7-43d3-ae57-21655b75ab29" xlink:to="loc_us-gaap_LeaseContractualTermDomain_9f45eeaf-bd60-4d31-821f-c41122295e55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_4559802e-75b5-4e4a-93ff-8eecef529eca" xlink:href="nktr-20211231.xsd#nktr_MissionBayLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_9f45eeaf-bd60-4d31-821f-c41122295e55" xlink:to="loc_nktr_MissionBayLeaseMember_4559802e-75b5-4e4a-93ff-8eecef529eca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_d6b840a4-2fde-4374-ad8e-1a41a9ab41a7" xlink:href="nktr-20211231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_9f45eeaf-bd60-4d31-821f-c41122295e55" xlink:to="loc_nktr_ThirdStreetLeaseMember_d6b840a4-2fde-4374-ad8e-1a41a9ab41a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="extended" id="ib4469f05d4e649a88a883f0066aa664c_LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_32e291ac-d6a3-4b9a-8051-34e1a1b49972" xlink:href="nktr-20211231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_32e291ac-d6a3-4b9a-8051-34e1a1b49972" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_93721e76-d251-49fe-80ed-c77db1ffd58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_93721e76-d251-49fe-80ed-c77db1ffd58e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput_8cf098ec-2e91-400b-a1a1-a6d21f6d4180" xlink:href="nktr-20211231.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_RoyaltiesLiabilityMeasurementInput_8cf098ec-2e91-400b-a1a1-a6d21f6d4180" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_385cd248-8fdf-40ce-9057-17d89c879a3a" xlink:href="nktr-20211231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_385cd248-8fdf-40ce-9057-17d89c879a3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_9abd55d9-a8d2-4b38-a431-984c0b7172b0" xlink:href="nktr-20211231.xsd#nktr_TransactionCostsRelatedToRevisedRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_9abd55d9-a8d2-4b38-a431-984c0b7172b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_24ff4673-a356-43fc-a7ae-6880c1bbf04b" xlink:href="nktr-20211231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_24ff4673-a356-43fc-a7ae-6880c1bbf04b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_f461af1b-d83d-4349-928a-7264c31f2e02" xlink:href="nktr-20211231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_f461af1b-d83d-4349-928a-7264c31f2e02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_a7879c59-29c2-4da1-abb1-815c94670f12" xlink:href="nktr-20211231.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_a7879c59-29c2-4da1-abb1-815c94670f12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_a6328a9a-8c3d-413f-9525-4b7e58cde0f8" xlink:href="nktr-20211231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_a6328a9a-8c3d-413f-9525-4b7e58cde0f8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_5a44fa8a-8132-43d3-a86f-18be9d22ace1" xlink:href="nktr-20211231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_5a44fa8a-8132-43d3-a86f-18be9d22ace1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_5a90af2b-802d-430b-a7f4-04f51dbdd124" xlink:href="nktr-20211231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_5a90af2b-802d-430b-a7f4-04f51dbdd124" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4ed2271c-d9e5-43a3-ace3-c1627ac991ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4ed2271c-d9e5-43a3-ace3-c1627ac991ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ed2271c-d9e5-43a3-ace3-c1627ac991ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4ed2271c-d9e5-43a3-ace3-c1627ac991ed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ed2271c-d9e5-43a3-ace3-c1627ac991ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_135adcba-db84-4f2d-a178-db7a9018e0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4ed2271c-d9e5-43a3-ace3-c1627ac991ed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_135adcba-db84-4f2d-a178-db7a9018e0e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_9065d087-84ec-43f7-9557-49579bb0df1c" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_135adcba-db84-4f2d-a178-db7a9018e0e6" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_9065d087-84ec-43f7-9557-49579bb0df1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_e5127188-36ac-4842-bafb-18a6194469be" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_135adcba-db84-4f2d-a178-db7a9018e0e6" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_e5127188-36ac-4842-bafb-18a6194469be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_f9b09083-0bc1-4237-a7df-f0c3b793fb1d" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_135adcba-db84-4f2d-a178-db7a9018e0e6" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_f9b09083-0bc1-4237-a7df-f0c3b793fb1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ee433ab7-4828-4df8-9268-50348ed98f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ee433ab7-4828-4df8-9268-50348ed98f95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ee433ab7-4828-4df8-9268-50348ed98f95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ee433ab7-4828-4df8-9268-50348ed98f95" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ee433ab7-4828-4df8-9268-50348ed98f95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a4147ca-b270-4ca9-bff1-fe79f5dacbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ee433ab7-4828-4df8-9268-50348ed98f95" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a4147ca-b270-4ca9-bff1-fe79f5dacbfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FutureRoyaltiesMember_f29d4b32-d9f3-463a-a622-0bb40a33c397" xlink:href="nktr-20211231.xsd#nktr_FutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a4147ca-b270-4ca9-bff1-fe79f5dacbfa" xlink:to="loc_nktr_FutureRoyaltiesMember_f29d4b32-d9f3-463a-a622-0bb40a33c397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_04867a3a-4503-4356-af20-de7608664164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_04867a3a-4503-4356-af20-de7608664164" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_04867a3a-4503-4356-af20-de7608664164_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_04867a3a-4503-4356-af20-de7608664164" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_04867a3a-4503-4356-af20-de7608664164_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_70b00470-c5b1-451e-888c-7900f78bed34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_04867a3a-4503-4356-af20-de7608664164" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_70b00470-c5b1-451e-888c-7900f78bed34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d8b01fc8-64d1-48b7-a165-4111cb78ba8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_70b00470-c5b1-451e-888c-7900f78bed34" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d8b01fc8-64d1-48b7-a165-4111cb78ba8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputInceptionDiscountRateMember_b008a0b2-f52a-4efb-8e6a-2453369c9e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputInceptionDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_70b00470-c5b1-451e-888c-7900f78bed34" xlink:to="loc_us-gaap_MeasurementInputInceptionDiscountRateMember_b008a0b2-f52a-4efb-8e6a-2453369c9e66" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20211231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="extended" id="i26915b2f88a04914a6987812df9e2151_LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b3a4ccb-33bc-45e2-82a1-1520eed2e284" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b3a4ccb-33bc-45e2-82a1-1520eed2e284" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_15b1d05e-fbdc-4be3-b69a-c3245f47a0e1" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_15b1d05e-fbdc-4be3-b69a-c3245f47a0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds_2e407393-5330-49fe-9e20-36aca520abd0" xlink:href="nktr-20211231.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_RoyaltyMonetizationProceeds_2e407393-5330-49fe-9e20-36aca520abd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c2b2fe14-9220-4114-8d66-59fdd1a51d0b" xlink:href="nktr-20211231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c2b2fe14-9220-4114-8d66-59fdd1a51d0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a08c46c1-2e63-4c1c-ba46-a7861b27616f" xlink:href="nktr-20211231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a08c46c1-2e63-4c1c-ba46-a7861b27616f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_c54dcd0e-c035-4f38-8d96-c47e6a5ecde1" xlink:href="nktr-20211231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_c54dcd0e-c035-4f38-8d96-c47e6a5ecde1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_2d895e9e-969c-42c3-98b5-deb77c25c83c" xlink:href="nktr-20211231.xsd#nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_2d895e9e-969c-42c3-98b5-deb77c25c83c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_073f824d-f61f-4398-9901-c0fcb072b958" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_1bb803bc-b7b4-47c8-a861-914336b85cce" xlink:href="nktr-20211231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_1bb803bc-b7b4-47c8-a861-914336b85cce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_51659ec0-c9b4-4d80-84e6-26d29759b89d" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_51659ec0-c9b4-4d80-84e6-26d29759b89d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_0cf587ee-e731-4209-837a-30d79e5b885f" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b3a4ccb-33bc-45e2-82a1-1520eed2e284" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_0cf587ee-e731-4209-837a-30d79e5b885f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_75203bcb-826f-4824-9b2f-e3c32579aebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_0cf587ee-e731-4209-837a-30d79e5b885f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_75203bcb-826f-4824-9b2f-e3c32579aebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75203bcb-826f-4824-9b2f-e3c32579aebd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_75203bcb-826f-4824-9b2f-e3c32579aebd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75203bcb-826f-4824-9b2f-e3c32579aebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11b92dbd-e862-42c9-bc2c-f20f987c6b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_75203bcb-826f-4824-9b2f-e3c32579aebd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11b92dbd-e862-42c9-bc2c-f20f987c6b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_55eda24b-167a-496a-a365-6c306084369a" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11b92dbd-e862-42c9-bc2c-f20f987c6b0a" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_55eda24b-167a-496a-a365-6c306084369a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_6693c327-7c8e-4178-8670-799f343f3433" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11b92dbd-e862-42c9-bc2c-f20f987c6b0a" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_6693c327-7c8e-4178-8670-799f343f3433" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i9d34177209454855bd7f26c477ceb6a2_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9325f734-feeb-4594-9d24-b560e6a8fdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9325f734-feeb-4594-9d24-b560e6a8fdcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4257ffb9-fad9-4e73-b68f-1c160d6206f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4257ffb9-fad9-4e73-b68f-1c160d6206f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_545d305d-9d12-4486-98e5-35e280fe645c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_545d305d-9d12-4486-98e5-35e280fe645c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_dc4d3fcf-629b-46b1-b765-5afe21a16137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_dc4d3fcf-629b-46b1-b765-5afe21a16137" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_a2a81c56-454f-4dc8-8b2f-1a09717f6764" xlink:href="nktr-20211231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_a2a81c56-454f-4dc8-8b2f-1a09717f6764" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_3ddfe701-90be-48ac-931f-9eb3056905b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_3ddfe701-90be-48ac-931f-9eb3056905b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_3ddfe701-90be-48ac-931f-9eb3056905b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_3ddfe701-90be-48ac-931f-9eb3056905b4" xlink:to="loc_us-gaap_LossContingencyNatureDomain_3ddfe701-90be-48ac-931f-9eb3056905b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_3ddfe701-90be-48ac-931f-9eb3056905b4" xlink:to="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember_58348486-0955-4cfd-98b8-c6b847c072e4" xlink:href="nktr-20211231.xsd#nktr_LegalMattersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:to="loc_nktr_LegalMattersMember_58348486-0955-4cfd-98b8-c6b847c072e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_b16622f7-974e-4185-97cd-2ef0364cf62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_b16622f7-974e-4185-97cd-2ef0364cf62c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_7b643046-c025-4227-a4c3-1c1a6abf886f" xlink:href="nktr-20211231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:to="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_7b643046-c025-4227-a4c3-1c1a6abf886f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuritiesRelatedClaimsMember_b4c08262-3ffd-41a1-b07d-e264287f5dbc" xlink:href="nktr-20211231.xsd#nktr_SecuritiesRelatedClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:to="loc_nktr_SecuritiesRelatedClaimsMember_b4c08262-3ffd-41a1-b07d-e264287f5dbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonSecuritiesRelatedClaimsMember_39b74f1b-8cb8-458d-a006-4c825860b9d6" xlink:href="nktr-20211231.xsd#nktr_NonSecuritiesRelatedClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:to="loc_nktr_NonSecuritiesRelatedClaimsMember_39b74f1b-8cb8-458d-a006-4c825860b9d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ca478cf-22aa-463a-af60-f21ba8230edd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:to="loc_srt_RangeAxis_4ca478cf-22aa-463a-af60-f21ba8230edd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ca478cf-22aa-463a-af60-f21ba8230edd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4ca478cf-22aa-463a-af60-f21ba8230edd" xlink:to="loc_srt_RangeMember_4ca478cf-22aa-463a-af60-f21ba8230edd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05c3a3bc-25c6-4a0c-9a4a-96a66ec41aa7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4ca478cf-22aa-463a-af60-f21ba8230edd" xlink:to="loc_srt_RangeMember_05c3a3bc-25c6-4a0c-9a4a-96a66ec41aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e683fb4b-a723-4488-b41c-3e6e900374fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_05c3a3bc-25c6-4a0c-9a4a-96a66ec41aa7" xlink:to="loc_srt_MaximumMember_e683fb4b-a723-4488-b41c-3e6e900374fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_7a28dce8-67f4-42a2-bdf4-fea010b1b923" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:to="loc_srt_LitigationCaseAxis_7a28dce8-67f4-42a2-bdf4-fea010b1b923" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7a28dce8-67f4-42a2-bdf4-fea010b1b923_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_7a28dce8-67f4-42a2-bdf4-fea010b1b923" xlink:to="loc_srt_LitigationCaseTypeDomain_7a28dce8-67f4-42a2-bdf4-fea010b1b923_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_68829fee-ff09-43ef-88d5-ec7c5549ee11" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_7a28dce8-67f4-42a2-bdf4-fea010b1b923" xlink:to="loc_srt_LitigationCaseTypeDomain_68829fee-ff09-43ef-88d5-ec7c5549ee11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MulquinActionAndDamibaActionMember_7485ddfd-2302-44ff-9c5a-94d94551503d" xlink:href="nktr-20211231.xsd#nktr_MulquinActionAndDamibaActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_68829fee-ff09-43ef-88d5-ec7c5549ee11" xlink:to="loc_nktr_MulquinActionAndDamibaActionMember_7485ddfd-2302-44ff-9c5a-94d94551503d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DerivativeActionMember_1b220898-cef0-47da-8fc4-2afb72fac5c9" xlink:href="nktr-20211231.xsd#nktr_DerivativeActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_68829fee-ff09-43ef-88d5-ec7c5549ee11" xlink:to="loc_nktr_DerivativeActionMember_1b220898-cef0-47da-8fc4-2afb72fac5c9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i5290e4e9a91d41f2b0c6b35bc91de176_StockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7467c998-1dbd-4cee-8a6b-88b96f40acd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fc6e5c12-7835-417c-9554-f680c5a403e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7467c998-1dbd-4cee-8a6b-88b96f40acd7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fc6e5c12-7835-417c-9554-f680c5a403e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_5f47188b-715d-4743-89ae-1a9901471dcf" xlink:href="nktr-20211231.xsd#nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7467c998-1dbd-4cee-8a6b-88b96f40acd7" xlink:to="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_5f47188b-715d-4743-89ae-1a9901471dcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockValueAuthorizedInTransaction_e5ec11c2-a3e7-4ce7-821f-53c58316fae7" xlink:href="nktr-20211231.xsd#nktr_SaleOfStockValueAuthorizedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7467c998-1dbd-4cee-8a6b-88b96f40acd7" xlink:to="loc_nktr_SaleOfStockValueAuthorizedInTransaction_e5ec11c2-a3e7-4ce7-821f-53c58316fae7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f1c09ca4-729e-4985-8ebe-e2d4676e2248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7467c998-1dbd-4cee-8a6b-88b96f40acd7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f1c09ca4-729e-4985-8ebe-e2d4676e2248" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22c593f0-1af7-4f69-932f-38e2fa7ae22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f1c09ca4-729e-4985-8ebe-e2d4676e2248" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_22c593f0-1af7-4f69-932f-38e2fa7ae22b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_22c593f0-1af7-4f69-932f-38e2fa7ae22b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22c593f0-1af7-4f69-932f-38e2fa7ae22b" xlink:to="loc_us-gaap_EquityComponentDomain_22c593f0-1af7-4f69-932f-38e2fa7ae22b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b956398-5283-4686-89ef-60d26cec1734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22c593f0-1af7-4f69-932f-38e2fa7ae22b" xlink:to="loc_us-gaap_EquityComponentDomain_9b956398-5283-4686-89ef-60d26cec1734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ef88873e-55cd-4ae2-8ee6-e5db6776a851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b956398-5283-4686-89ef-60d26cec1734" xlink:to="loc_us-gaap_CommonStockMember_ef88873e-55cd-4ae2-8ee6-e5db6776a851" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended" id="i9b4525f3c55444b59de971db0347b9fe_StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_15ecccfc-e2ed-42f8-b5e9-6571101af27b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0fab24f2-68f8-431b-9f8f-0657b650ea3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15ecccfc-e2ed-42f8-b5e9-6571101af27b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0fab24f2-68f8-431b-9f8f-0657b650ea3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5cd554ec-fb7e-4e4c-a94c-a4b10e598d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_15ecccfc-e2ed-42f8-b5e9-6571101af27b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5cd554ec-fb7e-4e4c-a94c-a4b10e598d93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_da942874-73eb-4438-a725-bdac3047db46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5cd554ec-fb7e-4e4c-a94c-a4b10e598d93" xlink:to="loc_us-gaap_PlanNameAxis_da942874-73eb-4438-a725-bdac3047db46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_da942874-73eb-4438-a725-bdac3047db46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_da942874-73eb-4438-a725-bdac3047db46" xlink:to="loc_us-gaap_PlanNameDomain_da942874-73eb-4438-a725-bdac3047db46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9b755611-3e86-4a8f-9879-2f811995ca55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_da942874-73eb-4438-a725-bdac3047db46" xlink:to="loc_us-gaap_PlanNameDomain_9b755611-3e86-4a8f-9879-2f811995ca55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_e9252cb3-5c8f-4f05-9e36-02693018f367" xlink:href="nktr-20211231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9b755611-3e86-4a8f-9879-2f811995ca55" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_e9252cb3-5c8f-4f05-9e36-02693018f367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember_fcf7443c-4710-4bd9-8815-fbbf232a5c4f" xlink:href="nktr-20211231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9b755611-3e86-4a8f-9879-2f811995ca55" xlink:to="loc_nktr_EmployeeStockPurchasePlanMember_fcf7443c-4710-4bd9-8815-fbbf232a5c4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_52e6b919-4eee-4fdc-859b-6cde689bf3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5cd554ec-fb7e-4e4c-a94c-a4b10e598d93" xlink:to="loc_us-gaap_AwardTypeAxis_52e6b919-4eee-4fdc-859b-6cde689bf3ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52e6b919-4eee-4fdc-859b-6cde689bf3ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_52e6b919-4eee-4fdc-859b-6cde689bf3ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52e6b919-4eee-4fdc-859b-6cde689bf3ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb5742a-92b3-49b7-a935-b44483f88abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_52e6b919-4eee-4fdc-859b-6cde689bf3ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb5742a-92b3-49b7-a935-b44483f88abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_fb4b7a91-a033-4fdb-9ac5-20cc402f10c8" xlink:href="nktr-20211231.xsd#nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb5742a-92b3-49b7-a935-b44483f88abd" xlink:to="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_fb4b7a91-a033-4fdb-9ac5-20cc402f10c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails" xlink:type="extended" id="i389db37a2b574c969468c92d7c6d439b_LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_637d6957-3493-472f-b54e-32b6b6efe928" xlink:href="nktr-20211231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_77020283-7359-4d48-acb1-483c37b3fd27" xlink:href="nktr-20211231.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_637d6957-3493-472f-b54e-32b6b6efe928" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_77020283-7359-4d48-acb1-483c37b3fd27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_fa484ea1-17f6-4d8a-b9dd-8c6bae505495" xlink:href="nktr-20211231.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_637d6957-3493-472f-b54e-32b6b6efe928" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_fa484ea1-17f6-4d8a-b9dd-8c6bae505495" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1025a330-83a3-4382-9bf4-55360637dbaa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_fa484ea1-17f6-4d8a-b9dd-8c6bae505495" xlink:to="loc_dei_LegalEntityAxis_1025a330-83a3-4382-9bf4-55360637dbaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1025a330-83a3-4382-9bf4-55360637dbaa_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1025a330-83a3-4382-9bf4-55360637dbaa" xlink:to="loc_dei_EntityDomain_1025a330-83a3-4382-9bf4-55360637dbaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1025a330-83a3-4382-9bf4-55360637dbaa" xlink:to="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_c0cf1976-56c2-4160-a32d-f69748068d3e" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_c0cf1976-56c2-4160-a32d-f69748068d3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_0d5cad2d-ea36-4370-b541-deb267d1157a" xlink:href="nktr-20211231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:to="loc_nktr_EliLillyAndCompanyMember_0d5cad2d-ea36-4370-b541-deb267d1157a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_fcd7c3ba-91cf-4892-a11e-f3100ee31b48" xlink:href="nktr-20211231.xsd#nktr_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:to="loc_nktr_AmgenIncMember_fcd7c3ba-91cf-4892-a11e-f3100ee31b48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_3beafcb5-9122-4ff7-bd91-e962aac7adb2" xlink:href="nktr-20211231.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:to="loc_nktr_OtherPartnerMember_3beafcb5-9122-4ff7-bd91-e962aac7adb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_534c5c20-1aa0-410a-8172-86883894275e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_fa484ea1-17f6-4d8a-b9dd-8c6bae505495" xlink:to="loc_us-gaap_TypeOfArrangementAxis_534c5c20-1aa0-410a-8172-86883894275e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_534c5c20-1aa0-410a-8172-86883894275e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_534c5c20-1aa0-410a-8172-86883894275e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_534c5c20-1aa0-410a-8172-86883894275e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03fc480c-6c94-4d2c-9ad7-7c5b1b174a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_534c5c20-1aa0-410a-8172-86883894275e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03fc480c-6c94-4d2c-9ad7-7c5b1b174a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BempegaldesleukinMember_d093435e-a065-48aa-883a-c003031cbf12" xlink:href="nktr-20211231.xsd#nktr_BempegaldesleukinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03fc480c-6c94-4d2c-9ad7-7c5b1b174a09" xlink:to="loc_nktr_BempegaldesleukinMember_d093435e-a065-48aa-883a-c003031cbf12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_87c78023-ff28-4793-8e3e-8ec6151993e9" xlink:href="nktr-20211231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03fc480c-6c94-4d2c-9ad7-7c5b1b174a09" xlink:to="loc_nktr_NektarThreeFiveEightMember_87c78023-ff28-4793-8e3e-8ec6151993e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember_2f464a51-8763-4ad9-ac09-49e12432edfa" xlink:href="nktr-20211231.xsd#nktr_NeulastaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03fc480c-6c94-4d2c-9ad7-7c5b1b174a09" xlink:to="loc_nktr_NeulastaMember_2f464a51-8763-4ad9-ac09-49e12432edfa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended" id="i793a41179bda403e994281e8a4a3b145_LicenseandCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_3c7f1ad0-a74b-4e7a-a9b9-3ca9b2027660" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PotentialDevelopmentMilestones_3c7f1ad0-a74b-4e7a-a9b9-3ca9b2027660" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_9202ef24-b32d-43a3-8210-4a7ff484b6e8" xlink:href="nktr-20211231.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_9202ef24-b32d-43a3-8210-4a7ff484b6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_e30b8212-bc32-49b7-b461-39af377e1cf2" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_e30b8212-bc32-49b7-b461-39af377e1cf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_b8926702-e936-476f-9cf4-9984ae4ee71c" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_b8926702-e936-476f-9cf4-9984ae4ee71c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_4345ab6d-4d93-47ca-b030-0b0cca7769ac" xlink:href="nktr-20211231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_4345ab6d-4d93-47ca-b030-0b0cca7769ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a90c5fe3-4680-4b7d-8a98-09b3a0e73ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_SharesIssued_a90c5fe3-4680-4b7d-8a98-09b3a0e73ca6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_fd301d56-ae33-4060-bfe5-be1e3d912e0b" xlink:href="nktr-20211231.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_fd301d56-ae33-4060-bfe5-be1e3d912e0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_3f132a0f-12d1-49b0-929f-b806bf86fa69" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_3f132a0f-12d1-49b0-929f-b806bf86fa69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_96312df0-e936-4a4f-b667-cd2e5efde389" xlink:href="nktr-20211231.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_96312df0-e936-4a4f-b667-cd2e5efde389" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_48b499d8-288d-42b7-af95-0475cdd3ca74" xlink:href="nktr-20211231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_ReimbursementOfExpenses_48b499d8-288d-42b7-af95-0475cdd3ca74" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_62255fc5-dda9-4686-8346-735906b451ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_62255fc5-dda9-4686-8346-735906b451ea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap_c6971609-cd09-4d92-b300-3b048ca38b67" xlink:href="nktr-20211231.xsd#nktr_CompanyShareOfDevelopmentCostsAnnualCap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap_c6971609-cd09-4d92-b300-3b048ca38b67" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_caaaa266-e737-4aaa-8ca3-22f8b07cbb82" xlink:href="nktr-20211231.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_caaaa266-e737-4aaa-8ca3-22f8b07cbb82" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_ba5de2df-1b24-42bb-a8c6-91e237014f7f" xlink:href="nktr-20211231.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_EstimatedFairValueOfShares_ba5de2df-1b24-42bb-a8c6-91e237014f7f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_d0bb5d2a-ed83-4145-a5c2-f3ce1e7f0210" xlink:href="nktr-20211231.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_d0bb5d2a-ed83-4145-a5c2-f3ce1e7f0210" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_f0d3ecd4-67f2-4e2f-8fa3-520468c559b3" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_f0d3ecd4-67f2-4e2f-8fa3-520468c559b3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_467943fd-482a-4a51-9ae4-f85bec079dd5" xlink:href="nktr-20211231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_467943fd-482a-4a51-9ae4-f85bec079dd5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_d1f6dbd8-110b-4c57-aab6-873617ee629c" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_d1f6dbd8-110b-4c57-aab6-873617ee629c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_5bc44d64-2def-4f36-b2b2-fdc6e801d812" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_5bc44d64-2def-4f36-b2b2-fdc6e801d812" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7ed5e2c2-4f83-4f26-935c-196cc27b1222" xlink:href="nktr-20211231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7ed5e2c2-4f83-4f26-935c-196cc27b1222" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_3ff9677b-6ccc-4d79-a721-6b55cf8b9189" xlink:href="nktr-20211231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_3ff9677b-6ccc-4d79-a721-6b55cf8b9189" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_94d6de56-164a-4fd8-9a6d-838802d21111" xlink:href="nktr-20211231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_94d6de56-164a-4fd8-9a6d-838802d21111" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_72174e5e-9729-4d06-82b9-5c20e91326ab" xlink:href="nktr-20211231.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_72174e5e-9729-4d06-82b9-5c20e91326ab" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf36ba72-e909-4f90-922d-0aeba673fd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf36ba72-e909-4f90-922d-0aeba673fd36" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b20dbf89-04f2-45ad-845c-db788af6e6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b20dbf89-04f2-45ad-845c-db788af6e6a2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_3e71862e-91b7-4a0d-b37b-8381781fe729" xlink:href="nktr-20211231.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_3e71862e-91b7-4a0d-b37b-8381781fe729" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8a48e5f6-12a5-4278-8499-11a278603a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8a48e5f6-12a5-4278-8499-11a278603a34" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:href="nktr-20211231.xsd#nktr_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_f81ecce8-a9c4-4a12-be8d-d6f06eab8447_default" xlink:href="nktr-20211231.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:to="loc_nktr_MilestoneDomain_f81ecce8-a9c4-4a12-be8d-d6f06eab8447_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_b2f1bc78-f04d-454b-8c06-8df6d9ffa9aa" xlink:href="nktr-20211231.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:to="loc_nktr_MilestoneDomain_b2f1bc78-f04d-454b-8c06-8df6d9ffa9aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_6c1ae82e-8a8e-4fb4-a2ab-e812d6a4b75b" xlink:href="nktr-20211231.xsd#nktr_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_b2f1bc78-f04d-454b-8c06-8df6d9ffa9aa" xlink:to="loc_nktr_MilestoneOneMember_6c1ae82e-8a8e-4fb4-a2ab-e812d6a4b75b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:to="loc_dei_EntityDomain_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:to="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_61e494d3-17b1-4ef4-bb70-43a4f1f35fe0" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_61e494d3-17b1-4ef4-bb70-43a4f1f35fe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_1fa896c7-879c-4ab0-b375-21b44f05f3b9" xlink:href="nktr-20211231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_EliLillyAndCompanyMember_1fa896c7-879c-4ab0-b375-21b44f05f3b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_77a0f883-322e-466b-84eb-dfc8c224a570" xlink:href="nktr-20211231.xsd#nktr_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_EliLillyMember_77a0f883-322e-466b-84eb-dfc8c224a570" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_306f3b5b-d4a3-4544-8ddb-5d03a23347be" xlink:href="nktr-20211231.xsd#nktr_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_AmgenIncMember_306f3b5b-d4a3-4544-8ddb-5d03a23347be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_29e162fd-224c-4d6e-9b1e-4d78112f84f2" xlink:href="nktr-20211231.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_OtherPartnerMember_29e162fd-224c-4d6e-9b1e-4d78112f84f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TerminatedPartnershipMember_d1fb6c3c-9bfb-4b48-bd65-fe3ecaa79282" xlink:href="nktr-20211231.xsd#nktr_TerminatedPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_TerminatedPartnershipMember_d1fb6c3c-9bfb-4b48-bd65-fe3ecaa79282" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6f25e1a-7307-4e0d-8dc1-497474e88cf8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6f25e1a-7307-4e0d-8dc1-497474e88cf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_1a232b8d-d0ac-4f71-844c-6fd737c8bb0d" xlink:href="nktr-20211231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_BMSCollaborationAgreementMember_1a232b8d-d0ac-4f71-844c-6fd737c8bb0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_08800608-2310-460b-ba96-d21ad9fb80c4" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_08800608-2310-460b-ba96-d21ad9fb80c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_97670512-0c5f-44a4-a835-c5d0f34c17cf" xlink:href="nktr-20211231.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_Nektar358Member_97670512-0c5f-44a4-a835-c5d0f34c17cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_b0a1aae1-97d4-4451-a124-c1e2772dda34" xlink:href="nktr-20211231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_b0a1aae1-97d4-4451-a124-c1e2772dda34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_91947467-361a-4b45-9cc4-d1b0b7d07030" xlink:href="nktr-20211231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_DrugProductDevelopmentMember_91947467-361a-4b45-9cc4-d1b0b7d07030" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_33ffccc4-5b6e-4b87-8c04-be6adc4a1357" xlink:href="nktr-20211231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_NektarThreeFiveEightMember_33ffccc4-5b6e-4b87-8c04-be6adc4a1357" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember_8f28e028-3dd6-499c-ad0d-228475ce99b2" xlink:href="nktr-20211231.xsd#nktr_NektarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_NektarMember_8f28e028-3dd6-499c-ad0d-228475ce99b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65cc343b-1ab1-4468-8c57-40413273de1f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:to="loc_srt_ProductsAndServicesDomain_65cc343b-1ab1-4468-8c57-40413273de1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:to="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_83d9e4b4-6974-48a2-8fee-13f80a9c2a49" xlink:href="nktr-20211231.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:to="loc_nktr_Nektar214Member_83d9e4b4-6974-48a2-8fee-13f80a9c2a49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_a270fdc7-ba2a-4e37-b802-04c4ca60dbbc" xlink:href="nktr-20211231.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:to="loc_nktr_Nektar358Member_a270fdc7-ba2a-4e37-b802-04c4ca60dbbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f2c7b969-a58a-476c-b9f0-fe358e29175b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f2c7b969-a58a-476c-b9f0-fe358e29175b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ae7a36c7-dcdf-4ee5-bd9f-bdc86ac5f1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ae7a36c7-dcdf-4ee5-bd9f-bdc86ac5f1e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_6dc47d3a-d47b-4ed7-85fb-f0cb4554d058" xlink:href="nktr-20211231.xsd#nktr_OpdivoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ae7a36c7-dcdf-4ee5-bd9f-bdc86ac5f1e2" xlink:to="loc_nktr_OpdivoMember_6dc47d3a-d47b-4ed7-85fb-f0cb4554d058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc04c7fb-0389-4482-939a-88e1fa04a25b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:to="loc_srt_RangeMember_bc04c7fb-0389-4482-939a-88e1fa04a25b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:to="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_55cac7da-1c3a-4b3e-b305-34c9f57162e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:to="loc_srt_MaximumMember_55cac7da-1c3a-4b3e-b305-34c9f57162e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4058dce0-d5e4-41a7-8dc3-47cb75ae0a92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:to="loc_srt_MinimumMember_4058dce0-d5e4-41a7-8dc3-47cb75ae0a92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a080b2-82a0-46fb-b1cf-6624bf701875_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a080b2-82a0-46fb-b1cf-6624bf701875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_949137e5-58df-41b5-afcd-2e277233ebf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_949137e5-58df-41b5-afcd-2e277233ebf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_0d85a120-622a-4482-ba6f-43ecea92f037" xlink:href="nktr-20211231.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_949137e5-58df-41b5-afcd-2e277233ebf7" xlink:to="loc_nktr_SharePurchaseAgreementMember_0d85a120-622a-4482-ba6f-43ecea92f037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18d907c9-3964-4493-816b-b124e594c169_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18d907c9-3964-4493-816b-b124e594c169_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_533e69e9-9af0-4e0f-aa71-7ed1826b9858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_533e69e9-9af0-4e0f-aa71-7ed1826b9858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_38689af0-d34e-4054-8ec0-ded9f7c45dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_533e69e9-9af0-4e0f-aa71-7ed1826b9858" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_38689af0-d34e-4054-8ec0-ded9f7c45dac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_9ee8f213-95ef-41ed-82b5-d28e602238ed" xlink:href="nktr-20211231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_9ee8f213-95ef-41ed-82b5-d28e602238ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_07a6d6cf-3e28-41ea-851b-3d6112ef1dd3" xlink:href="nktr-20211231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:to="loc_nktr_DrugProductDevelopmentMember_07a6d6cf-3e28-41ea-851b-3d6112ef1dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_174a91e2-6616-402c-9c53-672eaf85f6f4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_174a91e2-6616-402c-9c53-672eaf85f6f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_10b68426-3cbd-4796-90a1-5cf31813b568" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_10b68426-3cbd-4796-90a1-5cf31813b568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f5aa860b-a841-43f7-b73f-8e1056a9a556" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10b68426-3cbd-4796-90a1-5cf31813b568" xlink:to="loc_srt_ParentCompanyMember_f5aa860b-a841-43f7-b73f-8e1056a9a556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_1d62c316-f60b-494e-bab2-9ab261350d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_1d62c316-f60b-494e-bab2-9ab261350d62" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails_1" xlink:type="simple" xlink:href="nktr-20211231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails_1"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails_1" xlink:type="extended" id="ifcf78c339d5943f18dc255ffa0651952_LicenseandCollaborationAgreementsAdditionalInformationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_3c7f1ad0-a74b-4e7a-a9b9-3ca9b2027660" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PotentialDevelopmentMilestones_3c7f1ad0-a74b-4e7a-a9b9-3ca9b2027660" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_9202ef24-b32d-43a3-8210-4a7ff484b6e8" xlink:href="nktr-20211231.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_9202ef24-b32d-43a3-8210-4a7ff484b6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_e30b8212-bc32-49b7-b461-39af377e1cf2" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_e30b8212-bc32-49b7-b461-39af377e1cf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_b8926702-e936-476f-9cf4-9984ae4ee71c" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_b8926702-e936-476f-9cf4-9984ae4ee71c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_4345ab6d-4d93-47ca-b030-0b0cca7769ac" xlink:href="nktr-20211231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_4345ab6d-4d93-47ca-b030-0b0cca7769ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a90c5fe3-4680-4b7d-8a98-09b3a0e73ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_SharesIssued_a90c5fe3-4680-4b7d-8a98-09b3a0e73ca6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_fd301d56-ae33-4060-bfe5-be1e3d912e0b" xlink:href="nktr-20211231.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_fd301d56-ae33-4060-bfe5-be1e3d912e0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_3f132a0f-12d1-49b0-929f-b806bf86fa69" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_3f132a0f-12d1-49b0-929f-b806bf86fa69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_96312df0-e936-4a4f-b667-cd2e5efde389" xlink:href="nktr-20211231.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_96312df0-e936-4a4f-b667-cd2e5efde389" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_48b499d8-288d-42b7-af95-0475cdd3ca74" xlink:href="nktr-20211231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_ReimbursementOfExpenses_48b499d8-288d-42b7-af95-0475cdd3ca74" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_62255fc5-dda9-4686-8346-735906b451ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_62255fc5-dda9-4686-8346-735906b451ea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap_c6971609-cd09-4d92-b300-3b048ca38b67" xlink:href="nktr-20211231.xsd#nktr_CompanyShareOfDevelopmentCostsAnnualCap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap_c6971609-cd09-4d92-b300-3b048ca38b67" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_caaaa266-e737-4aaa-8ca3-22f8b07cbb82" xlink:href="nktr-20211231.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_caaaa266-e737-4aaa-8ca3-22f8b07cbb82" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_ba5de2df-1b24-42bb-a8c6-91e237014f7f" xlink:href="nktr-20211231.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_EstimatedFairValueOfShares_ba5de2df-1b24-42bb-a8c6-91e237014f7f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_d0bb5d2a-ed83-4145-a5c2-f3ce1e7f0210" xlink:href="nktr-20211231.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_d0bb5d2a-ed83-4145-a5c2-f3ce1e7f0210" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_f0d3ecd4-67f2-4e2f-8fa3-520468c559b3" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_f0d3ecd4-67f2-4e2f-8fa3-520468c559b3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_467943fd-482a-4a51-9ae4-f85bec079dd5" xlink:href="nktr-20211231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_467943fd-482a-4a51-9ae4-f85bec079dd5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_d1f6dbd8-110b-4c57-aab6-873617ee629c" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_d1f6dbd8-110b-4c57-aab6-873617ee629c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_5bc44d64-2def-4f36-b2b2-fdc6e801d812" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_5bc44d64-2def-4f36-b2b2-fdc6e801d812" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7ed5e2c2-4f83-4f26-935c-196cc27b1222" xlink:href="nktr-20211231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7ed5e2c2-4f83-4f26-935c-196cc27b1222" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_3ff9677b-6ccc-4d79-a721-6b55cf8b9189" xlink:href="nktr-20211231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_3ff9677b-6ccc-4d79-a721-6b55cf8b9189" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_94d6de56-164a-4fd8-9a6d-838802d21111" xlink:href="nktr-20211231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_94d6de56-164a-4fd8-9a6d-838802d21111" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_72174e5e-9729-4d06-82b9-5c20e91326ab" xlink:href="nktr-20211231.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_72174e5e-9729-4d06-82b9-5c20e91326ab" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf36ba72-e909-4f90-922d-0aeba673fd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf36ba72-e909-4f90-922d-0aeba673fd36" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b20dbf89-04f2-45ad-845c-db788af6e6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b20dbf89-04f2-45ad-845c-db788af6e6a2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_3e71862e-91b7-4a0d-b37b-8381781fe729" xlink:href="nktr-20211231.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_3e71862e-91b7-4a0d-b37b-8381781fe729" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8a48e5f6-12a5-4278-8499-11a278603a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8a48e5f6-12a5-4278-8499-11a278603a34" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:href="nktr-20211231.xsd#nktr_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_f81ecce8-a9c4-4a12-be8d-d6f06eab8447_default" xlink:href="nktr-20211231.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:to="loc_nktr_MilestoneDomain_f81ecce8-a9c4-4a12-be8d-d6f06eab8447_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_b2f1bc78-f04d-454b-8c06-8df6d9ffa9aa" xlink:href="nktr-20211231.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:to="loc_nktr_MilestoneDomain_b2f1bc78-f04d-454b-8c06-8df6d9ffa9aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_6c1ae82e-8a8e-4fb4-a2ab-e812d6a4b75b" xlink:href="nktr-20211231.xsd#nktr_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_b2f1bc78-f04d-454b-8c06-8df6d9ffa9aa" xlink:to="loc_nktr_MilestoneOneMember_6c1ae82e-8a8e-4fb4-a2ab-e812d6a4b75b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:to="loc_dei_EntityDomain_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:to="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_61e494d3-17b1-4ef4-bb70-43a4f1f35fe0" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_61e494d3-17b1-4ef4-bb70-43a4f1f35fe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_1fa896c7-879c-4ab0-b375-21b44f05f3b9" xlink:href="nktr-20211231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_EliLillyAndCompanyMember_1fa896c7-879c-4ab0-b375-21b44f05f3b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_77a0f883-322e-466b-84eb-dfc8c224a570" xlink:href="nktr-20211231.xsd#nktr_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_EliLillyMember_77a0f883-322e-466b-84eb-dfc8c224a570" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_306f3b5b-d4a3-4544-8ddb-5d03a23347be" xlink:href="nktr-20211231.xsd#nktr_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_AmgenIncMember_306f3b5b-d4a3-4544-8ddb-5d03a23347be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_29e162fd-224c-4d6e-9b1e-4d78112f84f2" xlink:href="nktr-20211231.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_OtherPartnerMember_29e162fd-224c-4d6e-9b1e-4d78112f84f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TerminatedPartnershipMember_d1fb6c3c-9bfb-4b48-bd65-fe3ecaa79282" xlink:href="nktr-20211231.xsd#nktr_TerminatedPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_TerminatedPartnershipMember_d1fb6c3c-9bfb-4b48-bd65-fe3ecaa79282" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6f25e1a-7307-4e0d-8dc1-497474e88cf8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6f25e1a-7307-4e0d-8dc1-497474e88cf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_1a232b8d-d0ac-4f71-844c-6fd737c8bb0d" xlink:href="nktr-20211231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_BMSCollaborationAgreementMember_1a232b8d-d0ac-4f71-844c-6fd737c8bb0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_08800608-2310-460b-ba96-d21ad9fb80c4" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_08800608-2310-460b-ba96-d21ad9fb80c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_97670512-0c5f-44a4-a835-c5d0f34c17cf" xlink:href="nktr-20211231.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_Nektar358Member_97670512-0c5f-44a4-a835-c5d0f34c17cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_b0a1aae1-97d4-4451-a124-c1e2772dda34" xlink:href="nktr-20211231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_b0a1aae1-97d4-4451-a124-c1e2772dda34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_91947467-361a-4b45-9cc4-d1b0b7d07030" xlink:href="nktr-20211231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_DrugProductDevelopmentMember_91947467-361a-4b45-9cc4-d1b0b7d07030" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_33ffccc4-5b6e-4b87-8c04-be6adc4a1357" xlink:href="nktr-20211231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_NektarThreeFiveEightMember_33ffccc4-5b6e-4b87-8c04-be6adc4a1357" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember_8f28e028-3dd6-499c-ad0d-228475ce99b2" xlink:href="nktr-20211231.xsd#nktr_NektarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_NektarMember_8f28e028-3dd6-499c-ad0d-228475ce99b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65cc343b-1ab1-4468-8c57-40413273de1f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:to="loc_srt_ProductsAndServicesDomain_65cc343b-1ab1-4468-8c57-40413273de1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:to="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_83d9e4b4-6974-48a2-8fee-13f80a9c2a49" xlink:href="nktr-20211231.xsd#nktr_Nektar214Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:to="loc_nktr_Nektar214Member_83d9e4b4-6974-48a2-8fee-13f80a9c2a49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_a270fdc7-ba2a-4e37-b802-04c4ca60dbbc" xlink:href="nktr-20211231.xsd#nktr_Nektar358Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:to="loc_nktr_Nektar358Member_a270fdc7-ba2a-4e37-b802-04c4ca60dbbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f2c7b969-a58a-476c-b9f0-fe358e29175b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f2c7b969-a58a-476c-b9f0-fe358e29175b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ae7a36c7-dcdf-4ee5-bd9f-bdc86ac5f1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ae7a36c7-dcdf-4ee5-bd9f-bdc86ac5f1e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_6dc47d3a-d47b-4ed7-85fb-f0cb4554d058" xlink:href="nktr-20211231.xsd#nktr_OpdivoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ae7a36c7-dcdf-4ee5-bd9f-bdc86ac5f1e2" xlink:to="loc_nktr_OpdivoMember_6dc47d3a-d47b-4ed7-85fb-f0cb4554d058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc04c7fb-0389-4482-939a-88e1fa04a25b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:to="loc_srt_RangeMember_bc04c7fb-0389-4482-939a-88e1fa04a25b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:to="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_55cac7da-1c3a-4b3e-b305-34c9f57162e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:to="loc_srt_MaximumMember_55cac7da-1c3a-4b3e-b305-34c9f57162e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4058dce0-d5e4-41a7-8dc3-47cb75ae0a92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:to="loc_srt_MinimumMember_4058dce0-d5e4-41a7-8dc3-47cb75ae0a92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a080b2-82a0-46fb-b1cf-6624bf701875_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a080b2-82a0-46fb-b1cf-6624bf701875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_949137e5-58df-41b5-afcd-2e277233ebf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_949137e5-58df-41b5-afcd-2e277233ebf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_0d85a120-622a-4482-ba6f-43ecea92f037" xlink:href="nktr-20211231.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_949137e5-58df-41b5-afcd-2e277233ebf7" xlink:to="loc_nktr_SharePurchaseAgreementMember_0d85a120-622a-4482-ba6f-43ecea92f037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18d907c9-3964-4493-816b-b124e594c169_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18d907c9-3964-4493-816b-b124e594c169_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_533e69e9-9af0-4e0f-aa71-7ed1826b9858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_533e69e9-9af0-4e0f-aa71-7ed1826b9858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_38689af0-d34e-4054-8ec0-ded9f7c45dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_533e69e9-9af0-4e0f-aa71-7ed1826b9858" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_38689af0-d34e-4054-8ec0-ded9f7c45dac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_9ee8f213-95ef-41ed-82b5-d28e602238ed" xlink:href="nktr-20211231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_9ee8f213-95ef-41ed-82b5-d28e602238ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_07a6d6cf-3e28-41ea-851b-3d6112ef1dd3" xlink:href="nktr-20211231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:to="loc_nktr_DrugProductDevelopmentMember_07a6d6cf-3e28-41ea-851b-3d6112ef1dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_174a91e2-6616-402c-9c53-672eaf85f6f4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_174a91e2-6616-402c-9c53-672eaf85f6f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_10b68426-3cbd-4796-90a1-5cf31813b568" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_10b68426-3cbd-4796-90a1-5cf31813b568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f5aa860b-a841-43f7-b73f-8e1056a9a556" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10b68426-3cbd-4796-90a1-5cf31813b568" xlink:to="loc_srt_ParentCompanyMember_f5aa860b-a841-43f7-b73f-8e1056a9a556" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i015a409a18fa48c097763d2a07acf8f3_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b24f1ce1-8d42-418e-8a2a-a499d8a2c751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b24f1ce1-8d42-418e-8a2a-a499d8a2c751" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_94afbb55-d564-4fad-9aff-5de551e12260" xlink:href="nktr-20211231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_94afbb55-d564-4fad-9aff-5de551e12260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_7724bf32-e09b-46ff-bc11-ec09bfbf89f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_7724bf32-e09b-46ff-bc11-ec09bfbf89f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_77981ae2-14a9-4c17-9bb2-e69c6a192294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_77981ae2-14a9-4c17-9bb2-e69c6a192294" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_a5191b03-0392-426e-a898-b54ea963a375" xlink:href="nktr-20211231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForExecutives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_a5191b03-0392-426e-a898-b54ea963a375" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_416f1b6d-1289-4fb0-84f7-dd784bc86f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_416f1b6d-1289-4fb0-84f7-dd784bc86f92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e4c9b641-0641-4b1a-b9ed-42d478bbba1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e4c9b641-0641-4b1a-b9ed-42d478bbba1b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1b9d6b29-094c-4ba6-9428-6709183f52d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1b9d6b29-094c-4ba6-9428-6709183f52d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8121932f-4bb0-4225-9f14-9e11fe90789d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8121932f-4bb0-4225-9f14-9e11fe90789d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_276fb978-da03-4aee-ba55-8384441fc6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_276fb978-da03-4aee-ba55-8384441fc6d5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_62b35a4a-175a-4541-9272-39cf8b29f466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_62b35a4a-175a-4541-9272-39cf8b29f466" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6922dc67-fd4e-420f-a84f-89609ef8e27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6922dc67-fd4e-420f-a84f-89609ef8e27e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4f12deac-b12c-4567-ac4b-8afa742f06d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4f12deac-b12c-4567-ac4b-8afa742f06d6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ed505c91-a898-4863-8256-401760703f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ed505c91-a898-4863-8256-401760703f19" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_8a70fd2f-b8ab-4dc3-84e4-4baaa22a1440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_8a70fd2f-b8ab-4dc3-84e4-4baaa22a1440" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_ab8dd7c5-ae71-41f6-ae44-3d17a9fc1e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_ab8dd7c5-ae71-41f6-ae44-3d17a9fc1e61" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7228a8de-5e02-4c44-93f1-26d419a98883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:to="loc_us-gaap_AwardTypeAxis_7228a8de-5e02-4c44-93f1-26d419a98883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7228a8de-5e02-4c44-93f1-26d419a98883_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7228a8de-5e02-4c44-93f1-26d419a98883" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7228a8de-5e02-4c44-93f1-26d419a98883_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7228a8de-5e02-4c44-93f1-26d419a98883" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_52125142-55f0-4c63-a144-fb338b78a798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:to="loc_us-gaap_EmployeeStockOptionMember_52125142-55f0-4c63-a144-fb338b78a798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RSUsAndPSUsMember_a30d8474-0d58-4ba5-a52e-998b1b5383cd" xlink:href="nktr-20211231.xsd#nktr_RSUsAndPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:to="loc_nktr_RSUsAndPSUsMember_a30d8474-0d58-4ba5-a52e-998b1b5383cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_60eaa884-8e6b-4af3-be3d-f652ca1e6680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:to="loc_us-gaap_EmployeeStockMember_60eaa884-8e6b-4af3-be3d-f652ca1e6680" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_57358802-c3a8-448c-8c3a-01622ff54138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_57358802-c3a8-448c-8c3a-01622ff54138" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_da70740f-d33f-4a00-8825-f95bb102c89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:to="loc_us-gaap_PlanNameAxis_da70740f-d33f-4a00-8825-f95bb102c89f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_da70740f-d33f-4a00-8825-f95bb102c89f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_da70740f-d33f-4a00-8825-f95bb102c89f" xlink:to="loc_us-gaap_PlanNameDomain_da70740f-d33f-4a00-8825-f95bb102c89f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_270d74ba-a6df-4d0c-b08c-7aaf38aebcac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_da70740f-d33f-4a00-8825-f95bb102c89f" xlink:to="loc_us-gaap_PlanNameDomain_270d74ba-a6df-4d0c-b08c-7aaf38aebcac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_cee410d2-647a-45bc-9983-a7aab4ccb90f" xlink:href="nktr-20211231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_270d74ba-a6df-4d0c-b08c-7aaf38aebcac" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_cee410d2-647a-45bc-9983-a7aab4ccb90f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember_14c5fcc2-ab18-47c6-a003-00f19099b146" xlink:href="nktr-20211231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_270d74ba-a6df-4d0c-b08c-7aaf38aebcac" xlink:to="loc_nktr_EmployeeStockPurchasePlanMember_14c5fcc2-ab18-47c6-a003-00f19099b146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b4b18795-06d8-433d-b477-460b99e07a5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:to="loc_srt_TitleOfIndividualAxis_b4b18795-06d8-433d-b477-460b99e07a5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b4b18795-06d8-433d-b477-460b99e07a5d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b4b18795-06d8-433d-b477-460b99e07a5d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b4b18795-06d8-433d-b477-460b99e07a5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_72d0bea5-f389-4cee-8695-81654bbac137" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b4b18795-06d8-433d-b477-460b99e07a5d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_72d0bea5-f389-4cee-8695-81654bbac137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeMember_99279087-bd7e-48ab-9ee2-f455571474f4" xlink:href="nktr-20211231.xsd#nktr_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_72d0bea5-f389-4cee-8695-81654bbac137" xlink:to="loc_nktr_EmployeeMember_99279087-bd7e-48ab-9ee2-f455571474f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_fb3e3dd4-3fdf-45fa-abf4-231e9cfdb062" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_72d0bea5-f389-4cee-8695-81654bbac137" xlink:to="loc_srt_DirectorMember_fb3e3dd4-3fdf-45fa-abf4-231e9cfdb062" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended" id="i313a22f4ab644d3889996673178dfe4a_StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_129947ab-3d82-40a3-a7fd-22ede244a960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2257eed6-342c-4b37-93b9-5443bbeae79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_129947ab-3d82-40a3-a7fd-22ede244a960" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2257eed6-342c-4b37-93b9-5443bbeae79a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5643e1d0-76cf-42e5-8441-c850284f35d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_129947ab-3d82-40a3-a7fd-22ede244a960" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5643e1d0-76cf-42e5-8441-c850284f35d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f2f5cbd3-bf25-4cab-9c06-7180d45db709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5643e1d0-76cf-42e5-8441-c850284f35d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f2f5cbd3-bf25-4cab-9c06-7180d45db709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f2f5cbd3-bf25-4cab-9c06-7180d45db709_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2f5cbd3-bf25-4cab-9c06-7180d45db709" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f2f5cbd3-bf25-4cab-9c06-7180d45db709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2f5cbd3-bf25-4cab-9c06-7180d45db709" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3ffbd569-c7e2-4125-aad3-f2a4e16cf0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:to="loc_us-gaap_CostOfSalesMember_3ffbd569-c7e2-4125-aad3-f2a4e16cf0e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e9a2acd9-52d3-4f90-ad8d-5f14061561d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e9a2acd9-52d3-4f90-ad8d-5f14061561d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f29876d6-bd07-489f-b0d0-3b5a67c5e190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f29876d6-bd07-489f-b0d0-3b5a67c5e190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_c98838b1-e786-41df-a967-a8aa9028b4b7" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_c98838b1-e786-41df-a967-a8aa9028b4b7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails" xlink:type="extended" id="i5b162fdd4ed14c1c9880a3c37e4c7645_StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab63314a-2e9f-4caf-a019-41c60af6a796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab63314a-2e9f-4caf-a019-41c60af6a796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07af484c-f767-455f-b8a0-3abb1e2d3cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07af484c-f767-455f-b8a0-3abb1e2d3cdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b0e5e8e4-0fce-4c20-a481-594a4aa1de4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b0e5e8e4-0fce-4c20-a481-594a4aa1de4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0b3170b8-14ee-460a-a1c7-52d11967a520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0b3170b8-14ee-460a-a1c7-52d11967a520" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c1192468-bc4a-4963-ac51-13251ccd2b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c1192468-bc4a-4963-ac51-13251ccd2b8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77e285ea-9c72-4b0a-9b5b-4bdd4d57b8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab63314a-2e9f-4caf-a019-41c60af6a796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_477e4d49-2cb5-4f87-880d-761617954cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_477e4d49-2cb5-4f87-880d-761617954cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_810a218d-66f7-4789-8dcc-441ce966a902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_810a218d-66f7-4789-8dcc-441ce966a902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1433d6f1-2af8-48b5-9d2e-ac837247bede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1433d6f1-2af8-48b5-9d2e-ac837247bede" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f1a3f671-3290-4a55-83b5-a914f786ab06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f1a3f671-3290-4a55-83b5-a914f786ab06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e54238b3-8062-4a36-b7ff-1dc4cde74f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a5aae33-718f-46c9-b206-df28662f2286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab63314a-2e9f-4caf-a019-41c60af6a796" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a5aae33-718f-46c9-b206-df28662f2286" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7d4b2ff5-6546-407e-8a2d-530c4c9ba098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a5aae33-718f-46c9-b206-df28662f2286" xlink:to="loc_us-gaap_AwardTypeAxis_7d4b2ff5-6546-407e-8a2d-530c4c9ba098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d4b2ff5-6546-407e-8a2d-530c4c9ba098_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7d4b2ff5-6546-407e-8a2d-530c4c9ba098" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d4b2ff5-6546-407e-8a2d-530c4c9ba098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f467522a-ca54-447e-b483-7a2ca2687b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7d4b2ff5-6546-407e-8a2d-530c4c9ba098" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f467522a-ca54-447e-b483-7a2ca2687b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_16eebcc3-f466-411e-8e3f-fa8dacf197b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f467522a-ca54-447e-b483-7a2ca2687b3f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_16eebcc3-f466-411e-8e3f-fa8dacf197b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i8d4ea5b221db4331a63a6e9e02f0f040_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:href="nktr-20211231.xsd#nktr_IncomeTaxesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cf6e1604-a394-4421-a906-e9e4f5754877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cf6e1604-a394-4421-a906-e9e4f5754877" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetOperatingLossCarryforwardForIncomeTax_6e84c8ab-8628-4f01-8655-cbbb9daf11c6" xlink:href="nktr-20211231.xsd#nktr_NetOperatingLossCarryforwardForIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_nktr_NetOperatingLossCarryforwardForIncomeTax_6e84c8ab-8628-4f01-8655-cbbb9daf11c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_549a8b30-b241-4859-afed-2ed57bfebf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_549a8b30-b241-4859-afed-2ed57bfebf2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FederalOrphanDrugCredits_1b24c70a-9909-4fbc-8058-7441028ca0ea" xlink:href="nktr-20211231.xsd#nktr_FederalOrphanDrugCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_nktr_FederalOrphanDrugCredits_1b24c70a-9909-4fbc-8058-7441028ca0ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_480aaeb2-7f58-49e8-97dd-1c65345cf739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_480aaeb2-7f58-49e8-97dd-1c65345cf739" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_f3f7d5f6-8a12-4c32-be42-726ae41964fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_f3f7d5f6-8a12-4c32-be42-726ae41964fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_a7e475c6-3b4d-4cb8-b38b-cee97e2b418b" xlink:href="nktr-20211231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_a7e475c6-3b4d-4cb8-b38b-cee97e2b418b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureTable_8067123c-44cb-4b9c-9851-cd55acc4c8a0" xlink:href="nktr-20211231.xsd#nktr_IncomeTaxesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_nktr_IncomeTaxesDisclosureTable_8067123c-44cb-4b9c-9851-cd55acc4c8a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_697f2431-6d04-4dc9-9d55-0a23129f14c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_IncomeTaxesDisclosureTable_8067123c-44cb-4b9c-9851-cd55acc4c8a0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_697f2431-6d04-4dc9-9d55-0a23129f14c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_697f2431-6d04-4dc9-9d55-0a23129f14c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_697f2431-6d04-4dc9-9d55-0a23129f14c5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_697f2431-6d04-4dc9-9d55-0a23129f14c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1b49b5ac-81ae-4d54-a670-6ca7a8b2db5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_697f2431-6d04-4dc9-9d55-0a23129f14c5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1b49b5ac-81ae-4d54-a670-6ca7a8b2db5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c5eae0be-4f34-4cad-985e-69d637d3d0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1b49b5ac-81ae-4d54-a670-6ca7a8b2db5c" xlink:to="loc_us-gaap_DomesticCountryMember_c5eae0be-4f34-4cad-985e-69d637d3d0ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9e6312c6-4c4d-4210-b7da-2b12fd00cea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1b49b5ac-81ae-4d54-a670-6ca7a8b2db5c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9e6312c6-4c4d-4210-b7da-2b12fd00cea0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended" id="i5812a0c0998d4511a250703b07ddb3b4_SegmentReportingAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_124fb6ca-f95e-473f-956f-c45abd2bb442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfOperatingBusinessSegment_5574d13e-d516-4416-b854-9b760278d194" xlink:href="nktr-20211231.xsd#nktr_NumberOfOperatingBusinessSegment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_124fb6ca-f95e-473f-956f-c45abd2bb442" xlink:to="loc_nktr_NumberOfOperatingBusinessSegment_5574d13e-d516-4416-b854-9b760278d194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_47689116-8f21-4792-9618-a8661e961772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_124fb6ca-f95e-473f-956f-c45abd2bb442" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_47689116-8f21-4792-9618-a8661e961772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5cf2a71-962d-4b13-a4a3-06b9ff30a68e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_124fb6ca-f95e-473f-956f-c45abd2bb442" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5cf2a71-962d-4b13-a4a3-06b9ff30a68e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_124fb6ca-f95e-473f-956f-c45abd2bb442" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_657e19b2-5272-4acf-8f9a-779f69283d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_657e19b2-5272-4acf-8f9a-779f69283d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_657e19b2-5272-4acf-8f9a-779f69283d0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_657e19b2-5272-4acf-8f9a-779f69283d0c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_657e19b2-5272-4acf-8f9a-779f69283d0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84d96e2f-8622-4160-af97-2748e521c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_657e19b2-5272-4acf-8f9a-779f69283d0c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84d96e2f-8622-4160-af97-2748e521c5b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_372dac64-2dfe-49bf-adf8-512f75f7dbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84d96e2f-8622-4160-af97-2748e521c5b9" xlink:to="loc_us-gaap_SalesRevenueNetMember_372dac64-2dfe-49bf-adf8-512f75f7dbdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_f5650d8b-c7f7-401c-84b3-c5eb60250b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84d96e2f-8622-4160-af97-2748e521c5b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_f5650d8b-c7f7-401c-84b3-c5eb60250b42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0b077b87-6bef-4701-b67e-ae977724dd2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_srt_MajorCustomersAxis_0b077b87-6bef-4701-b67e-ae977724dd2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0b077b87-6bef-4701-b67e-ae977724dd2f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0b077b87-6bef-4701-b67e-ae977724dd2f" xlink:to="loc_srt_NameOfMajorCustomerDomain_0b077b87-6bef-4701-b67e-ae977724dd2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0b077b87-6bef-4701-b67e-ae977724dd2f" xlink:to="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UCBPharmaMember_76819973-404b-497e-85b9-f1f4b2b5abf8" xlink:href="nktr-20211231.xsd#nktr_UCBPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:to="loc_nktr_UCBPharmaMember_76819973-404b-497e-85b9-f1f4b2b5abf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_0e8f358e-8e8f-423a-9a28-ca435b1d3531" xlink:href="nktr-20211231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_0e8f358e-8e8f-423a-9a28-ca435b1d3531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_1f99317a-43f0-4262-b289-a72f4cc4e8dc" xlink:href="nktr-20211231.xsd#nktr_AstraZenecaAbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:to="loc_nktr_AstraZenecaAbMember_1f99317a-43f0-4262-b289-a72f4cc4e8dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PfizerMember_34b7a737-3086-4beb-bd6b-57d2c6d195e8" xlink:href="nktr-20211231.xsd#nktr_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:to="loc_nktr_PfizerMember_34b7a737-3086-4beb-bd6b-57d2c6d195e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_742d7394-e124-4a2b-89ab-caaf9d2d3aee" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_742d7394-e124-4a2b-89ab-caaf9d2d3aee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f31694ca-2c12-4acd-a057-50828b4f3955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f31694ca-2c12-4acd-a057-50828b4f3955" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f31694ca-2c12-4acd-a057-50828b4f3955_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f31694ca-2c12-4acd-a057-50828b4f3955" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f31694ca-2c12-4acd-a057-50828b4f3955_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3997a2a5-3420-4f91-b93a-e2f7c310df33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f31694ca-2c12-4acd-a057-50828b4f3955" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3997a2a5-3420-4f91-b93a-e2f7c310df33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a5fa891f-b7f5-4e52-8a94-138276d98f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3997a2a5-3420-4f91-b93a-e2f7c310df33" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a5fa891f-b7f5-4e52-8a94-138276d98f57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_884cf915-16ae-4017-afbe-ced98b17b220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3997a2a5-3420-4f91-b93a-e2f7c310df33" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_884cf915-16ae-4017-afbe-ced98b17b220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cbda1701-0cc6-4bb4-933c-83122e8b46b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_srt_StatementGeographicalAxis_cbda1701-0cc6-4bb4-933c-83122e8b46b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cbda1701-0cc6-4bb4-933c-83122e8b46b1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cbda1701-0cc6-4bb4-933c-83122e8b46b1" xlink:to="loc_srt_SegmentGeographicalDomain_cbda1701-0cc6-4bb4-933c-83122e8b46b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_993bb247-9e04-4907-9170-1391e30898f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cbda1701-0cc6-4bb4-933c-83122e8b46b1" xlink:to="loc_srt_SegmentGeographicalDomain_993bb247-9e04-4907-9170-1391e30898f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7324f35d-8149-4e20-b1fe-a24dde3cab61" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_993bb247-9e04-4907-9170-1391e30898f9" xlink:to="loc_country_US_7324f35d-8149-4e20-b1fe-a24dde3cab61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_866d9f5c-c1f0-4d4c-a7fc-03d43a168d41" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_993bb247-9e04-4907-9170-1391e30898f9" xlink:to="loc_country_IN_866d9f5c-c1f0-4d4c-a7fc-03d43a168d41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b97470a5-d802-47c4-a5c9-6e46455bf997" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_srt_ConsolidationItemsAxis_b97470a5-d802-47c4-a5c9-6e46455bf997" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b97470a5-d802-47c4-a5c9-6e46455bf997_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_b97470a5-d802-47c4-a5c9-6e46455bf997" xlink:to="loc_srt_ConsolidationItemsDomain_b97470a5-d802-47c4-a5c9-6e46455bf997_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0a19bb6d-6928-425d-af49-cb6c648f059f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_b97470a5-d802-47c4-a5c9-6e46455bf997" xlink:to="loc_srt_ConsolidationItemsDomain_0a19bb6d-6928-425d-af49-cb6c648f059f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_b255b8ce-fcfc-4f08-bae9-dd8d372666eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_0a19bb6d-6928-425d-af49-cb6c648f059f" xlink:to="loc_srt_ReportableGeographicalComponentsMember_b255b8ce-fcfc-4f08-bae9-dd8d372666eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="simple" xlink:href="nktr-20211231.xsd#SegmentReportingRevenuebyGeographicAreaDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="extended" id="iccc780bf4bd0421e91e34cae2a54261e_SegmentReportingRevenuebyGeographicAreaDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_548b0672-1f61-47d5-9a87-7c2820a6188e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_0f7e2908-3da2-429c-959d-dd503582a05e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_548b0672-1f61-47d5-9a87-7c2820a6188e" xlink:to="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_0f7e2908-3da2-429c-959d-dd503582a05e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0a46282-dbd1-4993-8bb4-556bbdbe0595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_0f7e2908-3da2-429c-959d-dd503582a05e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0a46282-dbd1-4993-8bb4-556bbdbe0595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b99f4e4c-bb0a-4533-9512-db373bba762c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_548b0672-1f61-47d5-9a87-7c2820a6188e" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b99f4e4c-bb0a-4533-9512-db373bba762c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_daf187cd-5394-40c8-9df2-f9bb8778c498" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b99f4e4c-bb0a-4533-9512-db373bba762c" xlink:to="loc_srt_StatementGeographicalAxis_daf187cd-5394-40c8-9df2-f9bb8778c498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_daf187cd-5394-40c8-9df2-f9bb8778c498_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_daf187cd-5394-40c8-9df2-f9bb8778c498" xlink:to="loc_srt_SegmentGeographicalDomain_daf187cd-5394-40c8-9df2-f9bb8778c498_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_72f3061b-a0f4-40ab-84f9-984bf2da5e85" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_daf187cd-5394-40c8-9df2-f9bb8778c498" xlink:to="loc_srt_SegmentGeographicalDomain_72f3061b-a0f4-40ab-84f9-984bf2da5e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c1ee1177-011a-486f-8c8b-1c1a239960de" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_72f3061b-a0f4-40ab-84f9-984bf2da5e85" xlink:to="loc_country_US_c1ee1177-011a-486f-8c8b-1c1a239960de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_3f6c04b1-52ad-4846-83b3-836d6a569a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_72f3061b-a0f4-40ab-84f9-984bf2da5e85" xlink:to="loc_us-gaap_NonUsMember_3f6c04b1-52ad-4846-83b3-836d6a569a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5b244009-2550-4790-8bb0-03d7ba9cf536" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b99f4e4c-bb0a-4533-9512-db373bba762c" xlink:to="loc_srt_ConsolidationItemsAxis_5b244009-2550-4790-8bb0-03d7ba9cf536" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5b244009-2550-4790-8bb0-03d7ba9cf536_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_5b244009-2550-4790-8bb0-03d7ba9cf536" xlink:to="loc_srt_ConsolidationItemsDomain_5b244009-2550-4790-8bb0-03d7ba9cf536_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cca692ac-f070-47e2-9369-46aa50f4a905" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_5b244009-2550-4790-8bb0-03d7ba9cf536" xlink:to="loc_srt_ConsolidationItemsDomain_cca692ac-f070-47e2-9369-46aa50f4a905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_15ee7a6a-b077-40dc-bb3b-115fe45f504d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_cca692ac-f070-47e2-9369-46aa50f4a905" xlink:to="loc_srt_ReportableGeographicalComponentsMember_15ee7a6a-b077-40dc-bb3b-115fe45f504d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#SelectedQuarterlyFinancialDataDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails" xlink:type="extended" id="i74c49ed0c5c940fd81fae54b6f03caab_SelectedQuarterlyFinancialDataDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:href="nktr-20211231.xsd#nktr_SelectedQuarterlyFinancialDataLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_47ebef14-2c2d-4ca9-94aa-d77d5a2eb1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_47ebef14-2c2d-4ca9-94aa-d77d5a2eb1f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2c6ccdbf-5f0b-4f7a-a45c-9acfdd049365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2c6ccdbf-5f0b-4f7a-a45c-9acfdd049365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_62e1a09e-ef56-446d-8bd1-f0a95775144e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_62e1a09e-ef56-446d-8bd1-f0a95775144e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8f91fe15-1ec0-403f-8f79-b42baac88980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_OperatingIncomeLoss_8f91fe15-1ec0-403f-8f79-b42baac88980" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c0414ac-e3d9-45b5-83b0-1100ffc58e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_NetIncomeLoss_2c0414ac-e3d9-45b5-83b0-1100ffc58e5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1588a556-14f9-4eea-8019-14b47fa43fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1588a556-14f9-4eea-8019-14b47fa43fa3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_62008ce7-64b9-46d1-bc90-1a3279dcb5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1588a556-14f9-4eea-8019-14b47fa43fa3" xlink:to="loc_us-gaap_EarningsPerShareBasic_62008ce7-64b9-46d1-bc90-1a3279dcb5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_48cf44b3-b159-4fa6-9d55-95ea5da2d7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1588a556-14f9-4eea-8019-14b47fa43fa3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_48cf44b3-b159-4fa6-9d55-95ea5da2d7bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataTable_56b3b431-f059-412d-83cf-475a92914525" xlink:href="nktr-20211231.xsd#nktr_SelectedQuarterlyFinancialDataTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_nktr_SelectedQuarterlyFinancialDataTable_56b3b431-f059-412d-83cf-475a92914525" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d2108ef5-fd22-4a9b-a7f8-6eed0556affd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataTable_56b3b431-f059-412d-83cf-475a92914525" xlink:to="loc_srt_ProductOrServiceAxis_d2108ef5-fd22-4a9b-a7f8-6eed0556affd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2108ef5-fd22-4a9b-a7f8-6eed0556affd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d2108ef5-fd22-4a9b-a7f8-6eed0556affd" xlink:to="loc_srt_ProductsAndServicesDomain_d2108ef5-fd22-4a9b-a7f8-6eed0556affd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8e3afb78-21e9-49e1-8ea2-75ea56771e4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d2108ef5-fd22-4a9b-a7f8-6eed0556affd" xlink:to="loc_srt_ProductsAndServicesDomain_8e3afb78-21e9-49e1-8ea2-75ea56771e4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5edb3604-4cf6-41ac-929a-abe37575d3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8e3afb78-21e9-49e1-8ea2-75ea56771e4a" xlink:to="loc_us-gaap_ProductMember_5edb3604-4cf6-41ac-929a-abe37575d3d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>nktr-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b154c77f-11f5-433c-8e4e-b6be98e0afac,g:2cfcd135-9f36-4467-b376-e4c05a9fe6a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_nktr_SecuritiesRelatedClaimsMember_9fcf0c8b-231b-4ae9-bbab-82893b40620c_terseLabel_en-US" xlink:label="lab_nktr_SecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Related Claims</link:label>
    <link:label id="lab_nktr_SecuritiesRelatedClaimsMember_label_en-US" xlink:label="lab_nktr_SecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Related Claims [Member]</link:label>
    <link:label id="lab_nktr_SecuritiesRelatedClaimsMember_documentation_en-US" xlink:label="lab_nktr_SecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities related claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuritiesRelatedClaimsMember" xlink:href="nktr-20211231.xsd#nktr_SecuritiesRelatedClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SecuritiesRelatedClaimsMember" xlink:to="lab_nktr_SecuritiesRelatedClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_846c788f-d7ec-452b-aad8-d13327d900ee_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value at</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d11469f8-c38e-4820-a258-752913ce5ef8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_0d761138-24b0-4d05-80b3-f51f00035e8e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e7342b61-8fbc-4ab2-9ef2-c2f32e059e5f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_23055e4c-e5e9-4f3f-99c9-1c05366a51f8_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a4c24060-6eb3-432e-a953-c41998c2b61e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c23a836-9041-4122-a820-102b3e787597_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_33c4b256-1fee-4cd4-bfa9-43a9258d290d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b832aeda-8977-4f8f-a28c-5bc27bd9c878_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0bffb7ff-efe0-4aae-8ce8-04d0db1270a8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_149ffd2e-c180-4930-adc6-4638ee230b50_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1771544c-8312-4130-a938-8433fc75273d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PfizerMember_48ba0c47-6431-4450-95eb-6877353c8760_terseLabel_en-US" xlink:label="lab_nktr_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_nktr_PfizerMember_label_en-US" xlink:label="lab_nktr_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_nktr_PfizerMember_documentation_en-US" xlink:label="lab_nktr_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PfizerMember" xlink:href="nktr-20211231.xsd#nktr_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PfizerMember" xlink:to="lab_nktr_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_429a1a77-bc00-45bb-8f59-8af54b84cdb7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_93a7bf57-e0e6-4b01-ad76-1d81f74f3ae8_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_cbff28d2-b8bb-4a26-8752-bdc7eef512d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f1aa7f6f-29e9-4016-a035-867e4c40d76c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_eea49e38-42e5-4ac3-9812-fa8ac5084820_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_76c88798-24ca-49b0-a053-e7ca9d38b2bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MissionBayLeaseMember_e27fa622-67ba-4ce3-81ae-653d10a9518e_terseLabel_en-US" xlink:label="lab_nktr_MissionBayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mission Bay Facility</link:label>
    <link:label id="lab_nktr_MissionBayLeaseMember_label_en-US" xlink:label="lab_nktr_MissionBayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mission Bay Lease [Member]</link:label>
    <link:label id="lab_nktr_MissionBayLeaseMember_documentation_en-US" xlink:label="lab_nktr_MissionBayLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mission bay lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember" xlink:href="nktr-20211231.xsd#nktr_MissionBayLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MissionBayLeaseMember" xlink:to="lab_nktr_MissionBayLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8ce0dff6-d188-4b69-b548-482bfc650172_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DerivativeActionMember_0625ee5c-b39a-4334-86c7-769cb888b4e8_terseLabel_en-US" xlink:label="lab_nktr_DerivativeActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Action</link:label>
    <link:label id="lab_nktr_DerivativeActionMember_label_en-US" xlink:label="lab_nktr_DerivativeActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Action [Member]</link:label>
    <link:label id="lab_nktr_DerivativeActionMember_documentation_en-US" xlink:label="lab_nktr_DerivativeActionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DerivativeActionMember" xlink:href="nktr-20211231.xsd#nktr_DerivativeActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DerivativeActionMember" xlink:to="lab_nktr_DerivativeActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarMember_b3951bf1-fab1-4ff8-abf4-c096604eea8d_terseLabel_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar</link:label>
    <link:label id="lab_nktr_NektarMember_label_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar [Member]</link:label>
    <link:label id="lab_nktr_NektarMember_documentation_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember" xlink:href="nktr-20211231.xsd#nktr_NektarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarMember" xlink:to="lab_nktr_NektarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_4b759bbb-01aa-47af-a600-b2a743c97399_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_938d7bfe-993b-4d35-ad59-0befe304e664_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_69df5291-c025-4197-9487-fff4d101d8f4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_83457beb-2e46-4f1e-9035-b34a84ad4bdd_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_62587b4e-f640-4fab-9f49-5f64d76015f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c8fb8705-bea4-4d6d-b1c5-f168050a1b03_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b3ef30b8-aaf1-4470-9e4c-72d0c16cf04f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited and canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2e88326b-c181-4060-850f-d8a4e8052ab1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_31016b6c-16ad-484a-9bed-01b089c61daa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2287f81d-cf5c-4f9f-b055-1d1c258b251b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_005dcc53-5ed7-46d4-b4ae-ff6d7eacc2b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3b14912b-46fb-446e-b611-74d3a644f412_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares available for stock options grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmgenIncMember_2cb6ac5b-721a-49d2-a151-3422cbc0e010_terseLabel_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen, Inc.</link:label>
    <link:label id="lab_nktr_AmgenIncMember_a1fef385-c211-46e0-b7c4-10bdabb12cba_verboseLabel_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen, Inc.</link:label>
    <link:label id="lab_nktr_AmgenIncMember_label_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Inc [Member]</link:label>
    <link:label id="lab_nktr_AmgenIncMember_documentation_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember" xlink:href="nktr-20211231.xsd#nktr_AmgenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmgenIncMember" xlink:to="lab_nktr_AmgenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8b913904-e0ad-4e1c-b5e1-9d716b10b524_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4f827760-3eac-4dc0-a554-55e08e1d4eb9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_66ae2246-48a2-4851-a646-854dcf520218_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_868b6046-f6cf-4575-8c22-a247183b2d2d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c1642a3d-a493-4c82-922f-934d0b8fd21c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_db937816-8f4c-41a2-b4a6-f8cade957f65_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment_da58165c-c0b5-4ae1-a4e1-b1b6e8a2ba05_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional indication payment</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Indication Payment</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Additional Indication Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementAdditionalIndicationPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:to="lab_nktr_CollaborativeArrangementAdditionalIndicationPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OpdivoMember_7ca56813-9931-4dd3-a52a-7dc13e0b4298_terseLabel_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo</link:label>
    <link:label id="lab_nktr_OpdivoMember_label_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo [Member]</link:label>
    <link:label id="lab_nktr_OpdivoMember_documentation_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember" xlink:href="nktr-20211231.xsd#nktr_OpdivoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoMember" xlink:to="lab_nktr_OpdivoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_df0332e6-85b6-4351-825d-475eeb717fc6_terseLabel_en-US" xlink:label="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, RSUs And PSUs</link:label>
    <link:label id="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_label_en-US" xlink:label="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, RSUs And PSUs [Member]</link:label>
    <link:label id="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_documentation_en-US" xlink:label="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, RSUs And PSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:href="nktr-20211231.xsd#nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:to="lab_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d250fb7-2d18-4c63-af71-e480072567e5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_ed62cdc6-2169-4ab7-b249-6ec3dc322b67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UCBPharmaMember_c4c81770-2ee2-4258-9026-c088c662e78e_terseLabel_en-US" xlink:label="lab_nktr_UCBPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB</link:label>
    <link:label id="lab_nktr_UCBPharmaMember_label_en-US" xlink:label="lab_nktr_UCBPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U C B Pharma [Member]</link:label>
    <link:label id="lab_nktr_UCBPharmaMember_documentation_en-US" xlink:label="lab_nktr_UCBPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UCBPharmaMember" xlink:href="nktr-20211231.xsd#nktr_UCBPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UCBPharmaMember" xlink:to="lab_nktr_UCBPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EmployeeStockPurchasePlanMember_474f0a2f-c38e-46d9-b0c3-48a32ad26065_terseLabel_en-US" xlink:label="lab_nktr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_nktr_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_nktr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_nktr_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_nktr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember" xlink:href="nktr-20211231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EmployeeStockPurchasePlanMember" xlink:to="lab_nktr_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AuditorInformationAbstract_label_en-US" xlink:label="lab_nktr_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_nktr_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_nktr_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AuditorInformationAbstract" xlink:href="nktr-20211231.xsd#nktr_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AuditorInformationAbstract" xlink:to="lab_nktr_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c845e5b3-2cb9-4920-be33-0e61bf93e426_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_75e1d879-e171-4238-88f4-65e113722dff_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_f7fe20c6-bd42-4b95-a269-96c4fd4abd4f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_492f68a9-c93e-4a38-bd07-9410b88e305e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_61b4b33e-9b12-490f-9635-f2cfc66cb0ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bdbe3390-32ec-40d1-9c34-09ced8038669_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1df66c33-850e-4dbe-878e-a39eb245e2c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_46924b37-a9cc-4ab3-a881-aa5b728cb6ee_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_label_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:href="nktr-20211231.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:to="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_138368bc-1e25-4aac-925a-db790a487cbe_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1423bf62-b75c-4587-a04a-98f33b1b5b04_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_897e34b5-a6f3-4332-a813-84fc1caa5d3a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_cc246fb8-d457-4cdc-88d2-114cc183ecf3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_fa790374-7730-4ebc-bb41-c510b34bf800_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_15c00bab-16f7-482d-a8a9-e69140e18dca_terseLabel_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_label_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_documentation_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:href="nktr-20211231.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:to="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_712cdec9-d585-49d3-a6e7-d607e369a92a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c97d6ccc-c71d-4208-b1ee-68570980dbcd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1eafac76-67be-420f-bfe0-0cceca61039b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of restricted stock vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_371f6d20-2aae-419a-8e12-b52659138ec5_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:href="nktr-20211231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a9c1dcb-9391-4ddc-9e57-0c47feed0e37_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e73457e0-884a-4bd7-8135-d362236c47ae_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_6ce72e92-0bb4-46a6-89af-18cf23f7baaa_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Phase Two Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a52190fb-75b7-4fb1-8684-37255c039f98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_54e84422-46df-4b05-b2cf-c04d239f81d5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_11cf77d1-97d4-4fb6-8a19-67acaf0437b3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d78b85c9-362f-42bf-9be6-a42b2468e618_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_55a17eec-bbd2-48ff-90a3-a291960847b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b28c28a-632c-432e-92b0-03344ac3ee43_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_be34a7ba-292b-4fac-a8ad-1c038c7dfa07_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage revenue from customers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_63a57ca6-012c-4977-8af8-42e527336c08_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2021 or 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8805d0e6-4914-4cdf-8a8b-1141a1b342be_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_fea582af-50e3-4463-a0da-9b60baa87193_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing production costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Production Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in production costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInProductionCosts" xlink:to="lab_nktr_PercentageOfSharingInProductionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c7013562-0e4d-4fb2-9a29-34dc94871146_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f85dceee-6a00-49a9-a471-88a4f1cc8912_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_4c29c099-5e50-4dd2-ba8e-9d4af3d48d5a_negatedLabel_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized transaction costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_label_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities On Sale Of Future Royalties Unamortized Transaction Costs</link:label>
    <link:label id="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_documentation_en-US" xlink:label="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities on sale of future royalties, unamortized transaction costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:href="nktr-20211231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:to="lab_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9bf08f8c-f483-4519-82da-cf761ec27f3a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_6cdeb549-0dd4-4377-83b4-d0cdf5aca119_terseLabel_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B M S Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember" xlink:href="nktr-20211231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BMSCollaborationAgreementMember" xlink:to="lab_nktr_BMSCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncomeTaxesDisclosureTable_f27ee9df-de33-4a88-81fa-b02cd8dca91c_terseLabel_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureTable_label_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureTable_documentation_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureTable" xlink:href="nktr-20211231.xsd#nktr_IncomeTaxesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncomeTaxesDisclosureTable" xlink:to="lab_nktr_IncomeTaxesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_ed0243d0-f5f9-4f97-8ba9-c85ed110d212_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OtherPartnerMember_94bf327d-8bc7-4170-b6ef-a73c9d06c881_terseLabel_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_label_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner [Member]</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_documentation_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember" xlink:href="nktr-20211231.xsd#nktr_OtherPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OtherPartnerMember" xlink:to="lab_nktr_OtherPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_e34b46b8-fdb0-4a31-bea2-2854d452bff9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from development derivative liability</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_62188335-a2b5-465d-8cc8-621115340fcb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_7e89d218-bc46-4d94-81b0-a0b094ba81c9_negatedLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_62ec2eac-0b37-4db6-be5e-e84f7142b603_negatedTerseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash royalty revenue related to sale future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20211231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c3a86c1a-f89e-420a-ba2c-245d18622770_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_31608827-289f-4d70-a7d4-944202a91b01_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e6149967-1ea8-4156-b9fa-038309d542ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_2fece61c-5d8c-4904-8ad2-3b48a8f71e60_terseLabel_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.75% Senior Secured Notes Due October 2020</link:label>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_label_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seven Point Seven Five Percent Senior Secured Notes Due October Two Thousand And Twenty [Member]</link:label>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_documentation_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seven point seven five percent senior secured notes due October two thousand and twenty.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:href="nktr-20211231.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:to="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6e9206ef-25fc-46b8-960e-128660b6a1d5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockValueAuthorizedInTransaction_6ef1f12f-3aea-4541-84da-501299318480_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_nktr_SaleOfStockValueAuthorizedInTransaction_label_en-US" xlink:label="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Value Authorized In Transaction</link:label>
    <link:label id="lab_nktr_SaleOfStockValueAuthorizedInTransaction_documentation_en-US" xlink:label="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Value Authorized In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:href="nktr-20211231.xsd#nktr_SaleOfStockValueAuthorizedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:to="lab_nktr_SaleOfStockValueAuthorizedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_23298dc2-e1e1-4807-a6d2-7d1c8d282c67_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets recognized in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ea79b969-38da-4ae7-a3b5-553b3efcb062_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_FederalOrphanDrugCredits_5d0072b5-d596-4583-a96b-62e48fb245cd_terseLabel_en-US" xlink:label="lab_nktr_FederalOrphanDrugCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal orphan drug credits</link:label>
    <link:label id="lab_nktr_FederalOrphanDrugCredits_label_en-US" xlink:label="lab_nktr_FederalOrphanDrugCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Orphan Drug Credits</link:label>
    <link:label id="lab_nktr_FederalOrphanDrugCredits_documentation_en-US" xlink:label="lab_nktr_FederalOrphanDrugCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal orphan drug credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FederalOrphanDrugCredits" xlink:href="nktr-20211231.xsd#nktr_FederalOrphanDrugCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_FederalOrphanDrugCredits" xlink:to="lab_nktr_FederalOrphanDrugCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e60ebebd-0bc8-4460-89df-7cb9f64f60d3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_72d65d4d-081a-41bd-98bd-1064ce2a45f3_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_51ad3a4d-5d06-47ca-8993-267e7ed24dcf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_25326866-8546-4a55-b00e-165efa11c480_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7463c977-9442-4b63-9cca-18e08a0ec15e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a50c0fb0-382c-4a79-8786-f69b8183609a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_97f5c0c9-2284-413b-965c-56e678fe171d_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:href="nktr-20211231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AreaOfLeasedSpaceDelivered_bb749294-f04e-41a1-a70a-5ff4670c1d1f_terseLabel_en-US" xlink:label="lab_nktr_AreaOfLeasedSpaceDelivered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased space delivered (in sq ft)</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpaceDelivered_label_en-US" xlink:label="lab_nktr_AreaOfLeasedSpaceDelivered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Leased Space Delivered</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpaceDelivered_documentation_en-US" xlink:label="lab_nktr_AreaOfLeasedSpaceDelivered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased space delivered.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpaceDelivered" xlink:href="nktr-20211231.xsd#nktr_AreaOfLeasedSpaceDelivered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AreaOfLeasedSpaceDelivered" xlink:to="lab_nktr_AreaOfLeasedSpaceDelivered" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_bffa0a83-6940-497b-b8a4-8620bf093525_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:to="lab_nktr_BristolMyersSquibbCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_7c86f17f-e724-4ca5-b360-3d9524916291_negatedLabel_en-US" xlink:label="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_label_en-US" xlink:label="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</link:label>
    <link:label id="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_documentation_en-US" xlink:label="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:href="nktr-20211231.xsd#nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:to="lab_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_2f93acb5-a9b7-459d-af03-64d5957aab8b_negatedLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liabilities related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_be71f9ed-a1e4-4f71-a5c3-693ecfdce3d2_terseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liabilities related to sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_519776df-2850-4a81-b36b-1784582e4c55_verboseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_label_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:href="nktr-20211231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_672d731e-ec93-461d-9627-2316e7c0b314_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_72305066-e449-4e44-9a54-addb3d8abd2f_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional payments for development milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestones" xlink:to="lab_nktr_PotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MulquinActionAndDamibaActionMember_8239e947-628a-440a-828c-bc3c906e357e_terseLabel_en-US" xlink:label="lab_nktr_MulquinActionAndDamibaActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mulquin Action And Damiba Action</link:label>
    <link:label id="lab_nktr_MulquinActionAndDamibaActionMember_label_en-US" xlink:label="lab_nktr_MulquinActionAndDamibaActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mulquin Action And Damiba Action [Member]</link:label>
    <link:label id="lab_nktr_MulquinActionAndDamibaActionMember_documentation_en-US" xlink:label="lab_nktr_MulquinActionAndDamibaActionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mulquin Action And Damiba Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MulquinActionAndDamibaActionMember" xlink:href="nktr-20211231.xsd#nktr_MulquinActionAndDamibaActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MulquinActionAndDamibaActionMember" xlink:to="lab_nktr_MulquinActionAndDamibaActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ec46eb0f-0a1c-4bf6-a7a9-7f199bef7e4d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic ( in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_1fa696bb-10f0-4d69-b9e7-0af6f042aca6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previous claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_3ef69f3c-5320-4c33-a72c-c3842af95c51_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_10d400f1-4c88-416e-acc1-3efa81ef9a90_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner_ca6a5293-4d20-4bf1-9d9a-493edeef698d_terseLabel_en-US" xlink:label="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net expense reimbursements from collaboration partner</link:label>
    <link:label id="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner_label_en-US" xlink:label="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Expense Reimbursements From Collaboration Partner</link:label>
    <link:label id="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner_documentation_en-US" xlink:label="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net expense reimbursements from collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:href="nktr-20211231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:to="lab_nktr_NetExpenseReimbursementsFromCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_155c72dc-f337-405c-979b-13d8618ab246_terseLabel_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 Clinical Development</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_label_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase One Clinical Development [Member]</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_documentation_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 clinical development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember" xlink:href="nktr-20211231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PhaseOneClinicalDevelopmentMember" xlink:to="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4064f3f5-5208-4e8f-bb95-5c666a385ce2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb7197d9-831f-46b3-a1c7-9e90042896a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7db49f95-7a50-4bea-9af4-9d6df64f3954_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at inception on February 12, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9d597c79-9445-42b5-a1bd-4fba183731fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_8e27063f-8940-42fb-858d-7f56f1131476_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_656a9adb-87a2-4cbf-b5e3-0339fddecbc8_totalLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties non current net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_d6265722-2365-481e-9fdb-1d83e8d81df1_verboseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received From License Agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:href="nktr-20211231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_9b2ee25f-026b-48ac-9c69-c1d7f1ca3e1e_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future development, regulatory and sales milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Regulatory And Sales Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development regulatory and sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:to="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_77ef10b5-700c-4483-b74c-2bc203fb3957_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_929b497c-7c80-4337-805b-7504bc5953dc_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_c6eac922-0932-464b-96ad-8a12848a241f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense in connection with 401(k) retirement plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_42a73f05-7aac-484f-a04e-594b16b861c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units Issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_643e9a38-a01c-4aa1-823e-66257a3bc59f_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:href="nktr-20211231.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NumberOfOperatingBusinessSegment_9daa5aa6-e547-46b8-a349-b8b2c07d5907_terseLabel_en-US" xlink:label="lab_nktr_NumberOfOperatingBusinessSegment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating business segment</link:label>
    <link:label id="lab_nktr_NumberOfOperatingBusinessSegment_label_en-US" xlink:label="lab_nktr_NumberOfOperatingBusinessSegment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Business Segment</link:label>
    <link:label id="lab_nktr_NumberOfOperatingBusinessSegment_documentation_en-US" xlink:label="lab_nktr_NumberOfOperatingBusinessSegment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating business segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfOperatingBusinessSegment" xlink:href="nktr-20211231.xsd#nktr_NumberOfOperatingBusinessSegment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfOperatingBusinessSegment" xlink:to="lab_nktr_NumberOfOperatingBusinessSegment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_4ca2d7d1-68ca-403f-9e60-20b525ed471b_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_0104ba0f-ed17-48f4-8b83-5655c780295c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d7e46650-5375-4477-835e-2923d227d40d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_4f3a1357-7d59-4de9-b861-be1a14ae2d34_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_1592d129-b255-402e-8f83-013d601e2dfc_terseLabel_en-US" xlink:label="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting unit evaluated for goodwill</link:label>
    <link:label id="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_label_en-US" xlink:label="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reporting Units To Evaluate Goodwill For Impairment</link:label>
    <link:label id="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_documentation_en-US" xlink:label="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units to evaluate goodwill for impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:href="nktr-20211231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:to="lab_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_a8b458ea-c1a8-4d51-8907-73dfec0e9e37_negatedTerseLabel_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to RPI</link:label>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_label_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial Repayment Of Royalty Sale Proceeds</link:label>
    <link:label id="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds_documentation_en-US" xlink:label="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial repayment of royalty sale proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:href="nktr-20211231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:to="lab_nktr_PartialRepaymentOfRoyaltySaleProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_d710c4a8-baab-43f5-8d9a-ac3b9fb0e27e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_01d413df-ea9c-41ad-83b1-e52ae6299d2a_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Related to the Sales of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_WriteOffOfPrepayment_b2ee2f7e-23a5-4fc3-9718-a11cd32d1cf3_terseLabel_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of prepayment</link:label>
    <link:label id="lab_nktr_WriteOffOfPrepayment_label_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Prepayment</link:label>
    <link:label id="lab_nktr_WriteOffOfPrepayment_documentation_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Prepayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment" xlink:href="nktr-20211231.xsd#nktr_WriteOffOfPrepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_WriteOffOfPrepayment" xlink:to="lab_nktr_WriteOffOfPrepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_2ea37545-cb7d-4cb7-bd7d-18ff69451800_terseLabel_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_label_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization [Policy Text Block]</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock" xlink:href="nktr-20211231.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationPolicyTextBlock" xlink:to="lab_nktr_OrganizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_1498a801-26a6-468e-a188-a4da2c42f5ea_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pursuant to the 2012 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase And Sale Agreement [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and sale agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreementMember" xlink:to="lab_nktr_PurchaseAndSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_1113486d-7ca8-4fc4-a640-353a53ed4ed1_terseLabel_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_nktr_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_nktr_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember" xlink:href="nktr-20211231.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LaboratoryEquipmentMember" xlink:to="lab_nktr_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_e3376dfc-3617-41bf-b540-4f385d1be7ee_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets and other costs for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Assets And Other Costs For Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equipment and other costs for terminated program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AstraZenecaAbMember_881adc6f-de25-4a34-8e5a-ae1964f59c6d_terseLabel_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Ab</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_label_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Ab [Member]</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_documentation_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca AB.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember" xlink:href="nktr-20211231.xsd#nktr_AstraZenecaAbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AstraZenecaAbMember" xlink:to="lab_nktr_AstraZenecaAbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CostOfBorrowingMember_682ebb07-3e44-40e7-aaeb-0943d40f815b_terseLabel_en-US" xlink:label="lab_nktr_CostOfBorrowingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Borrowing</link:label>
    <link:label id="lab_nktr_CostOfBorrowingMember_label_en-US" xlink:label="lab_nktr_CostOfBorrowingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Borrowing [Member]</link:label>
    <link:label id="lab_nktr_CostOfBorrowingMember_documentation_en-US" xlink:label="lab_nktr_CostOfBorrowingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Borrowing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CostOfBorrowingMember" xlink:href="nktr-20211231.xsd#nktr_CostOfBorrowingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CostOfBorrowingMember" xlink:to="lab_nktr_CostOfBorrowingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_52f329fc-8225-49a3-8013-dd6ba8d5179f_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f63b76e5-bccd-46e8-a493-febb02712942_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4a8c5992-30b9-4e31-9fee-86f3ba2f4f9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cba50751-7416-46b5-bbbc-4fa36074ef96_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7c430aef-cb46-4e9c-a10d-3821f5f27db8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_303b4cbe-eae5-4aa6-8a44-08d52fcceadd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_02e437a3-8dd0-462f-917f-b65f31e7b0a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_dd3af2d5-052c-4773-951d-25007f41ace4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_8b30f322-1b51-4188-b899-6fde02b02aad_terseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received upfront and milestone payment</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="nktr-20211231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_50645bd2-ec9a-495d-9bfc-2e5e9b83df92_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_55ebc659-f639-401d-8127-88a8bc561c57_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_4cdbaac8-3b87-4123-9fe1-26f17247c93f_terseLabel_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to revised royalty payments</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_label_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Related To Revised Royalty Payments</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_documentation_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Related To Revised Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:href="nktr-20211231.xsd#nktr_TransactionCostsRelatedToRevisedRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:to="lab_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_53fe3815-ed03-4bd2-9605-c84937229afe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_5448e32e-da56-4150-89ac-3adfd13c2d22_terseLabel_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_label_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses Current</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:href="nktr-20211231.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:to="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_3afac8c4-3063-456e-a8f6-42b27bc53bc5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0c07e589-655d-4b4c-8795-efb00957e3ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2d35f9c6-7c7b-413a-b65e-4093cd0fd4ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_aeb95900-151d-4deb-8d99-61462e8e8942_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Abstract]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Abstract]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_761574e4-9522-4681-b349-7f0be3e59c73_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations of U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_c999dd8c-2a66-48f2-a617-b0e6c7f03cca_terseLabel_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount allocated to transaction price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_label_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Amount Allocated To Transaction Price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_documentation_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount allocated to transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:href="nktr-20211231.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:to="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_03a59962-3dc0-4d1f-b316-d993361025f5_terseLabel_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_8f85bd1b-26f1-47ca-b577-bb8889fbf98e_negatedTerseLabel_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties</link:label>
    <link:label id="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:href="nktr-20211231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:to="lab_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7eccd4-7517-409b-906e-961e5ba18e54_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputInceptionDiscountRateMember_7f4ef074-7dc8-49cc-a09e-239aca807348_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputInceptionDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Inception Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputInceptionDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputInceptionDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f5fa8670-e2d4-48f7-8977-a1c30b8d8e6d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6d5da115-2d07-4a44-b85b-2d01aaeff2bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_571c2d46-5f5a-4505-8338-cdf458653ab5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_d64d3d2e-84d5-4379-a9df-9d644922e39c_terseLabel_en-US" xlink:label="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations under Director and Officer Indemnifications per incident</link:label>
    <link:label id="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_label_en-US" xlink:label="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations Under Director And Officer Indemnifications Per Incident</link:label>
    <link:label id="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_documentation_en-US" xlink:label="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations under director and officer indemnifications per incident.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:href="nktr-20211231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:to="lab_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4799acca-784d-4951-bfe4-61879fbc11bc_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract_367b6f3a-38a0-40c4-a893-2517f404bcb0_terseLabel_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax positions related to prior years:</link:label>
    <link:label id="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract_label_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related To Prior Years [Abstract]</link:label>
    <link:label id="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract_documentation_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related To Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:href="nktr-20211231.xsd#nktr_TaxPositionsRelatedToPriorYearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:to="lab_nktr_TaxPositionsRelatedToPriorYearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_c5b5a726-aee3-4de9-8c0a-5e5d0fe4ebd8_terseLabel_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_label_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Furniture And Other [Member]</link:label>
    <link:label id="lab_nktr_ComputerFurnitureAndOtherMember_documentation_en-US" xlink:label="lab_nktr_ComputerFurnitureAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture computer and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember" xlink:href="nktr-20211231.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ComputerFurnitureAndOtherMember" xlink:to="lab_nktr_ComputerFurnitureAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_850dda0e-c441-4826-9d20-f927d6ea606b_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d1e54cce-bddc-4023-bd77-3037f9fa5777_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d50be31e-0a13-4e04-8493-9c89b04ba04e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a542828c-c567-4c59-8031-35f84d0bc5df_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap_437961e5-0d0f-49e9-9612-3f7d37cb5b11_terseLabel_en-US" xlink:label="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company share of development costs, annual cap</link:label>
    <link:label id="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap_label_en-US" xlink:label="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Share Of Development Costs, Annual Cap</link:label>
    <link:label id="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap_documentation_en-US" xlink:label="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Share Of Development Costs, Annual Cap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:href="nktr-20211231.xsd#nktr_CompanyShareOfDevelopmentCostsAnnualCap"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:to="lab_nktr_CompanyShareOfDevelopmentCostsAnnualCap" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e86e5bf2-df23-47e7-ae2d-e55b18ad3148_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_fa60fd69-4bab-4840-951b-d0cbaa33e4ac_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3596d869-c534-4f3b-a3a8-03c7fad639f8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6e334fd8-c712-499d-bd8d-df1753a831a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1267ff70-db1a-432a-9feb-9e6e45330fe2_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_bb135630-a962-4aa6-b8f0-0837c02d86b9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_80163c51-e104-4085-8f46-1bf9189ab711_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_bcef2063-2a26-46eb-8b96-80ddbdaf4d02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average volatility factor</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_db603dbe-42e1-453b-8183-8c9c92eaa74f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e63098e-889d-4f81-b100-0df6ae1dbf35_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cadf3540-b436-49c6-9593-1c1a32bfc277_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfLeasesTable_1d802540-fd1e-49c1-8edb-59b8d83afa0d_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfLeasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Leases [Table]</link:label>
    <link:label id="lab_nktr_ScheduleOfLeasesTable_label_en-US" xlink:label="lab_nktr_ScheduleOfLeasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Leases [Table]</link:label>
    <link:label id="lab_nktr_ScheduleOfLeasesTable_documentation_en-US" xlink:label="lab_nktr_ScheduleOfLeasesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Leases [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable" xlink:href="nktr-20211231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfLeasesTable" xlink:to="lab_nktr_ScheduleOfLeasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_422ea2e1-19fa-4620-8a9d-b60487e42eb7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts_351108c6-396c-426e-8d1b-eee781d0c93d_terseLabel_en-US" xlink:label="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of future royalties transaction costs</link:label>
    <link:label id="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts_label_en-US" xlink:label="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Royalties Transaction Costs</link:label>
    <link:label id="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts_documentation_en-US" xlink:label="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Royalties Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:href="nktr-20211231.xsd#nktr_SaleOfFutureRoyaltiesTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:to="lab_nktr_SaleOfFutureRoyaltiesTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_cd777cc7-607b-4114-8f8e-d0c7f8284fc4_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LegalMattersMember_4a87d3ea-fb5f-4047-9f08-a2c2e93e6c59_terseLabel_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_nktr_LegalMattersMember_label_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters [Member]</link:label>
    <link:label id="lab_nktr_LegalMattersMember_documentation_en-US" xlink:label="lab_nktr_LegalMattersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember" xlink:href="nktr-20211231.xsd#nktr_LegalMattersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LegalMattersMember" xlink:to="lab_nktr_LegalMattersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NetOperatingLossCarryforwardForIncomeTax_3ae50564-d6d6-4d0b-9380-6df5ea00c91a_terseLabel_en-US" xlink:label="lab_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward for income tax</link:label>
    <link:label id="lab_nktr_NetOperatingLossCarryforwardForIncomeTax_label_en-US" xlink:label="lab_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryforward For Income Tax</link:label>
    <link:label id="lab_nktr_NetOperatingLossCarryforwardForIncomeTax_documentation_en-US" xlink:label="lab_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward for income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:href="nktr-20211231.xsd#nktr_NetOperatingLossCarryforwardForIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:to="lab_nktr_NetOperatingLossCarryforwardForIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e949958b-e0c5-410a-b1aa-c9ca1aa09583_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c3016161-e49b-49e7-a3c0-4940c4759cd2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_39d4e317-3f1f-4e7e-a3bf-5c7d17aafac8_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_df3a9147-22b4-4a57-a1ad-4ca007bb963b_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9a641493-5731-43a0-bbed-b369f9b43c8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_77ecd348-16af-4857-80c5-ff5b1cd2b0df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_7ce5a39e-8286-490e-b29d-7d839a50a624_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestones, royalties and sales milestones</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_label_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_documentation_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:href="nktr-20211231.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:to="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_81d98970-6e8f-4ac4-9742-f6732872405f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_5a1ecddd-d935-4389-bb5a-1d8dd79c2aa7_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3856110a-21ce-4632-a973-078b53f3d723_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1ae586a9-4471-4d48-9428-1561e1836255_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_30c2464b-0b93-466a-9373-dcd193c3fee5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_b3859042-0fc6-4f29-8696-c082839a76a3_terseLabel_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price allocated to performance obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_label_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Transaction Price Allocated To Performance Obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_documentation_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price allocated to performance obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:href="nktr-20211231.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:to="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_557d1249-6b50-460f-b128-44c10bb1c3cb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a6b0115d-3913-419b-97aa-6c341207005c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock to Bristol-Myers Squibb (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_419b14e4-cb90-47f7-92c3-8bb952b0fdb1_terseLabel_en-US" xlink:label="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums (discounts), net and other non-cash transactions</link:label>
    <link:label id="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_label_en-US" xlink:label="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Premiums (Discounts) Net And Other Non-Cash Transactions</link:label>
    <link:label id="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_documentation_en-US" xlink:label="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Premiums (Discounts) Net And Other Non-Cash Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:href="nktr-20211231.xsd#nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:to="lab_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_d1661579-b9fc-483c-b65f-567ef475e86b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_5fda1289-e7ad-4065-a1a6-9119553bd041_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8c65ebc5-b3b2-41f6-9f5f-2950967253a0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_577098ff-0549-4b5c-b8f0-01d55a72b16c_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_aeb8768b-67a2-4b1d-83b8-e0bde9b39bca_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a780ccdd-97dc-4b85-ad4d-30f3a3e7da4e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 shares authorized; 185,468 shares and 180,091 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4ecae17d-069d-4d50-b636-08b83cb7f4dd_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_4429342a-375e-45a5-8308-4cd683256e5b_terseLabel_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability Related to Potential Future Royalties</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Liability Related To Sale Of Potential Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:href="nktr-20211231.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:to="lab_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract_99aadb0c-37e6-44e1-8990-0267aec67af9_terseLabel_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax positions related to current year:</link:label>
    <link:label id="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract_label_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related To Current Year [Abstract]</link:label>
    <link:label id="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract_documentation_en-US" xlink:label="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related To Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:href="nktr-20211231.xsd#nktr_TaxPositionsRelatedToCurrentYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:to="lab_nktr_TaxPositionsRelatedToCurrentYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2165a2b7-01b6-42a5-95de-f961f0e96a84_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized over a weighted-average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_4cb52c6d-b540-49c3-ac64-0e53da9b8d97_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7f01ce9-8bcc-4a62-ba7f-89e95b7ad8d6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_72a957bc-bf86-4c8e-a913-7a87edf621d7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b418f66a-da7b-474b-a06d-0f99db14bae4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_903f2bc9-fa7e-4735-987b-ff5a64cf6b46_terseLabel_en-US" xlink:label="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and Significant Supplier Concentrations</link:label>
    <link:label id="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_label_en-US" xlink:label="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory And Significant Supplier Concentrations [Policy Text Block]</link:label>
    <link:label id="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and significant supplier concentrations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:href="nktr-20211231.xsd#nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:to="lab_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_8b40124d-eb4d-435b-ae55-2449d0e14380_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09903a0c-e4e9-492c-a5e0-c53b75a6e900_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_40ac579f-2da7-43da-9655-c7f042089487_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based payments, first payment</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, First Payment</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-Based Payments, First Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_53b03986-9d43-403e-80d9-56099cc2d8f7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_0903c9c6-40f5-4841-85c9-8d5f01690e66_terseLabel_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of transaction related to purchase and sale agreement if threshold is not achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_label_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_documentation_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:href="nktr-20211231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:to="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndNonCashRoyaltiesMember_26e992fa-b7ad-4189-8003-db20b422081e_terseLabel_en-US" xlink:label="lab_nktr_CashAndNonCashRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And NonCash Royalties</link:label>
    <link:label id="lab_nktr_CashAndNonCashRoyaltiesMember_label_en-US" xlink:label="lab_nktr_CashAndNonCashRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And NonCash Royalties [Member]</link:label>
    <link:label id="lab_nktr_CashAndNonCashRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_CashAndNonCashRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And NonCash Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndNonCashRoyaltiesMember" xlink:href="nktr-20211231.xsd#nktr_CashAndNonCashRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndNonCashRoyaltiesMember" xlink:to="lab_nktr_CashAndNonCashRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_d0fa98a5-e5f7-48e0-a9c3-64de32162cd3_terseLabel_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_label_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals [Member]</link:label>
    <link:label id="lab_nktr_SFJPharmaceuticalsMember_documentation_en-US" xlink:label="lab_nktr_SFJPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SFJ Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember" xlink:href="nktr-20211231.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SFJPharmaceuticalsMember" xlink:to="lab_nktr_SFJPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_fde350d8-cc75-45bc-856e-2eb085431d94_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_1de35b02-4213-427c-b1f2-45001eefd40a_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_6384c706-dc56-47cb-8d4e-9519c8887729_terseLabel_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and leasehold improvements</link:label>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_nktr_BuildingAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Leasehold Improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember" xlink:href="nktr-20211231.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BuildingAndLeaseholdImprovementsMember" xlink:to="lab_nktr_BuildingAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a670436e-3e74-49dd-836b-076ece3c6c44_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_9d66cc7a-5e2b-461c-be86-0b35a6b33285_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_64dd2097-9be7-4848-97ba-565d5d380bc1_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_99e1a0bd-8bc7-4754-8feb-386f55528e2a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_0eee7b5a-42ac-4c55-8909-378028782757_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_706853cb-10dd-4c28-b734-b6629364895f_terseLabel_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_label_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_documentation_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares" xlink:href="nktr-20211231.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedFairValueOfShares" xlink:to="lab_nktr_EstimatedFairValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_d020bbf8-0f5c-4d4c-972e-33f6ad4ece5e_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Sale of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9fa72a80-e464-46ad-9482-5f88d22d9d22_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_5b089874-cbc4-47a9-9313-b8b04b5e7f55_terseLabel_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Performance Incentive Plan</link:label>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_label_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Performance Incentive Plan [Member]</link:label>
    <link:label id="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_documentation_en-US" xlink:label="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand seventeen performance incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:href="nktr-20211231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:to="lab_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_427719e6-2d67-4901-8f34-b083a0f21f32_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4bfafd57-6946-4781-8359-237552ee2b48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: portion representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_e7cfe2a0-8185-441f-a9e1-0cd3604e9366_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:to="lab_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3a3c4df7-5081-46b5-bf61-8b6fb85e9cc3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_b27b23eb-009f-451b-8378-1c8870b4cf31_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_d1a9aae5-690d-4fb6-8211-86ecd19b12c3_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DeferredTaxAssetsLeaseLiability_a3141773-d8fc-4aca-97b8-5b3d8e91f329_terseLabel_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLeaseLiability" xlink:href="nktr-20211231.xsd#nktr_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DeferredTaxAssetsLeaseLiability" xlink:to="lab_nktr_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock_4278e39b-5a40-4e9e-9d36-7ccd4ea78600_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Assets and Other Costs for Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock_label_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Assets and Other Costs for Terminated Program [Policy Text Block]</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Assets and Other Costs for Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:to="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_63e160f3-5d9b-4819-bc9d-abb05dfa3e0e_terseLabel_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR-358</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_label_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar Three Five Eight [Member]</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_documentation_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar three five eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember" xlink:href="nktr-20211231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarThreeFiveEightMember" xlink:to="lab_nktr_NektarThreeFiveEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b724e607-c06c-4cf5-b3d5-f01b303f0c12_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_4ace4733-b4c6-4184-bf91-06afec47a6f2_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73d4c6d8-b960-4887-9b4f-47964f5eecdb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2cc4d10d-f00e-46b3-9e93-5317844b1ecf_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from contracts with customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_643fc3c7-62db-4e4d-bcfa-2c9af6653264_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced if conditions occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received If Conditions Occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received, if conditions occur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:href="nktr-20211231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c9cc2761-d2b6-4d14-a36c-f147ff858a2a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_9df2e0a5-22ea-4eca-8d45-212b02199d53_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9ccb7bd1-f771-4f65-8f16-1a3a3fafa493_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5305159a-5e6f-43dc-9617-02b94c3c2a53_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_05170700-fb5b-45d6-a1aa-7f8a05738c09_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_cf3b6dc0-81e4-4786-a523-f9fffcb722b9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6e666817-9789-4e59-83b6-3879b537d7fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_222aea66-b500-4b37-b926-4c8500d9676b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_4cbef968-55ce-401a-8c5f-869bc3f7fe66_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_7490efa1-9844-4b57-b20e-96f6b2aa62d1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_28302e56-a18f-4011-bbdf-97c216507151_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b70cd47c-070d-41bd-8f8a-b5a708efb471_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_28c2b5d7-9cde-41a8-9823-9d14831de682_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d735686a-2e14-445a-9a3e-a7cab67684b8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c6af3dd3-01a8-460b-8005-60b0a65e1739_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aff0f760-7bd6-4cf0-89f4-f1b01bd87427_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_495be980-4d62-4bd7-80d3-6881a4b37515_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4e461973-4569-489e-8df9-af85a221eaff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ReimbursementOfExpenses_0f305f0c-54ac-4424-adc0-e84557c172cf_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_label_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_documentation_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses" xlink:href="nktr-20211231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementOfExpenses" xlink:to="lab_nktr_ReimbursementOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e05d25d1-8ea0-4ce9-ba49-e3ccd4a3b1dd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f60fc07-9d95-4d63-b7ec-03d95c6c7a29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_25e10d2a-f9a2-4539-b3fa-5c6f561c5077_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e8d9adf2-b57f-4858-afd6-9f436994d40e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_200c30b7-79ef-406e-a4d7-f3eac326bfac_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ed3fcba6-7b75-41a5-afc7-133a4b96f6db_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_279bccb2-62b6-4a14-991f-2b76875e2319_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5d9be1bd-128d-4279-9ba4-86d4f5443000_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b807b9f-84c7-4dbd-a37d-4828288bdf50_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3f3a89a3-3c1b-4c58-b469-6552da27c092_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_5134fd99-7d1f-4b2e-8498-dc7298badfd7_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:href="nktr-20211231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1e102b2f-49fb-4a85-864a-4714f4a14018_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_c5c8139b-464e-497f-9c7d-1321c74a1172_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_8ca3ac85-36ac-4fb1-8873-413151c59138_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_37e0a6c7-0c80-48f0-ae06-b16c425d6bb6_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_label_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration Other Revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue" xlink:href="nktr-20211231.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationOtherRevenue" xlink:to="lab_nktr_LicenseCollaborationOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ba749449-b73c-49aa-b84f-305cfe9f1b1d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_964e06e4-3fe8-473c-aa28-9ca89e8bf20a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_8df7992b-3f5e-46a2-bee8-f666562a789a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_8fa986bf-6ba4-40e6-bea9-4d0415a3dd13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5dd20e16-1c46-4065-8ac6-6bd57576a325_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c95e886e-b23f-47a6-b488-9bccc668b24c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_677a0905-52d0-4310-8dbd-149126ebe8ac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_95dced5e-572e-4580-97fd-0f79b8520883_terseLabel_en-US" xlink:label="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Significant Customer Concentrations</link:label>
    <link:label id="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_label_en-US" xlink:label="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Significant Customer Concentrations [Policy Text Block]</link:label>
    <link:label id="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and significant customer concentrations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:href="nktr-20211231.xsd#nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:to="lab_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b9db54a6-a3f8-4fd4-8738-aaae2c66e377_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_fdf1bc5d-1ed0-4478-90d5-6d586b841130_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_907d5fd0-155f-4a62-b086-0a8f8229f189_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_5d839c84-af29-44f8-8b53-d4f0ab4ee356_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_041119ff-a10e-462a-ad32-116b06be4a76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration and Other Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_31c64d79-4bd7-4435-8278-9a7a3eb45c41_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_bdf09768-7cf8-493d-9a83-24dcb0702aa8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_FutureRoyaltiesMember_cf194649-0197-4dbb-9937-575243efa3c9_terseLabel_en-US" xlink:label="lab_nktr_FutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Royalties</link:label>
    <link:label id="lab_nktr_FutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_FutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_FutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_FutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FutureRoyaltiesMember" xlink:href="nktr-20211231.xsd#nktr_FutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_FutureRoyaltiesMember" xlink:to="lab_nktr_FutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_42782d11-ea5f-489d-aab1-624c476462ed_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_5d5a3145-0cab-43e0-ba45-4efee7ec4d24_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based payments, first indication, period to be paid</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, First Indication, Period to be Paid</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, First Indication, Period to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3da8e5db-e172-41d7-b9ba-d5404fefd082_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_55b7832b-56c4-473c-991c-7896c9bbdf3a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7916fcaf-39de-402e-aabc-abd9e0a85201_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_384d760c-6c8b-498c-a34a-db7fef57926d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_94aa6c1e-a679-4ebd-8301-a54ae5dd6209_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_50aad490-e35a-44c8-967d-046be5b1d660_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0b88b0ed-aaff-4deb-b348-8efccb206fd5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_26078764-09d9-41ba-b5f2-af08b91168c9_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_61a5fa73-6bb4-4bc5-b2ca-9ad0f3d5daa6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_76765234-13cd-48e1-8ace-b021094ddfae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e71fd957-b5bd-414a-abf5-8aa12399e566_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_21d6d38d-21ed-41a9-bce9-2927668e96dd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_531678fc-621f-4aed-a94b-a2da52e8eb16_terseLabel_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Liability Related to the Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:href="nktr-20211231.xsd#nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:to="lab_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0b184585-1919-4986-b531-93fbba2c2558_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_1fe0533f-895f-49c4-bf4b-16ca835b8dc8_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based payments, second indication, period to be paid</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, Second Indication, Period to be Paid</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, Second Indication, Period to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a6ede711-a3bc-4eeb-b3ac-fa46d7bb5d17_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_93babc7d-fd7a-4781-8589-8e359f65682d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_0f12e6ae-4816-4730-9acb-f9c6df00b79f_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_6152d4c6-5188-484a-86cd-a3245fc012de_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount repaid</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2c851193-34c7-4482-9c12-af4a98f268d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3084bb16-3dce-44c2-86a1-fc0930507044_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_a3b28167-2986-4413-a9e1-60d32672b6dc_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">India</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_81274293-283e-4d78-9834-dcc1d140224d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6889207e-fa8e-422a-aa3d-d636c1a797cf_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4db7b750-9b9e-4cb2-b38b-82e4cf76aedc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_3b507e9c-bd8a-4527-a7f2-4a9f94b5bbf2_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b1ef3eea-ea65-471b-be71-b72a0ee94bc8_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_21d4afb7-9699-4581-afd4-f71fc7a6bab3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1936c259-8de4-4abf-baa3-d38211e5606e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_05e617da-c217-4a83-b4cc-f575911e487a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_de42b044-9e20-43cf-9f63-fdabe098b4bc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2e065bca-6780-4374-bfab-af72476185ac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options term under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_6149de60-381b-4c87-9e3d-46d5daf37975_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_082c0b64-4ed0-4c74-9241-edc6a2176112_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b0845536-42ce-42bf-87c0-6320f5fbec26_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_681bcca1-c539-453f-9f62-9bb7513325bf_terseLabel_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to sale of potential future royalties</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_label_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Related To Sale Of Potential Future Royalties</link:label>
    <link:label id="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:href="nktr-20211231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:to="lab_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c367488c-46cd-4f60-a260-9a2fccd4cbe1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_c1ee7d36-badc-47ec-94f6-815e1e54d3d6_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional development and regulatory milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d7ecc854-aba1-49f5-9f57-6ebe62de6eb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_cffcc8ec-b448-44ea-a1ec-5183d0154d95_terseLabel_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global commercialization profits and losses sharing percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_label_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits And Losses Sharing Percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_documentation_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits and losses sharing percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage" xlink:href="nktr-20211231.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProfitsAndLossesSharingPercentage" xlink:to="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_96fba542-2f40-4576-a398-b51248dc110a_terseLabel_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration received under agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_label_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Consideration Received From Agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_documentation_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate consideration received from agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements" xlink:href="nktr-20211231.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AggregateConsiderationReceivedFromAgreements" xlink:to="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3448fdcf-903b-4cfa-ae21-2c8738a9f9ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cb192800-c6ff-4147-a919-3ef834b5631a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_b7aadc8b-9c5b-4fff-bd94-11b3376f994f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneDomain_9fc3203a-435e-4a97-808e-de90600d48ce_terseLabel_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_label_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_documentation_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain" xlink:href="nktr-20211231.xsd#nktr_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneDomain" xlink:to="lab_nktr_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LeaseExtensionTerm_895338c0-ade7-4c65-9e2b-57f88f453dcc_terseLabel_en-US" xlink:label="lab_nktr_LeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term</link:label>
    <link:label id="lab_nktr_LeaseExtensionTerm_label_en-US" xlink:label="lab_nktr_LeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Extension Term</link:label>
    <link:label id="lab_nktr_LeaseExtensionTerm_documentation_en-US" xlink:label="lab_nktr_LeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeaseExtensionTerm" xlink:href="nktr-20211231.xsd#nktr_LeaseExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LeaseExtensionTerm" xlink:to="lab_nktr_LeaseExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_bb234ec6-e501-4913-9029-0ee060df9b75_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RSUsAndPSUsMember_195fad89-8fd0-455c-b0e6-4b973c9155f0_terseLabel_en-US" xlink:label="lab_nktr_RSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_nktr_RSUsAndPSUsMember_label_en-US" xlink:label="lab_nktr_RSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs [Member]</link:label>
    <link:label id="lab_nktr_RSUsAndPSUsMember_documentation_en-US" xlink:label="lab_nktr_RSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RSUsAndPSUsMember" xlink:href="nktr-20211231.xsd#nktr_RSUsAndPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RSUsAndPSUsMember" xlink:to="lab_nktr_RSUsAndPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_d3465611-65f4-44b6-b3ad-b13ee7b0a46f_terseLabel_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember" xlink:href="nktr-20211231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyAndCompanyMember" xlink:to="lab_nktr_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonSecuritiesRelatedClaimsMember_f4f7d6fd-d80b-4e1b-846a-9c395900cdab_terseLabel_en-US" xlink:label="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Securities Related Claims</link:label>
    <link:label id="lab_nktr_NonSecuritiesRelatedClaimsMember_label_en-US" xlink:label="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Securities Related Claims [Member]</link:label>
    <link:label id="lab_nktr_NonSecuritiesRelatedClaimsMember_documentation_en-US" xlink:label="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-securities related claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonSecuritiesRelatedClaimsMember" xlink:href="nktr-20211231.xsd#nktr_NonSecuritiesRelatedClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonSecuritiesRelatedClaimsMember" xlink:to="lab_nktr_NonSecuritiesRelatedClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_62189fad-88df-47e9-b713-02fc5e3755ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_cc4abeea-e73e-4d97-88e9-c0cd886bcba9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited and canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d2150356-978f-4d20-ac16-35f924b65869_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_23c3b889-1b46-4118-83c3-6703e8769a6a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_dc1d0f5a-6567-482e-9b2c-845de3583c21_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5d82042b-8b40-445b-8ad9-ed265b13ef38_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f6cbcbfd-26f4-4925-bbcb-f833e318d828_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_cb0dbe38-1396-4f82-b21d-e238e34ff808_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_44f3d81d-5e49-4915-8585-c0ebb52df97f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_b02d6d37-ea27-48f9-b846-39b69f08e202_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_64d0d622-cc57-45a3-8023-e70fabfb57df_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ea2c4c83-f3ef-4461-8503-db0a1ea60751_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b08b46d6-d236-48fc-b659-817604e4092a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_85f4002f-25ee-42ca-aa47-5eec6e2bcb97_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_02670365-8c1f-40c0-b58b-1cf30e2b5ea3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7d16a17-4c20-4d7d-a29e-1a662c3ba79d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf05282c-fd67-4dc2-b37a-d4b634ccdbbf_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_d92415fe-ad2f-4887-9c80-35e0cad53ec0_negatedTerseLabel_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: lease incentives</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_label_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_documentation_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability tenant improvement reimbursements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:href="nktr-20211231.xsd#nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:to="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_679e4a33-2510-4060-b02d-027768e9da07_terseLabel_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</link:label>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_label_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability [Text Block]</link:label>
    <link:label id="lab_nktr_DevelopmentDerivativeLiabilityTextBlock_documentation_en-US" xlink:label="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:href="nktr-20211231.xsd#nktr_DevelopmentDerivativeLiabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:to="lab_nktr_DevelopmentDerivativeLiabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_608b7f8c-74f6-4b52-91d1-55560a24d9f8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_3510dd92-c152-45e9-8d02-5c242c91f298_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_601606cf-03f9-4353-89d0-fbe0e34d9994_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e51fb17c-6ba2-4c5f-b699-e598643f1724_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_59947b4c-7ac3-4302-8766-5ba8f5805e0e_terseLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_89026a43-0c81-4495-ac70-96a99b7049d4_totalLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Restricted Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, restricted cash, cash equivalents, and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="nktr-20211231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_48de4754-e886-4087-9b5e-03a33a5bd522_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_983a0253-5d25-4f6b-bbf6-e1b5b2dc1045_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_97407e56-26a0-49dc-b0ff-841e13b3eb4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_42c79788-15e7-4d34-9067-1413ee1c7a70_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_89bc73fc-75c5-4558-845a-c25b9e80e6bc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_76e1e6e5-2c80-4adc-87f0-be11d91531d8_totalLabel_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property, plant and equipment, net</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property Plant And Equipment Net</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentNet_documentation_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property, plant and equipment, Net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:href="nktr-20211231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:to="lab_nktr_DepreciablePropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_e748e9be-1367-4bbf-8c85-6b6f2dc274f7_terseLabel_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:label id="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:href="nktr-20211231.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:to="lab_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e71e6354-9a0b-4668-9461-e45d54b36f2f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, increase (decrease) amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_6f1fb406-a2b1-4076-933a-84da56c5aaab_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty cost of borrowing</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b152737e-606a-4402-9eae-9597b712b50c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b428d4e1-7cef-4130-aed5-246e7c21b14e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_94fecc97-427d-4a32-b6ca-5790c3281228_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based payments, first indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, First Indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, First Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_80b2844a-4351-435d-978e-3b675d8d2c7e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_bd4f2c4a-45de-477f-bb17-e60d2c117e5d_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_47bb45f2-9065-4ed3-9bc9-6961c1a19e77_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_4b665113-ec41-49ab-96ea-de0b88bc4ba5_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_565b40c9-3707-4c32-8402-d756dd42a0cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1412a31d-a67c-4161-89e0-5e550a8128af_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LesseeOperatingLeaseTableTextBlock_9835b48b-7608-4871-bb69-1cefce737370_terseLabel_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Information</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseTableTextBlock_label_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease [Table Text Block]</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseTableTextBlock_documentation_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LesseeOperatingLeaseTableTextBlock" xlink:href="nktr-20211231.xsd#nktr_LesseeOperatingLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LesseeOperatingLeaseTableTextBlock" xlink:to="lab_nktr_LesseeOperatingLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_15092d24-7b6d-4806-9871-76c65c999c0f_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2cb0b4bb-ece3-4afe-a4ae-38e69fe09720_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2155408d-3cee-43dc-94bb-148ee14dc857_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_63939746-f1e8-4fce-9a22-9ca7ac84fd2b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2c0f108e-a081-4018-b73c-07104414515c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_f596ef67-d786-41e2-bbf0-725940ea1dfc_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by geographic area</link:label>
    <link:label id="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_label_en-US" xlink:label="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Areas, Revenues from External Customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:to="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_53f51e47-9305-472f-9d19-c27a90825cf2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_feb25e2f-7875-49f7-a6d5-3ba410a99494_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e6e26108-de72-468b-a5a7-ff6e01b58760_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NumberOfConsecutiveTermsToExtendLease_f101ca11-0c7f-46c3-95ab-7114f4c6799e_terseLabel_en-US" xlink:label="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive terms to extend lease</link:label>
    <link:label id="lab_nktr_NumberOfConsecutiveTermsToExtendLease_label_en-US" xlink:label="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Consecutive Terms To Extend Lease</link:label>
    <link:label id="lab_nktr_NumberOfConsecutiveTermsToExtendLease_documentation_en-US" xlink:label="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive five year terms to extend lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:href="nktr-20211231.xsd#nktr_NumberOfConsecutiveTermsToExtendLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:to="lab_nktr_NumberOfConsecutiveTermsToExtendLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_42f5f992-a63d-4f6c-86bd-3cc975fec30d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_07bbdee4-760d-40ab-9bb8-1948915ae065_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7c0a91b5-a179-4252-b3aa-f558a7811b4d_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f05c9622-2f62-4639-bace-9045bc459955_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c58fd5e2-3574-4569-af1e-a316ddde7078_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receipts from SFJ</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_9f33b9ca-9d70-4d58-910f-bfbc790f46a6_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_TerminatedPartnershipMember_de49b37c-3fc2-47ec-bdce-d389cf0dfef7_terseLabel_en-US" xlink:label="lab_nktr_TerminatedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Partnership</link:label>
    <link:label id="lab_nktr_TerminatedPartnershipMember_label_en-US" xlink:label="lab_nktr_TerminatedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Partnership [Member]</link:label>
    <link:label id="lab_nktr_TerminatedPartnershipMember_documentation_en-US" xlink:label="lab_nktr_TerminatedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Partnership [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TerminatedPartnershipMember" xlink:href="nktr-20211231.xsd#nktr_TerminatedPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_TerminatedPartnershipMember" xlink:to="lab_nktr_TerminatedPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a7af39bb-fb6a-4bae-9fad-fb912294caa7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_623c49be-edf3-4f0d-b483-9d35f4c7fd31_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced under certain conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received Under Certain Conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received under certain conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:href="nktr-20211231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_65b2b19e-530a-4d42-86b5-3f7487e04f9b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0d6d025a-9c16-483e-a237-4b5ca4a2a539_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_ef2d4c02-82f5-46f8-a65e-eb18ec0483cf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_aaea29b4-b300-414f-9932-8cc3d3c11f97_terseLabel_en-US" xlink:label="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period subject to lock-up and stand-still provisions period</link:label>
    <link:label id="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_label_en-US" xlink:label="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Subject To Lock Up And Stand Still Provisions Period</link:label>
    <link:label id="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_documentation_en-US" xlink:label="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period subject to lock-up and stand-still provisions period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:href="nktr-20211231.xsd#nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:to="lab_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ce8ce1a0-01ce-4624-a0f9-62bf9db876a7_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_f39ff69c-fce6-4127-86ad-0f3bd3781e0b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3fe2c81d-add4-4171-bcae-36da6c14e280_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fa1b9d16-7d06-4038-8ea8-328d3a0dfc2b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c603af9d-b58b-4742-a4c6-957fd5a963bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_86a12e6c-c2be-4778-b161-7f2f3b6b92cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_5a76ff46-460a-43e9-9969-1a526a1ffc52_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_91ca6d1d-1719-40f6-929f-56a4de1417f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9d7b76e0-d5ee-4940-9c67-f5bd695112c4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_c9066948-44e3-492a-9e1f-49e942d1c9c6_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_c94dfde1-b1c1-45a3-ac7e-e3cd56acb670_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6af457ab-f743-46d1-adf9-7ef895b3e4ed_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_5706dd81-de36-457d-b768-be11647df886_terseLabel_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_label_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investment Maturity Period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:href="nktr-20211231.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:to="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a53ba59b-01ab-4b7f-b850-d661806bbb7e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a232f7e3-a44e-44f5-b22a-110186e55a20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_6e1cab71-eb21-476c-902d-b8cd89583885_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching 401(k) employer contribution, maximum amount</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_92b3a2fb-c2b0-4f2e-8332-de2d85e42a69_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_d12d86ef-ee65-409c-8ba7-6197cb8c4f4d_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementCommittedFunding_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementCommittedFunding" xlink:to="lab_nktr_CollaborativeArrangementCommittedFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_33cd69e0-a66d-4df2-9b3a-58aadb42871f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c6148845-aa8f-4107-9a32-343b6be4e99e_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nktr-20211231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_65e7e55d-3200-4f10-900c-cbc3f3cbed71_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_17252430-3515-40dc-8d93-5a5eb1495da4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3c291e20-880b-405e-ad04-56163bf5f544_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_853e0e77-0a40-438c-ab37-795405033b5a_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_cc228b9a-3154-4493-88b9-ea97aaadfece_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_bb5f837b-a73e-4970-ab58-e01b5832f132_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_2c906d32-7cc9-493f-9ee4-7932b4e611b9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_960c734e-087a-4e21-809a-ff39a3f04591_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_1ee95764-d196-4824-b9d5-98e297e99101_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ff08a247-0e1b-4673-adc0-f10cbf8cdf85_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_b50a4105-392d-49cc-9be3-ede8290d5f30_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar's</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a98a5219-b7bb-47bd-b003-f78fe7df029f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_24331162-3745-4f65-8add-127eac7cb05d_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_25b9189b-d1e6-4c55-b639-c11511d218a5_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MergerAndAcquisitionRelatedClaimsMember_718c66e5-946b-4db4-84ab-bf02f725097e_terseLabel_en-US" xlink:label="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and Acquisition Related Claims</link:label>
    <link:label id="lab_nktr_MergerAndAcquisitionRelatedClaimsMember_label_en-US" xlink:label="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger And Acquisition Related Claims [Member]</link:label>
    <link:label id="lab_nktr_MergerAndAcquisitionRelatedClaimsMember_documentation_en-US" xlink:label="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and acquisition related claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:href="nktr-20211231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:to="lab_nktr_MergerAndAcquisitionRelatedClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_b88d8f51-b5f0-4d45-9501-ebd0fe9de6f0_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_a4a8afb9-6740-4fea-86f5-d78c1a096824_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_c6b72e26-77f0-4def-90c8-72eafee3cbe5_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_9c1aaf83-2328-4749-a1f8-d2ac4cf12156_verboseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCompanyMember" xlink:to="lab_nktr_BristolMyersSquibbCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e0243a4-7982-4c22-b6f6-774c63d109fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_ecfaa7b6-7355-4b4f-92a2-2621c69a75f9_terseLabel_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember" xlink:href="nktr-20211231.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SharePurchaseAgreementMember" xlink:to="lab_nktr_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_ef692236-b20b-4cbe-8fbd-d4df1727ff9d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue period of recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NeulastaMember_aa46f924-2c8e-40c1-a507-8cbae922b1ee_terseLabel_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta</link:label>
    <link:label id="lab_nktr_NeulastaMember_label_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta [Member]</link:label>
    <link:label id="lab_nktr_NeulastaMember_documentation_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember" xlink:href="nktr-20211231.xsd#nktr_NeulastaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NeulastaMember" xlink:to="lab_nktr_NeulastaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f08c010-35ef-4554-9a91-10bf2dcf9d78_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_60fb6e91-bf4a-49b9-b3b4-090ea1a551c0_terseLabel_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sales of future royalties</link:label>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_label_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount</link:label>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_documentation_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:href="nktr-20211231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:to="lab_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_126bea3d-b033-40a7-9a9b-a8200564509f_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures, and other</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6c1ae902-0318-4a57-b0f1-d906d007c621_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_9e92cdb9-4422-4779-a94d-c740ad391588_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_743aa360-7044-40b6-8ae3-f66ae8d9ea53_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1dc2b895-1ad3-4785-9f37-8ec72378b2aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_4ae7d502-f860-4db0-a847-9ec9b419df93_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_ca3bc887-5e2c-4d87-8bed-8821dda20124_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar214Member_7cfc8015-470e-4e2d-9d1a-95c1240c4249_terseLabel_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214</link:label>
    <link:label id="lab_nktr_Nektar214Member_label_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214 [Member]</link:label>
    <link:label id="lab_nktr_Nektar214Member_documentation_en-US" xlink:label="lab_nktr_Nektar214Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar 214.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member" xlink:href="nktr-20211231.xsd#nktr_Nektar214Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar214Member" xlink:to="lab_nktr_Nektar214Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfbb47c3-f0be-4934-8cd8-4c5b596c172c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0aa46643-20ef-46c8-a12b-f59e192da410_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5f6c4b25-42e8-42f4-a17e-9a6e9d110d2c_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_20844841-01dd-4e95-9ff7-4a2e82a93b5b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_f817fa4c-e2b1-4d8f-b441-e88dcac51f1e_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_57c828b2-a644-42d8-8dc6-11b8f7caf952_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_9821b85e-ff7b-40dd-96ab-9261e9cb8c71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_09f97b25-323a-4d1d-be1e-020bb590cec0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement Type</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_39f5ed7b-5dee-43cf-89f1-5c55360db618_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2012Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2012</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2012Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_5af4e330-b286-4943-8845-af57232d6108_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a43e5fc4-07c7-454c-81c5-cebb7c0579a3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_02bfec90-2661-4d1c-99be-48048bd36cd1_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_60bff10d-5805-4133-acf7-f4e688b260a0_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_98c9b4d3-d924-412d-9770-1f5e102aa1cf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_87006f4e-f04d-4544-9a35-8ba77cd5b24e_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_label_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Consideration Received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_documentation_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived" xlink:href="nktr-20211231.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockConsiderationReceived" xlink:to="lab_nktr_SaleOfStockConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_df3e9807-6b5a-4b6f-b78d-2e681afe7c3b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a5ff12c6-ed9b-4522-832f-8dd95ca9510e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing net loss per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_edcbbd94-0cc9-4006-8248-ced73ac39b9d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PreferredStockShareDesignated_ce524ae0-180a-4c3a-95e2-e9495cc6ee61_terseLabel_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated (in shares)</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_label_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated" xlink:href="nktr-20211231.xsd#nktr_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PreferredStockShareDesignated" xlink:to="lab_nktr_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_cf188c63-99e2-4d62-812e-d9b1bfd96747_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of future royalties, net of $3.8 million of transaction costs</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_label_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of Future Royalties, Net</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_documentation_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of Future Royalties, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:href="nktr-20211231.xsd#nktr_ProceedsFromSaleOfFutureRoyaltiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:to="lab_nktr_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_4a97941f-b97e-40b9-9f9a-d6783889ca17_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_231503e2-fb41-4427-a697-88e6a4ed5360_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Provision Related to Continuing Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_2ab457b0-d444-4a33-adb1-aac35c1b56cc_terseLabel_en-US" xlink:label="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plan's share limit reduction for every one restricted stock unit granted</link:label>
    <link:label id="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_label_en-US" xlink:label="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Plans Share Limit For Every One Share</link:label>
    <link:label id="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_documentation_en-US" xlink:label="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation plan's share limit for every one share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:href="nktr-20211231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:to="lab_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_14889f37-7a5a-4aa3-9f61-76ba34391bda_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_aaafdeee-1a9e-48a6-8a65-dfcb3906bd62_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_860e835a-e627-4191-a473-6f771947293f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_4a583d04-f58f-4442-801a-02084f87472f_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_3c95031a-bb11-4472-b105-1424af1a25ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Portfolio of Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_ef2c8e01-4a93-4abe-b389-1850c1bc1517_terseLabel_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of transaction related to purchase and sale agreement</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_label_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</link:label>
    <link:label id="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_documentation_en-US" xlink:label="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:href="nktr-20211231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:to="lab_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e4ad3012-4608-4ba2-9efb-7e37a1a8f747_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities_bce45330-bad8-4acf-b5cd-308001017be3_terseLabel_en-US" xlink:label="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable recognized in exchange for long-term liabilities</link:label>
    <link:label id="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities_label_en-US" xlink:label="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Activities, Accounts Receivable Recognized In Exchange For Long-Term Liabilities</link:label>
    <link:label id="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities_documentation_en-US" xlink:label="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Activities, Accounts Receivable Recognized In Exchange For Long-Term Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:href="nktr-20211231.xsd#nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:to="lab_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_6b97a4f0-0ff0-4c85-9e42-c4bf68abbedd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3974ba5a-7f6e-496e-8e21-3284b369f845_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82f49b09-c3d6-4c3e-ad27-096591fa1d20_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NKTR181Member_93a9a896-cf58-4424-a68d-4a1bf1dec017_terseLabel_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181</link:label>
    <link:label id="lab_nktr_NKTR181Member_label_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:label id="lab_nktr_NKTR181Member_documentation_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member" xlink:href="nktr-20211231.xsd#nktr_NKTR181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NKTR181Member" xlink:to="lab_nktr_NKTR181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_47137f77-04cf-4443-a7e5-b81d907664bd_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_55854a89-9e55-4d2f-b1b2-3d3854231355_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_4c8f0823-371c-40e3-8fee-569adf6fe949_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7766f7e5-92bd-43e0-8d8a-9404204ddc0a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_5e36c0b9-43f9-439f-bb0a-8a62f7271c8e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_40777902-5ab4-4eb6-9495-6b3419b214df_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_fb3a175f-5c3d-417f-8682-b458bcc43a07_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneAxis_e4053611-7077-4800-b12e-18948a0fcdd3_terseLabel_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_label_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_documentation_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis" xlink:href="nktr-20211231.xsd#nktr_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneAxis" xlink:to="lab_nktr_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_b5473d5e-b15c-4502-9cd2-77a808be45a3_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EmployeeMember_5199d5f0-9a92-43bc-960a-4ff59660f3c6_terseLabel_en-US" xlink:label="lab_nktr_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_nktr_EmployeeMember_label_en-US" xlink:label="lab_nktr_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_nktr_EmployeeMember_documentation_en-US" xlink:label="lab_nktr_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeMember" xlink:href="nktr-20211231.xsd#nktr_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EmployeeMember" xlink:to="lab_nktr_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_45d0bd35-5276-4e88-801d-e9ca6d05dd14_terseLabel_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties</link:label>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_label_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds</link:label>
    <link:label id="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_documentation_en-US" xlink:label="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:href="nktr-20211231.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:to="lab_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_440b784e-7161-4973-a551-562e4e810e6e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_b9896f2a-419e-4005-bdf1-9a044c603337_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c7c90e7-fab2-49ec-b586-e836b7df4044_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_a0885b37-c200-47b7-ae95-1baf37439fbc_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5e63cf77-cdc3-4dd1-a4ee-71d1f7b652e5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_0e792a56-ca41-409c-84cb-f6abe6de215a_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8eb732a3-cc72-448c-9d40-65cd3e9ba274_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8b877b7d-948a-4d66-b548-c98374cf415c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and other credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_e0a5e52a-8564-4ad0-9d51-e1fba76087b6_terseLabel_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Development</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_label_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Development [Member]</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_documentation_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug product development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember" xlink:href="nktr-20211231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DrugProductDevelopmentMember" xlink:to="lab_nktr_DrugProductDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b16c0c9c-0d2a-420d-afaf-44e108884d7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_bc83b91e-992b-42fc-9979-eb22da28e940_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_caa6024b-1a23-49f9-9d04-81b8df1fe6ba_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_bb07fd8c-2f04-41ad-b245-5f190fbebc70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for award grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_e5f95f07-f594-495b-b142-5f61e980d91c_negatedTerseLabel_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, net</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:href="nktr-20211231.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:to="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_3f9e2969-cb72-44fb-bce1-6c8ba8d5d278_periodStartLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties&#8212;beginning balance</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_c3d82e27-485e-4fed-b342-b3c287cfe17e_periodEndLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to the sales of future royalties &#8211; ending balance</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_b2a2b780-69dd-49f8-be45-1eb50bccfc85_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets and other costs for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_label_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Assets and Other Costs for Terminated Program [Member]</link:label>
    <link:label id="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Assets and Other Costs for Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:to="lab_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_cbe14ca9-c5b2-486c-89da-ae4dbabde456_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_d470f1c8-cd0a-49a5-92c6-38f9fc449ec4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d24a950b-3e81-49c5-9bc5-0b9ec54d43a3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c4286a24-ac1b-4086-8a94-4918c8a95504_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e4abbfab-860e-4809-afb0-1ef86f656488_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7935002e-0b01-4651-89fe-d693f738898f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LeasesLineItems_89024346-c36a-4792-871b-4ae638dba8bf_terseLabel_en-US" xlink:label="lab_nktr_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_nktr_LeasesLineItems_label_en-US" xlink:label="lab_nktr_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_nktr_LeasesLineItems_documentation_en-US" xlink:label="lab_nktr_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems" xlink:href="nktr-20211231.xsd#nktr_LeasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LeasesLineItems" xlink:to="lab_nktr_LeasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_2fb8401f-cc7d-4997-8209-86435b365d45_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0bf8031b-866f-461e-b276-7b96ba295ac2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_012a7d2b-9474-45b9-94aa-4b3886c4bc1d_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of royalty rights</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_label_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Potential Future Royalties Gross</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_documentation_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of potential future royalties gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:href="nktr-20211231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:to="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_95df9bcc-f981-4d28-a646-35e66106667e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_eb508683-f161-4449-bb2b-b40bd1906498_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4385d816-0fe8-4c14-8ee9-b7d1d9b4c321_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ab617c9c-1bb4-41ee-abae-aac29e47ea44_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_ded81a17-3504-48be-b48a-736681cd3431_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets_8257cdb8-7e06-45ee-bca1-b435a7e32e80_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on revaluation of liability related to the sale of future royalties</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_705004e5-6711-4513-9892-5e909c8d2ef5_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of advance payments to contract manufacturers and equipment for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment From Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equipment from terminated program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_496092f6-1dcb-4d24-ac4b-6fa9ef59203e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_105e3e02-0b38-46d8-afea-0b46f5da5213_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_7af2a0bc-596b-434e-a3d0-9095d1325ba9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_c3b1a771-5134-435e-a897-9da8b595fbd4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation matters, liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8a88085b-c96c-4dc0-92d2-4d4ac745aefe_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0a1e9895-e635-40ad-9c29-5f0db304f8c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_e2b149f9-4132-4137-8924-23278913977a_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_cb48cf1b-fce4-4049-96c1-73e4eebc6f40_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_fccb35fc-1995-472b-bb07-f33c34a9b473_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a90541cb-8fbf-497b-8c7f-c4596461b868_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c6c91a5c-b10a-4017-8bd3-7c131998eb97_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ea9efce8-7d72-46a6-b5cf-5d14e88387dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_c171d653-addb-4580-a8da-ddc5201282e7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_7500387b-ba0e-424f-9a50-adde39aa0da0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of development derivative liability</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_9ef12172-4f01-452e-97d0-f652b42c48b2_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Obligation</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_1acbdd48-c7a5-4f4d-a406-3e0357cb9732_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_980f2c7b-88af-4b4c-8435-53201740c570_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_082f8f61-a0a3-47c5-b4da-f80865f1bb65_terseLabel_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty monetization proceeds</link:label>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_label_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Monetization Proceeds</link:label>
    <link:label id="lab_nktr_RoyaltyMonetizationProceeds_documentation_en-US" xlink:label="lab_nktr_RoyaltyMonetizationProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds" xlink:href="nktr-20211231.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltyMonetizationProceeds" xlink:to="lab_nktr_RoyaltyMonetizationProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c509b9db-d5d0-4882-8290-889374132a56_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_27c1226b-c35f-452f-9841-c53d1e6aff2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8dbead8-9208-4b26-9fa5-23571f4e5819_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e013e90f-2652-4f1d-b9fb-391910bcff8b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_61982596-5337-4c8d-8535-74dcc05e286b_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_0c5cc07d-772d-4766-b46d-6d5fb082faab_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_df07a93b-915c-4632-afcc-0f70e7c39e52_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_87d4fec7-e6fe-43ae-8888-06daa4a91be3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_a43c1266-a41c-40d2-a560-405859680816_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Purchase and Sale Agreement</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020 [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreement2020Member_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreement2020Member" xlink:to="lab_nktr_PurchaseAndSaleAgreement2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataTable_1158a8d4-a4f7-45b5-84e2-7732ddfe9368_terseLabel_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data [Table]</link:label>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataTable_label_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data [Table]</link:label>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataTable_documentation_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected quarterly financial data.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataTable" xlink:href="nktr-20211231.xsd#nktr_SelectedQuarterlyFinancialDataTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataTable" xlink:to="lab_nktr_SelectedQuarterlyFinancialDataTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcc07496-1d7d-49cd-989b-b1ecf043eb97_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b2013422-1466-4047-aef3-5be1ec4880da_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyMember_cef5dd35-316d-42da-b857-be3a8d30351b_terseLabel_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_nktr_EliLillyMember_label_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_nktr_EliLillyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember" xlink:href="nktr-20211231.xsd#nktr_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyMember" xlink:to="lab_nktr_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e6ebccf3-8e96-401b-9c55-af028052431a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common stock reserved for issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_989f94a1-bfac-4309-8b4d-a3291cd0b48c_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nktr-20211231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_53167f4b-681c-4792-80ba-db6f105b4f7f_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_0e94363a-c775-45af-a3e3-cd7097102277_terseLabel_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sales of future royalties</link:label>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_label_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non Deductible Expense For Liability Related Sale Of Future Royalties, Amount</link:label>
    <link:label id="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_documentation_en-US" xlink:label="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:href="nktr-20211231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:to="lab_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_d0c28afc-ec19-43ef-aa61-dd93eb9c7b5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7066e165-a304-4547-8b21-0e6aa64bba14_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0e5bf64-6b01-474c-9759-7b9a9f1b53f1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d0f8a0a3-f3ce-4724-a8d5-0fbb21fe5853_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9cb9db86-5a07-443b-a86a-b02d820615ce_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ab5965d1-c048-4d0b-b103-0ea9ab947eb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1b747ba4-1aeb-4b7e-b897-700e5e08cf99_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0c42538a-ab52-44d7-8a53-17975ab8ea32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_58499269-22aa-44bd-929f-82eb4623ffe3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period for stock-based compensation award granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_43ac86d7-dd9f-4365-9f79-f98ab1390431_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8e9e560e-ef00-4ee3-a8a8-0865e89a3288_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity Under Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7c3f3983-d172-4cda-8509-8f2f4ed83172_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_d01ce8ef-4f6c-4955-ae03-23dc592aea16_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapses in statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneOneMember_f2f26e3a-0fbc-48e4-a395-d021fd7b163c_terseLabel_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_label_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_documentation_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember" xlink:href="nktr-20211231.xsd#nktr_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneOneMember" xlink:to="lab_nktr_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_5e677f7f-9abc-41c4-8b19-ecd5f13d243e_terseLabel_en-US" xlink:label="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, period may increase or decrease due to tax examination</link:label>
    <link:label id="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_label_en-US" xlink:label="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Period Increase (Decrease) Reasonable Period Of Change</link:label>
    <link:label id="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_documentation_en-US" xlink:label="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, period increase (decrease) reasonable period of change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:href="nktr-20211231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:to="lab_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_686db7a2-65ac-42ab-a788-8e396921f515_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_998932c0-4a26-4922-9c04-91f0ee2958a7_terseLabel_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Street Facility</link:label>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_label_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Street Lease [Member]</link:label>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_documentation_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third street lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember" xlink:href="nktr-20211231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ThirdStreetLeaseMember" xlink:to="lab_nktr_ThirdStreetLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f467ae8c-4308-4375-b5ed-28fd91de2c93_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_c6f0acff-4ba9-41e9-a7cc-70f36ec30569_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_ebb9358f-6ae8-4a4e-adbe-6e580426b2cb_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_347b9c26-0c7b-48a2-ba0b-bf7852e609b4_terseLabel_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property, plant and equipment at cost</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property Plant And Equipment Gross</link:label>
    <link:label id="lab_nktr_DepreciablePropertyPlantAndEquipmentGross_documentation_en-US" xlink:label="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable Property, plant and equipment, Gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:href="nktr-20211231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:to="lab_nktr_DepreciablePropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d377d850-d056-4c67-aab9-eb4d8cc30bfb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_a926d755-b306-4de2-8004-3c66f00c1c1e_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9dc0f225-0eb1-4a25-949c-e32066abe484_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8afc5766-a36a-4e20-a445-a205fc5b161a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20648d47-75c4-4c93-af08-88776005719e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ee8e9813-88b9-4b6b-8f8f-4189498d7eb0_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_b05fcc2a-3161-4f5c-8479-8b718d212b34_terseLabel_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties liability, measurement input</link:label>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_label_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Liability, Measurement Input</link:label>
    <link:label id="lab_nktr_RoyaltiesLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput" xlink:href="nktr-20211231.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RoyaltiesLiabilityMeasurementInput" xlink:to="lab_nktr_RoyaltiesLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3115fdcd-dcb1-41cd-aaf3-cea21273a7ca_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30637b11-2ac2-46ad-ab6b-95debb7645c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_224172cb-fb6b-4bd1-bf1f-c9a4e2895657_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_ca61f9fc-258c-48b4-abbc-d6c4721612af_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Principles of Consolidation and Use of Estimates</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_646b7c8d-6e1c-46db-810a-ced4161dea5d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_7262649f-313e-493c-baea-5a1ae3ab81cb_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments related to contract manufacturing, clinical development and certain other items</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_66989233-50e5-472a-adb7-bf7077786b81_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cb43ed6b-25ad-49e9-a81c-541c541c413e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_e3af429f-1ee9-4506-a188-fce261665961_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, penalties recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_248bcf60-ca8e-48b2-b228-95f76f7800f6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_8dcd8699-d2e8-4e24-8e34-c1d2f92b3f7d_terseLabel_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year two</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_label_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made For Milestone Not Achieved Year Two</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_documentation_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:href="nktr-20211231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:to="lab_nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne_c070660e-7d35-453d-bf32-5a1397d7883a_terseLabel_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year one</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne_label_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made For Milestone Not Achieved Year One</link:label>
    <link:label id="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne_documentation_en-US" xlink:label="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment made for milestone not achieved year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:href="nktr-20211231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:to="lab_nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SalesMilestoneRevenue_d874b77e-ebc3-4a50-aa26-59dfbdb91fcf_terseLabel_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_label_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_documentation_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue" xlink:href="nktr-20211231.xsd#nktr_SalesMilestoneRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SalesMilestoneRevenue" xlink:to="lab_nktr_SalesMilestoneRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_bdec501c-a2cc-4d4c-932b-c9a7cf17fa18_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to the sales of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:href="nktr-20211231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_86381137-9ad4-47d3-a006-0f8b49b10afa_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-based payments, second indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, Second Indication</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Success-based Payments, Second Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:to="lab_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5abc11a4-eec3-4725-9e2d-6311078aa47a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_9162c88d-de98-47e7-9364-9b542dcd0806_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_0b6daf39-f5d5-4632-b627-21198597733c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncomeTaxesDisclosureLineItems_5db4b1bb-b01b-4ea3-82a3-ca01b3b9d8f4_terseLabel_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureLineItems_label_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:label id="lab_nktr_IncomeTaxesDisclosureLineItems_documentation_en-US" xlink:label="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureLineItems" xlink:href="nktr-20211231.xsd#nktr_IncomeTaxesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems" xlink:to="lab_nktr_IncomeTaxesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ea059ba8-6939-4dcc-92c0-ceb0452450a0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_77b001be-e6a8-4fe7-9425-c0f032516205_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a864dfc1-dfdd-4bbb-a6c8-095c4f374983_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_5fca67aa-fd35-46f0-9640-4a19af06b48b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BempegaldesleukinMember_dc1ff901-8ff2-49e1-910a-f7bd31aba851_terseLabel_en-US" xlink:label="lab_nktr_BempegaldesleukinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin</link:label>
    <link:label id="lab_nktr_BempegaldesleukinMember_label_en-US" xlink:label="lab_nktr_BempegaldesleukinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin [Member]</link:label>
    <link:label id="lab_nktr_BempegaldesleukinMember_documentation_en-US" xlink:label="lab_nktr_BempegaldesleukinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BempegaldesleukinMember" xlink:href="nktr-20211231.xsd#nktr_BempegaldesleukinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BempegaldesleukinMember" xlink:to="lab_nktr_BempegaldesleukinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5a85ddb1-2c28-4baf-8343-9f1ea7d121c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_StockOptionsRSUsAndPSUsMember_1b3ec606-2324-44be-9986-e6b7a49c13f8_verboseLabel_en-US" xlink:label="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, RSUs and PSUs</link:label>
    <link:label id="lab_nktr_StockOptionsRSUsAndPSUsMember_label_en-US" xlink:label="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, RSUs And PSUs [Member]</link:label>
    <link:label id="lab_nktr_StockOptionsRSUsAndPSUsMember_documentation_en-US" xlink:label="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, RSUs And PSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsRSUsAndPSUsMember" xlink:href="nktr-20211231.xsd#nktr_StockOptionsRSUsAndPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_StockOptionsRSUsAndPSUsMember" xlink:to="lab_nktr_StockOptionsRSUsAndPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_524729f1-3f5c-45d6-b151-acedf18f60e1_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements And Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_4fe154c1-d300-4293-9b17-1cca5617c440_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d90a254a-de80-454f-85d5-3952276b4887_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_32ada2c0-35ad-4187-8d1c-87397a7a54d6_terseLabel_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control severance payment period for executives</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_label_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Control Severance Payment Period For Executives</link:label>
    <link:label id="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_documentation_en-US" xlink:label="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in control severance payment period for executives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:href="nktr-20211231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForExecutives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:to="lab_nktr_ChangeInControlSeverancePaymentPeriodForExecutives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_f2e7ae4c-c21f-4ec7-a7e7-f9d4cb51564e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4fe5af76-d3ef-4f52-bca9-d73e07f4514f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_764a230b-b3a4-40be-b670-c20d01505528_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding phase 3 development costs on an indication by indication basis borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_label_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_documentation_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding Phase three development costs on an indication by indication basis borne.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:href="nktr-20211231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:to="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_42d353a9-7645-416f-93b6-0e8876d06f48_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_eaca9685-fd05-4b29-a63e-b670d4904ccc_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_40dcaae1-26d9-4b58-b8d7-31a0315c6be5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_e0a3e906-4b3c-44e2-9306-fb21ced37eb0_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_8f95b671-0cbf-4c22-9365-11a0899f6957_terseLabel_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated Or Takeda P L C</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_label_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated Or Takeda P L C [Member]</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_documentation_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated or takeda PLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:href="nktr-20211231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:to="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_c8316887-b5df-42ec-9511-87b2b302220d_terseLabel_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_label_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Laboratory And Other Equipment [Member]</link:label>
    <link:label id="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_documentation_en-US" xlink:label="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing laboratory and other equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:href="nktr-20211231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:to="lab_nktr_ManufacturingLaboratoryAndOtherEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AreaOfLeasedSpace_09f552c9-3173-447f-9de7-a1fc333e4b08_terseLabel_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease space (in sq ft)</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpace_label_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Leased Space</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpace_documentation_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased space.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpace" xlink:href="nktr-20211231.xsd#nktr_AreaOfLeasedSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AreaOfLeasedSpace" xlink:to="lab_nktr_AreaOfLeasedSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_975d4eca-d31e-4eb3-97a0-ff6beab2b550_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cbf492e9-f345-4c17-8ddf-671d9e295d56_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_Nektar358Member_f07a6c59-2f6a-40c8-84d7-78c9e1ddbb10_terseLabel_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:label id="lab_nktr_Nektar358Member_label_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358 [Member]</link:label>
    <link:label id="lab_nktr_Nektar358Member_documentation_en-US" xlink:label="lab_nktr_Nektar358Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar-358</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member" xlink:href="nktr-20211231.xsd#nktr_Nektar358Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_Nektar358Member" xlink:to="lab_nktr_Nektar358Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_0f16dbb9-83d2-46d4-970b-167b32a11991_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataLineItems_882ca2a0-d48d-4b89-8c19-ff51c5b59673_terseLabel_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data [Line Items]</link:label>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataLineItems_label_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data [Line Items]</link:label>
    <link:label id="lab_nktr_SelectedQuarterlyFinancialDataLineItems_documentation_en-US" xlink:label="lab_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected quarterly financial data.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:href="nktr-20211231.xsd#nktr_SelectedQuarterlyFinancialDataLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:to="lab_nktr_SelectedQuarterlyFinancialDataLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_7f03037d-0b87-4c5a-85ad-924a3317f40c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_d790d7ac-94ad-457b-ae0a-9c8c54067d61_terseLabel_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Components</link:label>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_label_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Components [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ReportableGeographicalComponentsMember" xlink:to="lab_srt_ReportableGeographicalComponentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8fe089e2-28d1-4063-ae75-e0105569929a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum 401(k) per employee, percentage of annual salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_adb11812-866b-4324-9260-7996ce8786f5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6d354627-e2ca-437c-b864-398810e7d90f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_17def096-3544-4ebb-a8cd-934e15295ca0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotes_5d53252d-1f67-4042-993a-422c3fb3e13f_verboseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes, principal amount</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_label_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>nktr-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b154c77f-11f5-433c-8e4e-b6be98e0afac,g:2cfcd135-9f36-4467-b376-e4c05a9fe6a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/Cover" xlink:type="simple" xlink:href="nktr-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_acdcf597-0586-4a57-9a6a-525cf0cb3e72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_DocumentType_acdcf597-0586-4a57-9a6a-525cf0cb3e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b4359d06-8ed6-4ca4-97a0-2f5bb4ed8524" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_DocumentAnnualReport_b4359d06-8ed6-4ca4-97a0-2f5bb4ed8524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9384880a-4ecc-4390-8252-e1b3e40a7b47" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_DocumentPeriodEndDate_9384880a-4ecc-4390-8252-e1b3e40a7b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dafa62f5-971a-4eac-bbe9-de169e8c9e61" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_CurrentFiscalYearEndDate_dafa62f5-971a-4eac-bbe9-de169e8c9e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_919062bd-f437-4c42-8db3-71003a13a62c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_DocumentTransitionReport_919062bd-f437-4c42-8db3-71003a13a62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5e5cd4b2-fb87-4dea-bc24-88e4444629e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityFileNumber_5e5cd4b2-fb87-4dea-bc24-88e4444629e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2c7e8828-a904-4a8a-97ac-ef03852cda0f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityRegistrantName_2c7e8828-a904-4a8a-97ac-ef03852cda0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_db4bfde6-f91e-4910-89ff-f2daf3da7c0b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityIncorporationStateCountryCode_db4bfde6-f91e-4910-89ff-f2daf3da7c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_273f4d6b-572d-4a38-ac13-b97cf42e0cf3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityTaxIdentificationNumber_273f4d6b-572d-4a38-ac13-b97cf42e0cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_82640b34-9524-4146-9cdb-5050794b5355" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityAddressAddressLine1_82640b34-9524-4146-9cdb-5050794b5355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_389f9b5d-334b-4026-ba49-d085715ea4da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityAddressCityOrTown_389f9b5d-334b-4026-ba49-d085715ea4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e71f239e-183d-4b86-abdb-acb2e3a7e69a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityAddressStateOrProvince_e71f239e-183d-4b86-abdb-acb2e3a7e69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_05a3fea5-5375-4417-9885-3b608269d939" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityAddressPostalZipCode_05a3fea5-5375-4417-9885-3b608269d939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_48fd9913-dce6-4e8e-8779-7304c72280b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_CityAreaCode_48fd9913-dce6-4e8e-8779-7304c72280b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d114a439-1c75-4a51-abd0-812333082db7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_LocalPhoneNumber_d114a439-1c75-4a51-abd0-812333082db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d72089e7-fe63-4059-9e51-edc77e26775f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_Security12bTitle_d72089e7-fe63-4059-9e51-edc77e26775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8b3350eb-c44b-489c-85df-96ddb5372c1d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_TradingSymbol_8b3350eb-c44b-489c-85df-96ddb5372c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3bc9313f-e611-4b75-b857-208e5a3bb253" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_SecurityExchangeName_3bc9313f-e611-4b75-b857-208e5a3bb253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6b99117e-6098-4538-a189-7f1b4ab98c46" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6b99117e-6098-4538-a189-7f1b4ab98c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_464ed314-468f-49a2-bb39-e0555ccbebd2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityVoluntaryFilers_464ed314-468f-49a2-bb39-e0555ccbebd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_78224431-a5c6-4735-984d-6e46f85ed2b6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityCurrentReportingStatus_78224431-a5c6-4735-984d-6e46f85ed2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_87021888-4457-4073-8674-cad91116d082" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityInteractiveDataCurrent_87021888-4457-4073-8674-cad91116d082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8e12655e-1fb1-473e-a119-117f74c78c4c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityFilerCategory_8e12655e-1fb1-473e-a119-117f74c78c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ba5dcb90-7b2f-48f0-9473-0705cf67d44b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntitySmallBusiness_ba5dcb90-7b2f-48f0-9473-0705cf67d44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_75ef7837-0df2-4240-a079-b0c3549c2330" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityEmergingGrowthCompany_75ef7837-0df2-4240-a079-b0c3549c2330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_5de5b099-175f-48de-b710-5fcdfb35606a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_IcfrAuditorAttestationFlag_5de5b099-175f-48de-b710-5fcdfb35606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bc4c2b7b-4f33-44f3-8fda-0c0702ab6e12" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityShellCompany_bc4c2b7b-4f33-44f3-8fda-0c0702ab6e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_349aeff2-20a0-4ca1-ac5b-365a65a0fdb6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityPublicFloat_349aeff2-20a0-4ca1-ac5b-365a65a0fdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6ce1e46f-be6e-46ab-9fb8-016a54e4c9cb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6ce1e46f-be6e-46ab-9fb8-016a54e4c9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ad1b8197-3198-4220-85ba-567b6de3ed40" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ad1b8197-3198-4220-85ba-567b6de3ed40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_03f88e38-d7fc-4b50-9c5f-8601eb6a2e92" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_AmendmentFlag_03f88e38-d7fc-4b50-9c5f-8601eb6a2e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1dc3b23d-8b0e-4533-b50a-c425a9d681a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_DocumentFiscalYearFocus_1dc3b23d-8b0e-4533-b50a-c425a9d681a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_cd57da9d-762a-48bd-a87a-33f54b7d6b2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_DocumentFiscalPeriodFocus_cd57da9d-762a-48bd-a87a-33f54b7d6b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b182ec6b-880b-4ca2-85a5-a5dc2d1fffec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_659948e1-d082-41d5-9227-192d1ad2ad39" xlink:to="loc_dei_EntityCentralIndexKey_b182ec6b-880b-4ca2-85a5-a5dc2d1fffec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/AuditInformation" xlink:type="simple" xlink:href="nktr-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AuditorInformationAbstract_3744ee4c-ad36-4392-afb2-b0bbee538ee4" xlink:href="nktr-20211231.xsd#nktr_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_461aecad-9a38-45a2-af32-49cd22ec8548" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_AuditorInformationAbstract_3744ee4c-ad36-4392-afb2-b0bbee538ee4" xlink:to="loc_dei_AuditorName_461aecad-9a38-45a2-af32-49cd22ec8548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_02ee35e9-1fea-4bf0-9ebf-54643aa956aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_AuditorInformationAbstract_3744ee4c-ad36-4392-afb2-b0bbee538ee4" xlink:to="loc_dei_AuditorLocation_02ee35e9-1fea-4bf0-9ebf-54643aa956aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a57d34d2-22df-40ed-ab6a-88212c5d81e1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_AuditorInformationAbstract_3744ee4c-ad36-4392-afb2-b0bbee538ee4" xlink:to="loc_dei_AuditorFirmId_a57d34d2-22df-40ed-ab6a-88212c5d81e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ef7c301d-6ae9-473c-8ccb-ca6eb31cccab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d46b70b6-36e3-4dc0-86b3-3f08e0c68ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef7c301d-6ae9-473c-8ccb-ca6eb31cccab" xlink:to="loc_us-gaap_AssetsAbstract_d46b70b6-36e3-4dc0-86b3-3f08e0c68ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1effd825-9cd1-4ab5-b6b8-b3743f259893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46b70b6-36e3-4dc0-86b3-3f08e0c68ac3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1effd825-9cd1-4ab5-b6b8-b3743f259893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff2fd9d-0145-4d10-94ef-90bcca74aa58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1effd825-9cd1-4ab5-b6b8-b3743f259893" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff2fd9d-0145-4d10-94ef-90bcca74aa58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_78a6899f-a563-462a-a60a-6ecacaf65f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1effd825-9cd1-4ab5-b6b8-b3743f259893" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_78a6899f-a563-462a-a60a-6ecacaf65f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_86ac7a2c-96fb-4273-affc-1f255f3830d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1effd825-9cd1-4ab5-b6b8-b3743f259893" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_86ac7a2c-96fb-4273-affc-1f255f3830d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fb6b2121-3bf3-4c60-8614-a8c50b072769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1effd825-9cd1-4ab5-b6b8-b3743f259893" xlink:to="loc_us-gaap_InventoryNet_fb6b2121-3bf3-4c60-8614-a8c50b072769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_48ab6ae7-8a02-4e55-b0a7-615b2c59c310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1effd825-9cd1-4ab5-b6b8-b3743f259893" xlink:to="loc_us-gaap_OtherAssetsCurrent_48ab6ae7-8a02-4e55-b0a7-615b2c59c310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a1d23675-ee13-4cf4-95cf-9f7d3d77193e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1effd825-9cd1-4ab5-b6b8-b3743f259893" xlink:to="loc_us-gaap_AssetsCurrent_a1d23675-ee13-4cf4-95cf-9f7d3d77193e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3a6036fc-8ed3-49ab-a432-4a2a15b1f044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46b70b6-36e3-4dc0-86b3-3f08e0c68ac3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3a6036fc-8ed3-49ab-a432-4a2a15b1f044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a02d8c63-6c55-4042-bf60-c92f7807cafe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46b70b6-36e3-4dc0-86b3-3f08e0c68ac3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a02d8c63-6c55-4042-bf60-c92f7807cafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_09d8a204-1287-41c0-8fb1-94a04de76b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46b70b6-36e3-4dc0-86b3-3f08e0c68ac3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_09d8a204-1287-41c0-8fb1-94a04de76b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b245bdc2-90a7-4fa5-81cd-e908bac69026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46b70b6-36e3-4dc0-86b3-3f08e0c68ac3" xlink:to="loc_us-gaap_Goodwill_b245bdc2-90a7-4fa5-81cd-e908bac69026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_801cf59b-902a-4f88-a1b6-7ad4856d8575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46b70b6-36e3-4dc0-86b3-3f08e0c68ac3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_801cf59b-902a-4f88-a1b6-7ad4856d8575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_737ae438-0ebc-4c59-87f8-e2c64b24dfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d46b70b6-36e3-4dc0-86b3-3f08e0c68ac3" xlink:to="loc_us-gaap_Assets_737ae438-0ebc-4c59-87f8-e2c64b24dfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef7c301d-6ae9-473c-8ccb-ca6eb31cccab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a47fa098-1427-49dc-ba32-93648e295527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a47fa098-1427-49dc-ba32-93648e295527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fe4dd019-b47e-4ed7-86f4-cf1d0736710f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a47fa098-1427-49dc-ba32-93648e295527" xlink:to="loc_us-gaap_AccountsPayableCurrent_fe4dd019-b47e-4ed7-86f4-cf1d0736710f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_694ceb5e-e745-44e1-b5e9-6063356a0b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a47fa098-1427-49dc-ba32-93648e295527" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_694ceb5e-e745-44e1-b5e9-6063356a0b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_669afd11-650f-4444-98ef-24ebb4cbafbc" xlink:href="nktr-20211231.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a47fa098-1427-49dc-ba32-93648e295527" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_669afd11-650f-4444-98ef-24ebb4cbafbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_de969e62-02c0-4c20-8680-1d5fa6d46657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a47fa098-1427-49dc-ba32-93648e295527" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_de969e62-02c0-4c20-8680-1d5fa6d46657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b3f2ab36-3591-4c07-9cb6-bdc01eeb9c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a47fa098-1427-49dc-ba32-93648e295527" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b3f2ab36-3591-4c07-9cb6-bdc01eeb9c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_52f8c6ef-c76c-4e75-a6bc-0fe0cdf419dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a47fa098-1427-49dc-ba32-93648e295527" xlink:to="loc_us-gaap_LiabilitiesCurrent_52f8c6ef-c76c-4e75-a6bc-0fe0cdf419dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_93ebc4bd-8a78-4ea0-929d-8e8f4d8b2edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_93ebc4bd-8a78-4ea0-929d-8e8f4d8b2edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f97f6692-08de-490d-8220-44df123cbb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f97f6692-08de-490d-8220-44df123cbb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_d9ef9319-4677-406a-a790-ad4370ce2f43" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_d9ef9319-4677-406a-a790-ad4370ce2f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bb5b57ca-721b-4c06-b995-05330e8fd184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bb5b57ca-721b-4c06-b995-05330e8fd184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3d751c74-1da4-47fe-b871-e4825f7e1b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:to="loc_us-gaap_Liabilities_3d751c74-1da4-47fe-b871-e4825f7e1b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a3ebd392-39bd-4e47-92d0-49ea2f826665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a3ebd392-39bd-4e47-92d0-49ea2f826665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3029d6cc-6f57-4dbb-8b43-e48d01c60a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3029d6cc-6f57-4dbb-8b43-e48d01c60a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9c4f7cc6-78c7-4661-8074-81f0a5237242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3029d6cc-6f57-4dbb-8b43-e48d01c60a25" xlink:to="loc_us-gaap_PreferredStockValue_9c4f7cc6-78c7-4661-8074-81f0a5237242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3565b844-d9c7-48a8-90fb-0caaf9ae11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3029d6cc-6f57-4dbb-8b43-e48d01c60a25" xlink:to="loc_us-gaap_CommonStockValue_3565b844-d9c7-48a8-90fb-0caaf9ae11e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1900d095-fead-4802-b03d-5030e307690d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3029d6cc-6f57-4dbb-8b43-e48d01c60a25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1900d095-fead-4802-b03d-5030e307690d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_83941f1e-bff9-48df-840d-0921d31a3233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3029d6cc-6f57-4dbb-8b43-e48d01c60a25" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_83941f1e-bff9-48df-840d-0921d31a3233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a4f52b2b-8ab7-4a32-971d-d7b9bdb721ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3029d6cc-6f57-4dbb-8b43-e48d01c60a25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a4f52b2b-8ab7-4a32-971d-d7b9bdb721ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b184013-3964-47e8-ad09-0d3039cc7e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3029d6cc-6f57-4dbb-8b43-e48d01c60a25" xlink:to="loc_us-gaap_StockholdersEquity_7b184013-3964-47e8-ad09-0d3039cc7e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e2bbbbf9-11da-4e8b-bb10-4fae9015c6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f926452-90ee-4b11-ae28-ab35df9a0b99" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e2bbbbf9-11da-4e8b-bb10-4fae9015c6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_242a6092-9064-4a68-878e-967145bfc02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_62868f33-58dc-4a32-b4e2-cb1e7653ae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_242a6092-9064-4a68-878e-967145bfc02a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_62868f33-58dc-4a32-b4e2-cb1e7653ae4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_13ef5a53-ad95-4a16-ba48-e0ed76ff65ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_242a6092-9064-4a68-878e-967145bfc02a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_13ef5a53-ad95-4a16-ba48-e0ed76ff65ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated_5784a2a1-5656-4763-95b1-2c36f2fe6f48" xlink:href="nktr-20211231.xsd#nktr_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_242a6092-9064-4a68-878e-967145bfc02a" xlink:to="loc_nktr_PreferredStockShareDesignated_5784a2a1-5656-4763-95b1-2c36f2fe6f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7f85dab4-02fa-4c46-ab2b-042117123847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_242a6092-9064-4a68-878e-967145bfc02a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7f85dab4-02fa-4c46-ab2b-042117123847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d5ae29a1-8628-437d-8987-c045dde0193f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_242a6092-9064-4a68-878e-967145bfc02a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d5ae29a1-8628-437d-8987-c045dde0193f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_35978db2-8c11-4a52-b928-6d7cbdad0f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_242a6092-9064-4a68-878e-967145bfc02a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_35978db2-8c11-4a52-b928-6d7cbdad0f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f7542a92-4155-4335-bae1-27d7ff5d8b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_242a6092-9064-4a68-878e-967145bfc02a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f7542a92-4155-4335-bae1-27d7ff5d8b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_09bfbdb9-9820-4faf-8deb-6e6ace8f4c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_242a6092-9064-4a68-878e-967145bfc02a" xlink:to="loc_us-gaap_CommonStockSharesIssued_09bfbdb9-9820-4faf-8deb-6e6ace8f4c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8ef8089d-edd7-4265-8004-2e202936f3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_242a6092-9064-4a68-878e-967145bfc02a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8ef8089d-edd7-4265-8004-2e202936f3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_93082396-2013-4cf1-8978-8e5a0e9a99f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_668c3e63-bb92-4d79-8ea3-cb479af3ed80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_93082396-2013-4cf1-8978-8e5a0e9a99f5" xlink:to="loc_us-gaap_StatementTable_668c3e63-bb92-4d79-8ea3-cb479af3ed80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_61c74750-2518-4c28-a167-a4f2218df167" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_668c3e63-bb92-4d79-8ea3-cb479af3ed80" xlink:to="loc_srt_ProductOrServiceAxis_61c74750-2518-4c28-a167-a4f2218df167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_61c74750-2518-4c28-a167-a4f2218df167" xlink:to="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6e14e423-b005-4a57-a60d-1f13fc6d4bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:to="loc_us-gaap_ProductMember_6e14e423-b005-4a57-a60d-1f13fc6d4bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c72a306d-814b-4776-8fcc-db427c4d9021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:to="loc_us-gaap_RoyaltyMember_c72a306d-814b-4776-8fcc-db427c4d9021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_c4d3020e-eabc-4b21-bfcb-5bb6880089a6" xlink:href="nktr-20211231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_c4d3020e-eabc-4b21-bfcb-5bb6880089a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_b2503d9f-9611-41a5-8dc6-bba075888119" xlink:href="nktr-20211231.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7a3b50ac-34ee-4fef-8094-4be630911266" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_b2503d9f-9611-41a5-8dc6-bba075888119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_668c3e63-bb92-4d79-8ea3-cb479af3ed80" xlink:to="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_cbc37273-122b-4809-9585-1fbb73ddce38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_RevenuesAbstract_cbc37273-122b-4809-9585-1fbb73ddce38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37f82e3b-4904-40ba-9474-18055cf140b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_cbc37273-122b-4809-9585-1fbb73ddce38" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37f82e3b-4904-40ba-9474-18055cf140b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ed599bf1-a9b9-4ff3-872f-e9b50a71d9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ed599bf1-a9b9-4ff3-872f-e9b50a71d9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_817d6ef4-82c6-47c5-abf3-217e73627379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_817d6ef4-82c6-47c5-abf3-217e73627379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b37c87be-2bde-4404-9066-6c8c48c54ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b37c87be-2bde-4404-9066-6c8c48c54ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_509d3bf8-9fdd-46e6-92f4-2ef589815d63" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram_509d3bf8-9fdd-46e6-92f4-2ef589815d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d6234d75-95f1-4e38-8b51-e054b23e21d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1fb9221e-ae1d-4c81-8749-a27190036ab9" xlink:to="loc_us-gaap_CostsAndExpenses_d6234d75-95f1-4e38-8b51-e054b23e21d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_34e7456a-501c-4817-9a51-ee6d002008e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_OperatingIncomeLoss_34e7456a-501c-4817-9a51-ee6d002008e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_25cff60c-665e-4c00-ae23-ffcdf7674385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_25cff60c-665e-4c00-ae23-ffcdf7674385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a03ac9d5-032e-44b7-9a09-a25eba5d451c" xlink:href="nktr-20211231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a03ac9d5-032e-44b7-9a09-a25eba5d451c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_a5316795-d504-441a-b6cd-ca42381260e8" xlink:href="nktr-20211231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_a5316795-d504-441a-b6cd-ca42381260e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bf2b8641-ac5c-4f20-adc5-698fd0bdf972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bf2b8641-ac5c-4f20-adc5-698fd0bdf972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_197db2af-5812-490c-babf-6f578cc7a698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_us-gaap_InterestExpense_197db2af-5812-490c-babf-6f578cc7a698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d6ca9d03-2c0f-4252-8006-1e2a19a283fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_38c03667-219b-4209-91b4-d1c5ddccebc0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d6ca9d03-2c0f-4252-8006-1e2a19a283fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d7c4456-6998-4ebc-b18d-0fe26afa56c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2d7c4456-6998-4ebc-b18d-0fe26afa56c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2af272de-9e5e-4eff-8951-18e6089f3cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2af272de-9e5e-4eff-8951-18e6089f3cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_05b385d0-d331-4ff8-8fba-553e85510010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_NetIncomeLoss_05b385d0-d331-4ff8-8fba-553e85510010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7d1e690d-552b-4b0a-a7a7-6988dd80afd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_7d1e690d-552b-4b0a-a7a7-6988dd80afd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ef3fd452-5aee-473f-b0d4-909f2115ac5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7d1e690d-552b-4b0a-a7a7-6988dd80afd4" xlink:to="loc_us-gaap_EarningsPerShareBasic_ef3fd452-5aee-473f-b0d4-909f2115ac5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d2a61f49-9554-45be-b1ee-c8f779f6f4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7d1e690d-552b-4b0a-a7a7-6988dd80afd4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d2a61f49-9554-45be-b1ee-c8f779f6f4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3208f566-43b0-4bab-892a-35fab1a00e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5cacb8cf-7847-43f2-a270-379cf438188e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3208f566-43b0-4bab-892a-35fab1a00e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_30fb4459-1a61-436f-8b27-20c9307f2124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3208f566-43b0-4bab-892a-35fab1a00e0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_30fb4459-1a61-436f-8b27-20c9307f2124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f965c9c-9a29-4d03-8f32-11653adaf041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3208f566-43b0-4bab-892a-35fab1a00e0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f965c9c-9a29-4d03-8f32-11653adaf041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2ee0f01-333e-4536-8261-db16a8e10cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d9a257bf-be58-4b69-811d-c3200bb63b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2ee0f01-333e-4536-8261-db16a8e10cc9" xlink:to="loc_us-gaap_NetIncomeLoss_d9a257bf-be58-4b69-811d-c3200bb63b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3719c0b-b752-4a0f-8a35-2222519b2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2ee0f01-333e-4536-8261-db16a8e10cc9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3719c0b-b752-4a0f-8a35-2222519b2d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1dbc7695-ec30-4985-8402-5b9930fa5051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3719c0b-b752-4a0f-8a35-2222519b2d86" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1dbc7695-ec30-4985-8402-5b9930fa5051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cb0e8ad5-2ab6-4ad7-8c5a-f44626620704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3719c0b-b752-4a0f-8a35-2222519b2d86" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cb0e8ad5-2ab6-4ad7-8c5a-f44626620704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_97441c54-f076-4bb8-acac-b6ab08c16b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_e3719c0b-b752-4a0f-8a35-2222519b2d86" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_97441c54-f076-4bb8-acac-b6ab08c16b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ae3d25fe-7c67-4474-afcb-1b7a1718a40d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2ee0f01-333e-4536-8261-db16a8e10cc9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ae3d25fe-7c67-4474-afcb-1b7a1718a40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_943b8d13-6c63-47be-a1ee-7244badea4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ea24f2c-53ca-4e58-91b9-9aea42604466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_943b8d13-6c63-47be-a1ee-7244badea4a1" xlink:to="loc_us-gaap_StatementTable_1ea24f2c-53ca-4e58-91b9-9aea42604466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1fbe31c0-5826-4f03-97a5-a03cb7f6f65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ea24f2c-53ca-4e58-91b9-9aea42604466" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1fbe31c0-5826-4f03-97a5-a03cb7f6f65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1fbe31c0-5826-4f03-97a5-a03cb7f6f65b" xlink:to="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9419422c-885d-49c1-b7a4-4974fc5b2a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:to="loc_us-gaap_CommonStockMember_9419422c-885d-49c1-b7a4-4974fc5b2a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_52b84b74-d0b3-4fe9-8fe5-33587f02e481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_52b84b74-d0b3-4fe9-8fe5-33587f02e481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9182f806-8672-42e4-b4c7-8dc48a833ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9182f806-8672-42e4-b4c7-8dc48a833ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f46a22f1-c743-47e8-8b28-d86c0ae5bf80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_330b94fd-ca61-43fa-843e-cd6fefcec082" xlink:to="loc_us-gaap_RetainedEarningsMember_f46a22f1-c743-47e8-8b28-d86c0ae5bf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c1bd2e2-9d27-452d-98be-1d75ee29a61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ea24f2c-53ca-4e58-91b9-9aea42604466" xlink:to="loc_us-gaap_StatementLineItems_0c1bd2e2-9d27-452d-98be-1d75ee29a61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c1bd2e2-9d27-452d-98be-1d75ee29a61e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3478f963-ea12-4272-b4ac-ed7f774aa756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_SharesOutstanding_3478f963-ea12-4272-b4ac-ed7f774aa756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b0377f2-630f-4165-b064-b594624bbd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_StockholdersEquity_6b0377f2-630f-4165-b064-b594624bbd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bf82a8af-2fcf-48da-9042-c35eba00261e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bf82a8af-2fcf-48da-9042-c35eba00261e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_83fea252-cdcf-4b64-b3a4-a85a86392d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_83fea252-cdcf-4b64-b3a4-a85a86392d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32a6f998-2170-4ee0-87e6-7dc6f6126a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32a6f998-2170-4ee0-87e6-7dc6f6126a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f287012b-ad7e-4fac-8ce6-0df5a4d7923a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f287012b-ad7e-4fac-8ce6-0df5a4d7923a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_fb0f2700-c0a2-4119-9287-34f615d42a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_SharesOutstanding_fb0f2700-c0a2-4119-9287-34f615d42a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4198d7ab-ffc6-4ad3-a02b-060512568af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56c634db-6b29-4182-ae11-7d763d428525" xlink:to="loc_us-gaap_StockholdersEquity_4198d7ab-ffc6-4ad3-a02b-060512568af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ab6caac4-3af8-4769-a01b-46be3d76ca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18cc09ca-89b8-46dc-9497-96c3e54b01da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab6caac4-3af8-4769-a01b-46be3d76ca9a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18cc09ca-89b8-46dc-9497-96c3e54b01da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_53fc9942-3ee5-4ac7-94fa-dca728d9a740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18cc09ca-89b8-46dc-9497-96c3e54b01da" xlink:to="loc_us-gaap_ProfitLoss_53fc9942-3ee5-4ac7-94fa-dca728d9a740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18cc09ca-89b8-46dc-9497-96c3e54b01da" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_b2d6ead5-85af-4710-ab5d-617bccc54041" xlink:href="nktr-20211231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_b2d6ead5-85af-4710-ab5d-617bccc54041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_9e34e369-52b0-4dda-b9bb-5c42a96d441d" xlink:href="nktr-20211231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_9e34e369-52b0-4dda-b9bb-5c42a96d441d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_1dbb55b0-6ca1-4a8f-aa96-51808e24755b" xlink:href="nktr-20211231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_1dbb55b0-6ca1-4a8f-aa96-51808e24755b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_1a84fc91-b6b5-4603-adef-fcadf73fe9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_1a84fc91-b6b5-4603-adef-fcadf73fe9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a95bc054-704d-4bb7-851a-d940fee7cb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a95bc054-704d-4bb7-851a-d940fee7cb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0db6b725-49c4-4fbe-b497-cd52cd40377e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0db6b725-49c4-4fbe-b497-cd52cd40377e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_bfc0d06c-c830-4827-a756-949586562421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:to="loc_us-gaap_DepreciationAndAmortization_bfc0d06c-c830-4827-a756-949586562421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_abbbce0d-f4d7-4fa0-b809-f9d85506ba0e" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_abbbce0d-f4d7-4fa0-b809-f9d85506ba0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_3d29a6f3-5254-45c0-beef-5c32124bb424" xlink:href="nktr-20211231.xsd#nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:to="loc_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions_3d29a6f3-5254-45c0-beef-5c32124bb424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bd41cab-4a36-42d5-bf48-93cb2a303d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_32276409-7dde-4a5b-9996-38acfedf70f2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bd41cab-4a36-42d5-bf48-93cb2a303d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e0351278-5529-4be8-9580-ecf302bcd9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bd41cab-4a36-42d5-bf48-93cb2a303d9b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e0351278-5529-4be8-9580-ecf302bcd9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bcba7e99-7410-4b93-aa24-b53074926a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bd41cab-4a36-42d5-bf48-93cb2a303d9b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bcba7e99-7410-4b93-aa24-b53074926a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_dcd7a4e8-2d56-4e16-88a1-01c5f51d0e1d" xlink:href="nktr-20211231.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bd41cab-4a36-42d5-bf48-93cb2a303d9b" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_dcd7a4e8-2d56-4e16-88a1-01c5f51d0e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8a556030-0062-4abe-803d-11e4c4e7833f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bd41cab-4a36-42d5-bf48-93cb2a303d9b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8a556030-0062-4abe-803d-11e4c4e7833f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_caeca45d-c519-4c24-a34c-7aeac11bf508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bd41cab-4a36-42d5-bf48-93cb2a303d9b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_caeca45d-c519-4c24-a34c-7aeac11bf508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f9ed2fab-7bb3-488c-a6b6-6e9229219cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bd41cab-4a36-42d5-bf48-93cb2a303d9b" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f9ed2fab-7bb3-488c-a6b6-6e9229219cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_d6d16123-1c84-4020-bcd3-4b761af4642b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bd41cab-4a36-42d5-bf48-93cb2a303d9b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_d6d16123-1c84-4020-bcd3-4b761af4642b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_96ebcbae-db81-427a-acda-c3780e68114a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7bd41cab-4a36-42d5-bf48-93cb2a303d9b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_96ebcbae-db81-427a-acda-c3780e68114a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_456081c2-5d34-4f73-93de-1f4cf67155cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18cc09ca-89b8-46dc-9497-96c3e54b01da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_456081c2-5d34-4f73-93de-1f4cf67155cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e617bf0-b83c-4f8d-b366-ab4e0018b346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab6caac4-3af8-4769-a01b-46be3d76ca9a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e617bf0-b83c-4f8d-b366-ab4e0018b346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5526b7e7-51c1-410f-b72e-98ea9d75cd65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e617bf0-b83c-4f8d-b366-ab4e0018b346" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5526b7e7-51c1-410f-b72e-98ea9d75cd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b06b101c-3e00-4376-8984-4f4b8e3a625d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e617bf0-b83c-4f8d-b366-ab4e0018b346" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b06b101c-3e00-4376-8984-4f4b8e3a625d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fabf61cf-0f60-4ab0-9892-fe0e73a09482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e617bf0-b83c-4f8d-b366-ab4e0018b346" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fabf61cf-0f60-4ab0-9892-fe0e73a09482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ecc66b2b-4f49-4ef6-986e-eb6bfcb543ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e617bf0-b83c-4f8d-b366-ab4e0018b346" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ecc66b2b-4f49-4ef6-986e-eb6bfcb543ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc66f13f-759a-4561-adf7-149dfbb62908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8e617bf0-b83c-4f8d-b366-ab4e0018b346" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc66f13f-759a-4561-adf7-149dfbb62908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b2e3408-4439-49a4-ae29-28fae2b478f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab6caac4-3af8-4769-a01b-46be3d76ca9a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b2e3408-4439-49a4-ae29-28fae2b478f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_2d2d5a2b-3d2d-4888-88c6-d8605fe83322" xlink:href="nktr-20211231.xsd#nktr_ProceedsFromSaleOfFutureRoyaltiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b2e3408-4439-49a4-ae29-28fae2b478f4" xlink:to="loc_nktr_ProceedsFromSaleOfFutureRoyaltiesNet_2d2d5a2b-3d2d-4888-88c6-d8605fe83322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_7f3348e3-77a5-4e0e-a821-7b5840241700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b2e3408-4439-49a4-ae29-28fae2b478f4" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_7f3348e3-77a5-4e0e-a821-7b5840241700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_77fa293a-38a9-4fcd-873a-b174e83c6c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b2e3408-4439-49a4-ae29-28fae2b478f4" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_77fa293a-38a9-4fcd-873a-b174e83c6c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_24bcdf92-2126-4af5-9882-bd4b2023dc87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b2e3408-4439-49a4-ae29-28fae2b478f4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_24bcdf92-2126-4af5-9882-bd4b2023dc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f097627d-8b62-41d0-948f-92ee94975ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9b2e3408-4439-49a4-ae29-28fae2b478f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f097627d-8b62-41d0-948f-92ee94975ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59d4b6fb-1188-4754-9804-8849d3e04b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab6caac4-3af8-4769-a01b-46be3d76ca9a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59d4b6fb-1188-4754-9804-8849d3e04b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_49de3914-98a3-4fa4-9ea6-046a3d5a6734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab6caac4-3af8-4769-a01b-46be3d76ca9a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_49de3914-98a3-4fa4-9ea6-046a3d5a6734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f52da820-aa19-4b6d-8f57-266c1e315ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab6caac4-3af8-4769-a01b-46be3d76ca9a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f52da820-aa19-4b6d-8f57-266c1e315ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7d27bf1-8dab-40cb-bf1a-5c8f5e7f0b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab6caac4-3af8-4769-a01b-46be3d76ca9a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7d27bf1-8dab-40cb-bf1a-5c8f5e7f0b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e7772126-8cbd-49f0-912d-b82f77852692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab6caac4-3af8-4769-a01b-46be3d76ca9a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e7772126-8cbd-49f0-912d-b82f77852692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_5ea84e7d-60ff-4ce9-8fc1-7ed9d3791ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e7772126-8cbd-49f0-912d-b82f77852692" xlink:to="loc_us-gaap_InterestPaidNet_5ea84e7d-60ff-4ce9-8fc1-7ed9d3791ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_a649ceaa-e09b-4d26-b13b-0265d9506005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e7772126-8cbd-49f0-912d-b82f77852692" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_a649ceaa-e09b-4d26-b13b-0265d9506005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_884a4982-0a6c-45e7-a3f3-775c8fededa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e7772126-8cbd-49f0-912d-b82f77852692" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_884a4982-0a6c-45e7-a3f3-775c8fededa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities_bca9c218-ccd2-4265-9332-9a4d287c1f9d" xlink:href="nktr-20211231.xsd#nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e7772126-8cbd-49f0-912d-b82f77852692" xlink:to="loc_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities_bca9c218-ccd2-4265-9332-9a4d287c1f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="nktr-20211231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_10ce8901-1f20-4f51-be20-acfbafa09b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts_031316d5-0f82-4203-b7a0-fd8d0939b4de" xlink:href="nktr-20211231.xsd#nktr_SaleOfFutureRoyaltiesTransactionCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ce8901-1f20-4f51-be20-acfbafa09b1f" xlink:to="loc_nktr_SaleOfFutureRoyaltiesTransactionCosts_031316d5-0f82-4203-b7a0-fd8d0939b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20211231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c73dbcca-8998-41f4-b6ce-ad43351a5a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_4543f0ab-e242-46ac-9285-da009d842272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c73dbcca-8998-41f4-b6ce-ad43351a5a6b" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_4543f0ab-e242-46ac-9285-da009d842272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock_a84be845-5450-4f20-9900-3f208cda00cf" xlink:href="nktr-20211231.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_nktr_OrganizationPolicyTextBlock_a84be845-5450-4f20-9900-3f208cda00cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_b349f10b-5df3-4593-8d02-aaa67cad9be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_b349f10b-5df3-4593-8d02-aaa67cad9be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_61b38cbb-0de6-4b2b-87ab-3923f7aed53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_61b38cbb-0de6-4b2b-87ab-3923f7aed53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_07eaf784-3a56-47cb-aef0-d4864601e049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_07eaf784-3a56-47cb-aef0-d4864601e049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b1d79e3f-cd37-4708-88aa-430995839e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b1d79e3f-cd37-4708-88aa-430995839e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_eb915eda-4064-4569-aa97-0fb276812be0" xlink:href="nktr-20211231.xsd#nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock_eb915eda-4064-4569-aa97-0fb276812be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_24ea2668-9f31-45e9-bb02-b246c9ea3eb4" xlink:href="nktr-20211231.xsd#nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock_24ea2668-9f31-45e9-bb02-b246c9ea3eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_afe64d0a-376e-4b95-bdf8-ded7f7405881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_afe64d0a-376e-4b95-bdf8-ded7f7405881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_0e2ec8dd-c655-4d1a-9baa-80ec316c1e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_0e2ec8dd-c655-4d1a-9baa-80ec316c1e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_05b885be-adfd-4ecb-bd11-5df518ce3e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_05b885be-adfd-4ecb-bd11-5df518ce3e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b1f1cc44-1522-49fa-b4d2-0671768034fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b1f1cc44-1522-49fa-b4d2-0671768034fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3f63981c-9bac-4608-b62d-892f5ec811ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3f63981c-9bac-4608-b62d-892f5ec811ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock_75bc7743-6f1e-4ead-9aba-834e9a4b5b2c" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock_75bc7743-6f1e-4ead-9aba-834e9a4b5b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_08e6277f-fb17-47db-9bb7-18a3d4f12027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_08e6277f-fb17-47db-9bb7-18a3d4f12027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5a923d69-e359-4c95-a014-cfa72cac2267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5a923d69-e359-4c95-a014-cfa72cac2267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_279996df-f7c0-4b5b-b163-4e9b738119b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_279996df-f7c0-4b5b-b163-4e9b738119b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_cddb1d41-858b-4543-839d-1178e8e92fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_cddb1d41-858b-4543-839d-1178e8e92fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_66f731e9-fb35-477f-937f-8b1364b3f0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4835272b-b523-4b7d-b0f8-eb8d4653d973" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_66f731e9-fb35-477f-937f-8b1364b3f0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_727e5fb0-3c76-4435-887c-85d0ba05633c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:href="nktr-20211231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_727e5fb0-3c76-4435-887c-85d0ba05633c" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7747156e-8812-4ee0-bd52-f67540d79a69" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_srt_RangeAxis_7747156e-8812-4ee0-bd52-f67540d79a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2e325f9c-20e3-4c0c-bd4a-aab93aa08aaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7747156e-8812-4ee0-bd52-f67540d79a69" xlink:to="loc_srt_RangeMember_2e325f9c-20e3-4c0c-bd4a-aab93aa08aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b529b7f4-df57-47c7-95e7-2cf7dfdf214c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2e325f9c-20e3-4c0c-bd4a-aab93aa08aaf" xlink:to="loc_srt_MinimumMember_b529b7f4-df57-47c7-95e7-2cf7dfdf214c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fdc34467-518e-404e-ab7c-7fafd5dc06d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2e325f9c-20e3-4c0c-bd4a-aab93aa08aaf" xlink:to="loc_srt_MaximumMember_fdc34467-518e-404e-ab7c-7fafd5dc06d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_010ccb26-a705-488b-9e73-ac2b20f723ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_010ccb26-a705-488b-9e73-ac2b20f723ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_117407c2-a8d1-49d9-b975-97317715188b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_010ccb26-a705-488b-9e73-ac2b20f723ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_117407c2-a8d1-49d9-b975-97317715188b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_7331f5d4-3851-4d34-b3ca-e2479ee215b8" xlink:href="nktr-20211231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_117407c2-a8d1-49d9-b975-97317715188b" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_7331f5d4-3851-4d34-b3ca-e2479ee215b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_0c897598-9b25-4dc7-bb5e-e1c977ea77eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_117407c2-a8d1-49d9-b975-97317715188b" xlink:to="loc_us-gaap_BuildingMember_0c897598-9b25-4dc7-bb5e-e1c977ea77eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aac728f9-9aee-4562-97b0-82900cf7891c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_srt_ProductOrServiceAxis_aac728f9-9aee-4562-97b0-82900cf7891c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d341c727-5fc1-4a02-8d8d-3fa2961acc4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_aac728f9-9aee-4562-97b0-82900cf7891c" xlink:to="loc_srt_ProductsAndServicesDomain_d341c727-5fc1-4a02-8d8d-3fa2961acc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_028719a0-975a-4313-b4a2-f5280e6e84a1" xlink:href="nktr-20211231.xsd#nktr_NKTR181Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d341c727-5fc1-4a02-8d8d-3fa2961acc4a" xlink:to="loc_nktr_NKTR181Member_028719a0-975a-4313-b4a2-f5280e6e84a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_7be8545f-a28b-4a68-aa35-1aeee3111ac9" xlink:href="nktr-20211231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d341c727-5fc1-4a02-8d8d-3fa2961acc4a" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_7be8545f-a28b-4a68-aa35-1aeee3111ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndNonCashRoyaltiesMember_d3027dc6-8712-485a-bda7-894f72b7306b" xlink:href="nktr-20211231.xsd#nktr_CashAndNonCashRoyaltiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d341c727-5fc1-4a02-8d8d-3fa2961acc4a" xlink:to="loc_nktr_CashAndNonCashRoyaltiesMember_d3027dc6-8712-485a-bda7-894f72b7306b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_248f78b0-c575-44e0-b276-ba8858c5906f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_248f78b0-c575-44e0-b276-ba8858c5906f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_515a7626-0c76-45e1-8aac-c91b3e537865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_248f78b0-c575-44e0-b276-ba8858c5906f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_515a7626-0c76-45e1-8aac-c91b3e537865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsRSUsAndPSUsMember_ce283d17-3332-4186-8c6b-f0b3cab4f4ad" xlink:href="nktr-20211231.xsd#nktr_StockOptionsRSUsAndPSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_515a7626-0c76-45e1-8aac-c91b3e537865" xlink:to="loc_nktr_StockOptionsRSUsAndPSUsMember_ce283d17-3332-4186-8c6b-f0b3cab4f4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4346becd-8117-4d06-bd47-18eb1b4572fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4346becd-8117-4d06-bd47-18eb1b4572fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3dbe196-13a3-47e9-abec-5561c4c28802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4346becd-8117-4d06-bd47-18eb1b4572fc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3dbe196-13a3-47e9-abec-5561c4c28802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_84feb216-48f7-471f-a789-3b96048bbef1" xlink:href="nktr-20211231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3dbe196-13a3-47e9-abec-5561c4c28802" xlink:to="loc_nktr_BMSCollaborationAgreementMember_84feb216-48f7-471f-a789-3b96048bbef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:href="nktr-20211231.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_511a35fe-d7b8-4be5-a400-17a2f2c668b6" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_e17917a1-b950-44f9-ac91-5bfa45aac5ac" xlink:href="nktr-20211231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_e17917a1-b950-44f9-ac91-5bfa45aac5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_3661668c-f137-4426-b3e4-1ae8e84c9e39" xlink:href="nktr-20211231.xsd#nktr_NetExpenseReimbursementsFromCollaborationPartner"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_NetExpenseReimbursementsFromCollaborationPartner_3661668c-f137-4426-b3e4-1ae8e84c9e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_194df37d-56f6-47d4-8f64-143292a55316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_194df37d-56f6-47d4-8f64-143292a55316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_2d07bd10-bf44-4b87-94a2-a6765b02838c" xlink:href="nktr-20211231.xsd#nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment_2d07bd10-bf44-4b87-94a2-a6765b02838c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e56e5e4-81b1-4f13-aefe-dc31bace93a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4e56e5e4-81b1-4f13-aefe-dc31bace93a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_29348e5d-4fda-4002-8d9b-cabd460784f7" xlink:href="nktr-20211231.xsd#nktr_SalesMilestoneRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_SalesMilestoneRevenue_29348e5d-4fda-4002-8d9b-cabd460784f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment_5a41fede-5b46-40e4-aabc-3c33f0d1ee20" xlink:href="nktr-20211231.xsd#nktr_WriteOffOfPrepayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_nktr_WriteOffOfPrepayment_5a41fede-5b46-40e4-aabc-3c33f0d1ee20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_c38676fe-f830-471e-8313-6dc49848160b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_c38676fe-f830-471e-8313-6dc49848160b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6a589015-ac1a-4669-a669-0cba600b7e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_e33575a4-e094-49a0-9033-571c451c0915" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6a589015-ac1a-4669-a669-0cba600b7e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20211231.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_49e7fc09-8baa-4487-b6dc-21258a7b946d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_d3e6939e-7d86-4e97-b941-b6ac26cef410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_49e7fc09-8baa-4487-b6dc-21258a7b946d" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_d3e6939e-7d86-4e97-b941-b6ac26cef410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_15071743-d1cd-44b8-a8ca-78a1e80e3248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3141c8e3-b457-4e25-9d77-8a181d3b8601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_15071743-d1cd-44b8-a8ca-78a1e80e3248" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3141c8e3-b457-4e25-9d77-8a181d3b8601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_51420e27-3ef5-4c8c-8fdb-c884daf4aac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_15071743-d1cd-44b8-a8ca-78a1e80e3248" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_51420e27-3ef5-4c8c-8fdb-c884daf4aac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_8ae8a112-d119-4ffe-8d02-97ef614a69b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_218264f8-86ea-48f7-bcf3-02525f5341d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_8ae8a112-d119-4ffe-8d02-97ef614a69b7" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_218264f8-86ea-48f7-bcf3-02525f5341d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f956ec1-871e-4db3-98ad-c2042a0e4f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_218264f8-86ea-48f7-bcf3-02525f5341d4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f956ec1-871e-4db3-98ad-c2042a0e4f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_27317315-ab45-4ae4-a105-88b06b9d07d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_218264f8-86ea-48f7-bcf3-02525f5341d4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_27317315-ab45-4ae4-a105-88b06b9d07d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6ea09a16-33b7-4527-98ae-bab92bdb4c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_218264f8-86ea-48f7-bcf3-02525f5341d4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6ea09a16-33b7-4527-98ae-bab92bdb4c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a8d09865-cf7f-4174-9ab8-c4b753d2a921" xlink:href="nktr-20211231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_218264f8-86ea-48f7-bcf3-02525f5341d4" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_a8d09865-cf7f-4174-9ab8-c4b753d2a921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_be93a5f4-59d2-40ad-966b-13e5380e6d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_0e48631e-ca5d-477a-9a02-5466a7c39a5c" xlink:href="nktr-20211231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be93a5f4-59d2-40ad-966b-13e5380e6d29" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_0e48631e-ca5d-477a-9a02-5466a7c39a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5c123be8-ad26-473c-aad8-ebc8c83775b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_0e48631e-ca5d-477a-9a02-5466a7c39a5c" xlink:to="loc_srt_RangeAxis_5c123be8-ad26-473c-aad8-ebc8c83775b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9410c84e-e5f8-401c-919b-ee1768d9b82d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5c123be8-ad26-473c-aad8-ebc8c83775b7" xlink:to="loc_srt_RangeMember_9410c84e-e5f8-401c-919b-ee1768d9b82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aa93622c-2c0e-46de-9f24-4301073aa6d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9410c84e-e5f8-401c-919b-ee1768d9b82d" xlink:to="loc_srt_MinimumMember_aa93622c-2c0e-46de-9f24-4301073aa6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b71fbfe5-0d15-477d-a959-bba78b749706" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9410c84e-e5f8-401c-919b-ee1768d9b82d" xlink:to="loc_srt_MaximumMember_b71fbfe5-0d15-477d-a959-bba78b749706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:href="nktr-20211231.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_0e48631e-ca5d-477a-9a02-5466a7c39a5c" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_81b212f0-ca45-40ef-be94-45bb66fe5163" xlink:href="nktr-20211231.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_81b212f0-ca45-40ef-be94-45bb66fe5163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_17f09dc9-f0dc-49b7-b587-16c79247ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_17f09dc9-f0dc-49b7-b587-16c79247ae24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_c3da947e-eeec-4844-9918-1fcd7dd7d47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_us-gaap_InterestReceivableCurrent_c3da947e-eeec-4844-9918-1fcd7dd7d47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_983d00e6-abda-4d72-89b1-48081102596b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_983d00e6-abda-4d72-89b1-48081102596b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da407772-a153-433a-8902-37e72c85e47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da407772-a153-433a-8902-37e72c85e47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_d38f31a4-b798-4958-bd95-fbe14f723750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_35a788bc-22aa-4784-a4c4-1f52d5fe0b3e" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_d38f31a4-b798-4958-bd95-fbe14f723750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_f2b9a3d9-904e-4491-8ad0-2fc3995bfeee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76726c36-859f-4ca2-861a-8c3460abec9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f2b9a3d9-904e-4491-8ad0-2fc3995bfeee" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76726c36-859f-4ca2-861a-8c3460abec9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_aa532de2-58ba-45e4-9448-b90df6716351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76726c36-859f-4ca2-861a-8c3460abec9f" xlink:to="loc_us-gaap_InvestmentTypeAxis_aa532de2-58ba-45e4-9448-b90df6716351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_aa532de2-58ba-45e4-9448-b90df6716351" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_98db5883-de6a-478d-9059-317090296f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_98db5883-de6a-478d-9059-317090296f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_464ae642-85fa-4a01-8fde-9df57347bde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:to="loc_us-gaap_CommercialPaperMember_464ae642-85fa-4a01-8fde-9df57347bde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fd6ac170-e458-4708-8650-18cb84bfb71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fd6ac170-e458-4708-8650-18cb84bfb71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f62824c5-d658-4993-97f1-56fded722935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f62824c5-d658-4993-97f1-56fded722935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4833659c-f2de-49d8-a4dc-7b37d43f0017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a5925498-be73-4b86-be3e-0014212e7bc7" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4833659c-f2de-49d8-a4dc-7b37d43f0017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9529d222-03c9-498e-aca0-c844dabe9aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76726c36-859f-4ca2-861a-8c3460abec9f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9529d222-03c9-498e-aca0-c844dabe9aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37f695bc-51e3-4a9b-8dae-da76b5e47a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9529d222-03c9-498e-aca0-c844dabe9aea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37f695bc-51e3-4a9b-8dae-da76b5e47a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_85bf03ef-76aa-4059-98fc-d1cd85db73b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37f695bc-51e3-4a9b-8dae-da76b5e47a5d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_85bf03ef-76aa-4059-98fc-d1cd85db73b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7fd32eac-4093-4a83-8595-33f56018431b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37f695bc-51e3-4a9b-8dae-da76b5e47a5d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7fd32eac-4093-4a83-8595-33f56018431b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_76726c36-859f-4ca2-861a-8c3460abec9f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f805489c-b94b-4058-a337-823e90705193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f805489c-b94b-4058-a337-823e90705193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f4462c9c-d189-4f40-8a19-0ec740fa8db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f4462c9c-d189-4f40-8a19-0ec740fa8db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9bc62439-3b41-4af0-95d4-d66152327efb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9bc62439-3b41-4af0-95d4-d66152327efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a62958d1-94bf-44b1-bd24-54065d552307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a62958d1-94bf-44b1-bd24-54065d552307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_bbc5a727-27b7-467a-81ac-2e9b0fce39e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_bbc5a727-27b7-467a-81ac-2e9b0fce39e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_a0572bea-c232-4557-936d-89cfb7c8d56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_us-gaap_Cash_a0572bea-c232-4557-936d-89cfb7c8d56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ba47fefe-9d5d-4467-adc8-c08be53b11c0" xlink:href="nktr-20211231.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ef2a375a-6b65-4122-bad5-60aa765fbb1b" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ba47fefe-9d5d-4467-adc8-c08be53b11c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20211231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_80951ace-04a5-4e45-aa90-3704f3bbdef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_53fa0db0-83d1-48e2-9f5a-2fa40cbe4945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_80951ace-04a5-4e45-aa90-3704f3bbdef4" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_53fa0db0-83d1-48e2-9f5a-2fa40cbe4945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7043a474-c8ef-4119-ab61-d71eeee2d44b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3df830cd-523f-4239-95cd-416329de2a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7043a474-c8ef-4119-ab61-d71eeee2d44b" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3df830cd-523f-4239-95cd-416329de2a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryScheduleofInventoriesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#InventoryScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_29102e08-a45c-497b-a3b5-efe0418a8542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e536001c-ada2-4209-9f60-efe5bfa90c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_29102e08-a45c-497b-a3b5-efe0418a8542" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e536001c-ada2-4209-9f60-efe5bfa90c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_44e20a05-5df7-49f3-acf8-5f0f9d2eec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_29102e08-a45c-497b-a3b5-efe0418a8542" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_44e20a05-5df7-49f3-acf8-5f0f9d2eec5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_fe9a8703-f2ea-4128-8d65-b4d371c2f8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_29102e08-a45c-497b-a3b5-efe0418a8542" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_fe9a8703-f2ea-4128-8d65-b4d371c2f8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a41520e1-3f5e-4072-afb0-7399315c5538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_29102e08-a45c-497b-a3b5-efe0418a8542" xlink:to="loc_us-gaap_InventoryNet_a41520e1-3f5e-4072-afb0-7399315c5538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="nktr-20211231.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5052ca67-23ca-488b-9114-dc2a55629774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4e6d7be1-fc44-4b9e-ab0a-01c778c61bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5052ca67-23ca-488b-9114-dc2a55629774" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4e6d7be1-fc44-4b9e-ab0a-01c778c61bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ac07fab9-fb38-475a-a2c6-e13c280ab88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_163ba738-b13d-43a4-9889-8b32871fb560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ac07fab9-fb38-475a-a2c6-e13c280ab88f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_163ba738-b13d-43a4-9889-8b32871fb560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b30c30bc-2ce2-499c-8996-8297abf761a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f014048-e29e-483e-8959-cdefdde7a199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b30c30bc-2ce2-499c-8996-8297abf761a9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f014048-e29e-483e-8959-cdefdde7a199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0133434-70a2-4bdd-8af6-ce3ca68a772b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f014048-e29e-483e-8959-cdefdde7a199" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0133434-70a2-4bdd-8af6-ce3ca68a772b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0133434-70a2-4bdd-8af6-ce3ca68a772b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BuildingAndLeaseholdImprovementsMember_eefd3e43-febe-4cdb-a2c5-6ca00f29e73c" xlink:href="nktr-20211231.xsd#nktr_BuildingAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:to="loc_nktr_BuildingAndLeaseholdImprovementsMember_eefd3e43-febe-4cdb-a2c5-6ca00f29e73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LaboratoryEquipmentMember_bec3aaeb-db16-442f-aa14-b053747fad7c" xlink:href="nktr-20211231.xsd#nktr_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:to="loc_nktr_LaboratoryEquipmentMember_bec3aaeb-db16-442f-aa14-b053747fad7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ComputerFurnitureAndOtherMember_38c472f6-4a34-4a22-a9c7-e8d2929f04ed" xlink:href="nktr-20211231.xsd#nktr_ComputerFurnitureAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:to="loc_nktr_ComputerFurnitureAndOtherMember_38c472f6-4a34-4a22-a9c7-e8d2929f04ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_6efecc3f-f6f2-43d9-858b-870a4d395aeb" xlink:href="nktr-20211231.xsd#nktr_ManufacturingLaboratoryAndOtherEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:to="loc_nktr_ManufacturingLaboratoryAndOtherEquipmentMember_6efecc3f-f6f2-43d9-858b-870a4d395aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_34748a3b-3a24-4508-b503-f262d1fbee0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf31de1a-7058-4d4c-b897-4c34253209cb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_34748a3b-3a24-4508-b503-f262d1fbee0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f014048-e29e-483e-8959-cdefdde7a199" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_141bf550-944c-420e-8f1a-6fdf8706716c" xlink:href="nktr-20211231.xsd#nktr_DepreciablePropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentGross_141bf550-944c-420e-8f1a-6fdf8706716c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c19d0f99-7e78-4e77-b91b-89895fb22a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c19d0f99-7e78-4e77-b91b-89895fb22a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_eb6d3f6b-5d49-4ca4-9af1-380c0270e1c0" xlink:href="nktr-20211231.xsd#nktr_DepreciablePropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_nktr_DepreciablePropertyPlantAndEquipmentNet_eb6d3f6b-5d49-4ca4-9af1-380c0270e1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_ec747558-74dc-400d-8ba2-fa7858d79418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_us-gaap_ConstructionInProgressGross_ec747558-74dc-400d-8ba2-fa7858d79418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ef3d36ff-fe1b-413e-b831-435008e35dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d972e2e8-f273-4e45-bd62-b89ae1ba4638" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ef3d36ff-fe1b-413e-b831-435008e35dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#PropertyPlantandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_85afe9df-e59a-49f2-b4ef-a735dd1b6851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fc784772-c125-41c8-ae48-4b4de87f8ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_85afe9df-e59a-49f2-b4ef-a735dd1b6851" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fc784772-c125-41c8-ae48-4b4de87f8ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SeniorSecuredNotes" xlink:type="simple" xlink:href="nktr-20211231.xsd#SeniorSecuredNotes"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SeniorSecuredNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2be63d02-a615-4f38-b635-4d561c23ad76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_99c4bc3d-ec6e-4c0c-99d7-91de92832ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2be63d02-a615-4f38-b635-4d561c23ad76" xlink:to="loc_us-gaap_LongTermDebtTextBlock_99c4bc3d-ec6e-4c0c-99d7-91de92832ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SeniorSecuredNotesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#SeniorSecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SeniorSecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f3150d06-d987-409a-9bad-89bf40a8cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_abbb83eb-6a7c-45b8-b55a-1e1fa32ef8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f3150d06-d987-409a-9bad-89bf40a8cb1d" xlink:to="loc_us-gaap_DebtInstrumentTable_abbb83eb-6a7c-45b8-b55a-1e1fa32ef8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfba12d1-b695-4bfa-ac2b-bce29fb6f6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_abbb83eb-6a7c-45b8-b55a-1e1fa32ef8c4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfba12d1-b695-4bfa-ac2b-bce29fb6f6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_48cf6d43-8e1b-4aa7-b472-df74682192b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfba12d1-b695-4bfa-ac2b-bce29fb6f6d5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_48cf6d43-8e1b-4aa7-b472-df74682192b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1cda6da4-d035-480b-ad9b-74276cf47985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_48cf6d43-8e1b-4aa7-b472-df74682192b7" xlink:to="loc_us-gaap_SeniorNotesMember_1cda6da4-d035-480b-ad9b-74276cf47985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8eb021a1-357a-4a82-99b2-f6e058dd2446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_abbb83eb-6a7c-45b8-b55a-1e1fa32ef8c4" xlink:to="loc_us-gaap_DebtInstrumentAxis_8eb021a1-357a-4a82-99b2-f6e058dd2446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e8d572f-61f6-45fd-852c-a227ecfbb252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8eb021a1-357a-4a82-99b2-f6e058dd2446" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e8d572f-61f6-45fd-852c-a227ecfbb252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_3d8d72f0-f2ec-4f36-8bc1-b4a403f05487" xlink:href="nktr-20211231.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e8d572f-61f6-45fd-852c-a227ecfbb252" xlink:to="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_3d8d72f0-f2ec-4f36-8bc1-b4a403f05487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_abbb83eb-6a7c-45b8-b55a-1e1fa32ef8c4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_f2bb6bda-c575-4ac0-985d-680663ebe2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:to="loc_us-gaap_SeniorNotes_f2bb6bda-c575-4ac0-985d-680663ebe2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eb3fd085-cc75-430c-91f6-be11cd585943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eb3fd085-cc75-430c-91f6-be11cd585943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_afe3d190-4c4d-4598-8f2f-09cb192f5640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_afe3d190-4c4d-4598-8f2f-09cb192f5640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_33cf2013-c5e6-4599-aa86-bac6db79f290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_24e60f41-eaf4-4bdf-95d5-fc3655a80a9b" xlink:to="loc_us-gaap_InterestReceivable_33cf2013-c5e6-4599-aa86-bac6db79f290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="simple" xlink:href="nktr-20211231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_15b81d8e-2310-4f44-ae90-5ed0a41a5054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DevelopmentDerivativeLiabilityTextBlock_bd673907-f321-4c79-9ee5-7523b8714ff6" xlink:href="nktr-20211231.xsd#nktr_DevelopmentDerivativeLiabilityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_15b81d8e-2310-4f44-ae90-5ed0a41a5054" xlink:to="loc_nktr_DevelopmentDerivativeLiabilityTextBlock_bd673907-f321-4c79-9ee5-7523b8714ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_915579e6-539f-417f-b56c-94b9af8a7ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_6fb8536d-d8ef-42a3-8d34-b657e4ee0bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_915579e6-539f-417f-b56c-94b9af8a7ef1" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_6fb8536d-d8ef-42a3-8d34-b657e4ee0bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_42a67ab8-1a44-4481-9aab-cbb146fd4899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f317e6b-b2f4-45ce-aef3-d496b5933c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_42a67ab8-1a44-4481-9aab-cbb146fd4899" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f317e6b-b2f4-45ce-aef3-d496b5933c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b9d68d09-f0c4-4c10-b4b4-7e32c31d799c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f317e6b-b2f4-45ce-aef3-d496b5933c00" xlink:to="loc_srt_CounterpartyNameAxis_b9d68d09-f0c4-4c10-b4b4-7e32c31d799c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1d2dbd9b-ef49-4d2a-adba-7f5a07d228bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b9d68d09-f0c4-4c10-b4b4-7e32c31d799c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1d2dbd9b-ef49-4d2a-adba-7f5a07d228bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SFJPharmaceuticalsMember_a144262c-e6d3-4eb8-a0d1-1078a23e91b9" xlink:href="nktr-20211231.xsd#nktr_SFJPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1d2dbd9b-ef49-4d2a-adba-7f5a07d228bf" xlink:to="loc_nktr_SFJPharmaceuticalsMember_a144262c-e6d3-4eb8-a0d1-1078a23e91b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2f10b84c-cc7c-48b9-b4b8-5b499832bc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f317e6b-b2f4-45ce-aef3-d496b5933c00" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2f10b84c-cc7c-48b9-b4b8-5b499832bc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d58a4982-2e18-4cae-8424-bb47630fe67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2f10b84c-cc7c-48b9-b4b8-5b499832bc5e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d58a4982-2e18-4cae-8424-bb47630fe67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CostOfBorrowingMember_9b08d053-4deb-479c-b517-1d6588290522" xlink:href="nktr-20211231.xsd#nktr_CostOfBorrowingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d58a4982-2e18-4cae-8424-bb47630fe67d" xlink:to="loc_nktr_CostOfBorrowingMember_9b08d053-4deb-479c-b517-1d6588290522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f317e6b-b2f4-45ce-aef3-d496b5933c00" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementCommittedFunding_6feb9e90-3ad8-44b0-8a92-8214717cc58e" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementCommittedFunding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementCommittedFunding_6feb9e90-3ad8-44b0-8a92-8214717cc58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_f217540f-679e-471a-927f-cf965b70dd36" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication_f217540f-679e-471a-927f-cf965b70dd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_e2c4411d-49eb-4612-a58c-c77216cd6af4" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid_e2c4411d-49eb-4612-a58c-c77216cd6af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_7d84661a-f766-4aae-909a-94262ea1b4d9" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment_7d84661a-f766-4aae-909a-94262ea1b4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_c9b46afb-153f-4cb8-ac5e-1f17263fd279" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication_c9b46afb-153f-4cb8-ac5e-1f17263fd279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_bbc719bf-e923-4b04-a7f2-e1e716d62682" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid_bbc719bf-e923-4b04-a7f2-e1e716d62682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_21b8b9b3-ae06-4080-8f79-fa4944eb8b90" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementAdditionalIndicationPayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_nktr_CollaborativeArrangementAdditionalIndicationPayment_21b8b9b3-ae06-4080-8f79-fa4944eb8b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_76d765a8-bbfb-4caa-af7c-0e6b569451ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e59df585-c2c9-439f-bbd1-2e30abba3f15" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_76d765a8-bbfb-4caa-af7c-0e6b569451ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_473951cb-bc30-42af-b86a-0e1917c6a81c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f22837cf-fc22-4cef-af25-6b25ab5da124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_473951cb-bc30-42af-b86a-0e1917c6a81c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f22837cf-fc22-4cef-af25-6b25ab5da124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_00bb9e83-fb79-4b58-8389-9cbf9316ec30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f22837cf-fc22-4cef-af25-6b25ab5da124" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_00bb9e83-fb79-4b58-8389-9cbf9316ec30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d7516dd0-7a3f-4450-8d61-51c9f4654cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_00bb9e83-fb79-4b58-8389-9cbf9316ec30" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d7516dd0-7a3f-4450-8d61-51c9f4654cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_dcad0751-6a9c-4114-bf22-bc66e7427c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d7516dd0-7a3f-4450-8d61-51c9f4654cd4" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_dcad0751-6a9c-4114-bf22-bc66e7427c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9ff49c0-2c96-4a52-9c0f-55f1b182de20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f22837cf-fc22-4cef-af25-6b25ab5da124" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9ff49c0-2c96-4a52-9c0f-55f1b182de20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e04f9ea3-e214-4836-8b73-517b55619ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9ff49c0-2c96-4a52-9c0f-55f1b182de20" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e04f9ea3-e214-4836-8b73-517b55619ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8dedf5c7-10ee-43cb-9d65-be2c879a6113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e04f9ea3-e214-4836-8b73-517b55619ab6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8dedf5c7-10ee-43cb-9d65-be2c879a6113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76259ea1-3c92-41a3-8311-a2a8f0c5aa80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f22837cf-fc22-4cef-af25-6b25ab5da124" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76259ea1-3c92-41a3-8311-a2a8f0c5aa80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76259ea1-3c92-41a3-8311-a2a8f0c5aa80" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3bcc8b75-a788-49a4-a6e1-1a714a0cb95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3bcc8b75-a788-49a4-a6e1-1a714a0cb95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_86ec7554-a5e3-4eb3-8a75-353053e600e4" xlink:href="nktr-20211231.xsd#nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:to="loc_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense_86ec7554-a5e3-4eb3-8a75-353053e600e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b2fa699f-6ba0-4ef8-a162-6df28d4951d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b2fa699f-6ba0-4ef8-a162-6df28d4951d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_f715dfb4-d707-4806-b3fc-1b100ee90aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_f715dfb4-d707-4806-b3fc-1b100ee90aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a614ca37-5ecd-4de4-8a92-1bdba35d45dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1b7e8509-6473-4f38-b753-78b1a55c31f1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a614ca37-5ecd-4de4-8a92-1bdba35d45dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeases" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0fde2c16-cfee-420b-be65-096467d3eaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_19acc890-724e-41ab-b09f-4c90616a77f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0fde2c16-cfee-420b-be65-096467d3eaa3" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_19acc890-724e-41ab-b09f-4c90616a77f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1da36ef0-b883-4ac9-b518-ca3158b9ec61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LesseeOperatingLeaseTableTextBlock_5ced2b99-8196-49c1-9dde-1c66001ad6cc" xlink:href="nktr-20211231.xsd#nktr_LesseeOperatingLeaseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1da36ef0-b883-4ac9-b518-ca3158b9ec61" xlink:to="loc_nktr_LesseeOperatingLeaseTableTextBlock_5ced2b99-8196-49c1-9dde-1c66001ad6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6fb79eb6-6309-4c58-900b-339901bb3513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1da36ef0-b883-4ac9-b518-ca3158b9ec61" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_6fb79eb6-6309-4c58-900b-339901bb3513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_31d068b2-1336-4def-93d1-fef9306cc091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1da36ef0-b883-4ac9-b518-ca3158b9ec61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_31d068b2-1336-4def-93d1-fef9306cc091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_89ffacef-75f6-4de4-9015-c57b5ae7885a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_066f36aa-0c87-4da6-bdfb-7f8ea39c9b9d" xlink:href="nktr-20211231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_89ffacef-75f6-4de4-9015-c57b5ae7885a" xlink:to="loc_nktr_ScheduleOfLeasesTable_066f36aa-0c87-4da6-bdfb-7f8ea39c9b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_ac14218e-875d-4985-be9f-fa1486ab92ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_066f36aa-0c87-4da6-bdfb-7f8ea39c9b9d" xlink:to="loc_us-gaap_LeaseContractualTermAxis_ac14218e-875d-4985-be9f-fa1486ab92ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_7bd49bab-0a9d-4248-8686-dc26259c33f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ac14218e-875d-4985-be9f-fa1486ab92ba" xlink:to="loc_us-gaap_LeaseContractualTermDomain_7bd49bab-0a9d-4248-8686-dc26259c33f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_b50315d8-2b20-46e0-9c42-76764a91aae8" xlink:href="nktr-20211231.xsd#nktr_MissionBayLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_7bd49bab-0a9d-4248-8686-dc26259c33f8" xlink:to="loc_nktr_MissionBayLeaseMember_b50315d8-2b20-46e0-9c42-76764a91aae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_27ce8b59-6629-4784-9ffd-2f6600053026" xlink:href="nktr-20211231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_7bd49bab-0a9d-4248-8686-dc26259c33f8" xlink:to="loc_nktr_ThirdStreetLeaseMember_27ce8b59-6629-4784-9ffd-2f6600053026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:href="nktr-20211231.xsd#nktr_LeasesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_066f36aa-0c87-4da6-bdfb-7f8ea39c9b9d" xlink:to="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpace_bd320543-9421-4c31-8f6a-cf41a0f43835" xlink:href="nktr-20211231.xsd#nktr_AreaOfLeasedSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_nktr_AreaOfLeasedSpace_bd320543-9421-4c31-8f6a-cf41a0f43835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1e9f7b0b-925a-40ac-bccf-aeefc7c3dcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_us-gaap_OperatingLeaseCost_1e9f7b0b-925a-40ac-bccf-aeefc7c3dcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_d2d69409-a574-4d08-bd29-8fd2db85e871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_us-gaap_OperatingLeasePayments_d2d69409-a574-4d08-bd29-8fd2db85e871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b50ce741-801c-4ab6-8c38-62a469be8ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b50ce741-801c-4ab6-8c38-62a469be8ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b96159a0-08cb-46e6-a7e1-04709f67b534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_cf9cb0b2-011c-4dbd-b0fd-d7bf5a5b6125" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b96159a0-08cb-46e6-a7e1-04709f67b534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesScheduleofOperatingLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_647ab33c-7cc3-4dc4-a5e6-b44b9738ae6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLeasesTable_f25eec48-6648-4b89-9a3b-56123ff2765d" xlink:href="nktr-20211231.xsd#nktr_ScheduleOfLeasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_647ab33c-7cc3-4dc4-a5e6-b44b9738ae6d" xlink:to="loc_nktr_ScheduleOfLeasesTable_f25eec48-6648-4b89-9a3b-56123ff2765d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_ad6cd46b-f4c7-43d3-ae57-21655b75ab29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_f25eec48-6648-4b89-9a3b-56123ff2765d" xlink:to="loc_us-gaap_LeaseContractualTermAxis_ad6cd46b-f4c7-43d3-ae57-21655b75ab29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_9f45eeaf-bd60-4d31-821f-c41122295e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_ad6cd46b-f4c7-43d3-ae57-21655b75ab29" xlink:to="loc_us-gaap_LeaseContractualTermDomain_9f45eeaf-bd60-4d31-821f-c41122295e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MissionBayLeaseMember_4559802e-75b5-4e4a-93ff-8eecef529eca" xlink:href="nktr-20211231.xsd#nktr_MissionBayLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_9f45eeaf-bd60-4d31-821f-c41122295e55" xlink:to="loc_nktr_MissionBayLeaseMember_4559802e-75b5-4e4a-93ff-8eecef529eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ThirdStreetLeaseMember_d6b840a4-2fde-4374-ad8e-1a41a9ab41a7" xlink:href="nktr-20211231.xsd#nktr_ThirdStreetLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_9f45eeaf-bd60-4d31-821f-c41122295e55" xlink:to="loc_nktr_ThirdStreetLeaseMember_d6b840a4-2fde-4374-ad8e-1a41a9ab41a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:href="nktr-20211231.xsd#nktr_LeasesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_ScheduleOfLeasesTable_f25eec48-6648-4b89-9a3b-56123ff2765d" xlink:to="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AreaOfLeasedSpaceDelivered_d702eaaf-636c-4cbb-91f0-0688c432268e" xlink:href="nktr-20211231.xsd#nktr_AreaOfLeasedSpaceDelivered"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:to="loc_nktr_AreaOfLeasedSpaceDelivered_d702eaaf-636c-4cbb-91f0-0688c432268e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ab8c6a2b-73c0-4a3e-9cff-9c90e9f74861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ab8c6a2b-73c0-4a3e-9cff-9c90e9f74861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfConsecutiveTermsToExtendLease_f427fb30-f546-4874-8b9d-80cfd6b954a2" xlink:href="nktr-20211231.xsd#nktr_NumberOfConsecutiveTermsToExtendLease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:to="loc_nktr_NumberOfConsecutiveTermsToExtendLease_f427fb30-f546-4874-8b9d-80cfd6b954a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LeaseExtensionTerm_0d58deb9-dbc5-46e7-9c1b-742641dc0959" xlink:href="nktr-20211231.xsd#nktr_LeaseExtensionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LeasesLineItems_e2867127-68c1-484f-8e59-45b7a55d7af7" xlink:to="loc_nktr_LeaseExtensionTerm_0d58deb9-dbc5-46e7-9c1b-742641dc0959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesScheduleofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_57925ce5-2cf6-43a0-aa6b-8cbe835c5344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d8782e74-bcc5-4854-9069-63612dda5958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_57925ce5-2cf6-43a0-aa6b-8cbe835c5344" xlink:to="loc_us-gaap_OperatingLeaseCost_d8782e74-bcc5-4854-9069-63612dda5958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_60c206ff-f3a4-475d-8a43-d47be586420f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_57925ce5-2cf6-43a0-aa6b-8cbe835c5344" xlink:to="loc_us-gaap_VariableLeaseCost_60c206ff-f3a4-475d-8a43-d47be586420f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1cc9a393-6ae3-416b-ae8f-5b52cf81d373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_57925ce5-2cf6-43a0-aa6b-8cbe835c5344" xlink:to="loc_us-gaap_LeaseCost_1cc9a393-6ae3-416b-ae8f-5b52cf81d373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_afe03e74-c937-444b-9755-2b5ea1a5eae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_afe03e74-c937-444b-9755-2b5ea1a5eae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d98800ca-75c5-4559-9fbd-a0ededb8983a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d98800ca-75c5-4559-9fbd-a0ededb8983a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a130e7bd-7b4b-4d96-9cd4-50087c14a932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a130e7bd-7b4b-4d96-9cd4-50087c14a932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5fd37e69-dcd6-4b65-a0f9-9e6552ddfeee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5fd37e69-dcd6-4b65-a0f9-9e6552ddfeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e0bc0647-ca66-425e-a66a-72927ca88f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e0bc0647-ca66-425e-a66a-72927ca88f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8157b697-1334-4bb5-957e-82f5b3c46704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8157b697-1334-4bb5-957e-82f5b3c46704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17335298-f48d-47e1-944b-cda3e0ce683b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17335298-f48d-47e1-944b-cda3e0ce683b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_96ef4bcf-a9b9-4166-9423-11e20734f890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_96ef4bcf-a9b9-4166-9423-11e20734f890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_cb2f133f-cf10-449c-8b74-9229003a9871" xlink:href="nktr-20211231.xsd#nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_cb2f133f-cf10-449c-8b74-9229003a9871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4de6ac04-4eec-4b3b-8711-f77477483c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_OperatingLeaseLiability_4de6ac04-4eec-4b3b-8711-f77477483c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e320f62e-99e2-4979-90a1-9941866a9267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e320f62e-99e2-4979-90a1-9941866a9267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e5fc9aaa-471b-4c32-aa6e-20b809cb9e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53ea1355-b88b-4675-9572-2a06ef904497" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e5fc9aaa-471b-4c32-aa6e-20b809cb9e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="simple" xlink:href="nktr-20211231.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20211231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_1bf07c55-2979-49a1-9d5b-1c8f1400eb16" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_cc53eb03-cb4e-46c0-afdc-5cb39d032873" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_1bf07c55-2979-49a1-9d5b-1c8f1400eb16" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_cc53eb03-cb4e-46c0-afdc-5cb39d032873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_b015c015-6726-4c6b-b842-42d76e7d2a4c" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_98819bd3-ae68-47a9-a0c4-1ec44f6ff606" xlink:href="nktr-20211231.xsd#nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_b015c015-6726-4c6b-b842-42d76e7d2a4c" xlink:to="loc_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock_98819bd3-ae68-47a9-a0c4-1ec44f6ff606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_19787153-c0c6-4e87-8e80-8fb96f35e2c1" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_19787153-c0c6-4e87-8e80-8fb96f35e2c1" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4ed2271c-d9e5-43a3-ace3-c1627ac991ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4ed2271c-d9e5-43a3-ace3-c1627ac991ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_135adcba-db84-4f2d-a178-db7a9018e0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4ed2271c-d9e5-43a3-ace3-c1627ac991ed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_135adcba-db84-4f2d-a178-db7a9018e0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_9065d087-84ec-43f7-9557-49579bb0df1c" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_135adcba-db84-4f2d-a178-db7a9018e0e6" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_9065d087-84ec-43f7-9557-49579bb0df1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_e5127188-36ac-4842-bafb-18a6194469be" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_135adcba-db84-4f2d-a178-db7a9018e0e6" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_e5127188-36ac-4842-bafb-18a6194469be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_f9b09083-0bc1-4237-a7df-f0c3b793fb1d" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_135adcba-db84-4f2d-a178-db7a9018e0e6" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_f9b09083-0bc1-4237-a7df-f0c3b793fb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ee433ab7-4828-4df8-9268-50348ed98f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ee433ab7-4828-4df8-9268-50348ed98f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a4147ca-b270-4ca9-bff1-fe79f5dacbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ee433ab7-4828-4df8-9268-50348ed98f95" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a4147ca-b270-4ca9-bff1-fe79f5dacbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FutureRoyaltiesMember_f29d4b32-d9f3-463a-a622-0bb40a33c397" xlink:href="nktr-20211231.xsd#nktr_FutureRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a4147ca-b270-4ca9-bff1-fe79f5dacbfa" xlink:to="loc_nktr_FutureRoyaltiesMember_f29d4b32-d9f3-463a-a622-0bb40a33c397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_04867a3a-4503-4356-af20-de7608664164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_04867a3a-4503-4356-af20-de7608664164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_70b00470-c5b1-451e-888c-7900f78bed34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_04867a3a-4503-4356-af20-de7608664164" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_70b00470-c5b1-451e-888c-7900f78bed34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d8b01fc8-64d1-48b7-a165-4111cb78ba8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_70b00470-c5b1-451e-888c-7900f78bed34" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d8b01fc8-64d1-48b7-a165-4111cb78ba8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputInceptionDiscountRateMember_b008a0b2-f52a-4efb-8e6a-2453369c9e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputInceptionDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_70b00470-c5b1-451e-888c-7900f78bed34" xlink:to="loc_us-gaap_MeasurementInputInceptionDiscountRateMember_b008a0b2-f52a-4efb-8e6a-2453369c9e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_7f9684ba-7f8c-4a45-897d-75ee4a881bb9" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_32e291ac-d6a3-4b9a-8051-34e1a1b49972" xlink:href="nktr-20211231.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_32e291ac-d6a3-4b9a-8051-34e1a1b49972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_93721e76-d251-49fe-80ed-c77db1ffd58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_93721e76-d251-49fe-80ed-c77db1ffd58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltiesLiabilityMeasurementInput_8cf098ec-2e91-400b-a1a1-a6d21f6d4180" xlink:href="nktr-20211231.xsd#nktr_RoyaltiesLiabilityMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_RoyaltiesLiabilityMeasurementInput_8cf098ec-2e91-400b-a1a1-a6d21f6d4180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_385cd248-8fdf-40ce-9057-17d89c879a3a" xlink:href="nktr-20211231.xsd#nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties_385cd248-8fdf-40ce-9057-17d89c879a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_9abd55d9-a8d2-4b38-a431-984c0b7172b0" xlink:href="nktr-20211231.xsd#nktr_TransactionCostsRelatedToRevisedRoyaltyPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments_9abd55d9-a8d2-4b38-a431-984c0b7172b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_24ff4673-a356-43fc-a7ae-6880c1bbf04b" xlink:href="nktr-20211231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved_24ff4673-a356-43fc-a7ae-6880c1bbf04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_f461af1b-d83d-4349-928a-7264c31f2e02" xlink:href="nktr-20211231.xsd#nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved_f461af1b-d83d-4349-928a-7264c31f2e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_a7879c59-29c2-4da1-abb1-815c94670f12" xlink:href="nktr-20211231.xsd#nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds_a7879c59-29c2-4da1-abb1-815c94670f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_a6328a9a-8c3d-413f-9525-4b7e58cde0f8" xlink:href="nktr-20211231.xsd#nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties_a6328a9a-8c3d-413f-9525-4b7e58cde0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_5a44fa8a-8132-43d3-a86f-18be9d22ace1" xlink:href="nktr-20211231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearTwo_5a44fa8a-8132-43d3-a86f-18be9d22ace1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_5a90af2b-802d-430b-a7f4-04f51dbdd124" xlink:href="nktr-20211231.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_77c88cf4-4a1f-4ddd-b8df-84bb528b7480" xlink:to="loc_nktr_PaymentMadeForMilestoneNotAchievedYearOne_5a90af2b-802d-430b-a7f4-04f51dbdd124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="simple" xlink:href="nktr-20211231.xsd#LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_ad7d4b43-73c8-48de-944d-e41324d46ebd" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_c94bb212-5a04-4f87-9142-d0f0df091622" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_ad7d4b43-73c8-48de-944d-e41324d46ebd" xlink:to="loc_nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward_c94bb212-5a04-4f87-9142-d0f0df091622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_0cf587ee-e731-4209-837a-30d79e5b885f" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract_ad7d4b43-73c8-48de-944d-e41324d46ebd" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_0cf587ee-e731-4209-837a-30d79e5b885f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_75203bcb-826f-4824-9b2f-e3c32579aebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_0cf587ee-e731-4209-837a-30d79e5b885f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_75203bcb-826f-4824-9b2f-e3c32579aebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11b92dbd-e862-42c9-bc2c-f20f987c6b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_75203bcb-826f-4824-9b2f-e3c32579aebd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11b92dbd-e862-42c9-bc2c-f20f987c6b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2012Member_55eda24b-167a-496a-a365-6c306084369a" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreement2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11b92dbd-e862-42c9-bc2c-f20f987c6b0a" xlink:to="loc_nktr_PurchaseAndSaleAgreement2012Member_55eda24b-167a-496a-a365-6c306084369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreement2020Member_6693c327-7c8e-4178-8670-799f343f3433" xlink:href="nktr-20211231.xsd#nktr_PurchaseAndSaleAgreement2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11b92dbd-e862-42c9-bc2c-f20f987c6b0a" xlink:to="loc_nktr_PurchaseAndSaleAgreement2020Member_6693c327-7c8e-4178-8670-799f343f3433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b3a4ccb-33bc-45e2-82a1-1520eed2e284" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_0cf587ee-e731-4209-837a-30d79e5b885f" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b3a4ccb-33bc-45e2-82a1-1520eed2e284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b3a4ccb-33bc-45e2-82a1-1520eed2e284" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_15b1d05e-fbdc-4be3-b69a-c3245f47a0e1" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_15b1d05e-fbdc-4be3-b69a-c3245f47a0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RoyaltyMonetizationProceeds_2e407393-5330-49fe-9e20-36aca520abd0" xlink:href="nktr-20211231.xsd#nktr_RoyaltyMonetizationProceeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_RoyaltyMonetizationProceeds_2e407393-5330-49fe-9e20-36aca520abd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c2b2fe14-9220-4114-8d66-59fdd1a51d0b" xlink:href="nktr-20211231.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c2b2fe14-9220-4114-8d66-59fdd1a51d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a08c46c1-2e63-4c1c-ba46-a7861b27616f" xlink:href="nktr-20211231.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_a08c46c1-2e63-4c1c-ba46-a7861b27616f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_c54dcd0e-c035-4f38-8d96-c47e6a5ecde1" xlink:href="nktr-20211231.xsd#nktr_PartialRepaymentOfRoyaltySaleProceeds"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_PartialRepaymentOfRoyaltySaleProceeds_c54dcd0e-c035-4f38-8d96-c47e6a5ecde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_2d895e9e-969c-42c3-98b5-deb77c25c83c" xlink:href="nktr-20211231.xsd#nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross_2d895e9e-969c-42c3-98b5-deb77c25c83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_073f824d-f61f-4398-9901-c0fcb072b958" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_073f824d-f61f-4398-9901-c0fcb072b958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_1bb803bc-b7b4-47c8-a861-914336b85cce" xlink:href="nktr-20211231.xsd#nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts_1bb803bc-b7b4-47c8-a861-914336b85cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_51659ec0-c9b4-4d80-84e6-26d29759b89d" xlink:href="nktr-20211231.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_0ec75c7b-7a28-4efa-9e63-237824f8865c" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_51659ec0-c9b4-4d80-84e6-26d29759b89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f92b1dd-32ae-4be6-87cc-63602ab56929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_20e2cf12-1be8-489a-b817-f2a99d4f27aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f92b1dd-32ae-4be6-87cc-63602ab56929" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_20e2cf12-1be8-489a-b817-f2a99d4f27aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9740079b-625c-4a1d-bea6-d7395e86b35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9740079b-625c-4a1d-bea6-d7395e86b35e" xlink:to="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_3ddfe701-90be-48ac-931f-9eb3056905b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_3ddfe701-90be-48ac-931f-9eb3056905b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_3ddfe701-90be-48ac-931f-9eb3056905b4" xlink:to="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LegalMattersMember_58348486-0955-4cfd-98b8-c6b847c072e4" xlink:href="nktr-20211231.xsd#nktr_LegalMattersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:to="loc_nktr_LegalMattersMember_58348486-0955-4cfd-98b8-c6b847c072e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_b16622f7-974e-4185-97cd-2ef0364cf62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_b16622f7-974e-4185-97cd-2ef0364cf62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_7b643046-c025-4227-a4c3-1c1a6abf886f" xlink:href="nktr-20211231.xsd#nktr_MergerAndAcquisitionRelatedClaimsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:to="loc_nktr_MergerAndAcquisitionRelatedClaimsMember_7b643046-c025-4227-a4c3-1c1a6abf886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SecuritiesRelatedClaimsMember_b4c08262-3ffd-41a1-b07d-e264287f5dbc" xlink:href="nktr-20211231.xsd#nktr_SecuritiesRelatedClaimsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:to="loc_nktr_SecuritiesRelatedClaimsMember_b4c08262-3ffd-41a1-b07d-e264287f5dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonSecuritiesRelatedClaimsMember_39b74f1b-8cb8-458d-a006-4c825860b9d6" xlink:href="nktr-20211231.xsd#nktr_NonSecuritiesRelatedClaimsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87ab3a72-94b3-42db-bea1-783773f207a3" xlink:to="loc_nktr_NonSecuritiesRelatedClaimsMember_39b74f1b-8cb8-458d-a006-4c825860b9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ca478cf-22aa-463a-af60-f21ba8230edd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:to="loc_srt_RangeAxis_4ca478cf-22aa-463a-af60-f21ba8230edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05c3a3bc-25c6-4a0c-9a4a-96a66ec41aa7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4ca478cf-22aa-463a-af60-f21ba8230edd" xlink:to="loc_srt_RangeMember_05c3a3bc-25c6-4a0c-9a4a-96a66ec41aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e683fb4b-a723-4488-b41c-3e6e900374fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_05c3a3bc-25c6-4a0c-9a4a-96a66ec41aa7" xlink:to="loc_srt_MaximumMember_e683fb4b-a723-4488-b41c-3e6e900374fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_7a28dce8-67f4-42a2-bdf4-fea010b1b923" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:to="loc_srt_LitigationCaseAxis_7a28dce8-67f4-42a2-bdf4-fea010b1b923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_68829fee-ff09-43ef-88d5-ec7c5549ee11" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_7a28dce8-67f4-42a2-bdf4-fea010b1b923" xlink:to="loc_srt_LitigationCaseTypeDomain_68829fee-ff09-43ef-88d5-ec7c5549ee11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MulquinActionAndDamibaActionMember_7485ddfd-2302-44ff-9c5a-94d94551503d" xlink:href="nktr-20211231.xsd#nktr_MulquinActionAndDamibaActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_68829fee-ff09-43ef-88d5-ec7c5549ee11" xlink:to="loc_nktr_MulquinActionAndDamibaActionMember_7485ddfd-2302-44ff-9c5a-94d94551503d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DerivativeActionMember_1b220898-cef0-47da-8fc4-2afb72fac5c9" xlink:href="nktr-20211231.xsd#nktr_DerivativeActionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_68829fee-ff09-43ef-88d5-ec7c5549ee11" xlink:to="loc_nktr_DerivativeActionMember_1b220898-cef0-47da-8fc4-2afb72fac5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c255211d-81be-4f1e-85c0-14a826b20ee6" xlink:to="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9325f734-feeb-4594-9d24-b560e6a8fdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9325f734-feeb-4594-9d24-b560e6a8fdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4257ffb9-fad9-4e73-b68f-1c160d6206f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4257ffb9-fad9-4e73-b68f-1c160d6206f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_545d305d-9d12-4486-98e5-35e280fe645c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_545d305d-9d12-4486-98e5-35e280fe645c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_dc4d3fcf-629b-46b1-b765-5afe21a16137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_dc4d3fcf-629b-46b1-b765-5afe21a16137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_a2a81c56-454f-4dc8-8b2f-1a09717f6764" xlink:href="nktr-20211231.xsd#nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a2833334-d009-42ba-8563-9b406232539d" xlink:to="loc_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident_a2a81c56-454f-4dc8-8b2f-1a09717f6764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquity" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d1c1f30b-8e7c-4403-8bcf-dc0af51281b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4d112962-3b47-496d-a3cb-d280aa843f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d1c1f30b-8e7c-4403-8bcf-dc0af51281b1" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4d112962-3b47-496d-a3cb-d280aa843f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bd54b20d-47c3-47ed-b6f1-98700120c3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_aec8809e-40e8-4df7-996b-3381fc76dd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bd54b20d-47c3-47ed-b6f1-98700120c3a8" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_aec8809e-40e8-4df7-996b-3381fc76dd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_eff7b963-b2ea-4805-996c-3f32a3236af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f1c09ca4-729e-4985-8ebe-e2d4676e2248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_eff7b963-b2ea-4805-996c-3f32a3236af8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f1c09ca4-729e-4985-8ebe-e2d4676e2248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22c593f0-1af7-4f69-932f-38e2fa7ae22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f1c09ca4-729e-4985-8ebe-e2d4676e2248" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_22c593f0-1af7-4f69-932f-38e2fa7ae22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b956398-5283-4686-89ef-60d26cec1734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22c593f0-1af7-4f69-932f-38e2fa7ae22b" xlink:to="loc_us-gaap_EquityComponentDomain_9b956398-5283-4686-89ef-60d26cec1734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ef88873e-55cd-4ae2-8ee6-e5db6776a851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b956398-5283-4686-89ef-60d26cec1734" xlink:to="loc_us-gaap_CommonStockMember_ef88873e-55cd-4ae2-8ee6-e5db6776a851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7467c998-1dbd-4cee-8a6b-88b96f40acd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f1c09ca4-729e-4985-8ebe-e2d4676e2248" xlink:to="loc_us-gaap_ClassOfStockLineItems_7467c998-1dbd-4cee-8a6b-88b96f40acd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fc6e5c12-7835-417c-9554-f680c5a403e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7467c998-1dbd-4cee-8a6b-88b96f40acd7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fc6e5c12-7835-417c-9554-f680c5a403e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_5f47188b-715d-4743-89ae-1a9901471dcf" xlink:href="nktr-20211231.xsd#nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7467c998-1dbd-4cee-8a6b-88b96f40acd7" xlink:to="loc_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod_5f47188b-715d-4743-89ae-1a9901471dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockValueAuthorizedInTransaction_e5ec11c2-a3e7-4ce7-821f-53c58316fae7" xlink:href="nktr-20211231.xsd#nktr_SaleOfStockValueAuthorizedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7467c998-1dbd-4cee-8a6b-88b96f40acd7" xlink:to="loc_nktr_SaleOfStockValueAuthorizedInTransaction_e5ec11c2-a3e7-4ce7-821f-53c58316fae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3f04ea00-9992-4bc1-b6bc-b4a21865d476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5cd554ec-fb7e-4e4c-a94c-a4b10e598d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3f04ea00-9992-4bc1-b6bc-b4a21865d476" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5cd554ec-fb7e-4e4c-a94c-a4b10e598d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_da942874-73eb-4438-a725-bdac3047db46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5cd554ec-fb7e-4e4c-a94c-a4b10e598d93" xlink:to="loc_us-gaap_PlanNameAxis_da942874-73eb-4438-a725-bdac3047db46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9b755611-3e86-4a8f-9879-2f811995ca55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_da942874-73eb-4438-a725-bdac3047db46" xlink:to="loc_us-gaap_PlanNameDomain_9b755611-3e86-4a8f-9879-2f811995ca55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_e9252cb3-5c8f-4f05-9e36-02693018f367" xlink:href="nktr-20211231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9b755611-3e86-4a8f-9879-2f811995ca55" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_e9252cb3-5c8f-4f05-9e36-02693018f367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember_fcf7443c-4710-4bd9-8815-fbbf232a5c4f" xlink:href="nktr-20211231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9b755611-3e86-4a8f-9879-2f811995ca55" xlink:to="loc_nktr_EmployeeStockPurchasePlanMember_fcf7443c-4710-4bd9-8815-fbbf232a5c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_52e6b919-4eee-4fdc-859b-6cde689bf3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5cd554ec-fb7e-4e4c-a94c-a4b10e598d93" xlink:to="loc_us-gaap_AwardTypeAxis_52e6b919-4eee-4fdc-859b-6cde689bf3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb5742a-92b3-49b7-a935-b44483f88abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_52e6b919-4eee-4fdc-859b-6cde689bf3ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb5742a-92b3-49b7-a935-b44483f88abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_fb4b7a91-a033-4fdb-9ac5-20cc402f10c8" xlink:href="nktr-20211231.xsd#nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb5742a-92b3-49b7-a935-b44483f88abd" xlink:to="loc_nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember_fb4b7a91-a033-4fdb-9ac5-20cc402f10c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_15ecccfc-e2ed-42f8-b5e9-6571101af27b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5cd554ec-fb7e-4e4c-a94c-a4b10e598d93" xlink:to="loc_us-gaap_ClassOfStockLineItems_15ecccfc-e2ed-42f8-b5e9-6571101af27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0fab24f2-68f8-431b-9f8f-0657b650ea3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15ecccfc-e2ed-42f8-b5e9-6571101af27b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0fab24f2-68f8-431b-9f8f-0657b650ea3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20211231.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65960681-05f7-4b30-94b5-1c2a05b142bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7e0bfee2-fcf2-4e95-bef2-2b7c1d812b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65960681-05f7-4b30-94b5-1c2a05b142bb" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7e0bfee2-fcf2-4e95-bef2-2b7c1d812b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_670d6ba2-3ef5-44a5-906d-e8a66354468b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_e442961f-a916-4299-899e-069954fb3226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_670d6ba2-3ef5-44a5-906d-e8a66354468b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_e442961f-a916-4299-899e-069954fb3226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e62ae53-2793-47a6-aa45-787a346fa518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_fa484ea1-17f6-4d8a-b9dd-8c6bae505495" xlink:href="nktr-20211231.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e62ae53-2793-47a6-aa45-787a346fa518" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_fa484ea1-17f6-4d8a-b9dd-8c6bae505495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1025a330-83a3-4382-9bf4-55360637dbaa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_fa484ea1-17f6-4d8a-b9dd-8c6bae505495" xlink:to="loc_dei_LegalEntityAxis_1025a330-83a3-4382-9bf4-55360637dbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1025a330-83a3-4382-9bf4-55360637dbaa" xlink:to="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_c0cf1976-56c2-4160-a32d-f69748068d3e" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_c0cf1976-56c2-4160-a32d-f69748068d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_0d5cad2d-ea36-4370-b541-deb267d1157a" xlink:href="nktr-20211231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:to="loc_nktr_EliLillyAndCompanyMember_0d5cad2d-ea36-4370-b541-deb267d1157a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_fcd7c3ba-91cf-4892-a11e-f3100ee31b48" xlink:href="nktr-20211231.xsd#nktr_AmgenIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:to="loc_nktr_AmgenIncMember_fcd7c3ba-91cf-4892-a11e-f3100ee31b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_3beafcb5-9122-4ff7-bd91-e962aac7adb2" xlink:href="nktr-20211231.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c494d9c0-fba8-4229-b115-42f27a0d8122" xlink:to="loc_nktr_OtherPartnerMember_3beafcb5-9122-4ff7-bd91-e962aac7adb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_534c5c20-1aa0-410a-8172-86883894275e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_fa484ea1-17f6-4d8a-b9dd-8c6bae505495" xlink:to="loc_us-gaap_TypeOfArrangementAxis_534c5c20-1aa0-410a-8172-86883894275e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03fc480c-6c94-4d2c-9ad7-7c5b1b174a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_534c5c20-1aa0-410a-8172-86883894275e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03fc480c-6c94-4d2c-9ad7-7c5b1b174a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BempegaldesleukinMember_d093435e-a065-48aa-883a-c003031cbf12" xlink:href="nktr-20211231.xsd#nktr_BempegaldesleukinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03fc480c-6c94-4d2c-9ad7-7c5b1b174a09" xlink:to="loc_nktr_BempegaldesleukinMember_d093435e-a065-48aa-883a-c003031cbf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_87c78023-ff28-4793-8e3e-8ec6151993e9" xlink:href="nktr-20211231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03fc480c-6c94-4d2c-9ad7-7c5b1b174a09" xlink:to="loc_nktr_NektarThreeFiveEightMember_87c78023-ff28-4793-8e3e-8ec6151993e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember_2f464a51-8763-4ad9-ac09-49e12432edfa" xlink:href="nktr-20211231.xsd#nktr_NeulastaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03fc480c-6c94-4d2c-9ad7-7c5b1b174a09" xlink:to="loc_nktr_NeulastaMember_2f464a51-8763-4ad9-ac09-49e12432edfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_637d6957-3493-472f-b54e-32b6b6efe928" xlink:href="nktr-20211231.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_fa484ea1-17f6-4d8a-b9dd-8c6bae505495" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsLineItems_637d6957-3493-472f-b54e-32b6b6efe928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_77020283-7359-4d48-acb1-483c37b3fd27" xlink:href="nktr-20211231.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_637d6957-3493-472f-b54e-32b6b6efe928" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_77020283-7359-4d48-acb1-483c37b3fd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42450ea9-37fb-49dc-9c2c-150584cdf8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42450ea9-37fb-49dc-9c2c-150584cdf8d3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:href="nktr-20211231.xsd#nktr_MilestoneAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_b2f1bc78-f04d-454b-8c06-8df6d9ffa9aa" xlink:href="nktr-20211231.xsd#nktr_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneAxis_f81ecce8-a9c4-4a12-be8d-d6f06eab8447" xlink:to="loc_nktr_MilestoneDomain_b2f1bc78-f04d-454b-8c06-8df6d9ffa9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_6c1ae82e-8a8e-4fb4-a2ab-e812d6a4b75b" xlink:href="nktr-20211231.xsd#nktr_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_b2f1bc78-f04d-454b-8c06-8df6d9ffa9aa" xlink:to="loc_nktr_MilestoneOneMember_6c1ae82e-8a8e-4fb4-a2ab-e812d6a4b75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a0e29770-d6fb-4303-9a7c-f4ee65be3a4b" xlink:to="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_61e494d3-17b1-4ef4-bb70-43a4f1f35fe0" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_61e494d3-17b1-4ef4-bb70-43a4f1f35fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_1fa896c7-879c-4ab0-b375-21b44f05f3b9" xlink:href="nktr-20211231.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_EliLillyAndCompanyMember_1fa896c7-879c-4ab0-b375-21b44f05f3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_77a0f883-322e-466b-84eb-dfc8c224a570" xlink:href="nktr-20211231.xsd#nktr_EliLillyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_EliLillyMember_77a0f883-322e-466b-84eb-dfc8c224a570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_306f3b5b-d4a3-4544-8ddb-5d03a23347be" xlink:href="nktr-20211231.xsd#nktr_AmgenIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_AmgenIncMember_306f3b5b-d4a3-4544-8ddb-5d03a23347be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_29e162fd-224c-4d6e-9b1e-4d78112f84f2" xlink:href="nktr-20211231.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_OtherPartnerMember_29e162fd-224c-4d6e-9b1e-4d78112f84f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TerminatedPartnershipMember_d1fb6c3c-9bfb-4b48-bd65-fe3ecaa79282" xlink:href="nktr-20211231.xsd#nktr_TerminatedPartnershipMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_74c82e56-2e12-46bd-8124-50c1b6c36b5b" xlink:to="loc_nktr_TerminatedPartnershipMember_d1fb6c3c-9bfb-4b48-bd65-fe3ecaa79282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6f25e1a-7307-4e0d-8dc1-497474e88cf8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_1a232b8d-d0ac-4f71-844c-6fd737c8bb0d" xlink:href="nktr-20211231.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_BMSCollaborationAgreementMember_1a232b8d-d0ac-4f71-844c-6fd737c8bb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_08800608-2310-460b-ba96-d21ad9fb80c4" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_BristolMyersSquibbCollaborationAgreementMember_08800608-2310-460b-ba96-d21ad9fb80c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_97670512-0c5f-44a4-a835-c5d0f34c17cf" xlink:href="nktr-20211231.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_Nektar358Member_97670512-0c5f-44a4-a835-c5d0f34c17cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_b0a1aae1-97d4-4451-a124-c1e2772dda34" xlink:href="nktr-20211231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_b0a1aae1-97d4-4451-a124-c1e2772dda34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_91947467-361a-4b45-9cc4-d1b0b7d07030" xlink:href="nktr-20211231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_DrugProductDevelopmentMember_91947467-361a-4b45-9cc4-d1b0b7d07030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_33ffccc4-5b6e-4b87-8c04-be6adc4a1357" xlink:href="nktr-20211231.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_NektarThreeFiveEightMember_33ffccc4-5b6e-4b87-8c04-be6adc4a1357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember_8f28e028-3dd6-499c-ad0d-228475ce99b2" xlink:href="nktr-20211231.xsd#nktr_NektarMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_018619e9-1785-45b4-89b8-b7d20baae327" xlink:to="loc_nktr_NektarMember_8f28e028-3dd6-499c-ad0d-228475ce99b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_65cc343b-1ab1-4468-8c57-40413273de1f" xlink:to="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar214Member_83d9e4b4-6974-48a2-8fee-13f80a9c2a49" xlink:href="nktr-20211231.xsd#nktr_Nektar214Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:to="loc_nktr_Nektar214Member_83d9e4b4-6974-48a2-8fee-13f80a9c2a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_Nektar358Member_a270fdc7-ba2a-4e37-b802-04c4ca60dbbc" xlink:href="nktr-20211231.xsd#nktr_Nektar358Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257e7716-eeb2-4960-b743-20d4b9c994ba" xlink:to="loc_nktr_Nektar358Member_a270fdc7-ba2a-4e37-b802-04c4ca60dbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ae7a36c7-dcdf-4ee5-bd9f-bdc86ac5f1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f2c7b969-a58a-476c-b9f0-fe358e29175b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ae7a36c7-dcdf-4ee5-bd9f-bdc86ac5f1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_6dc47d3a-d47b-4ed7-85fb-f0cb4554d058" xlink:href="nktr-20211231.xsd#nktr_OpdivoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ae7a36c7-dcdf-4ee5-bd9f-bdc86ac5f1e2" xlink:to="loc_nktr_OpdivoMember_6dc47d3a-d47b-4ed7-85fb-f0cb4554d058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bc04c7fb-0389-4482-939a-88e1fa04a25b" xlink:to="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_55cac7da-1c3a-4b3e-b305-34c9f57162e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:to="loc_srt_MaximumMember_55cac7da-1c3a-4b3e-b305-34c9f57162e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4058dce0-d5e4-41a7-8dc3-47cb75ae0a92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a89b4e6c-cc12-4fe6-81a7-eb56c6ceae35" xlink:to="loc_srt_MinimumMember_4058dce0-d5e4-41a7-8dc3-47cb75ae0a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_949137e5-58df-41b5-afcd-2e277233ebf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23a080b2-82a0-46fb-b1cf-6624bf701875" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_949137e5-58df-41b5-afcd-2e277233ebf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_0d85a120-622a-4482-ba6f-43ecea92f037" xlink:href="nktr-20211231.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_949137e5-58df-41b5-afcd-2e277233ebf7" xlink:to="loc_nktr_SharePurchaseAgreementMember_0d85a120-622a-4482-ba6f-43ecea92f037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_533e69e9-9af0-4e0f-aa71-7ed1826b9858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18d907c9-3964-4493-816b-b124e594c169" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_533e69e9-9af0-4e0f-aa71-7ed1826b9858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_38689af0-d34e-4054-8ec0-ded9f7c45dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_533e69e9-9af0-4e0f-aa71-7ed1826b9858" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_38689af0-d34e-4054-8ec0-ded9f7c45dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_d7cfe107-0ff4-44f7-9a85-4e1d7973a1a4" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_9ee8f213-95ef-41ed-82b5-d28e602238ed" xlink:href="nktr-20211231.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_9ee8f213-95ef-41ed-82b5-d28e602238ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_07a6d6cf-3e28-41ea-851b-3d6112ef1dd3" xlink:href="nktr-20211231.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_799aca2a-6d57-42ef-8022-a42eeead3aa5" xlink:to="loc_nktr_DrugProductDevelopmentMember_07a6d6cf-3e28-41ea-851b-3d6112ef1dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_10b68426-3cbd-4796-90a1-5cf31813b568" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_174a91e2-6616-402c-9c53-672eaf85f6f4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_10b68426-3cbd-4796-90a1-5cf31813b568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f5aa860b-a841-43f7-b73f-8e1056a9a556" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10b68426-3cbd-4796-90a1-5cf31813b568" xlink:to="loc_srt_ParentCompanyMember_f5aa860b-a841-43f7-b73f-8e1056a9a556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_1d62c316-f60b-494e-bab2-9ab261350d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_1d62c316-f60b-494e-bab2-9ab261350d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e63e6275-e50c-4d91-8c8b-cdea19b8c89c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_3c7f1ad0-a74b-4e7a-a9b9-3ca9b2027660" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PotentialDevelopmentMilestones_3c7f1ad0-a74b-4e7a-a9b9-3ca9b2027660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_9202ef24-b32d-43a3-8210-4a7ff484b6e8" xlink:href="nktr-20211231.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_9202ef24-b32d-43a3-8210-4a7ff484b6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_e30b8212-bc32-49b7-b461-39af377e1cf2" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_e30b8212-bc32-49b7-b461-39af377e1cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_b8926702-e936-476f-9cf4-9984ae4ee71c" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_b8926702-e936-476f-9cf4-9984ae4ee71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_4345ab6d-4d93-47ca-b030-0b0cca7769ac" xlink:href="nktr-20211231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_4345ab6d-4d93-47ca-b030-0b0cca7769ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a90c5fe3-4680-4b7d-8a98-09b3a0e73ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_SharesIssued_a90c5fe3-4680-4b7d-8a98-09b3a0e73ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_fd301d56-ae33-4060-bfe5-be1e3d912e0b" xlink:href="nktr-20211231.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_fd301d56-ae33-4060-bfe5-be1e3d912e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_3f132a0f-12d1-49b0-929f-b806bf86fa69" xlink:href="nktr-20211231.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_3f132a0f-12d1-49b0-929f-b806bf86fa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_96312df0-e936-4a4f-b667-cd2e5efde389" xlink:href="nktr-20211231.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_96312df0-e936-4a4f-b667-cd2e5efde389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_48b499d8-288d-42b7-af95-0475cdd3ca74" xlink:href="nktr-20211231.xsd#nktr_ReimbursementOfExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_ReimbursementOfExpenses_48b499d8-288d-42b7-af95-0475cdd3ca74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_62255fc5-dda9-4686-8346-735906b451ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_62255fc5-dda9-4686-8346-735906b451ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap_c6971609-cd09-4d92-b300-3b048ca38b67" xlink:href="nktr-20211231.xsd#nktr_CompanyShareOfDevelopmentCostsAnnualCap"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_CompanyShareOfDevelopmentCostsAnnualCap_c6971609-cd09-4d92-b300-3b048ca38b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_caaaa266-e737-4aaa-8ca3-22f8b07cbb82" xlink:href="nktr-20211231.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_caaaa266-e737-4aaa-8ca3-22f8b07cbb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_ba5de2df-1b24-42bb-a8c6-91e237014f7f" xlink:href="nktr-20211231.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_EstimatedFairValueOfShares_ba5de2df-1b24-42bb-a8c6-91e237014f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_d0bb5d2a-ed83-4145-a5c2-f3ce1e7f0210" xlink:href="nktr-20211231.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_d0bb5d2a-ed83-4145-a5c2-f3ce1e7f0210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_f0d3ecd4-67f2-4e2f-8fa3-520468c559b3" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_f0d3ecd4-67f2-4e2f-8fa3-520468c559b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_467943fd-482a-4a51-9ae4-f85bec079dd5" xlink:href="nktr-20211231.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_467943fd-482a-4a51-9ae4-f85bec079dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_d1f6dbd8-110b-4c57-aab6-873617ee629c" xlink:href="nktr-20211231.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_d1f6dbd8-110b-4c57-aab6-873617ee629c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_5bc44d64-2def-4f36-b2b2-fdc6e801d812" xlink:href="nktr-20211231.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_5bc44d64-2def-4f36-b2b2-fdc6e801d812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7ed5e2c2-4f83-4f26-935c-196cc27b1222" xlink:href="nktr-20211231.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7ed5e2c2-4f83-4f26-935c-196cc27b1222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_3ff9677b-6ccc-4d79-a721-6b55cf8b9189" xlink:href="nktr-20211231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_3ff9677b-6ccc-4d79-a721-6b55cf8b9189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_94d6de56-164a-4fd8-9a6d-838802d21111" xlink:href="nktr-20211231.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_94d6de56-164a-4fd8-9a6d-838802d21111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_72174e5e-9729-4d06-82b9-5c20e91326ab" xlink:href="nktr-20211231.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_72174e5e-9729-4d06-82b9-5c20e91326ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf36ba72-e909-4f90-922d-0aeba673fd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf36ba72-e909-4f90-922d-0aeba673fd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b20dbf89-04f2-45ad-845c-db788af6e6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b20dbf89-04f2-45ad-845c-db788af6e6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_3e71862e-91b7-4a0d-b37b-8381781fe729" xlink:href="nktr-20211231.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_3e71862e-91b7-4a0d-b37b-8381781fe729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8a48e5f6-12a5-4278-8499-11a278603a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_780c61d0-f181-4d85-9c7e-93601cc17b65" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8a48e5f6-12a5-4278-8499-11a278603a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails_1" xlink:type="simple" xlink:href="nktr-20211231.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetails_1"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe3d2eae-41dd-40b6-ba1c-3e4211942677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7464a4de-f818-4af8-8a59-9f5ade681c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe3d2eae-41dd-40b6-ba1c-3e4211942677" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7464a4de-f818-4af8-8a59-9f5ade681c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7640f877-27b6-412d-8814-a32d5b4b5ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5b6b0e05-b25f-4785-8521-8544f1b76b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7640f877-27b6-412d-8814-a32d5b4b5ddf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5b6b0e05-b25f-4785-8521-8544f1b76b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_9ec16660-b856-4a81-9382-259e05b08c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7640f877-27b6-412d-8814-a32d5b4b5ddf" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_9ec16660-b856-4a81-9382-259e05b08c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_78f2b0ef-6433-4764-a2f2-0a5dd7831eec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7640f877-27b6-412d-8814-a32d5b4b5ddf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_78f2b0ef-6433-4764-a2f2-0a5dd7831eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9fe22a29-46b9-41da-a62f-4ad9a570a9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7640f877-27b6-412d-8814-a32d5b4b5ddf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9fe22a29-46b9-41da-a62f-4ad9a570a9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef316629-5651-49a9-896e-25492e78b068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef316629-5651-49a9-896e-25492e78b068" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7228a8de-5e02-4c44-93f1-26d419a98883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:to="loc_us-gaap_AwardTypeAxis_7228a8de-5e02-4c44-93f1-26d419a98883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7228a8de-5e02-4c44-93f1-26d419a98883" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_52125142-55f0-4c63-a144-fb338b78a798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:to="loc_us-gaap_EmployeeStockOptionMember_52125142-55f0-4c63-a144-fb338b78a798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RSUsAndPSUsMember_a30d8474-0d58-4ba5-a52e-998b1b5383cd" xlink:href="nktr-20211231.xsd#nktr_RSUsAndPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:to="loc_nktr_RSUsAndPSUsMember_a30d8474-0d58-4ba5-a52e-998b1b5383cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_60eaa884-8e6b-4af3-be3d-f652ca1e6680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:to="loc_us-gaap_EmployeeStockMember_60eaa884-8e6b-4af3-be3d-f652ca1e6680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_57358802-c3a8-448c-8c3a-01622ff54138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0d37f63-bbcc-4d33-a7d5-68f344b1c999" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_57358802-c3a8-448c-8c3a-01622ff54138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_da70740f-d33f-4a00-8825-f95bb102c89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:to="loc_us-gaap_PlanNameAxis_da70740f-d33f-4a00-8825-f95bb102c89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_270d74ba-a6df-4d0c-b08c-7aaf38aebcac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_da70740f-d33f-4a00-8825-f95bb102c89f" xlink:to="loc_us-gaap_PlanNameDomain_270d74ba-a6df-4d0c-b08c-7aaf38aebcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_cee410d2-647a-45bc-9983-a7aab4ccb90f" xlink:href="nktr-20211231.xsd#nktr_TwoThousandSeventeenPerformanceIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_270d74ba-a6df-4d0c-b08c-7aaf38aebcac" xlink:to="loc_nktr_TwoThousandSeventeenPerformanceIncentivePlanMember_cee410d2-647a-45bc-9983-a7aab4ccb90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeStockPurchasePlanMember_14c5fcc2-ab18-47c6-a003-00f19099b146" xlink:href="nktr-20211231.xsd#nktr_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_270d74ba-a6df-4d0c-b08c-7aaf38aebcac" xlink:to="loc_nktr_EmployeeStockPurchasePlanMember_14c5fcc2-ab18-47c6-a003-00f19099b146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b4b18795-06d8-433d-b477-460b99e07a5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:to="loc_srt_TitleOfIndividualAxis_b4b18795-06d8-433d-b477-460b99e07a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_72d0bea5-f389-4cee-8695-81654bbac137" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b4b18795-06d8-433d-b477-460b99e07a5d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_72d0bea5-f389-4cee-8695-81654bbac137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EmployeeMember_99279087-bd7e-48ab-9ee2-f455571474f4" xlink:href="nktr-20211231.xsd#nktr_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_72d0bea5-f389-4cee-8695-81654bbac137" xlink:to="loc_nktr_EmployeeMember_99279087-bd7e-48ab-9ee2-f455571474f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_fb3e3dd4-3fdf-45fa-abf4-231e9cfdb062" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_72d0bea5-f389-4cee-8695-81654bbac137" xlink:to="loc_srt_DirectorMember_fb3e3dd4-3fdf-45fa-abf4-231e9cfdb062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bc76e71-3799-4ad6-9aaf-d5d5a3d7240a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b24f1ce1-8d42-418e-8a2a-a499d8a2c751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b24f1ce1-8d42-418e-8a2a-a499d8a2c751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_94afbb55-d564-4fad-9aff-5de551e12260" xlink:href="nktr-20211231.xsd#nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare_94afbb55-d564-4fad-9aff-5de551e12260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_7724bf32-e09b-46ff-bc11-ec09bfbf89f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_7724bf32-e09b-46ff-bc11-ec09bfbf89f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_77981ae2-14a9-4c17-9bb2-e69c6a192294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_77981ae2-14a9-4c17-9bb2-e69c6a192294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_a5191b03-0392-426e-a898-b54ea963a375" xlink:href="nktr-20211231.xsd#nktr_ChangeInControlSeverancePaymentPeriodForExecutives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_nktr_ChangeInControlSeverancePaymentPeriodForExecutives_a5191b03-0392-426e-a898-b54ea963a375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_416f1b6d-1289-4fb0-84f7-dd784bc86f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_416f1b6d-1289-4fb0-84f7-dd784bc86f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e4c9b641-0641-4b1a-b9ed-42d478bbba1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e4c9b641-0641-4b1a-b9ed-42d478bbba1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1b9d6b29-094c-4ba6-9428-6709183f52d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1b9d6b29-094c-4ba6-9428-6709183f52d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8121932f-4bb0-4225-9f14-9e11fe90789d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8121932f-4bb0-4225-9f14-9e11fe90789d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_276fb978-da03-4aee-ba55-8384441fc6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_276fb978-da03-4aee-ba55-8384441fc6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_62b35a4a-175a-4541-9272-39cf8b29f466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_62b35a4a-175a-4541-9272-39cf8b29f466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6922dc67-fd4e-420f-a84f-89609ef8e27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6922dc67-fd4e-420f-a84f-89609ef8e27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4f12deac-b12c-4567-ac4b-8afa742f06d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4f12deac-b12c-4567-ac4b-8afa742f06d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ed505c91-a898-4863-8256-401760703f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ed505c91-a898-4863-8256-401760703f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_8a70fd2f-b8ab-4dc3-84e4-4baaa22a1440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_8a70fd2f-b8ab-4dc3-84e4-4baaa22a1440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_ab8dd7c5-ae71-41f6-ae44-3d17a9fc1e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41974a20-59e5-41c1-8d19-df9bee3029ba" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_ab8dd7c5-ae71-41f6-ae44-3d17a9fc1e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec8411d9-7563-4f8c-bc7c-268ae7ff7aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5643e1d0-76cf-42e5-8441-c850284f35d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec8411d9-7563-4f8c-bc7c-268ae7ff7aed" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5643e1d0-76cf-42e5-8441-c850284f35d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f2f5cbd3-bf25-4cab-9c06-7180d45db709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5643e1d0-76cf-42e5-8441-c850284f35d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f2f5cbd3-bf25-4cab-9c06-7180d45db709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2f5cbd3-bf25-4cab-9c06-7180d45db709" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3ffbd569-c7e2-4125-aad3-f2a4e16cf0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:to="loc_us-gaap_CostOfSalesMember_3ffbd569-c7e2-4125-aad3-f2a4e16cf0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e9a2acd9-52d3-4f90-ad8d-5f14061561d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e9a2acd9-52d3-4f90-ad8d-5f14061561d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f29876d6-bd07-489f-b0d0-3b5a67c5e190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f29876d6-bd07-489f-b0d0-3b5a67c5e190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_c98838b1-e786-41df-a967-a8aa9028b4b7" xlink:href="nktr-20211231.xsd#nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b4b9552-3397-4bf7-9410-37d4e1f1224c" xlink:to="loc_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember_c98838b1-e786-41df-a967-a8aa9028b4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_129947ab-3d82-40a3-a7fd-22ede244a960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5643e1d0-76cf-42e5-8441-c850284f35d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_129947ab-3d82-40a3-a7fd-22ede244a960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2257eed6-342c-4b37-93b9-5443bbeae79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_129947ab-3d82-40a3-a7fd-22ede244a960" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2257eed6-342c-4b37-93b9-5443bbeae79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa7a957d-1fa5-4c6e-a719-f885e3155e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_385954cd-e95a-4e09-ba5a-d3d55fa892c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa7a957d-1fa5-4c6e-a719-f885e3155e3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_385954cd-e95a-4e09-ba5a-d3d55fa892c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_522d7bd6-fe26-4e60-bae2-b47256e8eacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa7a957d-1fa5-4c6e-a719-f885e3155e3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_522d7bd6-fe26-4e60-bae2-b47256e8eacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_4ef9a2f1-3348-475c-9fbd-f09744766f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa7a957d-1fa5-4c6e-a719-f885e3155e3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_4ef9a2f1-3348-475c-9fbd-f09744766f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f97e305f-049c-480f-8dc6-095d9c0a5a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa7a957d-1fa5-4c6e-a719-f885e3155e3e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f97e305f-049c-480f-8dc6-095d9c0a5a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_76f59d67-1826-4a31-9684-a68f48101698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa7a957d-1fa5-4c6e-a719-f885e3155e3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_76f59d67-1826-4a31-9684-a68f48101698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30bf5fdb-db6e-4c1f-ae4a-342175d31d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8e15978-8a35-4b36-8b8e-e42597c7b5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30bf5fdb-db6e-4c1f-ae4a-342175d31d68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8e15978-8a35-4b36-8b8e-e42597c7b5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c1866b66-9b6f-449a-892c-dd83521731cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8e15978-8a35-4b36-8b8e-e42597c7b5b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c1866b66-9b6f-449a-892c-dd83521731cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac30992f-e8c4-448b-bcfd-7ec9df610c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8e15978-8a35-4b36-8b8e-e42597c7b5b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac30992f-e8c4-448b-bcfd-7ec9df610c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fe1dd181-2781-4fdf-a393-f152f3f9e8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8e15978-8a35-4b36-8b8e-e42597c7b5b8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fe1dd181-2781-4fdf-a393-f152f3f9e8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4c1ce74b-a712-44c0-82e2-68549058564b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8e15978-8a35-4b36-8b8e-e42597c7b5b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4c1ce74b-a712-44c0-82e2-68549058564b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_83b1ae32-edab-4615-8da9-9970bc5e2015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c8e15978-8a35-4b36-8b8e-e42597c7b5b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_83b1ae32-edab-4615-8da9-9970bc5e2015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ea364a6-cced-453f-974d-4e0da0c387de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30bf5fdb-db6e-4c1f-ae4a-342175d31d68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ea364a6-cced-453f-974d-4e0da0c387de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e5cdeb9a-d479-4b57-baaa-ac96de00592e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ea364a6-cced-453f-974d-4e0da0c387de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e5cdeb9a-d479-4b57-baaa-ac96de00592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3987d41a-beff-40a5-8374-c9ec03544e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ea364a6-cced-453f-974d-4e0da0c387de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3987d41a-beff-40a5-8374-c9ec03544e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_812b38ca-02d9-4b69-bba4-62b999939868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ea364a6-cced-453f-974d-4e0da0c387de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_812b38ca-02d9-4b69-bba4-62b999939868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3133649d-c241-4d6f-9066-1297e885823e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ea364a6-cced-453f-974d-4e0da0c387de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3133649d-c241-4d6f-9066-1297e885823e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1bf8e4b3-72b1-4e93-bf7d-71adf5fa91a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ea364a6-cced-453f-974d-4e0da0c387de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1bf8e4b3-72b1-4e93-bf7d-71adf5fa91a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f056509-7d4f-4b7a-b8a6-bc9dfc2dee51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30bf5fdb-db6e-4c1f-ae4a-342175d31d68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f056509-7d4f-4b7a-b8a6-bc9dfc2dee51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_92cf7611-0f40-4e52-a868-c0e6c43e9150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f056509-7d4f-4b7a-b8a6-bc9dfc2dee51" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_92cf7611-0f40-4e52-a868-c0e6c43e9150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5f8c7d7d-d9e6-432a-9cd8-5f6161aeae26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f056509-7d4f-4b7a-b8a6-bc9dfc2dee51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5f8c7d7d-d9e6-432a-9cd8-5f6161aeae26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_05065c90-4939-406b-811a-d84b0c8966f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30bf5fdb-db6e-4c1f-ae4a-342175d31d68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_05065c90-4939-406b-811a-d84b0c8966f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e42c8e27-8c42-4501-a8e6-7b68804d47f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30bf5fdb-db6e-4c1f-ae4a-342175d31d68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e42c8e27-8c42-4501-a8e6-7b68804d47f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_fc690b24-6f81-4351-875b-7f89a8e7eb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30bf5fdb-db6e-4c1f-ae4a-342175d31d68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_fc690b24-6f81-4351-875b-7f89a8e7eb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b0bffe25-3b0a-4f1f-a103-fc50640888da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30bf5fdb-db6e-4c1f-ae4a-342175d31d68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b0bffe25-3b0a-4f1f-a103-fc50640888da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2fdf2ee7-4aff-4081-ae4c-739e0a52f6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a5aae33-718f-46c9-b206-df28662f2286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2fdf2ee7-4aff-4081-ae4c-739e0a52f6e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a5aae33-718f-46c9-b206-df28662f2286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7d4b2ff5-6546-407e-8a2d-530c4c9ba098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a5aae33-718f-46c9-b206-df28662f2286" xlink:to="loc_us-gaap_AwardTypeAxis_7d4b2ff5-6546-407e-8a2d-530c4c9ba098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f467522a-ca54-447e-b483-7a2ca2687b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7d4b2ff5-6546-407e-8a2d-530c4c9ba098" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f467522a-ca54-447e-b483-7a2ca2687b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_16eebcc3-f466-411e-8e3f-fa8dacf197b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f467522a-ca54-447e-b483-7a2ca2687b3f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_16eebcc3-f466-411e-8e3f-fa8dacf197b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab63314a-2e9f-4caf-a019-41c60af6a796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a5aae33-718f-46c9-b206-df28662f2286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab63314a-2e9f-4caf-a019-41c60af6a796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab63314a-2e9f-4caf-a019-41c60af6a796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07af484c-f767-455f-b8a0-3abb1e2d3cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07af484c-f767-455f-b8a0-3abb1e2d3cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b0e5e8e4-0fce-4c20-a481-594a4aa1de4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b0e5e8e4-0fce-4c20-a481-594a4aa1de4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0b3170b8-14ee-460a-a1c7-52d11967a520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0b3170b8-14ee-460a-a1c7-52d11967a520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c1192468-bc4a-4963-ac51-13251ccd2b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c1192468-bc4a-4963-ac51-13251ccd2b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77e285ea-9c72-4b0a-9b5b-4bdd4d57b8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_253b77e4-3d0d-4535-bd4c-662890abeee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77e285ea-9c72-4b0a-9b5b-4bdd4d57b8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab63314a-2e9f-4caf-a019-41c60af6a796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_477e4d49-2cb5-4f87-880d-761617954cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_477e4d49-2cb5-4f87-880d-761617954cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_810a218d-66f7-4789-8dcc-441ce966a902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_810a218d-66f7-4789-8dcc-441ce966a902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1433d6f1-2af8-48b5-9d2e-ac837247bede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1433d6f1-2af8-48b5-9d2e-ac837247bede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f1a3f671-3290-4a55-83b5-a914f786ab06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f1a3f671-3290-4a55-83b5-a914f786ab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e54238b3-8062-4a36-b7ff-1dc4cde74f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_179a4e47-ab5d-4a9a-8653-4a6e5308b9b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e54238b3-8062-4a36-b7ff-1dc4cde74f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_63590b90-6b86-4a8f-9029-01ee358185eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_adeb46d7-97eb-4c6c-bb87-360dee01180d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_63590b90-6b86-4a8f-9029-01ee358185eb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_adeb46d7-97eb-4c6c-bb87-360dee01180d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ee26e41d-51d4-490c-ab02-a5c61be15549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_de3c636b-6ce8-4971-ba64-ac7707fdd384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ee26e41d-51d4-490c-ab02-a5c61be15549" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_de3c636b-6ce8-4971-ba64-ac7707fdd384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9763dcc8-1e2d-4fc8-8c6f-1377af78fcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ee26e41d-51d4-490c-ab02-a5c61be15549" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9763dcc8-1e2d-4fc8-8c6f-1377af78fcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8e42360f-21b2-4b6e-afc4-56e235f83dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ee26e41d-51d4-490c-ab02-a5c61be15549" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8e42360f-21b2-4b6e-afc4-56e235f83dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0b741e21-818f-4f3d-b7f6-0611fef66606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ee26e41d-51d4-490c-ab02-a5c61be15549" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0b741e21-818f-4f3d-b7f6-0611fef66606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_3508e9a4-a276-4eb0-8c1d-5471f84378e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ee26e41d-51d4-490c-ab02-a5c61be15549" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_3508e9a4-a276-4eb0-8c1d-5471f84378e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a3029f14-b7a0-49b6-813b-276892498843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e1a90971-dd8d-4181-a8eb-ee4b843e8d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a3029f14-b7a0-49b6-813b-276892498843" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e1a90971-dd8d-4181-a8eb-ee4b843e8d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_df8c7d64-037b-44b9-93e8-43a11c0425d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a3029f14-b7a0-49b6-813b-276892498843" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_df8c7d64-037b-44b9-93e8-43a11c0425d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ed196aac-a862-475f-996f-44f16c0e7d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a3029f14-b7a0-49b6-813b-276892498843" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ed196aac-a862-475f-996f-44f16c0e7d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_50c07d10-c9d2-4c5e-a559-d93ec1f47e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b457ccbd-0cc0-4e4b-8507-a6ceef989c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50c07d10-c9d2-4c5e-a559-d93ec1f47e48" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b457ccbd-0cc0-4e4b-8507-a6ceef989c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_715d3a01-ae4f-4c67-9b80-43606b327b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b457ccbd-0cc0-4e4b-8507-a6ceef989c66" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_715d3a01-ae4f-4c67-9b80-43606b327b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d0bf2c49-f782-4cfd-8b78-9ee27fa1141c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b457ccbd-0cc0-4e4b-8507-a6ceef989c66" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d0bf2c49-f782-4cfd-8b78-9ee27fa1141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_272e5890-bc94-4908-aa0e-26364d61d850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b457ccbd-0cc0-4e4b-8507-a6ceef989c66" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_272e5890-bc94-4908-aa0e-26364d61d850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1df0f017-6454-464b-a897-b5dccc970be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b457ccbd-0cc0-4e4b-8507-a6ceef989c66" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1df0f017-6454-464b-a897-b5dccc970be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_abc699d6-252b-4838-a1e3-fc5a0792c2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50c07d10-c9d2-4c5e-a559-d93ec1f47e48" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_abc699d6-252b-4838-a1e3-fc5a0792c2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fa299046-4acc-4bad-89c4-74b433f47c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_abc699d6-252b-4838-a1e3-fc5a0792c2c8" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fa299046-4acc-4bad-89c4-74b433f47c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c852cf02-3614-4baa-bf78-b9fdd2a71522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_abc699d6-252b-4838-a1e3-fc5a0792c2c8" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c852cf02-3614-4baa-bf78-b9fdd2a71522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d946a095-08fa-410d-9bcc-9122cd541bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_abc699d6-252b-4838-a1e3-fc5a0792c2c8" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d946a095-08fa-410d-9bcc-9122cd541bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_648336b9-f872-4137-bd85-77bdf847b184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_abc699d6-252b-4838-a1e3-fc5a0792c2c8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_648336b9-f872-4137-bd85-77bdf847b184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fca8f684-6e72-4cf2-9dc4-2f96aad88f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50c07d10-c9d2-4c5e-a559-d93ec1f47e48" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fca8f684-6e72-4cf2-9dc4-2f96aad88f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_497ce86f-499e-4cff-b026-87fd86035569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureTable_8067123c-44cb-4b9c-9851-cd55acc4c8a0" xlink:href="nktr-20211231.xsd#nktr_IncomeTaxesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_497ce86f-499e-4cff-b026-87fd86035569" xlink:to="loc_nktr_IncomeTaxesDisclosureTable_8067123c-44cb-4b9c-9851-cd55acc4c8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_697f2431-6d04-4dc9-9d55-0a23129f14c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureTable_8067123c-44cb-4b9c-9851-cd55acc4c8a0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_697f2431-6d04-4dc9-9d55-0a23129f14c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1b49b5ac-81ae-4d54-a670-6ca7a8b2db5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_697f2431-6d04-4dc9-9d55-0a23129f14c5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1b49b5ac-81ae-4d54-a670-6ca7a8b2db5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c5eae0be-4f34-4cad-985e-69d637d3d0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1b49b5ac-81ae-4d54-a670-6ca7a8b2db5c" xlink:to="loc_us-gaap_DomesticCountryMember_c5eae0be-4f34-4cad-985e-69d637d3d0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9e6312c6-4c4d-4210-b7da-2b12fd00cea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1b49b5ac-81ae-4d54-a670-6ca7a8b2db5c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9e6312c6-4c4d-4210-b7da-2b12fd00cea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:href="nktr-20211231.xsd#nktr_IncomeTaxesDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureTable_8067123c-44cb-4b9c-9851-cd55acc4c8a0" xlink:to="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cf6e1604-a394-4421-a906-e9e4f5754877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cf6e1604-a394-4421-a906-e9e4f5754877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NetOperatingLossCarryforwardForIncomeTax_6e84c8ab-8628-4f01-8655-cbbb9daf11c6" xlink:href="nktr-20211231.xsd#nktr_NetOperatingLossCarryforwardForIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_nktr_NetOperatingLossCarryforwardForIncomeTax_6e84c8ab-8628-4f01-8655-cbbb9daf11c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_549a8b30-b241-4859-afed-2ed57bfebf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_549a8b30-b241-4859-afed-2ed57bfebf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_FederalOrphanDrugCredits_1b24c70a-9909-4fbc-8058-7441028ca0ea" xlink:href="nktr-20211231.xsd#nktr_FederalOrphanDrugCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_nktr_FederalOrphanDrugCredits_1b24c70a-9909-4fbc-8058-7441028ca0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_480aaeb2-7f58-49e8-97dd-1c65345cf739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_480aaeb2-7f58-49e8-97dd-1c65345cf739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_f3f7d5f6-8a12-4c32-be42-726ae41964fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_f3f7d5f6-8a12-4c32-be42-726ae41964fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_a7e475c6-3b4d-4cb8-b38b-cee97e2b418b" xlink:href="nktr-20211231.xsd#nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_IncomeTaxesDisclosureLineItems_99a63bac-f594-4bf8-befd-f5c2dd02b177" xlink:to="loc_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange_a7e475c6-3b4d-4cb8-b38b-cee97e2b418b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6da3c3d5-17ee-4900-b371-341669b8b587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_9e9b0644-c639-4a30-a6f2-164d28327ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6da3c3d5-17ee-4900-b371-341669b8b587" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_9e9b0644-c639-4a30-a6f2-164d28327ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_de56b604-22e3-4130-ace1-ea905896d661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6da3c3d5-17ee-4900-b371-341669b8b587" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_de56b604-22e3-4130-ace1-ea905896d661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d11d6533-a8fc-43d4-8bca-570eec5120a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6da3c3d5-17ee-4900-b371-341669b8b587" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d11d6533-a8fc-43d4-8bca-570eec5120a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_5ac8a09d-df87-485a-aeb2-67129ce443d0" xlink:href="nktr-20211231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6da3c3d5-17ee-4900-b371-341669b8b587" xlink:to="loc_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount_5ac8a09d-df87-485a-aeb2-67129ce443d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_e586cfe5-74b3-4e46-a9b4-9ab015cc0c72" xlink:href="nktr-20211231.xsd#nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6da3c3d5-17ee-4900-b371-341669b8b587" xlink:to="loc_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount_e586cfe5-74b3-4e46-a9b4-9ab015cc0c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_39c4d325-2a89-4fc4-b1bb-2663a0d3e1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6da3c3d5-17ee-4900-b371-341669b8b587" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfAssets_39c4d325-2a89-4fc4-b1bb-2663a0d3e1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_37bd2a6f-132c-4cc9-b62a-5989765f7019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6da3c3d5-17ee-4900-b371-341669b8b587" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_37bd2a6f-132c-4cc9-b62a-5989765f7019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9e830b00-ae68-4f93-9d26-044f5b7125fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6da3c3d5-17ee-4900-b371-341669b8b587" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9e830b00-ae68-4f93-9d26-044f5b7125fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a077553d-fc0c-4795-b8bd-b54d7ba97e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6da3c3d5-17ee-4900-b371-341669b8b587" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a077553d-fc0c-4795-b8bd-b54d7ba97e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0cf71ed6-27f1-421b-abaa-1437d5469252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0cf71ed6-27f1-421b-abaa-1437d5469252" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_28870be2-5b45-4ea7-9265-593100d8bcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_28870be2-5b45-4ea7-9265-593100d8bcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_df2af095-0429-4358-8f4b-60ec15862bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_df2af095-0429-4358-8f4b-60ec15862bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLeaseLiability_5340859d-96d5-4f24-b389-2a6c10b18e8a" xlink:href="nktr-20211231.xsd#nktr_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:to="loc_nktr_DeferredTaxAssetsLeaseLiability_5340859d-96d5-4f24-b389-2a6c10b18e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5349f118-b261-4ef9-a28e-f29be6037268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5349f118-b261-4ef9-a28e-f29be6037268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_21b2f13c-982e-4606-bd73-d5c460613895" xlink:href="nktr-20211231.xsd#nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:to="loc_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties_21b2f13c-982e-4606-bd73-d5c460613895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_aac781d6-dab0-4c8b-b85b-46229adf9e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_aac781d6-dab0-4c8b-b85b-46229adf9e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_9a97eb75-7bc1-41a1-9114-6369dae83cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_9a97eb75-7bc1-41a1-9114-6369dae83cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4477b60c-0c53-4253-9a78-66f748ad9e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4477b60c-0c53-4253-9a78-66f748ad9e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_868a4b2d-8a4d-44f8-b86b-c78a4fe5c332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_868a4b2d-8a4d-44f8-b86b-c78a4fe5c332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_09e7c03d-ea5a-4e70-b9cb-c67c397a96e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_38ab6c25-7cc1-4f3b-b698-942343920174" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_09e7c03d-ea5a-4e70-b9cb-c67c397a96e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ee53363e-1ec2-45c7-9dbf-fc0e9b24db48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0cf71ed6-27f1-421b-abaa-1437d5469252" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ee53363e-1ec2-45c7-9dbf-fc0e9b24db48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2816546e-4db1-4763-9785-5c4744c49b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ee53363e-1ec2-45c7-9dbf-fc0e9b24db48" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2816546e-4db1-4763-9785-5c4744c49b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_73542486-f1a6-4ea6-bcdb-13eb5d9b5ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ee53363e-1ec2-45c7-9dbf-fc0e9b24db48" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_73542486-f1a6-4ea6-bcdb-13eb5d9b5ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_d903d1b5-7fb9-4294-98aa-f8475c91da86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ee53363e-1ec2-45c7-9dbf-fc0e9b24db48" xlink:to="loc_us-gaap_DeferredTaxLiabilities_d903d1b5-7fb9-4294-98aa-f8475c91da86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c34e9f32-fef5-46ce-ad23-877a902ab64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0cf71ed6-27f1-421b-abaa-1437d5469252" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c34e9f32-fef5-46ce-ad23-877a902ab64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2e670c0d-2111-40a0-8011-5ead0c297192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_df7bbc94-c2f8-4005-b30a-146290b11612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e670c0d-2111-40a0-8011-5ead0c297192" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_df7bbc94-c2f8-4005-b30a-146290b11612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3060a3dd-bfa6-4abd-a5ef-b9236e120ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_df7bbc94-c2f8-4005-b30a-146290b11612" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3060a3dd-bfa6-4abd-a5ef-b9236e120ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract_671735cc-3118-4d2f-9e5e-3df997014bae" xlink:href="nktr-20211231.xsd#nktr_TaxPositionsRelatedToCurrentYearAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_df7bbc94-c2f8-4005-b30a-146290b11612" xlink:to="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract_671735cc-3118-4d2f-9e5e-3df997014bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6f68dd97-e655-43c8-ad7d-fbba6fc64b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract_671735cc-3118-4d2f-9e5e-3df997014bae" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6f68dd97-e655-43c8-ad7d-fbba6fc64b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_8074bf54-61f4-40c5-b9cb-2aa56b1de9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToCurrentYearAbstract_671735cc-3118-4d2f-9e5e-3df997014bae" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_8074bf54-61f4-40c5-b9cb-2aa56b1de9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_69d857fb-6641-4130-8412-0e309a863bb3" xlink:href="nktr-20211231.xsd#nktr_TaxPositionsRelatedToPriorYearsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_df7bbc94-c2f8-4005-b30a-146290b11612" xlink:to="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_69d857fb-6641-4130-8412-0e309a863bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_65538d48-477a-47cb-a1b3-514b0d464aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_69d857fb-6641-4130-8412-0e309a863bb3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_65538d48-477a-47cb-a1b3-514b0d464aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_03710888-5a51-4e48-a4d2-50f2942f9e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_69d857fb-6641-4130-8412-0e309a863bb3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_03710888-5a51-4e48-a4d2-50f2942f9e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_77d14172-f1fd-466b-85e5-f98ab667f5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_69d857fb-6641-4130-8412-0e309a863bb3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_77d14172-f1fd-466b-85e5-f98ab667f5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_ccf8d945-1b53-4c02-9781-83ca24171c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_TaxPositionsRelatedToPriorYearsAbstract_69d857fb-6641-4130-8412-0e309a863bb3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_ccf8d945-1b53-4c02-9781-83ca24171c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ceb7422b-839c-4921-aac4-7a23dd1163f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_df7bbc94-c2f8-4005-b30a-146290b11612" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ceb7422b-839c-4921-aac4-7a23dd1163f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReporting" xlink:type="simple" xlink:href="nktr-20211231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6ea84f11-46ce-4b69-aef7-c5426a27698b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_e70e06d1-2d4b-43db-bd95-832613333151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6ea84f11-46ce-4b69-aef7-c5426a27698b" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_e70e06d1-2d4b-43db-bd95-832613333151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f53a1c19-57b0-405b-a997-37c9c6ca2ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_d5c14806-131b-4ec3-8157-c37910273b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f53a1c19-57b0-405b-a997-37c9c6ca2ded" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_d5c14806-131b-4ec3-8157-c37910273b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_51a9ce0e-1fd6-4574-8680-222c6b2da5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_51a9ce0e-1fd6-4574-8680-222c6b2da5fa" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_657e19b2-5272-4acf-8f9a-779f69283d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_657e19b2-5272-4acf-8f9a-779f69283d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84d96e2f-8622-4160-af97-2748e521c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_657e19b2-5272-4acf-8f9a-779f69283d0c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84d96e2f-8622-4160-af97-2748e521c5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_372dac64-2dfe-49bf-adf8-512f75f7dbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84d96e2f-8622-4160-af97-2748e521c5b9" xlink:to="loc_us-gaap_SalesRevenueNetMember_372dac64-2dfe-49bf-adf8-512f75f7dbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_f5650d8b-c7f7-401c-84b3-c5eb60250b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_84d96e2f-8622-4160-af97-2748e521c5b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_f5650d8b-c7f7-401c-84b3-c5eb60250b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0b077b87-6bef-4701-b67e-ae977724dd2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_srt_MajorCustomersAxis_0b077b87-6bef-4701-b67e-ae977724dd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0b077b87-6bef-4701-b67e-ae977724dd2f" xlink:to="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UCBPharmaMember_76819973-404b-497e-85b9-f1f4b2b5abf8" xlink:href="nktr-20211231.xsd#nktr_UCBPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:to="loc_nktr_UCBPharmaMember_76819973-404b-497e-85b9-f1f4b2b5abf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_0e8f358e-8e8f-423a-9a28-ca435b1d3531" xlink:href="nktr-20211231.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_0e8f358e-8e8f-423a-9a28-ca435b1d3531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_1f99317a-43f0-4262-b289-a72f4cc4e8dc" xlink:href="nktr-20211231.xsd#nktr_AstraZenecaAbMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:to="loc_nktr_AstraZenecaAbMember_1f99317a-43f0-4262-b289-a72f4cc4e8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PfizerMember_34b7a737-3086-4beb-bd6b-57d2c6d195e8" xlink:href="nktr-20211231.xsd#nktr_PfizerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:to="loc_nktr_PfizerMember_34b7a737-3086-4beb-bd6b-57d2c6d195e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_742d7394-e124-4a2b-89ab-caaf9d2d3aee" xlink:href="nktr-20211231.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_972453c7-e26b-4bf4-8fd6-64f46a3831fa" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_742d7394-e124-4a2b-89ab-caaf9d2d3aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f31694ca-2c12-4acd-a057-50828b4f3955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f31694ca-2c12-4acd-a057-50828b4f3955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3997a2a5-3420-4f91-b93a-e2f7c310df33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f31694ca-2c12-4acd-a057-50828b4f3955" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3997a2a5-3420-4f91-b93a-e2f7c310df33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a5fa891f-b7f5-4e52-8a94-138276d98f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3997a2a5-3420-4f91-b93a-e2f7c310df33" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a5fa891f-b7f5-4e52-8a94-138276d98f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_884cf915-16ae-4017-afbe-ced98b17b220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3997a2a5-3420-4f91-b93a-e2f7c310df33" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_884cf915-16ae-4017-afbe-ced98b17b220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cbda1701-0cc6-4bb4-933c-83122e8b46b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_srt_StatementGeographicalAxis_cbda1701-0cc6-4bb4-933c-83122e8b46b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_993bb247-9e04-4907-9170-1391e30898f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cbda1701-0cc6-4bb4-933c-83122e8b46b1" xlink:to="loc_srt_SegmentGeographicalDomain_993bb247-9e04-4907-9170-1391e30898f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7324f35d-8149-4e20-b1fe-a24dde3cab61" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_993bb247-9e04-4907-9170-1391e30898f9" xlink:to="loc_country_US_7324f35d-8149-4e20-b1fe-a24dde3cab61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_866d9f5c-c1f0-4d4c-a7fc-03d43a168d41" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_993bb247-9e04-4907-9170-1391e30898f9" xlink:to="loc_country_IN_866d9f5c-c1f0-4d4c-a7fc-03d43a168d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b97470a5-d802-47c4-a5c9-6e46455bf997" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_srt_ConsolidationItemsAxis_b97470a5-d802-47c4-a5c9-6e46455bf997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0a19bb6d-6928-425d-af49-cb6c648f059f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_b97470a5-d802-47c4-a5c9-6e46455bf997" xlink:to="loc_srt_ConsolidationItemsDomain_0a19bb6d-6928-425d-af49-cb6c648f059f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_b255b8ce-fcfc-4f08-bae9-dd8d372666eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_0a19bb6d-6928-425d-af49-cb6c648f059f" xlink:to="loc_srt_ReportableGeographicalComponentsMember_b255b8ce-fcfc-4f08-bae9-dd8d372666eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_124fb6ca-f95e-473f-956f-c45abd2bb442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_14c703e6-6564-4a97-b89f-c4b37c1b2059" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_124fb6ca-f95e-473f-956f-c45abd2bb442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NumberOfOperatingBusinessSegment_5574d13e-d516-4416-b854-9b760278d194" xlink:href="nktr-20211231.xsd#nktr_NumberOfOperatingBusinessSegment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_124fb6ca-f95e-473f-956f-c45abd2bb442" xlink:to="loc_nktr_NumberOfOperatingBusinessSegment_5574d13e-d516-4416-b854-9b760278d194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_47689116-8f21-4792-9618-a8661e961772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_124fb6ca-f95e-473f-956f-c45abd2bb442" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_47689116-8f21-4792-9618-a8661e961772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5cf2a71-962d-4b13-a4a3-06b9ff30a68e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_124fb6ca-f95e-473f-956f-c45abd2bb442" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5cf2a71-962d-4b13-a4a3-06b9ff30a68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="simple" xlink:href="nktr-20211231.xsd#SegmentReportingRevenuebyGeographicAreaDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2921b048-775c-437a-9ec4-8e4b208b7629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b99f4e4c-bb0a-4533-9512-db373bba762c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2921b048-775c-437a-9ec4-8e4b208b7629" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b99f4e4c-bb0a-4533-9512-db373bba762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_daf187cd-5394-40c8-9df2-f9bb8778c498" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b99f4e4c-bb0a-4533-9512-db373bba762c" xlink:to="loc_srt_StatementGeographicalAxis_daf187cd-5394-40c8-9df2-f9bb8778c498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_72f3061b-a0f4-40ab-84f9-984bf2da5e85" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_daf187cd-5394-40c8-9df2-f9bb8778c498" xlink:to="loc_srt_SegmentGeographicalDomain_72f3061b-a0f4-40ab-84f9-984bf2da5e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c1ee1177-011a-486f-8c8b-1c1a239960de" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_72f3061b-a0f4-40ab-84f9-984bf2da5e85" xlink:to="loc_country_US_c1ee1177-011a-486f-8c8b-1c1a239960de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_3f6c04b1-52ad-4846-83b3-836d6a569a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_72f3061b-a0f4-40ab-84f9-984bf2da5e85" xlink:to="loc_us-gaap_NonUsMember_3f6c04b1-52ad-4846-83b3-836d6a569a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5b244009-2550-4790-8bb0-03d7ba9cf536" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b99f4e4c-bb0a-4533-9512-db373bba762c" xlink:to="loc_srt_ConsolidationItemsAxis_5b244009-2550-4790-8bb0-03d7ba9cf536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cca692ac-f070-47e2-9369-46aa50f4a905" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_5b244009-2550-4790-8bb0-03d7ba9cf536" xlink:to="loc_srt_ConsolidationItemsDomain_cca692ac-f070-47e2-9369-46aa50f4a905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_15ee7a6a-b077-40dc-bb3b-115fe45f504d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_cca692ac-f070-47e2-9369-46aa50f4a905" xlink:to="loc_srt_ReportableGeographicalComponentsMember_15ee7a6a-b077-40dc-bb3b-115fe45f504d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_548b0672-1f61-47d5-9a87-7c2820a6188e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_b99f4e4c-bb0a-4533-9512-db373bba762c" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_548b0672-1f61-47d5-9a87-7c2820a6188e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_0f7e2908-3da2-429c-959d-dd503582a05e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_548b0672-1f61-47d5-9a87-7c2820a6188e" xlink:to="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_0f7e2908-3da2-429c-959d-dd503582a05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0a46282-dbd1-4993-8bb4-556bbdbe0595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_0f7e2908-3da2-429c-959d-dd503582a05e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0a46282-dbd1-4993-8bb4-556bbdbe0595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialData" xlink:type="simple" xlink:href="nktr-20211231.xsd#SelectedQuarterlyFinancialData"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialData" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3d08e83a-1985-44e3-afea-39659773299c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_a0c74035-6062-45fe-a03f-6c28029808db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3d08e83a-1985-44e3-afea-39659773299c" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_a0c74035-6062-45fe-a03f-6c28029808db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="simple" xlink:href="nktr-20211231.xsd#SelectedQuarterlyFinancialDataTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_922dff12-217c-434f-82f0-bcbc699a92a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5ed6eb60-87f7-462d-84cb-f4c65aeaf89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_922dff12-217c-434f-82f0-bcbc699a92a4" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5ed6eb60-87f7-462d-84cb-f4c65aeaf89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails" xlink:type="simple" xlink:href="nktr-20211231.xsd#SelectedQuarterlyFinancialDataDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_29e4bd1d-7ba0-4ded-807a-c4270a523351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataTable_56b3b431-f059-412d-83cf-475a92914525" xlink:href="nktr-20211231.xsd#nktr_SelectedQuarterlyFinancialDataTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_29e4bd1d-7ba0-4ded-807a-c4270a523351" xlink:to="loc_nktr_SelectedQuarterlyFinancialDataTable_56b3b431-f059-412d-83cf-475a92914525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d2108ef5-fd22-4a9b-a7f8-6eed0556affd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataTable_56b3b431-f059-412d-83cf-475a92914525" xlink:to="loc_srt_ProductOrServiceAxis_d2108ef5-fd22-4a9b-a7f8-6eed0556affd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8e3afb78-21e9-49e1-8ea2-75ea56771e4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d2108ef5-fd22-4a9b-a7f8-6eed0556affd" xlink:to="loc_srt_ProductsAndServicesDomain_8e3afb78-21e9-49e1-8ea2-75ea56771e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5edb3604-4cf6-41ac-929a-abe37575d3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8e3afb78-21e9-49e1-8ea2-75ea56771e4a" xlink:to="loc_us-gaap_ProductMember_5edb3604-4cf6-41ac-929a-abe37575d3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:href="nktr-20211231.xsd#nktr_SelectedQuarterlyFinancialDataLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataTable_56b3b431-f059-412d-83cf-475a92914525" xlink:to="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_47ebef14-2c2d-4ca9-94aa-d77d5a2eb1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_47ebef14-2c2d-4ca9-94aa-d77d5a2eb1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2c6ccdbf-5f0b-4f7a-a45c-9acfdd049365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2c6ccdbf-5f0b-4f7a-a45c-9acfdd049365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_62e1a09e-ef56-446d-8bd1-f0a95775144e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_62e1a09e-ef56-446d-8bd1-f0a95775144e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8f91fe15-1ec0-403f-8f79-b42baac88980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_OperatingIncomeLoss_8f91fe15-1ec0-403f-8f79-b42baac88980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c0414ac-e3d9-45b5-83b0-1100ffc58e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_NetIncomeLoss_2c0414ac-e3d9-45b5-83b0-1100ffc58e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1588a556-14f9-4eea-8019-14b47fa43fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_SelectedQuarterlyFinancialDataLineItems_21c48c50-d404-46dc-a2e8-3976e47e4f7c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1588a556-14f9-4eea-8019-14b47fa43fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_62008ce7-64b9-46d1-bc90-1a3279dcb5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1588a556-14f9-4eea-8019-14b47fa43fa3" xlink:to="loc_us-gaap_EarningsPerShareBasic_62008ce7-64b9-46d1-bc90-1a3279dcb5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_48cf44b3-b159-4fa6-9d55-95ea5da2d7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1588a556-14f9-4eea-8019-14b47fa43fa3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_48cf44b3-b159-4fa6-9d55-95ea5da2d7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>nktr-20211231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nktr-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )- L4# 2(  A$! Q$!_\0
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M/^"D/@'_ (0+X>>*=-\%^/M?7QU/?VVD:1H^E6]SJ#/:.J2AH5N.<[LKL+'
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M4U#_ (*%: GC+Q7X<T3X0_%SQG/X9U2?1]0O?#'AF._M5N(F*L Z7'&<9&X
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M7^$$\:_%[Q1\';BS\(W<NF:MI4L6FP.YGPZKJ+R9$A& 85B!90!O&X*WL_[
M7Q"\7_%#]E_PSKWC2^DU?4Y)KJ"#5IX3%+?VL<S)#.ZD#YF5>O? ))))K?\
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MB0*=%^T!X(F\*7'B 7^HK:P7PTR2QDT2^34Q=E598!8&$71D*,L@419*'?\
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MU3Q0W@36K[QU:/K$]U_8.M1B,PHL;2$:<ZR->(D,2QAEBS@^6K5I_$/PG?\
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M_P )Z-XC;4;^ZT_5Y)8K.&QT:^NKQVBW><&M(H6G3RBC"3?&/+(PVTD"J_\
MPOSP_#XA\3PW,T">&]$\/Z=XA&O6\YN$NH;M[E46.-%)8_Z,NW86,AE 5<XW
M+X8M/I??;XN>S\NEM[7L]1+^;_AW[JA=>=[._?='7^"?$7A_Q!H5O_PCFMV^
MNV-K%#%]HAOOM;@&%)(_-D+,Q=HY(WRYW,'5CG=D[]>9V?QD\ :?X7U/Q?!<
MWL-O=:DEI=VYTB^_M-K[;'$D!L#%]J$I18R(Q%DIA\;3N-C1?V@O ?B#0[S5
M['6I9+&SMKB[G:33KJ-T2"8PS#RWB#ETE4H8P-X./EY&6_>EI_6E_P M?34B
M*Y8J_I^GYZ'HE%>7^)?C_H/@?QEXGTKQ)_Q*-)T/3]*O6U4F27S7OKBXMXXO
M*2,L"'@49R<F3H,9-R/X_P#@F7P?<>)1?:BMC;WZZ7):2:)?)J(NVV[;?[ 8
M1<F0AU8*(LE#O^[S4_U^2_5?>NY;33L_ZTO^6IZ)17BOA_\ :N\':CX-E\2Z
MD+ZQLGUF_P!)L[>RTZ\U"[N%M7<23&VA@,T8"H2X9 (C\KD&NW_X7%X.;5[3
M2TUI)K^\:S6UAA@ED^TBZ222"2(JI$D;)!,QD4E%$4A8C:V!:I-=;?BKK[UT
MW%M?RO\ @[/Y)]=CLZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^8_V
MJ?C!\1/AQXFO+?PM)8VNCQ?#_P 0:XUQ),IGCO+8V_E2K$]NZML,J *9 K":
M0L/W2AQ:R4>]_P $W^2-(0<W9>7XM+]3UOXY^!]7^('@2.PT$V1U:SU;3-6M
MXM1F>""8VE[#<F-Y$21D#"(KN"-@D<&N(\-_ ?Q!I,?@(7-WII.@^--<\1W?
ME2R'=;WO]I>4D>8QF0?;8MP. -KX)P,UM3_:@O\ P+X<\;7'CGPUI^@ZKX=L
M--OXX8=<\ZUGCOYI+>V\^X>",6Y$T;"4A9$1?F#..*ZOX+_'2R^-'@WQ!J-E
M+HK:AHMY+I]V_AW6$U?3VD$22H\%TJ)YJE)4SE%*L'4CY<E2?)":W2U?X+]%
MI_F1&3J1BOYM/OB_TD]?/T.(_9U_9LU7X0^)+.;4XK6:ST/2YM'TS4!XHU?4
MI[F)Y8SO^R7#"VL04@B+10K("V-K(J!6@\:?L6^&/B;??%'4?$VC>'Y?$/B#
M5X=2T'Q%_9\5S?::(;.UCB#M)'RHGMW8PY:-T<AL[F YOP3\?O'4WP!\#W'B
M'58/^$XU"Y\,7;:G#:Q(FI:;J%];1R,(L%4=5EE@?:!@A9%V>8@'8Z#^TMI^
MK_M,ZGX(C\4:-/ SW&BVF@)>0->I?6T*7#SO&/WJHX>XB^;*@VBD8+G.DHR3
M:OJN9:;Z<LFU\VMMGI9#YMY/JU_E;TM=Z[KN6M/\+_&3P_\ $&[\80>'O VL
M:AK'AS3-,U&WD\2WEC%!=6LMV[M"1ITQ>-_M((W;2NTCGK4EE\#_ !9X)L_#
M>O\ A_4M,UOQM8OJ;ZK;ZG--96.IC4;A;BY1)$65[;RY4C,;>7)\J%"/GWKR
M?@/XA>/++Q5X?M_%GB[6;#Q/??:(]:\*>(_#Z6FD12>1)*JZ/?PVFRXD1D0K
M&]W,S0^:7 D0[5\!^)_'GA_X+_#CXIZO\1]8\5C6HM&;5M"U:QTR*U*W[PQ,
M;=K>U@D1XWG5EWR2 JK*5)8,I9R=UW2O_B;T[6?7I;J)KET_I\JLGZVVV?4]
M/^!/PW\3> ]$\1#Q%K%P]QJU\;JUTTZ]?:XFD1B%(Q%'>7W[V8,R-,<QHJM*
M5"D+N/&>&O@?XL?XD:%XCUO0? ^E:WIMQYFI>//#LDD>K^)(UA:$175NMK&L
M:29CD93<3JC0J%4_*Z06?[4NEM^T1KOA5O$VDW5E"EUIEOX?M[N![];RTMUN
MI)S$O[X+(K7$7S J#:+C!<Y;8^*O'^@_#_P=\5=4\9RZI!KEQI3ZCX1^Q6D6
MFVUM?S11*MK((EN?-B,\;;I9G639(-B[U\N8_O'&2V:C^-U'SUM?S7Q"E[O-
M![Z__;?=>W>_P]SL/ 'P?UGPJOPO%W<V,G_"+Z!>:5>^3(Y\R6;[-M:/*#*C
MR7R6VGD<'G'D'BO]EWXH:K\&=#^'L&L:;=:;;^$(]":.#Q-J&CQ6-\(Y$DN=
MMM;DZA&ZO&/)G9$ B/RDR$CV7]J3QGJW@/X3MJ>C:M?Z'=2:SI-E)?:58I>W
M<4$]_!#-Y,#0S"20QR.%7RW))&%)P*\;UCXL?$;PQHNLWWA[5_%WBG1DU+P[
M:V5_XX\/0Z'>3W5QJ:PW5G&CV-MF%H'B'FF [6D;:Y(PBC[[LNLDOGT_]+T\
M]M;&JE*"NO7\?^!KY7OI<[RS_9]\0R?$"#7K^YTEK-O&)\0W$$4TI8V[>'AI
MK1C,8!?SLM@G&SG.[Y:T_"?@WXO>%=%\/>![:_\ #5OX9T=X+8>+4N99-4GL
M(<;8OL#VQA25D58FE^T,/O2+&"0BN_X7]K]OX,\57M]X8T'3-?\ #&LC2=66
M^\4"WT6S4V\5P+F34);=7$7ESQKQ;EO,8+MVYD&?X%_:>O\ XE7W@6S\.>&=
M+U!O$$6J7%Y>Q^(-]E;1:?>Q6EQ);3);M]J5VDW1';'O 7=LR2M\S;7I'[E&
M\7Z<M_+=/L8RC:*OTT_%W7W_ *-=&94WP1^).I_&K0/%6L:C9:C8:+K]WJ,=
MXWB6_P 364MO=0Q6ZZ0(!:0R1)<(OG!WD?RR6;YR!!^R?\.?'5GX2^&%[XPT
MS3- L_#/AIK&RL[=YQ?3R7'DEOM4,D2"W,:PA2@:3>S%B4P%K2\/_M&?$'Q2
M/#8T_P"%^E*_BC3)M3T9KKQ6401P&+SA=E;-C#D2J8_*$V[(WB+G;7\<_M@K
MX1^&7A;Q_P#V)H=IX;U?18]9=O$?BF'3+F8LGF-9V,/E2&[N54'Y&\E26C"N
M=S;)IZ*R\E\_>7XZ_/7=HTDI3D^__!O9??\ =HM$=/\ !_\ 9E\)^ YKG7=8
M\'^%+SQP^NZIJJ>(H-,A>]5+B]GEA_TAHQ('6&5$//&" 2,$T/#WP(\0Z1'X
M$$E[IN_0?&FN>([AEDD8-;WG]I>2J H,R#[;%N!P/E?#' ST\/Q7\1ZUX]U#
M3/#W@Z+5O#6CWUOINKZI-JHMKN&:2&.8M!;-$4FBCCGA+L9D;EPB.5 ;R/P_
M^WQH7B+1?%NI6=GH&H_V=X=OO$VF6.D^)X[N\FM[5@&BOX5A!L)F#Q,$_>C#
M.,YC()&\DHKM^%KW^Y73ZVTV#6I>VO,_QES+_P!N>G3J8^J?LN?%3Q6NORZ[
MJNEW6K:AX/UCPW-J5UXIU&]COKF[$&RZ6R>V6#3UW6_S16X8 ..7V GVSQO\
M)M7\2WOCF:UN;*-=<\&+X=MA,[@I< W1WOA#B/\ ?IR,GAOEZ9XSX^?'KQ=X
M=U&YT#P7I=BNJV-YX7FDO-0O_*2:#4=2DMW@Q]FEVY\@(7QD+,SK\T85[WAW
MX\>)-:TVPTSPWX=3Q+XJOM1U\B#7-76RMXK33]0>U8FXALV^8LT*QQ^3G:3O
MD)4NXTY02>RNOPN]O\3]/)(I2EI+T?WVDO\ TA?\.RUXO^$'CF7Q!X@UOPMK
M.GZ;?7GAG1]&@+3R1.[6MY<2W,9D$3^2LL4_EK,JNZ%BP3*KGC_!O[._CWPB
MMSKD*:/+KUKXL7Q-IVDZEXHU#58I%;2QI\L$VI7-NUP"%W2(_E/C"IM"\CK/
M&W[3%[\/_&?AG2==\/:+HEOK5QI]FEGJGBJVCUN:6ZDCB+6MA&DBW$4,DJK(
M_G(?W<I5655+Y2_%KQ6?@G;Z^=5_XFS?$0:$;C[/%_QY?\)*;+RMNS;_ ,>_
MR;L;OXL[N:N/-)WB_B?+?S<D_NNUY;VW=\K6BNUE]W(U_P"DQ];_ (9/Q0_9
MQ\;?$[7HM>U6+0KW4-9T0:'K-C;>*-:TFQLX5N)I$VI:,AU)?+N9$=)S ',8
M9?*$C*+_ (?^ /CC2O$7AC37;P^G@_P[XJU?Q!!?K?W$FH7,5]%?@1M 8 D;
M1O>@9\Y]ZJ3\I^4[WA']I#5]?\5:/!J'@^UTGPOK&O:KX<L=5&LF:Z:ZL3=%
MG>V^SJJ0NMG+AO-+!L I@[JY?_AIKQ-_;_ACQ3JNAQ:%\+[[P[K/B.&:SO5O
M;B^M+>*&6%YHV@0V\IB8N(XY)%.\AFRN*QE)*#3^&SO\[O[][=7YFCYY2Y?M
M;?.SAI^3MIIW*'@_]EOQKI/A%;6_N] BU;3= \,:?IZV]S-/;SW6C7MQ<(9F
M:!3'',K0@E5=HRSX#[%+]AX]\%_&3Q]8::UZV@VEL9+A;OPWH?BO4M("*PB%
MO+_:L%M]HF9"DY,2Q0(PG4-N\H,^)X/_ &U-.\0>$_$^M7%EX>O%\,QV.I:Q
M_P (GXF76X;73+@N'G\R.!29X/*E:2WVYVJ"CN653Z3X@^+&N:)\(=.\92^'
M-,TV[NDCN+BW\0:_'IUCI<#@L)+R[:-BF%V*1'%(1(X7E09!I6O+F=3OKZOK
M\[;]+:6:9,9<TKQW?Z)*WR5O6ZW31ROP%^!/B/X81[=9O-,N67P5HOAD-92R
MOF>R^V!Y#O0?(PN(R#R<A\@8!/)Z3^RSXKL?A1XK\,2:AHQO]5^&>E>#()%F
ME\I;RVBO$DD8^5D1$W*88 L<-E1QG9T3]JO6?'-AX57P;X.T?7]2UJRUB\>1
MO$VS38QIUW':S-%=1VTAGCD:3,;B(;AM+*H)*Q>./VF/$.O?#6ZU/X;>&H;^
M]_X0A/%UU-?:BMO-IT5S%*;40Q&&1;F;,,S%',:8C&6^<"BI5E%5*LOG\N?_
M .V\OP-*?-SI+R_!P2_%1\V6?B'\$_'FH7'BC3?#+^'9=#\5:MI>LW]YK%Y<
M)<V<EJ+2.6**%87617CLT*N9$*,S?*PQBAX=_9M\0>%?BM>Z];6VGZCIUMK.
MI^(],NK[Q;K&6NKI)B(CIJ_Z';[7N94-PHE+1C_5;W+#$^/?QN^)?@N&QD\/
MW%C%82?#+6?$,]W)(GGK?0):F.986MF5MC2J AD5&$TA8#RD#]CJ?[4%_P"!
M?#GC:X\<^&M/T'5?#MAIM_'##KGG6L\=_-);VWGW#P1BW(FC82D+(B+\P9QQ
M3E!T[MO577W/ET].71+IZLPAK3@DM)6T^2W]>>S]?0U/@S\._$OP)MX?#J6N
MGZ[H^LZLU_<ZA:L;>6TN)X)9KQS$L.UHS<QC9EP0MSM_Y9*'SU^!GBA?C:WB
M7SM(/A\>,%\4*_VF7[64;0GTYX3%Y6T%9!&X;S#N5WR%*@/T_P %_CI9?&CP
M;X@U&RET5M0T6\ET^[?P[K":OI[2"))4>"Z5$\U2DJ9RBE6#J1\N3\\_!_XY
M>*/%%O\ "H67Q&\=>)_'FOPV.H:AX8\0>$(-/TF:R;RQJ$\5T-,M\QPK*61X
M[APS>4O[S?@N-_:<JT=HKY/5?)<MV^BW>XV[4Y2Z/FOZZW^;O9=^AVNO_LN^
M*3I/A^[L9+/4=;TK5O$<WV2+Q5JF@1/;:G?-=(WVRQ3SMZ;(0T14HVY^<JC5
MZ5X@^"]U-\&/!?@C1WL+5M OM"G.7G$ BL;RWFD6,R-+)RD+! [L<E0S]6KS
M?2_$/Q!_X57XS^*9^).KW,OA_4]>F7PS=V&F#2YK2POKF,6Y9;5+A2T,&!)]
MHR'(8[@"AV_$WCS5?%UYXZUEOBHOPB\*^%)K?38+F1-.\F>ZEM8+@RWLEW%(
M!'FY@C6.-H6.)"7.]-D1ERJZZ-2]+.Z_%^M_(TFFYN^]Y+U=_>_SZ:>8OC3]
MG/Q/J'Q4U/6/#^N6-EX6U+0=2TTVDSR)=6%U?W-HUW+ P5E*-'!+(%.")G)R
M5?Y+B_L[ZO\ #?5KRY^%NJ?8[:^TN"VN[7Q5J][JJS26LRM;P W+3-'!)#)=
M0N4(,>^-U1RI4];XP\3>+]8^!4&M>"I-.UKQ+>VMG)]J\/S174#1N\8N9[%I
MF6.5EB,KP^8=K,J;@P)4^<>&?C9JOA'1_%]VFO:Q\2(+%M,^QZ;XKTH^'M?C
MENKD6[*\+65JAMB2C1S>7RZSH6^4%3EY?<7V=/75O5=4G)VNK?<1?F2F^O\
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M-UJZ^,X_%.DV%Y=S06]Q'_9$>G20W$BQ.8FP9F5E20#"<'+ 2Z=^T!XJTWQ
M^D^,_ FG^'7CCTJXEN+'Q";Z*.&^N9+922;:([XY40,N-N'R'(7F77/C!K%X
MWP@U33T&FZ;XFUR\BGME99OM=BFGW\]NV]D!3?Y$$ORX(SMR1G,\SIP<KV6O
M_MK?_I*_%=Q\SFY+RU].5_G'\T]-#SO4_P!F/QYJ%GI>N77]CW?BNWU?7+N7
M3M+\5:KH-J(-1ECE&V]LXQ.S1F")2C)LD#.3M(7'8:+^SYKOAOQEX#\0:?\
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MEMRYC3Y< @[W@[P3+X6T&[T^]\2:WXJNKR62:XU/6YHFG8LH7:J11QPQ*%
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M?PY%X4O)]+N+99]3TZ-&6.*X9X' 9=\A#PB-@97YP<5[914M*4>5[?\ #_\
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M_AO+4[32?''BBZ7P^=$TVQU>XTG07L[ZWOYWL[H6\;+=L#:WBN?FD6$JT =
M=_)&R?VJO'B^+S\,#_PC(^(0\0MI0UP:9<_V8;<:3_:1E^R?:?,#X_<[?M!&
M?GZ?)4\RY.?I:_RO;\&5RN]O-K[E=GUY17GWP.^*T?Q<^"GA3Q]<V\6DKJ^F
M)?7$)ES';M@^8-Y ^4,&Y..!79:/KVF>(K5KG2M1M-3ME<QF:SG65 P )7*D
MC."./<5I*+A)Q>Z,XOF2:+]%%%24%%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7\(_\C!XW_P"PQ'_Z
M06==17+^$?\ D8/&_P#V&(__ $@LZ .HHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KQCQU^T]H_@WXUZ%\-;?P[KGB'5;WR'O[K2;=98]+CG\
MT0O(F?,<$PN6**0B*68@8!]GKY8_:6_9Q\9_%SXV> ?$.@Q>']+M-)N;=V\5
MVTT]IK>G1QR-)+$2I*W4,@.U8R4"L[%@P.0X_'%/:^OH#^&7?I]Z_0]$3]IW
M1EM_'.JW7AGQ#8^$/!\M];ZAXJN!9_89)K0XFCA1;DW#G=E0?)"EE(R#6=_P
MUSX>_L\Q_P#"+^)O^$L75O[&/@XQV8U/[1]D^V'YOM/V<I]F_>[A/C'R_?\
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M3V\J3P2J'CEC8,KJ1D$$<$$=ZEH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?PC_R,'C?_ +#$?_I!
M9UU%<OX1_P"1@\;_ /88C_\ 2"SH ZBBBB@ HHHH **** "BBB@ HHKD?'_C
MB3PR+#2])M5U7Q5J[/'IFG,Y5#M \R>9ADI!$&4N^/XD107=%8 3QQ\0H_"U
MQ:Z3IMBVO^*]05FL=%@D"%E! :::3!$,"DC=(0>H55=RJ-Y5XQ_9/F^+6OZ)
MXI\<>.M4;Q+I:3I;6^D6&G/I=HDK0NT<=O>VMR&(:")O-?+EER-HVHGKO@7P
M/'X/MKJ>YNFU?Q!J+++J>L3(%DNI "  O/EQ("0D8.%!/5BS-T] 'G_P[^$;
M> _$VN^(;WQ?K_C'6-6LK+3I+G7([&/R;>U>Y>*.-+2V@4?->3$E@Q.0,@#%
M=Y/!'=0R0S1K+#(I1XY%#*RD8((/4$5)10!Y=<_!"#PO<2ZE\-;\>!=09C))
MIL,1DT:\8G)$MED*A)R3) 8I">69AE3N>"_B,VN:E+X?U_36\-^+[>/S9-,D
ME$L5Q$" 9[6; $T.2!G"NF5$B(64'M:Y[QIX&TSQWIL5M?\ G6]S;2?:++4;
M-_*NK&< @2PR8^5L$@@@JREE8,K,I .AHKA/"'C#4;'6E\(^+VB7Q $9['48
M4\NWUB%>LD8S\DJC'F0YX^\N4/'=T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%5[C4+6UN;:VFN88;BZ9E@ADD"O*54LP
M0'EB%!)QV!- %BBBB@ KE_"/_(P>-_\ L,1_^D%G745R_A'_ )&#QO\ ]AB/
M_P!(+.@#J**** "BBB@ HHHH **** ,+QMXQL/ ?ANZUG4?-DAAVQQV]NN^:
MYF=@D4$2Y^:21V5%7N6'2L/X<>#K_3YK[Q/XF\J7QAK*I]J$+;XK"W7)BLH6
MQRD>YBS8'F2,[X *JN'X9_XN]XY7Q;+^\\(^'YI;?P_&>4O;L!HY]0]T4%X8
M3W!F<;EDC(]5H **** "BBB@ HHHH PO&G@VP\=:#)IE^983N$UM>6K;+BSG
M7F.>%\';(IY!Y'4$$$@XGP_\97]U?77A7Q0(H?%VFQ^8TD*[(=3ML[5O( 2<
M*3@/'DF)SM)*F-W[BN3^(G@=O&&GVL^GW8TKQ+I<INM)U39N^SS8P5=<C?#(
MN4D3/S*>"&"LH!UE%<M\/?'"^-M*G^T6ATK7=/F-GJNDR/N>SN  2N[ W(RE
M71\ .C*V!D@=30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7P#^V VF>'?VQ?AOX@WP>+]:\W3;>'P?>K=6E[ //E"W6F7285_FD#
M2Q+G/DKYA"D+7W]5>XT^UNKFVN9K:&:XM69H)I(PSQ%E*L4)&5)4D''8D41T
MG&?9W_K^OQ!_#*/?_-/]/Z6A^9OQ6U3XOW?QN^+NH77AKQ)I?BS5/AIJ2Z=8
MQW5C-%IMC'>@1M;F"X=V+QH23CS#-+P@0!A9W>&O[=8JFB_\,QGQL?E*)_8(
M/_"/_+@$>2(OMO7^$7'7YZ_3&BH4;4_9^5O_ "?FOZ^?>[ZV+<KS<_-O[X*.
MGW?=IYGD'[**^)&_9@^'(\0O<1^(SH4 E?4DD>56V?NS*K$.6V[-P)!Z\BNN
M^'L=[%J7C)-0N(+J\&L)OEM8&AC;_0;3&$9W(XP/O'D$\=*[&N7\(_\ (P>-
M_P#L,1_^D%G6]27/-S[LQA'EBH]CJ****S+"BBB@ HHHH *\T^+FK7FO7>F_
M#S0[J6TU7Q COJ%];L5DT[2T(%Q,K#E))-PAB/4/(7&1$PKN?$GB+3O"'A[4
MM<U>Y6RTO3K>2ZNKA^D<:*68^_ / KCO@[X=U&.QU'Q=XBMFM?%/BB1+NYM9
M?OV%LH(M;'V\J-COQP99)V'#4 =QI.DV>@Z59Z9IUK%9:?90I;6UK H6.&)%
M"HB@=    /05;HHH **** "BBB@ HHHH **** ///B-X=U+2=5@\=^%[5KO7
MM/A$%_I<1 .L6 8LT'.!YT9+/"Q.-Q9"565F'8^&_$>G>+M!L=9TBZ6]TV^B
M6:"= 1N4^H."I'0J0"""" 1BM*O*M1_XLOXRDU5/D\">(KL?V@G\&DZC(P"W
M(_NPSL0LG992LF,22L #U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KE_"/_(P>-_\ L,1_^D%G745R_A'_ )&#QO\
M]AB/_P!(+.@#J**** "BBB@ HHKG/B%XVM?AWX-U/Q!=PRW8M440V<&/-NYW
M81PV\>>-\DKI&N>-SB@#C?%__%S_ (G6'@Y/WGA[PZT&LZ^1RD]SNWV-F?7#
M+]I<=0([<$%9:]5KC/A-X)NO!/A)8]6FBO/$NI3-J>MWD.=D]]*!YA3//EH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)Y\-F(U=4VJJJ3@@'=N))H [CQ3XV\/>!]&OM6\1:YIVA:78HLEU>:C=)!%
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M9W <TYOA[X^\7P>*++Q;X[73=+U"54TR'P7:OI]W8PI(6!:[D>1GD==JL55
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M:_GM<]K^$OQ(L/C!\,_#7C72X9;:QURQCO8[><@R1;ARC8)&5.0<>E3>$?\
MD8/&_P#V&(__ $@LZK?"SX7Z7\*?A9X>\"63-?Z7I&GIIX>[52UPH7#,X VY
M8DDC&.:/A[I=EHNI>,K+3[."PLX]839;VL2QQIFQM"<*H &22?J36]3EYWR;
M7T,(7Y5S;G8T45R?Q2\<-\/?!-_JUO;#4-4)2TTS3]V/ME[,XBMX<]@TCH"W
M\*[F/ -9EG+2?\7+^-JQ_P"L\/> OG?^[/K,\/RCW^SVTN['3=>(>L=>JURW
MPR\#K\/?!ECI#W)U#4,O=:CJ#+AKV\E<R7$Y';?(SL%'"@A1@ "NIH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MJZEIEGK5A/8ZA:07UE.I2:VN8UDCD4]0RL""/8U:HH \J;]G_3O#K&7X?Z[J
MWP[D'(L=)E6;2S_LFPF#PHI[^2(G./O"C_A*/BKX-^76_"6F^.K%.NH>$;H6
M=VP[DV-V^P#O\MTY/.%Z9]5HH \YT+]H+P-K&J0Z1=:NWAK7ICMCT;Q-;R:7
M>2'N(X[A4\X?[46]?0FO1JS]>\/Z7XHTN;3=:TVSU?3IAB6SOX$GAD'HR,"#
M^(KSK_AG70=$^?P5K&O_  [D'W8?#M__ *$OH!8SK+:J/]V('WX& #U6BO*O
M(^,GA/B*Y\*_$*S7HMTLVAWH7W=!<12M]$A';CK7G]Y^W]\,/"OB2Z\-^-9K
MSPIXCM"RSZ?%Y6LLK*<,"-.>X9,'M*J'U H ^E:*\K^#?[27@[X_^%=7UWP-
M)>:M#ITLD!M9H/LMQ.Z*#A$E*D D[0S[1N!R1C-?!?B;]M'PW>>/-<L/B#\)
MO&5SX^O-7O;31)H[N1;FT2*YDMHH=--OYBK)&T6V1H6^:829+8P #]2**\B^
M%'Q*\7^*/V8_!GC:;PT=>\7ZEH=C>R:5;7L$ NWD5"TJ2$B-%96,H4G@';UK
MBO&O[6OB3X6+:3>-OA#J&A6MY(L-M(/%>B%YY"P79''+=Q,[?,ORIGKVH ^D
MJ*\&\=?M27F@:/KDOA_X3^/_ !)JFFGR4A_L*XAMIK@$AXQ*J2,ZKM8&2*.1
M"0 K-D9X;PQ^TI'X\\5>![;Q#\1;CX;ZL\T4-_X.3PK>6PO[PW&$@%YJ%JA\
MM@8D*HB,26PXS@ 'TGXW\?>&_AKX?FUWQ9KVG>'-'A(5[[4[E((@QSA0S$98
MX.%')["N8C^+T^N>(]/TKPQX0UO7+&_T]=0B\3-'';:.B/"9(=TSMYC;SL4B
M**0KOR0,4WP?\+_AW\-]6O["QC@?7-:G34;G^V=2DOKVZ=&;9)FXD=\*68+M
MX7)QBO2* /(!X#^)WQ"\*Q6GC3QG#X)OOM[32Q_#K(\RTV*%@:ZNXV?=OW,9
M(TB)& ,<D]?H7P@\%^&_'&K>,].\-V,'BS55V7FMM'YEW*F%&SS6RRI\B_(I
M"Y4'%=A10 4444 %%%4]8U2#0]*O-1NA,;:TB:>7[/"\TFU02=L: LQP/NJ"
M3V% %RBN,N?C%X.M1J#'7()8['3++5Y)+=7E22VO))H[1HF0$3-*]O*J)'N9
MB% 'SKGL(I!-&C@, P# ,I4C/J#R#0 ^BBB@ HHHH **** "BBB@ HHHH **
MRM=\4:9X9;3AJ=S]C2_NDLH)71O+\YP=B,X&U-Q&U2Q 9F51EF4'(TSXJ>&-
M9GL(+'43<W%]?W^FP0QP2&1IK*>2WNR5VY6..6)D,APF2F&.]-P!UE%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<O
MX1_Y&#QO_P!AB/\ ](+.NHKE_"/_ ",'C?\ [#$?_I!9T =17E5K_P 7.^,\
MUR?WGASP&_DV_P#=N-9EA(E?W%O;RA 1QON90?FBKI/BMXVN/ _A,RZ9!'>^
M(M1G33-%L9"0MQ>RY$8;'.Q0&D<C[L<4C=JN_#GP3;_#OP5I7A^WGDO&M8R;
MB]F $EW<.QDGN'Q_'+*[R-[N: .DHHHH **** "BBB@ HJKJ6J6>CV<EW?W<
M%C:1C+SW,BQHH]2Q( K&\-_$?PIXRM]1G\.^)=)\0QZ:VR\.D7L=V;=MNX*X
MB+%6*\A3R>U '1T5X:/VN/#VI?-X<\$_$;Q9;DJJW6F^#[V&!\X^[)<I"I'J
M<X_,9YCX[?$*?4_!O@_Q'XC\)ZQIG@2=+U]7\/ZY=P::YN@46SCOY1,88K9E
M^T.?,DV%A K<L%H ^F:*^,_@-\3OB9(WB2?X??"33M1\ .MM_9=K'XVBDL8+
ML+)]H%I<>2ZO 0;<%8LQI(LNTDLP7Z8\:>*/&6A>%--O]!\$1^)]:E:,7FCI
MK$5K]G4H2Y2:1=LFUL*!\N[.>* .THKQK2/C9X^;5K*RUSX#^+M,AN)Q";^S
MU32+V"$%@/,?;=JX0 Y)V9X. :Z7XF?&[0/A)>64>OZ?XDDM;J-Y3J&D>';[
M4K: *0,2O;12;"<\ CG!H ] HKS#P'^TY\+/B9XBC\/^'/&VEWOB"0.R:/*[
M6]ZP0$OB"4+(< $G"\!2>QKTM)XY))(TD5GC(#JK E21D CMP<T 24444 %%
M%% !1110 4444 %%%% !16#XR\>^&OAWI+:IXI\0:7X<TY<YNM5O([:/(YP&
M<@$^U8WA7XLZ1\3/ ^J>(_ 1;Q1%;>=%:J\<ME%>SH@95CEEC :-BRCSE#)R
M<$E2  =O6)XP\;^'OA[HDNL^*-=TWP[I,9VO?:I=);0AB"0-[D#)P<#J<5Y
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MI47AG1]330[C3Q]CBB<"06SR/<1E"N_[5%M<,0J_='J'@O6/ 7PIT_3K*_\
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M _>1:/I#.K\#(,DL!8#KRH4^_H >V>,O"WQDM_$%[JG@SQYX=N-.F<-%X?\
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M^ ?A.?B9K/B"&+P*(;>Y_MFUAENHS%.Z)$X6)69@S2(. ?O<U\Q6?[=_PO\
MBIKVK>!OAKXTNKSQ3XTUV&SL[JST>^62TM390+<7:;X!\Z+#,J9Z/L9AY89@
MVG%V9*::NCZ%\&_\7.^)FH^-)/WGA_P^T^B>'U/W9IPVV^O1Z_.@MT/4"*<@
ME9J]5K/\/:!I_A70=.T72;6.QTO3[>.UM;:/[L42*%51] !7A_B/]N;X4:3=
M7EGHVI:EXXU"T65Y[?PMILMY'$L0)E9[G"VZ*@!W,\H QR12&?0%%?+VH?M[
M?#EO@_/XHE\7^'/!^LW3SV^GV>J7T6LA)5&4:9--EE.T@J2JOD;L9SQ7@GB#
M]JSP?K'B+5M'\7?M%^+/%#V-L]P+/X4Z5#I>GW,GEAUMH;E&EN)'8L$4B=5W
M<,R8- 'Z >,/'/ASX>Z,^K^*=>TSPYI:ML-[JMW';0[L$A=[D#. >.O%><>&
M?VK/!7C[Q#8:7X,M?$7C.&ZF6%]8T?0[EM+M@Q^_)>2*D)4#GY&8X' -?*'C
M/_@I9X*;P'X=EA^$VH:Q?V<SB*S\=-) UG'$@5+O[5)!.LCL"X)W[N#ELMS>
MNO\ @HSXP\2:EKDWA#PC8W/AR6VEBT:3[583W<<Q11'/.(]1(,:ONW(J<\#>
M#D4 ?7OQ'D^+5QK4%EX"@\'V&DF!6FUCQ%+=7$R2EF!1+2%4# *%.YIUR6QM
MXR6?#?X>^._#VN2ZKXQ^*-WXP+P-"NDVVC6FG:=$Q93YBJJO,6&W W3,,,W!
MZCXPL?VBOC[XX\+:;I]U'K&BZK;2237.J:+I]X3?*2OEKY,&@W^U%*D[D<!@
MYRW*@3MJWQW\3>*O$6IW,6J-I^O6TMI)I/\ 9'BN2T@ADV!C!&YL/)8!.&RK
MC<P!&30!]:Z]^R_\']3\57?BOQ+X/TO7=6N[@S/=>))7U"-9&/2..Y=XXQZ*
MB@#& !6_;>,_AA\-;?5M,M=:\*>&HM&MVO-0L+6YMK;['"FU6DEB4C8HRHR0
M.H'<5\4:E\"?'GB/3M%TW_A'M4O],T>>6XTNW;X<Z7,T$DA4R,LFLZS.ZDE%
M_P!8>=BXSA:[S1_AQ\2;6XU2[O-*^,*ZCJ>?MEYH^E_#VQEN-Q!;S'\QW;.%
MSEN<<YH ^A;O]J+X66NDZ!JD?C&SU'3M>GEMM-N=*BEODN9(R!(H,"/@J6 .
M<?H:\@_:F_X*,> _V:)+C1[C1O$VK^)9([N*T5-&EM[(7,2KM#SW'E+)&6=<
MO;^;@9]5SSS?!WX@76#.W[0$L6 %B_X3S0[0JN. 5MG4 ]. 2..IYS\3?\%.
M?AOKGA_P_P##W5+CP]\4K2QMY[ZVN=2^(GB*WUA&EE$+1) 8+RX6$D12Y&V,
MN%7[VWY0#[6_93_X*.:9\</#T.F-X-\<>(/$6EA(-6U72?#Z26I+.ZP3.L4S
MF$RHA8K]U660 L%!/T8OQL=_$'BG2D^'_CACH,,DWVPZ2JVVHE&5=EI(9!YK
M-NR!P,*22*_(C_@F?\*=%\73>--9\7>!/B!XKT)1;VEI-X2NI[:T28;WD\\P
MSPR22!3'L"E@!(^Y<E#7W+?? []GZ:W\K4_AQ\6]-4$%O.M_$VH*I[95'G0_
M4 X]10!]#WWQ\?3]+\.WLGPU^(#MK%Q) ;6#15EFL=CJN^Y"RD1HV[*G)R%;
MTK3?XTV4.L>(["?PIXRA70X)9WO%\.W,L%X$8+MM6C5C.S;@551D@$]C7R?)
M\$/V1[<_Z3XJF\*+_$OB"]DT_GU)OH@1V[@<K_>&>N\._L<_"'QE&5\&?%G6
MI85.1'X=U/2;E%7GC;]DD';[Q^8XY)YH ]PO/VBO!6GZ?X<U/5K'Q1I;:Q/)
M;6$5]X/U5;A) ZQD2(+8M#N+K@R;0P.02 <><?$73_V9OB!X[\8WGBJSTV+Q
M=X?LVN==U80W>FW<-O$5C+M=1B-I%7Y%!5VP ,<"J'_#"K6/_(-^)FO1=RLZ
MLBL1TW"UEM]WOGGT*TO_  R#XQL>;+XAVKXZXE\26<S_ .R9H->7"]\;#G'T
M( .D^%?C3X*_#/3;/5=)^,OVW0O$SM!I2^)_&;WULSPL%=+5KJ5F# NH90Q.
M2HQTJK>:Y\1]/\1:];^&OCM\.?$<NGM++=:'XDTE$GT^-9,,));6[0H$+*F7
MBZXSR:YR[_9>\=YC9[R'6)83F*6;XB^*H-A_OA);FY7/;:0>N<\5E77[,?BJ
M2349+_P+#J$FI1M#=RVOQ6U*9KI"06$RS6"!@2%.UBX)'/09 /?_  ;X^\03
M?#VXU3Q%_P (IJ/B#-P;"V\+:R9;74-@_=HLLZ1['9OE(.Y5.#N/;BE_:HU7
M2Y)X/$7P7\?:;<VPW7']FC3M5BB4;=S$VUVS@#/=!P#WR!XQ??LLV]U:Z7;Z
MM\'?%>IVVDR/-80V>O:)<+:,S!G,*SB(([%0?EP"0"6'9LW[/NBKJ7B"_O/A
MO\6K"^\0026^L3+8>%+F2^@D<22">2$R--N90QW,SL5!.3B@#ZLU3XT^&M!^
M'NG^,M5_M.PTJ^6,QVXTJYN;T,Y"A#;0))+N!." IQWKAE_;;^#>US)XGOK<
MQC,B7'A[4HFCQUWJ]N"OX@5\^S?LZ?#>72]$T^Z\(?%8:7H<DDVGPMX/TJ2.
MR9W#R-&B63$%F52=H)) K17X/_#5=5\0:G_9WQ9;4?$,<D6L73_#ZW:74(Y&
M5Y$G8Z7F16959E;()4$\B@"G^W5_P4-MO@/KEAX5\+W]P;V^T)M8M]8T>WM;
MV.65IY(8H2\KE(T#02F1O+D8_*JA22PU?V8?^"F'A;XP:+)9:KI.ORZUIHDE
MU"^M-,0Q16:E +J:..5V49D"$1A]S+D*NX(/B3]OW]FV]DNH/&_A6'Q''X-T
M'18[2>/Q-X;N--EAD^TS.PC\JQBMUC)F4C<P8NS]<BO;?V!?@3XH^&'PSU'_
M (2S2OB=K&GZU<1ZC8Z7X'U2?3+*-'B7,[SK=VQEDD 0?N\@+"OS,'P #ZO^
M(?[3_C:^N/#)^%/@23Q)H&OAEA\2:AINJ[+=TE,<@EM4M%,:@@$-++$'!)7(
M!-7OAOKGQTM_$_C*?Q1IM_X@6PMWATRR6RT[1M(OIQ,@WP.+FZN\; Q5I=JE
M2=R!\ 87_"!V5]T^!GQ7U,-SYOB#QY',DJ_[0EUJ1SVPKIQCMBC_ (4:NH<+
M^S7X*N2>"?%?B43!O9\6ESN7'8YY[8YH KS_  QM]#\5Z/XTO_#GPJ\&^*KV
M[DN_$-UXOU6X\07MJS3;PEG/,8?+S%N; VHA("JRKD[%[\5/!UQ=>*[/7_VH
MM%EMM5P+#3_#M[IMI=:3'YF\&-T,DKMM 0N^1@D@*2,6=%^ _B'30HTGX8_!
M/P2 ,*++2I-0V G=@;8+3//TR>?:NUL_AO\ %#R1#-\3='TF'.3'X9\(1VBC
MW N+BYP>G7/.?8  \Z76/@AJ%QX6N[V[\:>/M3\-8.GWIL->U>3S!*90[I!$
MT<LBM@[F0LJA>B@5UOA?X@>$?"<U]+X(^#/BFVDOY3/=2:7X/&DM<N26+R&X
M\C<Q+%LMSDGOQ6__ ,*/U:^_Y"_Q;\>ZH#U2.XL;!?H/LEI$V.O5B>>IP"#_
M (9E\"W7.K)K_B4G[RZ_XFU*_C/_ &REN&C ]@H!Y]30!A^(_P!HS7/#L>^_
M^'%QX:CQGS/%WB?1]/7'K^ZNIS^G0'N #PS?M@ZOJS%=(_X5W=*>%;0_$6H>
M(Y?3_566FD$@YX60YP1P0<>X>'?@/\-O"$GF:)\/_#&DS9R9K/1[>.1CW9G"
M;F)[DG)[UW*J%4 # '  H ^5O^%Q?&OQ!_R!]*N)4;I':_#N\MY#])=3U*S4
M=A\T?.?X<'!_9?[2WB/_ %6H7VA[O^?J]T;3]O?HECJ?OW/\(SU:OJJB@#Y5
M'[.7QK\0'_B<?%^33HS]Y8;F]N'QZ*]K+8 'D\[2/53QCX8^)7_!*WQ-XG^(
MUSJ&D>-;K5(/$7B*\LX[_5=(G1FN!:WUW+*[R7$LC0^;;) )Y6W2/,7^8!6E
M_9&B@#Y!^ O[ 'P+TWP/H5W=>#;C4_$-O:166I7&KR7-M))=0IY<IDM5F,0.
M\.01O!# J[KM8_07A?X"_#3P2XDT#X?^&-'FSDS6>D6\<A.,9+A-Q. .2<UW
ME% !1110 4444 %%<5XF^-WP[\%L5U_Q[X9T1@<;=0UBW@;/'&'<'/(X]Q7/
M_P##3WP_N/\ D&7FM>(_1O#OAO4M40^^^VMW4#IR3CD<\B@#U6J>J:/8:Y:F
MVU&RM[^V;K#=1+(AXQT8$="?SKS;_A?%S>?\@GX7_$#5L_=_XE<-CN_\#)X,
M<\<X]>F#1_PM+X@W/_'M\&-;@W<K_:6MZ7%@>C>5<2X/TR/>@"UJ?[,_PFU:
MZ:[G^&_A=+YNM[;:3#!<]2?];&JOU.>O7GJ,UP'QM_91T;6/@QX^TKP;_P )
M-;ZY?:!J%KI^FV_B[48[.XG>VD6*)X)+G[/L9BJG<H&."0N:[7_A.?BS-\T/
MPKTJ).FV\\6JCY^D=K(,?\"S[5D>+_''QOC\)ZU_8_PPT==;:RG73Y(/%"3[
M+GRV\IG22WB4J&QD;N>G<D 'S5JW[+OB:^U'PTGAC0OC-HAL=>TBZM(?%NN>
M'=0T+1XH-0MYI)X;9;N22)HXHY-H@4%ON$%785[=\1_V7_$/Q(N(;KQ+<?#K
MQO=6ZA(+S7/!TUOJ,:@DA4OK>]#1CG^&/J<]L5^4O[('CCX]P_MDZ=<:?%XN
M\1>)TU(-XKTF6;]_/9HP6Y2<7,B1JP3<$\YE ?9@@XK]F/\ A?IL_P#D+_#?
MX@:1C[W_ !(Q?X_\ I)\]^F>GN,@'G/PT^%_Q2^">K75QIFCP^(M&E@\E=(E
M^(>H7,$/S [X(+VTD,;84@#[3M^?!!^\,?7/C+^U!X1\27<W_"E['Q5X;:>2
M2*."\@L[B&$DE8_,CNK@S,H_B^SQ!@ <*3M'L,/[3_PN\Y(=1\76OAFX<[5M
M_%,,VBREO[NR\2)L^V,UZ-I.LZ?KUFMWIE];:C:-PL]I,LL9^C*2* /$?"7[
M7&FW.AW-YXZ\!^.OAM>6KL)H=5\,WUU;;54$R)=6\+Q%.OWBC?*?EQ@UL>%_
MVQ/@?XPACDTSXK^$RTF=L-YJL5I,<9R/*F*OD8.1CC\:]BKS_P"(?[/_ ,-O
MBPQD\7>"-#URZ_AO;FR3[4GNDX D4^ZL* .NT7Q-I'B2$RZ3JMCJD0Y+V5PD
MR]<=5)K2KP;QS^QO\/\ 7? MIH?AO0/#_AS4K'RQ::U?:!;:Q<HJ\;'>Z#2.
M", MY@? &&%>::9^SS\0/!.I6MO<^%]+\2:2TJ1OJ7@/QEK'A6[A0L 9&L_M
M#0O@<E1, =H&, "@#[$HKYN^)*^$_@E>:;;ZY\<O'O@1-0#&WO+VXCOK-=I
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MD/N!&PC'4@'O=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&/#\OBLG[W_"5ZG=ZT&^HNY90?3&,8XZ<5ZK10!SWAGX>>%?!:@>'O#.CZ$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_H :#_X/)O\ Y#H_M#QG_P! #0?_  >3?_(= '445R_]H>,_^@!H/_@\F_\
MD.C^T/&?_0 T'_P>3?\ R'0!U%%<O_:'C/\ Z &@_P#@\F_^0Z/[0\9_] #0
M?_!Y-_\ (= '445Q6B/X[TW1K"SNM,T34+JWMXXI;M]:G5IW50&D(^R'!8@G
M&3UJ[_:'C/\ Z &@_P#@\F_^0Z .HHKE_P"T/&?_ $ -!_\ !Y-_\AT?VAXS
M_P"@!H/_ (/)O_D.@#J**Y?^T/&?_0 T'_P>3?\ R'1_:'C/_H :#_X/)O\
MY#H ZBBN7_M#QG_T -!_\'DW_P AT?VAXS_Z &@_^#R;_P"0Z .HHKE_[0\9
M_P#0 T'_ ,'DW_R'1_:'C/\ Z &@_P#@\F_^0Z .HHKE_P"T/&?_ $ -!_\
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M!H/_ (/)O_D.@#J**Y?^T/&?_0 T'_P>3?\ R'1_:'C/_H :#_X/)O\ Y#H
MZBBN7_M#QG_T -!_\'DW_P AT?VAXS_Z &@_^#R;_P"0Z .HHKBH7\=QZS=7
MC:9HCVLMO#%':'6I]L;HTI:0'[)R6#H,8_Y9CKGB[_:'C/\ Z &@_P#@\F_^
M0Z .HHKE_P"T/&?_ $ -!_\ !Y-_\AT?VAXS_P"@!H/_ (/)O_D.@#J**Y?^
MT/&?_0 T'_P>3?\ R'1_:'C/_H :#_X/)O\ Y#H ZBBN7_M#QG_T -!_\'DW
M_P AT?VAXS_Z &@_^#R;_P"0Z .HHKE_[0\9_P#0 T'_ ,'DW_R'1_:'C/\
MZ &@_P#@\F_^0Z .HHKE_P"T/&?_ $ -!_\ !Y-_\AT?VAXS_P"@!H/_ (/)
MO_D.@#J**Y?^T/&?_0 T'_P>3?\ R'6CX5MM4M='"ZS)%)J#W%Q*WDRM*B(\
MSO'&&95)"HRKG:/NT :]%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!!>V5OJ5G/:7<$5U:SQM%-!,@=)$88964\$$$@@]:\\
MN?A#\)_ 'PKU'0;WPCX7TWX>V9EU.\T^^L(6T^,@F1YI$=2O&,Y(X  &  *]
M*JO?Z?:ZK93V=[;0WEI.ACEM[B,/'(IX*LIX(/H:3OK;<I.S39XIX/\ VJ_"
M_C;X4:9XS\">%/%'BS1;O4Y]'L+/1=-B61A 74SGS98XH(,1DAIGCZJN Q"U
M>D_:V^'%KX(TSQC>ZI+I_AB^\/MXC_M*ZBVI!;B6*(1NH);SFDE"JBAMQ1@#
MTSY/KW[-?Q>L/@'JGP_\):WX?L;C7/%^I:IK%RNIW%G(^D7-W+.;:"=;60Q3
M.CJC-Y9"C=C=7J'PZ^!+Z#IVIPZAH6@Z5;?V#INB:3HMA=R7]MI\=H)G4B66
M"-F;S9BWF;-QV*3R*F4G[-S2ULM.M^2[_P#)FON:TTN12YU![7?I;GLO_);_
M (;ZV@7]KOPS?>$?!FN:)X9\5>)9_%6D2:]:Z+H]C%-J$-A&4$D\D9F (5I8
MUV1L\C%L(K8./<+>87$$<JJZK(H8+(A1AD9P5/(/L>:^)];_ &%_$MY\)?AW
MHO\ Q2^M>)-!\%W'A*X_M2YG6SLII#&\>IVC"!F,\#QDJ"D9._\ UB;>?LOP
MYI<NA^'M+TV>^FU.>SM8K>2^N?\ 6W#(@4R/_M,1D^YK>2C[UN[MZ7=OP47Z
MO?=+*+E:+?5:^ME^MUZ+SN]&BBBLRPHHHH **** "BBB@#SOX[_'KP=^SC\/
M;SQCXUU!K/383Y<,$*A[B\F()6&%,C<[8/4@  EB "1C>-OVE=%\ WFD'4O#
M7B=M#OHK&6?Q''8QC3K#[7,(8$ED>52[EV7<L"RE P+;00:T_P!HWX6S_&3X
M*>,?">GIIZZUJFE75GIUUJ0(CMYI86C#E@K,@PY!*@G!(P<UY-\3O@+\2_'7
MQ+^&[7,?AO7?ACX1M;6<^';G7;K3WNM5C*XNI@EG,LT<07,<19 6Y8@<$IZS
MM+:\?N][F^>BMYM+1783TC>.]G]_NV_-_<WKHCN/B-^U[\/?A9=1V>NW-Y'J
M-QXBC\,V-A#$CS7URP@+O$N\?NH_M"AW8K@JP )VAM77OC\GAOXN>'O %]X&
M\3K=:_/+%IVK1/ITMI*D4?F2SE%NS<)$@(!=X1\S*.K+GB/'W[-.L>+O@OI_
MA^*31O\ A+E\30Z]=ZC<,^S:=76_N(XY!&7P0H55V@$HF< 9'>:/\+M57]H[
MQ)\1-5FLI].?P_9Z%HD,;LT]NHFEFNRZE %WN8,;6.1$,@8%%/:+EW=__ 4[
M_.5UY?()_:Y>VGSDU^$;-_\ !/4:*** "BBB@ HHHH **** "O,/'7[1O@GX
M??%;P7\.-1OI+CQCXKE*66FV:!WBC".WGS$D;(\QE1U8GHI 8CT^O(_C!\&K
MSQ]\0OA;XDTH:;:OX9\0#5-3FN-R3W%NMI<PI&A5#N(>XR Q  +<YX(OBC?:
MZOZ7U!_#*V]G;UMH.TW]I'1+GX@7'A34O#WB3PU/Y-_<6%_K=E';P:I'9,BW
M+P+YAE"KO5E:6.-77YD+#FJ'A[]KCX?>)OB1I/@2QN;Q_$U[X?\ ^$DN;0PJ
M?[,MO+CD5+DACME9900B[R "3@%=WE7_  S;\5O%7Q"^)WB3QD?#&HW_ (DL
MKC0M$U2WU^[_ .)%H\A53;PVAL@HE==S/-YN2VT  9)]2\8? ?4-6^.WAKQI
MH-QI^@Z?I_AW5M*N98%*W?VJZ%LL,ZJ$VOL6WY+,#\J 9'2+OD3ZN+^^TFK^
MONKUOK9W*=N9KHG^%X[?+F_![W1H?!#]ICPY\>+Z\M-(TG7-(FAT^UUB#^V(
M(4%Y8W+2+!<QF*63"N87^239(, E!7KE?-7[)O[-OB;X&ZOJ-UK+Z#8VTFBV
M.E/;>'KB:5=7NX&D,NK7?F11[;F4.H8#S#QS(W%?2M;SY;^[Y_F[?>K/]%LL
MU>[OY?DK_C=?J]V4445F4%%%% !1110 4444 >/:3^U5X%\2>-OB%X6T!]2\
M2:IX%L5N]771K)KH&0F0&U@5"7EG!C(*JN,L!NR&"O\ #'[3&@>(K'4#=:)K
MOA_6--UJRT*^T/5(K<7EM-=")X7?RIGCV>7*')$A*A7R R[:P]2^"_C#P[\6
MOB3XY\#MX<L;G6O"=KI.BV]X9(XXM0CGNI6FG5(B/++7"ME=S,0V0,Y/*_L^
M_LS^+/ =GX:3QA#HT^IVNLW/B'7]8M]<N-2N->U"2S>W$SB2T@$:KYK[8@65
M55.6.32AJDY;VU]>=[>L5\KK?6Q/1OE^7_@*M?\ [>_7;1/I=+_;>^&OB3PW
MXFUOP]-J/B*QT77[;PQ"VG01G^U=0GV"**T+R*K L^W?(8T^4G=MPQ]2^&/Q
M*TOXK>&&UG2X;NR,-W<:?>:?J"*ES974$C1S02A69=RNI&59E(P58@@UX??_
M ++VM0Z?\8X+*P\*WT/BCQ!IVKZ'IMY/=VT-M';6]M%M,ML$DM95,#&.2$OL
M.PX/*UZ3^S=\(;KX+_#N?2-0FAFU/4-6OM9NEM[F:ZCADN9VD\I9YOWDVQ2J
M^:X#.5+$ G%7&SC=]E]]HZ??S7]$M.I+?W>[^Z\M?_2?O>_3U2BBBI ****
M"BBB@ HHHH HZ[KFG^&-%O\ 5]6O8=.TNQ@>YNKNY<)'#$BEF=F/0  G->/>
M%_VL_#GQ!^%]CXZ\%^&/%GC+2]0U6XTJTM])T^,32>2SAKAC+*D<,!$9(>9X
MR=RC 8A:]GO]/M=5LI[.]MH;RTG0QRV]Q&'CD4\%64\$'T-?)6O?LU_%ZP^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7[=N@>/_ (H:UX9LU7Q"M[J&FQ>%[+08/].GLKBPCNIKRZ6650D46YMS87&
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M[P&=)76O$5A=:S+K6L0275I96,'EKO$$<D33/(\T:@"5 !EB3@ N^%/QLO\
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M5UJ&F6EN8;72YRP$T@DG1R4VDM&JL^/NJV&PWIO_ %O_ /(R^Y]@6NW];?\
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M=%>3S2*D5VM^BAK=9@D3"(!%BC^7Y<5]DT4 >5?\,G?!#_HC?P__ /"7L?\
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M)&2 0":MV?QR\*7_ ,0F\%0G7#KZRO 0_AO4DM-R*6;_ $MK<6Y&%.&\S!/
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M[=Y<$1J&3>4Y)"A@I&3<HQC;HE?UM&__ +=;SMHKNVD.5SES=6[>FMONTO\
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MM2U(6,-G8K'$S;YEBE+2%IT145""<EB@YKRK2OVYC?\ C'5_$-G%>:IX3O\
MPMH%SH/AIXX(9CJE]?W%KY<DV#L^=$5B695$;%03P?:;C]E?PXN@>!;'2=>\
M1>'M3\':/_8&GZ]IEQ +V2Q,:1R0S"2%XG#B)&)\L%67*%#63)^Q'\-1!<V]
MM%JMA:-H^FZ/:PVMYM^P"PGDGM;B%]I<3K+(6+.S!L#*G+9VER^TNOAYG_X#
M[^WR<+7^TF]K&"YN2SWLOOO'?[I;?9TW*>K?M<2>&_#'C"/5O"2P^//#>MZ?
MX?E\/VVI^9:7%U?^5]D:.[:%6$+"4%G:$,NQQL; W9FE?ME7MKJEQ;^+/ T7
MARSL/%][X0U&^AUDW4=O-#8"[AF7-O'N2;E%!VD90GEMJZ7Q*_93?4OA#XNT
M?PQJS:CX[UW4[/6YO$WB>4+/->6SQ&&7?;Q*D+(D*JA2$HI&6BDRP;SG6OV+
M_&?BCX%^+_!.K:CI-SJWCCQBGB75]4GU2:1M+4/;DM R6L7VF4K;D;=EL@\T
M[=H4 YZNZV=EKTO>FFUU_P"?CUTV+NE:]^OY2W_\DM;SW/J#X/\ CJ\^)WPM
M\+>+K[16\.W.N:?#J!TN2?SFMUE4.BE]JY.TJ3\HQG':NPJOI^GV^DZ?;6-I
M$L%K;1+##$@P$10 JCV  JQ6D^5R;AMT(AS<JYMPHHHJ"PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN7\<:AXTT^*T/
M@[0-!UZ5F;[2NN:Y/I@C'&TH8K.YWD\Y!"XP.N> #J**\J_X23XW_P#1//A_
M_P"%Y??_ "FK\1/VA/VHOCEHW[07Q(LO^%F^+M">S\3:C -)TGQ1>O96FRZD
M40P\QAHDQM4^6F5 .U<XH _H0HKRK_A)/C?_ -$\^'__ (7E]_\ *:MCPGK7
MQ0O-<AB\3>#_  CI&CE6\V[TGQ7=7]PIP=H6&338%8$X!)D&!SSTH [VBOST
M_:UUCQ!X"_:W\1_$#1C-<Z;X>^'EM'K^F0KN-QIES=74,T@']Z%C%-](VK'\
M<:E:^-/V1?V:O@_+/JT4'BC0H-1U.30M,N]1NH;.SM R,(;6.27!N7MN0N!M
M.>*B,N:FZGFE;KO--KT4;^>JZ%RCRU.1]KW^47;UO*WW/J?I'17PGXT\1>)/
MVH?V._A/?Z7J/AM_':ZK ;WPAXP*0VWB2^LA+%=:?)#(5W$NC2^6PXVJ3MP&
M'._#*Q\!?&SQO^SAIUW\.+73_#EKI?BNSE\(^(B-7@LKFWF@21$:?>'19 VP
M]%&%4*  ->7WY0OJF_FE'FOZ=/N;M=7SO[L9/JON=VK>NGY]F?H=17YX:GXW
MDTO]C^\\!)=:A>:7XG^(&H^"]"DLHKC4;DZ&M_)YWE1PAY9%CMHIXU";B%"@
M=.+>F?%#4Y/V']4\,C4]6L%\%^*K7P?KNHSP3Z=?0Z$+Z(+.Z2*DT&;&6(,S
M*& WDXY(B/OJ\/[MK^?+OVMSQOOU_E*DN5VEW:^[FV[WY)=NG<_02BOD+P3?
M> _!O[9V@>#_ (2)I^D6,OA_4E\6^'M%@^S6T3PO;-:74D "J)&\UE$V"9$8
M<L,&O+OB?\,G^*7QX_:=TC2?A6/&7B^X_L2#1O%)>P@'AZX;3H]D_P!HFF6X
MCVL!)_HZ.3Y>#U%/HFENF_NER^FNZU2"*3DXMVM;\4G^I^AU%?GK%XF\<?"G
MX\^.M3T_Q;(6F^(/A#P[J]@UE \&IK<V$$4\KLR&5&Z,GEN@!SN#9 '5?&;]
MICQUX?\ C2W_  B_B&8^&]+\<Z/X1O\ 3KV*PM[1VN4C:6*-6CDNII LA?SO
M-MT7  C?:S,]&DT[WM^*@_N]^.HM4FWT5_\ TK3U]U_<?<%%? G@GXN_%S6?
MA;^SWX@N_BGJ<FI?$;Q3_9FI_P#$HTL16UJJWGRVZBUR'(BC)9V<;E!"A25.
MI\-_V@/B1IVL> M1\2>.)M<TG4/%GB/PK?V4VE6D2-;V$=TT5WF&)7\_-N"P
M5EC(.!&I^8DO=<D_LW_#E_\ DDO^ -JSLM?ZE_\ (L^YZ*_,R\_;2^+6@ZCI
MCP>(&U#1O%WAVTU6RO-9@TX2Z6EQJMM:"]%M;Q@0Q^7.Y6&:>Y(*J7?Y7!][
M^+'Q1\=?"Z;PWX+T?Q_=?$/4];\5+I5S?:79Z1'KVE0M9/<);L)6CL?/D*91
MI8HQY;$!';#$<6DG;=V^?,HM?)O^GH)VYG&^RO\ *W-?YK^K:GUQ17PGIG[2
M_P 5;>\\(P:_JUIIJ-X<\87%[-"^FW27$NG%1:7$LENTT4<J*?WD22;0X<%<
M  ><^+/'GC/Q!IVK>,-3\77NHW4W[/4'B&?3+VQL9]-GNI2PDWVSVY0JS@2$
M8Y("DF,",0Y>ZY=+-_A4?_N-^EUYHI1;=O-+\8+_ -O7W/U/TRHKY)\!?%#Q
M;XR\7>+9;WXD6/PVT3P3>Z)I\6EWFGV1L;^&XM+>5GN"^R16F:8QP^3+$JD+
M\LARIX.+]I;QSKGQJ\.P6GB&;4/ 7BG5_$>ABQU&.PME*V4$V&MH(XVN$"/&
MJF2:Y)D)R(8PRA:JWIW[I-_=:WWW7IUL*C^^2?3_ (>_W6?Z'WE17AG[#7_)
MH/PC_P"Q>M?_ $&O<ZTJ0]G.4.SL94Y^TA&?=!11169H%%%% !1110 4444
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M%^(&J66I^*/!?A[Q)J5B-MK>:OI4%U-;C=NQ&\B$KSSP1S76T4+2UN@;[B8
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M)/RR-#&'&/F '/ (]4\+^#]!\#Z7_9GAS1-.\/Z=YC3?8]+M([:'S&.6?8@
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MUJ?BCQ5J.AZ/XJ\67>I:EX=O/$<32YA5HX+?^SRSI'%?M!!;-"ZAY8V<LJ2
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M<?L57-]XL\2ZW=>+=,>YUC3-:THWR>'C_:4T5_*CQF[NVN6:Y-N(Q'&,(HC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999505048632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,274,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of registrant&#8217;s definitive Proxy Statement to be filed for its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508848312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Redwood City, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Auditor Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999504004776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 25,218<span></span>
</td>
<td class="nump">$ 198,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">708,737<span></span>
</td>
<td class="nump">862,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">22,492<span></span>
</td>
<td class="nump">38,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">15,801<span></span>
</td>
<td class="nump">15,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">23,333<span></span>
</td>
<td class="nump">21,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">795,581<span></span>
</td>
<td class="nump">1,138,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">64,828<span></span>
</td>
<td class="nump">136,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">60,510<span></span>
</td>
<td class="nump">59,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">117,025<span></span>
</td>
<td class="nump">126,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,744<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,117,189<span></span>
</td>
<td class="nump">1,538,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,747<span></span>
</td>
<td class="nump">22,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">15,735<span></span>
</td>
<td class="nump">14,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">26,809<span></span>
</td>
<td class="nump">44,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">15,468<span></span>
</td>
<td class="nump">20,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">17,441<span></span>
</td>
<td class="nump">13,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">85,200<span></span>
</td>
<td class="nump">115,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">125,736<span></span>
</td>
<td class="nump">136,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Development derivative liability</a></td>
<td class="nump">27,726<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">195,427<span></span>
</td>
<td class="nump">200,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">3,592<span></span>
</td>
<td class="nump">8,980<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">437,681<span></span>
</td>
<td class="nump">461,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2021 or 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized; 185,468 shares and 180,091 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,516,641<span></span>
</td>
<td class="nump">3,388,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,157)<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,832,995)<span></span>
</td>
<td class="num">(2,309,158)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">679,508<span></span>
</td>
<td class="nump">1,077,295<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,117,189<span></span>
</td>
<td class="nump">$ 1,538,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999503919224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">185,468,000<span></span>
</td>
<td class="nump">180,091,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">185,468,000<span></span>
</td>
<td class="nump">180,091,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999502575144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 101,907<span></span>
</td>
<td class="nump">$ 152,915<span></span>
</td>
<td class="nump">$ 114,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">24,897<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
<td class="nump">21,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">400,269<span></span>
</td>
<td class="nump">408,678<span></span>
</td>
<td class="nump">434,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">122,844<span></span>
</td>
<td class="nump">104,682<span></span>
</td>
<td class="nump">98,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram', window );">Impairment of assets and other costs for terminated program</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">548,010<span></span>
</td>
<td class="nump">578,026<span></span>
</td>
<td class="nump">554,652<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(446,103)<span></span>
</td>
<td class="num">(425,111)<span></span>
</td>
<td class="num">(440,035)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="num">(8,023)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liabilities related to the sales of future royalties</a></td>
<td class="num">(47,313)<span></span>
</td>
<td class="num">(30,267)<span></span>
</td>
<td class="num">(25,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="num">(24,410)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">2,569<span></span>
</td>
<td class="nump">18,282<span></span>
</td>
<td class="nump">46,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,851)<span></span>
</td>
<td class="num">(21,310)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expense, net</a></td>
<td class="num">(77,177)<span></span>
</td>
<td class="num">(18,836)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(523,280)<span></span>
</td>
<td class="num">(443,947)<span></span>
</td>
<td class="num">(440,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (523,837)<span></span>
</td>
<td class="num">$ (444,440)<span></span>
</td>
<td class="num">$ (440,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic ( in dollars per share)</a></td>
<td class="num">$ (2.86)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (2.86)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding used in computing net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">183,298<span></span>
</td>
<td class="nump">178,581<span></span>
</td>
<td class="nump">174,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">183,298<span></span>
</td>
<td class="nump">178,581<span></span>
</td>
<td class="nump">174,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 23,725<span></span>
</td>
<td class="nump">$ 17,504<span></span>
</td>
<td class="nump">$ 20,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,999<span></span>
</td>
<td class="nump">41,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">77,746<span></span>
</td>
<td class="nump">48,563<span></span>
</td>
<td class="nump">36,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 436<span></span>
</td>
<td class="nump">$ 55,849<span></span>
</td>
<td class="nump">$ 16,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of equipment and other costs for terminated program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507226312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (523,837)<span></span>
</td>
<td class="num">$ (444,440)<span></span>
</td>
<td class="num">$ (440,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(1,568)<span></span>
</td>
<td class="num">(927)<span></span>
</td>
<td class="nump">5,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="num">(294)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,862)<span></span>
</td>
<td class="num">(1,290)<span></span>
</td>
<td class="nump">5,311<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (525,699)<span></span>
</td>
<td class="num">$ (445,730)<span></span>
</td>
<td class="num">$ (435,356)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507405416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,717,575<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 3,147,925<span></span>
</td>
<td class="num">$ (6,316)<span></span>
</td>
<td class="num">$ (1,424,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">23,377<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">23,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">99,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(435,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,311<span></span>
</td>
<td class="num">(440,667)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">1,405,391<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,271,097<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
<td class="num">(1,864,718)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">23,373<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">23,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">94,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(445,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,290)<span></span>
</td>
<td class="num">(444,440)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">1,077,295<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">3,388,730<span></span>
</td>
<td class="num">(2,295)<span></span>
</td>
<td class="num">(2,309,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">33,238<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">33,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">94,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(525,699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
<td class="num">(523,837)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 679,508<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 3,516,641<span></span>
</td>
<td class="num">$ (4,157)<span></span>
</td>
<td class="num">$ (2,832,995)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999502327800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">118 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (523,837,000)<span></span>
</td>
<td class="num">$ (444,440,000)<span></span>
</td>
<td class="num">$ (440,667,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="num">(77,746,000)<span></span>
</td>
<td class="num">(48,563,000)<span></span>
</td>
<td class="num">(36,303,000)<span></span>
</td>
<td class="num">$ (333,451,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liabilities related to sales of future royalties</a></td>
<td class="nump">47,313,000<span></span>
</td>
<td class="nump">30,267,000<span></span>
</td>
<td class="nump">25,044,000<span></span>
</td>
<td class="nump">244,273,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="nump">24,410,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of development derivative liability</a></td>
<td class="nump">8,023,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash research and development expense</a></td>
<td class="nump">16,703,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">94,674,000<span></span>
</td>
<td class="nump">94,261,000<span></span>
</td>
<td class="nump">99,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14,146,000<span></span>
</td>
<td class="nump">14,182,000<span></span>
</td>
<td class="nump">13,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram', window );">Impairment of advance payments to contract manufacturers and equipment for terminated program</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,351,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions', window );">Amortization of premiums (discounts), net and other non-cash transactions</a></td>
<td class="num">(6,730,000)<span></span>
</td>
<td class="num">(3,943,000)<span></span>
</td>
<td class="nump">11,394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">12,397,000<span></span>
</td>
<td class="nump">1,913,000<span></span>
</td>
<td class="nump">6,411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(509,000)<span></span>
</td>
<td class="num">(2,627,000)<span></span>
</td>
<td class="num">(1,284,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities', window );">Operating leases, net</a></td>
<td class="nump">2,340,000<span></span>
</td>
<td class="nump">2,743,000<span></span>
</td>
<td class="nump">13,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(2,688,000)<span></span>
</td>
<td class="nump">4,476,000<span></span>
</td>
<td class="nump">1,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(11,690,000)<span></span>
</td>
<td class="nump">2,382,000<span></span>
</td>
<td class="nump">12,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">1,203,000<span></span>
</td>
<td class="nump">4,697,000<span></span>
</td>
<td class="nump">1,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="num">(23,524,000)<span></span>
</td>
<td class="nump">8,644,000<span></span>
</td>
<td class="nump">4,349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(605,000)<span></span>
</td>
<td class="num">(5,516,000)<span></span>
</td>
<td class="num">(16,565,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(412,660,000)<span></span>
</td>
<td class="num">(313,287,000)<span></span>
</td>
<td class="num">(328,681,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(960,689,000)<span></span>
</td>
<td class="num">(987,533,000)<span></span>
</td>
<td class="num">(1,380,865,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">1,166,951,000<span></span>
</td>
<td class="nump">1,449,304,000<span></span>
</td>
<td class="nump">1,614,036,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">11,504,000<span></span>
</td>
<td class="nump">41,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(14,989,000)<span></span>
</td>
<td class="num">(7,258,000)<span></span>
</td>
<td class="num">(26,285,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">202,777,000<span></span>
</td>
<td class="nump">496,213,000<span></span>
</td>
<td class="nump">206,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfFutureRoyaltiesNet', window );">Proceeds from sale of future royalties, net of $3.8 million of transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">146,250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(250,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities', window );">Cash receipts from development derivative liability</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="nump">33,238,000<span></span>
</td>
<td class="nump">23,396,000<span></span>
</td>
<td class="nump">23,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">36,238,000<span></span>
</td>
<td class="num">(80,354,000)<span></span>
</td>
<td class="nump">23,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="num">(92,000)<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="num">(102,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(173,737,000)<span></span>
</td>
<td class="nump">102,592,000<span></span>
</td>
<td class="num">(98,542,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">198,955,000<span></span>
</td>
<td class="nump">96,363,000<span></span>
</td>
<td class="nump">194,905,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">25,218,000<span></span>
</td>
<td class="nump">198,955,000<span></span>
</td>
<td class="nump">96,363,000<span></span>
</td>
<td class="nump">$ 25,218,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,742,000<span></span>
</td>
<td class="nump">19,199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">325,000<span></span>
</td>
<td class="nump">539,000<span></span>
</td>
<td class="nump">555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="nump">1,057,000<span></span>
</td>
<td class="nump">2,133,000<span></span>
</td>
<td class="nump">57,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities', window );">Accounts receivable recognized in exchange for long-term liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of Premiums (Discounts) Net And Other Non-Cash Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of equipment from terminated program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfEquipmentFromTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Investing and Financing Activities, Accounts Receivable Recognized In Exchange For Long-Term Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfFutureRoyaltiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale of Future Royalties, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfFutureRoyaltiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507035528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfFutureRoyaltiesTransactionCosts', window );">Sale of future royalties transaction costs</a></td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfFutureRoyaltiesTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Future Royalties Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfFutureRoyaltiesTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508032824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At December&#160;31, 2021, we had approximately $798.8 million in cash and investments in marketable securities.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation, Principles of Consolidation and Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Nektar Therapeutics Europe GmbH, Nektar Therapeutics (India) Private Limited (Nektar India),  Inheris Biopharma, Inc. (Inheris) and certain other entities in Europe. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in the valuation of our development derivative liability as further described in Note 6; our assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at estimated fair value. The disclosed fair value related to our cash equivalents and investments is based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. Development derivative liability is recorded at its estimated fair value based on management&#8242;s estimates of several unobservable inputs, including the probabilities of success of ongoing clinical trials and various other inputs described above and in Note 6.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the years ended December&#160;31, 2021 and 2020, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments in Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and investments are held or issued by financial institutions that management believes are of high credit quality. However, they are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have seen credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#8217; equity as accumulated other comprehensive income (loss). We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Significant Customer Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments, as well as reimbursable costs from collaborative research and development agreements. Our accounts receivable included $21.4 million and $38.7 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) as of December&#160;31, 2021 and December&#160;31, 2020, respectively. The remaining accounts receivable related primarily to product sales. We perform a regular review of our partners&#8217; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Significant Supplier Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We state property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjA3OTA_047a9ea0-7fde-4ef1-8171-92c0f31dcfa0">three</span> to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting units equals its fair value.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 7 for additional information regarding our leases.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue, including Non-cash royalty revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2021, we have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 8. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our aggregate royalty and non-cash royalty revenue of $77.7&#160;million, $79.6&#160;million and $77.5&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively, represents revenue for granting licenses for which we had satisfied in prior periods. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. As described further in Note 11, we recognized $50.0&#160;million of milestones in the year ended December 31, 2020 because we had previously satisfied the performance obligation. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program. As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs), performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs, PSUs and ESPP shares on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For options and RSUs that vest upon the achievement of performance milestones, we recognize expense provided that we believe that the performance milestones are probable of achievement, and we estimate the vesting period based on our evaluation of the  estimated date of achievement of these milestones. For PSUs, we recognize expense based on the grant date fair value regardless of whether the market condition is met. Additionally, we do not adjust the expense based on the number of shares ultimately issued, which may be higher or lower than the grant amount. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#8217; stock to the index. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The fair value of an RSU is equal to the closing price of our common stock on the grant date. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented. For the years ended December 31, 2021,  2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded weighted average outstanding stock options, RSUs and PSUs totaling 18.4 million, 17.4 million and 17.9 million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our comprehensive loss includes our net loss, gains and losses from the foreign currency translation of the assets and liabilities of our foreign subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507036648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents, and Marketable Securities</a></td>
<td class="text">Cash and Investments in Marketable Securities<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,218&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,955&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,941&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,828&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,662&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. All of our long-term investments as of December&#160;31, 2021 and 2020 had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTU0_0003ae67-eceb-4b3d-a922-f92cdc2a62bd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTU0_c526c77b-95f7-450d-b638-74b09846bea6">one</span></span> and two years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2021 and 2020, we sold available-for-sale securities totaling $11.5&#160;million and $41.7&#160;millions, respectively. We did not sell any available-for-sale securities in the year ended December 31, 2019. Gross realized gains and losses on those sales were not significant. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our accrued interest receivable, which totaled $1.4&#160;million and $5.1&#160;million at December&#160;31, 2021 and December&#160;31, 2020, respectively, in other current assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our portfolio of cash and investments in marketable securities includes (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December&#160;31, 2020, our gross unrealized gains and losses totaled $1.1&#160;million and $0.2&#160;million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both December&#160;31, 2021 and 2020, we had letter of credit arrangements in favor of our landlords and certain vendors totaling $8.1 million. These letters of credit are secured by investments of similar amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507158328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inventory consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,801&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507071880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Property, plant and equipment consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,385&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,977&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,829&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,684&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,796&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,386&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,450&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,039)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,488)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,347&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,962&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,163&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,662&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Building and leasehold improvements include our manufacturing, research and development and administrative facilities and the related improvements to these facilities. Laboratory and manufacturing equipment include assets that support both our manufacturing and research and development efforts. Construction-in-progress includes assets being built to enhance our manufacturing and research and development efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Depreciation and amortization expense for property, plant and equipment for the years ended December&#160;31, 2021, 2020, and 2019 was $13.0 million, $12.5 million, and $11.0 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507055512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Senior Secured Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Senior Secured Notes</a></td>
<td class="text">Senior Secured Notes&#160;&#160;&#160;&#160;On October 5, 2015, we completed the sale and issuance of $250.0&#160;million in aggregate principal amount of 7.75% senior secured notes due 2020 (the Notes). The Notes bore interest at a rate of 7.75% per annum and were to mature on October 5, 2020. On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $250.0&#160;million and accrued interest of $4.8&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999588483464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DevelopmentDerivativeLiabilityTextBlock', window );">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</a></td>
<td class="text">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability<div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we entered into a co-development agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ will pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth. On February 11, 2021, we entered into a collaboration agreement with MSD International GmbH (MSD), an affiliate of Merck, Sharp &amp; Dohme, pursuant to which MSD will provide Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at no cost for use in the SCCHN Clinical Trial but will not bear any other costs of the trial.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SFJ will have primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we will be the sponsor of the SCCHN Clinical Trial and will also have sole responsibility for regulatory interactions and filings for bempegaldesleukin. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the opportunity to receive Success Payments as outlined below, SFJ has no right to reimbursement of costs incurred by SFJ for the SCCHN Clinical Trial in the event that the Melanoma Clinical Trial and the SCCHN Clinical Trial do not achieve FDA approval. We will pay SFJ a series of success-based annual payments (collectively, the Success Payments) in the event of FDA approval of bempegaldesleukin for the Melanoma Indication, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication. The Success Payments do not begin until the substantial completion of the SCCHN Clinical Trial. The total success-based annual payments for the first indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $450.0&#160;million, paid in annual contractual payments over five years, with the first payment being $30.0&#160;million, with the earliest possible payment expected to occur in late 2024 or early 2025, subject to the substantial completion of the SCCHN Clinical Trial. The total success-based payments for the second indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $150.0&#160;million, paid in annual contractual payments over seven years. Finally, in the event of FDA approval for </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bempegaldesleukin for any indication other than the Melanoma Indication or the SCCHN Indication, we will make a one-time payment of $37.5&#160;million to SFJ. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SCCHN Clinical Trial provides for an interim futility analysis, and unless the futility criteria are met, SFJ is required to complete the SCCHN Trial, but if the futility criteria are met, SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. We and BMS, pursuant to the BMS Collaboration Agreement, remain solely responsible for conducting the Phase 3 clinical trials of bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including the treatment of previously untreated unresectable or metastatic melanoma (the &#8220;Melanoma Indication&#8221; and the &#8220;Melanoma Clinical Trial&#8221;). If the success criterion for the interim futility analysis is not met and SFJ winds down the SCCHN Clinical Trial, then the Success Payments, if any, for the Melanoma Indication and/or the additional bempegaldesleukin indication are reduced pro rata based on the costs incurred by SFJ for the SCCHN Clinical Trial over the aggregate commitment of $150.0&#160;million.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SFJ Agreement provides for certain positive and negative covenants, including restrictions on our ability to incur liens on our intellectual property related to bempegaldesleukin (the bempegaldesleukin IP), or assign or convey any right to receive income with respect to the bempegaldesleukin IP (other than royalty and other license fee obligations to licensors), except for the issuance of senior secured debt secured by all or substantially all of our assets, including the bempegaldesleukin IP. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SFJ Agreement expires upon the payment of all Success Payments to SFJ, unless earlier terminated as provided under the SFJ Agreement. The SFJ Agreement may be terminated by either party for a safety or health concern for the patients, whether by the independent data monitoring committee or by mutual agreement of both parties. The SFJ Agreement may also be terminated by either party for material breach or insolvency of the counterparty.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present the SFJ Agreement as a Development derivative liability in our Consolidated Balance Sheets, which we remeasure to fair value at each reporting date. As SFJ conducts the SCCHN Clinical Trial, we record non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remits funding to us to support our internal costs of conducting the trial, we also record a corresponding increase to the development derivative liability. We present the gain (loss) from the remeasurement as Change in fair value of development derivative liability in our Consolidated Statements of Operations. The following table presents the changes in the development derivative liability for the year ended December&#160;31, 2021:</span></div><div style="margin-top:10pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at inception on February 12, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We valued the derivative using a scenario-based discounted cash flow method, whereby each scenario makes assumptions about the probability and timing of cash flows, and we discount such cash flows to present value using a risk-adjusted rate. The key inputs to the valuation include our estimates of the following: (i) the probability of the Melanoma Clinical Trial, the SCCHN Clinical Trial and another bempegaldesleukin trial meeting their primary endpoints, (ii) the probability and timing of achieving FDA approval in the Melanoma Indication, the SCCHN Indication and any other bempegaldesleukin indication, (iii) the timing of the substantial completion of the SCCHN Clinical Trial that SFJ must achieve before receiving a Success Payment, (iv) the probability of termination of the study due to meeting the interim futility criteria, (v) the amount of costs incurred by SFJ if the success criterion for the interim futility analysis is not met, (vi) SFJ&#8217;s cost of borrowing, currently estimated at 1.5%, and (vii) the Company&#8217;s imputed cost of borrowing for debt with similar terms, currently estimated at 12.7%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DevelopmentDerivativeLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Derivative Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DevelopmentDerivativeLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507143624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases&#160;&#160;&#160;&#160;Our leases consist of a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. 19, LLC (ARE) for our 155,215 square foot corporate office and R&amp;D facility located at 455 Mission Bay Boulevard, San Francisco, California (the Mission Bay Facility) and a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) for an additional 135,936 square foot facility to support our R&amp;D operations at 360 Third Street, San Francisco, <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California (the Third Street Facility). The following table presents key information regarding these leases (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mission Bay Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Street Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commencement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renewal terms</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMS0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo1NzBkM2IxNWJkODY0NDhlYTY5MGYyNDhlY2RjM2VmNl8xOQ_aafbf748-eb94-4830-9eeb-f3b77f87a1d3">five</span>-year terms</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMy0xLTEtMTEyOTgvdGV4dHJlZ2lvbjoxZmUzNGY5ZGNjNmE0MzIyYmMyMDNmMGRiNWZiYzJkYV83_acadf74a-e2c3-4130-9183-4f9108ef96cd">five</span>-year term</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The monthly base rent for both facilities will escalate over the term of the lease at various intervals. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Both leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance costs and taxes. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the Third Street Lease, our fixed annual base rent on an&#160;industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize rent expense for these operating leases on a straight-line basis over the lease period. The components of lease expense, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the years ended December&#160;31, 2021, 2020 and 2019, we  paid $16.8 million, $16.2&#160;million and $8.4&#160;million, respectively, of operating lease payments related to our lease liabilities, which we include in net cash used in operating activities in our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the maturities of our operating lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: portion representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: lease incentives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2021, the weighted-average remaining lease term is 8.1 years and the weighted-average discount rate used to determine the operating lease liability was 5.8%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507041256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract', window );"><strong>Liability Related To Sale Of Potential Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liabilities Related to the Sales of Future Royalties</a></td>
<td class="text">Liabilities Related to the Sales of Future Royalties<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the 2012 Transaction Royalties.&#160;Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the effective interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are remitted directly to RPI. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2020, UCB served notice of a Declaratory Judgment of Patent Invalidity, filed in the United States District Court for the District of Delaware, seeking a declaration of invalidity of certain of our patents that we had licensed to UCB and pursued similar actions in other jurisdictions. On October 14, 2021, RPI and we entered into a Letter Agreement which permitted us to enter into a Settlement Agreement, effective October 13, 2021, with UCB to effect the negotiation between RPI and UCB in which UCB and RPI agreed to a reduction in the royalty term and annual decreases in the royalty rate over the remaining royalty term in exchange for UCB&#8217;s withdrawal of all of UCB&#8217;s litigation and challenges. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded that we should account for the decrease in royalty payments to RPI as a result of these agreements as a modification of our liability. Due to the significance of the change in the estimated royalty payments, we concluded that we should treat the modification as an extinguishment of the prior liability and recognize a new liability based on the revised royalty payments and term, discounted to fair value. Accordingly, we estimated the fair value to be approximately $84.7&#160;million, reflecting a discount rate of 16.0%, and we began amortizing the liability prospectively at this rate commencing in the three months ended December 31, 2021. As a result, we recognized a loss of $23.5&#160;million on the revaluation of the prior liability in the three months ended December 31, 2021, and we wrote off of the remaining $0.9&#160;million of unamortized transaction costs. We present these charges in Loss on revaluation of liability related to the sale of future royalties line in our Consolidated Statement of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time that certain return thresholds are met as described below, of (a) MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB, as amended, (b) ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as amended, (c) REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $208.0&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2020, we received aggregate cash proceeds of $150.0&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $3.8&#160;million in transaction costs, which will be amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these products, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, to be received by HCR in the first quarter of 2021. We recorded the $150.0&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. As of December 31, 2021, our prospective effective interest rate used to amortize the liability is 15%.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account of each arrangement (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties&#8212;beginning<br/>balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282,658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,145&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,145&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the 2012 Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $7.0 million and $3.0 million, respectively, as a result of worldwide net sales of MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the 12 month periods ended December&#160;31, 2013 and 2012 not reaching certain minimum thresholds. The 2012 Purchase and Sale Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense, as well as the loss on the revaluation described above, over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the appropriate Royalty Obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There are a number of factors that could materially affect the amount and timing of royalty payments from our licensees, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI or HCR are made in U.S. dollars (USD) while significant portions of the underlying sales of the products of our licensees are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from our licensees, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the respective Royalty Obligation. Conversely, for the 2012 Purchase and Sale Agreement, if sales of these products are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the 2012 Royalty Obligation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507052360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In the normal course of business, we enter into various firm purchase commitments related to contract manufacturing, clinical development and certain other items. As of December&#160;31, 2021, these commitments were approximately $8.2 million, all of which we expect to pay in 2022.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018, about the clinical trials of bempegaldesleukin. The Mulquin complaint was amended in May 2019. The defendants moved to dismiss and the court granted the motion without prejudice in July 2020. The Mulquin plaintiffs again amended their complaint and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice. The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument occurred on December 10, 2021, and the matter remains pending with the court. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second putative securities class action was filed against the Company and certain of our executives in the U.S. District Court for the Northern District of California in August 2019 (Case No. 4-19-cv-05173, which we refer to as the Damiba action).  The Damiba plaintiffs challenged public statements Nektar made, between February 2019 and May 2019, about its bempegaldesleukin clinical trials and collaboration with Bristol-Myers Squibb. After the Damiba plaintiffs filed an amended complaint and the defendants moved to dismiss, the court dismissed the action without prejudice in January 2021. The Damiba plaintiffs subsequently voluntarily dismissed the action, with prejudice, in March 2021.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the two securities actions (the Mulquin action and the Damiba action), three additional sets of derivative actions have been filed against certain of the Company&#8217;s current and former officers and directors, purportedly on the Company&#8217;s behalf. These derivative actions are based on the allegations in the securities actions and on the premise that the Company&#8217;s officers and directors breached their fiduciary duties by exposing the Company to one or both of the securities actions. The first derivative action was filed in the U.S. District Court for the District of Delaware in February 2019 (Case No. 1:19-cv-00322-MN-JLH). After amending their complaint several times, the plaintiffs in that action voluntarily dismissed their claims without prejudice in April 2021.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second set of derivative actions was filed in February 2020 in the U.S. District Court for the Northern District of California (Case No. 4:20-cv-01088-JSW). The derivative actions in California were consolidated and the Company moved to dismiss on the basis that the plaintiffs had neither made a demand on the Company&#8217;s board of directors nor shown that a demand would be futile. On September 1, 2021, the court dismissed the action with prejudice.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third derivative complaint was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF). The parties agreed to stay further proceedings in this action until thirty days after the U.S. Court of Appeals for the Ninth Circuit&#8217;s final resolution of the appeal in the Mulquin action.  </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature and status of these securities class action lawsuits and derivative complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at either December&#160;31, 2021 or December 31, 2020. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We operate in a number of foreign countries. As a result, we are subject to numerous local laws and regulations that can result in claims made by foreign government agencies or other third parties that are often difficult to predict even after the application of good faith compliance efforts.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the course of our normal operating activities, we have agreed to certain contingent indemnification obligations as further described below. The term of our indemnification obligations is generally perpetual. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. To date, we have not incurred significant costs to defend lawsuits or settle claims based on our indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Consolidated Balance Sheets at either December&#160;31, 2021 or December 31, 2020.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications in Connection with Commercial Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. </span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification of Underwriters and Initial Purchasers of our Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with our sale of equity we have agreed to defend, indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director and Officer Indemnifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential amount of future payments we could be required to make under this </span></div>indemnification is unlimited; however, we have insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe any obligations under this indemnification would not be material, other than retention of up to $10.0 million per incident for merger and acquisition related claims, $10.0 million per incident for securities related claims and $10.0 million per incident for non-securities related claims per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999588680600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As discussed in Note 11, on April 3, 2018, we completed the issuance and sale of 8,284,600 shares of our common stock under a Share Purchase Agreement with BMS. These shares are unregistered and subject to certain lock-up and stand-still provisions for a five-year period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the SEC, which expires in March 2024. The 2021 Shelf Registration Statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $300.0&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which may be offered, issued and sold in &#8220;at-the-market&#8221; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities have been sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, shares of common stock reserved for future issuance are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and PSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2017 Performance Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507005672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.184%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NKTR-358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2021, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $1.7&#160;billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive other contingent payments, including contingent sales milestones and royalty payments, as described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;There have been no material changes to our collaboration agreements for the year ended December&#160;31, 2021, except as </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">described below.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb (BMS): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bempegaldesleukin (previously referred to as NKTR-214)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing and joint commercialization of bempegaldesleukin, 35% of the costs to BMS and 65% to Nektar. On January 9, 2020, we and BMS entered into Amendment No. 1 (the First Amendment) to the BMS Collaboration Agreement, pursuant to which, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. BMS has the right, at its sole discretion, to terminate co-funding its share of the development costs for the adjuvant melanoma collaboration study if the metastatic melanoma collaboration study fails to meet the primary endpoint of progression free survival. If BMS exercises such right, we have the right, in our sole discretion, to continue the adjuvant melanoma study. On January 12, 2022, we and BMS entered into an Amendment No. 2 to the BMS Collaboration Agreement, pursuant to which we and BMS allocated certain responsibilities for price negotiations and promotion, market access, patient support and related activities to each party. The cost sharing for the development, manufacturing and commercialization under our collaboration remains unchanged as a result of these amendments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million. Pursuant to Amendment No. 1 described below, we received a non-refundable, creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. We are eligible to receive potential future payments for development and regulatory milestones of approximately $1.4&#160;billion (which reflects the reduction for the creditable milestone for the muscle-invasive bladder cancer trial) and up to a total of $350.0&#160;million upon the achievement of certain sales milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#8217; expenses as research and development expense. For the years ended December&#160;31, 2021, 2020 and 2019, we recorded $101.5 million, $128.2 million and $105.4 million, respectively, as a reduction of research and development expenses for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses.  As of December&#160;31, 2021 and 2020, we have recorded an unbilled receivable of $21.4 million and $38.7 million, respectively, from BMS in accounts receivable in our Consolidated Balance Sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our share of development costs is limited to an annual cap of $125.0&#160;million. To the extent this annual cap is exceeded, BMS reimburses us for the excess, which we must repay to the extent that our share of development costs are less than the annual cap in a future year. For the year-ended December 31, 2020, our share of the development costs exceeded the annual cap and therefore we included the $4.0&#160;million reimbursement in our accounts receivable as of December 31, 2020 and recorded an off-setting liability in Other long-term liabilities. For the year-ended December 31, 2021, our share of the development costs was sufficiently lower than the cap such that we are required to repay the $4.0&#160;million and therefore have reclassified the liability as a reduction of our accounts receivable as of December 31, 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analogized to ASC 606 for the accounting for our two performance obligations, consisting of the delivery of the licenses to develop and commercialize bempegaldesleukin and our participation on joint steering and other collaboration committees. We determined that our committee participation is not material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During 2018, we aggregated the total consideration of $1.85&#160;billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $790.2&#160;million in stockholders&#8217; equity. We allocated the remaining $1,059.8&#160;million to the transaction price of the collaboration agreement, which we recognized in 2018. During the year ended December 31, 2020, we received $50.0&#160;million in aggregate for the achievements of the first patient, first visit in the registrational muscle-invasive bladder cancer trial and the registrational adjuvant melanoma trial, which we recognized as revenue in 2020 because we had previously satisfied our performance obligation of granting the licenses. We continue to exclude the variable consideration of the potential future development, regulatory and sales milestones of up to approximately $1.8&#160;billion from the transaction price as of December&#160;31, 2021 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eli Lilly and Company (Lilly): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NKTR-358 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $150.0&#160;million in September 2017 and are eligible for up to $250.0&#160;million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and certain drug product development and supply activities, (iii) will share with Lilly Phase 1B and 2 development costs with 75% of those costs borne by Lilly and 25% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from zero to 25% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $150.0&#160;million upfront payment as $125.9&#160;million to the license, $17.6&#160;million to our portion of the Phase 1 clinical development and $6.5&#160;million to the drug product development. We recognized the $125.9&#160;million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development through the three months ended March 31, 2020. As of December&#160;31, 2021, we have no deferred revenue related to this agreement.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to exclude the other milestones from the transaction price as of December&#160;31, 2021 due to the significant uncertainties involved with clinical development. </span></div><div style="margin-top:18pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Baxalta Incorporated/Takeda: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Hemophilia A program includes ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was approved by the FDA in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. We are entitled to royalties based on worldwide net sales of ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and an  sales milestone upon achievement of an annual worldwide net sales target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, we are entitled to single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement. As described in Note 8, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (naloxegol oxalate), previously referred to as naloxegol and NKTR-118,</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2014 and December 2014, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> /MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the US and EU, respectively. In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, excluding Europe, Canada and Israel, to RedHill Biopharma. These sublicenses did not change our rights under the agreement with AstraZeneca, and our royalty rate, royalty term and future potential sales milestones remain unchanged. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from AstraZeneca and RedHill Biopharma, we are entitled to significant and escalating double-digit royalty payments and sales milestones. For the net sales of MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the sublicense to Kirin, we are entitled to 40% of the royalties and sales milestones received by AstraZeneca. AstraZeneca is entitled to deduct a portion of its costs for a post-marketing study required by the FDA, subject to certain limits, only through a reduction of the royalties due to us. As of December 31, 2021, our cumulative share of these costs was not significant.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 8, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement, and HCR will bear the cost of any reductions for the post-marketing study.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the 2010 Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the 2010 Agreement, we received a $50.0 million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen. We recognized this revenue on a straight-line basis over the ten-year term of the 2010 Agreement through September 2021.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, as of December&#160;31, 2021, we have other collaboration agreements, including with our collaboration partner UCB Pharma, under which we are entitled to up to a total of $40.0 million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of December&#160;31, 2021, we have deferred revenue of approximately $2.0 million related to these other collaboration agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508032824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> 2017 Performance Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our 2017 Performance Incentive Plan (2017 Plan) provides for the issuance of our common stock to members of the Board of Directors, officers or employees, certain consultants and advisors and our subsidiaries. Our 2017 Plan has been amended and restated such that an aggregate 34,200,000 shares have been authorized for issuance as of December&#160;31, 2021, including 5,000,000 shares that were approved on June 10, 2021. Under the 2017 Plan, we may issue stock options, restricted stock, performance stock, stock units, stock appreciation rights and other similar types of awards. When the 2017 Plan was approved on June&#160;14, 2017, any shares of our common stock that were available for issuance under our 2012 Performance Incentive Plan (the 2012 Plan) ceased to be available for future grants. However, options and RSUs granted under the 2012 Plan </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remained outstanding, and any options or RSUs that were cancelled or forfeited became available for issuance under the 2017 Plan. Shares issued for RSUs, PSUs or any other &#8220;full-value award&#8221; will be counted against the share limit as 1.5 shares for every one share actually issued in connection with the award. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted or issued non-qualified stock options, RSUs and PSUs to employees, officers, and non-employee directors. For our employees, the requisite service period is generally four years for stock options, and three years for RSUs and PSUs. For our directors, the requisite service is generally one year for stock options and RSUs. The maximum term of a stock option or stock appreciation right is eight years from the date of grant. The per share exercise price of an option generally may not be less than the fair market value of a share of our common stock on the NASDAQ Stock Market on the date of grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Change in Control Plan (the CIC Plan), in the event of a change of control of Nektar and a subsequent termination of employment initiated by us or a successor company other than for Cause (as defined in the CIC Plan) within twelve months following a change of control, our employees are entitled to full acceleration of their unvested equity awards. Our Chief Executive Officer, Senior Vice Presidents and Vice Presidents (including Principal Fellows) are also entitled to full acceleration of unvested equity awards if the termination is initiated by the employee for a Good Reason Resignation (as defined in the CIC Plan) within twelve months following a change of control. Additionally, non-employee directors would also be entitled to full acceleration of vesting of all outstanding stock awards in the event of a change of control transaction.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under the terms of our the Employee Stock Purchase Plan (ESPP), employees may purchase shares of our common stock based on a percentage of their compensation subject to certain limits. Shares are purchased at 85% of the lower of the closing price on either the first day or last day of each six-month offering period. An aggregate 3,500,000 shares have been authorized for issuance under our ESPP, including 1,000,000 shares approved on June 17, 2020.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,795&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance. Stock-based compensation expense resulting from PSUs and our ESPP was not significant in the years ended December&#160;31, 2021, 2020, and 2019.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, total unrecognized compensation costs of $187.4 million related to unvested stock-based compensation arrangements are expected to be recognized as expense over a weighted-average period of 2.6 years.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Black-Scholes Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.25</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The average risk-free interest rate is based on the U.S.&#160;treasury yield curve in effect at the time of grant for periods commensurate with the expected life of the stock-based award. We have never paid dividends, nor do we expect to pay dividends in the foreseeable future; therefore, we used a dividend yield of zero. Our estimate of expected volatility is based on the daily historical trading data of our common stock at the time of grant over a historical period commensurate with the expected life of the stock-based award. We estimated the weighted-average expected life based on the contractual and vesting terms of the stock options, as well as historical cancellation and exercise data.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Stock Option Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:51.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited &amp; canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(504)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The intrinsic value of options exercised during the years ended December&#160;31, 2021, 2020 and 2019 totaled $17.3 million, $15.9 million and $30.6 million, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of RSU Activity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU award activity is as follows (in thousands except for per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,617)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair values of RSUs granted during the years ended December&#160;31, 2021, 2020 and 2019 were $14.68, $19.24 and $23.32, respectively. The fair value of restricted stock that vested in the years ended December&#160;31, 2021, 2020 and 2019 totaled $45.3 million, $33.3 million and $32.4 million, respectively.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Retirement Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of 60% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $6,000 per participant. For the years ended December&#160;31, 2021, 2020, and 2019, we recognized $3.6 million, $3.5 million, and $3.5 million, respectively, of compensation expense in connection with our 401(k) retirement plan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999506986952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Income (loss) before provision for income taxes includes the following components (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524,440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(441,494)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(523,280)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,947)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440,054)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The provision for income taxes consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets and Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785,748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,563)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Because of our lack of U.S.&#160;earnings history, other than income resulting from revenue recognized from the BMS Collaboration Agreement, and projected future losses, we have fully reserved our net U.S.&#160;deferred tax assets with a valuation allowance. The valuation allowance increased by $115.6 million and $95.0 million during the years ended December&#160;31, 2021 and 2020, respectively. The increase in the valuation allowance is consistent with the increase in net operating loss carryforwards in the respective periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Operating Loss and Tax Credit Carryforwards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December&#160;31, 2021, we had a net operating loss carryforward for federal income tax purposes of approximately $2.4 billion, portions of which will begin to expire in 2022 and a total state net operating loss carryforward of approximately $1.5 billion, portions of which will begin to expire in 2026. We have federal research credits of approximately $103.3&#160;million, which will begin to expire in 2023 and state research credits of approximately $47.0&#160;million which have no expiration date. We have federal orphan drug credits of $19.4&#160;million which will begin to expire in 2026. Utilization of some of the federal and state </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net operating loss and credit carryforwards are subject to annual limitations due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized tax benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have the following activity relating to unrecognized tax benefits (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,410&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If we are eventually able to recognize our uncertain tax positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Adjustments to the substantial majority of our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carryforwards rather than resulting in a cash outlay.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We file income tax returns in the U.S., California, Alabama, certain other states and India. As a result of our net operating loss and research credit carryforwards, substantially all of our domestic tax years remain open and subject to examination. We may be subject to examination in India from time to time, but we do not believe that any liability resulting from such an examination would have a material effect on our financial position or results of operations.</span></div>Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. During the years ended December&#160;31, 2021, 2020 and 2019, no significant interest or penalties were recognized relating to unrecognized tax benefits. Although it is reasonably possible that certain unrecognized tax benefits could change in the future, we do not anticipate any significant changes over the next twelve months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507002072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We operate in one business segment which focuses on applying our technology platforms to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our revenue is derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from UCB Pharma, Baxalta / Takeda, AstraZeneca and Pfizer  represented 36%, 23%, 16% and 13% of our revenue, respectively, for the year ended December&#160;31, 2021. Revenue from BMS, UCB Pharma, Baxalta / Takeda, and AstraZeneca represented 33%, 23%, 14% and 13% of our revenue for the year-ended December&#160;31, 2020. Revenue from UCB Pharma, Baxalta / Takeda, and AstraZeneca represented 28%, 19%, and 17% of our revenue for the year-ended December 31, 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. The following table sets forth revenue by geographic area (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of World</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;At December&#160;31, 2021, $56.1 million, or approximately 93%, of the net book value of our property, plant and equipment was located in the United States and $4.4 million, or approximately 7%, was located in India.&#160;At December&#160;31, 2020, $54.5 million, or approximately 91%, of the net book value of our property, plant and equipment was located in the United States&#160;and $5.1 million, or approximately 9%, was located in India.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507163784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data</a></td>
<td class="text">Selected Quarterly Financial Data (Unaudited)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as our audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and the results for any one quarter may not be indicative of our future performance. All data is in thousands except per share information.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,596)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,721)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted(1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Quarterly loss per share amounts may not total to the year-to-date loss per share due to rounding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL124452896-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999504922872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.</span></div>&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation, Principles of Consolidation and Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation, Principles of Consolidation and Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Nektar Therapeutics Europe GmbH, Nektar Therapeutics (India) Private Limited (Nektar India),  Inheris Biopharma, Inc. (Inheris) and certain other entities in Europe. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in the valuation of our development derivative liability as further described in Note 6; our assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at estimated fair value. The disclosed fair value related to our cash equivalents and investments is based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. Development derivative liability is recorded at its estimated fair value based on management&#8242;s estimates of several unobservable inputs, including the probabilities of success of ongoing clinical trials and various other inputs described above and in Note 6.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the years ended December&#160;31, 2021 and 2020, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, and Investments in Marketable Securities</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Investments in Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and investments are held or issued by financial institutions that management believes are of high credit quality. However, they are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have seen credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#8217; equity as accumulated other comprehensive income (loss). We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).</span></div>&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock', window );">Accounts Receivable and Significant Customer Concentrations</a></td>
<td class="text">Accounts Receivable and Significant Customer Concentrations&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments, as well as reimbursable costs from collaborative research and development agreements.We perform a regular review of our partners&#8217; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock', window );">Inventory and Significant Supplier Concentrations</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Significant Supplier Concentrations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We state property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjA3OTA_047a9ea0-7fde-4ef1-8171-92c0f31dcfa0">three</span> to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting units equals its fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. </span></div><div style="margin-top:10pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 7 for additional information regarding our leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue, including Non-cash royalty revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2021, we have sold our rights to receive sales-based royalties for CIMZIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  MIRCERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MOVANTIK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ADYNOVATE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and REBINYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as further described in Note 8. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our aggregate royalty and non-cash royalty revenue of $77.7&#160;million, $79.6&#160;million and $77.5&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively, represents revenue for granting licenses for which we had satisfied in prior periods. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, collaboration and other revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;License Grants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Milestone Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. As described further in Note 11, we recognized $50.0&#160;million of milestones in the year ended December 31, 2020 because we had previously satisfied the performance obligation. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of the triggering event.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and Development Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock', window );">Impairment of Assets and Other Costs for Terminated Program</a></td>
<td class="text">Impairment of Assets and Other Costs for Terminated ProgramOn January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs), performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs, PSUs and ESPP shares on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For options and RSUs that vest upon the achievement of performance milestones, we recognize expense provided that we believe that the performance milestones are probable of achievement, and we estimate the vesting period based on our evaluation of the  estimated date of achievement of these milestones. For PSUs, we recognize expense based on the grant date fair value regardless of whether the market condition is met. Additionally, we do not adjust the expense based on the number of shares ultimately issued, which may be higher or lower than the grant amount. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#8217; stock to the index. </span></div>&#8226;The fair value of an RSU is equal to the closing price of our common stock on the grant date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our comprehensive loss includes our net loss, gains and losses from the foreign currency translation of the assets and liabilities of our foreign subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements And Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and significant customer concentrations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of Assets and Other Costs for Terminated Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory and significant supplier concentrations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507155816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents</a></td>
<td class="text">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,218&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,955&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,941&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,828&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,662&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text">Our portfolio of cash and investments in marketable securities includes (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obligations of U.S. government agencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507078360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">Inventory consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,801&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999506963240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text">Property, plant and equipment consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,385&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,977&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,829&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,684&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,796&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment at cost</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,386&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,450&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,039)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,488)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property, plant and equipment, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,347&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,962&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,163&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,510&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,662&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508067448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
<td class="text">The following table presents the changes in the development derivative liability for the year ended December&#160;31, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at inception on February 12, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from SFJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the fair value of development derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508753064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LesseeOperatingLeaseTableTextBlock', window );">Schedule of Operating Lease Information</a></td>
<td class="text">The following table presents key information regarding these leases (dollars in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mission Bay Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Street Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commencement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Space delivered during the year ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Square footage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset and lease liability recognized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renewal terms</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMS0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo1NzBkM2IxNWJkODY0NDhlYTY5MGYyNDhlY2RjM2VmNl8xOQ_aafbf748-eb94-4830-9eeb-f3b77f87a1d3">five</span>-year terms</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMy0xLTEtMTEyOTgvdGV4dHJlZ2lvbjoxZmUzNGY5ZGNjNmE0MzIyYmMyMDNmMGRiNWZiYzJkYV83_acadf74a-e2c3-4130-9183-4f9108ef96cd">five</span>-year term</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense</a></td>
<td class="text">The components of lease expense, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments for Operating Leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the maturities of our operating lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31,</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: portion representing interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: lease incentives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, less current portion</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LesseeOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LesseeOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507071880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract', window );"><strong>Liability Related To Sale Of Potential Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock', window );">Schedule of Liability Related to Potential Future Royalties</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account of each arrangement (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period from inception to December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2012 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Purchase and Sale Agreement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties&#8212;beginning<br/>balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty monetization proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282,658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to RPI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties &#8211; ending balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,145&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,145&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability Related To Sale Of Potential Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507158328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Shares of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, shares of common stock reserved for future issuance are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and PSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2017 Performance Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.25</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999506974872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">License, Collaboration and Other Revenue</a></td>
<td class="text">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.184%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NKTR-358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neulasta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508759576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,795&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, shares of common stock reserved for future issuance are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and PSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2017 Performance Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for issuance under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant-date fair value of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.25</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity Under Equity Incentive Plans</a></td>
<td class="text">The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:51.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited &amp; canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(504)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>_______________________________________________________________(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Award Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU award activity is as follows (in thousands except for per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,617)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999502176696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before Income Tax, Domestic and Foreign</a></td>
<td class="text">Income (loss) before provision for income taxes includes the following components (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524,440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(441,494)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(523,280)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,947)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440,054)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text">The provision for income taxes consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Provision Related to Continuing Operations</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense on liability related to sales of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash royalty revenue related to sales of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on revaluation of liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785,748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,563)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">We have the following activity relating to unrecognized tax benefits (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapses in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,410&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507030520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of Revenue by Geographic Area</a></td>
<td class="text">The following table sets forth revenue by geographic area (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of World</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999506938168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Data</a></td>
<td class="text">The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as our audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and the results for any one quarter may not be indicative of our future performance. All data is in thousands except per share information.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Q4</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,596)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,631)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,721)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted(1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Quarterly loss per share amounts may not total to the year-to-date loss per share due to rounding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999501793320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>reporting_unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="nump">$ 798,783,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,198,558,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 798,783,000<span></span>
</td>
<td class="nump">$ 1,198,558,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetExpenseReimbursementsFromCollaborationPartner', window );">Net expense reimbursements from collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400,000<span></span>
</td>
<td class="nump">38,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment', window );">Number of reporting unit evaluated for goodwill | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">25,009,000<span></span>
</td>
<td class="nump">$ 24,921,000<span></span>
</td>
<td class="nump">$ 28,330,000<span></span>
</td>
<td class="nump">$ 23,647,000<span></span>
</td>
<td class="nump">$ 23,462,000<span></span>
</td>
<td class="nump">$ 30,033,000<span></span>
</td>
<td class="nump">$ 48,847,000<span></span>
</td>
<td class="nump">$ 50,573,000<span></span>
</td>
<td class="nump">$ 101,907,000<span></span>
</td>
<td class="nump">152,915,000<span></span>
</td>
<td class="nump">$ 114,617,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments related to contract manufacturing, clinical development and certain other items</a></td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesMilestoneRevenue', window );">Sales milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsRSUsAndPSUsMember', window );">Stock Options, RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average antidilutive securities excluded from computation of earnings per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">17.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NKTR181Member', window );">NKTR - 181</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_WriteOffOfPrepayment', window );">Write off of prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments related to contract manufacturing, clinical development and certain other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to the sales of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,746,000<span></span>
</td>
<td class="nump">$ 48,563,000<span></span>
</td>
<td class="nump">$ 36,303,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_CashAndNonCashRoyaltiesMember', window );">Cash And NonCash Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,700,000<span></span>
</td>
<td class="nump">$ 79,600,000<span></span>
</td>
<td class="nump">$ 77,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NetExpenseReimbursementsFromCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net expense reimbursements from collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NetExpenseReimbursementsFromCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units to evaluate goodwill for impairment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SalesMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestone revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SalesMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_WriteOffOfPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write Off Of Prepayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_WriteOffOfPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsRSUsAndPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsRSUsAndPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NKTR181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NKTR181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_CashAndNonCashRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_CashAndNonCashRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999503965224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Estimated Fair Value at</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 25,218<span></span>
</td>
<td class="nump">$ 198,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">708,737<span></span>
</td>
<td class="nump">862,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">64,828<span></span>
</td>
<td class="nump">136,662<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 798,783<span></span>
</td>
<td class="nump">$ 1,198,558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999502167032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">$ 11,504,000<span></span>
</td>
<td class="nump">$ 41,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">674,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Investments in Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LongTermInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LongTermInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999505151736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 763,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(674)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">762,625<span></span>
</td>
<td class="nump">1,003,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">6,285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">798,783<span></span>
</td>
<td class="nump">1,198,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">278,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">278,121<span></span>
</td>
<td class="nump">687,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Corporate commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">478,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">478,629<span></span>
</td>
<td class="nump">313,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Obligations of U.S. government agencies | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">5,875<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">23,968<span></span>
</td>
<td class="nump">179,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">$ 10,940<span></span>
</td>
<td class="nump">$ 9,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508927640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,166<span></span>
</td>
<td class="nump">$ 2,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">9,342<span></span>
</td>
<td class="nump">10,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,293<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 15,801<span></span>
</td>
<td class="nump">$ 15,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999505035688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">$ 201,386<span></span>
</td>
<td class="nump">$ 193,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(148,039)<span></span>
</td>
<td class="num">(138,488)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentNet', window );">Depreciable property, plant and equipment, net</a></td>
<td class="nump">53,347<span></span>
</td>
<td class="nump">54,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction-in-progress</a></td>
<td class="nump">7,163<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">60,510<span></span>
</td>
<td class="nump">59,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember', window );">Building and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">97,385<span></span>
</td>
<td class="nump">92,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">42,704<span></span>
</td>
<td class="nump">40,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">28,829<span></span>
</td>
<td class="nump">28,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">22,374<span></span>
</td>
<td class="nump">21,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures, and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DepreciablePropertyPlantAndEquipmentGross', window );">Depreciable property, plant and equipment at cost</a></td>
<td class="nump">$ 10,094<span></span>
</td>
<td class="nump">$ 9,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DepreciablePropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciable Property, plant and equipment, Gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DepreciablePropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DepreciablePropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciable Property, plant and equipment, Net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DepreciablePropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999509656664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999502282312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Senior Secured Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 13, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 05, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Principal amount repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 7.75% Senior Secured Notes Due October 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior secured notes, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Principal amount repaid</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999505087448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=nktr_CostOfBorrowingMember', window );">Cost of Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Counterparty cost of borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember', window );">SFJ Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementCommittedFunding', window );">Committed funding</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication', window );">Success-based payments, first indication</a></td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid', window );">Success-based payments, first indication, period to be paid</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment', window );">Success-based payments, first payment</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication', window );">Success-based payments, second indication</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid', window );">Success-based payments, second indication, period to be paid</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementAdditionalIndicationPayment', window );">Additional indication payment</a></td>
<td class="nump">$ 37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember', window );">SFJ Pharmaceuticals | Cost of Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Counterparty cost of borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementAdditionalIndicationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Indication Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementAdditionalIndicationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementCommittedFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Committed Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementCommittedFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-based Payments, First Indication</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-based Payments, First Indication, Period to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-Based Payments, First Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-based Payments, Second Indication</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Success-based Payments, Second Indication, Period to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=nktr_CostOfBorrowingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=nktr_CostOfBorrowingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_SFJPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999501732680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details) - Development Derivative Liability - Level 3<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at inception on February 12, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense', window );">Non-cash research and development expense</a></td>
<td class="nump">16,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Cash receipts from SFJ</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in the fair value of development derivative liability</a></td>
<td class="num">(8,023)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at end of period</a></td>
<td class="nump">$ 27,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999595613192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense | $</a></td>
<td class="nump">$ 19,153<span></span>
</td>
<td class="nump">$ 18,985<span></span>
</td>
<td class="nump">$ 14,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments | $</a></td>
<td class="nump">$ 16,800<span></span>
</td>
<td class="nump">$ 16,200<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, percent</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember', window );">Mission Bay Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AreaOfLeasedSpace', window );">Lease space (in sq ft) | ft&#178;</a></td>
<td class="nump">155,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember', window );">Third Street Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AreaOfLeasedSpace', window );">Lease space (in sq ft) | ft&#178;</a></td>
<td class="nump">135,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999503992680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Schedule of Operating Lease Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">$ 57,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember', window );">Mission Bay Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AreaOfLeasedSpaceDelivered', window );">Leased space delivered (in sq ft) | ft&#178;</a></td>
<td class="nump">2,012<span></span>
</td>
<td class="nump">4,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfConsecutiveTermsToExtendLease', window );">Number of consecutive terms to extend lease | term</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeaseExtensionTerm', window );">Lease extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember', window );">Third Street Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AreaOfLeasedSpaceDelivered', window );">Leased space delivered (in sq ft) | ft&#178;</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfConsecutiveTermsToExtendLease', window );">Number of consecutive terms to extend lease | term</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LeaseExtensionTerm', window );">Lease extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AreaOfLeasedSpaceDelivered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased space delivered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AreaOfLeasedSpaceDelivered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeaseExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease extension term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LeaseExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfConsecutiveTermsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive five year terms to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfConsecutiveTermsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_MissionBayLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nktr_ThirdStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507415064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Schedule of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 19,153<span></span>
</td>
<td class="nump">$ 18,985<span></span>
</td>
<td class="nump">$ 14,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">8,974<span></span>
</td>
<td class="nump">8,179<span></span>
</td>
<td class="nump">6,408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 28,127<span></span>
</td>
<td class="nump">$ 27,164<span></span>
</td>
<td class="nump">$ 21,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999501770472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 18,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">20,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">21,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">22,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">22,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2027 and thereafter</a></td>
<td class="nump">75,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">181,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: portion representing interest</a></td>
<td class="num">(37,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Less: lease incentives</a></td>
<td class="num">(653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">143,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="num">(17,441)<span></span>
</td>
<td class="num">$ (13,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">$ 125,736<span></span>
</td>
<td class="nump">$ 136,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability tenant improvement reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999498213688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 24, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,410<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement | Future Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,700<span></span>
</td>
<td class="nump">$ 84,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments', window );">Transaction costs related to revised royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement | Future Royalties | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.160<span></span>
</td>
<td class="nump">0.160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved', window );">Payment of transaction related to purchase and sale agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved', window );">Payment of transaction related to purchase and sale agreement if threshold is not achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds', window );">Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties', window );">Transaction costs related to sale of potential future royalties</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement | Measurement Input, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltiesLiabilityMeasurementInput', window );">Royalties liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember', window );">Pursuant to the 2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to the Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentMadeForMilestoneNotAchievedYearTwo', window );">Payment made for milestone not achieved year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentMadeForMilestoneNotAchievedYearOne', window );">Payment made for milestone not achieved year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentMadeForMilestoneNotAchievedYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment made for milestone not achieved year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentMadeForMilestoneNotAchievedYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentMadeForMilestoneNotAchievedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment made for milestone not achieved year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentMadeForMilestoneNotAchievedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltiesLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltiesLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TransactionCostsRelatedToRevisedRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs Related To Revised Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_TransactionCostsRelatedToRevisedRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nktr_FutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nktr_FutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputInceptionDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputInceptionDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999498250952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">118 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward', window );"><strong>Liability Related To Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties&#8212;beginning balance</a></td>
<td class="nump">$ 205,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(77,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48,563)<span></span>
</td>
<td class="num">$ (36,303)<span></span>
</td>
<td class="num">(333,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">47,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,267<span></span>
</td>
<td class="nump">$ 25,044<span></span>
</td>
<td class="nump">244,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="num">(23,522)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">198,344<span></span>
</td>
<td class="nump">$ 198,344<span></span>
</td>
<td class="nump">205,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(2,917)<span></span>
</td>
<td class="num">(2,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,917)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">195,427<span></span>
</td>
<td class="nump">195,427<span></span>
</td>
<td class="nump">200,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member', window );">2012 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward', window );"><strong>Liability Related To Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties&#8212;beginning balance</a></td>
<td class="nump">65,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(37,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">26,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="num">(23,522)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">78,282<span></span>
</td>
<td class="nump">78,282<span></span>
</td>
<td class="nump">65,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">78,282<span></span>
</td>
<td class="nump">78,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member', window );">2020 Purchase and Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward', window );"><strong>Liability Related To Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties&#8212;beginning balance</a></td>
<td class="nump">139,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyMonetizationProceeds', window );">Royalty monetization proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(40,168)<span></span>
</td>
<td class="num">(50,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">20,855<span></span>
</td>
<td class="nump">20,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PartialRepaymentOfRoyaltySaleProceeds', window );">Payments to RPI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liabilities related to the sales of future royalties &#8211; ending balance</a></td>
<td class="nump">120,062<span></span>
</td>
<td class="nump">120,062<span></span>
</td>
<td class="nump">$ 139,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts', window );">Less: unamortized transaction costs</a></td>
<td class="num">(2,917)<span></span>
</td>
<td class="num">(2,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,917)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liabilities related to the sales of future royalties, net</a></td>
<td class="nump">$ 117,145<span></span>
</td>
<td class="nump">$ 117,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities on sale of future royalties, unamortized transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PartialRepaymentOfRoyaltySaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Partial repayment of royalty sale proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PartialRepaymentOfRoyaltySaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltyMonetizationProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltyMonetizationProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999501702184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>action</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitments related to contract manufacturing, clinical development and certain other items</a></td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=nktr_MulquinActionAndDamibaActionMember', window );">Mulquin Action And Damiba Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Previous claims | action</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=nktr_DerivativeActionMember', window );">Derivative Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">New claims | action</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember', window );">Legal Matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember', window );">Merger and Acquisition Related Claims | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember', window );">Securities Related Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember', window );">Non-Securities Related Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident', window );">Obligations under Director and Officer Indemnifications per incident</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations under director and officer indemnifications per incident.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=nktr_MulquinActionAndDamibaActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=nktr_MulquinActionAndDamibaActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=nktr_DerivativeActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=nktr_DerivativeActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_LegalMattersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_MergerAndAcquisitionRelatedClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_SecuritiesRelatedClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=nktr_NonSecuritiesRelatedClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508417528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 03, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod', window );">Stock issued during period subject to lock-up and stand-still provisions period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfStockValueAuthorizedInTransaction', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock to Bristol-Myers Squibb (in shares)</a></td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockValueAuthorizedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock Value Authorized In Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockValueAuthorizedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period subject to lock-up and stand-still provisions period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999505023992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for issuance</a></td>
<td class="nump">26,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember', window );">Share-based Payment Arrangement, Option, RSUs And PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for issuance</a></td>
<td class="nump">23,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember', window );">2017 Performance Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for issuance</a></td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for issuance</a></td>
<td class="nump">1,043<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999501748392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - License, Collaboration and Other Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 436<span></span>
</td>
<td class="nump">$ 55,849<span></span>
</td>
<td class="nump">$ 16,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Bempegaldesleukin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">7,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. | Neulasta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 436<span></span>
</td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">$ 4,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BempegaldesleukinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BempegaldesleukinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999491628712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th"><div>Aug. 23, 2017</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Oct. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,889,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,492,000<span></span>
</td>
<td class="nump">$ 38,889,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,009,000<span></span>
</td>
<td class="nump">$ 24,921,000<span></span>
</td>
<td class="nump">$ 28,330,000<span></span>
</td>
<td class="nump">$ 23,647,000<span></span>
</td>
<td class="nump">23,462,000<span></span>
</td>
<td class="nump">$ 30,033,000<span></span>
</td>
<td class="nump">$ 48,847,000<span></span>
</td>
<td class="nump">$ 50,573,000<span></span>
</td>
<td class="nump">101,907,000<span></span>
</td>
<td class="nump">152,915,000<span></span>
</td>
<td class="nump">$ 114,617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones', window );">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Maximum | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones', window );">Eligible additional cash payments receivable upon achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember', window );">Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Opdivo | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member', window );">Nektar-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember', window );">NKTR-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_NektarMember', window );">Nektar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments', window );">Percentage of upfront payment, market access milestones, royalties and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfStockConsiderationReceived', window );">Sale of stock consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Nektar 214 | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,500,000<span></span>
</td>
<td class="nump">128,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,400,000<span></span>
</td>
<td class="nump">38,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CompanyShareOfDevelopmentCostsAnnualCap', window );">Company share of development costs, annual cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Bristol Myers Squibb Collaboration Agreement | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AggregateConsiderationReceivedFromAgreements', window );">Total consideration received under agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedFairValueOfShares', window );">Estimated fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RemainingAmountAllocatedToTransactionPrice', window );">Remaining amount allocated to transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,059,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones', window );">Potential future development, regulatory and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Bristol Myers Squibb Collaboration Agreement | Nektar 214</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions', window );">Percentage of regulatory milestones payments will be reduced under certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur', window );">Percentage of regulatory milestones payments will be reduced if conditions occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar-358 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar-358 | Maximum | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Nektar-358 | Minimum | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Phase 1 Clinical Development | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Drug Product Development | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyMember', window );">Eli Lilly | Nektar-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_TerminatedPartnershipMember', window );">Terminated Partnership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_MilestoneAxis=nktr_MilestoneOneMember', window );">Milestone One | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AggregateConsiderationReceivedFromAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate consideration received from agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AggregateConsiderationReceivedFromAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CompanyShareOfDevelopmentCostsAnnualCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company Share Of Development Costs, Annual Cap</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CompanyShareOfDevelopmentCostsAnnualCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible additional cash payments receivable upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received, if conditions occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received under certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of funding Phase three development costs on an indication by indication basis borne.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in Phase 2 development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in production costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development regulatory and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProfitsAndLossesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profits and losses sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProfitsAndLossesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RemainingAmountAllocatedToTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amount allocated to transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RemainingAmountAllocatedToTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received from license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar214Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar214Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_Nektar358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_Nektar358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_TerminatedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_TerminatedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999491404920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 17, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 10, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ChangeInControlSeverancePaymentPeriodForExecutives', window );">Change in control severance payment period for executives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized over a weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="nump">$ 30,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum 401(k) per employee, percentage of annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer', window );">Matching 401(k) employer contribution, maximum amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Compensation expense in connection with 401(k) retirement plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember', window );">2017 Performance Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare', window );">Share-based compensation plan's share limit reduction for every one restricted stock unit granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options term under equity incentive plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2017 Performance Incentive Plan | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock-based compensation award granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2017 Performance Incentive Plan | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock-based compensation award granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nktr_RSUsAndPSUsMember', window );">RSUs and PSUs | 2017 Performance Incentive Plan | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period for stock-based compensation award granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock shares available for stock options grants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for award grants (in shares) | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,300,000<span></span>
</td>
<td class="nump">$ 33,300,000<span></span>
</td>
<td class="nump">$ 32,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ChangeInControlSeverancePaymentPeriodForExecutives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in control severance payment period for executives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ChangeInControlSeverancePaymentPeriodForExecutives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation plan's share limit for every one share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_TwoThousandSeventeenPerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nktr_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nktr_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nktr_RSUsAndPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nktr_RSUsAndPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nktr_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999507402296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 94,674<span></span>
</td>
<td class="nump">$ 94,261<span></span>
</td>
<td class="nump">$ 99,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">2,779<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
<td class="nump">4,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">54,821<span></span>
</td>
<td class="nump">57,116<span></span>
</td>
<td class="nump">63,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">37,074<span></span>
</td>
<td class="nump">33,295<span></span>
</td>
<td class="nump">32,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember', window );">Impairment of assets and other costs for terminated program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999502274648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Average risk-free interest rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Average volatility factor</a></td>
<td class="nump">63.80%<span></span>
</td>
<td class="nump">64.10%<span></span>
</td>
<td class="nump">62.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted-average expected life</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 8.07<span></span>
</td>
<td class="nump">$ 10.70<span></span>
</td>
<td class="nump">$ 12.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999502439544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">13,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">2,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(2,481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited and canceled (in shares) | shares</a></td>
<td class="num">(504)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">13,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 24.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">14.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">12.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited and canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">46.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 23.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Life (in Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life, outstanding</a></td>
<td class="text">4 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, outstanding | $</a></td>
<td class="nump">$ 2,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, exercisable (in shares) | shares</a></td>
<td class="nump">8,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 26.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life, exercisable</a></td>
<td class="text">3 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, exercisable | $</a></td>
<td class="nump">$ 2,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999491542264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details) - Restricted Stock Units (RSU) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units Issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">7,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">6,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and released (in shares)</a></td>
<td class="num">(2,617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited and canceled (in shares)</a></td>
<td class="num">(1,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">9,930<span></span>
</td>
<td class="nump">7,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 22.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">14.68<span></span>
</td>
<td class="nump">$ 19.24<span></span>
</td>
<td class="nump">$ 23.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share)</a></td>
<td class="nump">25.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited and canceled (in dollars per share)</a></td>
<td class="nump">21.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 16.80<span></span>
</td>
<td class="nump">$ 22.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508124968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (524,440)<span></span>
</td>
<td class="num">$ (445,370)<span></span>
</td>
<td class="num">$ (441,494)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (523,280)<span></span>
</td>
<td class="num">$ (443,947)<span></span>
</td>
<td class="num">$ (440,054)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999501780920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">609<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax expense</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999501716424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, increase (decrease) amount</a></td>
<td class="num">$ (115,600)<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
<td class="nump">4,727<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
<td class="nump">$ 10,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Unrecognized tax benefits, penalties recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange', window );">Unrecognized tax benefits, period may increase or decrease due to tax examination</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetOperatingLossCarryforwardForIncomeTax', window );">Net operating loss carryforward for income tax</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
<td class="nump">103,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_FederalOrphanDrugCredits', window );">Federal orphan drug credits</a></td>
<td class="nump">19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NetOperatingLossCarryforwardForIncomeTax', window );">Net operating loss carryforward for income tax</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Income tax research credits</a></td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_FederalOrphanDrugCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_FederalOrphanDrugCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NetOperatingLossCarryforwardForIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforward for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NetOperatingLossCarryforwardForIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits, period increase (decrease) reasonable period of change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508874088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate</a></td>
<td class="num">$ (109,889)<span></span>
</td>
<td class="num">$ (93,229)<span></span>
</td>
<td class="num">$ (92,411)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(4,727)<span></span>
</td>
<td class="num">(3,081)<span></span>
</td>
<td class="num">(10,511)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">97,914<span></span>
</td>
<td class="nump">87,060<span></span>
</td>
<td class="nump">104,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount', window );">Non-cash interest expense on liability related to sales of future royalties</a></td>
<td class="nump">9,936<span></span>
</td>
<td class="nump">6,356<span></span>
</td>
<td class="nump">5,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount', window );">Non-cash royalty revenue related to sales of future royalties</a></td>
<td class="num">(7,891)<span></span>
</td>
<td class="num">(7,967)<span></span>
</td>
<td class="num">(7,624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfAssets', window );">Loss on revaluation of liability related to the sale of future royalties</a></td>
<td class="nump">4,940<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock-based compensation</a></td>
<td class="nump">6,627<span></span>
</td>
<td class="nump">7,929<span></span>
</td>
<td class="num">(672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">3,647<span></span>
</td>
<td class="nump">3,425<span></span>
</td>
<td class="nump">2,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999491395928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 564,712<span></span>
</td>
<td class="nump">$ 456,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and other credits</a></td>
<td class="nump">139,996<span></span>
</td>
<td class="nump">132,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DeferredTaxAssetsLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">34,680<span></span>
</td>
<td class="nump">35,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">33,408<span></span>
</td>
<td class="nump">32,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">23,757<span></span>
</td>
<td class="nump">32,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Development derivative liability</a></td>
<td class="nump">6,639<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">10,651<span></span>
</td>
<td class="nump">11,688<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">813,843<span></span>
</td>
<td class="nump">701,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(785,748)<span></span>
</td>
<td class="num">(670,103)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">28,095<span></span>
</td>
<td class="nump">31,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(27,204)<span></span>
</td>
<td class="num">(29,707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(564)<span></span>
</td>
<td class="num">(1,856)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(27,768)<span></span>
</td>
<td class="num">(31,563)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 327<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Liability Related to the Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999508874888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 78,665<span></span>
</td>
<td class="nump">$ 77,410<span></span>
</td>
<td class="nump">$ 27,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_TaxPositionsRelatedToCurrentYearAbstract', window );"><strong>Tax positions related to current year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">2,371<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
<td class="nump">49,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Reductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_TaxPositionsRelatedToPriorYearsAbstract', window );"><strong>Tax positions related to prior years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions</a></td>
<td class="num">(490)<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapses in statute of limitations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 80,604<span></span>
</td>
<td class="nump">$ 78,665<span></span>
</td>
<td class="nump">$ 77,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TaxPositionsRelatedToCurrentYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Positions Related To Current Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_TaxPositionsRelatedToCurrentYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_TaxPositionsRelatedToPriorYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Positions Related To Prior Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_TaxPositionsRelatedToPriorYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999504023032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfOperatingBusinessSegment', window );">Number of operating business segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 60,510<span></span>
</td>
<td class="nump">$ 59,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">56,100<span></span>
</td>
<td class="nump">54,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">India</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | UCB | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Baxalta Incorporated Or Takeda P L C | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Astra Zeneca Ab | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Pfizer | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | BMS | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment | Geographic Concentration Risk | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment | Geographic Concentration Risk | India</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage revenue from customers</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfOperatingBusinessSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfOperatingBusinessSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_UCBPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_UCBPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_AstraZenecaAbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_AstraZenecaAbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999498367896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenue by Geographic Area (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 25,009<span></span>
</td>
<td class="nump">$ 24,921<span></span>
</td>
<td class="nump">$ 28,330<span></span>
</td>
<td class="nump">$ 23,647<span></span>
</td>
<td class="nump">$ 23,462<span></span>
</td>
<td class="nump">$ 30,033<span></span>
</td>
<td class="nump">$ 48,847<span></span>
</td>
<td class="nump">$ 50,573<span></span>
</td>
<td class="nump">$ 101,907<span></span>
</td>
<td class="nump">$ 152,915<span></span>
</td>
<td class="nump">$ 114,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Reportable Geographical Components</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,114<span></span>
</td>
<td class="nump">64,966<span></span>
</td>
<td class="nump">27,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Reportable Geographical Components</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Revenue by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,793<span></span>
</td>
<td class="nump">$ 87,949<span></span>
</td>
<td class="nump">$ 87,524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139999504058312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SelectedQuarterlyFinancialDataLineItems', window );"><strong>Selected Quarterly Financial Data [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 25,009<span></span>
</td>
<td class="nump">$ 24,921<span></span>
</td>
<td class="nump">$ 28,330<span></span>
</td>
<td class="nump">$ 23,647<span></span>
</td>
<td class="nump">$ 23,462<span></span>
</td>
<td class="nump">$ 30,033<span></span>
</td>
<td class="nump">$ 48,847<span></span>
</td>
<td class="nump">$ 50,573<span></span>
</td>
<td class="nump">$ 101,907<span></span>
</td>
<td class="nump">$ 152,915<span></span>
</td>
<td class="nump">$ 114,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">6,163<span></span>
</td>
<td class="nump">5,311<span></span>
</td>
<td class="nump">7,667<span></span>
</td>
<td class="nump">5,756<span></span>
</td>
<td class="nump">4,323<span></span>
</td>
<td class="nump">5,570<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="nump">24,897<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
<td class="nump">21,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">99,614<span></span>
</td>
<td class="nump">103,738<span></span>
</td>
<td class="nump">101,313<span></span>
</td>
<td class="nump">95,604<span></span>
</td>
<td class="nump">102,724<span></span>
</td>
<td class="nump">100,531<span></span>
</td>
<td class="nump">96,436<span></span>
</td>
<td class="nump">108,987<span></span>
</td>
<td class="nump">400,269<span></span>
</td>
<td class="nump">408,678<span></span>
</td>
<td class="nump">434,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(112,910)<span></span>
</td>
<td class="num">(113,596)<span></span>
</td>
<td class="num">(110,205)<span></span>
</td>
<td class="num">(109,392)<span></span>
</td>
<td class="num">(110,721)<span></span>
</td>
<td class="num">(103,050)<span></span>
</td>
<td class="num">(77,709)<span></span>
</td>
<td class="num">(133,631)<span></span>
</td>
<td class="num">(446,103)<span></span>
</td>
<td class="num">(425,111)<span></span>
</td>
<td class="num">(440,035)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (145,645)<span></span>
</td>
<td class="num">$ (129,706)<span></span>
</td>
<td class="num">$ (125,519)<span></span>
</td>
<td class="num">$ (122,967)<span></span>
</td>
<td class="num">$ (117,203)<span></span>
</td>
<td class="num">$ (108,586)<span></span>
</td>
<td class="num">$ (80,000)<span></span>
</td>
<td class="num">$ (138,651)<span></span>
</td>
<td class="num">$ (523,837)<span></span>
</td>
<td class="num">$ (444,440)<span></span>
</td>
<td class="num">$ (440,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic ( in dollars per share)</a></td>
<td class="num">$ (790)<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
<td class="num">$ (690)<span></span>
</td>
<td class="num">$ (680)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (2.86)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (790)<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
<td class="num">$ (690)<span></span>
</td>
<td class="num">$ (680)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (2.86)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SelectedQuarterlyFinancialDataLineItems', window );"><strong>Selected Quarterly Financial Data [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,890<span></span>
</td>
<td class="nump">$ 5,194<span></span>
</td>
<td class="nump">$ 7,846<span></span>
</td>
<td class="nump">$ 4,795<span></span>
</td>
<td class="nump">$ 2,884<span></span>
</td>
<td class="nump">$ 5,691<span></span>
</td>
<td class="nump">$ 5,485<span></span>
</td>
<td class="nump">$ 3,444<span></span>
</td>
<td class="nump">$ 23,725<span></span>
</td>
<td class="nump">$ 17,504<span></span>
</td>
<td class="nump">$ 20,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SelectedQuarterlyFinancialDataLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selected quarterly financial data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SelectedQuarterlyFinancialDataLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>nktr-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktr="http://www.nektar.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktr-20211231.xsd" xlink:type="simple"/>
    <context id="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12aa694918fb4e37a8989f7f4021c7cc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i000e41e2d6664cc0a62610b6e74c65f6_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="ib73eda96963641c5adca30248e3b4212_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:SFJPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:CostOfBorrowingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i418e819404874602beccd76277d2832e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nktr:CostOfBorrowingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0e8124eb7354356b1cc17142addd673_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48e34961873b4743b7e5dc882aecad66_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97391b2936f841cc9e4d2b6c592beff9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i385bad4a34ed410299079777e10e8737_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee9f5c266bb64ec48742279a12b86e9f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie556d8a598764c54834d2305fb48307e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62a137c1f62e4f37bd438bf66515d037_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0375ded4b7c74c1491fe98ce48a475d8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16d34596d03d4f48ad22b490652d61c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie11c771d5728489f9c3498ced689a2e8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4f6ca9435254d8598fb70543671cc59_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i524617210c1844548d9aaa3cd1afdd18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9dd5c85b0364d75a8dee4e02e0abd75_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87de647067774165be013844df84c1bb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i53a02e6ed23c464682afde8d04213299_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icfc39458a49345bdbf9c5f0b59507c25_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idfb2fa6ca8a0403abea7fdab421e1e5a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic036604bec7a494eb87b4bb2add33694_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibdc8ae10616f484b97ae80d605c49cd3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7e86cae77d44493aad21052dab0a76b8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i875faed795c94a9cbe1dbe5c45959993_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie15c826afa424f9f83b6f1f31eae68e0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2c08dcd809044c649a36e6a8870b753f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i46aabdbcec054bbc98f62fc64f377f52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2dec94ffa8f54d9f8f0e8161b2c81580_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1387c3cbfa6f42a8878e29c7c2e63b8c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i617c9de53110471eb788bd49272cb303_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6dc92f30772f4416b1b6a460651e0081_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89a636947a9046a38a2ed739019eb13c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic7a330302e89494f86be51dbb5ad4eba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6ab4897a894445fb01edd925a1631d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i06602f496e114bfea3a9bdc411724138_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i218a36c4ef32491d8ed93aa732435402_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4958a2d31a14357b76df572e493fa94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7070fa33af194d52891eedefe4dfb853_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2bcba052d2f340589756a4df2f43f3c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i426f379da93c42a2b87f77f27a1dfc65_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd67d9937f7d47baafb15299a877ed6b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i526f6174d8c74127a9c60db3a5d90b76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7aac894909174929a2fae22e8d8a3906_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5cb2f5eb7d0d4cd0a19c316ad433666a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2206f8a53bc949e99e036f0c404e52a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbd923bc535f4746833b54075312bef7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e0d6be14b9b4e589ab67d81ec71404f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida774e4baed04895887759bea104497e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib53f800cf34743b584b3c807522f25a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d4b5ee692844d22bd172e136bf853f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i217337f2d85e411fa6cca2f9cc353fcb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia35126ada49c4aa5b6a31fd74e38aa13_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ee5e0af22004d498eafd130a613cee6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib29439b8ce094e458c12e418a5f1055e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:CashAndNonCashRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i57d6518d703e4cdba742d40dbc46673d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d18817442a34679beeb50708361c836_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8fd12c28a1fc4527927d94cbb3fecda6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief3930a5607f46ba9969d019065ed3bc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i255350b9923e4b0f90bb25e7e8e6ea4f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsRSUsAndPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i05da6e7840b44dd9b4425434109ffec4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76ba7fa3878f41e9baee05ebb5353b2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb1efb0d79f74d20bc94eefb71431fe8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16f975e3020e40db8824c97ec642e248_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb32306fdad746dd9da19728ea7271ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38f44a6188024f06a84a6f4b3d8acfbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a53b7985d374ead811b6e5a7dd2154f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51e7dc8250694c90b0688660e3c7810b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie572f0f09594489993a50e2018463f9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe4e66cfc3c244c896b83266e392cd87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e5ad5ce7ba243e78803676a3ada6929_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icbab848955664506b7524f1830aca69c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia01507cb6301463b804b5486907c00f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4e094fd9a7d4fc2abfa5a035a57ec8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b0eefc7a17f43a49c7d5e3ddf06a052_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72222465a5784d0f8b7df22ece9a04bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f9318818cfa4595b929b1a68fe6e107_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1773cfeb2884095bf5d3d8360db3e44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58c7a174caa0406d9fb512ac548781a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ComputerFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69cc5696809542c890b6fc09c58cab17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbd78d2a576c437caf2eb6a175e66c00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nktr:ManufacturingLaboratoryAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab142e35c42244cbb7c910e1ada05075_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d44c99d9de54043985c7720d72c53f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4580a99794e6481fb70ca26feccaa301_I20151005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-05</instant>
        </period>
    </context>
    <context id="i3a1cba01aa4941709dccf7ddad45a548_D20200413-20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <context id="i69f84d8d2acb4dbabece7f5d1ab1fdeb_I20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-13</instant>
        </period>
    </context>
    <context id="i16608bc88bb04b04bb4edbc265eb647e_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i3ec48343255d40459baca2d723015436_D20210213-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-13</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i493fa2ce12a84012947de2cfdd3a036b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fd0edc3092a4746b891c63c927e1490_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib40b92391c3f4d638cd40df255d8a24f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95ecd88a93ef4d27b3eb882445356c5c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaeeda31f60ae46789b8052b8ca1a2041_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7562d9991df643f7ab9b69837b951eed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic019febd6d76418e963113849a03e38e_D20120224-20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-24</startDate>
            <endDate>2012-02-24</endDate>
        </period>
    </context>
    <context id="ib0419ee4a57947ec9003b707328f0fb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c519c68cc924317ad61bfe414020531_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafb8479bd435454894df0145e038e535_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nktr:FutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i615094c1dcc2454fba893bc20ef68b47_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="i1848694a84f244f8b109984fa21ee94e_D20201230-20201230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="id15385c8744c4ad794e479a0863b4859_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputInceptionDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fa240bdb2564ada855ed34b4d6af58c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb5f300865a3412b8ef57ad27019eaf6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e574a6749b54555bcb0c1fc438d2730_I20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-24</instant>
        </period>
    </context>
    <context id="idea8f2c144d74987ad634c719924d556_I20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-16</instant>
        </period>
    </context>
    <context id="i859caff83678471fa0131b598ecb3b99_I20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2012-02-24</instant>
        </period>
    </context>
    <context id="i878fa93fa19746ff958887812ed98a82_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i877ea84e541241f8b6035538b2d966db_D20120225-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i819532be269b48eaa4fd913474d540a1_D20201217-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-17</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2012-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8fa71516bf964979bdea09b920eca1e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreement2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i431785ba16834d94834f5341637912ac_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="i10e97ae5ba424e32b4c21ebb7a264e1c_D20130301-20130331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="i26423d2e98f74cab9e74de71740ea6dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nktr:MulquinActionAndDamibaActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief3d1876c0504d8894ebee840c0649dc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">nktr:DerivativeActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3fab95cd4e2f4d70a9bd13e5489022fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if7023dcffb6c492e881c7d0fdf2c056c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:LegalMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec07825eabbf46b68172520ab32540ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad6b97c8cc6a493d936e8a7260315298_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8cfe16cd13d04edfb807fa9cb0df6eee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:MergerAndAcquisitionRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6394ee3aadea457c813b5c716e2e257a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:SecuritiesRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad260002e8644641b6913428ec9be8e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">nktr:NonSecuritiesRelatedClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id508c66eccd84a1490c07a8346141297_D20180403-20180403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="icdcb60f448fd48b6b0f24d116b1058d4_D20180403-20180403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="i08e56333c0594ef38a927dea5e5be643_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:ShareBasedPaymentArrangementOptionRSUsAndPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85e44fd2a3b7430fb8662bdf1cfee75a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79ae08e8c98b45bba0381fcf4454594a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if63a3ada72f2468d9d15c15cdadb2e60_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia282c760203f4d67bbae06f0bbf2f7ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8b027734ada457485944093d8bb55f4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BempegaldesleukinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iebc2021556634567a9c85d9130eca0e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i47aee40635594a2493940a5c79182830_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a0c941d02e442e5830f5ff54b267621_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7bb01347c4e24ca3bb28d9aab6838bd3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c290b7d2e5c4c6a88d47e27d7256c42_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff6585fd29ca4683aec5e1e6754a8a53_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i69b94286514e411f81a8255d0fe0adef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3df606808a1742a88e889573b9cf1eab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4daaf97620504beb90b1882227ff737f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3bb556020be549ee87413847caad7cad_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i8261a40efe0948f49707ae9d352985c9_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i0091cbcb2514452baa6df443b7072779_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="ie78f916daa434e17a021f7221225eb22_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i6c31a5edbd5f4e7ba1771e0dd2cfd00f_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i3a673492af0542c787de8ecf805aa6b6_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i0971825b2d534ad7a2466cf3158c182f_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i859a4f864b514e87a0cf719770bf6959_I20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="i8f0bd98c891a4594a3a511270a06abda_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icdecde4596554cde9aa263b142ab9462_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i7a15cd1d266049a6b956f4c5cda3ccfe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2c265cd979f48f49755e5233054afc9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8db809beaa2342b6907e26d5a756ecbc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar214Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i404b477314254c6c9c18783047bfaddb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fb38abf73194c0185c0ad4dedc15a76_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02fa6a90350c495998c00c9ec2be64b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7de3ce10d71c401f8c6b6d9fa8f5d1fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6fe08663b69b470d9befa4a3fea814cc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8045653e56804da78b7a3f7548e93f95_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i35bc8164332c4f0d942659ecdb9b7c2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6179d6e6ea6445b59e375f1714da51d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BristolMyersSquibbCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id10b0e192e72479c93c3fb96e48815dd_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ide4cc486142a4e91a1bc4da6d2ef22e4_I20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-23</instant>
        </period>
    </context>
    <context id="ie9610c03746f479f8ed2307f84e94aa8_D20170823-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-23</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i94624f38524b41d19de37806eae8205a_D20170823-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-23</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i571d31ed3414457d970b51bd263f4336_D20170823-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-23</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i4af4611c2c0a47adafeff233ec324125_D20170823-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-23</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i2e394a6636a846efaeb92892f815f0f7_D20170823-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-23</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="ifdf41eee0b3e48dd93b8a4402bac9137_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ib6e7e8305ef0454abcf6345f4b1ee7d3_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i6812a1be21d84f488147e73621f09203_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i45d391452d324672a836342487419576_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:Nektar358Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i60213b20f36548838d7b341fd83327c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i163fba6573974206a8cbfb1e757d6908_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i4620b301e5a3473081e7c8cfc28f8404_D20101001-20101031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-10-01</startDate>
            <endDate>2010-10-31</endDate>
        </period>
    </context>
    <context id="ib32493f3644b448eb1a1da39e4dbd1cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbc31f05452946b7981e6387e3c1acd2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a74676520a541cf835f2a6ff04233d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:TerminatedPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9260c5cf0a145fd9ef016e7007916ce_I20210610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-10</instant>
        </period>
    </context>
    <context id="iea9636cc4c9d490297fba185f90f9827_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i447e3d8d3d6a40ff8c71fa4631994b79_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nktr:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nktr:RSUsAndPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37ef7aa72e7f4284abbf69eb9fcf07de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c98c4e18c764ec4aabcffa64729091b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:TwoThousandSeventeenPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3636ccf59db74199a476bef6db7fa9b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie278c33e215c4682baa578128551c2d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic55f7a5b573548869eb6b5c0c65a71b4_D20200617-20200617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nktr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-17</endDate>
        </period>
    </context>
    <context id="i0035b332ba9d4aa3ae359c9299758ee5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f052c3b58374798bbb51692c71f38a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie44b9566b75c444fa92e9c77ccb22df0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2401bd6e0c9941d2ac71f0226fb724d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i973a75b3adfc4d628fdc8dbe94b83110_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d494d74848a4be6b679b6d322a4a6ad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f6ea4f6ff6546d4a7b6f841d44f50c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i029b733cde5b4e28800367770689c2a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic276dbba3c744c5dbce8ec6fa2c4d30c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idaa277296ff1492d902aa6bd17b985a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81a24d5a38eb49e09e58c801f3465307_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70a6b923db694bdea933ddef727104ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7a941c5289d14ecb98a14b23c2c6474d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i718223867ea449b3bb07403f12f97462_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0779bcc3fd547a7a0d232c80b0cca7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i613d6ffb709a4aceb22ec5c774efb691_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i059dd17f5075463e95e35460261b7a4b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i18610030b55b46f09cb8bfa3f26e3ca1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d291eb67ab54f4689d1aac2f2cdcca8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95d9b49258bb447fbbe2d19c4487ee71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i13d5a5ae922d40ae88de27a40c5ec05b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ddb03971de844cf8a92d843f8f0c1c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifaa6e3a9e6e143949bc208e33f67fd4c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00f01d527a214f5cbd961d14f04dc514_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e87ff4a4650460d9333eb26209aaf9e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec3ad0981f8e485fad0d799d0a405dbe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5301b257f77c4c11ae97c725f1ff567b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i12bc2ab5a68e4a6b955e5b5866281132_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i642a78ec6bfc491eba5a4895194b3e41_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i65153175938b412d9314b0291f9d87ec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:UCBPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic4ce7911bf79479fb3e7667b452ea08a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia9c9bb30fa1f4b63958f70078463ced9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie54219086ed7421ab34a8c373a1e98ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i147a96a3068f4b9e8496063ad3e68b0c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i556b5871a2d143a897968254b351cc82_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie398a4523e0f4e05958bb768906321dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if86c78562de248778afb80f62f503bbd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b5f29e74e4445c8bb936628105494a8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9cc4668d0303484c94ce77104f692749_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7dedd82fa6fc42e28334feede0e3e79a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i97b7c38b02314dca802effa14883baf0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18d3853c1171432d9635c5e80c47d4af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8740f4ce936345f3898f8e6e33e633b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieccfcb48be264718a52f70d827378b42_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f76e5747c79442ca44da532090382c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1f7d11d90fe4876a574e281c5a228d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f5f266f15a24dda8c245439158a48c1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i203df220ddd84ea7b49307ff1429d621_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0cb20ac5be2a460996fe341ee81ca9ec_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i33c68986b8dc461c9bc05ee9ec922665_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if45bc2183bdb469d98e2ab68aaa55e0c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic910537dd8174a69bd816bc2d30fd0ac_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iae0f8a52f2ff424fb8c210a60b2e720f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b314ab44ce4452395969bc75e04e13e_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic9f86406928947e18f670fa887c043db_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="reporting_unit">
        <measure>nktr:reporting_unit</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="term">
        <measure>nktr:term</measure>
    </unit>
    <unit id="action">
        <measure>nktr:action</measure>
    </unit>
    <unit id="segment">
        <measure>nktr:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml80L2ZyYWc6MmRmYzJiZTRkYzZkNGIyZjg4Y2Q3NmRjMDVkZDIwMTUvdGFibGU6YTFiOTcwMWExYzM0NDBhZDkxMWY3NDBjY2Q0NmM1ZTIvdGFibGVyYW5nZTphMWI5NzAxYTFjMzQ0MGFkOTExZjc0MGNjZDQ2YzVlMl8yLTEtMS0xLTExMjk4_dd656d16-3184-44aa-844f-ae10dc5321bc">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml80L2ZyYWc6MmRmYzJiZTRkYzZkNGIyZjg4Y2Q3NmRjMDVkZDIwMTUvdGFibGU6YTFiOTcwMWExYzM0NDBhZDkxMWY3NDBjY2Q0NmM1ZTIvdGFibGVyYW5nZTphMWI5NzAxYTFjMzQ0MGFkOTExZjc0MGNjZDQ2YzVlMl8zLTEtMS0xLTExMjk4_2dbbda4f-382f-4b12-9d56-c2098005b064">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml80L2ZyYWc6MmRmYzJiZTRkYzZkNGIyZjg4Y2Q3NmRjMDVkZDIwMTUvdGFibGU6YTFiOTcwMWExYzM0NDBhZDkxMWY3NDBjY2Q0NmM1ZTIvdGFibGVyYW5nZTphMWI5NzAxYTFjMzQ0MGFkOTExZjc0MGNjZDQ2YzVlMl80LTEtMS0xLTExMjk4_9b7fb7a4-65f8-459e-8a72-d3854a086f5a">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml80L2ZyYWc6MmRmYzJiZTRkYzZkNGIyZjg4Y2Q3NmRjMDVkZDIwMTUvdGFibGU6YTFiOTcwMWExYzM0NDBhZDkxMWY3NDBjY2Q0NmM1ZTIvdGFibGVyYW5nZTphMWI5NzAxYTFjMzQ0MGFkOTExZjc0MGNjZDQ2YzVlMl81LTEtMS0xLTExMjk4_88cfb539-7b0e-45f5-982c-78df3add12f5">0000906709</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib53f800cf34743b584b3c807522f25a0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjA3OTA_047a9ea0-7fde-4ef1-8171-92c0f31dcfa0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i05da6e7840b44dd9b4425434109ffec4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTU0_0003ae67-eceb-4b3d-a922-f92cdc2a62bd">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i05da6e7840b44dd9b4425434109ffec4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTU0_c526c77b-95f7-450d-b638-74b09846bea6">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LeaseExtensionTerm
      contextRef="idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMS0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo1NzBkM2IxNWJkODY0NDhlYTY5MGYyNDhlY2RjM2VmNl8xOQ_aafbf748-eb94-4830-9eeb-f3b77f87a1d3">P5Y</nktr:LeaseExtensionTerm>
    <nktr:LeaseExtensionTerm
      contextRef="i7562d9991df643f7ab9b69837b951eed_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMy0xLTEtMTEyOTgvdGV4dHJlZ2lvbjoxZmUzNGY5ZGNjNmE0MzIyYmMyMDNmMGRiNWZiYzJkYV83_acadf74a-e2c3-4130-9183-4f9108ef96cd">P5Y</nktr:LeaseExtensionTerm>
    <dei:DocumentType
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk5_42447439-035d-49a5-9dee-05d5dc8ada36">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6NTZjYjdlNTFiMTA5NDQyNDkwYTI3N2I3NWQ2ZjQ4NGYvdGFibGVyYW5nZTo1NmNiN2U1MWIxMDk0NDI0OTBhMjc3Yjc1ZDZmNDg0Zl8wLTAtMS0xLTExMjk4_16073e48-e449-4252-92f5-86345fd51dad">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV8yNjk_3798ae49-014d-405b-8594-d654af48a52a">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV8yNjk_0ff961f1-25ad-4224-8781-73a2e4658018">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6MmNkYWVhOTYzYzFhNGZkMTllNWFlNmM0MmZhMjI4MGYvdGFibGVyYW5nZToyY2RhZWE5NjNjMWE0ZmQxOWU1YWU2YzQyZmEyMjgwZl8wLTAtMS0xLTExMjk4_92edc377-f7e9-442c-9b73-346c194560c4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MTAw_311749c4-153a-407d-a751-79ecf6a2f28f">0-24006</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDky_88775e27-e345-4f56-bfcc-4c184bad9a91">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6ZjU2ZjIyNWE1ODA5NDkxNWFmN2I2Yzk0N2E2ZTBlMTcvdGFibGVyYW5nZTpmNTZmMjI1YTU4MDk0OTE1YWY3YjZjOTQ3YTZlMGUxN18wLTAtMS0xLTExMjk4_4aebe027-31ef-43bb-9d0b-4a6ab90e13e4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6ZjU2ZjIyNWE1ODA5NDkxNWFmN2I2Yzk0N2E2ZTBlMTcvdGFibGVyYW5nZTpmNTZmMjI1YTU4MDk0OTE1YWY3YjZjOTQ3YTZlMGUxN18wLTItMS0xLTExMjk4_5fb1629c-4d4e-4bda-ad39-9b7a40351bb7">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk0_b8a0844c-d712-4e43-9cac-5cbc8435c312">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDkw_93a67c3a-46da-4039-81fd-19b6c8864cfe">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDkx_fcc06692-d37d-4dc0-84c7-18cb12f85fd4">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk1_f1ed45d2-170a-41ae-8ff5-0b969f9b1524">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDg1_44fcbd34-4c3f-45ac-885c-26999032fc8d">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDg3_e84125e5-a3ac-423c-881f-43f28a62f4e1">482-5300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6OTEzODRkNzI1MjVlNDhmMmIwMTBkODRmNzZiMmEwZjYvdGFibGVyYW5nZTo5MTM4NGQ3MjUyNWU0OGYyYjAxMGQ4NGY3NmIyYTBmNl8xLTAtMS0xLTExMjk4_5d05f498-efed-4038-8702-1fcb456adf8e">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6OTEzODRkNzI1MjVlNDhmMmIwMTBkODRmNzZiMmEwZjYvdGFibGVyYW5nZTo5MTM4NGQ3MjUyNWU0OGYyYjAxMGQ4NGY3NmIyYTBmNl8xLTEtMS0xLTExMjk4_23ce98ed-9e23-42fc-b70b-8924c3130cec">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6OTEzODRkNzI1MjVlNDhmMmIwMTBkODRmNzZiMmEwZjYvdGFibGVyYW5nZTo5MTM4NGQ3MjUyNWU0OGYyYjAxMGQ4NGY3NmIyYTBmNl8xLTItMS0xLTExMjk4_d3e7cbe3-1d69-4afd-9295-4fb291326ea2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk2_45be4dd0-d0f3-4d55-9255-3d9109cbe9ec">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDg4_bd181e8a-2a24-4257-bd52-9a8dfa0d6da3">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk3_b229ca81-f602-4b7f-906d-f57ba1232019">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDg5_dfe997a3-b29b-4235-a065-45e2b1f54bc4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6ZWY0OGMyOTcyM2JhNGM1MWJhMTM3ZGJhZDI5ZTgxMjUvdGFibGVyYW5nZTplZjQ4YzI5NzIzYmE0YzUxYmExMzdkYmFkMjllODEyNV8wLTAtMS0xLTExMjk4_09f8aba0-133e-4381-8d98-27de2ef7cbb5">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6ZWY0OGMyOTcyM2JhNGM1MWJhMTM3ZGJhZDI5ZTgxMjUvdGFibGVyYW5nZTplZjQ4YzI5NzIzYmE0YzUxYmExMzdkYmFkMjllODEyNV8xLTQtMS0xLTExMjk4_386958d1-cafe-4db2-92a1-08fee7f09156">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGFibGU6ZWY0OGMyOTcyM2JhNGM1MWJhMTM3ZGJhZDI5ZTgxMjUvdGFibGVyYW5nZTplZjQ4YzI5NzIzYmE0YzUxYmExMzdkYmFkMjllODEyNV8yLTEtMS0xLTExMjk4_0cf059ab-eba5-4d64-a20d-d4bba0c1414e">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDkz_80a92b89-5932-48b2-9e46-bd2955a31c94">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDk4_cd4854b8-0381-40bf-b5d5-93b22cd0b4df">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i12aa694918fb4e37a8989f7f4021c7cc_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV8zMzky_e737bac0-538b-4b94-bf3e-61db8e90d98f"
      unitRef="usd">3100000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i000e41e2d6664cc0a62610b6e74c65f6_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV8zNzEy_2a8b132e-487e-4849-9a05-423a2e0c0bd2"
      unitRef="shares">186274156</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xL2ZyYWc6NmNkNTRmZDk3MTc1NGFjMzg5YTY0YmUxY2M5YjAwMDUvdGV4dHJlZ2lvbjo2Y2Q1NGZkOTcxNzU0YWMzODlhNjRiZTFjYzliMDAwNV80MDg2_51cd2486-f489-4939-8078-5e52c86c0349">Portions of registrant&#x2019;s definitive Proxy Statement to be filed for its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <nktr:CollaborativeArrangementCommittedFunding
      contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml81OC9mcmFnOmQ1MzcxMTE1NDdjYTQ1MzZiOTA2ZmM1YTRiMDZiM2Y0L3RleHRyZWdpb246ZDUzNzExMTU0N2NhNDUzNmI5MDZmYzVhNGIwNmIzZjRfMTY0OTI2NzQ0MzIwNzg_0b016bce-c9e8-427f-aa65-fc3a2a2aae5f"
      unitRef="usd">150000000</nktr:CollaborativeArrangementCommittedFunding>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ib73eda96963641c5adca30248e3b4212_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml81OC9mcmFnOmQ1MzcxMTE1NDdjYTQ1MzZiOTA2ZmM1YTRiMDZiM2Y0L3RleHRyZWdpb246ZDUzNzExMTU0N2NhNDUzNmI5MDZmYzVhNGIwNmIzZjRfMTY0OTI2NzQ0MzI5MTU_0c2550ad-29b7-4bd4-9e27-653a30bc1fa5"
      unitRef="number">0.015</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i418e819404874602beccd76277d2832e_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml81OC9mcmFnOmQ1MzcxMTE1NDdjYTQ1MzZiOTA2ZmM1YTRiMDZiM2Y0L3RleHRyZWdpb246ZDUzNzExMTU0N2NhNDUzNmI5MDZmYzVhNGIwNmIzZjRfMTY0OTI2NzQ0MzI5OTk_fa8c9cfb-41c9-40df-9d30-d48aac16b0be"
      unitRef="number">0.127</us-gaap:DerivativeLiabilityMeasurementInput>
    <dei:AuditorFirmId
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml82NC9mcmFnOmY3ZmY5MTJiNjAzMTQwYWNiOGJjYzQ0MzBmMGFiYzY3L3RhYmxlOjQ2MjJjNTE4NDhkZjQ0MGFiZDM3YTVhM2ZmM2JiNmMxL3RhYmxlcmFuZ2U6NDYyMmM1MTg0OGRmNDQwYWJkMzdhNWEzZmYzYmI2YzFfMS0wLTEtMS0yMzA5MC90ZXh0cmVnaW9uOjI4MTJiZjhkZWNhNjRiMzliZTg2NDExNDEzYWFmMzgwXzE2NDkyNjc0NDE4Njk_7e9ec53d-de8b-4cb8-8dee-4b118494551f">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml82Ny9mcmFnOmRjOTFjMGNjZTc3ODRiMTRhMDFiM2QwYmZhNjI0NjAzL3RleHRyZWdpb246ZGM5MWMwY2NlNzc4NGIxNGEwMWIzZDBiZmE2MjQ2MDNfMTQyOTM2NTExNjg5MjY_d6ad7d4e-5362-4e46-b177-ac881a7aee64">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml82Ny9mcmFnOmRjOTFjMGNjZTc3ODRiMTRhMDFiM2QwYmZhNjI0NjAzL3RleHRyZWdpb246ZGM5MWMwY2NlNzc4NGIxNGEwMWIzZDBiZmE2MjQ2MDNfMTQyOTM2NTExNjg5Mjc_5d553094-83ca-43ee-a274-d26275f7db40">Redwood City, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNC0xLTEtMS0xMTI5OA_dc513e74-9bc4-4f52-9753-86cdd697371f"
      unitRef="usd">25218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNC0zLTEtMS0xMTI5OA_fff9b0ae-ca3a-4df3-869f-ca77b25e9bbb"
      unitRef="usd">198955000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNS0xLTEtMS0xMTI5OA_c8d45786-ca28-46d9-8cda-9b6852b2bc24"
      unitRef="usd">708737000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNS0zLTEtMS0xMTI5OA_580d2afc-817b-4845-b9c8-b2251f0d003c"
      unitRef="usd">862941000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNi0xLTEtMS0xMTI5OA_6f5dec94-a1db-4ec6-807f-aeae57ef6287"
      unitRef="usd">22492000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNi0zLTEtMS0xMTI5OA_45e1d2a7-fe57-42eb-adc1-e0ef523d7b45"
      unitRef="usd">38889000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNy0xLTEtMS0xMTI5OA_dd7d3bde-04a4-4d0f-8b4a-e71fff8873fe"
      unitRef="usd">15801000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNy0zLTEtMS0xMTI5OA_109acf31-ec2d-48a9-afcc-7993d877f697"
      unitRef="usd">15292000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfOS0xLTEtMS0xMTI5OA_3c17f497-13b2-48fa-a239-1e39c4b5dc0f"
      unitRef="usd">23333000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfOS0zLTEtMS0xMTI5OA_88a55ada-a6e8-4b72-8762-e4365ae16e40"
      unitRef="usd">21928000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTAtMS0xLTEtMTEyOTg_d2f8eced-4004-4fb8-bd04-e88267ee5aec"
      unitRef="usd">795581000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTAtMy0xLTEtMTEyOTg_8cc3619c-db9a-4c26-ad04-e8285281919e"
      unitRef="usd">1138005000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTEtMS0xLTEtMTEyOTg_7cd8637a-6841-473b-97be-d3629d6d5c0d"
      unitRef="usd">64828000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTEtMy0xLTEtMTEyOTg_a09392b5-64a2-4778-af4a-5f56cb4fe169"
      unitRef="usd">136662000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTItMS0xLTEtMTEyOTg_77f62c26-94da-414c-870b-9e39adf8724d"
      unitRef="usd">60510000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTItMy0xLTEtMTEyOTg_82befe2b-ed67-41ff-badc-b5bfce58d33e"
      unitRef="usd">59662000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTMtMS0xLTEtMTEyOTg_f8862e50-cd3a-44a0-9be0-0bc8abbb1ae3"
      unitRef="usd">117025000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTMtMy0xLTEtMTEyOTg_9ecc2ac7-64b2-4b6f-99b1-a71871faa61f"
      unitRef="usd">126476000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTQtMS0xLTEtMTEyOTg_c0c322ee-d8b5-46ac-b521-88e0d8a8ff12"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTQtMy0xLTEtMTEyOTg_ce7631e4-ca61-45f7-b845-6f9fca1ae4f9"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTUtMS0xLTEtMTEyOTg_0faa186a-cb87-41fe-a6d5-05bcdebbd129"
      unitRef="usd">2744000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTUtMy0xLTEtMTEyOTg_ab8610e5-74f8-4bb9-9553-2aacc03a0e7d"
      unitRef="usd">1461000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTYtMS0xLTEtMTEyOTg_6cc7caa0-3619-4c8b-a732-fee5749fc598"
      unitRef="usd">1117189000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMTYtMy0xLTEtMTEyOTg_374599e8-acb3-43d4-8ecb-161564d607d4"
      unitRef="usd">1538767000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjAtMS0xLTEtMTEyOTg_db2ddfa9-118b-4f0a-870a-5518138098d3"
      unitRef="usd">9747000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjAtMy0xLTEtMTEyOTg_c80c600f-0677-4ba8-9045-bbd12a8e2682"
      unitRef="usd">22139000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjEtMS0xLTEtMTEyOTg_7c8bf5d7-e7c7-4615-aab1-44e02f19c20f"
      unitRef="usd">15735000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjEtMy0xLTEtMTEyOTg_fbd1344a-9d74-4423-be59-48e8983284f7"
      unitRef="usd">14532000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjItMS0xLTEtMTEyOTg_49e817fc-8dbe-4742-a58d-64a0d4abc283"
      unitRef="usd">26809000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjItMy0xLTEtMTEyOTg_6f96aa49-c05c-4193-9172-eef578c83c46"
      unitRef="usd">44207000</nktr:AccruedClinicalTrialExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjQtMS0xLTEtMTEyOTg_27aa9ed5-a337-47bb-9ce5-e8e2fa7f5710"
      unitRef="usd">15468000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjQtMy0xLTEtMTEyOTg_8b328b4a-de7f-4777-a818-3339b5c45cec"
      unitRef="usd">20986000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjUtMS0xLTEtMTEyOTg_66d512d5-9874-4d29-bc17-9d5ef3f0fd0e"
      unitRef="usd">17441000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjUtMy0xLTEtMTEyOTg_f610b78c-f7d6-422f-9923-726bb2433721"
      unitRef="usd">13915000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjctMS0xLTEtMTEyOTg_2a119f9b-dd7d-4159-8a2e-532f640ce824"
      unitRef="usd">85200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjctMy0xLTEtMTEyOTg_77a0bea9-cc8b-46c9-a433-8f60ca975395"
      unitRef="usd">115779000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjgtMS0xLTEtMTEyOTg_e58738d2-0049-4a76-97d3-e84ff220a0f1"
      unitRef="usd">125736000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjgtMy0xLTEtMTEyOTg_0ce6db69-322e-49b2-811e-bed098e8d767"
      unitRef="usd">136373000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjYtMS0xLTEtMTMxMDM_30a23f51-00aa-42c9-bd6b-b8d3a880323d"
      unitRef="usd">27726000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjYtMy0xLTEtMTMxMTc_75d31081-1001-426a-89f0-d98a1d06bb4d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjktMS0xLTEtMTEyOTg_1933e1a0-43f9-4d09-b0f1-edc598fa8549"
      unitRef="usd">195427000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMjktMy0xLTEtMTEyOTg_890d277a-2fcd-4404-8e8d-51fd7d8a5b00"
      unitRef="usd">200340000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzEtMS0xLTEtMTEyOTg_79f65ada-3ad8-4bdb-8a79-d73aa1ba8f46"
      unitRef="usd">3592000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzEtMy0xLTEtMTEyOTg_672d4da7-ee1c-4c7b-b62d-6f5cfb893ff9"
      unitRef="usd">8980000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzItMS0xLTEtMTEyOTg_235c4054-07d8-43a4-84a8-f5731e6ffe7f"
      unitRef="usd">437681000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzItMy0xLTEtMTEyOTg_9bea22ef-0819-4875-8fa3-d825f9eb0f48"
      unitRef="usd">461472000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzMtMS0xLTEtMTEyOTg_88c6eddf-2b08-4ae3-be72-926f3e47635c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzMtMy0xLTEtMTEyOTg_d35eeeaa-9aae-4b92-a979-636972a669e2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV8yMQ_26ff4440-462b-401b-9868-e57e8e861dde"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV8yMQ_43e5d71b-4b6a-4ca0-ad22-d5389ee5e29e"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV8zNQ_83b660a1-148b-4b68-a47f-9fa9b8430cee"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV8zNQ_c25c5bf7-4be2-4340-96ec-80ba78898406"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_0883444e-0270-44b4-aa56-2857dfd3c028"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_241f3d23-510e-4e8f-8c0b-20e9d474cc32"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_64090482-e09a-4689-96a7-b218cd7265f3"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_d2748ced-5d29-48f3-9239-12c9aa06470f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <nktr:PreferredStockShareDesignated
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_d79e82f3-6c6c-47a6-99b2-052d7ff19809"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4ODJjNGExOTc1ZTU0MGJiYTIxNGExOGJjODQ2NTg3NV81Nw_f159bb67-772e-49f3-9be9-add941593037"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMS0xLTEtMTEyOTg_0f50fce2-0106-4184-9288-9e8211444b39"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzUtMy0xLTEtMTEyOTg_0bf9111c-b4dc-482a-b675-0818137b8ca1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF8xOA_8ce5475e-5fac-4b60-a8e8-d437f591dd35"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF8xOA_fdc66911-dc3b-4da9-82d0-7b13bd9cfd5c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF8zMg_1be04ced-cd02-4ada-9ec3-1386ed9665e9"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF8zMg_7cbd56c2-6895-43ca-94fb-2b0ce9b71b6a"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF81NA_154e7e2b-d40e-4062-9adf-496dcc4d1d18"
      unitRef="shares">185468000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF81NA_d87f0c32-a1f1-4c9f-8260-f829dd55789f"
      unitRef="shares">185468000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF82OA_2a07a5ae-7fef-40a7-84bc-396757de7409"
      unitRef="shares">180091000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjpiOTEwOWI5ZGEyMzA0NWQ2OGE0Y2U5YjY3YWE4MTZiZF82OA_f27899d6-7c11-40aa-a3ca-0c32761a3fd8"
      unitRef="shares">180091000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMS0xLTEtMTEyOTg_c50bd5a8-9ad6-40b3-9a09-d6e03d50f75f"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzYtMy0xLTEtMTEyOTg_0dd2a4e3-ac40-4fff-920e-6157ff979f8e"
      unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzctMS0xLTEtMTEyOTg_39ae51d7-7486-43ff-9efa-50514d542645"
      unitRef="usd">3516641000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzctMy0xLTEtMTEyOTg_71c292e8-b5c1-4d52-b738-ec7f7fda8a34"
      unitRef="usd">3388730000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzgtMS0xLTEtMTEyOTg_5ff49d1d-f9cc-445b-bc32-6742bf423b90"
      unitRef="usd">-4157000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzgtMy0xLTEtMTEyOTg_319cd2af-1fa1-4864-9afd-8d211cab6bf9"
      unitRef="usd">-2295000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzktMS0xLTEtMTEyOTg_3041b845-5f61-46ba-a762-c8dcbe4c1290"
      unitRef="usd">-2832995000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfMzktMy0xLTEtMTEyOTg_b4ac66a4-0c80-4230-b248-1b0dc38df49b"
      unitRef="usd">-2309158000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNDAtMS0xLTEtMTEyOTg_07bc894e-8af7-43cc-90df-cb38d3d009de"
      unitRef="usd">679508000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNDAtMy0xLTEtMTEyOTg_86b3f435-5c29-431a-be01-3bac25b9888c"
      unitRef="usd">1077295000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNDEtMS0xLTEtMTEyOTg_0c5c43cf-ed09-474d-8182-29888cf21a06"
      unitRef="usd">1117189000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83MC9mcmFnOjY5ZTEzMTFjNjg1ODQwZWJhZTE3YzQxZjg1NGRkNGViL3RhYmxlOjI1ODFkZGExNDFlNjQ5OWJhMmY3Mjc2NzExOTUyYjQzL3RhYmxlcmFuZ2U6MjU4MWRkYTE0MWU2NDk5YmEyZjcyNzY3MTE5NTJiNDNfNDEtMy0xLTEtMTEyOTg_f58a3d27-cd3f-4349-bb68-6f0f1a9c751a"
      unitRef="usd">1538767000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97391b2936f841cc9e4d2b6c592beff9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMy0xLTEtMS0xMTI5OA_b4ecb503-365f-475e-a2af-f689be2205ac"
      unitRef="usd">23725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i385bad4a34ed410299079777e10e8737_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMy0zLTEtMS0xMTI5OA_9d5efb4b-12f0-4e63-aa46-e4bb044ed8f3"
      unitRef="usd">17504000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee9f5c266bb64ec48742279a12b86e9f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMy01LTEtMS0xMTI5OA_197e3070-4208-4333-b0f2-01de0901ba63"
      unitRef="usd">20117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie556d8a598764c54834d2305fb48307e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNC0xLTEtMS0xMTI5OA_9a2b6b2a-8d29-468f-acca-e093ec5d2da3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62a137c1f62e4f37bd438bf66515d037_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNC0zLTEtMS0xMTI5OA_8346a722-d13b-42ef-bcf4-223fe7283e39"
      unitRef="usd">30999000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0375ded4b7c74c1491fe98ce48a475d8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNC01LTEtMS0xMTI5OA_5b690ba7-cfcb-404c-837d-597a01abe1f5"
      unitRef="usd">41222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16d34596d03d4f48ad22b490652d61c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNS0xLTEtMS0xMTI5OA_81d1e213-22ea-400f-9fae-8efcfadb5d3f"
      unitRef="usd">77746000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie11c771d5728489f9c3498ced689a2e8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNS0zLTEtMS0xMTI5OA_dbeb7368-fdb1-4156-a2a7-1efa9571bea2"
      unitRef="usd">48563000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4f6ca9435254d8598fb70543671cc59_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNS01LTEtMS0xMTI5OA_35a28b03-d4e1-402c-acda-0c0f718f1743"
      unitRef="usd">36303000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i524617210c1844548d9aaa3cd1afdd18_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNi0xLTEtMS0xMTI5OA_b4e74109-d371-4dd5-a216-69d602d0f8ff"
      unitRef="usd">436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9dd5c85b0364d75a8dee4e02e0abd75_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNi0zLTEtMS0xMTI5OA_9804daa5-d722-46ea-8444-8ae66150e57b"
      unitRef="usd">55849000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87de647067774165be013844df84c1bb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNi01LTEtMS0xMTI5OA_fd3d4c31-baef-4d08-853a-d158db8167b3"
      unitRef="usd">16975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNy0xLTEtMS0xMTI5OA_168102cc-aa5e-4458-b8c6-f2d40de3482d"
      unitRef="usd">101907000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNy0zLTEtMS0xMTI5OA_a58216c5-64de-45ca-9399-eae00685a046"
      unitRef="usd">152915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfNy01LTEtMS0xMTI5OA_30d49b83-bdbe-4897-9a25-915e4deebda1"
      unitRef="usd">114617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfOS0xLTEtMS0xMTI5OA_d6e0e43a-cf82-40a0-99f1-0d06d585d28b"
      unitRef="usd">24897000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfOS0zLTEtMS0xMTI5OA_9ea1d736-ef6c-4d0a-89ba-840d35d642b1"
      unitRef="usd">19477000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfOS01LTEtMS0xMTI5OA_76f68591-42d4-48ab-8831-a746a0393f33"
      unitRef="usd">21374000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTAtMS0xLTEtMTEyOTg_19ea17e3-84a2-47a0-bac0-ddc74a2293c8"
      unitRef="usd">400269000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTAtMy0xLTEtMTEyOTg_dc79fbf4-93da-40ce-8dbe-2b76d516e650"
      unitRef="usd">408678000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTAtNS0xLTEtMTEyOTg_ecf7babb-fb77-4e6a-8e3d-91b371e53639"
      unitRef="usd">434566000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTEtMS0xLTEtMTEyOTg_4682c30e-bea1-4e32-a234-270ab4aa8614"
      unitRef="usd">122844000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTEtMy0xLTEtMTEyOTg_2449c209-2167-4484-a0f2-5f103915c08c"
      unitRef="usd">104682000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTEtNS0xLTEtMTEyOTg_cc3badd7-f45d-4808-bd96-7f1c14dcc285"
      unitRef="usd">98712000</us-gaap:GeneralAndAdministrativeExpense>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTItMS0xLTEtMTEyOTg_50214c2a-082b-4088-9646-872ab804c9da"
      unitRef="usd">0</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTItMy0xLTEtMTEyOTg_44d457c8-8407-4533-a197-f0c1ab814006"
      unitRef="usd">45189000</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTItNS0xLTEtMTEyOTg_9c2ab5f9-bc84-415c-9c22-01f1f3068cc9"
      unitRef="usd">0</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgram>
    <us-gaap:CostsAndExpenses
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTMtMS0xLTEtMTEyOTg_da2f45f0-12f3-4ca0-a151-3d0f340bfef8"
      unitRef="usd">548010000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTMtMy0xLTEtMTEyOTg_c519b605-5a8b-4348-94f1-978b4314866e"
      unitRef="usd">578026000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTMtNS0xLTEtMTEyOTg_2a466a9f-78d0-4906-bdfe-d09852af3631"
      unitRef="usd">554652000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTQtMS0xLTEtMTEyOTg_b37c216a-df66-438c-bd57-5233c9f5d99d"
      unitRef="usd">-446103000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTQtMy0xLTEtMTEyOTg_747fc9e0-34ac-4ba8-b8a0-61288d1d08a4"
      unitRef="usd">-425111000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTQtNS0xLTEtMTEyOTg_51c45e74-989f-478c-910f-cf6bd7ec82ac"
      unitRef="usd">-440035000</us-gaap:OperatingIncomeLoss>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTYtMS0xLTEtMjA4NTc_8e96ec95-0538-4d56-89b6-42f4e0e09556"
      unitRef="usd">-8023000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTYtMy0xLTEtMjI5OTg_30903be2-1f6c-4456-b00c-b4bf9e087cfd"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTYtNS0xLTEtMjI5OTg_cc0a9630-2774-4c13-89f6-fccf602f1c4e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTctMS0xLTEtMTEyOTg_95e36d59-f3ed-4ffd-bd58-233f9d5ef9c9"
      unitRef="usd">47313000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTctMy0xLTEtMTEyOTg_b60d35d1-da15-4ca2-8f58-ea55b639d8ef"
      unitRef="usd">30267000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTctNS0xLTEtMTEyOTg_5cb9a8a6-5700-46c5-ae27-a5dfe4de3c20"
      unitRef="usd">25044000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtMS0xLTEtMTM5Mjk_808cf332-41ec-4e3d-b9f4-66468f50fca6"
      unitRef="usd">-24410000</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtMy0xLTEtMTM5OTA_9dde7904-930e-4d2b-98dd-c696926f9223"
      unitRef="usd">0</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtNS0xLTEtMTM5OTA_a7f1279a-8114-498a-941b-0e5a2733f309"
      unitRef="usd">0</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtMS0xLTEtMTEyOTg_42107f15-2daf-491d-bca1-cafc36921976"
      unitRef="usd">2569000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtMy0xLTEtMTEyOTg_74319ac7-a2c7-40a9-ba9e-61fdb1dfaa80"
      unitRef="usd">18282000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTgtNS0xLTEtMTEyOTg_b35c5fd5-b518-4d42-84f5-6079dd1598ba"
      unitRef="usd">46335000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtMS0xLTEtMTYzNDU_c6d49e7b-5f4a-4c96-bda5-d3ff07d6b892"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtMy0xLTEtMTYzNDU_97e25835-48c6-4c94-b2ec-aea83ff5c9c9"
      unitRef="usd">6851000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtNS0xLTEtMTYzNDU_f58d3bd2-e5d1-44ec-baf2-a3c110980b23"
      unitRef="usd">21310000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTktMS0xLTEtMTEyOTg_de2384ce-0eef-4c07-a701-fc22048265d5"
      unitRef="usd">-77177000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTktMy0xLTEtMTEyOTg_24f4a1da-45d8-4b5c-bbaa-25d804469acb"
      unitRef="usd">-18836000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMTktNS0xLTEtMTEyOTg_0807c467-8e05-4cbc-b4c3-0c924fb07afc"
      unitRef="usd">-19000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjAtMS0xLTEtMTEyOTg_d0f3c153-2bbf-4b0b-8f69-f07162228abe"
      unitRef="usd">-523280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjAtMy0xLTEtMTEyOTg_7dfada6b-4071-4b6e-8f2e-bfe292f9a97b"
      unitRef="usd">-443947000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjAtNS0xLTEtMTEyOTg_6ab2136c-2090-4f52-bf2d-cdfaf17d6aff"
      unitRef="usd">-440054000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtMS0xLTEtMTEyOTg_82462a48-cb24-462e-85f2-cb79b1f3ee22"
      unitRef="usd">557000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtMy0xLTEtMTEyOTg_3402ab4f-ad65-423e-b6ef-053e7993d0f8"
      unitRef="usd">493000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjEtNS0xLTEtMTEyOTg_ccc1fbd3-8bb9-42b5-a35c-4e8e1b094423"
      unitRef="usd">613000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjItMS0xLTEtMTEyOTg_eee0cea3-c3df-4d1d-8224-71d18f30fec1"
      unitRef="usd">-523837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjItMy0xLTEtMTEyOTg_599ee55a-d8e8-45b3-97ef-3e6333a649c0"
      unitRef="usd">-444440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjItNS0xLTEtMTEyOTg_ecda7f48-d6a2-4b30-914a-04911a5187e6"
      unitRef="usd">-440667000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtMS0xLTEtMjA5MTE_0d95e51d-12a5-42a9-a318-1424998ef631"
      unitRef="usdPerShare">-2.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtMS0xLTEtMjA5MTE_cc51a471-97a7-45e3-a6c6-d32354e17714"
      unitRef="usdPerShare">-2.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtMy0xLTEtMjA5MTE_7e6ab542-01f4-4337-81b8-29fe4fd14a4b"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtMy0xLTEtMjA5MTE_fc1092f0-176a-406a-ae9f-a3dfb89b7708"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtNS0xLTEtMjA5MTE_2546ffc0-c075-43a6-9283-d71d22ee5a70"
      unitRef="usdPerShare">-2.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjYtNS0xLTEtMjA5MTE_7be8e084-92bc-4665-aa62-f4382ae50ae8"
      unitRef="usdPerShare">-2.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctMS0xLTEtMjA5MDQ_179be33e-6f1b-4897-8cec-c86d6e0288ea"
      unitRef="shares">183298000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctMS0xLTEtMjA5MDQ_3acf3b77-1493-4e4c-b238-d97a47388d8a"
      unitRef="shares">183298000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctMy0xLTEtMjA5MDQ_1dd6db55-57e9-4e66-bf35-adca953c5070"
      unitRef="shares">178581000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctMy0xLTEtMjA5MDQ_bda172d5-b93d-4d66-a320-501de64a3e25"
      unitRef="shares">178581000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctNS0xLTEtMjA5MDQ_03150b26-e82f-4f1f-a884-5b0be103f36a"
      unitRef="shares">174993000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83My9mcmFnOmY3ZWU0ZjE0Y2YzYjQ3M2Y5NTFjOGYxZTE2NjkwZjExL3RhYmxlOjdmMjlkZmQ1NjFjZDRhODQ5ZDBjYmE3MDY3MjA1NzI3L3RhYmxlcmFuZ2U6N2YyOWRmZDU2MWNkNGE4NDlkMGNiYTcwNjcyMDU3MjdfMjctNS0xLTEtMjA5MDQ_96744acb-e085-4b77-a515-39a1c68592c8"
      unitRef="shares">174993000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfMi0xLTEtMS0xMTI5OA_1fa00922-0128-400e-8c13-bd35ebd933d3"
      unitRef="usd">-523837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfMi0zLTEtMS0xMTI5OA_917a061b-89e0-4447-8826-7d2a9902d9ad"
      unitRef="usd">-444440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfMi01LTEtMS0xMTI5OA_9d6fffae-3273-4246-938f-d6f45724065a"
      unitRef="usd">-440667000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNC0xLTEtMS0xMTI5OA_5b9fdbcc-4be4-47f4-a75d-ff8d89bf79b1"
      unitRef="usd">-1568000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNC0zLTEtMS0xMTI5OA_4af918b0-4b80-4777-baa2-0863eef34fdd"
      unitRef="usd">-927000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNC01LTEtMS0xMTI5OA_86b01ad0-ef17-4280-8560-5ea2865e65ac"
      unitRef="usd">5693000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNS0xLTEtMS0xMTI5OA_f81a1565-cc5f-4912-b7dc-06b67a6a661a"
      unitRef="usd">-294000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNS0zLTEtMS0xMTI5OA_a97006dc-6b16-4e65-98d8-7f945f267de6"
      unitRef="usd">-363000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNS01LTEtMS0xMTI5OA_8768ad66-0c4f-4513-be4b-7c9821df23af"
      unitRef="usd">-382000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNi0xLTEtMS0xMTI5OA_7f8fc6da-62a5-45a9-9e8e-24982672da80"
      unitRef="usd">-1862000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNi0zLTEtMS0xMTI5OA_325bb386-695a-4a23-92d6-2fd5d6ffd22e"
      unitRef="usd">-1290000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNi01LTEtMS0xMTI5OA_e826c2b5-eb0d-4d5f-bcdf-e5be9704d54f"
      unitRef="usd">5311000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNy0xLTEtMS0xMTI5OA_5a21a8cd-d1d3-4ee1-ab87-d81a94331166"
      unitRef="usd">-525699000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNy0zLTEtMS0xMTI5OA_5c0849ba-801f-412b-85e8-16da41018fc1"
      unitRef="usd">-445730000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83Ni9mcmFnOmExMjE5MGU5NTFiYjRkM2ZhYTQxMTk3MzQ3YmMzMTIxL3RhYmxlOmFmMDhlMDg5ZDVkNDQzYWNhMDM1YTQ0N2RjYjNiNjRiL3RhYmxlcmFuZ2U6YWYwOGUwODlkNWQ0NDNhY2EwMzVhNDQ3ZGNiM2I2NGJfNy01LTEtMS0xMTI5OA_62ab51f2-205e-4f94-b033-0557392fc844"
      unitRef="usd">-435356000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="icfc39458a49345bdbf9c5f0b59507c25_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS0xLTEtMS0xMTI5OA_9ebd9e9c-78b6-4921-b58e-c45a69c47a8f"
      unitRef="shares">173530000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icfc39458a49345bdbf9c5f0b59507c25_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS0zLTEtMS0xMTI5OA_5e19a671-693c-4680-be54-9aea29a2c124"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idfb2fa6ca8a0403abea7fdab421e1e5a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS01LTEtMS0xMTI5OA_6a7efba7-f24b-4257-b2a6-818c8287b065"
      unitRef="usd">3147925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic036604bec7a494eb87b4bb2add33694_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS03LTEtMS0xMTI5OA_a6e6e9f5-3307-4b8d-b748-b29ce2a186f2"
      unitRef="usd">-6316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdc8ae10616f484b97ae80d605c49cd3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS05LTEtMS0xMTI5OA_4c5916e9-b1d0-4740-9646-a5c675556dc1"
      unitRef="usd">-1424051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e86cae77d44493aad21052dab0a76b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMS0xMS0xLTEtMTEyOTg_6a711624-aa76-4d5c-baac-decaa6fa004f"
      unitRef="usd">1717575000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i875faed795c94a9cbe1dbe5c45959993_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMi0xLTEtMS0xMTI5OA_f5bf99c1-b139-4901-9b21-1b23beeb3c31"
      unitRef="shares">2975000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i875faed795c94a9cbe1dbe5c45959993_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMi0zLTEtMS0xMTI5OA_0a37187b-4a24-41f0-b7f4-fe273056bf1a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie15c826afa424f9f83b6f1f31eae68e0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMi01LTEtMS0xMTI5OA_fafbf0be-30e3-46a9-aab0-9a868cc33321"
      unitRef="usd">23377000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMi0xMS0xLTEtMTEyOTg_af5b5ab0-0049-40a7-9832-303104f679cd"
      unitRef="usd">23377000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie15c826afa424f9f83b6f1f31eae68e0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMy01LTEtMS0xMTI5OA_c369df01-bdde-4d01-94f4-af2309dae374"
      unitRef="usd">99795000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMy0xMS0xLTEtMTEyOTg_91c8c936-ee62-4497-b7ba-e319183cb236"
      unitRef="usd">99795000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2c08dcd809044c649a36e6a8870b753f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNi03LTEtMS0xMTI5OA_ccdd25df-d531-422d-b195-488661fcf0d7"
      unitRef="usd">5311000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i46aabdbcec054bbc98f62fc64f377f52_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNi05LTEtMS0xMTI5OA_1f035804-6af5-4220-a42f-d035be90ff2a"
      unitRef="usd">-440667000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNi0xMS0xLTEtMTEyOTg_dad04754-8d58-4cc6-90df-f573e60bf2f3"
      unitRef="usd">-435356000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i2dec94ffa8f54d9f8f0e8161b2c81580_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy0xLTEtMS0xMTI5OA_edf40442-1008-47c5-8b3b-bc5aceadd13b"
      unitRef="shares">176505000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2dec94ffa8f54d9f8f0e8161b2c81580_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy0zLTEtMS0xMTI5OA_7aee2c2c-aa80-4f3c-a480-973922a4afe1"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1387c3cbfa6f42a8878e29c7c2e63b8c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy01LTEtMS0xMTI5OA_849e1677-849e-4a1a-afa1-5fab55e87e07"
      unitRef="usd">3271097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i617c9de53110471eb788bd49272cb303_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy03LTEtMS0xMTI5OA_34c25c60-76ca-423b-933c-41566cc13662"
      unitRef="usd">-1005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6dc92f30772f4416b1b6a460651e0081_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy05LTEtMS0xMTI5OA_9f05ceb3-6bec-4d0c-b2b2-c5be16559db2"
      unitRef="usd">-1864718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i89a636947a9046a38a2ed739019eb13c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfNy0xMS0xLTEtMTEyOTg_678cd4be-69cd-408b-9e62-cf1e63e7e7df"
      unitRef="usd">1405391000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic7a330302e89494f86be51dbb5ad4eba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOC0xLTEtMS0xMTI5OA_9e617f26-2185-4474-be55-a2cf67e16095"
      unitRef="shares">3586000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic7a330302e89494f86be51dbb5ad4eba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOC0zLTEtMS0xMTI5OA_a9c9a09c-e73d-4c7f-9408-00554898226f"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id6ab4897a894445fb01edd925a1631d2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOC01LTEtMS0xMTI5OA_02664b4c-a2d8-4800-a239-ed0cd1d09f2d"
      unitRef="usd">23372000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOC0xMS0xLTEtMTEyOTg_88a4ca7d-4949-482f-a327-5ab6d3fe2bd9"
      unitRef="usd">23373000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id6ab4897a894445fb01edd925a1631d2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOS01LTEtMS0xMTI5OA_a5e24de8-8eba-46fd-9610-bc682bef2723"
      unitRef="usd">94261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfOS0xMS0xLTEtMTEyOTg_fe649b0a-8b2b-4f88-9050-77c597ea0979"
      unitRef="usd">94261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i06602f496e114bfea3a9bdc411724138_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTAtNy0xLTEtMTEyOTg_8ae194ff-66f5-4510-bc7c-7a5147dbe6f8"
      unitRef="usd">-1290000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i218a36c4ef32491d8ed93aa732435402_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTAtOS0xLTEtMTEyOTg_97216144-a0a5-47f5-8263-87b1aecd8f10"
      unitRef="usd">-444440000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTAtMTEtMS0xLTExMjk4_cb7f7908-d476-4ebe-bc73-235c849d279e"
      unitRef="usd">-445730000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ie4958a2d31a14357b76df572e493fa94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtMS0xLTEtMTEyOTg_d12b247f-8d38-48b6-924a-c93297298338"
      unitRef="shares">180091000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie4958a2d31a14357b76df572e493fa94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtMy0xLTEtMTEyOTg_7122c8f5-b774-415c-84c3-f002a0355ace"
      unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7070fa33af194d52891eedefe4dfb853_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtNS0xLTEtMTEyOTg_1ea3f2ee-2433-4fc8-83f9-47936c427cfa"
      unitRef="usd">3388730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2bcba052d2f340589756a4df2f43f3c8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtNy0xLTEtMTEyOTg_23bb13f0-910d-4b25-b76a-a9c2bc3a9f32"
      unitRef="usd">-2295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i426f379da93c42a2b87f77f27a1dfc65_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtOS0xLTEtMTEyOTg_4546717f-4f50-40cc-a8a1-8946a53c7fbd"
      unitRef="usd">-2309158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTEtMTEtMS0xLTExMjk4_df69fe49-5bfc-4fcb-a467-97fb0a4db097"
      unitRef="usd">1077295000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idd67d9937f7d47baafb15299a877ed6b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTItMS0xLTEtMTEyOTg_37735157-3876-4347-9040-2fa8980fe00d"
      unitRef="shares">5377000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idd67d9937f7d47baafb15299a877ed6b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTItMy0xLTEtMTEyOTg_2788d14e-c0db-4b22-a6c4-0b3c4089760d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i526f6174d8c74127a9c60db3a5d90b76_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTItNS0xLTEtMTEyOTg_1ec3f8f6-6616-4089-a312-2bc8706a6a64"
      unitRef="usd">33237000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTItMTEtMS0xLTExMjk4_a61a8375-8d18-4abd-9736-96cdf51890bf"
      unitRef="usd">33238000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i526f6174d8c74127a9c60db3a5d90b76_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTMtNS0xLTEtMTEyOTg_13d57d28-50a5-4884-bc95-37701cdbb0b8"
      unitRef="usd">94674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTMtMTEtMS0xLTExMjk4_aa4c419e-efb9-4a94-b6c4-4c61e04d8653"
      unitRef="usd">94674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7aac894909174929a2fae22e8d8a3906_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTQtNy0xLTEtMTEyOTg_92621598-c9a2-44d0-bc3e-e783489d3b18"
      unitRef="usd">-1862000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5cb2f5eb7d0d4cd0a19c316ad433666a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTQtOS0xLTEtMTEyOTg_5930acc2-45c7-4c5a-915f-1483ea43171d"
      unitRef="usd">-523837000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTQtMTEtMS0xLTExMjk4_26ea8808-bc0d-46a4-9085-d9e19cc051cd"
      unitRef="usd">-525699000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i2206f8a53bc949e99e036f0c404e52a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtMS0xLTEtMTEyOTg_15afee35-032a-4158-9980-1c83aa844c04"
      unitRef="shares">185468000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2206f8a53bc949e99e036f0c404e52a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtMy0xLTEtMTEyOTg_9fec5269-d3fe-4174-bf12-d51f4966f38c"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibbd923bc535f4746833b54075312bef7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtNS0xLTEtMTEyOTg_d690813f-4a85-4028-b0a1-a61af9ad3999"
      unitRef="usd">3516641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e0d6be14b9b4e589ab67d81ec71404f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtNy0xLTEtMTEyOTg_0d9db531-3133-49a8-ae29-27420162105f"
      unitRef="usd">-4157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida774e4baed04895887759bea104497e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtOS0xLTEtMTEyOTg_87fb1d15-15c9-4fc4-80c3-9df41a9b157e"
      unitRef="usd">-2832995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml83OS9mcmFnOjNmMWY3MjM4MWM5YzRhNzc4OGI3NmI4ZjE3ZWNiNjc5L3RhYmxlOjZkY2Y3MGRkZmNjYzQ1N2RiNzNjZTcyZDNlYTI1MjcxL3RhYmxlcmFuZ2U6NmRjZjcwZGRmY2NjNDU3ZGI3M2NlNzJkM2VhMjUyNzFfMTUtMTEtMS0xLTExMjk4_dd8807f0-df84-431b-8c6a-3c4754c690dd"
      unitRef="usd">679508000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMy0xLTEtMS0xMTI5OA_84b242ad-a860-4f8a-9f9d-c8f02ca324f7"
      unitRef="usd">-523837000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMy0zLTEtMS0xMTI5OA_61d698f6-d03e-43ff-bb1b-add153054df0"
      unitRef="usd">-444440000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMy01LTEtMS0xMTI5OA_cc22e81b-076b-4658-9137-0cb9c24bee34"
      unitRef="usd">-440667000</us-gaap:ProfitLoss>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNS0xLTEtMS0xMTI5OA_4dc797b9-5fce-4e00-a7f5-b3f907f18b6c"
      unitRef="usd">77746000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNS0zLTEtMS0xMTI5OA_d4ae87b4-cf9b-4aa8-add7-79be305a3c92"
      unitRef="usd">48563000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNS01LTEtMS0xMTI5OA_7c88818a-b341-4cc4-9c29-e720d3e57b89"
      unitRef="usd">36303000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNi0xLTEtMS0xMTI5OA_51de2009-6b02-43da-a850-67a25403e0a2"
      unitRef="usd">47313000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNi0zLTEtMS0xMTI5OA_57988cbc-534a-41d0-ab64-8b2890b6cf63"
      unitRef="usd">30267000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNi01LTEtMS0xMTI5OA_ef6d62c8-b159-4168-b067-84b3d9741aec"
      unitRef="usd">25044000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0xLTEtMS0xNTUwNg_b1e87c18-1747-4cf7-ab27-1ec9c586b642"
      unitRef="usd">-24410000</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0zLTEtMS0xNTUwNg_4b28b2f6-f4d0-4c97-9df4-d55eb3ccbb7c"
      unitRef="usd">0</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy01LTEtMS0xNTUwNg_c9eb67f8-bcbf-4158-90ae-45d014337381"
      unitRef="usd">0</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0xLTEtMS0xMzE2MA_e9a94fb5-a10e-4f88-bd61-e10814c59215"
      unitRef="usd">-8023000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0zLTEtMS0xMzE2Nw_b37ba5c5-035f-4245-870d-ad55cf379a0d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy01LTEtMS0xMzE3NA_428fe477-4290-43d5-8790-786394c99bdd"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS0xLTEtMS0xNTUxMw_d612dd6a-6d14-41ef-bdaa-cf223a0f6f2b"
      unitRef="usd">16703000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS0zLTEtMS0xNTUxMw_ba504876-131b-4a48-b7e0-68cc252c0eed"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS01LTEtMS0xNTUxMw_96cbd83d-6d06-4e8d-9d06-c7f82b84732f"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0xLTEtMS0xMTI5OA_9578e354-e236-4cf1-920d-9c9aa23ce776"
      unitRef="usd">94674000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy0zLTEtMS0xMTI5OA_bb8990b9-7222-41c9-b0ce-da9c5ebd0c3f"
      unitRef="usd">94261000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNy01LTEtMS0xMTI5OA_cd9e4131-f3fc-4456-aed5-e02baffe05c2"
      unitRef="usd">99795000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOC0xLTEtMS0xMTI5OA_96a6848f-1b99-44f1-b621-408d68c52322"
      unitRef="usd">14146000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOC0zLTEtMS0xMTI5OA_7071fcd4-85c6-462c-a651-c9c770cc8b92"
      unitRef="usd">14182000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOC01LTEtMS0xMTI5OA_f9a55592-8969-4d62-b0f6-346a76955738"
      unitRef="usd">13156000</us-gaap:DepreciationAndAmortization>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS0xLTEtMS0xMTI5OA_38975538-0ecd-42d3-b706-3c8bd5d83de6"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS0zLTEtMS0xMTI5OA_1675b268-3285-4e99-97d8-5d57f74462c8"
      unitRef="usd">20351000</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfOS01LTEtMS0xMTI5OA_253c8b07-dee0-478d-bcac-4a5ba5db7f4d"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTAtMS0xLTEtMTEyOTg_0497e470-2968-4e16-9deb-ac3da7d7dca6"
      unitRef="usd">-6730000</nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions>
    <nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTAtMy0xLTEtMTEyOTg_07cbddd4-68ec-4e50-ae91-ea089baf3832"
      unitRef="usd">-3943000</nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions>
    <nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTAtNS0xLTEtMTEyOTg_399e94f0-abc4-45f3-816f-58c6fd97d6f3"
      unitRef="usd">11394000</nktr:AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTItMS0xLTEtMTEyOTg_e5dc9ddf-706a-4cab-b6d9-db7400216311"
      unitRef="usd">-12397000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTItMy0xLTEtMTEyOTg_8ab15f3a-53ce-482a-9991-6ff9c4406289"
      unitRef="usd">-1913000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTItNS0xLTEtMTEyOTg_5d9d8530-a04b-4fd2-b17c-309d63544eba"
      unitRef="usd">-6411000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTMtMS0xLTEtMTEyOTg_deebbc35-17b6-4a63-a682-9ae561bac1d7"
      unitRef="usd">509000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTMtMy0xLTEtMTEyOTg_a8362f0d-4054-4556-928c-cae3d51545e8"
      unitRef="usd">2627000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTMtNS0xLTEtMTEyOTg_9b48a314-29a1-4d9d-8496-541ad73a5428"
      unitRef="usd">1284000</us-gaap:IncreaseDecreaseInInventories>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTQtMS0xLTEtMTEyOTg_d182bdfc-983a-418f-aa83-d097a19a1ef3"
      unitRef="usd">-2340000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTQtMy0xLTEtMTEyOTg_3ead489b-c576-4ca8-b6be-4f9b4cff96c8"
      unitRef="usd">-2743000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTQtNS0xLTEtMTEyOTg_db2c2b47-8ddf-48d7-b01d-ba9eea803286"
      unitRef="usd">-13090000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTUtMS0xLTEtMTEyOTg_569dc6e3-bae8-43e6-8610-d6369df33ea0"
      unitRef="usd">2688000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTUtMy0xLTEtMTEyOTg_6514e487-096e-4eda-8015-51d7b806ec78"
      unitRef="usd">-4476000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTUtNS0xLTEtMTEyOTg_08b3ae13-8ce3-4c47-b6db-5479fb3f9182"
      unitRef="usd">-1190000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTYtMS0xLTEtMTEyOTg_591b947a-5828-49c7-ae68-cc2a8a3fd3d0"
      unitRef="usd">-11690000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTYtMy0xLTEtMTEyOTg_71c33919-a896-4f16-86a7-769d5cbea5f2"
      unitRef="usd">2382000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTYtNS0xLTEtMTEyOTg_65dc6bff-4c1b-4534-9833-9b7cb308d666"
      unitRef="usd">12967000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTctMS0xLTEtMTEyOTg_233445d9-1731-4174-ba9a-e399bcdcaaa7"
      unitRef="usd">1203000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTctMy0xLTEtMTEyOTg_49bdfd26-2252-4a5e-b54e-e510470287b2"
      unitRef="usd">4697000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTctNS0xLTEtMTEyOTg_ae752d6c-4e33-46a3-8542-f9759dcc18bb"
      unitRef="usd">1530000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTgtMS0xLTEtMTEyOTg_f957424f-39ed-4abb-8f81-5225fc23a5b9"
      unitRef="usd">-23524000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTgtMy0xLTEtMTEyOTg_dfb5350b-5fe7-4005-b397-805d0881650d"
      unitRef="usd">8644000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTgtNS0xLTEtMTEyOTg_35b39636-118f-4825-83ae-9091e867d181"
      unitRef="usd">4349000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTktMS0xLTEtMTEyOTg_6ec0a31c-4582-4463-8aeb-7c9ef0315330"
      unitRef="usd">-605000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTktMy0xLTEtMTEyOTg_a2fdaa3d-4bb5-4c78-9445-d27e9cc09f9d"
      unitRef="usd">-5516000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMTktNS0xLTEtMTEyOTg_c1499095-ceda-4e68-87c9-2def842b8cff"
      unitRef="usd">-16565000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjAtMS0xLTEtMTEyOTg_7f600b86-b16d-48bb-b467-d92213010448"
      unitRef="usd">-412660000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjAtMy0xLTEtMTEyOTg_81eccb73-d549-4ded-8ea9-7812d52ae57d"
      unitRef="usd">-313287000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjAtNS0xLTEtMTEyOTg_dd8ab7f7-563e-43b7-9a1d-831474060a17"
      unitRef="usd">-328681000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjItMS0xLTEtMTEyOTg_75bfcf66-68a0-4b75-bbeb-84e0f3be2a32"
      unitRef="usd">960689000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjItMy0xLTEtMTEyOTg_5a20c8ef-2e6f-4646-b83b-ee3c8d198e9a"
      unitRef="usd">987533000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjItNS0xLTEtMTEyOTg_c064afd4-d9e9-4611-8b2f-ee9aa960aa36"
      unitRef="usd">1380865000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjMtMS0xLTEtMTEyOTg_92b90b97-026f-406e-83c4-09583f780c8a"
      unitRef="usd">1166951000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjMtMy0xLTEtMTEyOTg_2a4260db-d1cb-4580-ba37-5317de5d1a41"
      unitRef="usd">1449304000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjMtNS0xLTEtMTEyOTg_79acefa1-4fbb-48b3-ba74-6bfc2a9c3e93"
      unitRef="usd">1614036000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjQtMS0xLTEtMTEyOTg_439f05fe-62c9-473c-92af-3467f9c9960d"
      unitRef="usd">11504000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjQtMy0xLTEtMTEyOTg_1b030a74-a7da-4f26-b0c7-08e5e42b2b29"
      unitRef="usd">41700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjQtNS0xLTEtMTEyOTg_f80a2cfd-edc0-4f1c-ac84-2c1b461bec49"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjUtMS0xLTEtMTEyOTg_d75745ab-7626-4d48-8776-baebec93083b"
      unitRef="usd">14989000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjUtMy0xLTEtMTEyOTg_ae0fe13b-3544-487b-87ac-e058f7281a01"
      unitRef="usd">7258000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjUtNS0xLTEtMTEyOTg_933c04cb-3777-4475-858a-95a0f713f6b3"
      unitRef="usd">26285000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjctMS0xLTEtMTEyOTg_a891af03-3405-442e-af5e-ad500b7a812d"
      unitRef="usd">202777000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjctMy0xLTEtMTEyOTg_71f766ee-bfaf-4262-a21c-ce21db03a96f"
      unitRef="usd">496213000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMjctNS0xLTEtMTEyOTg_1670f85f-fcbb-46b1-b2c1-f7b5368cf9f6"
      unitRef="usd">206886000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <nktr:SaleOfFutureRoyaltiesTransactionCosts
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzAtMC0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo4YjhhZTE5YjgyYTI0ZTVjYjYyNjRkMmQzMzczMmZlNV81MQ_fe2231ad-e724-47c2-b114-3830d8e9f96b"
      unitRef="usd">3800000</nktr:SaleOfFutureRoyaltiesTransactionCosts>
    <nktr:ProceedsFromSaleOfFutureRoyaltiesNet
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzAtMS0xLTEtMTEyOTg_156a1537-92c5-48ed-9f0f-6b8d264dbaa2"
      unitRef="usd">0</nktr:ProceedsFromSaleOfFutureRoyaltiesNet>
    <nktr:ProceedsFromSaleOfFutureRoyaltiesNet
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzAtMy0xLTEtMTEyOTg_a6680598-92c2-4845-818f-508ed8c602f6"
      unitRef="usd">146250000</nktr:ProceedsFromSaleOfFutureRoyaltiesNet>
    <nktr:ProceedsFromSaleOfFutureRoyaltiesNet
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzAtNS0xLTEtMTEyOTg_004b167d-ea5c-4931-98fe-b0c7fe49d61b"
      unitRef="usd">0</nktr:ProceedsFromSaleOfFutureRoyaltiesNet>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzEtMS0xLTEtMTEyOTg_908e546b-4cff-4eed-95ff-23414a799a47"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzEtMy0xLTEtMTEyOTg_f26694b2-16a7-4fc4-8b97-f84ed93390cf"
      unitRef="usd">250000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzEtNS0xLTEtMTEyOTg_5dc918ae-05a7-4672-9ed3-f4e0fdb036b4"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItMS0xLTEtMTMyMzI_ddb69855-da34-4b46-b71f-868e31ec1c0e"
      unitRef="usd">3000000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItMy0xLTEtMTMyMzk_67549080-51fd-4202-89c6-8a4b2d19c711"
      unitRef="usd">0</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItNS0xLTEtMTMyNDY_546fae13-d985-485e-b0e4-fdadf525b676"
      unitRef="usd">0</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItMS0xLTEtMTEyOTg_976ecad4-2c47-428f-aa14-75cf1c505bf5"
      unitRef="usd">33238000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItMy0xLTEtMTEyOTg_2c925ba1-98e0-43b6-8446-21ff16a4bc3e"
      unitRef="usd">23396000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzItNS0xLTEtMTEyOTg_0d7a2f08-03da-4bb4-94e9-f709d170d9e6"
      unitRef="usd">23355000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzMtMS0xLTEtMTEyOTg_3652e645-c043-4ec3-8570-65e6d7be8559"
      unitRef="usd">36238000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzMtMy0xLTEtMTEyOTg_8346e957-05bc-4dc0-9df2-2f451391341e"
      unitRef="usd">-80354000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzMtNS0xLTEtMTEyOTg_60a47580-4a3e-4149-94b6-4ac66debe91c"
      unitRef="usd">23355000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzQtMS0xLTEtMTEyOTg_03613112-695c-4b4a-a7e4-ff823132e2d6"
      unitRef="usd">-92000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzQtMy0xLTEtMTEyOTg_171a8bf1-fc4b-42b5-bf59-22bcd31607b3"
      unitRef="usd">20000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzQtNS0xLTEtMTEyOTg_ea5c04e7-e8f1-4a50-abb3-f95036972ea4"
      unitRef="usd">-102000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzUtMS0xLTEtMTEyOTg_1535c3b1-0fa7-47b2-82a5-fc656c733dcb"
      unitRef="usd">-173737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzUtMy0xLTEtMTEyOTg_0bfd1194-6c4e-47bb-9aff-3547256c366a"
      unitRef="usd">102592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzUtNS0xLTEtMTEyOTg_93b5f0d8-ec5e-49f5-9351-af4c67852fdd"
      unitRef="usd">-98542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzYtMS0xLTEtMTEyOTg_bc0e0971-e1ac-4fe5-9a52-c0d20738f789"
      unitRef="usd">198955000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i89a636947a9046a38a2ed739019eb13c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzYtMy0xLTEtMTEyOTg_11e9f675-c691-4d35-9297-8311121edccc"
      unitRef="usd">96363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7e86cae77d44493aad21052dab0a76b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzYtNS0xLTEtMTEyOTg_971c9d69-48fc-452a-a657-538d14fc0d5c"
      unitRef="usd">194905000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzctMS0xLTEtMTEyOTg_795a40e5-8fc1-4565-90aa-448c2be25349"
      unitRef="usd">25218000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzctMy0xLTEtMTEyOTg_3ac6388e-cbca-4ef2-9ec1-9126859140cd"
      unitRef="usd">198955000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i89a636947a9046a38a2ed739019eb13c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzctNS0xLTEtMTEyOTg_b120133e-1c1b-4535-8aa0-1d6c0369518d"
      unitRef="usd">96363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzktMS0xLTEtMTEyOTg_ad798c3b-1e35-4040-8de1-f021c7653d5d"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzktMy0xLTEtMTEyOTg_958ef441-81a7-49a8-8a90-7b000fcec3c4"
      unitRef="usd">9742000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfMzktNS0xLTEtMTEyOTg_c39396f4-0aa5-4faa-b787-f2192c95c85b"
      unitRef="usd">19199000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDAtMS0xLTEtMTEyOTg_a814bea9-865d-4110-bf75-faf59cf2e129"
      unitRef="usd">325000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDAtMy0xLTEtMTEyOTg_7c7f2554-4295-4161-8c68-c08b104f7ade"
      unitRef="usd">539000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDAtNS0xLTEtMTEyOTg_010e43df-8df9-4e2c-8044-0205b392d2a1"
      unitRef="usd">555000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDEtMS0xLTEtMTEyOTg_c0bbb956-284e-43c8-a863-4d7c3661b846"
      unitRef="usd">1057000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDEtMy0xLTEtMTEyOTg_cd9899f6-b415-4da9-9a72-7645aeed7c38"
      unitRef="usd">2133000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDEtNS0xLTEtMTEyOTg_15e8ecd4-f2ca-4585-8c78-ba1736c65ff0"
      unitRef="usd">57691000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDQtMS0xLTEtMjI1ODA_b8eb7205-8521-4190-b75c-2b094186d6f2"
      unitRef="usd">0</nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities>
    <nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDQtMy0xLTEtMjI1ODA_6aa383ea-b9c3-4914-a067-ad1b1bb5faf8"
      unitRef="usd">4000000</nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities>
    <nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84Mi9mcmFnOmQ5NmNhYzc3ZWZlNTQ5NTE4NTBlYmNhY2ZhNWU0ZDMwL3RhYmxlOmM2ZmUzODhlNDFiODQzMzY4MTI3M2NhMWE4Yzg3MDY3L3RhYmxlcmFuZ2U6YzZmZTM4OGU0MWI4NDMzNjgxMjczY2ExYThjODcwNjdfNDQtNS0xLTEtMjI1ODA_3e3a07d5-e09e-4303-8806-0eaf280dd716"
      unitRef="usd">0</nktr:NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwNDM_5beb9637-e82d-4045-af44-23a6c1876b53">Organization and Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At December&#160;31, 2021, we had approximately $798.8 million in cash and investments in marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation, Principles of Consolidation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Nektar Therapeutics Europe GmbH, Nektar Therapeutics (India) Private Limited (Nektar India),  Inheris Biopharma, Inc. (Inheris) and certain other entities in Europe. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in the valuation of our development derivative liability as further described in Note 6; our assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at estimated fair value. The disclosed fair value related to our cash equivalents and investments is based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. Development derivative liability is recorded at its estimated fair value based on management&#x2032;s estimates of several unobservable inputs, including the probabilities of success of ongoing clinical trials and various other inputs described above and in Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the years ended December&#160;31, 2021 and 2020, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cash and investments are held or issued by financial institutions that management believes are of high credit quality. However, they are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have seen credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#x2019; equity as accumulated other comprehensive income (loss). We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Significant Customer Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments, as well as reimbursable costs from collaborative research and development agreements. Our accounts receivable included $21.4 million and $38.7 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS) as of December&#160;31, 2021 and December&#160;31, 2020, respectively. The remaining accounts receivable related primarily to product sales. We perform a regular review of our partners&#x2019; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Significant Supplier Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We state property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjA3OTA_047a9ea0-7fde-4ef1-8171-92c0f31dcfa0"&gt;three&lt;/span&gt; to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting units equals its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see Note 7 for additional information regarding our leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty revenue, including Non-cash royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2021, we have sold our rights to receive sales-based royalties for CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,  MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as further described in Note 8. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our aggregate royalty and non-cash royalty revenue of $77.7&#160;million, $79.6&#160;million and $77.5&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively, represents revenue for granting licenses for which we had satisfied in prior periods. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. As described further in Note 11, we recognized $50.0&#160;million of milestones in the year ended December 31, 2020 because we had previously satisfied the performance obligation. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Assets and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#x2019;s plan for the wind-down of Inheris and the NKTR-181 program. As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs), performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs, PSUs and ESPP shares on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For options and RSUs that vest upon the achievement of performance milestones, we recognize expense provided that we believe that the performance milestones are probable of achievement, and we estimate the vesting period based on our evaluation of the  estimated date of achievement of these milestones. For PSUs, we recognize expense based on the grant date fair value regardless of whether the market condition is met. Additionally, we do not adjust the expense based on the number of shares ultimately issued, which may be higher or lower than the grant amount. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#x2019; stock to the index. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The fair value of an RSU is equal to the closing price of our common stock on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented. For the years ended December 31, 2021,  2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded weighted average outstanding stock options, RSUs and PSUs totaling 18.4 million, 17.4 million and 17.9 million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Comprehensive loss is the change in stockholders&#x2019; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our comprehensive loss includes our net loss, gains and losses from the foreign currency translation of the assets and liabilities of our foreign subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <nktr:OrganizationPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzY_e917d6b8-c582-48a6-a9d8-1c8cdfe84aee">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer, autoimmune disease and viral infections.&lt;/span&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</nktr:OrganizationPolicyTextBlock>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTA0OA_d3fa843a-88f4-468f-b27e-58f8c12b1081"
      unitRef="usd">798800000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzc_a6dcdec0-2c55-4777-be40-0fd85d1c536d">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation, Principles of Consolidation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Nektar Therapeutics Europe GmbH, Nektar Therapeutics (India) Private Limited (Nektar India),  Inheris Biopharma, Inc. (Inheris) and certain other entities in Europe. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to the selling prices of performance obligations and amounts of variable consideration in collaboration agreements, royalty revenue, and other assumptions required for revenue recognition as described further below; the net realizable value of inventory; the impairment of investments, goodwill and long-lived assets; contingencies, accrued clinical trial, contract manufacturing and other expenses; non-cash royalty revenue and non-cash interest expense from our liabilities related to our sales of future royalties; assumptions used in the valuation of our development derivative liability as further described in Note 6; our assumptions used in stock-based compensation; and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, we assess estimates each period, update them to reflect current information, and will generally reflect any changes in estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwNDQ_5d9b596c-8c00-47fb-9550-1587c610b5b6">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzA_1335c46d-6762-40f1-816a-033a1e25fdae">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recorded amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at estimated fair value. The disclosed fair value related to our cash equivalents and investments is based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. Development derivative liability is recorded at its estimated fair value based on management&#x2032;s estimates of several unobservable inputs, including the probabilities of success of ongoing clinical trials and various other inputs described above and in Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC 820-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For the years ended December&#160;31, 2021 and 2020, there were no transfers between Level 1 and Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzE_8d4afa71-decd-4676-abaa-412987c8e77d">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We consider all investments in marketable securities with an original maturity of three months or less when purchased to be cash equivalents. We classify investments in securities with remaining maturities of less than one year, or where our intent is to use the investments to fund current operations or to make them available for current operations, as short-term investments. We classify investments in securities with remaining maturities of over one year as long-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cash and investments are held or issued by financial institutions that management believes are of high credit quality. However, they are exposed to credit risk in the event of default by the third parties that hold or issue such assets. Our investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds and places restrictions on maturities and concentrations by type and issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industry. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have seen credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments are designated as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders&#x2019; equity as accumulated other comprehensive income (loss). We review our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, we recognize a loss in our Consolidated Statement of Operations, whereas if the decline in fair value is not due to credit-related factors, we recognize the loss in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&#160;&#160;&#160;&#160;We include coupon interest on securities classified as available-for-sale, as well as amortization of premiums and accretion of discounts to maturity, in interest income. The cost of securities sold is based on the specific identification method.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <nktr:AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzI_9ca4770a-1299-4ac0-898e-9d3ad72a8c96">Accounts Receivable and Significant Customer Concentrations&#160;&#160;&#160;&#160;Our customers are primarily pharmaceutical and biotechnology companies that are primarily located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), other contingent payments, as well as reimbursable costs from collaborative research and development agreements.We perform a regular review of our partners&#x2019; credit risk and payment histories when circumstances warrant, including payments made subsequent to year-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.</nktr:AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock>
    <nktr:NetExpenseReimbursementsFromCollaborationPartner
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfODg1Mw_46678e18-bacc-4c8c-ad39-fe836d627347"
      unitRef="usd">21400000</nktr:NetExpenseReimbursementsFromCollaborationPartner>
    <nktr:NetExpenseReimbursementsFromCollaborationPartner
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTY0OTI2NzQ0ODIyNDU_98109d9d-23d2-4a0f-8e5f-e82ab5050d10"
      unitRef="usd">38700000</nktr:NetExpenseReimbursementsFromCollaborationPartner>
    <nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMjI_532975cc-c4fe-4398-981f-0d7deb322c53">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Significant Supplier Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We generally manufacture inventory upon receipt of firm purchase orders from our collaboration partners, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. Inventory includes direct materials, direct labor, and manufacturing overhead, and we determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities when we purchase or manufacture it. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;</nktr:InventoryAndSignificantSupplierConcentrationsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTA5OTUxMTYzNTk5Nzc_e91ef43d-9aba-4c03-a53b-990148512d31">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We state property, plant and equipment at cost, net of accumulated depreciation. We capitalize major improvements and expense maintenance and repairs as incurred. We generally recognize depreciation on a straight-line basis. We depreciate manufacturing, laboratory and other equipment over their estimated useful lives of generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjA3OTA_047a9ea0-7fde-4ef1-8171-92c0f31dcfa0"&gt;three&lt;/span&gt; to ten years, depreciate buildings over the estimated useful life of generally twenty years and amortize leasehold improvements over the shorter of the estimated useful lives or the remaining term of the related lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Goodwill represents the excess of the price paid for another entity over the fair value of the assets acquired and liabilities assumed in a business combination. We are organized in one reporting unit and evaluate the goodwill for the Company as a whole. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment at least annually in the fourth quarter of each year using an October&#160;1 measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated discounted net cash flows associated with the asset. In the case of goodwill impairment, we compare the carrying value of the reporting unit to its fair value, which we generally measure using market capitalization for our single reporting unit. If an impairment exists, we write down goodwill such that the carrying value of the reporting units equals its fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8d4b5ee692844d22bd172e136bf853f3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTA5OTUxMTYzNTk5Nzg_fd27603a-5e84-4941-a21f-bf46385f70fb">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i217337f2d85e411fa6cca2f9cc353fcb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjA4NzM_3a20333a-2099-4eae-91a1-bb274c2d6118">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTc1OTIxODYxMjExODc_056b89af-e433-49ca-8bae-6bf7f5dd96e0"
      unitRef="reporting_unit">1</nktr:NumberOfReportingUnitsToEvaluateGoodwillForImpairment>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMjE_de4e98d5-40fa-4106-bad4-2d3fb0cc564a">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. We have elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our facilities leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term. We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see Note 7 for additional information regarding our leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMjY_99f37107-550b-4757-8549-f4191f4b82be">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwNDc_fa0763c4-d124-419f-9332-464005aabf2b">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers. We recognize costs related to shipping and handling of product to customers in cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty revenue, including Non-cash royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for our collaboration arrangements that include sales-based royalties, we have granted our collaboration partner a license to our intellectual property.  Pursuant to these arrangements, our collaboration partners are typically obligated to pay a royalty that is based on the net sales of their approved drugs that are sold in the countries where we have intellectual property rights covering their drugs.  As of December 30, 2021, we have sold our rights to receive sales-based royalties for CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,  MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as further described in Note 8. For collaboration arrangements that include sales-based royalties, we have concluded that the license is the predominant item to which the royalties relate, which include commercial milestone payments based on the level of sales. Accordingly, we recognize royalty revenue when the underlying sales occur based on our best estimates of sales of the drugs. Our aggregate royalty and non-cash royalty revenue of $77.7&#160;million, $79.6&#160;million and $77.5&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively, represents revenue for granting licenses for which we had satisfied in prior periods. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;License Grants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Milestone Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. As described further in Note 11, we recognized $50.0&#160;million of milestones in the year ended December 31, 2020 because we had previously satisfied the performance obligation. If we update the transaction price before the triggering event, we recognize the increase in the transaction price as a contract asset. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and Development Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia35126ada49c4aa5b6a31fd74e38aa13_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTY0OTI2NzQ0NzI5OTE_a9c5f31c-652a-41c5-bd47-080c1cab7d34"
      unitRef="usd">77700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ee5e0af22004d498eafd130a613cee6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTY0OTI2NzQ0NzMxMTA_54b2fdf3-d491-4ef8-8bea-b8ca1ef3bae6"
      unitRef="usd">79600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib29439b8ce094e458c12e418a5f1055e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTY0OTI2NzQ0NzMxMjU_4c3953be-643a-4c80-bf61-bc1bf4add9ca"
      unitRef="usd">77500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nktr:SalesMilestoneRevenue
      contextRef="i57d6518d703e4cdba742d40dbc46673d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfODI0NjMzNzI2NTI5NQ_8d70991b-958a-416c-ac04-d4d6b3646e20"
      unitRef="usd">50000000</nktr:SalesMilestoneRevenue>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzQ_3b678c19-6f5a-411e-b3fa-45a03686e69f">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development activities for our drug candidates and technology development and for certain third parties under collaboration agreements. For our drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated unbilled costs of our clinical study activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients and completion of certain clinical trial activities. We generally recognize costs associated with the start-up and reporting phases of the clinical trials as incurred. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third party vendors, including our contract research organizations. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses ratable over the service period, as we believe that this methodology may be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process to be sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us in the future which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMjc_67d61304-6318-4b32-997c-5c6c24c6d246">Impairment of Assets and Other Costs for Terminated ProgramOn January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#x2019;s plan for the wind-down of Inheris and the NKTR-181 program.</nktr:ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock>
    <nktr:WriteOffOfPrepayment
      contextRef="i8d18817442a34679beeb50708361c836_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMjk0NTA_95a1a7b2-f6dd-4283-a141-cb73e248bace"
      unitRef="usd">19700000</nktr:WriteOffOfPrepayment>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i8d18817442a34679beeb50708361c836_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMjk1NTI_314ade53-eab0-45b4-a485-ccbada8b7592"
      unitRef="usd">25500000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMTU_eedaf040-d26d-4158-a086-791abaa1898b">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Stock-based compensation arrangements include grants of stock options, restricted stock units (RSUs), performance stock units (PSUs) under our equity incentive plans, as well as shares issued under our Employee Stock Purchase Plan (ESPP), through which employees may purchase our common stock at a discount to the market price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We expense the grant date fair value of options, RSUs, PSUs and ESPP shares on a straight-line basis over the requisite service periods in our Consolidated Statements of Operations and recognize forfeitures of options, RSUs and PSUs as they occur. For options and RSUs that vest upon the achievement of performance milestones, we recognize expense provided that we believe that the performance milestones are probable of achievement, and we estimate the vesting period based on our evaluation of the  estimated date of achievement of these milestones. For PSUs, we recognize expense based on the grant date fair value regardless of whether the market condition is met. Additionally, we do not adjust the expense based on the number of shares ultimately issued, which may be higher or lower than the grant amount. We report expense amounts in cost of goods sold, research and development expense, and general and administrative expense based on the function of the applicable employee. Stock-based compensation charges are non-cash charges and have no effect on our reported cash flows. We estimate the grant date fair value of our stock-based compensation awards as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;We use the Black-Scholes option pricing model for the respective grant to determine the estimated fair value of the option on the date of grant (grant date fair value) and the estimated fair value of common stock purchased under the ESPP. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including but not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The number of shares issuable under PSUs is based on our total shareholder return as compared to other companies within the Nasdaq biotechnology index over the measurement period and may be capped based on our absolute total shareholder return over such period. We use the Monte Carlo simulation model to determine the estimated grant date fair value. The Monte Carlo simulation model incorporates assumptions such as the volatility of our stock, the volatility of the stock of other peer companies within the index, and the correlation of both our stock and our peer companies&#x2019; stock to the index. &lt;/span&gt;&lt;/div&gt;&#x2022;The fair value of an RSU is equal to the closing price of our common stock on the grant date.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTA5OTUxMTYzNTk5ODA_af317193-4262-433d-8dbf-070a1813ac38">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We account for income taxes under the liability method. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax reporting bases of assets and liabilities, measured using enacted tax rates and laws that we expect to be in effect when we expect the differences to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We record a valuation allowance against deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. When we establish or reduce the valuation allowance related to the deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period we make such determination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We utilize a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount of benefit, determined on a cumulative probability basis, that is more than 50% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMTY_538b9753-fd3d-4815-ac34-9e95edb55d65">Net Loss Per Share&#160;&#160;&#160;&#160;For all periods presented in the Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8fd12c28a1fc4527927d94cbb3fecda6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzQxNzU_87812c34-dd98-404c-8c7a-cb3a6e4f11f8"
      unitRef="shares">18400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ief3930a5607f46ba9969d019065ed3bc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMTY0OTI2NzQ0NzE4Mjc_8fcd695d-3789-400f-bc25-a29c5722b36e"
      unitRef="shares">17400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i255350b9923e4b0f90bb25e7e8e6ea4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzQxODI_48b45b65-5ad2-449d-97d0-16cfcb85e317"
      unitRef="shares">17900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwMzU_c4573a0c-5a15-4011-914e-b3fa7d2e5ffc">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Comprehensive loss is the change in stockholders&#x2019; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. Our comprehensive loss includes our net loss, gains and losses from the foreign currency translation of the assets and liabilities of our foreign subsidiaries, and unrealized gains and losses on investments in available-for-sale securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml84OC9mcmFnOmJiOTIxYjQzMzk0NjQ0N2Q4ZGE0ZjU2YzNkZWNkYTYyL3RleHRyZWdpb246YmI5MjFiNDMzOTQ2NDQ3ZDhkYTRmNTZjM2RlY2RhNjJfMzkwNDI_194b8a15-e590-464b-bd1c-7e4f6be9c14f">&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed recent accounting pronouncements and concluded they are either not applicable to us or that we do not expect adoption to have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjU1OA_cfcea5a8-b1ce-4888-b235-1f1240873e1f">Cash and Investments in Marketable Securities&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. All of our long-term investments as of December&#160;31, 2021 and 2020 had maturities between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTU0_0003ae67-eceb-4b3d-a922-f92cdc2a62bd"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTU0_c526c77b-95f7-450d-b638-74b09846bea6"&gt;one&lt;/span&gt;&lt;/span&gt; and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2021 and 2020, we sold available-for-sale securities totaling $11.5&#160;million and $41.7&#160;millions, respectively. We did not sell any available-for-sale securities in the year ended December 31, 2019. Gross realized gains and losses on those sales were not significant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report our accrued interest receivable, which totaled $1.4&#160;million and $5.1&#160;million at December&#160;31, 2021 and December&#160;31, 2020, respectively, in other current assets on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;At December&#160;31, 2020, our gross unrealized gains and losses totaled $1.1&#160;million and $0.2&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At both December&#160;31, 2021 and 2020, we had letter of credit arrangements in favor of our landlords and certain vendors totaling $8.1 million. These letters of credit are secured by investments of similar amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjU1Mw_01876556-f6f6-4080-b05b-3585b677f5dc">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfMi0xLTEtMS0xMTI5OA_c7114042-5315-4626-a732-7a8f2dff350a"
      unitRef="usd">25218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfMi0zLTEtMS0xMTI5OA_e200782b-17f8-47da-9505-d519aa76d664"
      unitRef="usd">198955000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfMy0xLTEtMS0xMTI5OA_718b6149-d770-48f0-9217-6235d5417607"
      unitRef="usd">708737000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfMy0zLTEtMS0xMTI5OA_3be10219-b233-4659-8bf6-bb2f3186eefe"
      unitRef="usd">862941000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfNC0xLTEtMS0xMTI5OA_20889c9d-c41c-450d-b354-ba42e0d83e6a"
      unitRef="usd">64828000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfNC0zLTEtMS0xMTI5OA_1b748d46-a94a-4447-8e63-acbe94decca1"
      unitRef="usd">136662000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfNS0xLTEtMS0xMTI5OA_9252ad8a-03d0-4c33-8e2f-56bf672340c3"
      unitRef="usd">798783000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmJlN2NlNDRlYWY4ODRhNDJhMDY4OWI1NmZhYzFjYmMwL3RhYmxlcmFuZ2U6YmU3Y2U0NGVhZjg4NGE0MmEwNjg5YjU2ZmFjMWNiYzBfNS0zLTEtMS0xMTI5OA_0be2731f-da81-4c4c-a212-de40485b52a2"
      unitRef="usd">1198558000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i76ba7fa3878f41e9baee05ebb5353b2b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTYx_85cf2432-13ef-4855-9943-767b29077267">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="idb1efb0d79f74d20bc94eefb71431fe8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfNTYx_b86c9272-6077-4444-82bf-de2bbed4300f">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMzI5ODUzNDg4ODA4NQ_5419bec3-0f40-4bd9-abb6-fa3850afe7d7"
      unitRef="usd">11500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMzI5ODUzNDg4ODA5NQ_0e198e32-2fe6-42b3-83af-2c85c1ec4869"
      unitRef="usd">41700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMzg0ODI5MDcwMTQ4NA_7e6572a8-471c-482b-b36f-9fb2e980ed8c"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:InterestReceivableCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfOTU5_8a63bd09-e29a-4927-afd6-bef2329265a4"
      unitRef="usd">1400000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfOTY2_d561be33-a0bc-4938-b78b-b91c5d1b43ff"
      unitRef="usd">5100000</us-gaap:InterestReceivableCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjU1NQ_cab7de91-6cdf-461b-8feb-6077dd9e3f78">Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:29pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i16f975e3020e40db8824c97ec642e248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMi0zLTEtMS0xMTI5OA_d4637de1-8b29-4823-8abf-28b6189d413f"
      unitRef="usd">278475000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i16f975e3020e40db8824c97ec642e248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMi01LTEtMS0xMTI5OA_67bdc7b1-ab5b-4abc-9659-7a519e907b54"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i16f975e3020e40db8824c97ec642e248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMi03LTEtMS0xMTI5OA_daae9b9a-f232-4123-92ee-27e6ed49c10a"
      unitRef="usd">361000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16f975e3020e40db8824c97ec642e248_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMi05LTEtMS0xMTI5OA_cdbbd8be-ee60-4d66-ad2c-c85e0a219ec0"
      unitRef="usd">278121000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb32306fdad746dd9da19728ea7271ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMi0xMS0xLTEtMTEyOTg_220f1962-0a79-4852-918e-c6813d902625"
      unitRef="usd">687469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i38f44a6188024f06a84a6f4b3d8acfbb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMy0zLTEtMS0xMTI5OA_3df67151-2759-4021-9d98-46ce94199309"
      unitRef="usd">478932000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i38f44a6188024f06a84a6f4b3d8acfbb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMy01LTEtMS0xMTI5OA_0490281b-0432-4f0d-aa86-9fe76d44ac52"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i38f44a6188024f06a84a6f4b3d8acfbb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMy03LTEtMS0xMTI5OA_19300527-af8e-41c8-a7d8-2c656120bdd6"
      unitRef="usd">308000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i38f44a6188024f06a84a6f4b3d8acfbb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMy05LTEtMS0xMTI5OA_db9a35f7-4461-4cda-acad-4a77e0b0aa6d"
      unitRef="usd">478629000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a53b7985d374ead811b6e5a7dd2154f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfMy0xMS0xLTEtMTEyOTg_c38eb8f6-7b6d-4c97-a054-e067786a3ae0"
      unitRef="usd">313497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i51e7dc8250694c90b0688660e3c7810b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNC0zLTEtMS0xMTI5OA_79a50f3b-ecae-4732-b223-70c56fbc064d"
      unitRef="usd">5880000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i51e7dc8250694c90b0688660e3c7810b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNC01LTEtMS0xMTI5OA_7fd1502c-3b10-4cd4-a1fa-4eb3317c8078"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i51e7dc8250694c90b0688660e3c7810b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNC03LTEtMS0xMTI5OA_5d34b33a-52ce-4e3a-8c70-a7e082a04b50"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51e7dc8250694c90b0688660e3c7810b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNC05LTEtMS0xMTI5OA_21f95854-7ef8-40f0-8ec1-a5bb2b69d899"
      unitRef="usd">5875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie572f0f09594489993a50e2018463f9e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNC0xMS0xLTEtMTEyOTg_186a24ef-fdb0-4fb5-977e-7e4166929b56"
      unitRef="usd">2382000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNS0zLTEtMS0xMTI5OA_a9dcbb7c-b384-4404-8cb8-081ade9c882b"
      unitRef="usd">763287000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNS01LTEtMS0xMTI5OA_b975a3e0-6f12-463c-822d-616061d10669"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNS03LTEtMS0xMTI5OA_f06e6e64-b6ac-4f1e-8212-116c0e099f96"
      unitRef="usd">674000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNS05LTEtMS0xMTI5OA_6999760c-65a6-4630-8aeb-4406b4c3af00"
      unitRef="usd">762625000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNS0xMS0xLTEtMTEyOTg_e2c7f180-e732-47fb-9cb7-58e7af4930be"
      unitRef="usd">1003348000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ibe4e66cfc3c244c896b83266e392cd87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNi05LTEtMS0xMTI5OA_3abe657c-beee-46f1-8f58-e52a743a54a8"
      unitRef="usd">23968000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0e5ad5ce7ba243e78803676a3ada6929_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNi0xMS0xLTEtMTEyOTg_c76d32b2-8621-4895-b320-a0bc758f353a"
      unitRef="usd">179302000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icbab848955664506b7524f1830aca69c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNy05LTEtMS0xMTI5OA_10f30504-4fe6-4288-bd2e-02a6d077c4fc"
      unitRef="usd">10940000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia01507cb6301463b804b5486907c00f4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfNy0xMS0xLTEtMTEyOTg_014d3f53-4abb-40f2-8646-14b4d2b93a7b"
      unitRef="usd">9623000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfOC05LTEtMS0xMTI5OA_5d9ccc23-586e-473d-b212-bbca0d3828a3"
      unitRef="usd">1250000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfOC0xMS0xLTEtMTEyOTg_71d8fada-aac0-4f89-b0fd-aa99b15a125b"
      unitRef="usd">6285000</us-gaap:Cash>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfOS05LTEtMS0xMTI5OA_1b156f5a-ad84-479a-bff1-0b99cec1d2be"
      unitRef="usd">798783000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RhYmxlOmFjZGFiMDQwODJmMTRlMGQ5ZWEwMzNlYTRhZWQ3N2NmL3RhYmxlcmFuZ2U6YWNkYWIwNDA4MmYxNGUwZDllYTAzM2VhNGFlZDc3Y2ZfOS0xMS0xLTEtMTEyOTg_8cadea41-ad46-48bc-82e1-b7b99843f0eb"
      unitRef="usd">1198558000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjMyOA_dcf3bf92-10b2-403b-b267-4e7853da83e2"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjMzNQ_2fea6ddb-595e-4f68-ac5f-d074199649bd"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjQ1OQ_8f0cc5aa-0d58-4191-88d0-fda23fb148b8"
      unitRef="usd">8100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85MS9mcmFnOjIwOWQ4NWI4OGYwOTQxZTE5NmM2NmZiNzk0ZDY5NmIwL3RleHRyZWdpb246MjA5ZDg1Yjg4ZjA5NDFlMTk2YzY2ZmI3OTRkNjk2YjBfMjQ1OQ_a83a0b03-0079-41c6-a2f8-0c961c115264"
      unitRef="usd">8100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RleHRyZWdpb246ZjY1ZjlhZTI5ZGYwNDU2OWJjYjZjN2M1OGYxYWM3ZDFfNzk_9578d656-c35e-4889-9b20-fe25980fa5ab">Inventory&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RleHRyZWdpb246ZjY1ZjlhZTI5ZGYwNDU2OWJjYjZjN2M1OGYxYWM3ZDFfODA_f820c9d4-252b-4497-a63a-577a710352ba">Inventory consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfMi0xLTEtMS0xMTI5OA_5580a0b8-b326-43cd-8c34-ef2b502c68a0"
      unitRef="usd">3166000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfMi0zLTEtMS0xMTI5OA_d970d167-5b24-4694-b2e3-699bd1c2e240"
      unitRef="usd">2422000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfMy0xLTEtMS0xMTI5OA_8828fd80-d493-4b60-be8e-b984cb9b432e"
      unitRef="usd">9342000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfMy0zLTEtMS0xMTI5OA_24d0d78a-2e20-4ae5-a139-1070f813538d"
      unitRef="usd">10703000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfNC0xLTEtMS0xMTI5OA_54d0017d-a12d-4373-90fa-f0380f034423"
      unitRef="usd">3293000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfNC0zLTEtMS0xMTI5OA_5c94d2b4-524c-46c6-8073-541d81bbf9cd"
      unitRef="usd">2167000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfNS0xLTEtMS0xMTI5OA_25b63123-406c-4f2b-8060-afe9581e16a2"
      unitRef="usd">15801000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85NC9mcmFnOmY2NWY5YWUyOWRmMDQ1NjliY2I2YzdjNThmMWFjN2QxL3RhYmxlOjFhNWRhODc4Njg4MzRlZTc4YmVjZjRiYTdlZWNjNjIyL3RhYmxlcmFuZ2U6MWE1ZGE4Nzg2ODgzNGVlNzhiZWNmNGJhN2VlY2M2MjJfNS0zLTEtMS0xMTI5OA_cd6d87e2-1d00-4a08-b3a6-79764bba81e1"
      unitRef="usd">15292000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RleHRyZWdpb246ZjZhNTYwNmM1ZTY0NGY2MmEzYmMzNTg0NTNmZmZkMTlfNjc2_03e7a2f3-78a6-4e1f-b301-7f7b75b688f9">Property, Plant and Equipment&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Property, plant and equipment consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Building and leasehold improvements include our manufacturing, research and development and administrative facilities and the related improvements to these facilities. Laboratory and manufacturing equipment include assets that support both our manufacturing and research and development efforts. Construction-in-progress includes assets being built to enhance our manufacturing and research and development efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Depreciation and amortization expense for property, plant and equipment for the years ended December&#160;31, 2021, 2020, and 2019 was $13.0 million, $12.5 million, and $11.0 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RleHRyZWdpb246ZjZhNTYwNmM1ZTY0NGY2MmEzYmMzNTg0NTNmZmZkMTlfNjc3_42b9b59e-b4a6-4c25-b059-e12c28daade2">Property, plant and equipment consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="ia4e094fd9a7d4fc2abfa5a035a57ec8f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMi0xLTEtMS0xMTI5OA_ad567efe-79d8-46ea-81db-9fd58b52c93e"
      unitRef="usd">97385000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i9b0eefc7a17f43a49c7d5e3ddf06a052_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMi0zLTEtMS0xMTI5OA_ced0b81c-1718-497a-b152-aad106a30694"
      unitRef="usd">92977000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i72222465a5784d0f8b7df22ece9a04bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMy0xLTEtMS0xMTI5OA_4223e2f1-bf4a-44f1-a86a-0d294f825b78"
      unitRef="usd">42704000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i9f9318818cfa4595b929b1a68fe6e107_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMy0zLTEtMS0xMTI5OA_e673c7ef-7dc2-4ba2-a325-776f4a383fa1"
      unitRef="usd">40121000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="ia1773cfeb2884095bf5d3d8360db3e44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNC0xLTEtMS0xMTI5OA_dbd57fc6-3c17-499b-843c-12b3aaeed433"
      unitRef="usd">28829000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i58c7a174caa0406d9fb512ac548781a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNC0zLTEtMS0xMTI5OA_99eb91fd-909d-4358-9a66-236e0f8ffe61"
      unitRef="usd">28684000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i69cc5696809542c890b6fc09c58cab17_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNS0xLTEtMS0xMTI5OA_381a62e6-448b-40a1-8267-08b88809038d"
      unitRef="usd">22374000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="icbd78d2a576c437caf2eb6a175e66c00_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNS0zLTEtMS0xMTI5OA_27cbc066-8ab6-4702-bf46-bfebd6aa64ab"
      unitRef="usd">21796000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="iab142e35c42244cbb7c910e1ada05075_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNi0xLTEtMS0xMTI5OA_d3ffe330-30fa-4844-87b0-db27c1acbe15"
      unitRef="usd">10094000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i5d44c99d9de54043985c7720d72c53f7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNi0zLTEtMS0xMTI5OA_741adb2c-0659-4f7c-8f97-1313568c1523"
      unitRef="usd">9872000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNy0xLTEtMS0xMTI5OA_de076e28-4ebc-44af-a764-2a44e42a6bae"
      unitRef="usd">201386000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <nktr:DepreciablePropertyPlantAndEquipmentGross
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfNy0zLTEtMS0xMTI5OA_c9fb028b-d7bc-4413-9f6e-521c336726a3"
      unitRef="usd">193450000</nktr:DepreciablePropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfOC0xLTEtMS0xMTI5OA_30b755b8-0cf0-4518-bfb7-e408853c5645"
      unitRef="usd">148039000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfOC0zLTEtMS0xMTI5OA_7bed803d-7ed8-467f-b325-8a82b57a5ded"
      unitRef="usd">138488000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <nktr:DepreciablePropertyPlantAndEquipmentNet
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfOS0xLTEtMS0xMTI5OA_9410946c-e9cc-425d-bf14-4b6298eb9554"
      unitRef="usd">53347000</nktr:DepreciablePropertyPlantAndEquipmentNet>
    <nktr:DepreciablePropertyPlantAndEquipmentNet
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfOS0zLTEtMS0xMTI5OA_26ca192e-aca4-4f86-948b-466b899090db"
      unitRef="usd">54962000</nktr:DepreciablePropertyPlantAndEquipmentNet>
    <us-gaap:ConstructionInProgressGross
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMTAtMS0xLTEtMTEyOTg_4a4f4d6d-cff4-4068-b727-475f787473ba"
      unitRef="usd">7163000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMTAtMy0xLTEtMTEyOTg_e1c62d2e-8728-474d-bc19-2805862995b6"
      unitRef="usd">4700000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMTEtMS0xLTEtMTEyOTg_7a00f9c5-c53e-440e-af87-35d05b9e4a7f"
      unitRef="usd">60510000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RhYmxlOjUzYWI2Mjg4MWZlMzQ3ZmFiOTllMTg5OTc0YzQyZmU1L3RhYmxlcmFuZ2U6NTNhYjYyODgxZmUzNDdmYWI5OWUxODk5NzRjNDJmZTVfMTEtMy0xLTEtMTEyOTg_6c7730a6-8e2a-455a-9ba3-026897597b14"
      unitRef="usd">59662000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RleHRyZWdpb246ZjZhNTYwNmM1ZTY0NGY2MmEzYmMzNTg0NTNmZmZkMTlfNjQ3_8474d6b2-f6f8-498c-b305-695ab24aae52"
      unitRef="usd">13000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RleHRyZWdpb246ZjZhNTYwNmM1ZTY0NGY2MmEzYmMzNTg0NTNmZmZkMTlfNjUx_2d8840f7-ab37-4774-a85e-85a0f0117bb0"
      unitRef="usd">12500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml85Ny9mcmFnOmY2YTU2MDZjNWU2NDRmNjJhM2JjMzU4NDUzZmZmZDE5L3RleHRyZWdpb246ZjZhNTYwNmM1ZTY0NGY2MmEzYmMzNTg0NTNmZmZkMTlfNjU5_652d98f7-3f84-43d1-b55e-eac4235579c2"
      unitRef="usd">11000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzExNTI_09e15b18-28eb-44c5-b216-c77a5ea5c30b">Senior Secured Notes&#160;&#160;&#160;&#160;On October 5, 2015, we completed the sale and issuance of $250.0&#160;million in aggregate principal amount of 7.75% senior secured notes due 2020 (the Notes). The Notes bore interest at a rate of 7.75% per annum and were to mature on October 5, 2020. On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $250.0&#160;million and accrued interest of $4.8&#160;million.</us-gaap:LongTermDebtTextBlock>
    <us-gaap:SeniorNotes
      contextRef="i4580a99794e6481fb70ca26feccaa301_I20151005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzk0_618ad44b-6626-4e36-bccc-1a43673a773c"
      unitRef="usd">250000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4580a99794e6481fb70ca26feccaa301_I20151005"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzEzMA_ee1014f1-569c-438d-a469-a3ee333182a4"
      unitRef="number">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4580a99794e6481fb70ca26feccaa301_I20151005"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzMyMw_08c99bfc-dfe9-4a93-89b5-15aaefddbaf3"
      unitRef="number">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i3a1cba01aa4941709dccf7ddad45a548_D20200413-20200413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzEwMzQ_26896866-870d-44d2-b6bc-5d9826c0fb07"
      unitRef="usd">250000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:InterestReceivable
      contextRef="i69f84d8d2acb4dbabece7f5d1ab1fdeb_I20200413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDAvZnJhZzowZWY1ZmIwNzZjMTA0NDBiYjI5NWFkNjEzZWQyODE4ZS90ZXh0cmVnaW9uOjBlZjVmYjA3NmMxMDQ0MGJiMjk1YWQ2MTNlZDI4MThlXzEwNjE_a0e55484-8440-4ffc-97fe-f5c11bb96812"
      unitRef="usd">4800000</us-gaap:InterestReceivable>
    <nktr:DevelopmentDerivativeLiabilityTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNDUz_d93ee9d1-cff5-434e-8d49-e6b9c368c596">Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2021, we entered into a co-development agreement (the SFJ Agreement) with SFJ Pharmaceuticals XII, L.P., a SFJ Pharmaceuticals Group company (SFJ), pursuant to which SFJ will pay up to $150.0&#160;million in committed funding to support a Phase 2/3 study of bempegaldesleukin in combination with Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (the SCCHN Clinical Trial) whose tumors express PD-L1 (the SCCHN Indication). SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth. On February 11, 2021, we entered into a collaboration agreement with MSD International GmbH (MSD), an affiliate of Merck, Sharp &amp;amp; Dohme, pursuant to which MSD will provide Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at no cost for use in the SCCHN Clinical Trial but will not bear any other costs of the trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SFJ will have primary responsibility for the clinical trial management of the SCCHN Clinical Trial, and we will be the sponsor of the SCCHN Clinical Trial and will also have sole responsibility for regulatory interactions and filings for bempegaldesleukin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the opportunity to receive Success Payments as outlined below, SFJ has no right to reimbursement of costs incurred by SFJ for the SCCHN Clinical Trial in the event that the Melanoma Clinical Trial and the SCCHN Clinical Trial do not achieve FDA approval. We will pay SFJ a series of success-based annual payments (collectively, the Success Payments) in the event of FDA approval of bempegaldesleukin for the Melanoma Indication, the SCCHN Indication, or both, and in the event of FDA approval of one additional bempegaldesleukin indication. The Success Payments do not begin until the substantial completion of the SCCHN Clinical Trial. The total success-based annual payments for the first indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $450.0&#160;million, paid in annual contractual payments over five years, with the first payment being $30.0&#160;million, with the earliest possible payment expected to occur in late 2024 or early 2025, subject to the substantial completion of the SCCHN Clinical Trial. The total success-based payments for the second indication approved by FDA, whether for the Melanoma Indication or the SCCHN Indication, is an aggregate of $150.0&#160;million, paid in annual contractual payments over seven years. Finally, in the event of FDA approval for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;bempegaldesleukin for any indication other than the Melanoma Indication or the SCCHN Indication, we will make a one-time payment of $37.5&#160;million to SFJ. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SCCHN Clinical Trial provides for an interim futility analysis, and unless the futility criteria are met, SFJ is required to complete the SCCHN Trial, but if the futility criteria are met, SFJ has the responsibility to wind down the SCCHN Clinical Trial at its sole cost. We and BMS, pursuant to the BMS Collaboration Agreement, remain solely responsible for conducting the Phase 3 clinical trials of bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including the treatment of previously untreated unresectable or metastatic melanoma (the &#x201c;Melanoma Indication&#x201d; and the &#x201c;Melanoma Clinical Trial&#x201d;). If the success criterion for the interim futility analysis is not met and SFJ winds down the SCCHN Clinical Trial, then the Success Payments, if any, for the Melanoma Indication and/or the additional bempegaldesleukin indication are reduced pro rata based on the costs incurred by SFJ for the SCCHN Clinical Trial over the aggregate commitment of $150.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SFJ Agreement provides for certain positive and negative covenants, including restrictions on our ability to incur liens on our intellectual property related to bempegaldesleukin (the bempegaldesleukin IP), or assign or convey any right to receive income with respect to the bempegaldesleukin IP (other than royalty and other license fee obligations to licensors), except for the issuance of senior secured debt secured by all or substantially all of our assets, including the bempegaldesleukin IP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SFJ Agreement expires upon the payment of all Success Payments to SFJ, unless earlier terminated as provided under the SFJ Agreement. The SFJ Agreement may be terminated by either party for a safety or health concern for the patients, whether by the independent data monitoring committee or by mutual agreement of both parties. The SFJ Agreement may also be terminated by either party for material breach or insolvency of the counterparty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We present the SFJ Agreement as a Development derivative liability in our Consolidated Balance Sheets, which we remeasure to fair value at each reporting date. As SFJ conducts the SCCHN Clinical Trial, we record non-cash research and development expense with a corresponding increase to the development derivative liability, and as SFJ remits funding to us to support our internal costs of conducting the trial, we also record a corresponding increase to the development derivative liability. We present the gain (loss) from the remeasurement as Change in fair value of development derivative liability in our Consolidated Statements of Operations. The following table presents the changes in the development derivative liability for the year ended December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at inception on February 12, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We valued the derivative using a scenario-based discounted cash flow method, whereby each scenario makes assumptions about the probability and timing of cash flows, and we discount such cash flows to present value using a risk-adjusted rate. The key inputs to the valuation include our estimates of the following: (i) the probability of the Melanoma Clinical Trial, the SCCHN Clinical Trial and another bempegaldesleukin trial meeting their primary endpoints, (ii) the probability and timing of achieving FDA approval in the Melanoma Indication, the SCCHN Indication and any other bempegaldesleukin indication, (iii) the timing of the substantial completion of the SCCHN Clinical Trial that SFJ must achieve before receiving a Success Payment, (iv) the probability of termination of the study due to meeting the interim futility criteria, (v) the amount of costs incurred by SFJ if the success criterion for the interim futility analysis is not met, (vi) SFJ&#x2019;s cost of borrowing, currently estimated at 1.5%, and (vii) the Company&#x2019;s imputed cost of borrowing for debt with similar terms, currently estimated at 12.7%.&lt;/span&gt;&lt;/div&gt;</nktr:DevelopmentDerivativeLiabilityTextBlock>
    <nktr:CollaborativeArrangementCommittedFunding
      contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNDU2_363db331-2bf6-4f70-b158-ed5287fbff7f"
      unitRef="usd">150000000</nktr:CollaborativeArrangementCommittedFunding>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndication
      contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNDcy_ad9bb2ba-5fe4-4276-9142-71c9397f622a"
      unitRef="usd">450000000</nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndication>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid
      contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTUw_44bbccee-7d57-4978-97ee-72671c995db3">P5Y</nktr:CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsFirstPayment
      contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNDg4_86fe9564-437b-4627-9c7a-c1406d7b4110"
      unitRef="usd">30000000</nktr:CollaborativeArrangementSuccessBasedPaymentsFirstPayment>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndication
      contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTAz_79348d19-0725-48bf-adc4-0cec8966cc30"
      unitRef="usd">150000000</nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndication>
    <nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid
      contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTQ5_65f46f4d-4346-4597-903f-525fae8f475c">P7Y</nktr:CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid>
    <nktr:CollaborativeArrangementAdditionalIndicationPayment
      contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTE5_066fcc6b-cba4-4574-b43a-34f9397d8cf9"
      unitRef="usd">37500000</nktr:CollaborativeArrangementAdditionalIndicationPayment>
    <nktr:CollaborativeArrangementCommittedFunding
      contextRef="ic9ea183a0a924e59ba043d77ac87777e_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTM0_0b016bce-c9e8-427f-aa65-fc3a2a2aae5f"
      unitRef="usd">150000000</nktr:CollaborativeArrangementCommittedFunding>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNDU0_d72c3109-a5e1-487a-87fc-b9356102886c">The following table presents the changes in the development derivative liability for the year ended December&#160;31, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at inception on February 12, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from SFJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the fair value of development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i16608bc88bb04b04bb4edbc265eb647e_I20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGFibGU6MWUzYTgxNmQxNWRjNGFlOWE2NjY5MDZkNDk5YWRjNDUvdGFibGVyYW5nZToxZTNhODE2ZDE1ZGM0YWU5YTY2NjkwNmQ0OTlhZGM0NV8xLTItMS0xLTE3OTA5_314f99d6-f538-4a5a-a9a1-e3db970a076a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense
      contextRef="i3ec48343255d40459baca2d723015436_D20210213-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGFibGU6MWUzYTgxNmQxNWRjNGFlOWE2NjY5MDZkNDk5YWRjNDUvdGFibGVyYW5nZToxZTNhODE2ZDE1ZGM0YWU5YTY2NjkwNmQ0OTlhZGM0NV8yLTItMS0xLTE3OTA5_63a9603a-95e4-4f5b-9250-ec0ac60f6246"
      unitRef="usd">16703000</nktr:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i3ec48343255d40459baca2d723015436_D20210213-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGFibGU6MWUzYTgxNmQxNWRjNGFlOWE2NjY5MDZkNDk5YWRjNDUvdGFibGVyYW5nZToxZTNhODE2ZDE1ZGM0YWU5YTY2NjkwNmQ0OTlhZGM0NV8zLTItMS0xLTE3OTA5_bc3cccf1-15c5-4df3-94f4-24f51531a8e2"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i3ec48343255d40459baca2d723015436_D20210213-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGFibGU6MWUzYTgxNmQxNWRjNGFlOWE2NjY5MDZkNDk5YWRjNDUvdGFibGVyYW5nZToxZTNhODE2ZDE1ZGM0YWU5YTY2NjkwNmQ0OTlhZGM0NV80LTItMS0xLTE3OTA5_1ce2b489-d24b-4c10-8a40-fda05902023f"
      unitRef="usd">8023000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i493fa2ce12a84012947de2cfdd3a036b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGFibGU6MWUzYTgxNmQxNWRjNGFlOWE2NjY5MDZkNDk5YWRjNDUvdGFibGVyYW5nZToxZTNhODE2ZDE1ZGM0YWU5YTY2NjkwNmQ0OTlhZGM0NV81LTItMS0xLTE3OTA5_4efe193f-5f05-4f4b-aa53-ba4717e6db7f"
      unitRef="usd">27726000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ib73eda96963641c5adca30248e3b4212_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTU5_0c2550ad-29b7-4bd4-9e27-653a30bc1fa5"
      unitRef="number">0.015</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i418e819404874602beccd76277d2832e_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xNjUzL2ZyYWc6OTY1MGRkZGU4YmE2NDA2MTlmMDBmNmNlNWJkZDY4ODAvdGV4dHJlZ2lvbjo5NjUwZGRkZThiYTY0MDYxOWYwMGY2Y2U1YmRkNjg4MF80OTQ3ODAyMzMxNTUy_fa8c9cfb-41c9-40df-9d30-d48aac16b0be"
      unitRef="number">0.127</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIyMTQ_8510b3fb-26b0-4261-9466-0f4ddfb73caa">Operating Leases&#160;&#160;&#160;&#160;Our leases consist of a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. 19, LLC (ARE) for our 155,215 square foot corporate office and R&amp;amp;D facility located at 455 Mission Bay Boulevard, San Francisco, California (the Mission Bay Facility) and a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) for an additional 135,936 square foot facility to support our R&amp;amp;D operations at 360 Third Street, San Francisco, &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California (the Third Street Facility). The following table presents key information regarding these leases (dollars in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mission Bay Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third Street Facility&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease commencement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Space delivered during the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Square footage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset and lease liability recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Space delivered during the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Square footage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset and lease liability recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Renewal terms&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Two consecutive &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMS0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo1NzBkM2IxNWJkODY0NDhlYTY5MGYyNDhlY2RjM2VmNl8xOQ_aafbf748-eb94-4830-9eeb-f3b77f87a1d3"&gt;five&lt;/span&gt;-year terms&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMy0xLTEtMTEyOTgvdGV4dHJlZ2lvbjoxZmUzNGY5ZGNjNmE0MzIyYmMyMDNmMGRiNWZiYzJkYV83_acadf74a-e2c3-4130-9183-4f9108ef96cd"&gt;five&lt;/span&gt;-year term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The monthly base rent for both facilities will escalate over the term of the lease at various intervals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Both leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance costs and taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For the Third Street Lease, our fixed annual base rent on an&#160;industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize rent expense for these operating leases on a straight-line basis over the lease period. The components of lease expense, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the years ended December&#160;31, 2021, 2020 and 2019, we  paid $16.8 million, $16.2&#160;million and $8.4&#160;million, respectively, of operating lease payments related to our lease liabilities, which we include in net cash used in operating activities in our Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: portion representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: lease incentives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2021, the weighted-average remaining lease term is 8.1 years and the weighted-average discount rate used to determine the operating lease liability was 5.8%.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <nktr:AreaOfLeasedSpace
      contextRef="i9fd0edc3092a4746b891c63c927e1490_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzE1Mg_0fff6f53-aefe-4ad4-bf42-2e84d49efc04"
      unitRef="sqft">155215</nktr:AreaOfLeasedSpace>
    <nktr:AreaOfLeasedSpace
      contextRef="ib40b92391c3f4d638cd40df255d8a24f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzQxMQ_15b1ad44-c68d-45af-8a7e-be174da2b7fa"
      unitRef="sqft">135936</nktr:AreaOfLeasedSpace>
    <nktr:LesseeOperatingLeaseTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIyMTU_acca60b4-9214-4280-a903-f7d9f3e5bfe7">The following table presents key information regarding these leases (dollars in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mission Bay Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third Street Facility&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease commencement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Space delivered during the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Square footage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset and lease liability recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Space delivered during the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Square footage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset and lease liability recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Renewal terms&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Two consecutive &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMS0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo1NzBkM2IxNWJkODY0NDhlYTY5MGYyNDhlY2RjM2VmNl8xOQ_aafbf748-eb94-4830-9eeb-f3b77f87a1d3"&gt;five&lt;/span&gt;-year terms&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMy0xLTEtMTEyOTgvdGV4dHJlZ2lvbjoxZmUzNGY5ZGNjNmE0MzIyYmMyMDNmMGRiNWZiYzJkYV83_acadf74a-e2c3-4130-9183-4f9108ef96cd"&gt;five&lt;/span&gt;-year term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</nktr:LesseeOperatingLeaseTableTextBlock>
    <nktr:AreaOfLeasedSpaceDelivered
      contextRef="i95ecd88a93ef4d27b3eb882445356c5c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzQtMS0xLTEtMTEyOTg_153374b2-7c1c-48fe-afe6-4355eafe34e1"
      unitRef="sqft">4940</nktr:AreaOfLeasedSpaceDelivered>
    <nktr:AreaOfLeasedSpaceDelivered
      contextRef="iaeeda31f60ae46789b8052b8ca1a2041_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzQtMy0xLTEtMTEyOTg_95e1b483-fad1-474d-b8ca-44483f034c7f"
      unitRef="sqft">0</nktr:AreaOfLeasedSpaceDelivered>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i95ecd88a93ef4d27b3eb882445356c5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzUtMS0xLTEtMTEyOTg_dcee13a6-5f0c-4770-a6e0-b863aa3b8ef8"
      unitRef="usd">2133000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iaeeda31f60ae46789b8052b8ca1a2041_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzUtMy0xLTEtMTEyOTg_f294ac18-4a60-4c59-8b19-75ce97c3dfa2"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nktr:AreaOfLeasedSpaceDelivered
      contextRef="idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzctMS0xLTEtMTEyOTg_bec3d44c-1735-4b14-b077-6bf1df948aed"
      unitRef="sqft">2012</nktr:AreaOfLeasedSpaceDelivered>
    <nktr:AreaOfLeasedSpaceDelivered
      contextRef="i7562d9991df643f7ab9b69837b951eed_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzctMy0xLTEtMTEyOTg_a6b3f0e8-134d-4036-9209-6262c791b64c"
      unitRef="sqft">0</nktr:AreaOfLeasedSpaceDelivered>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzgtMS0xLTEtMTEyOTg_9aed2a57-268a-4d7e-b697-7842cf5747bd"
      unitRef="usd">1057000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7562d9991df643f7ab9b69837b951eed_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzgtMy0xLTEtMTEyOTg_40394114-13de-406a-bddb-f6f04185c1cb"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nktr:NumberOfConsecutiveTermsToExtendLease
      contextRef="idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMS0xLTEtMTEyOTgvdGV4dHJlZ2lvbjo1NzBkM2IxNWJkODY0NDhlYTY5MGYyNDhlY2RjM2VmNl80_2bf00cb7-5eec-4141-876f-86a4819db2c1"
      unitRef="term">2</nktr:NumberOfConsecutiveTermsToExtendLease>
    <nktr:NumberOfConsecutiveTermsToExtendLease
      contextRef="i7562d9991df643f7ab9b69837b951eed_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTphMTJjMDE4YjgyNzk0MzUzYWY0YjI5YmE0NTVjZTM4MC90YWJsZXJhbmdlOmExMmMwMThiODI3OTQzNTNhZjRiMjliYTQ1NWNlMzgwXzktMy0xLTEtMTEyOTgvdGV4dHJlZ2lvbjoxZmUzNGY5ZGNjNmE0MzIyYmMyMDNmMGRiNWZiYzJkYV80_26a7ee75-5736-4030-8150-bf3fd5f22e39"
      unitRef="term">1</nktr:NumberOfConsecutiveTermsToExtendLease>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIyMTE_9bab286a-f8f0-464b-b4ec-f13306de6536">The components of lease expense, which we include in operating expenses in our Consolidated Statements of Operations, were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzItMS0xLTEtMTEyOTg_001e9244-3d2e-42db-b308-ce9417b9b7c8"
      unitRef="usd">19153000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzItMy0xLTEtMTEyOTg_9cb6684e-c99d-448e-a067-0c83d3f237bc"
      unitRef="usd">18985000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzItNS0xLTEtMTEyOTg_1d8ca285-b4d1-41ce-85e1-2006225d4162"
      unitRef="usd">14697000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzMtMS0xLTEtMTEyOTg_b51460a8-4ac9-4279-a435-ea2be1fb1945"
      unitRef="usd">8974000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzMtMy0xLTEtMTEyOTg_26d31982-1124-4dcd-93ba-31390b57d427"
      unitRef="usd">8179000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzMtNS0xLTEtMTEyOTg_53fdd521-8b0a-44c1-84d0-49a172769905"
      unitRef="usd">6408000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzQtMS0xLTEtMTEyOTg_1ccb3072-bf06-4c47-87cf-6ec0415c26b2"
      unitRef="usd">28127000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzQtMy0xLTEtMTEyOTg_a9a3a4be-2f00-46d7-ab4b-72747a158da0"
      unitRef="usd">27164000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZToxMzU1ODU0YWYyZDQ0NmVhYWVhZjhlZjc0ZTVhYzczYy90YWJsZXJhbmdlOjEzNTU4NTRhZjJkNDQ2ZWFhZWFmOGVmNzRlNWFjNzNjXzQtNS0xLTEtMTEyOTg_7b4d01c4-cd01-4691-9a8c-31bd24feb900"
      unitRef="usd">21105000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzE3NTk_cfe7ac70-44f1-4e66-9fc6-7e8c7d4d283b"
      unitRef="usd">16800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzE3NjY_e8aad39f-1bd5-48b8-ac17-59de78109e31"
      unitRef="usd">16200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzM4NDgyOTA3MTIyOTM_c0b7dad2-22a1-42c3-bd39-8e47cfedb4b1"
      unitRef="usd">8400000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIyMTI_68b70490-23d3-4e06-b28c-594284740601">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Year ending December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: portion representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: lease incentives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzEtMS0xLTEtMTEyOTg_9733a0a9-eba4-4eef-a36d-2dbf93383d43"
      unitRef="usd">18626000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzItMS0xLTEtMTEyOTg_6e386cc6-a200-4182-bc38-c201b6581a7f"
      unitRef="usd">20909000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzMtMS0xLTEtMTEyOTg_3b6de05c-b2cb-4c4f-aaa3-7b25460fbeb9"
      unitRef="usd">21572000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzQtMS0xLTEtMTEyOTg_1d6d9b93-47ce-4f2a-87cb-7130d55ab779"
      unitRef="usd">22255000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzUtMS0xLTEtMTEyOTg_36c74cbc-722b-4dad-8c2b-0dc3b6f03e56"
      unitRef="usd">22957000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzYtMS0xLTEtMTEyOTg_541051c0-2f50-48a8-aaac-d79e40c20069"
      unitRef="usd">75411000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzctMS0xLTEtMTEyOTg_b6ec2b35-8549-4ec0-80e0-df12eb2fefbc"
      unitRef="usd">181730000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzgtMS0xLTEtMTEyOTg_4615f19e-70da-4f23-85ef-7dd9baa67f02"
      unitRef="usd">37900000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <nktr:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzktMS0xLTEtMTEyOTg_818bdd41-5ff5-463c-b08d-1c8e73b3f4cc"
      unitRef="usd">653000</nktr:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzEwLTEtMS0xLTExMjk4_1b07773c-c04f-4e4e-8390-837a69a1ad7a"
      unitRef="usd">143177000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzExLTEtMS0xLTExMjk4_bc71d796-ded5-42ef-8f44-83b26b9fe904"
      unitRef="usd">17441000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90YWJsZTo5NTMwM2ZmZjRmNmY0NjM0OWVkNmI3YjU3MTk2N2JhNi90YWJsZXJhbmdlOjk1MzAzZmZmNGY2ZjQ2MzQ5ZWQ2YjdiNTcxOTY3YmE2XzEyLTEtMS0xLTExMjk4_1ae67e49-ef12-4541-80d2-a0b494494902"
      unitRef="usd">125736000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIxMTQ_5c008641-38c9-4afe-b483-c7ce70976144">P8Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDMvZnJhZzo3ODFjMWU3MmRhZjc0NjM1YTQ3ODM5ZmQ2NTcyOGU0ZC90ZXh0cmVnaW9uOjc4MWMxZTcyZGFmNzQ2MzVhNDc4MzlmZDY1NzI4ZTRkXzIyMDg_ba2d0e98-db3d-413d-9647-5300189b4c9e"
      unitRef="number">0.058</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzg2MTE_158e5c94-1fb9-4df3-92e4-46099fe8cfdd">Liabilities Related to the Sales of Future Royalties&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On February&#160;24, 2012, we entered into a purchase and sale agreement (the 2012 Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the 2012 Transaction Royalties) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the 2012 Transaction Royalties.&#160;Although we sold all of our rights to receive royalties from the CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (the 2012 Royalty Obligation) that is amortized using the effective interest method over the estimated life of the 2012 Purchase and Sale Agreement as royalties from the CIMZIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products are remitted directly to RPI. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 5, 2020, UCB served notice of a Declaratory Judgment of Patent Invalidity, filed in the United States District Court for the District of Delaware, seeking a declaration of invalidity of certain of our patents that we had licensed to UCB and pursued similar actions in other jurisdictions. On October 14, 2021, RPI and we entered into a Letter Agreement which permitted us to enter into a Settlement Agreement, effective October 13, 2021, with UCB to effect the negotiation between RPI and UCB in which UCB and RPI agreed to a reduction in the royalty term and annual decreases in the royalty rate over the remaining royalty term in exchange for UCB&#x2019;s withdrawal of all of UCB&#x2019;s litigation and challenges. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded that we should account for the decrease in royalty payments to RPI as a result of these agreements as a modification of our liability. Due to the significance of the change in the estimated royalty payments, we concluded that we should treat the modification as an extinguishment of the prior liability and recognize a new liability based on the revised royalty payments and term, discounted to fair value. Accordingly, we estimated the fair value to be approximately $84.7&#160;million, reflecting a discount rate of 16.0%, and we began amortizing the liability prospectively at this rate commencing in the three months ended December 31, 2021. As a result, we recognized a loss of $23.5&#160;million on the revaluation of the prior liability in the three months ended December 31, 2021, and we wrote off of the remaining $0.9&#160;million of unamortized transaction costs. We present these charges in Loss on revaluation of liability related to the sale of future royalties line in our Consolidated Statement of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2020, we entered into a purchase and sale agreement (the 2020 Purchase and Sale Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Pursuant to the 2020 Purchase and Sale Agreement, we agreed to sell to HCR certain of our rights to receive royalty payments (the 2020 Transaction Royalties) arising from the worldwide net sales, from and after October 1, 2020 until such time that certain return thresholds are met as described below, of (a) MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain License Agreement, dated September 20, 2009, by and between Nektar and AstraZeneca AB, as amended, (b) ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain Exclusive Research, Development, License and Manufacturing and Supply Agreement, dated September 26, 2005, by and among Nektar, Baxalta US Inc. and Baxalta GmbH, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as amended, (c) REBINYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under that certain Settlement and License Agreement, dated December 21, 2016, by and among Nektar, Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/G and (d) licensed products under that certain Right to Sublicense Agreement, dated October 27, 2017, by and among Nektar, Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Purchase and Sale Agreement will automatically expire, and the payment of the 2020 Transaction Royalties to HCR will cease, when HCR has received payments of the 2020 Transaction Royalties equal to $210.0&#160;million (the 2025 Threshold), if the 2025 Threshold is achieved on or prior to December 31, 2025, or $240.0&#160;million, if the 2025 Threshold is not achieved on or prior to December 31, 2025 (or, if earlier, the date on which the last royalty payment under the relevant license agreements is made). If HCR has received payments of the 2020 Transaction Royalties equal to at least $208.0&#160;million on or prior to December 31, 2025, we have the option to pay the difference between the 2025 Threshold and such 2020 Transaction Royalties, and the 2025 Threshold will be met and the 2020 Purchase and Sale Agreement will expire. After the 2020 Purchase and Sale Agreement expires, all rights to receive the 2020 Transaction Royalties return to Nektar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2020, we received aggregate cash proceeds of $150.0&#160;million for the 2020 Transaction Royalties. As part of the sale, we incurred approximately $3.8&#160;million in transaction costs, which will be amortized to interest expense over the estimated life of the 2020 Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from these products, as a result of the limits on the 2020 Transaction Royalties to be received by HCR and our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these non-cash royalties as revenue, commencing with royalties for the three months ended December 31, 2020, to be received by HCR in the first quarter of 2021. We recorded the $150.0&#160;million in proceeds from this transaction as a liability (the 2020 Royalty Obligation) that will be amortized using the effective interest method over the estimated life of the 2020 Purchase and Sale Agreement. As of December 31, 2021, our prospective effective interest rate used to amortize the liability is 15%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account of each arrangement (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year-Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period from inception to December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties&#x2014;beginning&lt;br/&gt;balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty monetization proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to RPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Pursuant to the 2012 Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $7.0 million and $3.0 million, respectively, as a result of worldwide net sales of MIRCERA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the 12 month periods ended December&#160;31, 2013 and 2012 not reaching certain minimum thresholds. The 2012 Purchase and Sale Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As royalties are remitted to RPI and HCR by our licensees, the balances of the respective Royalty Obligations will be effectively repaid over the lives of the agreements. To determine the amortization of the Royalty Obligations, we are required to estimate the total amount of future royalty payments to be received by RPI and HCR, respectively. The sum of these amounts less the net proceeds we received will be recorded as non-cash interest expense, as well as the loss on the revaluation described above, over the lives of the respective Royalty Obligations. We periodically assess the estimated royalty payments to RPI and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;HCR from our licensees and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the appropriate Royalty Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;There are a number of factors that could materially affect the amount and timing of royalty payments from our licensees, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI or HCR are made in U.S. dollars (USD) while significant portions of the underlying sales of the products of our licensees are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from our licensees, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the respective Royalty Obligation. Conversely, for the 2012 Purchase and Sale Agreement, if sales of these products are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the 2012 Royalty Obligation.&lt;/span&gt;&lt;/div&gt;</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="ic019febd6d76418e963113849a03e38e_D20120224-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzcxOA_33f67797-3a39-4817-855d-b5694b057d29"
      unitRef="usd">124000000</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="ic019febd6d76418e963113849a03e38e_D20120224-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzEyMTU_d595b9f5-9e91-4d60-a90b-b5ec7309ebb3"
      unitRef="usd">124000000</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ib0419ee4a57947ec9003b707328f0fb9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM4NDgyOTA3MTEzMzA_ef667043-198e-4746-b6ac-e3405ea6089d"
      unitRef="usd">84700000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="i7c519c68cc924317ad61bfe414020531_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM4NDgyOTA3MTEzNDU_71125cda-e245-4dd2-a1fc-587ea5894133"
      unitRef="number">0.160</nktr:RoyaltiesLiabilityMeasurementInput>
    <nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties
      contextRef="iafb8479bd435454894df0145e038e535_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzE2NDkyNjc0NDM0ODY3_d9e4395f-a757-4391-babe-000d3cd4c045"
      unitRef="usd">-23500000</nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties>
    <nktr:TransactionCostsRelatedToRevisedRoyaltyPayments
      contextRef="iafb8479bd435454894df0145e038e535_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM4NDgyOTA3MTEzNTI_7670af4c-baa3-4ecb-a5af-a782594f5394"
      unitRef="usd">900000</nktr:TransactionCostsRelatedToRevisedRoyaltyPayments>
    <nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved
      contextRef="i615094c1dcc2454fba893bc20ef68b47_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzI4Njg_736bee69-9fe6-4414-b91a-d52b10e0659e"
      unitRef="usd">210000000</nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved>
    <nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved
      contextRef="i615094c1dcc2454fba893bc20ef68b47_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzI5NjQ_85f9d51f-b0fb-42ea-bd04-cd95c6ad061f"
      unitRef="usd">240000000</nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved>
    <nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds
      contextRef="i615094c1dcc2454fba893bc20ef68b47_D20201216-20201216"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzMyMjg_e8325800-08ba-4258-8e6f-b363163900d5"
      unitRef="usd">208000000</nktr:MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i1848694a84f244f8b109984fa21ee94e_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM2NDQ_192cf146-4f85-4d54-8b60-37f3fce90ff6"
      unitRef="usd">150000000</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties
      contextRef="i1848694a84f244f8b109984fa21ee94e_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM3MzA_a35d2037-2c66-4034-abd8-d9af97a00e11"
      unitRef="usd">3800000</nktr:TransactionCostsRelatedToSaleOfPotentialFutureRoyalties>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i1848694a84f244f8b109984fa21ee94e_D20201230-20201230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzQzMzE_fe1ac853-c05b-4738-a6b3-2e14d9238817"
      unitRef="usd">150000000</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:RoyaltiesLiabilityMeasurementInput
      contextRef="id15385c8744c4ad794e479a0863b4859_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzM4NDgyOTA3MTU2NjA_513ad7ef-a140-4887-a1b4-5970cedd2417"
      unitRef="number">0.15</nktr:RoyaltiesLiabilityMeasurementInput>
    <nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzg2MTI_84bd8064-568a-4900-897c-69b9bb7a3389">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account of each arrangement (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year-Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period from inception to December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2012 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020 Purchase and Sale Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties&#x2014;beginning&lt;br/&gt;balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty monetization proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to RPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities related to the sales of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i3fa240bdb2564ada855ed34b4d6af58c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItMS0xLTEtMTEyOTg_78dc06a1-c471-4ecf-a751-945112a5537d"
      unitRef="usd">65880000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ifb5f300865a3412b8ef57ad27019eaf6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItMy0xLTEtMTEyOTg_48c6076a-b1b6-4784-8dda-2f85936a2ed4"
      unitRef="usd">139375000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItNS0xLTEtMTEyOTg_a6f3671b-1ce9-4687-bbd6-8753817acd10"
      unitRef="usd">205255000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i9e574a6749b54555bcb0c1fc438d2730_I20120224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItNy0xLTEtMTEyOTg_75761ba9-b843-463d-9464-787d56781798"
      unitRef="usd">0</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="idea8f2c144d74987ad634c719924d556_I20201216"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItOS0xLTEtMTEyOTg_d2d19180-aca6-40f7-9978-cbb912956b14"
      unitRef="usd">0</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i859caff83678471fa0131b598ecb3b99_I20120224"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzItMTEtMS0xLTExMjk4_70c37eba-cf47-4f89-be32-2ac0bc5e69f2"
      unitRef="usd">0</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i878fa93fa19746ff958887812ed98a82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtMS0xLTEtMTEyOTg_dc94702b-d662-4b7c-be3f-f1faadea0a42"
      unitRef="usd">0</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtMy0xLTEtMTEyOTg_c5eed882-4863-4b47-9b84-4df668aad76c"
      unitRef="usd">0</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtNS0xLTEtMTEyOTg_725445b1-b34c-413b-8e45-573175a83942"
      unitRef="usd">0</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i877ea84e541241f8b6035538b2d966db_D20120225-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtNy0xLTEtMTEyOTg_448a2ce3-2618-4e5e-88e2-c8b376dc6072"
      unitRef="usd">124000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i819532be269b48eaa4fd913474d540a1_D20201217-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtOS0xLTEtMTEyOTg_83a93bdb-d191-4de5-9ac1-957315a28cbb"
      unitRef="usd">150000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:RoyaltyMonetizationProceeds
      contextRef="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzMtMTEtMS0xLTExMjk4_36d0e077-f0ee-4eb3-b0fd-11d2bacb0de5"
      unitRef="usd">274000000</nktr:RoyaltyMonetizationProceeds>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i878fa93fa19746ff958887812ed98a82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtMS0xLTEtMTEyOTg_89721545-d20e-4103-aa3c-cfe4d9c0587d"
      unitRef="usd">37578000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtMy0xLTEtMTEyOTg_a1db148a-5c17-4916-a15f-ff2f3b0abf24"
      unitRef="usd">40168000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtNS0xLTEtMTEyOTg_a7c04246-ae24-4b6d-9d81-35f46111422c"
      unitRef="usd">77746000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i877ea84e541241f8b6035538b2d966db_D20120225-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtNy0xLTEtMTEyOTg_a662cf65-4451-46e0-b367-547f2895d890"
      unitRef="usd">282658000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i819532be269b48eaa4fd913474d540a1_D20201217-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtOS0xLTEtMTEyOTg_bf9ce76a-674a-4c7c-bc6c-2c6f1b0a69ce"
      unitRef="usd">50793000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzQtMTEtMS0xLTExMjk4_91de4b11-338d-4e41-8425-23f6c43bddf6"
      unitRef="usd">333451000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i878fa93fa19746ff958887812ed98a82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtMS0xLTEtMTEyOTg_853fdc60-dc32-41f4-a7b3-7b2231a927ec"
      unitRef="usd">26458000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtMy0xLTEtMTEyOTg_fe836f52-9d5f-4aee-9b20-6593f59e2ed8"
      unitRef="usd">20855000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtNS0xLTEtMTEyOTg_4d7a251e-6cd1-4955-b6c9-17b485f65b73"
      unitRef="usd">47313000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i877ea84e541241f8b6035538b2d966db_D20120225-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtNy0xLTEtMTEyOTg_17ae864a-9662-4c33-82e8-05732eda9676"
      unitRef="usd">223418000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i819532be269b48eaa4fd913474d540a1_D20201217-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtOS0xLTEtMTEyOTg_d3ceaba9-988a-4b2c-bdd9-74858d79b9c9"
      unitRef="usd">20855000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzUtMTEtMS0xLTExMjk4_7cc4affc-13be-4997-8d4b-7d2e2b774f48"
      unitRef="usd">244273000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i878fa93fa19746ff958887812ed98a82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtMS0xLTEtMTEyOTg_3270bdb6-1e2c-412c-8f3b-c9eef9f0b524"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtMy0xLTEtMTEyOTg_c03ad4c4-f429-4371-a4f8-fac2c6bc7d86"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtNS0xLTEtMTEyOTg_303a5b4d-6f73-40df-9996-f4b70405058a"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i877ea84e541241f8b6035538b2d966db_D20120225-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtNy0xLTEtMTEyOTg_6669d6c1-4a44-41e0-aad1-1598b46a2f75"
      unitRef="usd">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i819532be269b48eaa4fd913474d540a1_D20201217-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtOS0xLTEtMTEyOTg_d1f09425-331d-4c33-93db-6cc02d212d08"
      unitRef="usd">0</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:PartialRepaymentOfRoyaltySaleProceeds
      contextRef="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzYtMTEtMS0xLTExMjk4_91ca03ce-3ee5-4852-b523-b0c57030bd38"
      unitRef="usd">10000000</nktr:PartialRepaymentOfRoyaltySaleProceeds>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i878fa93fa19746ff958887812ed98a82_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMS0xLTEtMTQ2MDU_b64d8854-8802-47be-947c-5f6b4aeacaca"
      unitRef="usd">23522000</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i9ce52a283f6e4630ae642dd2745543b9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMy0xLTEtMTQ2MDU_820a2bb9-0e2b-4e9e-9790-38177a63ba61"
      unitRef="usd"
      xsi:nil="true"/>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctNS0xLTEtMTQ2MDU_e39a7759-0264-4808-a349-4bcb34550739"
      unitRef="usd">23522000</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i877ea84e541241f8b6035538b2d966db_D20120225-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctNy0xLTEtMTQ1OTE_55178002-e5c9-4f96-ae2c-2bfacb440582"
      unitRef="usd">23522000</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i819532be269b48eaa4fd913474d540a1_D20201217-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctOS0xLTEtMTQ1OTE_9bbc2fee-bb28-4ddd-baf4-696104db8b23"
      unitRef="usd">0</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross
      contextRef="i52f963cb904641a49f13d02ff98dc4ca_D20120225-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMTEtMS0xLTE0NTkx_56c25cba-8b73-4c52-b843-3eecab6986af"
      unitRef="usd">23522000</nktr:GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMS0xLTEtMTEyOTg_7287224f-16cf-47a3-b184-d535a8c0b272"
      unitRef="usd">78282000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMy0xLTEtMTEyOTg_78afca95-4e9d-403e-8d48-6cec35c38f8d"
      unitRef="usd">120062000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctNS0xLTEtMTEyOTg_11647d84-0177-45d6-ad9d-ee180d3a64b2"
      unitRef="usd">198344000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctNy0xLTEtMTEyOTg_3d331b2e-2541-48d6-af0b-fdcd0e9939f9"
      unitRef="usd">78282000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctOS0xLTEtMTEyOTg_18396234-bacc-42e1-9b2f-cecaa4e1c3c2"
      unitRef="usd">120062000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzctMTEtMS0xLTExMjk4_4aa66d4b-5bd3-4ac1-a1bc-632c04877489"
      unitRef="usd">198344000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtMS0xLTEtMTEyOTg_b390683d-fdea-4d13-925a-8d8a2134cf9a"
      unitRef="usd">0</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtMy0xLTEtMTEyOTg_f085c4f2-4323-4aa0-be14-da66cdcfadcc"
      unitRef="usd">2917000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtNS0xLTEtMTEyOTg_b589d544-d438-4c13-bbbb-f622421c449a"
      unitRef="usd">2917000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtNy0xLTEtMTEyOTg_626785d0-a09b-4729-8aec-8887582e2a73"
      unitRef="usd">0</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtOS0xLTEtMTEyOTg_7b20c5b7-4633-4798-9c67-ad6817c71cb8"
      unitRef="usd">2917000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzgtMTEtMS0xLTExMjk4_32376e3a-9925-45a7-978c-e8218d3e10f4"
      unitRef="usd">2917000</nktr:LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktMS0xLTEtMTEyOTg_feb88c0b-27f0-4b05-8310-75ea0cea8311"
      unitRef="usd">78282000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktMy0xLTEtMTEyOTg_d561ced9-128b-4ec7-ac63-8012b6d6d402"
      unitRef="usd">117145000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktNS0xLTEtMTEyOTg_83a5974b-74d8-4145-add5-3bdd96527eda"
      unitRef="usd">195427000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i8fa71516bf964979bdea09b920eca1e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktNy0xLTEtMTEyOTg_cfe61588-97e2-4ce0-98f3-f731efdab833"
      unitRef="usd">78282000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ie4f4adf2dc4243ccbacef216d657fb2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktOS0xLTEtMTEyOTg_ae2e3193-3f9e-48ac-aa59-0f2afa792881"
      unitRef="usd">117145000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90YWJsZTo0YTg3M2MwZGEyNjM0NmI5YjE5MjZiNGQwZDJiZmI3Yy90YWJsZXJhbmdlOjRhODczYzBkYTI2MzQ2YjliMTkyNmI0ZDBkMmJmYjdjXzktMTEtMS0xLTExMjk4_aac49e51-afac-45e4-9edf-18a47f9d0267"
      unitRef="usd">195427000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:PaymentMadeForMilestoneNotAchievedYearTwo
      contextRef="i431785ba16834d94834f5341637912ac_D20140301-20140331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzUwODI_fccc4a0e-f896-4cfd-a34b-2bcfaf3db304"
      unitRef="usd">7000000</nktr:PaymentMadeForMilestoneNotAchievedYearTwo>
    <nktr:PaymentMadeForMilestoneNotAchievedYearOne
      contextRef="i10e97ae5ba424e32b4c21ebb7a264e1c_D20130301-20130331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMDYvZnJhZzo1Yjc2NGRiODFjYTg0NzU2OGY0NTZkNmJmN2U3ZDdkZS90ZXh0cmVnaW9uOjViNzY0ZGI4MWNhODQ3NTY4ZjQ1NmQ2YmY3ZTdkN2RlXzUwODk_c12683c1-1fa1-462a-b5a7-65edc492acce"
      unitRef="usd">3000000</nktr:PaymentMadeForMilestoneNotAchievedYearOne>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzk0Nzg_e31a4238-8900-49e7-bf49-2823c342a937">Commitments and Contingencies&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In the normal course of business, we enter into various firm purchase commitments related to contract manufacturing, clinical development and certain other items. As of December&#160;31, 2021, these commitments were approximately $8.2 million, all of which we expect to pay in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California (Case No. 18-cv-06607, which we refer to as the Mulquin action).  The Mulquin plaintiffs have challenged public statements Nektar made, between January 2017 and June 2018, about the clinical trials of bempegaldesleukin. The Mulquin complaint was amended in May 2019. The defendants moved to dismiss and the court granted the motion without prejudice in July 2020. The Mulquin plaintiffs again amended their complaint and the defendants again moved to dismiss.  In December 2020, the court dismissed the action with prejudice. The plaintiffs filed a notice of appeal in January 2021 and appellate briefing in the U.S. Court of Appeals for the Ninth Circuit was completed in September 2021. Oral argument occurred on December 10, 2021, and the matter remains pending with the court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A second putative securities class action was filed against the Company and certain of our executives in the U.S. District Court for the Northern District of California in August 2019 (Case No. 4-19-cv-05173, which we refer to as the Damiba action).  The Damiba plaintiffs challenged public statements Nektar made, between February 2019 and May 2019, about its bempegaldesleukin clinical trials and collaboration with Bristol-Myers Squibb. After the Damiba plaintiffs filed an amended complaint and the defendants moved to dismiss, the court dismissed the action without prejudice in January 2021. The Damiba plaintiffs subsequently voluntarily dismissed the action, with prejudice, in March 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the two securities actions (the Mulquin action and the Damiba action), three additional sets of derivative actions have been filed against certain of the Company&#x2019;s current and former officers and directors, purportedly on the Company&#x2019;s behalf. These derivative actions are based on the allegations in the securities actions and on the premise that the Company&#x2019;s officers and directors breached their fiduciary duties by exposing the Company to one or both of the securities actions. The first derivative action was filed in the U.S. District Court for the District of Delaware in February 2019 (Case No. 1:19-cv-00322-MN-JLH). After amending their complaint several times, the plaintiffs in that action voluntarily dismissed their claims without prejudice in April 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A second set of derivative actions was filed in February 2020 in the U.S. District Court for the Northern District of California (Case No. 4:20-cv-01088-JSW). The derivative actions in California were consolidated and the Company moved to dismiss on the basis that the plaintiffs had neither made a demand on the Company&#x2019;s board of directors nor shown that a demand would be futile. On September 1, 2021, the court dismissed the action with prejudice.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A third derivative complaint was filed in February 2021 in the Court of Chancery of the State of Delaware (C.A. No. 2021-0118-PAF). The parties agreed to stay further proceedings in this action until thirty days after the U.S. Court of Appeals for the Ninth Circuit&#x2019;s final resolution of the appeal in the Mulquin action.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the nature and status of these securities class action lawsuits and derivative complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Consolidated Balance Sheets at either December&#160;31, 2021 or December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We operate in a number of foreign countries. As a result, we are subject to numerous local laws and regulations that can result in claims made by foreign government agencies or other third parties that are often difficult to predict even after the application of good faith compliance efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During the course of our normal operating activities, we have agreed to certain contingent indemnification obligations as further described below. The term of our indemnification obligations is generally perpetual. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. To date, we have not incurred significant costs to defend lawsuits or settle claims based on our indemnification obligations. If any of our indemnification obligations is triggered, we may incur substantial liabilities. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Consolidated Balance Sheets at either December&#160;31, 2021 or December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications in Connection with Commercial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations,  nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnification of Underwriters and Initial Purchasers of our Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In connection with our sale of equity we have agreed to defend, indemnify and hold harmless our underwriters or initial purchasers, as applicable, as well as certain related parties from and against certain liabilities, including liabilities under the Securities Act of 1933, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Director and Officer Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As permitted under Delaware law, and as set forth in our Certificate of Incorporation and our Bylaws, we indemnify our directors, executive officers, other officers, employees, and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential amount of future payments we could be required to make under this &lt;/span&gt;&lt;/div&gt;indemnification is unlimited; however, we have insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe any obligations under this indemnification would not be material, other than retention of up to $10.0 million per incident for merger and acquisition related claims, $10.0 million per incident for securities related claims and $10.0 million per incident for non-securities related claims per our insurance policy. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzI3Ng_75cd393c-73a2-4e5b-9d5e-e0e76bc71f47"
      unitRef="usd">8200000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i26423d2e98f74cab9e74de71740ea6dd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzE2NDkyNjc0NjcxMDU_f7de4db7-b0c0-4c8e-8fda-657c68b85865"
      unitRef="action">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ief3d1876c0504d8894ebee840c0649dc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzE2NDkyNjc0NjcwOTU_7d51a6c7-98f7-42d1-b002-af91592bf38a"
      unitRef="action">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i3fab95cd4e2f4d70a9bd13e5489022fd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzQ1MTQ_5c6381ab-746e-4ba7-8e3b-c6af11bac62b"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="if7023dcffb6c492e881c7d0fdf2c056c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzQ1MTQ_d8ed32d3-ba61-484f-b134-6c301e0f1978"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="iec07825eabbf46b68172520ab32540ae_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzU3MzY_9367375d-4207-45b0-8675-dd1d2a7190e7"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="iad6b97c8cc6a493d936e8a7260315298_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzU3MzY_f12ddfef-749d-4e36-a334-0952883b8c21"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident
      contextRef="i8cfe16cd13d04edfb807fa9cb0df6eee_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzg5OTg_5aa27454-82ec-4fcf-bf13-614277631691"
      unitRef="usd">10000000</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
    <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident
      contextRef="i6394ee3aadea457c813b5c716e2e257a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzkwNTc_0def215c-bf03-4e3d-b3d5-b134781d0770"
      unitRef="usd">10000000</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
    <nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident
      contextRef="iad260002e8644641b6913428ec9be8e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTIvZnJhZzo4YjhhMTc1NDM0YjY0ZWZiYTkxYjQzOGNhOWY0MzZjZi90ZXh0cmVnaW9uOjhiOGExNzU0MzRiNjRlZmJhOTFiNDM4Y2E5ZjQzNmNmXzkxMDc_98e43a62-4083-4fb7-9328-863c4c7af836"
      unitRef="usd">10000000</nktr:ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90ZXh0cmVnaW9uOmE0MmE3MGVjYjA0NTRiNjdiNWFkYWI2ZjZhNzg1NzE5Xzg4ODU_200cff5e-9e0d-4031-a81e-757c7d819e8d">Stockholders&#x2019; Equity &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As discussed in Note 11, on April 3, 2018, we completed the issuance and sale of 8,284,600 shares of our common stock under a Share Purchase Agreement with BMS. These shares are unregistered and subject to certain lock-up and stand-still provisions for a five-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently have an effective shelf registration statement on Form S-3 (the 2021 Shelf Registration Statement) on file with the SEC, which expires in March 2024. The 2021 Shelf Registration Statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $300.0&#160;million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, all of which may be offered, issued and sold in &#x201c;at-the-market&#x201d; sales pursuant to an equity distribution agreement with Cowen and Company, LLC (the Equity Distribution Agreement). No securities have been sold under the 2021 Shelf Registration Statement or the Equity Distribution Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, shares of common stock reserved for future issuance are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options, RSUs and PSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for future grant under the 2017 Performance Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id508c66eccd84a1490c07a8346141297_D20180403-20180403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90ZXh0cmVnaW9uOmE0MmE3MGVjYjA0NTRiNjdiNWFkYWI2ZjZhNzg1NzE5XzEzMQ_247c1882-2fcb-4eea-874b-de0d335d2002"
      unitRef="shares">8284600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod
      contextRef="icdcb60f448fd48b6b0f24d116b1058d4_D20180403-20180403"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90ZXh0cmVnaW9uOmE0MmE3MGVjYjA0NTRiNjdiNWFkYWI2ZjZhNzg1NzE5Xzg4ODY_9730197a-6bcf-4e64-b0ad-79f5c143aeec">P5Y</nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod>
    <nktr:SaleOfStockValueAuthorizedInTransaction
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90ZXh0cmVnaW9uOmE0MmE3MGVjYjA0NTRiNjdiNWFkYWI2ZjZhNzg1NzE5XzM4NDgyOTA3MTYxNDI_79140d18-6e7e-4445-9753-562beeab0059"
      unitRef="usd">300000000</nktr:SaleOfStockValueAuthorizedInTransaction>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90ZXh0cmVnaW9uOmE0MmE3MGVjYjA0NTRiNjdiNWFkYWI2ZjZhNzg1NzE5Xzk4OTU2MDQ2NjgxNTE_2e123217-4f49-4e71-b14b-2995f6fcc5d5">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, shares of common stock reserved for future issuance are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options, RSUs and PSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for future grant under the 2017 Performance Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for issuance under the employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average volatility factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i08e56333c0594ef38a927dea5e5be643_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90YWJsZTpiOGZiMDJmNWJlNTY0M2U0ODZjYTgwYTQ5ZGViOWEzOS90YWJsZXJhbmdlOmI4ZmIwMmY1YmU1NjQzZTQ4NmNhODBhNDlkZWI5YTM5XzAtMS0xLTEtMjIxNjQ_08f10518-b9f9-41f5-9fef-6d30178830a9"
      unitRef="shares">23922000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i85e44fd2a3b7430fb8662bdf1cfee75a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90YWJsZTpiOGZiMDJmNWJlNTY0M2U0ODZjYTgwYTQ5ZGViOWEzOS90YWJsZXJhbmdlOmI4ZmIwMmY1YmU1NjQzZTQ4NmNhODBhNDlkZWI5YTM5XzEtMS0xLTEtMjIxNjQ_3a86d01f-c524-4343-9ec8-87facd414e2b"
      unitRef="shares">1142000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i79ae08e8c98b45bba0381fcf4454594a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90YWJsZTpiOGZiMDJmNWJlNTY0M2U0ODZjYTgwYTQ5ZGViOWEzOS90YWJsZXJhbmdlOmI4ZmIwMmY1YmU1NjQzZTQ4NmNhODBhNDlkZWI5YTM5XzItMS0xLTEtMjIxNjQ_952c3a28-324e-4673-a17d-ded0994fd483"
      unitRef="shares">1043000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTUvZnJhZzphNDJhNzBlY2IwNDU0YjY3YjVhZGFiNmY2YTc4NTcxOS90YWJsZTpiOGZiMDJmNWJlNTY0M2U0ODZjYTgwYTQ5ZGViOWEzOS90YWJsZXJhbmdlOmI4ZmIwMmY1YmU1NjQzZTQ4NmNhODBhNDlkZWI5YTM5XzMtMS0xLTEtMjIxNjQ_ae3da3f7-2ec1-4e78-831a-03870d398537"
      unitRef="shares">26107000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzIxMDc4_d289009c-f634-44ad-a48d-76aa8b3b09ef">License and Collaboration Agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bristol-Myers Squibb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NKTR-358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amgen, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2021, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $1.7&#160;billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive other contingent payments, including contingent sales milestones and royalty payments, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;There have been no material changes to our collaboration agreements for the year ended December&#160;31, 2021, except as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb (BMS): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bempegaldesleukin (previously referred to as NKTR-214)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to the BMS Collaboration Agreement, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#x2019;s Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#x2019;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 67.5% of costs to BMS and 32.5% to Nektar. The parties share costs for the manufacturing and joint commercialization of bempegaldesleukin, 35% of the costs to BMS and 65% to Nektar. On January 9, 2020, we and BMS entered into Amendment No. 1 (the First Amendment) to the BMS Collaboration Agreement, pursuant to which, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. BMS has the right, at its sole discretion, to terminate co-funding its share of the development costs for the adjuvant melanoma collaboration study if the metastatic melanoma collaboration study fails to meet the primary endpoint of progression free survival. If BMS exercises such right, we have the right, in our sole discretion, to continue the adjuvant melanoma study. On January 12, 2022, we and BMS entered into an Amendment No. 2 to the BMS Collaboration Agreement, pursuant to which we and BMS allocated certain responsibilities for price negotiations and promotion, market access, patient support and related activities to each party. The cost sharing for the development, manufacturing and commercialization under our collaboration remains unchanged as a result of these amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0&#160;billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0&#160;million. Pursuant to Amendment No. 1 described below, we received a non-refundable, creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational muscle-invasive bladder cancer trial, which was achieved on January 30, 2020, and also received a non-refundable, non-creditable milestone payment of $25.0&#160;million for the first patient, first visit in the registrational adjuvant melanoma trial, which we achieved on July 27, 2020. We are eligible to receive potential future payments for development and regulatory milestones of approximately $1.4&#160;billion (which reflects the reduction for the creditable milestone for the muscle-invasive bladder cancer trial) and up to a total of $350.0&#160;million upon the achievement of certain sales milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808 and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#x2019; reimbursement of our expenses as a reduction of research and development expense and our reimbursement of BMS&#x2019; expenses as research and development expense. For the years ended December&#160;31, 2021, 2020 and 2019, we recorded $101.5 million, $128.2 million and $105.4 million, respectively, as a reduction of research and development expenses for BMS&#x2019; share of our expenses, net of our share of BMS&#x2019; expenses.  As of December&#160;31, 2021 and 2020, we have recorded an unbilled receivable of $21.4 million and $38.7 million, respectively, from BMS in accounts receivable in our Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our share of development costs is limited to an annual cap of $125.0&#160;million. To the extent this annual cap is exceeded, BMS reimburses us for the excess, which we must repay to the extent that our share of development costs are less than the annual cap in a future year. For the year-ended December 31, 2020, our share of the development costs exceeded the annual cap and therefore we included the $4.0&#160;million reimbursement in our accounts receivable as of December 31, 2020 and recorded an off-setting liability in Other long-term liabilities. For the year-ended December 31, 2021, our share of the development costs was sufficiently lower than the cap such that we are required to repay the $4.0&#160;million and therefore have reclassified the liability as a reduction of our accounts receivable as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analogized to ASC 606 for the accounting for our two performance obligations, consisting of the delivery of the licenses to develop and commercialize bempegaldesleukin and our participation on joint steering and other collaboration committees. We determined that our committee participation is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During 2018, we aggregated the total consideration of $1.85&#160;billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $790.2&#160;million in stockholders&#x2019; equity. We allocated the remaining $1,059.8&#160;million to the transaction price of the collaboration agreement, which we recognized in 2018. During the year ended December 31, 2020, we received $50.0&#160;million in aggregate for the achievements of the first patient, first visit in the registrational muscle-invasive bladder cancer trial and the registrational adjuvant melanoma trial, which we recognized as revenue in 2020 because we had previously satisfied our performance obligation of granting the licenses. We continue to exclude the variable consideration of the potential future development, regulatory and sales milestones of up to approximately $1.8&#160;billion from the transaction price as of December&#160;31, 2021 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eli Lilly and Company (Lilly): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NKTR-358 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $150.0&#160;million in September 2017 and are eligible for up to $250.0&#160;million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and certain drug product development and supply activities, (iii) will share with Lilly Phase 1B and 2 development costs with 75% of those costs borne by Lilly and 25% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from zero to 25% of development costs, and (v) will have the opportunity to receive a royalty rate up to the low twenties based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We identified our license grant to Lilly, our Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $150.0&#160;million upfront payment as $125.9&#160;million to the license, $17.6&#160;million to our portion of the Phase 1 clinical development and $6.5&#160;million to the drug product development. We recognized the $125.9&#160;million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development through the three months ended March 31, 2020. As of December&#160;31, 2021, we have no deferred revenue related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to exclude the other milestones from the transaction price as of December&#160;31, 2021 due to the significant uncertainties involved with clinical development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Baxalta Incorporated/Takeda: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hemophilia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;This Hemophilia A program includes ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was approved by the FDA in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. We are entitled to royalties based on worldwide net sales of ADYNOVATE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and an  sales milestone upon achievement of an annual worldwide net sales target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, we are entitled to single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement. As described in Note 8, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca AB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (naloxegol oxalate), previously referred to as naloxegol and NKTR-118,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In September 2014 and December 2014, MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; /MOVENTIG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was approved in the US and EU, respectively. In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the EU, Iceland, Liechtenstein, Norway and Switzerland. In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, excluding Europe, Canada and Israel, to RedHill Biopharma. These sublicenses did not change our rights under the agreement with AstraZeneca, and our royalty rate, royalty term and future potential sales milestones remain unchanged. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For net sales of MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from AstraZeneca and RedHill Biopharma, we are entitled to significant and escalating double-digit royalty payments and sales milestones. For the net sales of MOVANTIK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under the sublicense to Kirin, we are entitled to 40% of the royalties and sales milestones received by AstraZeneca. AstraZeneca is entitled to deduct a portion of its costs for a post-marketing study required by the FDA, subject to certain limits, only through a reduction of the royalties due to us. As of December 31, 2021, our cumulative share of these costs was not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note 8, we sold our rights to receive these royalties to HCR pursuant to the 2020 Purchase and Sale Agreement, and HCR will bear the cost of any reductions for the post-marketing study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amgen, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;: Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the 2010 Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the 2010 Agreement, we received a $50.0 million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen. We recognized this revenue on a straight-line basis over the ten-year term of the 2010 Agreement through September 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In addition, as of December&#160;31, 2021, we have other collaboration agreements, including with our collaboration partner UCB Pharma, under which we are entitled to up to a total of $40.0 million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of December&#160;31, 2021, we have deferred revenue of approximately $2.0 million related to these other collaboration agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzIxMDc5_d58212ae-35a0-404b-ae8f-649c14ceea8d">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bristol-Myers Squibb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NKTR-358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amgen, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neulasta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="if63a3ada72f2468d9d15c15cdadb2e60_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzItNC0xLTEtMTEyOTg_06a557db-d9e6-4e2b-8ff7-089a975c6eb7"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ia282c760203f4d67bbae06f0bbf2f7ca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzItNi0xLTEtMTEyOTg_497dba3e-2566-4e8e-bc5d-641df16c97e4"
      unitRef="usd">50000000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ic8b027734ada457485944093d8bb55f4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzItOC0xLTEtMTEyOTg_0728977d-25d7-49b1-b2b8-3e69f1f11db3"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="iebc2021556634567a9c85d9130eca0e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzMtNC0xLTEtMTEyOTg_4b1bfaec-ec34-46d4-bfb9-cc1b00d58c3c"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i47aee40635594a2493940a5c79182830_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzMtNi0xLTEtMTEyOTg_9c62359c-0648-48ff-a0a7-39605e8e0048"
      unitRef="usd">1259000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i3a0c941d02e442e5830f5ff54b267621_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzMtOC0xLTEtMTEyOTg_dbe66bb9-28e1-4344-907d-b639b5ca8752"
      unitRef="usd">7019000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i7bb01347c4e24ca3bb28d9aab6838bd3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzQtNC0xLTEtMTEyOTg_f30ea82c-c702-4353-b088-9ac2923b4d12"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i8c290b7d2e5c4c6a88d47e27d7256c42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzQtNi0xLTEtMTEyOTg_0e500ac4-f922-4b40-8d1b-cdace08fcf03"
      unitRef="usd">4167000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="iff6585fd29ca4683aec5e1e6754a8a53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzQtOC0xLTEtMTEyOTg_ed489c84-6b5d-43a8-b557-4b14c4d79334"
      unitRef="usd">5000000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i69b94286514e411f81a8255d0fe0adef_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzYtNC0xLTEtMTEyOTg_562897a2-c564-4e24-8e10-029953c54205"
      unitRef="usd">436000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i3df606808a1742a88e889573b9cf1eab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzYtNi0xLTEtMTEyOTg_999e76a1-8b7a-4877-aebd-6233891d99ff"
      unitRef="usd">423000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i4daaf97620504beb90b1882227ff737f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzYtOC0xLTEtMTEyOTg_3416f5bb-f180-40ea-b5b8-6af0c9848880"
      unitRef="usd">4956000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzctNC0xLTEtMTEyOTg_c3e5eb9c-acea-417d-8a41-b09bba01c863"
      unitRef="usd">436000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzctNi0xLTEtMTEyOTg_440726ff-7a21-425b-91e9-ca36b2b48567"
      unitRef="usd">55849000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90YWJsZTphMmRmZTAwMDc4MmE0NjQ2YjJhZmY2OTEyMjJjYmJkMi90YWJsZXJhbmdlOmEyZGZlMDAwNzgyYTQ2NDZiMmFmZjY5MTIyMmNiYmQyXzctOC0xLTEtMTEyOTg_8e6c374d-a56a-4fb0-87f8-633917f710e1"
      unitRef="usd">16975000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:PotentialDevelopmentMilestones
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE5MzE_0dd1bd97-2f09-4e07-8421-eba68f17bedd"
      unitRef="usd">1700000000</nktr:PotentialDevelopmentMilestones>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="i3bb556020be549ee87413847caad7cad_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzMwOTc_89ddbd80-86a1-48d6-adf9-7770813024ec"
      unitRef="number">0.65</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="i8261a40efe0948f49707ae9d352985c9_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzMxMTY_dd174715-0367-41f3-81e6-9e7ae8968a5a"
      unitRef="number">0.35</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i0091cbcb2514452baa6df443b7072779_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzM0NzI_de8c8037-200b-4100-b975-85964a1b5ca3"
      unitRef="number">0.675</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="ie78f916daa434e17a021f7221225eb22_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzM0OTU_add1c346-abac-4951-987e-c6834242624a"
      unitRef="number">0.325</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i8261a40efe0948f49707ae9d352985c9_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzM1Nzc_5ee74dd2-79d2-41c8-8d3b-8c12c421d640"
      unitRef="number">0.35</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i3bb556020be549ee87413847caad7cad_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzM2MDA_cc2015a3-d38c-40d3-a8cc-05065b5188d2"
      unitRef="number">0.65</nktr:PercentageOfSharingInProductionCosts>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="i6c31a5edbd5f4e7ba1771e0dd2cfd00f_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzQ0OTU_01b3d545-7e90-4c9b-92a2-b6de01dab3e1"
      unitRef="usd">1000000000</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <us-gaap:SharesIssued
      contextRef="i3a673492af0542c787de8ecf805aa6b6_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzQ4NTE_2fba0e33-929d-4bae-8215-2db3312be250"
      unitRef="shares">8284600</us-gaap:SharesIssued>
    <nktr:SaleOfStockConsiderationReceived
      contextRef="i0971825b2d534ad7a2466cf3158c182f_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzQ5NjU_ecc820af-5b26-4731-b1d3-873d59c19761"
      unitRef="usd">850000000</nktr:SaleOfStockConsiderationReceived>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i859a4f864b514e87a0cf719770bf6959_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE3NTkyMTg2MTA3OTg1_baafe73d-7ea6-4dcb-8e0d-365c29f74539"
      unitRef="usd">25000000</nktr:PotentialDevelopmentMilestones>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i859a4f864b514e87a0cf719770bf6959_I20200109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE3NTkyMTg2MTA4MTk2_b32b8497-3492-4ec6-8796-70c59a62dce4"
      unitRef="usd">25000000</nktr:PotentialDevelopmentMilestones>
    <nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones
      contextRef="i8f0bd98c891a4594a3a511270a06abda_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE3NTkyMTg2MTA4OTE0_1efbc2bf-7929-46eb-b5c9-d2bc11fcf470"
      unitRef="usd">1400000000</nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones>
    <nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones
      contextRef="icdecde4596554cde9aa263b142ab9462_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE3NTkyMTg2MTA5MDk3_08e67d19-2623-40c6-b9d9-0d89bc48d0fb"
      unitRef="usd">350000000</nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones>
    <nktr:ReimbursementOfExpenses
      contextRef="i7a15cd1d266049a6b956f4c5cda3ccfe_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzY4NjE_c791a206-3b49-429a-9775-862a0f128c48"
      unitRef="usd">101500000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="ie2c265cd979f48f49755e5233054afc9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzY4Njg_89c06efc-9afa-47f4-afd3-0b75f0382f46"
      unitRef="usd">128200000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i8db809beaa2342b6907e26d5a756ecbc_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzY4NzY_2d69b25c-0fa0-4845-917a-1a9aa65952a9"
      unitRef="usd">105400000</nktr:ReimbursementOfExpenses>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i404b477314254c6c9c18783047bfaddb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzcwNzQ_900113af-deb8-424c-b80d-bd586f1802e1"
      unitRef="usd">21400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8fb38abf73194c0185c0ad4dedc15a76_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzcwODI_cd9bfe0e-99b8-416f-97fb-4e01b56bc9d5"
      unitRef="usd">38700000</us-gaap:AccountsReceivableNetCurrent>
    <nktr:CompanyShareOfDevelopmentCostsAnnualCap
      contextRef="i02fa6a90350c495998c00c9ec2be64b1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzcyMzA_be7f676b-013e-4535-92cd-25d7b1127f33"
      unitRef="usd">125000000</nktr:CompanyShareOfDevelopmentCostsAnnualCap>
    <nktr:CompanyShareOfDevelopmentCostsAnnualCap
      contextRef="i7de3ce10d71c401f8c6b6d9fa8f5d1fc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzM4NDgyOTA3NTU2OTY_9bce6f8a-aee6-4292-8c2c-189e89a419fe"
      unitRef="usd">4000000</nktr:CompanyShareOfDevelopmentCostsAnnualCap>
    <nktr:CompanyShareOfDevelopmentCostsAnnualCap
      contextRef="i7de3ce10d71c401f8c6b6d9fa8f5d1fc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzMyOTg1MzQ5NDYwMTE_9bce6f8a-aee6-4292-8c2c-189e89a419fe"
      unitRef="usd">4000000</nktr:CompanyShareOfDevelopmentCostsAnnualCap>
    <nktr:AggregateConsiderationReceivedFromAgreements
      contextRef="i6fe08663b69b470d9befa4a3fea814cc_D20180101-20181231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzg0MDU_dea4291f-d78d-49c4-a21a-ad58ad848da5"
      unitRef="usd">1850000000</nktr:AggregateConsiderationReceivedFromAgreements>
    <nktr:EstimatedFairValueOfShares
      contextRef="i8045653e56804da78b7a3f7548e93f95_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzg3NTY_fa40fddf-8c00-4b92-a16a-2579e70ebb03"
      unitRef="usd">790200000</nktr:EstimatedFairValueOfShares>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i6fe08663b69b470d9befa4a3fea814cc_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzg4MTE_968ee0f0-e629-4307-b532-a071dbc0fd77"
      unitRef="usd">1059800000</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i35bc8164332c4f0d942659ecdb9b7c2a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzgyNDYzMzcyNzA5NzI_f642e23b-3eab-4e09-bf82-c1beee10b4db"
      unitRef="usd">50000000</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:PotentialDevelopmentRegulatoryAndSalesMilestones
      contextRef="i6179d6e6ea6445b59e375f1714da51d8_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzkwMDE_d232865e-f850-4fb3-b25b-9faaa0fc6e2b"
      unitRef="usd">1800000000</nktr:PotentialDevelopmentRegulatoryAndSalesMilestones>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="id10b0e192e72479c93c3fb96e48815dd_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzk5Njc_b7e807e9-a258-44d6-a85e-d20161e6a7c1"
      unitRef="usd">150000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="ide4cc486142a4e91a1bc4da6d2ef22e4_I20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwMDE1_0134fbcd-c6a5-4bf1-8bb6-3f4a5c072e01"
      unitRef="usd">250000000</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="ie9610c03746f479f8ed2307f84e94aa8_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwMjk4_3e273014-766a-4e61-b14b-201558d3a626"
      unitRef="number">0.75</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="i94624f38524b41d19de37806eae8205a_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwMzM1_c512f23b-6aa9-4037-a1c8-35ae53b6d5cd"
      unitRef="number">0.25</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i571d31ed3414457d970b51bd263f4336_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwNDg1_541c17e4-9ea6-4cc6-9855-810adb173ec4"
      unitRef="number">0</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i4af4611c2c0a47adafeff233ec324125_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwNDkx_1c4dff30-6214-4983-a161-fd69f5b4b9d8"
      unitRef="number">0.25</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
      contextRef="i2e394a6636a846efaeb92892f815f0f7_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzEwOTA0_a62f2fde-6bab-46e0-9d74-9ae5a1beaff7"
      unitRef="number">0.50</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
      contextRef="i2e394a6636a846efaeb92892f815f0f7_D20170823-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzExMTM5_c612f492-0b97-4313-b1a5-f0878d6ef1e5"
      unitRef="number">0.75</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="id10b0e192e72479c93c3fb96e48815dd_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY2ODM3_a22bab55-15fa-4400-8eb5-4923fcc2d7d8"
      unitRef="usd">150000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="ifdf41eee0b3e48dd93b8a4402bac9137_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY2ODYw_8abf7805-105c-4d53-815b-93aa6b927b08"
      unitRef="usd">125900000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="ib6e7e8305ef0454abcf6345f4b1ee7d3_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY2ODgw_2554deac-dc32-41f4-b83a-9fdd4423789b"
      unitRef="usd">17600000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i6812a1be21d84f488147e73621f09203_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY2OTM5_82b34425-f11d-4ef0-ab5b-db6460b4f42a"
      unitRef="usd">6500000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45d391452d324672a836342487419576_D20170801-20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY3NTU5_4c5b4796-40ff-4ee5-b1ef-53046f602cdf"
      unitRef="usd">125900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i60213b20f36548838d7b341fd83327c8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDY4MDY0_ff058a85-6c3c-4c37-ae65-301c355e4568"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments
      contextRef="i163fba6573974206a8cbfb1e757d6908_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE4NjUw_f8d84318-cbf6-451e-85a0-fb8503759394"
      unitRef="number">0.40</nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i4620b301e5a3473081e7c8cfc28f8404_D20101001-20101031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE2NDkyNjc0NDc0ODEz_0c2f0640-bf3e-489d-adbe-51b47349ccb1"
      unitRef="usd">50000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ib32493f3644b448eb1a1da39e4dbd1cf_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzE0MjkzNjUxMjE5NjM4_b781ab90-02bd-42d9-88b1-a2e924f2b747">P10Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <nktr:PotentialDevelopmentMilestones
      contextRef="icbc31f05452946b7981e6387e3c1acd2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzIwNDQy_a29d1584-26a0-460d-9bce-de139e353d31"
      unitRef="usd">40000000</nktr:PotentialDevelopmentMilestones>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2a74676520a541cf835f2a6ff04233d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMTgvZnJhZzpjZDUxYWViMjJlNTc0ZGJiYjg1MjYwYzdhMDMzZDQzMi90ZXh0cmVnaW9uOmNkNTFhZWIyMmU1NzRkYmJiODUyNjBjN2EwMzNkNDMyXzIxMDI2_1872d2c8-feac-42a1-82d0-64e8ce481e8f"
      unitRef="usd">2000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMjg_d8b5a27b-0c31-472b-95ab-88b38480e917">Stock-Based Compensation&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; 2017 Performance Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our 2017 Performance Incentive Plan (2017 Plan) provides for the issuance of our common stock to members of the Board of Directors, officers or employees, certain consultants and advisors and our subsidiaries. Our 2017 Plan has been amended and restated such that an aggregate 34,200,000 shares have been authorized for issuance as of December&#160;31, 2021, including 5,000,000 shares that were approved on June 10, 2021. Under the 2017 Plan, we may issue stock options, restricted stock, performance stock, stock units, stock appreciation rights and other similar types of awards. When the 2017 Plan was approved on June&#160;14, 2017, any shares of our common stock that were available for issuance under our 2012 Performance Incentive Plan (the 2012 Plan) ceased to be available for future grants. However, options and RSUs granted under the 2012 Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;remained outstanding, and any options or RSUs that were cancelled or forfeited became available for issuance under the 2017 Plan. Shares issued for RSUs, PSUs or any other &#x201c;full-value award&#x201d; will be counted against the share limit as 1.5 shares for every one share actually issued in connection with the award. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted or issued non-qualified stock options, RSUs and PSUs to employees, officers, and non-employee directors. For our employees, the requisite service period is generally four years for stock options, and three years for RSUs and PSUs. For our directors, the requisite service is generally one year for stock options and RSUs. The maximum term of a stock option or stock appreciation right is eight years from the date of grant. The per share exercise price of an option generally may not be less than the fair market value of a share of our common stock on the NASDAQ Stock Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our Change in Control Plan (the CIC Plan), in the event of a change of control of Nektar and a subsequent termination of employment initiated by us or a successor company other than for Cause (as defined in the CIC Plan) within twelve months following a change of control, our employees are entitled to full acceleration of their unvested equity awards. Our Chief Executive Officer, Senior Vice Presidents and Vice Presidents (including Principal Fellows) are also entitled to full acceleration of unvested equity awards if the termination is initiated by the employee for a Good Reason Resignation (as defined in the CIC Plan) within twelve months following a change of control. Additionally, non-employee directors would also be entitled to full acceleration of vesting of all outstanding stock awards in the event of a change of control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Under the terms of our the Employee Stock Purchase Plan (ESPP), employees may purchase shares of our common stock based on a percentage of their compensation subject to certain limits. Shares are purchased at 85% of the lower of the closing price on either the first day or last day of each six-month offering period. An aggregate 3,500,000 shares have been authorized for issuance under our ESPP, including 1,000,000 shares approved on June 17, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of assets and other costs for terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance. Stock-based compensation expense resulting from PSUs and our ESPP was not significant in the years ended December&#160;31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, total unrecognized compensation costs of $187.4 million related to unvested stock-based compensation arrangements are expected to be recognized as expense over a weighted-average period of 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Black-Scholes Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table lists the Black-Scholes option-pricing model assumptions used to calculate the fair value of employee and director stock options, as well as the resulting grant-date fair value:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average volatility factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The average risk-free interest rate is based on the U.S.&#160;treasury yield curve in effect at the time of grant for periods commensurate with the expected life of the stock-based award. We have never paid dividends, nor do we expect to pay dividends in the foreseeable future; therefore, we used a dividend yield of zero. Our estimate of expected volatility is based on the daily historical trading data of our common stock at the time of grant over a historical period commensurate with the expected life of the stock-based award. We estimated the weighted-average expected life based on the contractual and vesting terms of the stock options, as well as historical cancellation and exercise data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited &amp;amp; canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_______________________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The intrinsic value of options exercised during the years ended December&#160;31, 2021, 2020 and 2019 totaled $17.3 million, $15.9 million and $30.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of RSU Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU award activity is as follows (in thousands except for per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair values of RSUs granted during the years ended December&#160;31, 2021, 2020 and 2019 were $14.68, $19.24 and $23.32, respectively. The fair value of restricted stock that vested in the years ended December&#160;31, 2021, 2020 and 2019 totaled $45.3 million, $33.3 million and $32.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;401(k) Retirement Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We sponsor a 401(k) retirement plan whereby eligible employees may elect to contribute up to the lesser of 60% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) plan permits us to make matching contributions on behalf of all participants, up to a maximum of $6,000 per participant. For the years ended December&#160;31, 2021, 2020, and 2019, we recognized $3.6 million, $3.5 million, and $3.5 million, respectively, of compensation expense in connection with our 401(k) retirement plan.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i85e44fd2a3b7430fb8662bdf1cfee75a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NTU2Njk_05b27207-9167-4161-ade3-3e586d2c0c58"
      unitRef="shares">34200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib9260c5cf0a145fd9ef016e7007916ce_I20210610"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIxMzg5_631503c6-d66a-48a9-a68b-1ddde21668e1"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare
      contextRef="i85e44fd2a3b7430fb8662bdf1cfee75a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIzMTI5_550ddb1d-a284-4a0d-891f-5b3a96576dcf"
      unitRef="number">1.5</nktr:ShareBasedCompensationPlansShareLimitForEveryOneShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="iea9636cc4c9d490297fba185f90f9827_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIxNzQ4_43eec72a-a9df-4f81-945f-05686d9947e6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i447e3d8d3d6a40ff8c71fa4631994b79_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDI0MzUy_9c0e2ddf-490f-408c-a4ed-ccaceadd1ea3">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i37ef7aa72e7f4284abbf69eb9fcf07de_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIxODM4_f1fd37c2-9e3f-4e2c-bc90-e204e33e4c0c">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i0c98c4e18c764ec4aabcffa64729091b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIyMTk0_2daf90a0-1378-411b-8e55-2bcb71b10438">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <nktr:ChangeInControlSeverancePaymentPeriodForExecutives
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDI4NDU2_42688a39-ea2f-43c0-82c7-224d5bdc7d20">P12M</nktr:ChangeInControlSeverancePaymentPeriodForExecutives>
    <nktr:ChangeInControlSeverancePaymentPeriodForExecutives
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDI4ODMy_42688a39-ea2f-43c0-82c7-224d5bdc7d20">P12M</nktr:ChangeInControlSeverancePaymentPeriodForExecutives>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i3636ccf59db74199a476bef6db7fa9b5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDI1Mjgy_e60b145e-5c46-43c4-a0fe-1df2f81ec7e9"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie278c33e215c4682baa578128551c2d8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NTU2ODE_7f0ad506-4d11-4408-9d23-8758d47fcf43"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ic55f7a5b573548869eb6b5c0c65a71b4_D20200617-20200617"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE2NDkyNjc0NDIzNzEx_3bc48911-d974-4aa1-ae08-b304afeed7ba"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMzM_cc20908d-07bb-4856-8482-0c61b71ddec9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize total stock-based compensation expense in our Consolidated Statements of Operations as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of assets and other costs for terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0035b332ba9d4aa3ae359c9299758ee5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzItMS0xLTEtMTEyOTg_8410c5e5-2a04-4c8c-8343-0744e7333b82"
      unitRef="usd">2779000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8f052c3b58374798bbb51692c71f38a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzItMy0xLTEtMTEyOTg_ba7c80d8-2826-49a1-a73b-40043b229158"
      unitRef="usd">2825000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie44b9566b75c444fa92e9c77ccb22df0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzItNS0xLTEtMTEyOTg_d2c7f3bb-ab82-4421-9295-2d13d542b85b"
      unitRef="usd">4294000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2401bd6e0c9941d2ac71f0226fb724d4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzMtMS0xLTEtMTEyOTg_e44d2db0-dbfd-4950-a6e0-a1f8ca59d2ef"
      unitRef="usd">54821000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i973a75b3adfc4d628fdc8dbe94b83110_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzMtMy0xLTEtMTEyOTg_bc9fdff8-9873-42ed-9f23-ac17f22c4e26"
      unitRef="usd">57116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d494d74848a4be6b679b6d322a4a6ad_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzMtNS0xLTEtMTEyOTg_f847d6e9-15a3-461f-9948-ef7fa2a20669"
      unitRef="usd">63224000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5f6ea4f6ff6546d4a7b6f841d44f50c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzQtMS0xLTEtMTEyOTg_307a184b-3e88-44da-8b29-5ae6de5b9e5c"
      unitRef="usd">37074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i029b733cde5b4e28800367770689c2a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzQtMy0xLTEtMTEyOTg_b2ad349b-1f90-473f-bd0d-b4cb241038d6"
      unitRef="usd">33295000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic276dbba3c744c5dbce8ec6fa2c4d30c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzQtNS0xLTEtMTEyOTg_766a131f-5c31-4e17-bc9b-8ac552f4ba52"
      unitRef="usd">32277000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idaa277296ff1492d902aa6bd17b985a1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzUtMS0xLTEtMTEyOTg_d9026eac-bfb3-42da-8946-fda1a95b8719"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81a24d5a38eb49e09e58c801f3465307_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzUtMy0xLTEtMTEyOTg_fe7b5329-366b-42a1-96ec-09406058a4a4"
      unitRef="usd">1025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i70a6b923db694bdea933ddef727104ed_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzUtNS0xLTEtMTEyOTg_6e969084-3919-4df0-bb57-6aa1f51b18f9"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzYtMS0xLTEtMTEyOTg_d10d0dd8-eb66-4912-8564-88fddbed6ad4"
      unitRef="usd">94674000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzYtMy0xLTEtMTEyOTg_63cabd6b-31bf-4584-b236-5855cbc97384"
      unitRef="usd">94261000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2NGY0ODQ0MTgwZjI0YmIwODllODQ3YjdmOTVlYWNhYy90YWJsZXJhbmdlOjY0ZjQ4NDQxODBmMjRiYjA4OWU4NDdiN2Y5NWVhY2FjXzYtNS0xLTEtMTEyOTg_652e0742-6980-4529-a9b5-b04d67037b40"
      unitRef="usd">99795000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzM2Mg_3fad7141-72e5-4541-985b-c9af69d1c198"
      unitRef="usd">187400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMjk_9d4f9e83-f52e-4205-a170-de744b527738">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzItMS0xLTEtMTEyOTg_e556e83b-ae71-4998-be0f-f1a2d9d90000"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzItMy0xLTEtMTEyOTg_6ade4514-026e-4bec-aee8-c28ee8a61b8d"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzItNS0xLTEtMTEyOTg_3fdbcd11-ec38-43ac-86ce-6bfdb3cac2bc"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzMtMS0xLTEtMTEyOTg_c7795fd5-82dd-44ba-a390-f83c85c4c188"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzMtMy0xLTEtMTEyOTg_634c6af3-25f3-485f-8f45-073a438e5e80"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzMtNS0xLTEtMTEyOTg_2219e1d9-a5fb-4093-9079-a94d356de0cd"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzQtMS0xLTEtMTEyOTg_5bca2561-1f1a-4042-a024-66c847841baa"
      unitRef="number">0.638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzQtMy0xLTEtMTEyOTg_f125c71b-d0c4-4e05-b205-0910986f191a"
      unitRef="number">0.641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzQtNS0xLTEtMTEyOTg_09eec4e5-8cd2-4e76-bc72-eb0e2321ed8a"
      unitRef="number">0.622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzUtMS0xLTEtMTEyOTg_298f45d4-0168-49b1-bd3f-368f15a31019">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzUtMy0xLTEtMTEyOTg_ba23a3d3-c8f5-4186-b85c-238f193fb8e8">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzUtNS0xLTEtMTEyOTg_bb76a933-bbef-4792-988b-cb623a277c3e">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzYtMS0xLTEtMTEyOTg_65a06501-e1bb-410f-b0a8-efff72bdf511"
      unitRef="usdPerShare">8.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzYtMy0xLTEtMTEyOTg_d1f54af8-6e7e-473c-94a2-44c1ab7c6115"
      unitRef="usdPerShare">10.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo5YjQyM2UxYzlkMzA0OGM4YjhiODBlMGY4NDk0NGI4ZC90YWJsZXJhbmdlOjliNDIzZTFjOWQzMDQ4YzhiOGI4MGUwZjg0OTQ0YjhkXzYtNS0xLTEtMTEyOTg_f41b519f-31c5-4ea4-b099-2a17c0ec4ab1"
      unitRef="usdPerShare">12.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7a941c5289d14ecb98a14b23c2c6474d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzExNzE_fccf7b10-c450-4fa4-95bf-be6d86f13edb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMzc_4bfde961-cc7b-4bfd-9873-509fc24ce802">The table below presents a summary of stock option activity under our equity incentive plans (in thousands, except for price per share and contractual life information):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited &amp;amp; canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;_______________________________________________________________(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31, 2021.</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzEtMS0xLTEtMTEyOTg_65231f30-9734-4178-9e84-77154bb2dc49"
      unitRef="shares">13637000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzEtMy0xLTEtMTEyOTg_7de07f15-3116-416b-8169-da02f1153935"
      unitRef="usdPerShare">24.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzItMS0xLTEtMTEyOTg_85463d3c-becd-4bb9-94f3-526b8463565d"
      unitRef="shares">2890000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzItMy0xLTEtMTEyOTg_8aa4ae37-db72-4b97-8f87-2523c76ff5b4"
      unitRef="usdPerShare">14.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzMtMS0xLTEtMTEyOTg_e4954bc1-feea-4f60-a6a6-84d91646fe69"
      unitRef="shares">2481000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzMtMy0xLTEtMTEyOTg_e39ad9cf-37ea-458e-97f1-cc40a02ab624"
      unitRef="usdPerShare">12.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzQtMS0xLTEtMTEyOTg_fd64b4cf-2e81-4abc-adf0-8343d2c2c774"
      unitRef="shares">504000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzQtMy0xLTEtMTEyOTg_b7106a6d-9491-4515-9a7a-68c82a0e664a"
      unitRef="usdPerShare">46.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzUtMS0xLTEtMTEyOTg_17039465-c9e3-4e71-8b48-fd27e96d862e"
      unitRef="shares">13542000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzUtMy0xLTEtMTEyOTg_7380af15-93ba-455f-bf0d-069743187776"
      unitRef="usdPerShare">23.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzUtNS0xLTEtMTEyOTg_bf5ec6ec-9dd8-445a-8611-136210fad4bf">P4Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzUtNy0xLTEtMTEyOTg_f217ab66-2217-4adc-b5ed-ec7756a0dbd6"
      unitRef="usd">2711000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzctMS0xLTEtMTEyOTg_083bfe61-d178-4003-bea9-e5fb9bedec01"
      unitRef="shares">8236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzctMy0xLTEtMTEyOTg_a5c40468-ff6a-474a-8de5-032b7b58c870"
      unitRef="usdPerShare">26.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzctNS0xLTEtMTEyOTg_0b8ec953-8e03-4949-ad0a-6e55931330f2">P3Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTpmNmQxYWY3YzgxNmE0NzhmOTA4YmY1OWY5NmQ4ZTBjOS90YWJsZXJhbmdlOmY2ZDFhZjdjODE2YTQ3OGY5MDhiZjU5Zjk2ZDhlMGM5XzctNy0xLTEtMTEyOTg_159d3842-09e3-4d28-8678-c6488f9af5cd"
      unitRef="usd">2267000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIwNjQ_30df7ceb-2935-43a7-87ea-c5250f2a22d0"
      unitRef="usd">17300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIwNjg_1eebdcfe-3aea-4727-9e74-a674a68dbdfe"
      unitRef="usd">15900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIwNzU_11661f9b-aeb6-43e7-8240-c604ff890bc8"
      unitRef="usd">30600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMzE_69a78c70-6c46-4d8d-819c-52891de0873b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU award activity is as follows (in thousands except for per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Units Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i718223867ea449b3bb07403f12f97462_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzEtMS0xLTEtMTEyOTg_ef8e8f89-fafd-42c8-9ee7-27f5fa9c0df0"
      unitRef="shares">7094000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i718223867ea449b3bb07403f12f97462_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzEtMy0xLTEtMTEyOTg_f5c4514a-8ce9-4e7b-bf9e-478b15eb3cc9"
      unitRef="usdPerShare">22.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzItMS0xLTEtMTEyOTg_22ae8b9c-3a5c-48e4-90c8-b13e98d41341"
      unitRef="shares">6544000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzItMy0xLTEtMTEyOTg_8a90d4ae-f191-4025-ac72-ca81b0bc300d"
      unitRef="usdPerShare">14.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzMtMS0xLTEtMTEyOTg_fa189e50-115f-4303-b99b-cc80260d3291"
      unitRef="shares">2617000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzMtMy0xLTEtMTEyOTg_779cdf16-24ed-4acc-810a-f0f334344f66"
      unitRef="usdPerShare">25.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzQtMS0xLTEtMTEyOTg_195e9932-f2d9-4ad4-8e63-7805e0db0cf1"
      unitRef="shares">1091000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzQtMy0xLTEtMTEyOTg_318990fe-060c-4cf6-9fe2-324a61a8bf51"
      unitRef="usdPerShare">21.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib0779bcc3fd547a7a0d232c80b0cca7d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzUtMS0xLTEtMTEyOTg_5f59320b-9973-4252-8077-362bf5364b1f"
      unitRef="shares">9930000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib0779bcc3fd547a7a0d232c80b0cca7d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90YWJsZTo2OGRiMGI4ODNiNjM0MjkyYjc0MzY5NTNjZDVjOGU3ZC90YWJsZXJhbmdlOjY4ZGIwYjg4M2I2MzQyOTJiNzQzNjk1M2NkNWM4ZTdkXzUtMy0xLTEtMTEyOTg_7a01d0c5-8740-4a94-a39d-e43c4ff91d08"
      unitRef="usdPerShare">16.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzM4NDgyOTA3MTE4MjI_bdc7319b-90aa-4dd3-85b9-3089a55daa38"
      unitRef="usdPerShare">14.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i613d6ffb709a4aceb22ec5c774efb691_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzM4NDgyOTA3MTE4MzA_a3d5d2d1-6514-4425-8d6e-b0d7aca198c5"
      unitRef="usdPerShare">19.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i059dd17f5075463e95e35460261b7a4b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzM4NDgyOTA3MTE4Mzg_a7c8a142-4faa-4f5d-8c11-fab02a6ceb55"
      unitRef="usdPerShare">23.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMDA_1cbebaa2-fdc0-45bb-ae35-738c1a4e05cd"
      unitRef="usd">45300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i613d6ffb709a4aceb22ec5c774efb691_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMDQ_09305eb7-ad44-4a85-b454-0d5b630118fa"
      unitRef="usd">33300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i059dd17f5075463e95e35460261b7a4b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzIzMTE_87b0ff36-bd52-45fd-bd6f-87480317d846"
      unitRef="usd">32400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE3NTkyMTg2MDU3OTQ0_3b2fa454-1cae-497b-bd1e-a7ea04d3e039"
      unitRef="number">0.60</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE3NTkyMTg2MDU4MTgy_7eb7f825-f70b-4aaa-b1fa-dad2632e4330"
      unitRef="usd">6000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE3NTkyMTg2MDU4MjU2_53dd7f6f-4cda-4727-a802-aafdecf63255"
      unitRef="usd">3600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE3NTkyMTg2MDU4MjYx_33b397d6-9833-471d-87ab-be2c010ca65a"
      unitRef="usd">3500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjQvZnJhZzo3N2MzY2JlY2EzODQ0YzEyYjcyNDU3NThiYjA3NjZhNS90ZXh0cmVnaW9uOjc3YzNjYmVjYTM4NDRjMTJiNzI0NTc1OGJiMDc2NmE1XzE3NTkyMTg2MDU4Mjcw_49980921-e55f-4a2a-91f6-867f9c977d2f"
      unitRef="usd">3500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNzM_32d2032e-aae1-42c0-a3b3-5b26f6c870f3">Income Taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Income (loss) before provision for income taxes includes the following components (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(445,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(441,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(523,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(440,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provision for Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93,229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense on liability related to sales of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash royalty revenue related to sales of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Realization of our deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Because of our lack of U.S.&#160;earnings history, other than income resulting from revenue recognized from the BMS Collaboration Agreement, and projected future losses, we have fully reserved our net U.S.&#160;deferred tax assets with a valuation allowance. The valuation allowance increased by $115.6 million and $95.0 million during the years ended December&#160;31, 2021 and 2020, respectively. The increase in the valuation allowance is consistent with the increase in net operating loss carryforwards in the respective periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Operating Loss and Tax Credit Carryforwards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As of December&#160;31, 2021, we had a net operating loss carryforward for federal income tax purposes of approximately $2.4 billion, portions of which will begin to expire in 2022 and a total state net operating loss carryforward of approximately $1.5 billion, portions of which will begin to expire in 2026. We have federal research credits of approximately $103.3&#160;million, which will begin to expire in 2023 and state research credits of approximately $47.0&#160;million which have no expiration date. We have federal orphan drug credits of $19.4&#160;million which will begin to expire in 2026. Utilization of some of the federal and state &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net operating loss and credit carryforwards are subject to annual limitations due to the &#x201c;change in ownership&#x201d; provisions of the Internal Revenue Code of 1986 and similar state provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We have the following activity relating to unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses in statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;If we are eventually able to recognize our uncertain tax positions, our effective tax rate may be reduced. We currently have a full valuation allowance against our U.S. net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Adjustments to the substantial majority of our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carryforwards rather than resulting in a cash outlay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We file income tax returns in the U.S., California, Alabama, certain other states and India. As a result of our net operating loss and research credit carryforwards, substantially all of our domestic tax years remain open and subject to examination. We may be subject to examination in India from time to time, but we do not believe that any liability resulting from such an examination would have a material effect on our financial position or results of operations.&lt;/span&gt;&lt;/div&gt;Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. During the years ended December&#160;31, 2021, 2020 and 2019, no significant interest or penalties were recognized relating to unrecognized tax benefits. Although it is reasonably possible that certain unrecognized tax benefits could change in the future, we do not anticipate any significant changes over the next twelve months.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNjc_93283c18-d9c9-4014-a795-ba3a95da5251">Income (loss) before provision for income taxes includes the following components (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(445,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(441,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(523,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443,947)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(440,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzItMS0xLTEtMTEyOTg_c911626c-055d-4a39-9d7a-31f1d5b3fcb3"
      unitRef="usd">-524440000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzItMy0xLTEtMTEyOTg_2c93685a-70e7-488c-ac00-eb3365229f28"
      unitRef="usd">-445370000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzItNS0xLTEtMTEyOTg_bd070876-e8b1-4aff-b28d-1aace17b5c65"
      unitRef="usd">-441494000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzMtMS0xLTEtMTEyOTg_ca3608d9-2b7a-43fa-a0da-e2c19777cae1"
      unitRef="usd">1160000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzMtMy0xLTEtMTEyOTg_0592b8b9-e6fc-474d-b80a-9ec71b7ea33b"
      unitRef="usd">1423000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzMtNS0xLTEtMTEyOTg_28a82e8a-23e9-473f-accb-89d4fa8e9214"
      unitRef="usd">1440000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzQtMS0xLTEtMTEyOTg_c3d2bb37-cacb-469f-85d2-0a474e9047e3"
      unitRef="usd">-523280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzQtMy0xLTEtMTEyOTg_c3c22425-dd5c-4ae4-b05b-4e05459d4766"
      unitRef="usd">-443947000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo3NDA5ZGMwOTk0ZjY0ZTkxYjZkYmM5ZmE1NjhjNWI4MS90YWJsZXJhbmdlOjc0MDlkYzA5OTRmNjRlOTFiNmRiYzlmYTU2OGM1YjgxXzQtNS0xLTEtMTEyOTg_a61f9db5-3be5-4735-8b1a-f7a9884c719c"
      unitRef="usd">-440054000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNzU_d5bfc599-a7e9-4c1d-9c6c-9b45299de08e">The provision for income taxes consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzMtMS0xLTEtMTEyOTg_a44c351c-8833-4d7e-8cda-2d123549b260"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzMtMy0xLTEtMTEyOTg_8ff4d8e2-b05b-4cf4-8b47-db1f43cfdce2"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzMtNS0xLTEtMTEyOTg_172c6bbe-c640-4f7d-9607-8c7b62994e87"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzQtMS0xLTEtMTEyOTg_6d8ab60a-8058-408c-a45c-d80ca953f484"
      unitRef="usd">50000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzQtMy0xLTEtMTEyOTg_8985e59a-b147-4da5-acdb-bcd75a7005ce"
      unitRef="usd">165000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzQtNS0xLTEtMTEyOTg_bc001a88-ca6a-4b41-8792-bd0cf1bf392b"
      unitRef="usd">139000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzUtMS0xLTEtMTEyOTg_e70f2b9e-eaba-4eb3-9e5d-2e6bcd353c55"
      unitRef="usd">609000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzUtMy0xLTEtMTEyOTg_cae47cd5-74f7-435d-a17b-4ed0c5cc22f4"
      unitRef="usd">364000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzUtNS0xLTEtMTEyOTg_ad44f8c8-9a0b-4e4e-84c9-7c8fe0f8875b"
      unitRef="usd">495000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzYtMS0xLTEtMTEyOTg_7375ae29-5b8f-431a-9e08-25d6ce410b3c"
      unitRef="usd">659000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzYtMy0xLTEtMTEyOTg_d2388ee1-28cb-445b-b7d5-7926e98fd86f"
      unitRef="usd">529000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzYtNS0xLTEtMTEyOTg_a71f991b-72f3-46ff-b03b-3d72d9665f2c"
      unitRef="usd">634000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzgtMS0xLTEtMTEyOTg_be14d625-8f13-4991-9a0e-464fb986bf5e"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzgtMy0xLTEtMTEyOTg_868e2f5c-e052-49bf-8dac-be95a81f1478"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzgtNS0xLTEtMTEyOTg_676af439-7cfa-47cb-a430-ab39260936d5"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzktMS0xLTEtMTEyOTg_23cc9eb5-d5f8-4d0a-a500-a708c36745c2"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzktMy0xLTEtMTEyOTg_784db96b-1643-41e7-b912-1f1788b4977f"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzktNS0xLTEtMTEyOTg_d41d00c1-7818-4cd7-a50f-64bfae507608"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEwLTEtMS0xLTExMjk4_0f219243-90ff-48b5-b144-f3fd034ffdae"
      unitRef="usd">-102000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEwLTMtMS0xLTExMjk4_a479fe3f-80a7-4b0e-bb66-0d75d1db38c4"
      unitRef="usd">-36000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEwLTUtMS0xLTExMjk4_4d8006b2-e006-40fc-9425-4b479ef2d50c"
      unitRef="usd">-21000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzExLTEtMS0xLTExMjk4_04af13a6-66c4-4b60-a860-141a042487bf"
      unitRef="usd">-102000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzExLTMtMS0xLTExMjk4_aaa231fa-ae97-4a55-ad06-394d5f5809c4"
      unitRef="usd">-36000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzExLTUtMS0xLTExMjk4_20cd8ff5-97f0-49c6-b0d4-1809f8fd9578"
      unitRef="usd">-21000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEyLTEtMS0xLTExMjk4_f45aa302-6425-4774-a550-e312613e5f03"
      unitRef="usd">557000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEyLTMtMS0xLTExMjk4_261e7d9b-487c-4154-81b3-6416a8d17ca3"
      unitRef="usd">493000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozMzRkODk1ZTIzNDI0Zjk0OWQ3MWJkZGIxNDYxOWIyZi90YWJsZXJhbmdlOjMzNGQ4OTVlMjM0MjRmOTQ5ZDcxYmRkYjE0NjE5YjJmXzEyLTUtMS0xLTExMjk4_35886f8c-d58f-47fc-bc31-94e4b75ed0dd"
      unitRef="usd">613000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNjk_2494d964-3173-4e2a-9862-a9208d59ed98">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax provision related to continuing operations differs from the amount computed by applying the statutory income tax rate of 21% to our pretax loss as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93,229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense on liability related to sales of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash royalty revenue related to sales of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on revaluation of liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzItMS0xLTEtMTEyOTg_e85537d4-72ae-4596-99f6-446fd295c354"
      unitRef="usd">-109889000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzItMy0xLTEtMTEyOTg_f408643f-28b6-4215-bb60-59245cb8493d"
      unitRef="usd">-93229000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzItNS0xLTEtMTEyOTg_7c86764b-8646-436d-a0c9-8c23b097159e"
      unitRef="usd">-92411000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzMtMS0xLTEtMTEyOTg_fb7529fb-47fb-439e-8197-926de7b2dccc"
      unitRef="usd">4727000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzMtMy0xLTEtMTEyOTg_e1771577-4714-45bb-91c1-a3e4b1c61d3d"
      unitRef="usd">3081000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzMtNS0xLTEtMTEyOTg_8f4b5d46-b1a4-4850-a487-ae535da7f27b"
      unitRef="usd">10511000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzUtMS0xLTEtMTEyOTg_f6cf5e72-0ebe-4601-9ba6-1dcb045182fd"
      unitRef="usd">97914000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzUtMy0xLTEtMTEyOTg_21eae999-59f7-43cc-b9bc-36da5a6b63e8"
      unitRef="usd">87060000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzUtNS0xLTEtMTEyOTg_90abd1d9-dc65-44ff-baaa-f40a3d485471"
      unitRef="usd">104440000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtMS0xLTEtMTgyMTI_12cfe79f-97a6-42ea-875d-6914498bb6ed"
      unitRef="usd">9936000</nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtMy0xLTEtMTgyMTI_14795ae9-9dbc-48f6-84ac-a2b74ce982ed"
      unitRef="usd">6356000</nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtNS0xLTEtMTgyMTI_9731d1f1-03b2-4778-97d2-e3b878db4a15"
      unitRef="usd">5259000</nktr:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzctMS0xLTEtMTkwNTc_d8ec3150-9f14-4b72-8b60-bdec810e02b5"
      unitRef="usd">-7891000</nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzctMy0xLTEtMTkwNTc_727930a9-9434-432a-8bb6-51e6fb22f0f8"
      unitRef="usd">-7967000</nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount>
    <nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzctNS0xLTEtMTkwNTc_9432dda4-4387-406c-a7f3-55c089cac9df"
      unitRef="usd">-7624000</nktr:EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzgtMS0xLTEtMTkwNjc_09c18455-5912-4045-995a-d8bf7251bae1"
      unitRef="usd">4940000</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzctMy0xLTEtMTkxNjg_0ce87c34-ec5f-4878-8968-4bf7fe413da0"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:IncomeTaxReconciliationDispositionOfAssets
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzctNS0xLTEtMTkxNjg_46fa1bed-fd2e-4a45-820a-801c4dc84b37"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtMS0xLTEtMTEyOTg_16240ea8-2980-4367-99ce-cb9c63b0b468"
      unitRef="usd">6627000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtMy0xLTEtMTEyOTg_a33a3c3e-3c0a-4f2a-ae9f-85e457d5dc64"
      unitRef="usd">7929000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzYtNS0xLTEtMTEyOTg_d0805ee5-b7cd-462f-b89b-f20fa5ea6da9"
      unitRef="usd">-672000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzktMS0xLTEtMTEyOTg_da7649e3-8f9b-49ff-85b9-484d756e383b"
      unitRef="usd">3647000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzktMy0xLTEtMTEyOTg_841ed5c5-7691-4aad-b1a2-a0d74d0438c6"
      unitRef="usd">3425000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzktNS0xLTEtMTEyOTg_58128f2b-0359-4f78-8901-71e1228f2f67"
      unitRef="usd">2132000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzEwLTEtMS0xLTExMjk4_41e0ab63-fb62-445b-8982-7c7d480dbe45"
      unitRef="usd">557000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzEwLTMtMS0xLTExMjk4_f95a7f23-2ca8-442e-8e51-4b06d400e5d4"
      unitRef="usd">493000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTozYjI1ZjBhYmZlYTM0N2MwODViNmYwMDI0Mjk0MDU3MS90YWJsZXJhbmdlOjNiMjVmMGFiZmVhMzQ3YzA4NWI2ZjAwMjQyOTQwNTcxXzEwLTUtMS0xLTExMjk4_e2fdd3db-cdd0-4d00-b2ec-807f84ebb809"
      unitRef="usd">613000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNjQ_5120d869-2e32-4b43-b906-f7723fc360ff">We measure deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. Significant components of our deferred tax assets for federal and state income taxes are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzMtMS0xLTEtMTEyOTg_780cd222-af15-496b-8dc3-c124ff617810"
      unitRef="usd">564712000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzMtMy0xLTEtMTEyOTg_2e016e37-04d2-4d1f-8ca9-f523d879d395"
      unitRef="usd">456284000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzQtMS0xLTEtMTEyOTg_e0527f2d-a0b2-4b51-988b-bae47add0199"
      unitRef="usd">139996000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzQtMy0xLTEtMTEyOTg_dd221d7c-6833-4ab9-a96a-4cc1269887c7"
      unitRef="usd">132994000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <nktr:DeferredTaxAssetsLeaseLiability
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzUtMS0xLTEtMTEyOTg_b55229ab-ee2c-4b4b-8708-85c3377eabff"
      unitRef="usd">34680000</nktr:DeferredTaxAssetsLeaseLiability>
    <nktr:DeferredTaxAssetsLeaseLiability
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzUtMy0xLTEtMTEyOTg_812db9df-68fe-43b7-99c0-26dd97f9a1d3"
      unitRef="usd">35672000</nktr:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzYtMS0xLTEtMTgyNzI_5ca59609-e06e-4529-9e3e-460d65b327a8"
      unitRef="usd">33408000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzYtMy0xLTEtMTgyNzI_2e08db5b-7587-40dd-a7eb-389d763c2ba8"
      unitRef="usd">32517000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzYtMS0xLTEtMTEyOTg_ef968d6a-7878-4a99-b8e1-e191407aee62"
      unitRef="usd">23757000</nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties>
    <nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzYtMy0xLTEtMTEyOTg_627e0c31-1afc-4a0d-8391-6f43bbda87b3"
      unitRef="usd">32737000</nktr:DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzctMS0xLTEtMTEyOTg_eda728d0-84af-4056-aaf7-84fefd3a49e1"
      unitRef="usd">6639000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzctMy0xLTEtMTEyOTg_0b973e1e-99ae-441b-9ec7-49ce59344544"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzgtMS0xLTEtMTEyOTg_f776626a-74ee-46a2-b1ab-f06f655abb0c"
      unitRef="usd">10651000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzgtMy0xLTEtMTEyOTg_c1385dfe-df42-45c3-bce9-7f8eaf546860"
      unitRef="usd">11688000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzktMS0xLTEtMTEyOTg_a442cb4e-6026-4715-b861-e9bb4a1f1e8b"
      unitRef="usd">813843000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzktMy0xLTEtMTEyOTg_30f7ec8e-73c9-4cdc-aa61-ac77f5a14467"
      unitRef="usd">701892000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzEwLTEtMS0xLTExMjk4_9833086e-3b68-48be-8502-98ad10cbb62a"
      unitRef="usd">785748000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzEwLTMtMS0xLTExMjk4_d79bc1c1-f98e-42b9-ba4a-ab6947c4ed80"
      unitRef="usd">670103000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzExLTEtMS0xLTExMjk4_1608aebe-60b4-4921-8e22-d45f0744bcad"
      unitRef="usd">28095000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzExLTMtMS0xLTExMjk4_d5870720-e25d-493f-b46f-79f255b42ca6"
      unitRef="usd">31789000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzEzLTEtMS0xLTExMjk4_1de19005-34a1-40a4-85b0-173e10e568d1"
      unitRef="usd">27204000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzEzLTMtMS0xLTExMjk4_12254c18-7194-4a52-bddb-29662df5792d"
      unitRef="usd">29707000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE0LTEtMS0xLTExMjk4_3e00aa88-4306-421f-b4cc-118050a40cc9"
      unitRef="usd">564000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE0LTMtMS0xLTExMjk4_26f045b3-9acc-44c2-a87f-11f76fc670a6"
      unitRef="usd">1856000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE1LTEtMS0xLTExMjk4_64a569c8-2810-4c35-9192-03567be45332"
      unitRef="usd">27768000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE1LTMtMS0xLTExMjk4_fea74daf-a1d9-404e-8f88-5a016d792a45"
      unitRef="usd">31563000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE2LTEtMS0xLTExMjk4_06c432b4-3776-4c59-b9b9-edb7b465a8e9"
      unitRef="usd">327000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTo5ZGY3ZWQ0YWM3Yzc0Njg0YjhiZjk0Y2ZkMzdjMjQ2MS90YWJsZXJhbmdlOjlkZjdlZDRhYzdjNzQ2ODRiOGJmOTRjZmQzN2MyNDYxXzE2LTMtMS0xLTExMjk4_f7c93b33-2025-423b-b467-34f7e95e6a1e"
      unitRef="usd">226000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzEzOTE_e590de1e-14f8-4635-865b-43d636a9b679"
      unitRef="usd">115600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzEzOTg_ce61f70a-8f0e-497a-8ce5-f2179b15fbca"
      unitRef="usd">-95000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <nktr:NetOperatingLossCarryforwardForIncomeTax
      contextRef="i18610030b55b46f09cb8bfa3f26e3ca1_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzE3NTY_4ce80f67-6b71-4cb0-89a9-08b13c92beb9"
      unitRef="usd">2400000000</nktr:NetOperatingLossCarryforwardForIncomeTax>
    <nktr:NetOperatingLossCarryforwardForIncomeTax
      contextRef="i0d291eb67ab54f4689d1aac2f2cdcca8_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzE4ODg_32c70c13-ef33-4877-8c19-82f4864bfb49"
      unitRef="usd">1500000000</nktr:NetOperatingLossCarryforwardForIncomeTax>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i95d9b49258bb447fbbe2d19c4487ee71_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzIyMjU_649b90c2-7bef-4a52-aa96-7cd4cfa11095"
      unitRef="usd">103300000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i13d5a5ae922d40ae88de27a40c5ec05b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzIzMDg_7b46d13d-b02c-4a0c-a331-16d7c1df30e9"
      unitRef="usd">47000000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <nktr:FederalOrphanDrugCredits
      contextRef="i95d9b49258bb447fbbe2d19c4487ee71_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzIzODE_43a1f0d3-0615-406c-a171-03ea7fe24a95"
      unitRef="usd">19400000</nktr:FederalOrphanDrugCredits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNjU_ebbd8fe8-451f-47b5-8970-0463ce8fc11d">We have the following activity relating to unrecognized tax benefits (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapses in statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzItMS0xLTEtMTEyOTg_a17dad01-7581-43a5-aeda-0361631c43a2"
      unitRef="usd">78665000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i89a636947a9046a38a2ed739019eb13c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzItMy0xLTEtMTEyOTg_ab321c82-5f44-4e80-94b9-9b6fb3543adf"
      unitRef="usd">77410000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7e86cae77d44493aad21052dab0a76b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzItNS0xLTEtMTEyOTg_980fd6c3-dc12-4436-bb85-2e75673ea6ad"
      unitRef="usd">27419000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzQtMS0xLTEtMTEyOTg_c77b5d29-633d-44d3-ad30-81bf37d83c11"
      unitRef="usd">2371000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzQtMy0xLTEtMTEyOTg_f24c9e6c-47e2-4d77-98b2-3cfffdcc31a2"
      unitRef="usd">2512000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzQtNS0xLTEtMTEyOTg_c1a8267f-559c-4d04-aa61-b55548a1450e"
      unitRef="usd">49858000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzUtMS0xLTEtMTEyOTg_3d523ba1-a2c4-4232-9cb9-0157307139a8"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzUtMy0xLTEtMTEyOTg_8b6f520e-8c87-4845-8ce0-b78daff695a9"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzUtNS0xLTEtMTEyOTg_14379a4a-a4be-4ee9-baa6-0b82967e10d5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzctMS0xLTEtMTEyOTg_f0407761-a99f-4628-9eee-33a51045d1f3"
      unitRef="usd">58000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzctMy0xLTEtMTEyOTg_bbfbbceb-0867-43d7-bd4c-55fb91073331"
      unitRef="usd">193000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzctNS0xLTEtMTEyOTg_81779632-65c1-46b9-8960-5a51e045a6ce"
      unitRef="usd">277000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzgtMS0xLTEtMTEyOTg_ba3614bd-3a90-4a11-8bdf-e323bfc509d5"
      unitRef="usd">490000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzgtMy0xLTEtMTEyOTg_16b057d0-cd4f-49c1-bdcc-e7499c57f834"
      unitRef="usd">1450000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzgtNS0xLTEtMTEyOTg_09e16ce9-83c0-420e-81ad-f8878acc4d30"
      unitRef="usd">144000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzktMS0xLTEtMTEyOTg_fd3d0537-5f45-4c47-bacd-cf2d88ac80d4"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzktMy0xLTEtMTEyOTg_8359b8e2-b3b5-4bcd-b9fd-5bb886c4d3fb"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzktNS0xLTEtMTEyOTg_928233cb-3491-4ec9-9664-1d696f79bc0a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzEwLTEtMS0xLTExMjk4_a4c78143-67c9-4b17-8fcd-2d705cb949b2"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzEwLTMtMS0xLTExMjk4_eab19d92-7403-49e9-ad32-7604afcbaeaa"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzEwLTUtMS0xLTExMjk4_7717ea05-48a8-4eda-ad6c-396d697c36aa"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib0e8124eb7354356b1cc17142addd673_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzExLTEtMS0xLTExMjk4_d46c9b09-303e-43ef-b87f-8960c71277b5"
      unitRef="usd">80604000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i48e34961873b4743b7e5dc882aecad66_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzExLTMtMS0xLTExMjk4_b030fe84-5d25-42b8-9f98-30762af36ae9"
      unitRef="usd">78665000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i89a636947a9046a38a2ed739019eb13c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90YWJsZTphNzM1ODY2Zjk4OGI0ZjZlYjcxNzM1OGNlNzViNTUwZC90YWJsZXJhbmdlOmE3MzU4NjZmOTg4YjRmNmViNzE3MzU4Y2U3NWI1NTBkXzExLTUtMS0xLTExMjk4_9f2a5483-7884-46b3-8290-84a87b91264d"
      unitRef="usd">77410000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_06265ed0-9962-4bc4-ab0d-89ac6720dc11"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_27470754-3312-4667-828d-68fdedd99b0c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_64d96f32-be31-438a-9150-7248e08b6397"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_697e0fbe-20d6-4903-b8dc-8a443a3de7c9"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_d321b5ba-87ea-4b35-9201-278930b5c6b5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzM4MjA_e81e6a1b-52de-4bc5-8f47-947232083077"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMjcvZnJhZzoxZjI0Mjk4OTBmYTA0MTllYTkyZjIwNmZiYWRiMjE0OS90ZXh0cmVnaW9uOjFmMjQyOTg5MGZhMDQxOWVhOTJmMjA2ZmJhZGIyMTQ5XzQwNjE_a679261a-fe22-4504-9862-4dfa44a57bcd">P12M</nktr:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzE0Mzg_b6271651-4fc0-47b0-924b-1972fac370b8">Segment Reporting&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;We operate in one business segment which focuses on applying our technology platforms to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our revenue is derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from UCB Pharma, Baxalta / Takeda, AstraZeneca and Pfizer  represented 36%, 23%, 16% and 13% of our revenue, respectively, for the year ended December&#160;31, 2021. Revenue from BMS, UCB Pharma, Baxalta / Takeda, and AstraZeneca represented 33%, 23%, 14% and 13% of our revenue for the year-ended December&#160;31, 2020. Revenue from UCB Pharma, Baxalta / Takeda, and AstraZeneca represented 28%, 19%, and 17% of our revenue for the year-ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Revenue by geographic area is based on the headquarters or shipping locations of our partners. The following table sets forth revenue by geographic area (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;At December&#160;31, 2021, $56.1 million, or approximately 93%, of the net book value of our property, plant and equipment was located in the United States and $4.4 million, or approximately 7%, was located in India.&#160;At December&#160;31, 2020, $54.5 million, or approximately 91%, of the net book value of our property, plant and equipment was located in the United States&#160;and $5.1 million, or approximately 9%, was located in India.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <nktr:NumberOfOperatingBusinessSegment
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzQ4_6bf06281-5f91-49d4-9ab4-9058209ebe2b"
      unitRef="segment">1</nktr:NumberOfOperatingBusinessSegment>
    <nktr:NumberOfOperatingBusinessSegment
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzM5MQ_6bf06281-5f91-49d4-9ab4-9058209ebe2b"
      unitRef="segment">1</nktr:NumberOfOperatingBusinessSegment>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2ddb03971de844cf8a92d843f8f0c1c8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzYyMA_6dce37a6-4a86-4b26-a2e0-cbb353752b73"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifaa6e3a9e6e143949bc208e33f67fd4c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzYyNA_2855bc24-14d9-45d4-a7b1-521d310220cf"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i00f01d527a214f5cbd961d14f04dc514_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzYyOA_1af18536-1eac-4cab-8d3b-4c9fae847a6b"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6e87ff4a4650460d9333eb26209aaf9e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzYzNQ_ec49d6cf-1569-456e-99db-c30d38dc9692"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iec3ad0981f8e485fad0d799d0a405dbe_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5Xzc2Mg_95a55f6b-c21b-4956-8bd8-915c0c15fed4"
      unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5301b257f77c4c11ae97c725f1ff567b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5Xzc2Ng_e85a701b-3a78-4428-8a69-06d42ad42799"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i12bc2ab5a68e4a6b955e5b5866281132_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5Xzc3NA_bc1e35f3-573a-4b81-a52c-1c17bd7b7707"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i642a78ec6bfc491eba5a4895194b3e41_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzM4NDgyOTA2OTk4MDU_dbd8a610-6551-4e0a-8cfb-9b7e32c9588d"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i65153175938b412d9314b0291f9d87ec_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzM4NDgyOTA2OTk4MTA_0603042c-36fe-4e3b-858b-cdab369e37b2"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic4ce7911bf79479fb3e7667b452ea08a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzM4NDgyOTA2OTk4MTU_abe9165c-c622-43af-962b-02c64c1d74f2"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia9c9bb30fa1f4b63958f70078463ced9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzM4NDgyOTA2OTk4MjA_f292d03d-de3e-4403-ae0b-79912eece923"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzE0NDA_863d4d7d-92cc-44b1-9028-75f37ad47f31">The following table sets forth revenue by geographic area (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rest of World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie54219086ed7421ab34a8c373a1e98ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzItMS0xLTEtMTEyOTg_71a99938-6a49-447d-a87e-b9697f43a523"
      unitRef="usd">10114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i147a96a3068f4b9e8496063ad3e68b0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzItMy0xLTEtMTEyOTg_da29bff3-a8f3-4917-8694-47a1acaaffd8"
      unitRef="usd">64966000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i556b5871a2d143a897968254b351cc82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzItNS0xLTEtMTEyOTg_a3510c35-c7fc-4a5c-bb78-86cadc1a1e4b"
      unitRef="usd">27093000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie398a4523e0f4e05958bb768906321dd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzMtMS0xLTEtMTEyOTg_dc29947d-19b7-410c-a2ee-3f9e0af465f8"
      unitRef="usd">91793000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if86c78562de248778afb80f62f503bbd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzMtMy0xLTEtMTEyOTg_69e43db3-1c30-4b10-842e-26f94dbf338d"
      unitRef="usd">87949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b5f29e74e4445c8bb936628105494a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzMtNS0xLTEtMTEyOTg_053e7a7d-d3f3-4dae-a7d0-bb9535cf62f7"
      unitRef="usd">87524000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzQtMS0xLTEtMTEyOTg_7919af32-d4a1-42f1-8028-87dea65ec411"
      unitRef="usd">101907000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53a02e6ed23c464682afde8d04213299_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzQtMy0xLTEtMTEyOTg_b222d92c-b9c7-4f5a-8c54-a29652994abb"
      unitRef="usd">152915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e81cb1fb34f40d48fc1afa21b233e7f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90YWJsZTozYjJlYmVmN2JhN2U0ZjhhODI4YzRjMDk4NzZlMDhiMi90YWJsZXJhbmdlOjNiMmViZWY3YmE3ZTRmOGE4MjhjNGMwOTg3NmUwOGIyXzQtNS0xLTEtMTEyOTg_c39763a7-5c9b-41bf-aba2-e1f004c6f0a3"
      unitRef="usd">114617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9cc4668d0303484c94ce77104f692749_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEwOTY_f67eebc2-7c3a-483f-bfec-f35201fc4684"
      unitRef="usd">56100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7dedd82fa6fc42e28334feede0e3e79a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzExMTc_5f41d5be-a737-4349-a832-89a81b18abd7"
      unitRef="number">0.93</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i97b7c38b02314dca802effa14883baf0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEyMTc_fe91bfa6-779d-4912-9489-630edda7cf20"
      unitRef="usd">4400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i18d3853c1171432d9635c5e80c47d4af_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEyMzg_b4ae67e9-7002-4251-8b8e-e2730787fd6c"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8740f4ce936345f3898f8e6e33e633b2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEyNzE_4b774fce-7f47-4a66-9ec6-61f0f88df5de"
      unitRef="usd">54500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ieccfcb48be264718a52f70d827378b42_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEyOTI_bd81eb21-4224-4509-b0bf-68915db131d4"
      unitRef="number">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3f76e5747c79442ca44da532090382c2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzEzOTI_4adf516b-d2ac-44c7-a291-c893e8c1904b"
      unitRef="usd">5100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id1f7d11d90fe4876a574e281c5a228d8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzAvZnJhZzoxNjRmYjQwY2ZjNmM0OGMxOTNlNWExMDk1NGU4MDBjOS90ZXh0cmVnaW9uOjE2NGZiNDBjZmM2YzQ4YzE5M2U1YTEwOTU0ZTgwMGM5XzE0MTM_72b0a9f9-6f39-4c5e-9e20-278ce66082f2"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90ZXh0cmVnaW9uOjk2NmQwM2ZhZjlhMzRlNzliYjI2MjI1M2M4MTgzZjRlXzkxNQ_6f8d78e5-a7a3-4de0-990d-cac3858acded">Selected Quarterly Financial Data (Unaudited)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as our audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and the results for any one quarter may not be indicative of our future performance. All data is in thousands except per share information.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_______________________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Quarterly loss per share amounts may not total to the year-to-date loss per share due to rounding.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90ZXh0cmVnaW9uOjk2NmQwM2ZhZjlhMzRlNzliYjI2MjI1M2M4MTgzZjRlXzkxNg_81474454-ee53-47d1-ae1d-e1210a161151">The following table sets forth certain unaudited quarterly financial data. In our opinion, the unaudited information set forth below has been prepared on the same basis as our audited information and includes all adjustments necessary to present fairly the information set forth herein. We have experienced fluctuations in our quarterly results and expect these fluctuations to continue in the future. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results will not be meaningful, and the results for any one quarter may not be indicative of our future performance. All data is in thousands except per share information.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Q4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;_______________________________________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Quarterly loss per share amounts may not total to the year-to-date loss per share due to rounding.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f5f266f15a24dda8c245439158a48c1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItMS0xLTEtMTEyOTg_42828279-379b-4be2-8a5b-0bc4f92e442e"
      unitRef="usd">4795000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i203df220ddd84ea7b49307ff1429d621_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItMy0xLTEtMTEyOTg_fa3651ab-1acf-42df-8ad6-4efc6ffb8ca5"
      unitRef="usd">7846000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cb20ac5be2a460996fe341ee81ca9ec_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItNS0xLTEtMTEyOTg_51b183e4-1abb-4d61-a8e2-22e7c1c17d96"
      unitRef="usd">5194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33c68986b8dc461c9bc05ee9ec922665_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItNy0xLTEtMTEyOTg_ffe8879b-e3e5-4ac5-9a81-25eff994a699"
      unitRef="usd">5890000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if45bc2183bdb469d98e2ab68aaa55e0c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItOS0xLTEtMTEyOTg_b01cd864-008f-4c2d-b890-c5f934aefcb6"
      unitRef="usd">3444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic910537dd8174a69bd816bc2d30fd0ac_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItMTEtMS0xLTExMjk4_d1261334-d8d1-401a-9843-5a20d6bd1edf"
      unitRef="usd">5485000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae0f8a52f2ff424fb8c210a60b2e720f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItMTMtMS0xLTExMjk4_8ec221c7-87ca-40d1-93c6-fdcbc169f151"
      unitRef="usd">5691000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b314ab44ce4452395969bc75e04e13e_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzItMTUtMS0xLTExMjk4_83c194c2-2dd6-4a35-a22c-42395a4b6e82"
      unitRef="usd">2884000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtMS0xLTEtMTEyOTg_8cf8f8ef-8137-4f81-88e8-d67b50895b22"
      unitRef="usd">23647000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtMy0xLTEtMTEyOTg_bf2b6f5b-324a-4235-9b19-fc792e55493c"
      unitRef="usd">28330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtNS0xLTEtMTEyOTg_fd73e35f-d1ae-489e-b114-d853bc13178d"
      unitRef="usd">24921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtNy0xLTEtMTEyOTg_48a4c3ba-7d0a-43d9-a943-e832f7d0116a"
      unitRef="usd">25009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtOS0xLTEtMTEyOTg_7c3fd665-f182-423f-a8c6-ea0b1dc4159f"
      unitRef="usd">50573000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtMTEtMS0xLTExMjk4_0fb19239-99c6-4782-b1c1-61872e0d19d3"
      unitRef="usd">48847000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtMTMtMS0xLTExMjk4_fdd10f4d-b057-4c6d-91a1-78187f99684e"
      unitRef="usd">30033000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzMtMTUtMS0xLTExMjk4_dba90637-6533-415f-98cb-ef8268992f00"
      unitRef="usd">23462000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtMS0xLTEtMTEyOTg_66c7b642-d67a-466e-8c1b-8987ab430142"
      unitRef="usd">5756000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtMy0xLTEtMTEyOTg_3b8910a2-7735-4adb-9d01-7a387c2bb4b1"
      unitRef="usd">7667000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtNS0xLTEtMTEyOTg_fae9bd48-e6ed-4914-adf1-269ef0f0d17f"
      unitRef="usd">5311000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtNy0xLTEtMTEyOTg_a571e47e-3aef-4ffa-ac65-64864528f050"
      unitRef="usd">6163000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtOS0xLTEtMTEyOTg_9d9f326f-05cc-4870-a408-1ca2a684533b"
      unitRef="usd">3811000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtMTEtMS0xLTExMjk4_d5aeb51a-f959-4aa3-86aa-3d22dadafaf4"
      unitRef="usd">5773000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtMTMtMS0xLTExMjk4_94145f1d-0da9-4b66-a73c-8ff63f852fa9"
      unitRef="usd">5570000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzQtMTUtMS0xLTExMjk4_234ff348-3ff1-4e29-90cf-1d05ce2904d0"
      unitRef="usd">4323000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtMS0xLTEtMTEyOTg_30b60c89-5baa-4cee-9752-6c49f9f250e5"
      unitRef="usd">95604000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtMy0xLTEtMTEyOTg_f16547f4-81d1-4633-a076-d17e2c9ea975"
      unitRef="usd">101313000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtNS0xLTEtMTEyOTg_6ef9a1a0-6c6d-41e2-b210-7265e5db57ba"
      unitRef="usd">103738000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtNy0xLTEtMTEyOTg_ca18ef3b-d9f5-452a-a263-fcfbe9a7b977"
      unitRef="usd">99614000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtOS0xLTEtMTEyOTg_9905e0c1-ff8f-4718-996d-ab4fc90e6206"
      unitRef="usd">108987000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtMTEtMS0xLTExMjk4_92faf230-e6c5-4158-916a-60d52ec0ccb5"
      unitRef="usd">96436000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtMTMtMS0xLTExMjk4_3b3407cd-2543-4ffa-95fb-bba56e291ad0"
      unitRef="usd">100531000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzUtMTUtMS0xLTExMjk4_84313116-e7e2-4ca3-99bb-3ea939e164c8"
      unitRef="usd">102724000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtMS0xLTEtMTEyOTg_8689f98d-1ca2-44ee-b0a2-d2143c529422"
      unitRef="usd">-109392000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtMy0xLTEtMTEyOTg_11806283-4b4f-411d-9b3b-10eed9c6b40e"
      unitRef="usd">-110205000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtNS0xLTEtMTEyOTg_a38d1212-e063-4512-a47e-9d141ce73396"
      unitRef="usd">-113596000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtNy0xLTEtMTEyOTg_1479f561-c0e8-4e6e-9bd0-17f724a315a1"
      unitRef="usd">-112910000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtOS0xLTEtMTEyOTg_a76c8123-adfc-4fbc-b37a-4d4060f082ad"
      unitRef="usd">-133631000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtMTEtMS0xLTExMjk4_a2e4eade-a0d8-40a4-9cc5-a734e8d92d33"
      unitRef="usd">-77709000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtMTMtMS0xLTExMjk4_6e3cc735-ba84-4780-beae-3bc2b58d1044"
      unitRef="usd">-103050000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzYtMTUtMS0xLTExMjk4_2d59ff3a-ad08-4b59-950a-524151d8e1e8"
      unitRef="usd">-110721000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctMS0xLTEtMTEyOTg_7fe46a07-3bc7-4a6a-aec8-29768a123b1a"
      unitRef="usd">-122967000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctMy0xLTEtMTEyOTg_407df18c-7363-4b9c-a1c3-ecbcc6ce669f"
      unitRef="usd">-125519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctNS0xLTEtMTEyOTg_8cf9dd32-7411-4705-889f-8386a1127d9e"
      unitRef="usd">-129706000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctNy0xLTEtMTEyOTg_62bdfd23-a7a3-447e-9481-5bc28f35faff"
      unitRef="usd">-145645000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctOS0xLTEtMTEyOTg_9d2cc85c-174a-4936-acb9-cd95da56b9ba"
      unitRef="usd">-138651000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctMTEtMS0xLTExMjk4_6e05cd72-674d-45c9-a6d5-b43fb8fc29dc"
      unitRef="usd">-80000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctMTMtMS0xLTExMjk4_4845c4b6-2a61-4828-a301-f6025b2c9f66"
      unitRef="usd">-108586000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzctMTUtMS0xLTExMjk4_ea066ad7-c0d6-4220-b864-9570aac29d41"
      unitRef="usd">-117203000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMS0xLTEtMjE5MDc_4fc8a287-b170-41fa-b2bc-e364a5276661"
      unitRef="usdPerShare">-680</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id87122bff7084f81bb25125a0364cf3a_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMS0xLTEtMjE5MDc_b96d22e8-30f2-4603-875c-8da9a167e4da"
      unitRef="usdPerShare">-680</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMy0xLTEtMjE5MDc_5bd07dc2-7a33-4536-b26c-54babc9735ba"
      unitRef="usdPerShare">-690</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie63118ced5a04becacc19904fd8f5dcc_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMy0xLTEtMjE5MDc_9be4df16-e19a-4ce2-a3ee-3363989ef87b"
      unitRef="usdPerShare">-690</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtNS0xLTEtMjE5MDc_43038e49-8c04-4400-bbf0-cd74aac510f6"
      unitRef="usdPerShare">-700</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i29b8c5addc0245e990a039a3225a025e_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtNS0xLTEtMjE5MDc_c61aa13a-1afb-447c-8274-abc9cafa2bd4"
      unitRef="usdPerShare">-700</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtNy0xLTEtMjE5MDc_4e3974ac-23e6-4e26-a2ff-d9484f9589d0"
      unitRef="usdPerShare">-790</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtNy0xLTEtMjE5MDc_6091c83e-b56b-4d16-9d9f-7d2d839414eb"
      unitRef="usdPerShare">-790</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtOS0xLTEtMjE5MDc_103a1a95-fc65-4e74-b6cc-dfa1ec50e473"
      unitRef="usdPerShare">-0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i65c10b4fd84d4ecb914cd9758f5b6602_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtOS0xLTEtMjE5MDc_b34554bd-c674-4d57-86a1-8c50e3a76c00"
      unitRef="usdPerShare">-0.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTEtMS0xLTIxOTA3_bcfb21f7-5a1c-467b-ba72-d270e0a8c89b"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id77f5a951e9745d5ab72253029d61fbf_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTEtMS0xLTIxOTA3_deb2cf50-620b-488e-a96e-5821242f095b"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTMtMS0xLTIxOTA3_23eff66a-c66f-46da-87c5-52cf934d90b7"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic9f86406928947e18f670fa887c043db_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTMtMS0xLTIxOTA3_9e8bf4ee-3eba-45cd-bb85-04924e1f6361"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTUtMS0xLTIxOTA3_6c7a4082-b524-491b-8bda-783e8cc1c210"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ief0c747f45984a2bae3d09fcaf72c57b_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwMjM5MjZkZmMzYjRjZmY5MjRiMDIwN2ViMDgxZjQyL3NlYzoxMDIzOTI2ZGZjM2I0Y2ZmOTI0YjAyMDdlYjA4MWY0Ml8xMzYvZnJhZzo5NjZkMDNmYWY5YTM0ZTc5YmIyNjIyNTNjODE4M2Y0ZS90YWJsZTo1MzcxNDkzMDlkNzQ0YmFlYWUzMDBjYTA2MTY1NTNhNy90YWJsZXJhbmdlOjUzNzE0OTMwOWQ3NDRiYWVhZTMwMGNhMDYxNjU1M2E3XzgtMTUtMS0xLTIxOTA3_8cbc105f-1eaf-409f-8419-fc189d4b200c"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MUC.[H5@_#(@FM]=2;) T3P.:.;#.M-8P?,9-W&=:PET&=OJV+YZI1$WT939
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M*C"_4^7B5F0$7"LC?!4)9%#8(=N:1)9ND2J0'EU2B@NMQ[6T?E]-[BHU.[=
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M,26PCLT#<'\IA-Z?F!<</@?=_@M02P,$%     @ AI9<5 D+><XD @  =04
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M'0X^VEKIILD; U7I&^N@T+:IWQ9V+H)V#O;^J!2>#!>@F[3)7U!+ P04
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MUJ+I?VXY _G& )YOA-#/%^;KQ/@UZNI?4$L#!!0    ( (:67%2>V1+^X@(
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ML<*C@>!;)+0U>-,-(Z9! _V"Z;3/E(#9 G!J-.%,<EID6)$,S11\(*=*(KY
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M3[CLFJQ-?755C;'QZ/Y]Q[(,2#X^DC+^9V1VW'9S=[1']PT#<'Z0,WDHY&Z
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M-ON\_!^$9A<I6D'"S%6=%Z4,ZIZD^=8\Y\:XNQ9BJZC?;-GX,)O8;UE53^U
MC7H5I7Z%^3S+>B?A;VGC&B:C-S)H12EM9*]V>M?('@Z3P):D&S(^-EZ2)#QV
M5P1!\C2*F;L@")(!SD7>Q^[2,<9X1$:7+CD8*[G.6$6M92-;'<B?4'5;&4#9
M*@OQ5)1V88Z-]R;#)0Y)GC#B<IR[0!;2V'7YA0ND46@]_LQJ")!SFK!1HZ4'
MHZ5>H_UF7-HJ@V=1[H0M\6".O;E>,4^[UEXI-FGBAO/<!9X;RH<XX9T=>&=>
MWO.-J-?2Q.Y*%$U@R%M>2PBP4FU- H#GIG@61NX,]L!X9L[DTI B;N'BSFGZ
M$"<T23BH@/#*%");*9I\$XAZ>4*SCQ)4 (3.A CX,<(-09Z3\T).V1UI'.)E
M]ZA5_F-J].0RR%5EB%@?1LD09_R,QXD;;7,426/B!C"&S)(L&HU+0@=JU$MM
M(6%_D!==2)HU$Y5J=/'/.#_J+A8G6%['D2E%^"%(1J)XG-\@3@CS\OM:;2'R
MK ="W(GELZAS&6S%ZZ'X0NG5#1144,7U;@4/D'&:UMI"_KTK.N^%'54 Z1X$
MM$U3VT:M&U&A]F&77'2.0&C((FSA?9V=6F204<2OHSX?+;"Q":Q_5>RJ-GBW
M+-I<[< L[S]8\6%,H" =-T&]#V^P%/B^W:.AR;@?^Z1$Q[: .$9 D"SC2-5'
MD(0 =-P[!AE&_#JLR\_MF;AJ6ZD[!SBJYQZ=10:A1?Q*ZW/>&=@H/@E9_ZG$
M$Z(K= AE&:)F,62&B(4% HPY&9=#9-!#Q"^(OM8@%K5JT*)%7$DQC<(,(8(
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M#=+LAFU%CP58'T#GI3%X-+S \/QDOP%02P,$%     @ AI9<5-H]I> B*0
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MM%GAQ3'*-/:2A#EZ $0PU7<(;-*K5W"'3,)2X6PG^P[\L>[(O#IVL!&EB_K
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MOXS2:.>X%U7MO"->+5I>X0.Z;^V=H5T\LA2B066%5F"P7$87Z7P]]?$AX+O
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M:0"?_F<2_QWE^9/L*'W]YWBEX*IP>H,&9CY'&8T=0J%E(]"1MZL1+!,(3)7
MK6V9*A#T%I[FLS1.>Q3)A?"EP:DZJLI@Q1Q"8[@J>,,$,*E;Y;S3<7P\>P:V
M)V@'@LH3A+)%?T<IO/ A ^F7,7S<S6&C*=M<.31H'3#ZP/@P(VI#&IA2K0Q4
M.[(#I^F).W]-^C>=>1H#:5\120'9I-\*THD1HAR4]Z$I6,-,@*5-JG9/Q6##
M>&]UK_1 7KPG*PK3$NPHP=M.XY,'EO'?'E&R5Y42315ZCZ4[HJ3V!3KNCNUM
MU5?UO7G?&R^9J;BR('!+KBGE+0+3]YM^X703:GRC'76,,*VI1:/Q!G2^U921
M8>$#C$U_^0M02P,$%     @ AI9<5$+//^<P"P  [!\  !D   !X;"]W;W)K
M<VAE971S+W-H965T,34N>&ULQ5EK<^.V%?TK&,?)V#.R7O:N=_8UXT<WZS:;
M>.(T::?3#R )28A!@@N UJJ_ON=>@!1E2]I-FFF^V!(%W.>YYUZ KY?6W?N%
M4D%\*DWEWQPL0JA?CD8^7ZA2^J&M585?9M:5,N"KFX]\[90L>%-I1M/Q^/FH
ME+HZ>/N:G]VZMZ]M$XRNU*T3OBE+Z5:7RMCEFX/)0?O@1SU?!'HP>ONZEG-U
MI\+?ZUN';Z-.2J%+57EM*^'4[,W!Q>3EY1FMYP4_:[7TO<^"/,FLO:<O-\6;
M@S$9I(S* TF0^/>@KI0Q) AF?$PR#SJ5M+'_N97^CGV'+YGTZLJ:7W01%F\.
M7AR(0LUD8\*/=OE>)7^>D;S<&L]_Q3*M'1^(O/'!EFDS+"AU%?_+3RD.7[)A
MFC9,V>ZHB*V\ED&^?>WL4CA:#6GT@5WEW3!.5Y24N^#PJ\:^\/;*GERK!^2F
M1J2#N)@[I?C34H>%N'OW5W&[D/ ^5TW0N31>R*H0_2W7RND'2;$5WVF9::/#
MZO4HP#;2,,J3'9?1CND..R93\<%68>'%7ZI"%9L"1G"J\VS:>G8YW2OQ6N5#
M<3H9B.EX.MDC[[2+U"G+.]TIK_/SIO+!->1]#,=[5<QU-1<7!#$=M/+B6OO<
M6-\X)?YUD6$YX/?O/5:<=5:<L15G?WJ^_@P[Q ^5>*<RUX ?Q&0:<S<02R6P
M0SE5"%T%*Z3([4G1DR4[]4=AH5A]9]'Q;I/^<7,S$-\-;X<#B-RVX%MGFQK*
MREI6*W&$)<<#43?.-Q*Z8,ERH?,H>ZF-$;5<"6S #X>39^/A&!5K#)&/KDA*
MJ4. #[.F*@@N6.:;NK8.#I!JK\1T="I\:(J5L#.1J;)6<VD*Y8UJ[G4K)M.5
M9$ICQ_ZF5@!C(<4W7TW.SUZ)HUJ5F;-&_Z<I978L0-QBIIT/)Y1#$4#=@4,%
M#37D,(I94JF"] &/<H$]3>64!W?*S"C0;]XX1[O\QT:6MO$B!Y.*7+I<5[:4
M)(U"OT!CX%17*K]/V;BZ>O^]N()V"JKXR6EID)2%A;^A*:WS0GU"1_%>W%Z?
M?#?I[[I!I')V]GBX-4,:P!)S8S-(+EPS%WU8M(G+9'Z/N&<K<6GP$:1:$>AF
MT)+#_UQ%=%X@L',TD; 8;@)QL@^(QLC,NI@0N5D&'^ZNX0'6QWS!Q&_+[+TX
MPG/@2&+]; ;<RZ H?!^4R^\'X@X>UN(;6=:OQ+5=E&H;XDAR1)RS#[I03U @
M@Z@LK/.! = @U@#/KG2(K E17F4#<">=H+A9K'<LQ+?Y#;1\N$;\0J)^:Z>I
MHP,EOK;HUZF823'MR5M=O!G=JT*[;R&XRZ0!IP0!9S69XH4L'E+W[(O;: _@
M8:-]WC*$GQCGU+PQ,EB8KBE-DB>%" 9*3#7WO.Y)(0(?')JPD#&HELNXJ4@R
MDH1R441L=TV>,Z[E*G4+!#).1H C340##B5JG]+E:(2(^W69(>E=E&(.=,55
MR$BF;6V M\8AI1OE0,!9R,!?/R@CN5ZW1&VGJ,(R+F2^T! GWEU?"%D3\@@*
MOZ@U]Y%14G@PNV+$^.C_"<U-1 M5(WEA#,81%8_BL<RL!E']HX =;[H!D7WE
MVTFRC4KGZII$!F(;M0R([C* /6+N<QJ)/&11Z%32VUBZE3P4/VUQJHUGIC U
M@&>#-A'=#08%E#F%G*C+*":5/6"/\H,->+ _UFU0N!/T+$R>14S!4W#<0C&V
M]X11;."N'TBB8Z)!\. \T=KA6;\3@LRDYA@G"W-,?51X&];"(&I:P-H*7.0'
MD4[7]J>%B"#UT</3#07=6FPU "*66X^Z!P>T^]!O@#LXC5JS.8J*##)D,'C^
MC-RCO2OZ]FQ >?D5RVGQ'YVF)_E!Q[6,P?]C@B:_,T&>2B1F:"C>82@Q5,9[
MRV<KF_)3ZC<]K^TFO_XF']NF4<I[5"K5ZTG 0;++/OE\>CY\UDUG2"R8*Q7K
M-@),7=8G2V.WT"4FN1"["5J:67GM(X,TE:%Z9[RV*W*G:8\4$D<"3%J1^)$.
MISXVVD4L)CBIGF.I&5*#UK,O$4F]A)8]ZG<T.B"^X)[EGCD 74(CO=PPJ><P
MO9-+EQ_N-N<0$H&'XFIC .JF[@'TTYT BS*]T0""*8B$\@;43V,P),7I]_31
MJ."_? K^H2[T@VVG'T)A;IJB%;\Y]#KUH#'!PBIP+_VBBLUI%_;U9N&RQ1[/
MI=]\]6(Z';_: DC^9?*J:Z6/5VZ&.JW&6'LS2[02NT3*JETWLIUH(_A0(X&Q
MK#5.957A]V>9NV"UM=\."&0HQ<%>=H&N4?KY"QLA0Q0@;W(B/8<)1P8I(@?:
M:,KO&'&8A=B*CL_B*:LK\PUJ2P7>/QQN5G:N7"#,HE]H/IC&@\P\GE)SJ*MD
M#%*'+J &4$US(Y$2>HE<EQR[(]"%UK]2-GGL:2*QU%!*]6%D:DA/X\C >_KX
MYO:81Q>)[C9G/D15/:@5<VEOEHRS*$RQI8K50M78ZVC;1(NC'@4[NY*&@5<D
M9C8ZAT^H985RR8R>RQ@"2(P_X5@'Z]2G7-5AC61/_)%SV_&JTI::""($QPN5
MA>X+DH]F0A[UFJU)#V<QR-ZKS53L\F1;VC$ @',]#NL)?;W>0$J>C&RQ10Q:
M:H^C!9Q2KB0>HHG+MV B-BD2,C?4;K.DQ-A,IYNU(#BO- >YEBZ=5#!4RYG"
M%WS&$=L@A\@U\+IFB?8LOQX0("C21Z%JA3_05E#9E1;G%.LH9NVE!',>UI<-
MPW)]CB4"1L;9%,Q2NSS@L];GW2@E-RQP!6@7QUA+Y8 .@<+*5^T$E=N&"(]W
M<?^ANX%XB'FL6M+IOW^I5*POE4QWJ:1CX5W1V='H@JV[E(:!>$<WIQPS.E8O
MB:1*)?G>#BF?2>T$YI9&46=DDYVBDQ[%C@0-Q85GFU(_\WM(EX7GUH%2;'62
M2\]U""1!*A56_^:"!E0J+ZY6NF5PL8$RT %YA,^KMGR+SP0@#B4R&@K_J,/W
M[J :W[^):BG*53S[I:/_HW8=.H\X\<FM_]7.)\F>$QD?&4SOQV+F;)GFFI2@
M%@%78*@Y7V_TT@6;/Z=N*R[NT/-5FG%GF"I4'&P2\&<8=NR2H\"#0C(V9CUG
M.WP[ ']6?5NX-$ +JD^Z'\U5F:%DVGOKE^(=^?0S^_0>C$-H68E_[MD2=W2@
M11+ P#PO;[E;Q<AUR(/*9/I*?/_%L#P4D^>#\_&IN(K+T6%J A7EB$!V*$X'
MX_&XEQH>7'];>@[%B\%X>OK('T4M"$,<C4@%FS\]'YQ/GQ-V>%&1HM]);#PE
M# R*MB2Q*QV]"NTCTQ2"G9XALS1)+6S!%.H4,1B5?+N1#Q1TA^.;LDXW19EM
M(E;!_5EK.4^ NB2U5#NM=-_=:;6Z:>A;]!90I;0%$#UNC7?:WY_(XM?&D\&.
MJ8<0>:\(QW436Q090OOBS!5;HV*08TS1Q+[=15X'Y9?B2!\_<2&MVC&\#G;/
M9$PU51P2GG;C= ,(SDU4@M2VMX?(;&TU=[ CO<6DS:C&RRCZLG' U#O/B]OO
M?I*][5WGOAF6S4IVK>WX?3<"\4*.2J5$1KN;M4R!%%0:V6+B'TTB9,3#]G2E
MUMO3'-\D% TS<"_H3T\4[5$2XI-TNN3?=_>H_XA3"ZE#1"&/.>C\E8]7UCQU
M.,?X'(CTZ@'S7XOB@IA@,GSV=:PH"$EYN8HW_ITT7:(TJ,(?2V4S>>;D%NN1
M3R/C/.=W:YP.S[\>;GN+-^J]@2V5F_-[9A]'F?@RMGO:O<J^B&]PU\OC>_ /
MTLTQ% FC9M@Z'IX_.XC#?/LEV)K?YV(N"[;DC_3613E:@-]GUH;V"RGH7O"_
M_2]02P,$%     @ AI9<5+ZZWU80!P  WA   !D   !X;"]W;W)K<VAE971S
M+W-H965T,38N>&ULI5AK;^,V%OTK%^YLD0"*;<F6'S-)@"0S0;<[TP3)M,5B
MT0^,1-O$4*)+TG'<7]]S25FQ\^KN]DM,B9?W>>ZY5([7QGYS"RD]/52Z=B>=
MA??+][V>*Q:R$JYKEK+&SLS82G@\VGG/+:T493A4Z5[6[X]ZE5!UY_0XO+NV
MI\=FY;6JY;4EMZHJ83?G4IOU22?M;%_<J/G"\XO>Z?%2S.6M]#\OKRV>>JV6
M4E6R=LK49.7LI'.6OC\?LGP0^$7)M=M9$T=R9\PW?OAG>=+ILT-2R\*S!H&?
M>WDAM69%<./W1F>G-<D'=]=;[9<A=L1R)YR\,/I75?K%26?2H5+.Q$K[&[/^
M03;QY*RO,-J%O[2.LBF$BY7SIFH.PX-*U?%7/#1YV#DPZ;]R(&L.9,'O:"AX
M^5%X<7ILS9HL2T,;+T*HX32<4S47Y=9;["J<\Z=72VF%5_6</DL$YXY['EIY
MKU<T&LZCANP5#6E&7TSM%XX^U:4L]Q7TX$[K4[;UZ3Q[4^-'671ID":4];/T
M#7V#-L9!T#=X15^,C/YS=N>\!0Q^>T/GL-4Y##J'?R-O_YL&NEI9TG%9&*#>
M>3(S$G&;SN962G2#IP._D/1%N= 7YV(3!0X!'+^@LYM/1[>BIDLKZD*YPM!/
MIDOI-*'/GR_H -N'A%8F V-IGB=9FJ,35L)*O#8>ENW2P"\)VS-52!)U23??
MBVKYX2/-1*&T\AO2IH!(2<+3,,_WG#DW*RWOA2T3VO,CH0NA%4S72CP/X;+1
M?!CLO1+SUX6R)2&'3%:[0?]+:6LV=".%AG.7JH9-2=?"^EI:MU!+1-^][M)!
M%(P9@'.B+!5S@]"4#O)D.ACMY:(-UQN0UA)Y\2%OVW286$'4BA,Q&/7W//S+
M^/?":1/0Q7NVKT&7# XO[K0D$*Y#'AQ]DQM2=23CR(MSY#H(+B"R!=!!"07"
M.LABPZP<TNH.W[^8\Y<=:4I0F H%*&(5;N72R^I.6G1F.J8?5[7DU:21]=)6
M]*.HD<$-W@_Z^P^W2X&JE%*#ABW 4ZYLXS=MI+ DF3X(S1]-- 2 <X\EP9B@
M83(=]NG[[R99FGV@,$6.S.QH!0>$<XB $1320%J)NQB,E869U^H/&'A'69(.
M!OC=ZOC_'$N?.I8E?7#AWW$L3?KY>,>Q&UG+-<#)B77T=6T",<ABQ9.,9OSG
MJFX6?"8;?0CHJ9B/]2:,*UA Y1CP=P:MTF!: 2-KI35)5P@=VAVQAY!#%4$\
MO([> MQH: 44 4[8OA?:=5N#YZRV@9VJ"[TJ92M>0"N:T;L$6Z6LZF YV8Y-
MK-@:^C5BF5.&=QRAY>24<FF< NHY<S ##Y?6W"L7>BY.1X871Q==!;_73A2Q
M*4,0RA'4KZQ\]/CC8WUW@WU&J0FM$;SE%+HE,S)W(MM:B@TK8"YP"Q: !M/2
MN7S C8FSX9:R4#.%TH8N;-*9-%EB4112-RGA1N-;"FY6Q)<I+P.+L;1;V4!H
MA7%-+KQXD#LEP/V$7B;()#@Y4P],UC6:4>^ @LW57!@DTBILS:UQKLDDQ%1;
M4"1;6@^O'H-C-U ,1,T$R?X@+0K-HP!IS^#;Q)@AJ(TMN_2KI(4 4@4,RR./
MJUVL.&=OIFP8=S.4.% ZIQQZF'JWIG?8FMW'CPN-"WB^2J?!:MMC,>PFA%#)
M2)J/M6MPS)DAOBR$)N;)W>2C[9*8))Q3IHR4C0(")(&D$5#<;TP!2 M5+!A.
MVPY!/"\@AM^B7A< F]&J##/VUN.GVNJ]:F<.H],RM33# J3_A.S_S>3UZ17R
M"M0*\I[2U7[T;7[>\;4AS9DITTDRG>2\&":CZ9A^07^'N;1_ E+C(?ZFXRF-
MDF%_0E\-U^FIW@PB&1-=-D[2T9 7:9+V\]W.9.9UKU%O,QD8@QQ":-2 OG?I
MJ#O!/5EKI"@)C]GV,8B_FW2'C_L-RL"?>I/L=W%38+&)J;=2AVH CV9[3VMI
M/#3P2R6N <5"N 5A")3[-0^?(Y&(_[KJ%ZSCDHO<I;/PYH64<-8JIKJHE:.!
MUJ<1[?C\WP$()>#33PUF$1:C;,1/ _Q)IOTIKX=<S7R<\3JG+$LR7!&Q'O%Z
MB@&']3C2&!A=BAE(F,9Y,DS3/;RTN4\G:3+&!>*S=.X]\34LWGR:2Q%[%^:2
M!(4<#,;PHW_8"$=-J C+W?/%:)0/#I]!?C<IZ7   (\;!9A$@32V5@_2<3(<
MIF^J2/#*N6='D:\L1R"CMTNX#A^2LCP"5UJ^5UC)\^#14IA9X*))-VVZI,GE
M\Z,EWSQ7\"'<Z ,( >!2QJDKPZ'7 +*A-:"1=R?_Z+[TO=3;^>:LI)V'+VN>
M^# 7/S_;M^W'^UG\9GT4CU_^7X2=8\K!_@Q'^]UQWHF38?O@S3)\P>(&@XD?
ME@LI2FE9 /M\ ]L^L('V7QJG?P)02P,$%     @ AI9<5 ]].Y&S#@  62P
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M+W=O<FMS:&5E=',O<VAE970Q."YX;6S56FUO&[D1_BN$6Q0Y0)8E.;DX:1+
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MB602E)\QL2EK."'"7L$I#:^"C2NQ0!<0TK_27SI=8L<QT="'PAO"]VPRO0@
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M6^I#@FX+4,)Q!CCA#:)%0[MV2/MC\3,\%R<GTM.LB$)&%;YS48"[O0-*DX+
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MT@)\OS P-GZ@#?J?];WX-U!+ P04    " "&EEQ4A!;T<VH$  "\"0  &0
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M1CJ>%7:<KX!RL&ICRF'W 6>W!?8GJR$I;4(*7UT&1[PZG#O<53YZ$OP#NRF
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M-@MP1)[-+H5!YO*G,GB_3?1];K$G;-&%S18'+&&4X-6#YAA7 /=2)(P">[9
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M-E088>3JGE,C/TEV9"6JZI"\+B.!B&D2L"" P,LY0PYMR1Q0+H/(6\81R_P
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M>X(8.96$K^)#*)@1F?:NW3 YK&T)*P(VB9NR.^(Q0>7<!2;_\,>+B^M' !-
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MF$/'P_[&'G$@L"+7:HC$$5<@]W/J60@I(LQ8AIT*Z.JHV2/JV/R-U!@2"5%
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M.@1T _15"O92)!28851$PC9TO*C9E)N'0F^'G:1NBH!@D._0"^+AP3MKTCA
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M584J%\2D#=\0>@81J0]#!C$Y\+-!NT_8D/(*W6B8PJ=%*5;<CBYM:WM[,;^
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MH,"2M](]Z.X[;NHY]7RYEC9\H>MC,Q9!WEJGZPV8%-1"]2-_V]S##N \^0+
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MG)R=1F!Z/_8+IYO@@95VY*@PK>@)0^,#Z+S4VFT7/L'P*"X^ %!+ P04
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M#G@XWGN_\MI)RY(9G"KQC:<V'P:7 :28L4K8.[6YQIV><^<O4<+X-VQVME$
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MP@IS8Q$8O1[Q JO* I$;WSO,07^D-=R5M^A7+G:*9<XT7LCJ#UZ8<CH8#:#
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M%?VP4#L%>B^5LL>#<S#\ A?_ 5!+ P04    " "&EEQ45RI?]Q0#  !S!@
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M6\E[4=;TU9[;?[-;1LVB,">T6*^U7#-';C"HP"8SZSK=F_"$/NPU!F&_$T]
M8>RE,3,G2OPXV+7"@5A8O^88E/C)9/@G^PAR>A-YR0Q>P+9@-OQ'0E:RX-FO
M1=7\3!DKN>3ADR YH20%-?\.6,C )F@Z !;[:42)GZ;=NAJ&NQPZ2AR<//.B
M.$7S\+'HQHR-9T;I]-BZ-!TD,?UA26!!1\JS;H?!]+NO"VS 'H7.!X4<$L%1
M#X=%L-CG.KH_">=E('KQ\E[F&U(_T[E2+40$UC)H0S?HN8CCF8;W]1;AX=-!
MXF ',N>5/XK\)*5?>KZD*%K"?$EG]*F?#=EHU%_TC$G#Z0E%$S](Z/W %*>M
M@2=8).:@513Z87P41DAS;QZ[AI?ZL^!@><=[1XI*ZK4[.!DH&=%WIXOAZW V
M6W1'DN?AW<'N-Z'7$!B5<H6I:+78'NCNL-2]6-6X \J#LCCNN,<-SI=2\P#\
M7REE=R_L8#BQ7OP)4$L#!!0    ( (:67%1U+<8NZP8  .42   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;*U8:X_;-A;]*X2;+6Q B26*>DUG!IC'
M%AL@30:9M,5BT0^T1(^%2*)+4C.9_?5[2,FRG,CN--@O$B62]WGNN93.GZ3Z
MK#="&/*EKAI],=L8LSU;+G6^$377;^16-)A92U5S@T?UL-1;)7CA-M75DOI^
MO*QYV<PNS]V[.W5Y+EM3E8VX4T2W=<W5\[6HY-/%+)CM7GPL'S;&OEA>GF_Y
M@[@7YM?MG<+3<I!2E+5H="D;HL3Z8G85G%VG=KU;\%LIGO1H3*PG*RD_VX>W
MQ<7,MP:)2N3&2N"X/8H;4556$,SXLY<Y&U3:C>/Q3OK/SG?XLN):W,CJ][(P
MFXM9.B.%6/.V,A_ET[]$[T]DY>6RTNY*GKJU"9N1O-5&UOUF6%"737?G7_HX
MC#:D_I$-M-] G=V=(F?E+3?\\ES))Z+L:DBS ^>JVPWCRL8FY=XHS);89R[?
M-KFL!?G$OPA-YI_XJA)Z<;XT$&T7+/->S'4GAAX1$U#RBVS,1I-_-H4H#@4L
M8=-@&-T9=DU/2KP5^1L2!AZA/@U.R L'1T,G+_Q+1\EMJ?-*ZE8)\I^KE38*
MT/CCA HVJ&!.!3NBXAX54[25(')->G77 G4CR%ZY1VXQTJ;,"6\* F0!-\U4
MP$_KZB7.X8=>D%6G9JOD8^G*!8^D[)88EUH\5&V!@=D(S%8HQK)Y(%BQE8UH
M#))?-IB4K89=>G%&_BVXZK))D M1KX0:\F$O/BY!MG?G%9E'E'F,^0L[9BSR
MPF0W#CR6L<7.71)X0>SCRFAHK\PG[^#'"]QP2D*/ICO!H9>QI!_[GA^QQ8E$
M1D,BHQ<G\N[ F'&Y3"7MI%Q+L&=ZRW-Q,0.#:J$>Q>SRT^:DQ[D$ 6KD![8<
MYNX[$W;3*H6$GY&?12$4KQ"['W](:4!_FAS=&VX$B9"M.")!F TYC/V,A#$C
M+(O()VD@*.\DC^PGX@NZAQ8DCC(2T8S$(8-Q:X&%Q=Z"G:ZO[YWN8[,[0^:!
M3Q=D'L:XT&#1&U/T6J:L^7K'W2G 15&"*\M"7.,@)"?P%0_XBO\N45A>VIOQ
M453PO"!&DAO0:MFT-N$?MHB6[663T#NI<AIZ']JQMR,4JKW^?*]?#OI)4:X1
M7DW62M8.EKR6+5)O^:2U.U?/A&^WU;/=9^<U4MD:J9['"I5-+V) @W]851+F
MP#@[8VF-<-VC_;O)Z>U>UTHT8ET:P@U9][#;V^0,>65QD7EIFCD^R4 SM!]2
MCP7 R4<$CJM\0W( J[2<R;R$)A9*GI]B 01XD5UYL^'-@X"OY)%7+>\.(-85
MWN2"9(F7!8RDB>=;&O0=:Y+WLGF=<[W!+B.0(S/@%9NKDJ_*JC3/X]QHCFYM
M [ANC>UF2C[SRI1XEWE9&)/8"Z.81!Y%]0W2NT56SJ-H6O$R>?/$2S/K("R/
M$W>/*0C=T;8#S-Y/[)^TUL& =ZC_1@$#C_L3!"#SSZ_MJ:MPT$(T.ATQU"<$
MQH!3YG&":OX \<" %[,$5T8C0KT@I/^WVDZ&VDY>7-OWH*=R7>8<E7&S[[28
MV7&@J_LKK05>V_/ NSYPY71[.:EZNL9_%Z06W!UV!DJT]<#W2JN]4M+%6C8N
M6[8LM*V8ITT)U.,5JAJ"+"[S/JL61DH[J+OVY!+[YL#U_,!U6^53EMCT["K3
M6J4=^1\DS.H^00I'F.#V6V5GY#V^=WH^ T,YNLFY4L^PXHFKPH$C1G7C8 N
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M"3ZF5/=3I7LP<NM^9*RD,;)VPXW@(#.[ /-K*<WNP2H8_FQ=_@]02P,$%
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MY60Z> KN:3V_A^,*N2%TH@'>*3LG=,-P&K#7 O9^#^4+4-!)OKT1,,]QW&
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MM1>T"\#]I5)V:[@$@YH7?P%02P,$%     @ AI9<5&WF@WS  @  W0@  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#4N>&ULM99;;]HP%,>_RE'42:W4D1 (
MEPJ02FDUI%U06;>':0\F.8#5Q,YL!SII'WZVDT:PABR;-A[ 3L[O?Z[$&>VY
M>)1;1 5/2<SDV-DJE5ZYK@RWF!#9XBDR?6?-14*4WHJ-*U.!)+)0$KN^Y_7<
MA%#F3$;VVD),1CQ3,66X$""S)"'B^Q1COA\[;>?YPCW=;)6YX$Y&*=G@$M5#
MNA!ZYY8J$4V02<H9"%R/G>OVU=W0V%N#3Q3W\F -)I,5YX]F,X_&CF<"PAA#
M912(_MGA#<:Q$=)A?"LTG=*E 0_7S^IW-G>=RXI(O.'Q9QJI[=@9.!#AFF2Q
MNN?[-UCD$QB]D,?2?L,^MPV&#H295#PI8!U!0EG^2YZ*.AP [>X)P"\ ORG0
M*8!.4Z!; -VF0%  05.@5P ]6_N\6+;2,Z+(9"3X'H2QUFIF8=ME:5U@RLQ@
M+970=ZGFU&2)C'(!2PPS@1&\YPHEG,]0$1K+"W@-#\L9G)]=P!E0!A^W/).$
M17+D*NW<2+AAX6B:._)/.+I.10O:G4OP/=^KP&_J\1F&+>BT+=ZNP&?-\2KO
MMXWQ]K "OZO'/X2J!5Y@\> 8=W6_RJ;Y9=-\J]<Y&<Y*P9Q))3+]'U?PY:TV
M@+G"1'ZMD>^4\ATKWSTAOQ"4A30E,9"$9UI?8$IH5-6T7*AOA<PS;#?1U=T=
M]N6EA1]X^G-L=ELG=)1$MTRB6YM$,=CY0/^ ?JL?O(+*:9]E"+I#?(6B8CR.
MG >E\^!_-*A7RO>:Y":+-)A)XQ+27]I6-:>]WW7C*)Y^&4__+^*A3*% J<>'
M**P*IE[4=JRF6(,RN,$_FN;IX(^J,RP#&-8&,"_K@"'2'5G%5=68#E\X[PY>
MN'8/GO3FX']'Q(8R"3&N->;IDCD@\L,TWRB>VH?_BBM]E-CE5K]_H# &^OZ:
MZV85&W.>E&\TDY]02P,$%     @ AI9<5+:VZ+=( P  X@L  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&ULS59=3]LP%/TK5]$>F 1-G/0+U%:"5FA,
M;$)T; _3'MSDMK7FQ)GMMB#MQ\]V0MI!&F#C@3XT=N)S<NZYSO4=;(3\J9:(
M&FY3GJFAM]0Z/_%]%2\QI:HE<LS,D[F0*=5F*A>^RB72Q(%2[H=!T/53RC)O
M-'#WKN1H(%::LPRO)*A5FE)Y=X9<;(8>\>YO7+/%4ML;_FB0TP5.4=_D5]+,
M_(HE82EFBHD,),Z'WBDY&9.N!;@57QENU,X8;"@S(7[:R44R] *K"#G&VE)0
M<UGC&#FW3$;'KY+4J]YI@;OC>_9S%[P)9D85C@7_QA*]''I]#Q*<TQ77UV+S
M <N .I8O%ERY?]B4:P,/XI72(BW!1D'*LN)*;TLC=@ AV0,(2T#X $#:>P!1
M"8A<H(4R%]:$:CH:2+$!:5<;-CMPWCBTB89E-HU3+<U39G!Z-!9'$UR;;.8F
M-QI.%Q+1C39,+V%Z_A&NEM38%>-*LYAR!31+8!<R0<G6U"8#+AF=,<[T'1S!
M:9(PFRC*X2(KMIM-V\$$-65<O1_XVLBW(ORXE'I62 WW2#W'60M(> AA$)*;
MZ00.WM6QC)M9)ABW("(%R]]PWWA7&1A6!H:.K[W70*5!S.%,2(-DV:*!,ZHX
M(\<9[>7DG,Z$+%P]E9)F"Y>5POW/(CN*]RV!+V:HJ/M(%'R_--1PH3%5/QJ$
MM2MA[2>"764:94ZER7%<1CZKC[Q(1L%'BNUG:\IZ%+1(V!OXZQH=G4I'IU%'
MS;YLB*Y;L7;?ENV]2ECO"=O3E&F-"<Q765+O]%E!T=LQFG2"XE=O=K]Z>[_9
M[%4<HU)'MEHFD-,[9\DAS)DT&X 90;'[MNM$]1^):C>+.JY$';^*J$/(37T2
M"6@!,S0+65*GL_EE';A#*INV& FV]3;X#^'EO+8X!H^\C!JM)#MG /DG30IC
M839^<XI+[A=L/+*MK:2YN#Y;V#/3_,3K>D_G>5O"2=3(M7/^;64VYC=ZG-]>
MI\G&;=4FS66[[AC_#2\YN<BV,I/.VRJB9%O>2?>53Z^2\,'Q%9#.@XSX.PV8
M[7X_4;E@)@2.<X,+6CWCF2P:RF*B1>YZLIG0IL-SPZ5IPE':!>;Y7 A]/[%M
M7M76C_X 4$L#!!0    ( (:67%0[4W,\'P,  )T'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0W+GAM;)55;6_:,!#^*Z>H'UJ)-B^T@"I *K!JG=JI*FOW
M8=H'DQS$JF-GM@/MO]_9@<!60)N$B,^^>^ZY%Y_[*Z5?38YHX:T0T@R"W-KR
M.@Q-FF/!S(4J4=+)7.F"61+U(C2E1I9YHT*$211UPH)Q&0S[?N]1#_NJLH)+
M?-1@JJ)@^GV$0JT&01QL-I[X(K=N(QSV2[; *=KG\E&3%#8H&2]0&JXD:)P/
M@IOX>M1S^E[AA>/*[*S!13)3ZM4)=]D@B!PA%)A:A\#HL\0Q"N& B,:O-6;0
MN'2&N^L-^JV/G6*9,8-C);[SS.:#H!= AG-6"?ND5I]Q'<^5PTN5,/X?5FO=
M*("T,E85:V-B4'!9?]G;.@\[!DE\P"!9&R2>=^W(LYPPRX9]K5:@G3:AN84/
MU5L3.2Y=4:96TRDG.SL<J_,)+JDV)67:PLU"(_K5BML<IK=?X#%G%'V*E>4I
M$P:8S&#79(*:+YG++=QS-N."VW<XARFU3U8)!#6'6\8UO#!1>6FOP>D$+>/"
MG)'I/Z#?.Q5HPPEP"=]R51FB9?JAI92XP,)T'?ZH#C\Y$'X<PX.2-C?P26:8
M_0D04BZ;A":;A(Z2HX@33"^@';<@B9+X>3J!TY.S([#MIDYM#]L^ +M-8:M)
M!$<##\A,I3$#ZO G3"NMN5S B!EN6O LU<R@7K(9U>%.EI5U.DJF9,W<I6C!
MF(FT$EZ 'T]*"*!F7S&=_3Q"^K(A?>E)7QXCO?1U9Y8JE6+I'='O%F>ZHBD
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MK,!2,EZ"P,7$N2#OYB0P#M;B;X9KN?,.1LH]Y]_,X#J=.)Z)"'-,E$%0_7C
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M%.:+A A2NI$]!VK8QCO\M7A3)A.^*A7H?3'[@2+1^]$5<3\X/(^]/WH"C-L
MXU[.#9/V[IK1#5S1A.5,;7JPHQ8[^HV?)_&V9=KK#==R058T03C5Y5=^AX4Z
MTZ>YI\S-&F:T>U[#T"=A]UDD.Y<&Z8WF<\9$"GK&="8OR![QMV3_=^9O6S5)
M\#_D+WB>OR <!=%!_MR=^[= L;1]C 1[WNM+K)UM>Z4+VR$<S,],#V7O]2VF
M;L!NJ%BR4NJ/?:&1WOE0%QE1]S3U0/'*WO+W7.F>P;YFN@]$80ST_PO.U=/
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M/-8)%FW#;B>*U[:%K;C2#=$.2WW'86$ >G_-N=I-S ?Z6S/]!U!+ P04
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MLJ0,5A4D45K\)P]E(XX"H'\B )4!J!W@G@C 90#N&^"6 6[? *\,\-H!P8D
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MF78+X/U2*;M_< [J7GK\%U!+ P04    " "&EEQ48*^F3I<"  !E!@  &0
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M-]\5(*V!N;X60C\M;(#F2V7Z"U!+ P04    " "&EEQ4-FT;].$*  "G10
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M7FX(7A*6-^#?KV)N3O4F_PT!S>]F.?D_4$L#!!0    ( (:67%1?2%5%X 4
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MLYMZ8P\23-E>F"_R^"=6^0PL7RR%=K]PK&P##^*]-C*KP!1!QO/RGSU5.EP
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MO5M%M[IV-J[H:W:BM]C 7"F6;]&M?\PWVBAZ)7^V..O7SOK.6?^&L_D!%7U
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MHK(&]#R5TIPWUD$]?\[^ 5!+ P04    " "&EEQ4KX\0JB\$  ""#P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6REEVUOXC@0@/_*"/5#*[4D=D*
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MIL)\H-^O.%?[@5%07KMG_P-02P,$%     @ AI9<5#>X7J-X P  H L  !D
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M<@;V^UI*<URX#9JA?/8+4$L#!!0    ( (:67%3&D\%>N0(  &\'   9
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M;(V7VX[B.!"&7\6*YF)&6CJQ<VX!T@QHM2/MH=7TS%Z;X(#52<S:#C1OO^5
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M) P.4=DI*D+4M$4=N!BU+D:#B;<IVDG-;-HUONHX-9@X3&)>*07"D)] U?5
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M>_9\C"^F^:&BI<G/.&^H6,=,H@16FM(_[VE;%/FQ87ZC^#8[2%MRI0N376Z
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MG&9?E.IM.0>?/WT!GT!*P?>$;06FD9B84HVJ]#;7S0BNZQ%8)T9@@V^,RD2
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M%\+MYA:-QVD EP*$"\,0[G%3+!SG CIJAG"^7;,I</L]QGD!@^O+'(UG=[$
M]T'4^"!J]<$OTIQU0.1L.^^9=9X/,C;$."\.*70 R@4! U,\1CDOAGO%!.-8
MZ,$IOL4X&@41Z-\=PD74?H #L' \$@%T ,(%'H\XW!,0SB\_H-TYRM'C+?3$
M 7'C@+CU9O/@ &)7A'V)V')#R>AKE4I;C763Z'1!+LH*<ZFR+"F.&GB+EIK4
M'5\8P]4&I6"*1A@E8*PQ2D6 FM14?$S12P$N@MLS&-QH< Q>4E,<@WO##,.\
M2VCL>QSSP74WQ[' P_W%CAY8L%8KC-)L5U8S%]V]P#IY :-<+R 4X@6,<KW
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "&EEQ4<W]PZ%T%  #%+P  #P
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M2[A%&_:7LBZOG>C^K->]97FW)F6ZK.NSL._*7%I9O:Q"?UE!?_(O4$L#!!0
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M;GY2[S)^'7*Y]GRO\?H_2?5X/C=?+W]9?N^<W)<+SO5M17GZ"U!+ P04
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M/LO.-OU;/AO_OGG^ E!+ 0(4 Q0    ( (:67%0'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " "&EEQ4GMD2_N("  !V"@  &
M    @($ &   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MAI9<5+D@M?3.!@  >1T  !@              ("!&!L  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( (:67%3<>C6]*P,  (X)   8
M          " @1PB  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " "&EEQ49KJ7+PH%  !S%@  &               @(%])0  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ AI9<5%6PNDM%"0  [2D
M !@              ("!O2H  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( (:67%3W,:K[)P(  (H$   8              " @3@T  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "&EEQ4VCVEX"(I
M  !+A0  &0              @(&5-@  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( (:67%1VMQ=ZG@4  '<-   9              "
M@>Y?  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ AI9<
M5%9F*3%D @  %04  !D              ("!PV4  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " "&EEQ4^#)\4M4#   F"0  &0
M        @(%>:   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( (:67%1/G#4TK (    &   9              " @6IL  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ AI9<5$+//^<P"P  [!\
M !D              ("!36\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " "&EEQ4OKK?5A '  #>$   &0              @(&T>@
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( (:67%0/?3N1
MLPX  %DL   9              " @?N!  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ AI9<5-(%=/@)#@  XB<  !D
M ("!Y9   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "&
MEEQ4A!;T<VH$  "\"0  &0              @($EGP  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( (:67%0)X=K;)!<  /](   9
M          " @<:C  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#
M%     @ AI9<5(L!>N#>#   /R(  !D              ("!(;L  'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "&EEQ4.%V?U!8*  #E
M&@  &0              @($VR   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;%!+ 0(4 Q0    ( (:67%0C(H0"H@0   T+   9              " @8/2
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ AI9<5#@[
MP>G:!   Z@H  !D              ("!7-<  'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6Q02P$"% ,4    " "&EEQ4.UVH16,K  #OD0  &0
M    @(%MW   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M (:67%2JUV5[\0,  (<)   9              " @0<( 0!X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ AI9<5/3Z;'ES @  ( 4  !D
M             ("!+PP! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " "&EEQ4M"Z3-"P#  #2!@  &0              @('9#@$ >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (:67%2<+VP* 0,
M (D&   9              " @3P2 0!X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ AI9<5&XUG?IY!   _@H  !D              ("!
M=!4! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "&EEQ4
M_;^$1NP#  !G"0  &0              @($D&@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (:67%2?RC]M10,   X'   9
M      " @4<> 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ AI9<5%<J7_<4 P  <P8  !D              ("!PR$! 'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "&EEQ4;%/4/B(&  "]#@
M&0              @($.)0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( (:67%1U+<8NZP8  .42   9              " @6<K 0!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ AI9<5!C;DS&1
M @  7 4  !D              ("!B3(! 'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " "&EEQ4%')K>>8$  #("@  &0
M@(%1-0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( (:6
M7%31!=NK5P8  "@=   9              " @6XZ 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ AI9<5,(.IZVA @  Z08  !D
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M=#0S+GAM;%!+ 0(4 Q0    ( (:67%0I0(FI80(  -D%   9
M  " @==2 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
MAI9<5&WF@WS  @  W0@  !D              ("!;U4! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " "&EEQ4MK;HMT@#  #B"P  &0
M            @(%F6 $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( (:67%0[4W,\'P,  )T'   9              " @>5; 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ AI9<5#\MC7). P
M90H  !D              ("!.U\! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " "&EEQ4GYO\+I,#  #V#   &0              @('
M8@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( (:67%1F
M$-K>GP(  $$'   9              " @8IF 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ AI9<5,T4"U,Q P  ,0H  !D
M     ("!8&D! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (:67%2?@X0ZO0(  #,(   9              "
M@15_ 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ AI9<
M5&?.TF); P  M0P  !D              ("!"8(! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    " "&EEQ4-FT;].$*  "G10  &0
M        @(&;A0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( (:67%1?2%5%X 4  *4:   9              " @;.0 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ AI9<5$:U73N- P  E@T
M !D              ("!RI8! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    " "&EEQ4?OF/.F\#  "+"@  &0              @(&.F@$
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( (:67%2OCQ"J
M+P0  ((/   9              " @32> 0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ AI9<5#>X7J-X P  H L  !D
M ("!FJ(! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "&
MEEQ4QI/!7KD"  !O!P  &0              @(%)I@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( (:67%2!5-AU.@,  -T+   9
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M970V.2YX;6Q02P$"% ,4    " "&EEQ4<4;R/W$$  #(%0  &0
M    @('CO $ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (
M (:67%1#;>U3E0,  / -   9              " @8O! 0!X;"]W;W)K<VAE
M971S+W-H965T-S$N>&UL4$L! A0#%     @ AI9<5+=]RNK#!0  #QH  !D
M             ("!5\4! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"
M% ,4    " "&EEQ4$"[4(S0#  #P$P  #0              @ %1RP$ >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (:67%27BKL<P    !,"   +
M      "  ;#. 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (:67%1S?W#H704
M ,4O   /              "  9G/ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " "&EEQ4K&U05SP"  "O*@  &@              @ $CU0$ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "&EEQ40&L7N@ "  #&
M*0  $P              @ &7UP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    4 !0 .<5  #(V0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>254</ContextCount>
  <ElementCount>476</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>97</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1007009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Senior Secured Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nektar.com/role/SeniorSecuredNotes</Role>
      <ShortName>Senior Secured Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - Liabilities Related to the Sales of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2138111 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2142112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2149113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2157114 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2161115 - Disclosure - Selected Quarterly Financial Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SelectedQuarterlyFinancialData</Role>
      <ShortName>Selected Quarterly Financial Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Inventory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OperatingLeases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Liabilities Related to the Sales of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2343309 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2350310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2358311 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SegmentReporting</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2362312 - Disclosure - Selected Quarterly Financial Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables</Role>
      <ShortName>Selected Quarterly Financial Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SelectedQuarterlyFinancialData</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails</Role>
      <ShortName>Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails</Role>
      <ShortName>Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Inventory - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryScheduleofInventoriesDetails</Role>
      <ShortName>Inventory - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Senior Secured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.nektar.com/role/SeniorSecuredNotesDetails</Role>
      <ShortName>Senior Secured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SeniorSecuredNotes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails</Role>
      <ShortName>Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Operating Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>Operating Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Operating Leases - Schedule of Operating Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails</Role>
      <ShortName>Operating Leases - Schedule of Operating Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Operating Leases - Schedule of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails</Role>
      <ShortName>Operating Leases - Schedule of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails</Role>
      <ShortName>Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Liabilities Related to the Sales of Future Royalties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail</Role>
      <ShortName>Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CommitmentsandContingencies</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2440420 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails</Role>
      <ShortName>License and Collaboration Agreements - License, Collaboration and Other Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - License and Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2444422 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2451427 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2459433 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail</Role>
      <ShortName>Segment Reporting - Revenue by Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="nktr-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2463435 - Disclosure - Selected Quarterly Financial Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="nktr-20211231.htm">nktr-20211231.htm</File>
    <File>nktr-20211231.xsd</File>
    <File>nktr-20211231_cal.xml</File>
    <File>nktr-20211231_def.xml</File>
    <File>nktr-20211231_lab.xml</File>
    <File>nktr-20211231_pre.xml</File>
    <File>nktr-20211231xexx311.htm</File>
    <File>nktr-20211231xexx312.htm</File>
    <File>nktr-20211231xexx321.htm</File>
    <File>nktr20211231-exx1040.htm</File>
    <File>nktr20211231-exx211.htm</File>
    <File>nktr20211231-exx231.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nktr-20211231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="755">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktr-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 32,
   "contextCount": 254,
   "dts": {
    "calculationLink": {
     "local": [
      "nktr-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktr-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nktr-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 646,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://www.nektar.com/20211231": 4,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 9
   },
   "keyCustom": 92,
   "keyStandard": 384,
   "memberCustom": 53,
   "memberStandard": 42,
   "nsprefix": "nktr",
   "nsuri": "http://www.nektar.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.nektar.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Cash and Investments in Marketable Securities",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities",
     "shortName": "Cash and Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Inventory",
     "role": "http://www.nektar.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Senior Secured Notes",
     "role": "http://www.nektar.com/role/SeniorSecuredNotes",
     "shortName": "Senior Secured Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DevelopmentDerivativeLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DevelopmentDerivativeLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Operating Leases",
     "role": "http://www.nektar.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - Liabilities Related to the Sales of Future Royalties",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties",
     "shortName": "Liabilities Related to the Sales of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Commitments and Contingencies",
     "role": "http://www.nektar.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Stockholders' Equity",
     "role": "http://www.nektar.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.nektar.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138111 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142112 - Disclosure - Stock-Based Compensation",
     "role": "http://www.nektar.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149113 - Disclosure - Income Taxes",
     "role": "http://www.nektar.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157114 - Disclosure - Segment Reporting",
     "role": "http://www.nektar.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161115 - Disclosure - Selected Quarterly Financial Data",
     "role": "http://www.nektar.com/role/SelectedQuarterlyFinancialData",
     "shortName": "Selected Quarterly Financial Data",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables",
     "shortName": "Cash and Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Inventory (Tables)",
     "role": "http://www.nektar.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.nektar.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LesseeOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.nektar.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LesseeOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Liabilities Related to the Sales of Future Royalties (Tables)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables",
     "shortName": "Liabilities Related to the Sales of Future Royalties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.nektar.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - License and Collaboration Agreements (Tables)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables",
     "shortName": "License and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343309 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.nektar.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.nektar.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358311 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.nektar.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2362312 - Disclosure - Selected Quarterly Financial Data (Tables)",
     "role": "http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables",
     "shortName": "Selected Quarterly Financial Data (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nktr:NetExpenseReimbursementsFromCollaborationPartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails",
     "shortName": "Cash and Investments in Marketable Securities - Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Details)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Cash and Investments in Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails",
     "shortName": "Cash and Investments in Marketable Securities - Schedule of Portfolio of Cash and Investments in Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Inventory - Schedule of Inventories (Details)",
     "role": "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails",
     "shortName": "Inventory - Schedule of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:DepreciablePropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:DepreciablePropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Property, Plant and Equipment - Additional Information (Details)",
     "role": "http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails",
     "shortName": "Property, Plant and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfSeniorDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Senior Secured Notes (Details)",
     "role": "http://www.nektar.com/role/SeniorSecuredNotesDetails",
     "shortName": "Senior Secured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i4580a99794e6481fb70ca26feccaa301_I20151005",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SeniorNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i418e819404874602beccd76277d2832e_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i418e819404874602beccd76277d2832e_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i16608bc88bb04b04bb4edbc265eb647e_I20210212",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details)",
     "role": "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails",
     "shortName": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i16608bc88bb04b04bb4edbc265eb647e_I20210212",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Operating Leases - Additional Information (Details)",
     "role": "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
     "shortName": "Operating Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Operating Leases - Schedule of Operating Lease Information (Details)",
     "role": "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails",
     "shortName": "Operating Leases - Schedule of Operating Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "idd1cc83ff58a4f018324d605fda64c56_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "nktr:AreaOfLeasedSpaceDelivered",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Operating Leases - Schedule of Lease Expense (Details)",
     "role": "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails",
     "shortName": "Operating Leases - Schedule of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:VariableLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)",
     "role": "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails",
     "shortName": "Operating Leases - Schedule of Future Minimum Lease Payments for Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Liabilities Related to the Sales of Future Royalties - Additional Information (Details)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
     "shortName": "Liabilities Related to the Sales of Future Royalties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ic019febd6d76418e963113849a03e38e_D20120224-20120224",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i48e34961873b4743b7e5dc882aecad66_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)",
     "role": "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail",
     "shortName": "Liabilities Related to the Sales of Future Royalties - Schedule of Liability Related to Potential Future Royalties (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i859caff83678471fa0131b598ecb3b99_I20120224",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.nektar.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i26423d2e98f74cab9e74de71740ea6dd_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "action",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "icdcb60f448fd48b6b0f24d116b1058d4_D20180403-20180403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "icdcb60f448fd48b6b0f24d116b1058d4_D20180403-20180403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)",
     "role": "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440420 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Details)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails",
     "shortName": "License and Collaboration Agreements - License, Collaboration and Other Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "nktr:PotentialDevelopmentMilestones",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - License and Collaboration Agreements - Additional Information (Details)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "License and Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i3bb556020be549ee87413847caad7cad_D20180212-20180213",
      "decimals": "INF",
      "lang": "en-US",
      "name": "nktr:ProfitsAndLossesSharingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ChangeInControlSeverancePaymentPeriodForExecutives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444422 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:ChangeInControlSeverancePaymentPeriodForExecutives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "role": "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i0035b332ba9d4aa3ae359c9299758ee5_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)",
     "role": "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i48e34961873b4743b7e5dc882aecad66_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)",
     "role": "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock Option Activity Under Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i48e34961873b4743b7e5dc882aecad66_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i718223867ea449b3bb07403f12f97462_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)",
     "role": "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Restricted Stock Unit Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "iaa30a4dcad864e348c8a1e95629b1957_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451427 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)",
     "role": "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "role": "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details)",
     "role": "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails",
     "shortName": "Income Taxes - Schedule of Income Tax Provision Related to Continuing Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ib0e8124eb7354356b1cc17142addd673_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i48e34961873b4743b7e5dc882aecad66_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "role": "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i7e86cae77d44493aad21052dab0a76b8_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "icfc39458a49345bdbf9c5f0b59507c25_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "icfc39458a49345bdbf9c5f0b59507c25_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NumberOfOperatingBusinessSegment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459433 - Disclosure - Segment Reporting - Additional Information (Details)",
     "role": "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nktr:NumberOfOperatingBusinessSegment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - Segment Reporting - Revenue by Geographic Area (Detail)",
     "role": "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail",
     "shortName": "Segment Reporting - Revenue by Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "ie54219086ed7421ab34a8c373a1e98ba_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463435 - Disclosure - Selected Quarterly Financial Data (Details)",
     "role": "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails",
     "shortName": "Selected Quarterly Financial Data (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8fcd52e9777c43dcac13c28c6d9971be_D20211001-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:SaleOfFutureRoyaltiesTransactionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20211231.htm",
      "contextRef": "i8d0ef44da71d486b98ea8109059ae2ae_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nktr:SaleOfFutureRoyaltiesTransactionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 97,
   "tag": {
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INDIA",
        "terseLabel": "India"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.nektar.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktr_AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable and significant customer concentrations.",
        "label": "Accounts Receivable And Significant Customer Concentrations [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Significant Customer Concentrations"
       }
      }
     },
     "localname": "AccountsReceivableAndSignificantCustomerConcentrationsPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AggregateConsiderationReceivedFromAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate consideration received from agreements.",
        "label": "Aggregate Consideration Received From Agreements",
        "terseLabel": "Total consideration received under agreements"
       }
      }
     },
     "localname": "AggregateConsiderationReceivedFromAgreements",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen Inc.",
        "label": "Amgen Inc [Member]",
        "terseLabel": "Amgen, Inc.",
        "verboseLabel": "Amgen, Inc."
       }
      }
     },
     "localname": "AmgenIncMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of Premiums (Discounts) Net And Other Non-Cash Transactions",
        "label": "Amortization of Premiums (Discounts) Net And Other Non-Cash Transactions",
        "terseLabel": "Amortization of premiums (discounts), net and other non-cash transactions"
       }
      }
     },
     "localname": "AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation.",
        "label": "Amount Of Transaction Price Allocated To Performance Obligation",
        "terseLabel": "Amount of transaction price allocated to performance obligation"
       }
      }
     },
     "localname": "AmountOfTransactionPriceAllocatedToPerformanceObligation",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AreaOfLeasedSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased space.",
        "label": "Area Of Leased Space",
        "terseLabel": "Lease space (in sq ft)"
       }
      }
     },
     "localname": "AreaOfLeasedSpace",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "nktr_AreaOfLeasedSpaceDelivered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased space delivered.",
        "label": "Area Of Leased Space Delivered",
        "terseLabel": "Leased space delivered (in sq ft)"
       }
      }
     },
     "localname": "AreaOfLeasedSpaceDelivered",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "nktr_AstraZenecaAbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca AB.",
        "label": "Astra Zeneca Ab [Member]",
        "terseLabel": "Astra Zeneca Ab"
       }
      }
     },
     "localname": "AstraZenecaAbMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information [Abstract]",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.nektar.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nktr_BMSCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS collaboration agreement.",
        "label": "B M S Collaboration Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement"
       }
      }
     },
     "localname": "BMSCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BaxaltaIncorporatedOrTakedaPLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baxalta Incorporated or takeda PLC.",
        "label": "Baxalta Incorporated Or Takeda P L C [Member]",
        "terseLabel": "Baxalta Incorporated Or Takeda P L C"
       }
      }
     },
     "localname": "BaxaltaIncorporatedOrTakedaPLCMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BempegaldesleukinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bempegaldesleukin",
        "label": "Bempegaldesleukin [Member]",
        "terseLabel": "Bempegaldesleukin"
       }
      }
     },
     "localname": "BempegaldesleukinMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb collaboration agreement.",
        "label": "Bristol Myers Squibb Collaboration Agreement [Member]",
        "terseLabel": "Bristol Myers Squibb Collaboration Agreement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol-Myers Squibb",
        "verboseLabel": "BMS"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BuildingAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building and Leasehold Improvements.",
        "label": "Building And Leasehold Improvements [Member]",
        "terseLabel": "Building and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndLeaseholdImprovementsMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Line Items]",
        "label": "Cash And Investments In Marketable Securities [Line Items]",
        "terseLabel": "Cash and Investments in Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesLineItems",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Table]",
        "label": "Cash And Investments In Marketable Securities [Table]",
        "terseLabel": "Cash And Investments In Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesTable",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndNonCashRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And NonCash Royalties",
        "label": "Cash And NonCash Royalties [Member]",
        "terseLabel": "Cash And NonCash Royalties"
       }
      }
     },
     "localname": "CashAndNonCashRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments.",
        "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments",
        "terseLabel": "Cash and investments in marketable securities",
        "totalLabel": "Total cash and investments in marketable securities"
       }
      }
     },
     "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ChangeInControlSeverancePaymentPeriodForExecutives": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in control severance payment period for executives.",
        "label": "Change In Control Severance Payment Period For Executives",
        "terseLabel": "Change in control severance payment period for executives"
       }
      }
     },
     "localname": "ChangeInControlSeverancePaymentPeriodForExecutives",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_CollaborativeArrangementAdditionalIndicationPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Additional Indication Payment",
        "label": "Collaborative Arrangement, Additional Indication Payment",
        "terseLabel": "Additional indication payment"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalIndicationPayment",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementCommittedFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Committed Funding",
        "label": "Collaborative Arrangement, Committed Funding",
        "terseLabel": "Committed funding"
       }
      }
     },
     "localname": "CollaborativeArrangementCommittedFunding",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-based Payments, First Indication",
        "label": "Collaborative Arrangement, Success-based Payments, First Indication",
        "terseLabel": "Success-based payments, first indication"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsFirstIndication",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-based Payments, First Indication, Period to be Paid",
        "label": "Collaborative Arrangement, Success-based Payments, First Indication, Period to be Paid",
        "terseLabel": "Success-based payments, first indication, period to be paid"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsFirstIndicationPeriodToBePaid",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsFirstPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-Based Payments, First Payment",
        "label": "Collaborative Arrangement, Success-Based Payments, First Payment",
        "terseLabel": "Success-based payments, first payment"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsFirstPayment",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-based Payments, Second Indication",
        "label": "Collaborative Arrangement, Success-based Payments, Second Indication",
        "terseLabel": "Success-based payments, second indication"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsSecondIndication",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Success-based Payments, Second Indication, Period to be Paid",
        "label": "Collaborative Arrangement, Success-based Payments, Second Indication, Period to be Paid",
        "terseLabel": "Success-based payments, second indication, period to be paid"
       }
      }
     },
     "localname": "CollaborativeArrangementSuccessBasedPaymentsSecondIndicationPeriodToBePaid",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.",
        "label": "Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones",
        "terseLabel": "Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CompanyShareOfDevelopmentCostsAnnualCap": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company Share Of Development Costs, Annual Cap",
        "label": "Company Share Of Development Costs, Annual Cap",
        "terseLabel": "Company share of development costs, annual cap"
       }
      }
     },
     "localname": "CompanyShareOfDevelopmentCostsAnnualCap",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ComputerFurnitureAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture computer and other.",
        "label": "Computer Furniture And Other [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerFurnitureAndOtherMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CostOfBorrowingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Borrowing",
        "label": "Cost of Borrowing [Member]",
        "terseLabel": "Cost of Borrowing"
       }
      }
     },
     "localname": "CostOfBorrowingMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Liability Related to the Sale of Future Royalties",
        "label": "Deferred Tax Assets, Liability Related to the Sale of Future Royalties",
        "terseLabel": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DepreciablePropertyPlantAndEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "nktr_DepreciablePropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciable Property, plant and equipment, Gross.",
        "label": "Depreciable Property Plant And Equipment Gross",
        "terseLabel": "Depreciable property, plant and equipment at cost"
       }
      }
     },
     "localname": "DepreciablePropertyPlantAndEquipmentGross",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DepreciablePropertyPlantAndEquipmentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciable Property, plant and equipment, Net.",
        "label": "Depreciable Property Plant And Equipment Net",
        "totalLabel": "Depreciable property, plant and equipment, net"
       }
      }
     },
     "localname": "DepreciablePropertyPlantAndEquipmentNet",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DerivativeActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Action",
        "label": "Derivative Action [Member]",
        "terseLabel": "Derivative Action"
       }
      }
     },
     "localname": "DerivativeActionMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_DevelopmentDerivativeLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Derivative Liability",
        "label": "Development Derivative Liability [Text Block]",
        "terseLabel": "Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability"
       }
      }
     },
     "localname": "DevelopmentDerivativeLiabilityTextBlock",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_DrugProductDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product development.",
        "label": "Drug Product Development [Member]",
        "terseLabel": "Drug Product Development"
       }
      }
     },
     "localname": "DrugProductDevelopmentMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Non-cash Royalty Revenue Related To Sales Of Future Royalties, Amount",
        "terseLabel": "Non-cash royalty revenue related to sales of future royalties"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Non Deductible Expense For Liability Related Sale Of Future Royalties, Amount",
        "terseLabel": "Non-cash interest expense on liability related to sales of future royalties"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly and Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible additional cash payments receivable upon achievement of certain sales milestones.",
        "label": "Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones",
        "terseLabel": "Eligible additional cash payments receivable upon achievement of certain sales milestones"
       }
      }
     },
     "localname": "EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee.",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EstimatedFairValueOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of shares.",
        "label": "Estimated Fair Value Of Shares",
        "terseLabel": "Estimated fair value of shares"
       }
      }
     },
     "localname": "EstimatedFairValueOfShares",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_FederalOrphanDrugCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal orphan drug credits.",
        "label": "Federal Orphan Drug Credits",
        "terseLabel": "Federal orphan drug credits"
       }
      }
     },
     "localname": "FederalOrphanDrugCredits",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_FutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Royalties",
        "label": "Future Royalties [Member]",
        "terseLabel": "Future Royalties"
       }
      }
     },
     "localname": "FutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross",
        "label": "Gain (Loss) ON Revaluation Of Liabilities Related To The Sale Of Future Royalties, Gross",
        "negatedLabel": "Loss on revaluation of liability related to the sale of future royalties"
       }
      }
     },
     "localname": "GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties",
        "label": "Gain (Loss) On Revaluation Of Liabilities Related To The Sales Of Future Royalties",
        "negatedTerseLabel": "Loss on revaluation of liability related to the sale of future royalties",
        "terseLabel": "Loss on revaluation of liability related to the sale of future royalties"
       }
      }
     },
     "localname": "GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of equipment and other costs for terminated program.",
        "label": "Impairment Of Assets And Other Costs For Terminated Program",
        "terseLabel": "Impairment of assets and other costs for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfAssetsAndOtherCostsForTerminatedProgram",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of Assets and Other Costs for Terminated Program",
        "label": "Impairment of Assets and Other Costs for Terminated Program [Member]",
        "terseLabel": "Impairment of assets and other costs for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfAssetsAndOtherCostsForTerminatedProgramMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of Assets and Other Costs for Terminated Program",
        "label": "Impairment of Assets and Other Costs for Terminated Program [Policy Text Block]",
        "terseLabel": "Impairment of Assets and Other Costs for Terminated Program"
       }
      }
     },
     "localname": "ImpairmentOfAssetsAndOtherCostsForTerminatedProgramPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_ImpairmentOfEquipmentFromTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of equipment from terminated program.",
        "label": "Impairment Of Equipment From Terminated Program",
        "terseLabel": "Impairment of advance payments to contract manufacturers and equipment for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfEquipmentFromTerminatedProgram",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncomeTaxesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Line Items]",
        "terseLabel": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureLineItems",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_IncomeTaxesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Table]",
        "terseLabel": "Income Taxes Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureTable",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "negatedTerseLabel": "Operating leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_InventoryAndSignificantSupplierConcentrationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory and significant supplier concentrations.",
        "label": "Inventory And Significant Supplier Concentrations [Policy Text Block]",
        "terseLabel": "Inventory and Significant Supplier Concentrations"
       }
      }
     },
     "localname": "InventoryAndSignificantSupplierConcentrationsPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LeaseExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease extension term.",
        "label": "Lease Extension Term",
        "terseLabel": "Lease extension term"
       }
      }
     },
     "localname": "LeaseExtensionTerm",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases [Line Items]",
        "label": "Leases [Line Items]",
        "terseLabel": "Leases [Line Items]"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LegalMattersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Matters",
        "label": "Legal Matters [Member]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability tenant improvement reimbursements.",
        "label": "Lessee Operating Lease Liability Tenant Improvement Reimbursements",
        "negatedTerseLabel": "Less: lease incentives"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursements",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LesseeOperatingLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease",
        "label": "Lessee, Operating Lease [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Information"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTableTextBlock",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities on sale of future royalties, unamortized transaction costs.",
        "label": "Liabilities On Sale Of Future Royalties Unamortized Transaction Costs",
        "negatedLabel": "Less: unamortized transaction costs"
       }
      }
     },
     "localname": "LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Line Items]",
        "terseLabel": "Liability Related to the Sale of Future Royalties [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesLineItems",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To Sale Of Future Royalties",
        "label": "Liability Related To Sale Of Future Royalties [Roll Forward]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesRollForward",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Abstract]",
        "terseLabel": "Liability Related To Sale Of Potential Future Royalties [Abstract]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract",
     "nsuri": "http://www.nektar.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail": {
       "order": 1.0,
       "parentTag": "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties noncurrent.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current",
        "periodEndLabel": "Liabilities related to the sales of future royalties \u2013 ending balance",
        "periodStartLabel": "Liabilities related to the sales of future royalties\u2014beginning balance"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties non current net of issuance costs.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs",
        "terseLabel": "Liabilities related to the sales of future royalties, net",
        "totalLabel": "Liabilities related to the sales of future royalties, net"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Text Block]",
        "terseLabel": "Liabilities Related to the Sales of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To The Sale Of Future Royalties [Roll Forward]",
        "label": "Liability Related To The Sale Of Future Royalties [Roll Forward]",
        "terseLabel": "Liability Related To The Sale Of Future Royalties [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesRollForward",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Line Items]",
        "terseLabel": "License And Collaboration Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsLineItems",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsTable",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LicenseCollaborationOtherRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.",
        "label": "License Collaboration Other Revenue",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationOtherRevenue",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LongTermInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investment maturity period.",
        "label": "Long Term Investment Maturity Period",
        "terseLabel": "Long term investment maturity period"
       }
      }
     },
     "localname": "LongTermInvestmentMaturityPeriod",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_ManufacturingLaboratoryAndOtherEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing laboratory and other equipment.",
        "label": "Manufacturing Laboratory And Other Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingLaboratoryAndOtherEquipmentMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MergerAndAcquisitionRelatedClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger and acquisition related claims.",
        "label": "Merger And Acquisition Related Claims [Member]",
        "terseLabel": "Merger and Acquisition Related Claims"
       }
      }
     },
     "localname": "MergerAndAcquisitionRelatedClaimsMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Milestone [Axis]",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds and Transactions",
        "label": "Minimum Transaction Royalties Payments Needed to Pay the Difference Between Thresholds",
        "terseLabel": "Minimum transaction royalties payments needed to pay the difference between the 2025 threshold and 2020 transaction royalties"
       }
      }
     },
     "localname": "MinimumTransactionRoyaltiesPaymentsNeededToPayTheDifferenceBetweenThresholds",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_MissionBayLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mission bay lease.",
        "label": "Mission Bay Lease [Member]",
        "terseLabel": "Mission Bay Facility"
       }
      }
     },
     "localname": "MissionBayLeaseMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MulquinActionAndDamibaActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mulquin Action And Damiba Action",
        "label": "Mulquin Action And Damiba Action [Member]",
        "terseLabel": "Mulquin Action And Damiba Action"
       }
      }
     },
     "localname": "MulquinActionAndDamibaActionMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NKTR181Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NKTR - 181 [Member]",
        "label": "NKTR - 181 [Member]",
        "terseLabel": "NKTR - 181"
       }
      }
     },
     "localname": "NKTR181Member",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar214Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar 214.",
        "label": "Nektar 214 [Member]",
        "terseLabel": "Nektar 214"
       }
      }
     },
     "localname": "Nektar214Member",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_Nektar358Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar-358",
        "label": "Nektar-358 [Member]",
        "terseLabel": "Nektar-358"
       }
      }
     },
     "localname": "Nektar358Member",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar [Member]",
        "label": "Nektar [Member]",
        "terseLabel": "Nektar"
       }
      }
     },
     "localname": "NektarMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarThreeFiveEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nektar three five eight.",
        "label": "Nektar Three Five Eight [Member]",
        "terseLabel": "NKTR-358"
       }
      }
     },
     "localname": "NektarThreeFiveEightMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NetExpenseReimbursementsFromCollaborationPartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net expense reimbursements from collaboration partner.",
        "label": "Net Expense Reimbursements From Collaboration Partner",
        "terseLabel": "Net expense reimbursements from collaboration partner"
       }
      }
     },
     "localname": "NetExpenseReimbursementsFromCollaborationPartner",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NetOperatingLossCarryforwardForIncomeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforward for income tax.",
        "label": "Net Operating Loss Carryforward For Income Tax",
        "terseLabel": "Net operating loss carryforward for income tax"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardForIncomeTax",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NeulastaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neulasta.",
        "label": "Neulasta [Member]",
        "terseLabel": "Neulasta"
       }
      }
     },
     "localname": "NeulastaMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense related to sale of royalties.",
        "label": "Non Cash Interest Expense Related To Sale Of Royalties",
        "negatedLabel": "Non-cash interest expense on liabilities related to the sales of future royalties",
        "terseLabel": "Non-cash interest expense on liabilities related to sales of future royalties",
        "verboseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash royalty revenue related to sale future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedLabel": "Non-cash royalty revenue related to the sales of future royalties",
        "negatedTerseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash royalty revenue related to sale of future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]",
        "terseLabel": "Non-cash royalty revenue related to the sales of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonSecuritiesRelatedClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-securities related claims.",
        "label": "Non Securities Related Claims [Member]",
        "terseLabel": "Non-Securities Related Claims"
       }
      }
     },
     "localname": "NonSecuritiesRelatedClaimsMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Investing and Financing Activities, Accounts Receivable Recognized In Exchange For Long-Term Liabilities",
        "label": "Noncash Investing and Financing Activities, Accounts Receivable Recognized In Exchange For Long-Term Liabilities",
        "terseLabel": "Accounts receivable recognized in exchange for long-term liabilities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NumberOfConsecutiveTermsToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive five year terms to extend lease.",
        "label": "Number Of Consecutive Terms To Extend Lease",
        "terseLabel": "Number of consecutive terms to extend lease"
       }
      }
     },
     "localname": "NumberOfConsecutiveTermsToExtendLease",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_NumberOfOperatingBusinessSegment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating business segment.",
        "label": "Number Of Operating Business Segment",
        "terseLabel": "Number of operating business segment"
       }
      }
     },
     "localname": "NumberOfOperatingBusinessSegment",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_NumberOfReportingUnitsToEvaluateGoodwillForImpairment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units to evaluate goodwill for impairment",
        "label": "Number Of Reporting Units To Evaluate Goodwill For Impairment",
        "terseLabel": "Number of reporting unit evaluated for goodwill"
       }
      }
     },
     "localname": "NumberOfReportingUnitsToEvaluateGoodwillForImpairment",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations under director and officer indemnifications per incident.",
        "label": "Obligations Under Director And Officer Indemnifications Per Incident",
        "terseLabel": "Obligations under Director and Officer Indemnifications per incident"
       }
      }
     },
     "localname": "ObligationsUnderDirectorAndOfficerIndemnificationsPerIncident",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_OpdivoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opdivo.",
        "label": "Opdivo [Member]",
        "terseLabel": "Opdivo"
       }
      }
     },
     "localname": "OpdivoMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization.",
        "label": "Organization [Policy Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_OtherPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other.",
        "label": "Other Partner [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPartnerMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PartialRepaymentOfRoyaltySaleProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partial repayment of royalty sale proceeds.",
        "label": "Partial Repayment Of Royalty Sale Proceeds",
        "negatedTerseLabel": "Payments to RPI"
       }
      }
     },
     "localname": "PartialRepaymentOfRoyaltySaleProceeds",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentMadeForMilestoneNotAchievedYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for milestone not achieved year one.",
        "label": "Payment Made For Milestone Not Achieved Year One",
        "terseLabel": "Payment made for milestone not achieved year one"
       }
      }
     },
     "localname": "PaymentMadeForMilestoneNotAchievedYearOne",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentMadeForMilestoneNotAchievedYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for milestone not achieved year two.",
        "label": "Payment Made For Milestone Not Achieved Year Two",
        "terseLabel": "Payment made for milestone not achieved year two"
       }
      }
     },
     "localname": "PaymentMadeForMilestoneNotAchievedYearTwo",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved",
        "label": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved",
        "terseLabel": "Payment of transaction related to purchase and sale agreement"
       }
      }
     },
     "localname": "PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved",
        "label": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved",
        "terseLabel": "Payment of transaction related to purchase and sale agreement if threshold is not achieved"
       }
      }
     },
     "localname": "PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received, if conditions occur.",
        "label": "Percentage Of Development Milestones Payments To Be Received If Conditions Occur",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced if conditions occur"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received under certain conditions.",
        "label": "Percentage Of Development Milestones Payments To Be Received Under Certain Conditions",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced under certain conditions"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of funding Phase three development costs on an indication by indication basis borne.",
        "label": "Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne",
        "terseLabel": "Percentage of funding phase 3 development costs on an indication by indication basis borne"
       }
      }
     },
     "localname": "PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in development costs.",
        "label": "Percentage Of Sharing In Development Costs",
        "terseLabel": "Percentage of sharing development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in Phase 2 development costs.",
        "label": "Percentage Of Sharing In Phase Two Development Costs",
        "terseLabel": "Percentage of sharing in Phase 2 development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInProductionCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sharing in production costs.",
        "label": "Percentage Of Sharing In Production Costs",
        "terseLabel": "Percentage of sharing production costs"
       }
      }
     },
     "localname": "PercentageOfSharingInProductionCosts",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.",
        "label": "Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments",
        "terseLabel": "Percentage of upfront payment, market access milestones, royalties and sales milestones"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PhaseOneClinicalDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 1 clinical development.",
        "label": "Phase One Clinical Development [Member]",
        "terseLabel": "Phase 1 Clinical Development"
       }
      }
     },
     "localname": "PhaseOneClinicalDevelopmentMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development and regulatory milestones.",
        "label": "Potential Development And Regulatory Milestones",
        "terseLabel": "Potential future additional development and regulatory milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development milestones.",
        "label": "Potential Development Milestones",
        "terseLabel": "Potential future additional payments for development milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestones",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentRegulatoryAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development regulatory and sales milestones.",
        "label": "Potential Development Regulatory And Sales Milestones",
        "terseLabel": "Potential future development, regulatory and sales milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentRegulatoryAndSalesMilestones",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_ProceedsFromSaleOfFutureRoyaltiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale of Future Royalties, Net",
        "label": "Proceeds From Sale of Future Royalties, Net",
        "terseLabel": "Proceeds from sale of future royalties, net of $3.8 million of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfFutureRoyaltiesNet",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of potential future royalties gross.",
        "label": "Proceeds From Sale Of Potential Future Royalties Gross",
        "terseLabel": "Proceeds from sale of royalty rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProfitsAndLossesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profits and losses sharing percentage.",
        "label": "Profits And Losses Sharing Percentage",
        "terseLabel": "Global commercialization profits and losses sharing percentage"
       }
      }
     },
     "localname": "ProfitsAndLossesSharingPercentage",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PurchaseAndSaleAgreement2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2012",
        "label": "Purchase and Sale Agreement 2012 [Member]",
        "terseLabel": "2012 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2012Member",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PurchaseAndSaleAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and Sale Agreement 2020",
        "label": "Purchase and Sale Agreement 2020 [Member]",
        "terseLabel": "2020 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreement2020Member",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PurchaseAndSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and sale agreement.",
        "label": "Purchase And Sale Agreement [Member]",
        "terseLabel": "Pursuant to the 2012 Purchase and Sale Agreement"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreementMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_RSUsAndPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RSUs and PSUs",
        "label": "RSUs and PSUs [Member]",
        "terseLabel": "RSUs and PSUs"
       }
      }
     },
     "localname": "RSUsAndPSUsMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RemainingAmountAllocatedToTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amount allocated to transaction price.",
        "label": "Remaining Amount Allocated To Transaction Price",
        "terseLabel": "Remaining amount allocated to transaction price"
       }
      }
     },
     "localname": "RemainingAmountAllocatedToTransactionPrice",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RoyaltiesLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Liability, Measurement Input",
        "label": "Royalties Liability, Measurement Input",
        "terseLabel": "Royalties liability, measurement input"
       }
      }
     },
     "localname": "RoyaltiesLiabilityMeasurementInput",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nktr_RoyaltyMonetizationProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of potential future royalties.",
        "label": "Royalty Monetization Proceeds",
        "terseLabel": "Royalty monetization proceeds"
       }
      }
     },
     "localname": "RoyaltyMonetizationProceeds",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SFJPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SFJ Pharmaceuticals",
        "label": "SFJ Pharmaceuticals [Member]",
        "terseLabel": "SFJ Pharmaceuticals"
       }
      }
     },
     "localname": "SFJPharmaceuticalsMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SaleOfFutureRoyaltiesTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Future Royalties Transaction Costs",
        "label": "Sale of Future Royalties Transaction Costs",
        "terseLabel": "Sale of future royalties transaction costs"
       }
      }
     },
     "localname": "SaleOfFutureRoyaltiesTransactionCosts",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SaleOfStockConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock consideration received.",
        "label": "Sale Of Stock Consideration Received",
        "terseLabel": "Sale of stock consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceived",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SaleOfStockValueAuthorizedInTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock Value Authorized In Transaction",
        "label": "Sale Of Stock Value Authorized In Transaction",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockValueAuthorizedInTransaction",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SalesMilestoneRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone revenue.",
        "label": "Sales Milestone Revenue",
        "terseLabel": "Sales milestone revenue"
       }
      }
     },
     "localname": "SalesMilestoneRevenue",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ScheduleOfLeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Leases [Table]",
        "label": "Schedule Of Leases [Table]",
        "terseLabel": "Schedule Of Leases [Table]"
       }
      }
     },
     "localname": "ScheduleOfLeasesTable",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Liability Related To Sale Of Potential Future Royalties",
        "label": "Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]",
        "terseLabel": "Schedule of Liability Related to Potential Future Royalties"
       }
      }
     },
     "localname": "ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_SecuritiesRelatedClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities related claims.",
        "label": "Securities Related Claims [Member]",
        "terseLabel": "Securities Related Claims"
       }
      }
     },
     "localname": "SecuritiesRelatedClaimsMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SelectedQuarterlyFinancialDataLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selected quarterly financial data.",
        "label": "Selected Quarterly Financial Data [Line Items]",
        "terseLabel": "Selected Quarterly Financial Data [Line Items]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialDataLineItems",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_SelectedQuarterlyFinancialDataTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selected quarterly financial data.",
        "label": "Selected Quarterly Financial Data [Table]",
        "terseLabel": "Selected Quarterly Financial Data [Table]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialDataTable",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seven point seven five percent senior secured notes due October two thousand and twenty.",
        "label": "Seven Point Seven Five Percent Senior Secured Notes Due October Two Thousand And Twenty [Member]",
        "terseLabel": "7.75% Senior Secured Notes Due October 2020"
       }
      }
     },
     "localname": "SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ShareBasedCompensationPlansShareLimitForEveryOneShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation plan's share limit for every one share.",
        "label": "Share Based Compensation Plans Share Limit For Every One Share",
        "terseLabel": "Share-based compensation plan's share limit reduction for every one restricted stock unit granted"
       }
      }
     },
     "localname": "ShareBasedCompensationPlansShareLimitForEveryOneShare",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "nktr_ShareBasedPaymentArrangementOptionRSUsAndPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option, RSUs And PSUs",
        "label": "Share-based Payment Arrangement, Option, RSUs And PSUs [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option, RSUs And PSUs"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionRSUsAndPSUsMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period subject to lock-up and stand-still provisions period.",
        "label": "Stock Issued During Period Subject To Lock Up And Stand Still Provisions Period",
        "terseLabel": "Stock issued during period subject to lock-up and stand-still provisions period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_StockOptionsRSUsAndPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, RSUs And PSUs",
        "label": "Stock Options, RSUs And PSUs [Member]",
        "verboseLabel": "Stock Options, RSUs and PSUs"
       }
      }
     },
     "localname": "StockOptionsRSUsAndPSUsMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_TaxPositionsRelatedToCurrentYearAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Positions Related To Current Year",
        "label": "Tax Positions Related To Current Year [Abstract]",
        "terseLabel": "Tax positions related to current year:"
       }
      }
     },
     "localname": "TaxPositionsRelatedToCurrentYearAbstract",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_TaxPositionsRelatedToPriorYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Positions Related To Prior Years",
        "label": "Tax Positions Related To Prior Years [Abstract]",
        "terseLabel": "Tax positions related to prior years:"
       }
      }
     },
     "localname": "TaxPositionsRelatedToPriorYearsAbstract",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_TerminatedPartnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminated Partnership [Member]",
        "label": "Terminated Partnership [Member]",
        "terseLabel": "Terminated Partnership"
       }
      }
     },
     "localname": "TerminatedPartnershipMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ThirdStreetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third street lease.",
        "label": "Third Street Lease [Member]",
        "terseLabel": "Third Street Facility"
       }
      }
     },
     "localname": "ThirdStreetLeaseMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_TransactionCostsRelatedToRevisedRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs Related To Revised Royalty Payments",
        "label": "Transaction Costs Related To Revised Royalty Payments",
        "terseLabel": "Transaction costs related to revised royalty payments"
       }
      }
     },
     "localname": "TransactionCostsRelatedToRevisedRoyaltyPayments",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_TransactionCostsRelatedToSaleOfPotentialFutureRoyalties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs related to sale of potential future royalties.",
        "label": "Transaction Costs Related To Sale Of Potential Future Royalties",
        "terseLabel": "Transaction costs related to sale of potential future royalties"
       }
      }
     },
     "localname": "TransactionCostsRelatedToSaleOfPotentialFutureRoyalties",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_TwoThousandSeventeenPerformanceIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen performance incentive plan.",
        "label": "Two Thousand Seventeen Performance Incentive Plan [Member]",
        "terseLabel": "2017 Performance Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenPerformanceIncentivePlanMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UCBPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Pharma.",
        "label": "U C B Pharma [Member]",
        "terseLabel": "UCB"
       }
      }
     },
     "localname": "UCBPharmaMember",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits, period increase (decrease) reasonable period of change",
        "label": "Unrecognized Tax Benefits Period Increase (Decrease) Reasonable Period Of Change",
        "terseLabel": "Unrecognized tax benefits, period may increase or decrease due to tax examination"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received from license agreements.",
        "label": "Upfront And Milestone Payments Received From License Agreements",
        "verboseLabel": "Upfront and milestone payments received from license agreements"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received under license agreement.",
        "label": "Upfront And Milestone Payments Received Under License Agreement",
        "terseLabel": "Received upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_WriteOffOfPrepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write Off Of Prepayment",
        "label": "Write Off Of Prepayment",
        "terseLabel": "Write off of prepayment"
       }
      }
     },
     "localname": "WriteOffOfPrepayment",
     "nsuri": "http://www.nektar.com/20211231",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r122",
      "r248",
      "r253",
      "r261",
      "r439",
      "r440",
      "r445",
      "r446",
      "r499",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r122",
      "r248",
      "r253",
      "r261",
      "r439",
      "r440",
      "r445",
      "r446",
      "r499",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r122",
      "r163",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r177",
      "r181",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r258",
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r122",
      "r163",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r177",
      "r181",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r258",
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r57",
      "r120",
      "r121",
      "r267",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r187",
      "r326",
      "r330",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r266",
      "r291",
      "r342",
      "r343",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r533",
      "r574",
      "r578",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r266",
      "r291",
      "r342",
      "r343",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r533",
      "r574",
      "r578",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r187",
      "r326",
      "r330",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Nektar's"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r183",
      "r326",
      "r328",
      "r536",
      "r573",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r183",
      "r326",
      "r328",
      "r536",
      "r573",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r266",
      "r291",
      "r332",
      "r342",
      "r343",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r533",
      "r574",
      "r578",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r266",
      "r291",
      "r332",
      "r342",
      "r343",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r533",
      "r574",
      "r578",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ReportableGeographicalComponentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Geographical Components [Member]",
        "terseLabel": "Reportable Geographical Components"
       }
      }
     },
     "localname": "ReportableGeographicalComponentsMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r120",
      "r121",
      "r267",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r326",
      "r329",
      "r576",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r326",
      "r329",
      "r576",
      "r604",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r189",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r502"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r23",
      "r190",
      "r191"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r225"
     ],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "nktr_DepreciablePropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r62",
      "r63",
      "r64",
      "r561",
      "r583",
      "r584"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r61",
      "r64",
      "r72",
      "r73",
      "r74",
      "r124",
      "r125",
      "r126",
      "r444",
      "r579",
      "r580",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r379",
      "r380",
      "r381",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r344",
      "r346",
      "r385",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r346",
      "r375",
      "r384"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r114",
      "r167",
      "r172",
      "r179",
      "r206",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r259",
      "r261",
      "r262",
      "r439",
      "r445",
      "r468",
      "r500",
      "r502",
      "r539",
      "r559"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r53",
      "r114",
      "r206",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r259",
      "r261",
      "r262",
      "r439",
      "r445",
      "r468",
      "r500",
      "r502"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "verboseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses",
        "terseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r196",
      "r213"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r193",
      "r197",
      "r213",
      "r544"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r195",
      "r213"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails",
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r195",
      "r213"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments",
        "verboseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails",
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r348",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r36",
      "r502",
      "r587",
      "r588"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r36",
      "r105"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails",
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Investments in Marketable Securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r99",
      "r105",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r99",
      "r469"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r433",
      "r434",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Corporate commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r233",
      "r546",
      "r565"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r241",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Total common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r502"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 185,468 shares and 180,091 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r80",
      "r550",
      "r569"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r187",
      "r466",
      "r467",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r187",
      "r466",
      "r467",
      "r586",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r187",
      "r466",
      "r467",
      "r586",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r156",
      "r157",
      "r187",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage revenue from customers"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r187",
      "r466",
      "r467",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation, Principles of Consolidation and Use of Estimates"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r314",
      "r315",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r333",
      "r340",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r85",
      "r536"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold",
        "verboseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r417",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r417"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r417",
      "r424",
      "r426"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r417",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r154",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r113",
      "r122",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r481",
      "r540",
      "r541",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r44",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior secured notes, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r45",
      "r113",
      "r122",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r45",
      "r113",
      "r122",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r306",
      "r309",
      "r310",
      "r311",
      "r478",
      "r479",
      "r481",
      "r482",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer",
        "terseLabel": "Matching 401(k) employer contribution, maximum amount"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r418",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r418",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r115",
      "r418",
      "r424",
      "r425",
      "r426"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred income tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "terseLabel": "Deferred Revenue Arrangement Type"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.",
        "label": "Deferred Revenue [Domain]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r418",
      "r424"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.",
        "label": "Deferred Tax Assets, Derivative Instruments",
        "terseLabel": "Development derivative liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r414",
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and other credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r395",
      "r411"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Compensation expense in connection with 401(k) retirement plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum 401(k) per employee, percentage of annual salary"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r103",
      "r223"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r103",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Development Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Development derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Counterparty cost of borrowing"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r348",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Black-Scholes Option-Pricing Model Assumptions Used to Calculate Fair Value of Employee Stock Options",
        "verboseLabel": "Schedule of Shares of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables",
      "http://www.nektar.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share",
        "verboseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r81",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r137",
      "r139",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r452",
      "r453",
      "r551",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic ( in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r81",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r139",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r452",
      "r453",
      "r551",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r387",
      "r397"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Recognized over a weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r72",
      "r73",
      "r74",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r151",
      "r207",
      "r305",
      "r312",
      "r379",
      "r380",
      "r381",
      "r420",
      "r421",
      "r451",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r579",
      "r580",
      "r581",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Portfolio of Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r272",
      "r281",
      "r282",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r455",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails",
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r272",
      "r333",
      "r334",
      "r339",
      "r340",
      "r455",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r272",
      "r281",
      "r282",
      "r333",
      "r334",
      "r339",
      "r340",
      "r455",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r272",
      "r281",
      "r282",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r455",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r459",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "negatedTerseLabel": "Change in the fair value of development derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Cash receipts from SFJ"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value at end of period",
        "periodStartLabel": "Fair value at inception on February 12, 2021"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r272",
      "r281",
      "r282",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails",
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityScheduleofFairValueofDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r280",
      "r303",
      "r450",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Estimated Fair Value at"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Fair value of liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture, fixtures, and other"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Areas, Revenues from External Customers [Abstract]",
        "terseLabel": "Revenue by geographic area"
       }
      }
     },
     "localname": "GeographicAreasRevenuesFromExternalCustomersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r155",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r220",
      "r221",
      "r502",
      "r538"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r116",
      "r427"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r77",
      "r167",
      "r171",
      "r175",
      "r178",
      "r181",
      "r537",
      "r547",
      "r553",
      "r571"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r116",
      "r427"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r398",
      "r407",
      "r413",
      "r422",
      "r428",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r135",
      "r136",
      "r166",
      "r396",
      "r423",
      "r429",
      "r572"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails",
      "http://www.nektar.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r393",
      "r394",
      "r407",
      "r408",
      "r412",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount",
        "terseLabel": "Loss on revaluation of liability related to the sale of future royalties"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credits",
        "terseLabel": "Income tax research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.nektar.com/role/IncomeTaxesScheduleofIncomeTaxProvisionRelatedtoContinuingOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r102",
      "r534"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "auth_ref": [
      "r242",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.",
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Obligation"
       }
      }
     },
     "localname": "IndemnificationGuaranteeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r76",
      "r164",
      "r477",
      "r480",
      "r552"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r96",
      "r100",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r218"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r51",
      "r502"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r32",
      "r218"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r31",
      "r218"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r494",
      "r496"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: portion representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41",
      "r114",
      "r173",
      "r206",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r257",
      "r259",
      "r261",
      "r262",
      "r440",
      "r445",
      "r446",
      "r468",
      "r500",
      "r501"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r114",
      "r206",
      "r468",
      "r502",
      "r543",
      "r563"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r114",
      "r206",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r257",
      "r259",
      "r261",
      "r262",
      "r440",
      "r445",
      "r446",
      "r468",
      "r500",
      "r501",
      "r502"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "negatedTerseLabel": "Change in fair value of development derivative liability",
        "terseLabel": "Change in fair value of development derivative liability"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Senior Secured Notes"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r45",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Litigation matters, liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "New claims"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Previous claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputInceptionDiscountRateMember": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate at inception of contract to determine present value of future cash flows.",
        "label": "Measurement Input, Inception Discount Rate [Member]",
        "terseLabel": "Measurement Input, Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputInceptionDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r99",
      "r101",
      "r104"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r65",
      "r68",
      "r74",
      "r78",
      "r104",
      "r114",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r140",
      "r167",
      "r171",
      "r175",
      "r178",
      "r181",
      "r206",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r257",
      "r259",
      "r261",
      "r262",
      "r453",
      "r468",
      "r548",
      "r567"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements And Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r167",
      "r171",
      "r175",
      "r178",
      "r181"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "verboseLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r488",
      "r496"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Operating lease liabilities, current portion",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion",
        "verboseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsforOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r485",
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r483"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r493",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r492",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r123",
      "r158",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r12",
      "r42"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r52",
      "r502"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r59",
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r66",
      "r69",
      "r72",
      "r73",
      "r75",
      "r79",
      "r305",
      "r470",
      "r475",
      "r476",
      "r549",
      "r568"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r89",
      "r91",
      "r194"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r348",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21",
      "r502"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2021 or 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r94",
      "r98"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Proceeds from Derivative Instrument, Financing Activities",
        "terseLabel": "Cash receipts from development derivative liability"
       }
      }
     },
     "localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r93",
      "r378"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued under equity compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r89",
      "r90",
      "r194"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r89",
      "r90",
      "r194"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetails",
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "netLabel": "Product sales",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r65",
      "r68",
      "r74",
      "r97",
      "r114",
      "r127",
      "r135",
      "r136",
      "r167",
      "r171",
      "r175",
      "r178",
      "r181",
      "r206",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r257",
      "r259",
      "r261",
      "r262",
      "r438",
      "r442",
      "r443",
      "r447",
      "r448",
      "r453",
      "r468",
      "r553"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r228",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r226",
      "r502",
      "r555",
      "r564"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r226",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r15",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r20",
      "r542",
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase commitments related to contract manufacturing, clinical development and certain other items"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SelectedQuarterlyFinancialData"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Repayment of senior notes",
        "terseLabel": "Principal amount repaid"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r389",
      "r535",
      "r622"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r312",
      "r382",
      "r502",
      "r562",
      "r582",
      "r584"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r207",
      "r379",
      "r380",
      "r381",
      "r420",
      "r421",
      "r451",
      "r579",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r162",
      "r163",
      "r170",
      "r176",
      "r177",
      "r183",
      "r184",
      "r187",
      "r325",
      "r326",
      "r536"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue recognized from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail",
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r110",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue period of recognition"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r491",
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets recognized in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.nektar.com/role/OperatingLeasesScheduleofOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r156",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "License, Collaboration and Other Revenue"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoDevelopmentAgreementwithSFJPharmaceuticalsandDevelopmentDerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Provision Related to Continuing Operations"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r346",
      "r374",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r346",
      "r374",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingRevenuebyGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income Before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r13",
      "r33",
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r38",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SelectedQuarterlyFinancialDataTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r84",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r167",
      "r168",
      "r174",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r348",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r354",
      "r364",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity Under Equity Incentive Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r48",
      "r111",
      "r152",
      "r153",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r298",
      "r303",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.",
        "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r167",
      "r169",
      "r175",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotes": {
     "auth_ref": [
      "r545",
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior Notes",
        "verboseLabel": "Senior secured notes, principal amount"
       }
      }
     },
     "localname": "SeniorNotes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/SeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service period for stock-based compensation award granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited and canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited and canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Units Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Average volatility factor"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available for award grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of common stock shares available for stock options grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Life (in Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited and canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r356",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r345",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.nektar.com/role/StockBasedCompensationScheduleofRestrictedStockUnitAwardActivityDetails",
      "http://www.nektar.com/role/StockholdersEquityScheduleofSharesofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited and canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r348",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options term under equity incentive plans"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r369",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Weighted-average expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofBlackScholesOptionPricingModelAssumptionsUsedtoCalculateFairValueofEmployeeStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r50",
      "r72",
      "r73",
      "r74",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r151",
      "r207",
      "r305",
      "r312",
      "r379",
      "r380",
      "r381",
      "r420",
      "r421",
      "r451",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r579",
      "r580",
      "r581",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r151",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r305",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of stock to Bristol-Myers Squibb (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r21",
      "r22",
      "r305",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r305",
      "r312",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationScheduleofStockOptionActivityUnderEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r21",
      "r22",
      "r312",
      "r347",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued under equity compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r27",
      "r28",
      "r114",
      "r192",
      "r206",
      "r468",
      "r502"
     ],
     "calculation": {
      "http://www.nektar.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets",
      "http://www.nektar.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r112",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r280",
      "r303",
      "r450",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesAdditionalInformationDetails",
      "http://www.nektar.com/role/LiabilitiesRelatedtotheSalesofFutureRoyaltiesScheduleofLiabilityRelatedtoPotentialFutureRoyaltiesDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetails",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r119",
      "r333",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Obligations of U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesScheduleofPortfolioofCashandInvestmentsinMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r392",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedLabel": "Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense",
        "terseLabel": "Unrecognized tax benefits, penalties recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Unrecognized tax benefits, interest recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapses in statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Valuation allowance, increase (decrease) amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r489",
      "r496"
     ],
     "calculation": {
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/OperatingLeasesScheduleofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r138",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average shares outstanding used in computing net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r137",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.nektar.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL124452896-108306"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123389529&loc=d3e10037-110241"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e13051-110250"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r623": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r624": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r625": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r626": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r627": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r628": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r629": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r630": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r631": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r632": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r633": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r634": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r635": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r636": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r637": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r638": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r639": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3505-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0000906709-22-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000906709-22-000005-xbrl.zip
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M1GH7A>,"HD V:2W1-O-,BB9-<UWA1V;X/8@"UQ4_<G?\R+WA!V"3#$PI[Y6
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M>)8D>!U)%"$21VW@5+DH.%=*N=4#^H$CP(6@RAA1R3C)?4 E!FN!<)5($$2
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M@-0LD42LM$*87*?020*Y,*)0/%E8?J.REIF'MC,>!"B5RU ')D0P5GG#F5+
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MB67<2NYGD)HS1Q!YB[F[[2(DKN]&]S.S)@2L=H"@HLX!L@41& 7OM6-* )U
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M@PE!.6%YM%R!<9HIPJEDUBS_='!M0+N_*6(3$E 58AYX$A"3-T0G9X,G,2F
M%=.T"?V$\@A*Y)T; 6GHL,BP[4$7W7[<[+JB]]/YO ^Y5>-\ML+B>7M,[EP$
M)R2J-.5>!DT5,&!2NQ44BD^[Q'R/*"P+8"ZBE24$Z8P2>2C9JSP[P P$Z\%
M#;;+_&[ VH-^O3&+DIB@%(00C7"Y^@"2'F>X4%109JOD96J((+F:RN3#LH*W
M/\+>S]?D8H&CBUSD=M#'KS=*6^0]Z!"UO+'WG$=K3*Z<1.Y2HN3FJ3\1 (88
MO"))").B,%YYDIB(E"I/B311+ #06O0;,2 5YQSC+W0[B1MGF4;/(T%Z4((O
MO_':^.#*>*,$[62?>S>$^-I=5&.8GX8S)]O:SW57^[F8+"-!B!29XUX+3I L
M*L5\3!1))&A9 UZ0JYJV7>\J4%?*NE75X)"[]U]#F09ES_4#Y SN?AZYRI?6
M!"=M':!6F6"-%])[1[BA*:!ID@)UK)XX;??.NH,+@,I_S&8!:@1*4KS:H$TS
M= O*1!NI#/@GNN@9*%*#,=Z[S,\\A]Y9'G"*,.S"^+3X%CS??&B$8C*$M5UU
MPM5'E<5P-.BV+J <[B/S\#XS#]>?=_W/A0PO.V98T IC_ZJRD4:M!J(2\3ZQ
MI">Y(C4INO*+B\]"JKP$XPG3FN>%-!C2Y_560A#+H_%>RC0AIW8J/LL]3?%K
MBP^U=Q:?F],F/R$^D%?5,IJWD^1"*NUL,#*G(.:,*P*F!L[KRTAN=XM71;>;
MMX>X&X3W(JIM.$7H.L<E0"Y O%T<'<\YB6$QCDMH!R"(XC)33R8LMX(X&;2E
MAAE.:N"XUJ*S&*?%'0E6T$@8QIT,)$I+DBE)X9G2BM$:.*VUZ"S&82$_)CE!
M/@A@(CCN/<.0RSFO##<^\AHXK+O!.>XZ[-'YT9R-WA'T=_IA%5V3"<P2KR.:
MEB""<L9$H8'IJ)E40; :N*9?2D@6XH124M+(%)D-3J#U<! D4%!:"F><Y#5P
M0K^2D"S&W2CKK6!&22I 4)H,=287G28)B(N0:N!NO@Q<M6?>:^S&_CSVJ5R\
M&^ Q*:(,,7D74H9> (RQ4G-O0Z+@? W<P%* MQ#S+*)SR6(TD%.G/7ATZ-08
MQIA.27.=:F">EP&\Q9A-G@<?\YBV!RDL@-$B%Z75P;F(?\7IE#G#YTT_+%T.
M1,[NVASTAX-N$7,.2H5A <-/N5^('][JGF*\ZH;E(([#:+?<A_)]$>"S\(Y1
M\1"QY&TCH-WN9+?5O++C@9;FF.L;''TC:8'=SW9LABGJ! 'T[U:8)*PFVH&-
M/&>ZRF!K(KDK)DH_86H7-9R_$.E%,:+!!\^0KPK)O',J)B&JTM%,Z[7T+J?T
MSMJR!T/(VS/EM7-Y^Z7!V8T$HUG9_,Y@FLGR8E!67&+XV5;9NV>Q>#]8Z]6]
MZ!5HDRQ52$D%%T"U0\U)FJ$>,0F>L9KHU9K/K*8:UU*G5.#428@^RB1 >PS2
M-0428][]CY!TF59+IVFURU<->*U32Q CB#M&M]6I]U+PF#NEN;#,)2(%"]KH
M" 9",D0BX?)5=<?E%-C+Q/ZQ'Q:Q<.5%KK6PFZK<RYM)SI<5&5:*I%]9?7Q#
M(GXB!Y1830V3GD69,[&T8T*ID#B5)N"!.MBRM6@L@64QTCJ1C!(^3S@8Y)DA
M:6JU)CXI.RVEGD>L[;*)S]H5SIU>3O>ZZP(^K7^M[LKLM]W^O)<GY[%D>P\&
MTR3BHS7!6.JJI0O<24J9)HXHYZ.KP;S:6N(73/X6,ZD8(N ?E%DEI<!/UCFF
MN*>".6^%8C5P]0N0W!]:-K_6B9K0%NWR>B<:F5)$6 R!K%1)A+P&BH>0H";6
M_"%%::<?!CVX7&#]:C I,W)]8?7M TG;YV=XMY_>;6;I*/=B[#FPP!1*JM4V
M32;\I 3).,?8WJ7)A-^2)XFL97?QLKN0'!D3O2'6 U(0+IA7EFA@*DJGI8+@
MPY2+3'-DS%IVU[+[!<YPUQ0A<W_Y741XH35'XHP\6@4;J-&&$Z%]<C'6O)3T
M\];^"B<ZS*<(1?+<.)]0)*P(*&HR$!=%A!@H6K2:[SKVRPC$_96P(RPYY2SA
MD@1AI;4F$!(L!);+QWA:@ZAB+1F+)_@Z @] 2=0T"$*3"<JK:),S24::0@T(
M_EJ,%L^U50)BE.(^;]6C243:G9QP/($S5(0Z<.UEFLQ83S<N 0<W1$@E.4B%
MGZ+3QFL4:"V% <N3E9-$AK4HKT7YSOSOIG3^S#[1T@=#E>"<!9'0X@JF)-*_
MZ*W7@:U,9:2UF/Y"+()J&Q4H<$H(Z5&<N9:):HKF5])8@X*^:U%>"E&>3^EB
M2CP!:AEH)K0-E@>>O%4@C*$R3I;MH3Q-."Y^^.7GMN]>FH5+,V<*J9O$WI%"
M5J?>R]1O!(Q]A%$Y_T& I8[Z@+9,10:),1 5A=3$L*5;$/&0%7SFEP*Q8 &\
M0OQ0IDR3\7LP0V 5)8'PO"\YFJ%D(#).=#(H8,(Y,S5#*%/-916N^X3E'B1Y
M_I;G*O3?L#Q73_V9G<Z%8B)Q(YGP@D9J(W(I0Y!:@6%$NAI(R:_MK!Y>9*2F
MD5.(7.3EL3I:3;RD/C+%$X:9:BTRBW22#VHS;_/(17\^>_DL7O"%2T)1&E@@
M3F@778*4&.<0.!.4R;7@K]GA2EI\!APIHU)<.2,4) ?>,F-9PG@VD:37@K\J
M%K^6XIEB$A0 B.<@3(R6>^.$(,R[8"G7-1EP^68"WX,$.7>6RUH.M'@%&@PG
M$A(14C@?4B[9GH1' =*3PK=K45E*$_8Z#S_O]F&SBPPSN.Z5G-)5E%1E*'/4
M Z/1B)2'CH4&S16CB5A&UI*ZO)*Z58Z/IN^]XD(J9.26"LDB1D!*,V<XFE,F
M<J5"*_7E4,!,2,WRS<C54$COA:3=653,/<W9YG).GI'$E41KQDW4G@N:HN&<
MZ;#$<[9+.[XX[WT*YC([2A5/WBFIN=6"$8PH@T_(OK3445DRF990A$],!GY8
M/H&X.T)S5F35)/R.BER=>C]+3A3#0(M0D(X+S8E![(()*3"3C""3O;+P?Q,
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M#)_%ZQBJE+8^!)ZB%-II1R+C#&F1)R$X'9=_YG_1&,YE/EY1'C$V\=A73K@
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MG;1N;1&7%)O9D %=U[U:=%N^$[;I6LJ+QNZ'/K+&X^(L)\1O8K^[HM]X#GU
M.IFGX"?'*U;Y*?]^FDC_Q96<:\M:$^U=6];EQ$;-UL+3=4&M1;?E.V&;V=#*
M/.:15;2MPVL&LU-B,]UT/':2(34)Z!L[^%"DIQ'6\7I]]'1M0Y<4F]DR=[HN
MQK7HMGPG;*_+HA^*,Z2?GS)%&R\ IJGV4+XOPCH!JC9:^-,6<CUG6-LY0W6Y
M[==?ZRG#FJORY<9?ZPI=BV[+=\*V?7Y<^&*Z5.V6-6R-_7 ,<=Q=.]7::"(E
MW[6R5ZVU<2FT4;-'S_:Q7]UHG<-?$VW+D%'*OJ9M3ZI-SV>_7RK+L]]]^>3&
M15< F392L,<Z;Y!^-AA696J>EM70T7N8[HL^[;8K%TYW52>?+G%^..B.1U^^
MY#OX[;RPJ/::YS>Z\,K?N;5%_.>C.T!"'LTN.BX_J<<1-'T)[K3ITO_/WILV
MMY$D:<)_):W>WGW)61 E4E=5RW;,*$JJ9K=4HDFJZIWYLI9 !H!L)3+1>9!"
M_?KUQ]WCR ,D1!5%4D+;]+0()"+C\/#;'Z<%_C7.+N)U]<./K7U8IOE!9]^[
M6_;5&=W1'6)TE\]E^UOS](?__( [@; 2WYQ[NHB3^SQY>LV&YEY=5K2,RSG=
M#+1+?[*Z><G0LS>9-[PJRHNX3 Y>%\5'9#![B(6-++0];]FW% [T^J]/'GZ%
MA0PSN0^+M(I*LRK*.DKS:=8D-#9 RX[P5EEDIHNLW"+Y@<-GT45:+](\JA<F
M6IHXQT-TB=Y+HO;__/\.GSQX=O3T&)_A$8^*&QU/:WQZ^//#AZ,H)F5_B5A"
M,E*O6?C[PY<#OW_Y:<JEV\% C\*!QM%QE@43C@HNPZD7O,/^TUE$ZZ^+$LI(
M-(MIL+@TVZ\?0,*KIB39)O"_-78SSO.&1M--+7*DMR]E,8</#OXQTGV6&O)U
MM"J+?VEF.X98"G 1SG 4F;C$IE:CB-/@&_J(:,#0C',3K>(U3X:^+-9QAGT9
M156<82JE+GCF#*B4IEZ-^(WM#<#.KK)8 SS%A"=S;G0R+HZ.I<X:J()1X<#H
MHCVWEE$T:>HH+^HH2Y<I@D=U,:+%F2D1'6]O0DO(BA5&&T7NT[JDV<F[Z6T-
MSH ..9_O]^9::E"J+J*B"9<V;:'FZ20OBI(/;1JOTIH>RHU)^NLO70W"J@ #
MPG Z@(Z/4\IJ9*;RKO1&H)=/#9\23A*4D$1)V>#%-*N$GKOLK=C\FO:+_HD-
MQI_T',BFC R.8];;*?JF:B;+5+ $Z0$:K:&=*<IU%*]H#N=80YH)W6Q\LZZ2
M&'=>+-.IWT1^ YTP%ZS1VJZ8/4V.=@T_'$6NQDTF.9V:BLD(QT4,+8LG*B7H
MEI6XODJ_N@-8+)H\EGRJ6=SD9.H+:="RDH9NIY!W!DJJHLEZ8.05[9[+ ]%%
MVILB)27+>(WWF"AI#(BIJ2(66EA.93I3V[AVO'GPVM"(NB<&VT#[6J=T<[OG
M>!EY.UK$0V0HI2M\,^)KG<\+O#ZC-\QC1_3]:QU75;-<R8&*3%Y;CJ.7GD[+
M\&#CZ)2X(G9D"AQS/L<-C ]4'4WHU"&WTEE*\Z53P&A-Q0H4W10Z2Q)>\S4H
M8 &>K.QT8K*4#FYDF:=^3,?1_>@BS;+N9^83ZG^J[L=\!-T/_:;UOB+>F2Z'
MOG![;C^GS=:O[!&.@J^PY-S,!7X.K-: SBW;)?(B.F2E,M@0"*5Z433S171A
M(MT.H4D,)RM4QDJJ4T9_T?ZJ?+WL3&A^,4GV),(\@&5"-$_6157DF,)(#J(U
M/,VT30F;QL9E 4_AFX*#STG30PZ D!TQ:Q9U E0Z+9J,N%\ZF]$>8)=!Z=DZ
MFI7%DEY$O-%*.YHKI@ :W6:)X^AM4W88<X_QEQXNU4LH5@HN#"D#4 YHR9M?
M,N)](]Z*"<HUQGZ2["O3ZJ/<\P;,'ILMTO8*Z8=%X;>L613$DRII/E OL.0S
M\/G3401'M:H'QY;DP@[@ENJ(8(H+86M*@'+&%4G6:EJF$WHKL45S@5G+GF[2
M1B(H(J(C77+VLJGRBHO%VFTP:$(/657&Q+U.WX.=7,:)P:XKD4$41GI1,#)=
M@:3@+4NA^S/C:U;\U.7G1)0\-:L:0Y?FWTU:"A/*X@NFJ=4J(S:+JZ>"$60P
MAL:('\GF8#ZX-:2#RXV]2"MC1^-SO6KSY'#UM)"J37/NLI1?S4>2Y3WFUN.
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MVQ[;*5ERQ%_*@D24HF2-- 8E)7J Y:G(;)XTXE.-5\(Y4D&+@],7)BM22XO
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ML>1!",*1S9VLD+G$Z51-LO:9XFU4O0 RC^69B$+MXN:+5MCW)!@60!A1Z#/
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M,7>GD'+4;^F$#N_+"8U:%RM:F#BK%VL@_2$'$5\744U'J-7AW\89#9D6=_3
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M;-7M8JH(P23%2M131<!%B=$HT-2J)30$V\Y87.T!RITFM81YN<+/:V,;@7<
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ML<"*@D;*B(Y282G:S'_$VKPHPJ0L8];P<2G&&9N:9 4PMI8"-Q$)<&M.!MR
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MTWL+;AD6?M$?=26F<:BN=;21EN3OZA/1G"L]!TH@.D6"CGFY]#+5NUJCG2.
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M%R8?")/_O N3WQ.Q:Q-; R_*9O?-Y[INI*9D!L>L^H<[<F2 9\RX[MY7PC@
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MG4W+U(/(X091'$A,8L<IOIK(4S&%F/%2DIBUAM?)/T^B'WR#/6AF+TFU*0"
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M_*BI;3(<,JZPKJ4%/Y&PMYRMTI5Q^$S6!T^T!P!M[PJAS6LL8D+1)8)1U&)
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M8XNO- LC?[=$BDO"21.RF?HYV P"^O#::IZ@@-XIICM#T4^'GBA"9+7(H:"
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M[9P+A&ZG*Z-D;LRIM"[>.7G]O+UK>*HZ1&;:YK+?C:(G2B-E,>+O<N)V*6C
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M2%B3K.'03YYQ*FNV;=K(B,9& ]N%X@5"&0$U@8U1\JXU4C9C "A8ML&I9',
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M@A7H?FO0I>IQEN0D3=:=\_J25J<&ZC*#X0F0NV07A,B^#/B&3'4_Y47GC>W
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M0"#Z5_.F6;@+#5Y]+R>@'J=K-RWA)\^5( /@MU=C'/E(9MMWA='P(JFFRGH
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MDHI;J &TKL_T649'9]J;-KV^(@K]P_M=V,KC1[>PE;(V)#$$ME)#S6(#DO]
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M/]O9U@"!>D:WQ:3(,D=<8\=$$L"@;L,L.S%U7_C%E(HU#4TV[;I>0M4NN&N
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MLTUN7K1+#.H*J4+NB%_C.#L@2;[6V'EYF;">6%(.3,6U!N9L#(XA7%VK3+"
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M+W ,X7CMH_W]2V9[O[L!V=YKA=!ZF?RRB,%4\PMZ[+M5I1H.$L[JV>[N;G&
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M#0L$:C]!+*E_PNF#2QP_??HXVOO[Y>MS;]-'HD. OHT[9/1HX10?XU(P3!0
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M@E6HOQ"!!WBQ(JVZF9'[L0#OYGKSN19,GBV>.$*US/>4XY_MW&N)65P;!4_
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M I.D)UIPV BXZ^T)59W@K*UH9K#$GNO R^6ORW*\\I)T)&.S_PP&4L\M_D5
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MXBTDG=\1)&B8@O\DU,()ZJ&1_DZ)KF>?627C3JKDY&-P)<,;]SQ-QLRH!R.
MA91T)EIU3!I0C-=X'[I,J.%6"03"F&ZS6%U^"^N;TL)!TOTC8O.'B,=C^4;F
M(0\RZ.(*$MNUL#PX58 XK$6H;5P^,#R,"EU .A9U5X)Q1(Y#=FI\)<]_04Q5
M9ZDJ%4AGKW<>G ,$Y^;Z\B.N#/'YPV*\+VS!]T,J>4=%@>H*5:/Y,)]GYC>)
M9<1PXU4B*A",6E>=@7YL"L4J:M*1#W,$HRY[^$&[P/B-F_T^,$A:7,0N \I.
M=JY.XA$IE0!E1V&2C##I_VJQ#]/K8O:_=7!2Q3;;UK<JN982?$TBEV7R&!KU
MS$4\LNR"B=EH0N[29^C7@+YWG6Y[PIU^M]$<-LQOR O><\:.8 #^G7(J $9'
M))';&@,=67/\-\W ;EET\]9)B%AK-BE'K= .:E#G&*+C0&K7U2EK[,S0PH$0
M3+ C\J%#Z0N&K'(6LKG++00548X$BB&DXPP UJ ^HRY.1*>K.C4L>4(>T_$=
M?H%B!LN9Q\D&1#JM&8J/&8DH'(3(O;]OCM'HCO"/+K4LE)S2H>K1#U_!=KV<
M1"F8^.F_6AA,BU!*F@1.K'(.2X/!U*S=]R[M/^91<2,=;]NN?-5:WFIPTL<P
M#E73X98-61@[F/V5TAM6,81*<J%TXA6\[<\8!R ^//H)1A%5R6(Z[=";EQPZ
M(='3K*;,D0(*"7ELU$-]*-@@PK19EDVB2R4C7/>JZ<I,S@K#5,TKH=>J%6<E
MG4B4LEK,&+KV9TM('L_]Q6?MWQ'5"F$&IE+.P85(9ARQ4BF 8E!"4&$#N?Q@
M@8"!83*.X7G'&>N^5:DHKD7#9/2NG7<?&Q]JE32+'>.>IW$P!FD.($"B7_U^
M\7?!=K$)I@C-IEJM.(QN[/FJ1&BP\,:,'LF[Q\9_V@$)+)#@R4,#$O1;KB\T
M/':C\DE&\K,^),&MT8>))!AD"'SL+$,\C?MVE5%HE8,/?!587GC:WO: ]?*%
M@D<EC@_KV_=RA/T-Y%R)7JVO+G 0AE0N@KOUHY1)0[HEINN]CLLSA;IR/2>A
M5XTT9V>,U?L2=9&F;85HVX+P7"5$*>,R52@!)SIKM1%A%J*:A6?KWJI,]="-
M-35@\V* L"<K:C,4RCG6<HVJTZVP?\\Y(4^/,B5(]$#%2&D2EKPBU\,@'%O4
MF2L=^4,J"/LZKM1]EX>H]A'_0*\%7YXT/V<)BB1@5QE[@R@:H9CD\A:-_7)F
MU5_8'PETWI<T&)(_JE+*Z"VX_8M.;@J*%;)]N)Q;[DD&4AFH;'@5XF%)* 6.
MM^?@S.+1V_*&3[@91/5E%#C=!\IV:\JA%PD,U..P9>/__"X[/AJ</!T\'D]&
M)\/3T63R=' Z/!H</4F'1V?'D]/!_PP>?7=OOW>PW  \^"M,Z@K/%Y8LQT''
M/QU&T>^8&V6XX54# 3R)NN)FW]"E_6)]S/V:0R_+HD_J:L/)/?MZ)G< <_N:
MNZ76J6+]Q9.Y O4-CACLZR)+'LISWF_1_9&*DY]$QX\>Q8/C1U&- 14*MX!%
M$T_>"22]$,UD#7[05D%8Q-=RL5$<^6&)]NQO?I;K[2LV!D;"H/SH22RRB+RA
MP=')$2-:^BZ%&9IR95#(@1>Z")(KJ3<- 3?+[ T>XHS2^_)@'I\\BI^>/':3
M2I[C1$*Z")Y[1'U=86B[AU/]EEK:KIH*?_*1\]9[+=](GKC.-GDB+$F"AX38
MH+6SY3E -\[#?B$[(?'LUAH)J7-C7P+F!KQA((WU6KDMJ!OS?89!#GSU>' :
MPQ,'BZ\_SM>$YK1LT2\27[^DK+TI[B1C"!3A;A4%U;&O!W$1TG5.A7%13SKB
M]?-?%LJ#78PW2IDL B_7/U,G!IM$YZ\OA>*%E&6ZJC(/QZZL.(<QK[.UZY17
MYTJ#L=&R/3O#52M)>+]TL:\GJ7I28-W,G1RHX5:('_=<LL\4=Z_O+"X<P& _
M#TALL6M[*40@-"G;7S:_@],/]B=/CK\>?_($_,G?"$WS&L'.*3[R@W$K[[?"
M?R8(6S:C(Q+_MT_:FI%#<_^N3/E2<1K 6_+$LX!B9$K\/91A7=@?R]KR !%:
M9A@_QWT-:P0?N;Y&.1[J*-N\G>)>/131'X1W2.NYO'197)>46?D8@5;4LZ3]
M1*QZ>-F7V,O^5),?%W#K,J<\W3CZV3WO%<+J?;%:H(*' >V*K4X@5J-L&].V
M$BN@4";*]M$M3:=#4_9ITCNI 0_.5:%Z)VE&,[BV+;5_-E;#9@2)]\'6YO3K
ML3:G8&U>P.?@4Y-PP#/70KZE-N<EDL0RW'R8KQ'C_B9K(&>K:R#W6/Y/OGL8
MA9._?EC[=]/K\S=O>?%=7GZH33D]NK=-6:8[_$L*W7=9E$=H49C"#<.*-]A3
MC=BXQO7<77 ;ZO-_M53C5+'Y*\/^^$*X(^F JNL6_O2Z!1<YJ1F/QK_=1(W^
M01NK5UWA;H*3$3/CV_5BX^)F4_EE,1N6N1[)+W]]^T8/N(WQ(U]HT?S=MR>_
M24=EM9KG\T'/XCF]P<_IL,+^1LD*GU!;X4"P/^"15DM!UJ,3VZ!=T0CTMFH_
M\&E\AEXURLR^)GSD=DZBJSTBQR+XV^".4ZLH4BYES,-''=1C>=E:0X*PJ3Y(
M/JGZ.@++18EB(6WQF&XIR#U&(]EZOBK3_H;,2N_G"2&AE\ILICJ(WO0H0_E$
M[)U@8JY-GM8UZI>8@4BIO4*:]A],UN=^D_C6[[6B9!P]LZ95= J1W)\)N7S?
MH_XD&)XJG;LSAT@0#",8Y368;$#;<"5\YW[BXX>^:?W1&9U[!BE<C)=*Y<[=
MK7+47FAQ&!?C:]0DWLY]?FDHK;P*+U'4\(N.[(NR^'(BK,%]\XP%'>'=X@#8
ME'T'>BA?*1W5JUM$@B!<%"YX(3#4G[Q&"7]."_-%4B0L,$K_7.,EZ6E/B AX
MG/.B:(FEADL2!3)PZ",='?S*>);:R+>DV-%4I1F1<E,R@32,G%HY<P'7FC=P
M>6D\X.!J=+<5E-'2TS_)<J^?"L'F\XL(]A:N,S*/;QS[D3SFZ3E9MCQA<CA8
M/C"K_-D8*=<HQI".Z+%"028P#? DM#4)[:!-#W>/R4/?K:]-3^ +YM6DF<!=
MF51971;;N1O?$D944F[:O%H+UWR&0EM4$FGAK*RG ONJL7M;$2QC[+MP#:ZT
MS'0[!*N-J.G;"CMA:#-?\3UD!9PYEHGWPB^-5#2*R2%Q$I.Q)*HHRW9':2IY
M:F0UK.09FW5OYQ^>MTBP'8-]*(Y#)9$4_=IO1H\<*D<M;\_ES>:C!6OW1Z[Q
MSKYW#%X'$E>2V7/O#YX(> EU+G: 3!VACYC;<(L]!M,N=ETE<R:L3(BX5F',
M$TR\DEUA0I&U)[_0%7I)G*9LDE * ]Q!6-+1G@QZIAX'J[3-\Q8;P;D[@6@=
MQ8G;[XL.>*+WLGU^BL;'C6@<,$>%S&7C]'T,7^KYUFN$!28C4E"&Q_1?M=]]
M\^R7Z&H&:_HBF:_\Q<WRQ7\*U.SHF[2']VY67;SG%X>!R9N7F=*8TD9,$)4.
M83/.WSBA_8@,NCI4YE"HUTS;\9.X_^]G*_[^M/_O@R-ZOQ4^(47UO,@2\+)F
MFN+^_OCHB)BOW)P;BIK@MH_5:0^6@!)9D5J@T.VN6@3T65*/DW^MF,@-YWN#
M6=YD<KFB+8.AB][)E!0+O_J7]!*#3GD9%AY<HC%I CXP#')&"7?)8R&(1.PD
M%EMQS5WR.$@>/]T" +V<,-GL.JJKT7]^5[QKJ@/<>L>#D^/_N3X^_'-^_5V4
MY,VJC\()?O3X;/[^1[F^S!T^[ V"_6 OR+S0%/''\AZ/ST[G[_&E[YT'/OEZ
M:DN/#R-PN)'S*.W)[&TX'H^_GO%X0IEQC>I<.AQ+;BTC!=$6GAN NR_:7@1E
MS3>^K/G*E34W\<#.#L_^TN:X>U+"A-[8V \,DC50\P'89E1I.<C+DMC4:U_,
MII-42M%"781CU19*M$?]WD1ZP;!V+0ZKC@I)WYA^:V'@0?9U>10)E ^U3"[:
M5LPGP5RWPKV>#=M&D(&$T)^(,^\D19'?H7$P!ZJMTT$5+]VQ&S@8--=$'F.<
MUB.X)7]98J'72=5(RB.V28ES=7]A^0U^#*K^'UL8/WUZQV;]<KOPU0U2KZ6W
MF_://MR&VBL, 5/LPGI&VFN2',9U_9,DA[<S%_ R?== A(4YW&1.SB:1;GM\
MW,&0>MJ'63D//5)6R5[P;B0]I!O-H@F<#K==40J"!DE!(.[.1CA8%%UCMSSQ
M2L%C@L&8I0U_ :Y=I-H=MA*F-\_F*;XF$\'>&FIZ1@DC:87;][5MJZ57=4C/
M8D1^<1QE*+# /C*3#5;T#ZHNY*ER^K0A<;]PAJ!.UVB:SC!50(U"#;,UEFY@
MY/E)APH?ES@U?$>?"I)U_AS!6!,/QZ9-N_[FC@  K1W?F'WR5"B=IFF(:N=A
MG)5Y.H(8NB+60X\'XA9D:5^>I1A#9S5S"3)Z2B@#/+T/*4Q;.7;#+X#S[T9!
MAVAA<+::'K:SW!T;,LF&DPB?$DUVQ@PO0R1%JGG?+EAG+LO'1+-X@#R(06[@
M)LG;S0HP#ZC/_;(PR_<V%=Z)TO6&DGR,W7*\Q _T1]'>Y<&K?4<441-^U-D!
M+IQB4,\6 %DE:1'@9;4I%5%G">K#+F2=> 9H0\W \U&.%\[]HB<A_IPY-A"2
MFD<U9CS=A&BB1[C6J\_$'3?8:'RCSW/SC2>7Z.\/7I&E="#.]#WL3]'1&<+\
MC WCT;)\5Y3BRF88\#"=S1$G",8@3UMPY*(]E#7,RK;.)?-9L8F G86(AH/!
M\>G^&CZ,;S$@?W2T!0'YES-)@DTU!FAYU74D*RB3^FH.;U)^EOWV^/#TR4;*
MK4O+%X?RX.3P]&PY^8 F$:] CM63TR^H./O=_XUY1&WW.XWI3]CL7.8'+XC9
M\>I?;38<:K8RVOOIQ=6^C6JXG(&'&M((DQ27,2=$\+S6EO3-JG1MHQ@Y)9#A
M2R1RK9W\L$O0&:#OVI9R)V]7+5;X&F =S]OKMB:_A1/#:"U_?G:.R<B"R J0
MICQYUTRKL@4'DSW<A;A"_)!$K[!;GY]Y?;J"3B#>H'R?/+Y(OY92A8O8+)$^
MBB@W49(:>_Z)A6 &+UZ4R/CR1VI@/LM.IT&[KXP?K#?*GB2?K.QK;W"R]BZ>
MS=BC'I /^:IP&+KH^$2++[=$>DZU?.(_3"(? %\$EN;<4<6SS7EQ%>UA%][,
MU0#&U.2!\X\?KOCU/GN/9=ODQ-V0= R:+J$NZ\FH/+"$A8X%\LY=S2SXJC.-
M3V8]9>W"V&W[#U]9EJC_3[+^P2[R?%O4#E156)15WGF:6YP4:L<)?L@]*RXD
MH:HC]2BYV$('"AO]!/?C-&%\'6]>MHC0<PHW\HFLBXZ #CP1/TFO1>!'VATF
M?XVS0T/X^,GAH_] ZX*+!!?+R4#^P DMGC]#\FH;<)=F*8ZFY2VF>&*Z7E9K
M8$J\SSBQ)W!QO(VDRWJ^\1B^0=J_)"-):U>X9W?S_5'. VIAX,!.,?EP&'VT
M>.1?_09O"2-@#[-GQG8@J!.7T[U]Z]VB^HA%A>DF:0:U *^ ?GV2575S0,G'
M'A\4=27^;&\PK^G_9'XRRFK,Q-+DP7M?HYV(H]?/#GX[CD@.C#04F5^8L[JA
MK]M6&#SE% ]1)BQ>\4!52OK>&,6-P-'-\$FBO3<7%_LBJ='6HSR%?7"3U'@H
M#O-D/"8N+;ZJI4Y T D2@OPPB,98#DL1Q=.'BT>> F;,YV6;]BQ: E3M5NG'
MK=*E;9]F%%,G[^&=BFQ(I4^P+/_&< ?_K0LWHG4"RR!(K2IC2J(@')[PD]Y=
M@(HG-RSY)!(&]CL'<BT2)0#7.4$B=$[Z<E.K<%DXU]V^2J^'CK_=K9>/6"_D
MH'H2%C9PJM8]%BDH!6F%;N_Z XK#-Y6N)V8*/)4QN.-OBBH(UX9,P<$EE=S-
M+06C:DJ2$@<<[\2(.*_26=;.0H41T63/9BP.B2)6'/VIUL2VE6XX-%JBK:1(
M@SJB4$R'&+:_/SY\&@VS/'<,B>!;ACS&\)4C]Y5V#E_" "M9N"@9WN_[LT='
M\*V9?$O:+@SPKYV+;)@7#1X;)4 3H#%QR/$97?K[X++P"?PGTGL79N>#86HR
MKT-V6ZX^=$D4D""':Y(%7)K,:3;(':=>+QHO> W\%XS(J1L1HH#4Y*+8O9ZG
M1,VW.4G:>Q)H)V,&RW;&Q&*Z\AR14)ZT!2-?>QTW$AN "1-=OW\D<^**EP>=
M,%VDVQ];ES^Z5-$_3_FPK$*_<KH?@*O[Z*/.A!Y<XH,Z$H@&F(WSO,IFF.5+
MBS&CN7U)L1#%,DR@^HT!D_?]R2.SNVF_#^Q?5N^=GZ1 7$>_9:,42[SG1HYP
M[Z??SO=]L\3O5W!(E=QH\@RK_.>&Q N__O,S^#KW9V$?-IH]Z9^3EK'@XB_.
M[<6?M\@3"6/_PIU,Y]=I,5I$>\]?G#-?[IPM7KZ(5Z=QN"6AHB22[E<>DI..
M"73<-HAKMM]>,UR_G?/[G9][XT!D3I;Y+C 4E\))!8?$)C,YZ!IJ&7B9U)X/
MW<#]7M"P/O]]W_1F5"0YY:P@MGVNM8']0W=\U+FQ=A&8IP/+^6&WW604 R6:
MVVG*WC7<%?Z[US[5;M2U1<B\D^,]0OID"WUAJ0EI!Y8SZ-.+R#R@<^%5X:2'
MCP?:E6\2NV%Y 38P%@SH<']9'D8#[?A:YP787D:&L)CK0VPMJ@%.5U,3=LIS
M5$ES)ZI&4Q="D5Z7XJ@X-:A9R7X92[Z*,&SL9*9=0$6T1WP]SSA)$;)+4'^[
M6)8_4NW%YTU,^+QTE*$_=3!+"%.<L#UO%J9!6.6PJ!VQM]SVS0[I3TN6B6P/
MTHN7N6A/8Q%T#%X)>F3@E61![[U\NT"\U?MT?$ )'^-ZU8RJ/@##]2ZYMI1D
M',S#D<Z%W&'93#4V9!8YV8)T"RZ;J+[;4JD.=M@D4PXR(3SOFVA)^XN_+\$B
MY=QMI0C_=L)Y>'S((FUZ;O#MKIGGSA3! "<LZRU1>P$;T2DA@C>$!Q?2):<]
M<Y85DPII^%L6KI"*Q[8%+J_:IL[&+KZ](T.O56+G:8EN)_-^C/DLHG]X/P.A
M>QO0$G\HK$; ,U0W)Y?C?@B:;W87(*J\=F@&IV9/L&$XKDEJ-ZNG?0E*]!7?
MI<Q6 4:5[=\,?4"<Z]7P@E R@S#84_+^B4D*K73")$0B)1O-4+ ,%=\=5+=.
MFX9Y.KN%:?Z)@VWEG'E=;+Z<?DT7L)G'R2[K^J%9^H3L9XT-MUR)R=OB6BHL
MT=[+JXO?+O9-;46RZZ%LB,7A#+2G?1F'(Z&!F!TXGT,@PA((\.KG?W1:B>NP
M$,"/-?AAJ080D%(O^H,LJO'LUL_'KI\0"X?:!#2[13IZIZOHEOK3FG:&V$FA
MA>!RXIUH.!.'$@D-ZU2R'J+'P,$5X(6=U^VL5>^\TW/VG2M+3,#$.[PHT@K7
M%MA;^N7R!3V>9X9?Q=W3A[0!]Q/,%Y)$U"2@0V[*! /P@II]=+2X/4';<]+>
M:R&D==NB:F(TQA0"VAOT>MV;!5M_I1,-+@,6]) ES?N"8@M4%]F:$#<M62,Z
MY W2D@C)+SS(*.V>2%S36&.6DA QB ;*=6E1++'K-[#]!L>[?H,UP^,S97JB
M48F,%Y7R[,V(CDX*0T&F$RLPK7!F//B#\.NN5, @]AU\ 4#%I4E7S/<,^_SU
M" O%Y)<E&)*B*%M&WEC?ZXGG$^*3;)J,NT[8DDY]8-^\D&/'U+V ./H=)I:)
M]>U6DC!:N71P05A@NY7T,3"(ADDEZX8%(K?MD,< M8!'B6;X"@X?AB&F]AYD
MVJ#WZ-&A^R_NX'1RH:9MEX_VR]\.CA]INV8 "Z)D!/41+_5I%H7V<B;C9"ZZ
MV;.VR)K%(?*6D4""QW&']Y PMQ;!RNH&OLU"/&!U71.]ZO*^0[D?C)=^W:<H
M2C1 ,<^2UO[GFG)DG$+)U9J+9V?_'SBD,ZS5O^5?'Q*],<6ZL &G+<R+/!ZB
M=Y-Y-B;EG9089X5U@M]><7/$=:=Z0BE_C;0N21F#GHV;U\=$<$=T$N16-]*X
M#<[5F#WQIGR?C6C,WDH_4@F#"0$CC-&U,DX&8XAF8=Y0#A8=J_=Q,,]A0S<G
M$W1,X:(O?^4X=%[.A>)1"DN.A1/NY3NA7>L[&34>1FT+1A&)' TS18VJK4GI
M+)@U1#\C].R (I-N6^]A]-HXW\Y/K]OK:P3CNQ>"DW<Y1V*B!O)8>2Y3-J5X
M3YRJ ]^NAB],C>LZUMK+'NI#F0&[.']S\-;S 7@I5 &L4!^*A.UW "*7?00_
M6WCN4*'OEO5(\F1>,]ZS2B<5D8 LR*'_>SF^1F<B7\SF4X1Q(HQ",T&S!?C3
MA#OM!VRN?X(PPESQ#.'YBQI$LQ+<F@ZVE)9DCL1>C0.GWG&Z7L%*)E:U:'"\
MP?&*S  N\=4?X=@#]==?DO/H65+-8'&.FSCZ):TH)X=O\GH"AK>"IQL=!G!5
M)HDDJC):"I*OZP[;4JX,5D<.EF2(JC4,YG4MC?'R.-\'XZO#*VXK3^SE9?2/
M\W\^_^WR9?23X'9?I.,\E1S?ERUE;%O&7WJ32?G0I.\5I[I)UQ@7H6B!/!X<
MNO_BDY?S?VITP/DK\=SHG,.PB _R[%WJ[#O&ZAB"4&&%#ELQHGP$&O*$\'[V
M!/"D"PRWLY=A%6=3SB9VU-8XJTEPBJ-EO4ZQ&I1BA8]2,?@D7FD9>0&1S'2D
M'WB>D1']G>TW']S++L62'\&93&K_='?W-:A%4Y)!]\>Z'06FJI5D ]IK/.?0
MCE0)'TF$]_A3N6U[9I/'!ZZ_//G^)>":R; >E7/N*&7."AZ[J;"/I-%UR=X)
M'X5@43!'I[?EO)0S#]KMRNFPDFL$>@R]=?M?D?@'*P^>1FEN0\M#$E2:+H1Q
M6H8%;]GFO2P,08_X0B>/S@('E_AV<ZI\A(L_FPUA] QA)7EYW'&*>MGU\@ F
M;5/*1<99C8)?A_ZFG>TGKAP,KK#DB!<W6'+B0C"^V[6P,?-L8B4(KJORMIFR
M0H4#H88[0!ZD;P?@Z4D@S.86<2TS&-TIUH72?'(0^+-^:Y#P>%2T=$JC&5AZ
M?Q8Z9]+6Y;K$;5GEXULLJ.:"]^L$O\_S+/HMR\5S=C0$]*=]"R4/X;5(?J2O
M&_=#?AQ4FG9^1OZCHI\1^1:F?&C7(E1.FG)8"H*20TEAR[<=4!Q^K=M];.;&
MH^V\&\F33L2RS&05XH_PBNI=]F:H:20$O43D1UJA[WY)TPU>ZC92B5_&7TAN
MJZ=KE>:&)B$V_[W4W?@D['_L?CQPH(O: 0+^,#* (K+12,[-D/5A^HTR-J7K
M10D2_@7/JB+L#H:+ X.W(U1+'"$TG3!"&,6!OX?QEGFFWBM[[3M-P"1152Z2
M'!%(!'PO%+;BMAMK6RBL,,5&+MAB*9$<2JZ<8/0D'[OBGO[E=372E?!;?/P2
M9;[<V4$R\,:',C<*W>E. E4?M>-U)>*&L(UV:DBFV<_,@7H)"A$]O#H4)G/?
ML.':+K;0!^QLS3#".Y @5<Y5#0?HI#'A U;/\O0@J<'4,0>V4MQ[TUQTE8>.
MCC#"RIOIPITU?I_Z!PI8,OS3:2#8N:D\J'TX^P@=KT!]G;R=0V"75@N887B\
M$@+[:._JM^?[NL;09? N,K9LR',,G;^\=/5Y7<*S*,P,KCJ'.XU3RC@TN$TY
M9=(-K0<2L<+UX GP?UY!.$K!HA)[]WRUS4<I2SQC8(C7Q[^^(*P-LWX'$:DK
M9'%6DV)\I!R=^?=2."Y.7/?933B;>8YPB63=B*%N22'&3-^S[]F%,S5 0M,B
M8.&3X-<%@WV6KJ$?\!E],*,./**M9V=E%=_CENU7F$0E8O2]4;P"Q_WA6N)G
MM),2T42,6;;3DO(/PQ1"?QC ZX+T9+BZC62!%Z_^>?GLX/@I8M[$4;([3?'B
M2P^R(MA)#]3G8VH^J9\S IFM+G9I.%!9X!:"-7AK\J*2XE,B73@/VCJ=M+G:
M;5=(-_9D[HO#^F;> @ELW9;+'7JM)_?R2Z99P2:M%10:='BZ1(IBH(1V$QZ0
M?^Q'J4#'!6,U+.E,X*W+;8M/WMI#/ 3YW\4_Q&<Q)S(9N.O=<)@\9"E9HE0V
M_7_=Q)^#2#B>?;;7F+K.E."/$U):3ZBY@\XYL]SAD.2Q\T]2. W*&;;S6-1\
MMZNN T(@.R<BQ%C?!^?H(&A.A(<,E-?9%XR-,\U/P'X9,TG?"*4,54AJ:5 F
MH0DR$&A"[X3!6-R+&0W2HTH@@NQ0C3H6TFU;E.KM3)$(KI(\.JE:X_F;N[5:
MP3#B6'$LX<FS,/];!!TJ!&N;(VVR%ZI: >^H@R-8Y;$[2\2Q+^&M-0SIML!J
M2RN5971IN#4DSFFRPXT$N)'!#C>R9GB\A64W2HE05R[FV-D:^ VG'F21HM<H
MS6#:&$;<T]Q*Z+(4: =#HZ241*G4OIC4&2:#@=VMHZ%/-0XTA5:;#_!J[\.P
M!=#937H4;(=PZHP<JH=/3-UP1G,O4G4=PX_D?##L,N$JRI_<MJ.V!$>YMBW9
M_BF<(%8=-)1;X?N_?1!7_+(J\V=AC]^L,$)\_H^_( :BPZ-_<DAC,3@Z'C@]
M9UHQ5]@\Z?KI_B;I/>[3H_FU1\2:::63X.+RQ7]?GN\ *Q\ 6-GK)<B\F%:E
M#R0DKJ-YD_X/GZ$U':W2)GWYYN+YF]UL?+K92(ITEB6HF56.,E^Z&>$D9:/H
M738NTH7.TKY8NE4.S^\7/PDHGV;KY\/H[^5D H]>'/R6P$N,IBE'Z[\UXVY_
M.@IWOKX4D9HT>ELA3F4/_D1\3U$R06E (>YX(_E,N1>^V/?'@U.?U=[8H?T2
MUG9388N'96U/<8&CM1T<W6EM;2+IR)M=;V]CRY>3H.L=KS'!+U[]\_SEV\M?
M=]O^ [;]#S!\S_\)P_?+;O@^F=4LYUF9C0^XBDY\376#FNGPAF"NSI_]UTM8
MLF^?;^N(?]$^QA]D_"ZW=?2^['I-(([))P>88(W@*$L93J$%-Y2!(U1<],_+
MR\M]XW9-TUDYG^(9Z\*OV!SW-JSAP_X<6PG^.RW241*=_Q1'/R7OP6@G,8/2
MX#ENIR7F99"M>'R Z9=LG"$4'1.^R;MTG'2U0+5X#M[!H; \OBQO2OA_JC$*
MBYW_<-7':K/<^^ D?@@XSPK(?Z<2U056C=5],*+H>W^_>+/O,BYP'B'D@$A8
M @9G@@I1^@]#"$V%NM-*E'@=6V^432*XL)YK=?3]X!@>E7T@0P[CKP /VHU2
M'T5[:'_HO]Y.X?51VF<?41#?#TZ7K\9A=/AME3"=I0V2'Z8PHN!(G6GNZ@+,
M%^)JR/WS*H%77@V/4123MJ*EP@)Q<QNVRX@1Y#EUVO$NS;!U"4;8"*Y27*1)
MQ7CBVU )RC<G<O]9$U#T(W!A.15)#DTG&=.?,>@@AZL4<9WX]X $C@A@?(*[
ME\+-,"9YZ6[JL@LY^DB82GA[@Y<R*69S]>"5K'B8MQ^>V\AEEQC7T]/#EWG>
M)UBD&08!,-[CDE8NY6:H42\C%7-;_R>F3LT8$6[>=[NGP7B4U752"& @[A"&
M!.(*_7J/1$+*>YX5H$6IB_2W_&WBX#Y:;; ]/K!;$H7+;-O6P"Z.H4@#XD(Q
MCKQ=)S2$W=7,XYH5./#,MXA+SI9*TLD$6S;C)?(]C#B#[J0ZEA\S3GY$P!9.
MW"F5FEP,C>IR/A][1)%&/^[,<3<2+H>-[#L"*!9P26I3!V^/-RS#7(IKQ#\(
MAA$/7<JA+E6><*$BTY+NU'G:<!F!JPZ2L^6US VHB54N]0E.K&B4,T?SP;]$
M#H=5:S=A^DO1G],9Q/1O2H*>T?%Y])W5[_QNVU8F&VWBH0O2OSS6:R1/K.0I
M+!#I[L;!3',Y ,/B)[@!3)=E&L*SAL E A1&X,0,B[X$ZI.6@+6"+AT50:W9
M96EU -^Y[DHH^MJ=@^5I(K^K)TCL<W2EB*_4WX)>B6GFAGG.T;LJK[X"#LR\
M2N?,261JC 277&Y/7+*97)=7N+H71715"/8PEE]A5;N['-).=?/RX%4<0&J]
MB]L8$<" +.^/CMPB#G[_W 2#TBU]][;[" #<VD829<3SKH=2M/OF8W#+"Z9U
MJ3W(QR(9T$3&WL7L,SI$"^]O1:4-L9.UA7O7 04A+_)#9JY<7>\79#K;=%CW
MSNPX6\? 8VXI0_.$[SI)LAP7!8QV2AJ9O#3!ARBY=4^>G5'CC0>/" Z 6&7"
M=E4]+EA-$.+U&<+34"TY&R$\AM HR)4)3O!%WU*2-TZEIXR?L,;94! )F&)T
M=%CCA>%O;DZH$G6=""K&\B(:3@<J:(D8+%R)0AFLJ"T3(RI21K^RFE51*/PV
ME_H\[LIV/RA)XN=T4&DQST.57L.[(LAORTZE2X/>.XK=Z[#?H-4/GEP']47>
M'83<X+[/"I9?J6#!W6156WO,%IP_U+8RRJG7,W'H6AFI0XQPL3J+*F19NN2.
M_5Z03#C%>;R4+F'Q);&BS1'X7Y;OX#'2>>W:9%!OJ,H$0%EAXU@,.[$DXI5Z
M-"W+7"&1-5.'@1>>0_@$<W$ T04!^,>HW(<>(R*-R2R-.=2@AEK8I<E8YY_>
M&=ZDK!@Y@38FCFK_S.[U9)..RSG7K6%I9..6H/9C)_J:2JT/(<9CQ3N[->9'
M[I(]Q(PT@V.//$N%W!9[^6[@%$P*OU3-)/FN(OS@&0P ET1>P<7A2^ZGL1#X
MJ2WG&[".,)?R"2=$+PMW<5-?>PB31N4]PT:U<UY;>DY*B@*YP\G4NMD49D1N
MM*K!*VTUO@^^HL<M;=)TS.>NMDHQ9$_1UW"XPS0K\;H:0^]Y^L6X[-VCQ2?W
MQK0=$)H13D-L2M1?28? : K[1-(4!96KJG9NV!X+WDD-&G/"'PP7JR;^K2J[
M*2( PT\?>8[I!LL<N+4S]O1$,;QGX[189%_64W0(KWEZ*11!B/\M]JVE["Q1
M_/"O-E-8/0XGM5]S#F[(O=<=E(5H=[OX5VBPEN!>(@S>&TEA()4G"VWHZ#_J
M)9Z"S=%(.@(3"M1JCD *:KR6C$EP#G9'W1HS"K^=8^R\2'89MRT"N=!N-(Y-
MS3EMW,:XH]K%1[AOV?7M6^0X22P W]?^&J%IQ!%CLBMD[P6;2K]F7XM9P[&!
MXKK-QKR1V'LBTXL,!^!9U)R@@JL3IS";E5O7*\Y&@ X6B _!Z<'<#@FFTB$U
M12]L7L*-%KRPT,\B:O"Z+ HXO1"%+.D;U+VGWB;\->KL9(U$0?#>XBH2$.A&
M^R8QULCQ=( [Y^4B9;M]4^8MDC]FU,JCR=;@JCH E(_"(X5[$R*CX#(#DX6>
M'?N6\D>^:9X?<!0D[KB[N[>W#F6]P^597-[)#I>W9GAP\?!"''$(78)ODE8N
MU.^<?IJ8B&FS8[A$252ANDB)0$7S"Z-4Z&"6PMC&KVY=\AK#-T).39TKS'GK
M#F+LX^(4$/E'F*CP-./I2I^)-1F(,FU$VWW*UH>>D/O1"*@M*0YP#I6?Y!J<
MW:IP77_S=@A&1?<MF14\I>C]@A0*NP)=4TOQK#& _N)52N%M,?9&.<<Y4G_.
MG'7.T=$CO,=3V++#21BLR5N0W&='68DI6QPXTZ])< "-3>QZ%6H8EU<$]JN7
M0G-C:PA3,.UP,[;IP?+OS<Z9/OP4UV:N/U-?D@UY"J?##04<<&YI::5L5ST=
M["UR6!R3K0_"PA7H%K';1)Z;F'S2>=NPYT+A3:R=H>#=3- S J<<W'UIWW:^
MXGU&F)/<] 7^87\F"WD0<<CF4VSR0JHW;<=<3I;@62G)Z^XGZ*+2<<<"[-H<
MB:W2<;!\!,2G[(OHUZ&7T*0NVEH38)UC9,I+#W/N,(LNT]HXM:;E+(!;6V7'
M<'J3&0:YGG&A^TU-K%/'%6D7DB9O3[Y(&PB<PM<4"W8\1$(\@]3^0JP@86?O
MB*M+QUE\:6&)V0M&^@S8A;A6U%,V\XE,+ESOX^T 'R_H@44/XF'0OV^)+7S;
MNZ0P?\O%QO%*G1,7ESKMEA6"F]T\N".O[NDHVVD&?A:-2>8FL2I][-OG'(H*
M1F-/,S4]PJ>H,TE.UV<40-UGQ\:?P@Y5P.=(.:?[PDF @C[)N&P;'\GK RY=
MU91??!$>D4&XWE"UAJN+/ 8.C=WA\OZ 1;LCS?[894NTZNB<H"K)]73%\4?I
M&O&R0QU"/;"Y:)5=8RU(#A_X*XM?N8*@+ ^:;>XS9'JD5#O:<Q<?>WHV^ XF
MI0H"<U'9SK 'T?E/BU4-9!_1S]'AT='C:';]P[MK?F'+.5=.J6RO*"+37XY%
M3JR0V)5\[$J*F(7&$]3D"&EXQ'BO\20:*POF"X;I^P.BB>#1T^SB)H<!TYA%
M?X3.06>WZ9?O)KM#4JAU5$BQ':D<R7HH0<(I.LR,C*;IF,B[=%7=ID%2D[ $
M.N/&/Z<[86RTM)K,JD/FGEX[\D'D?3\$S'W(XL"\GS/:KE@FHU1_#>%*5>9H
MR[&*0.5=FCS8VPC%Q>H_QXDZS.:U[L@"^V1/=^W"TBK9^5Y$4@;4A27+M%XR
MY9SZ&EIRCC56><L\*3Q$@ED6RKF^,(9/WZHM%)'C,3B(1LMT2@5>DVD<;K7S
MX(L'..?6VW+WY2P#XB4J;\$<'6O?*G8').P?V*/_:O&7E<S&$6QKS$&R&NT<
MUXQ^?;-+-S:+JE0V6,9I:O_,7JAOI8FB<A2ML1;+\_IX/&P$\B7)8^QC$XN$
M"#@B:"'T4TC84F?OF3JK[N@/.A?CP/D8[D/59V?/R!T8V@7:Y[YP#GO-4J>H
M70\06\E1$XNL+C-7%;W[(*2)#\F1!L..[1$"F1Z>E;W?45N>7PFI=)?6J>'Y
MXF]Y3AF30]$5;+(+/5PION)9,O8E%?(:3Z'S1I0(@OI5TK@$G2_46+QA+;P[
M;.'(KM,0T4JG&4YNDBR76A(<482:"EK5Z3#%0,B_%JR?/U.5A5KH%0UGP@H[
M2GD5Y"1>XO::Y&TVEO[:_IDEQ _2*^ =8?W,S*)FPEO\':9L\&]:9J2#4.OJ
MG@U*TP4. UCZ_$4G5.N(9S),5 ]3"POR +N%/)!'_G2J@KW80[4!6V?T+XF]
MC,N!+,E*AB\-BW_W3N%(R+)'O)%H-T@0?3EWY=TNSE\WZ;5V:G<<#ESO^[ZF
MA;GL0N ,&%^E^;PO^VY-N4MO9F ,4\P:V12TY/%9WXHQE\2_A-5G4LPD_!.O
MU*PR>_NUPQ9@L5 3KG!E9/_HQ[O"HJZ<-^$?41'%$O1)DY)TZ7?UM!)IG*"2
MF6H?<MF:QHO/+;R^"JV9I">EPVX(*$5?AI=O2EART4U6YEH^I-500'3P[[13
MBA?:%VFBNLG@7OQ]K%[.P![B L*'5@U2^HJ:&N^Q43T\&%Q36/%E4KIT3JC"
M:_)[TZK@=0G!^+0<\_FF!<B <$97@:PK\09IMN=(Q$F%!/ 6]$%Y4,BV.FJ8
M(?H(8./8O5X--PC8O,2DT8FN!+O3-%SA)L&H]Z<[8XN'[#RTX(K/6.WB*ED>
MGBY8BPIFVA5FE^X?9(SE:)4CW&52\ \'O;Z<O"'_CMVU67G#QV7NOPC!VS6E
M&APBJO"OY)<JBQG#G"#_.X==\!MF5H>?)/E"V.OX)TXA?!],O FO:Y/:Q[ES
MS([#M$@G6<-H&?A:=:,QI;YR,#1)9V!BOXWD=_9.C.[PZ)Q$(!A,YHN!@DMA
M!YS86W)&2.A;JS?H!=Y(Y\GUU+A> L0(U$0#7Z<-;DX2U$(( (P(=4,?_?AK
MNK :EFR<WS*7%'SKM^Q?XE00%ZL0^J@?5<=TE>,?*?@55\*=#6H1E09()73(
M$DN=PCVK$-J)Y %LTQQFM9'C#RQX<YOF-T)0NUF'!V$RPX[KAP3*_+B!WW#I
M?K%.^WY*P3_,*O&L_A^V5"CX6[],?) S%IH#9#PHKL%6-:XID)_LY-@(*5*U
M(@CPOG_R].SPS*K/CY)Z*LY2T&7 T&&JD]<I//H='4G?)+#E=#6P!1\W&__G
M=]GQT>#DZ>#Q>#(Z&9Z.)I.G@],A!.A/TN'1V?'D=/ _CP;?/3@TS%]M<M8:
MF#<>WO[*83D^B,7C"]G-_M7S7]0G^)SR,_U[F+8E9G.V['Q_VVG0\P <S1MQ
MCV2ZR;L3RZRK/-"I#V;/<Y9GA5?X<7R/X-I2X]J3X(Z=&TH7-7B^V,8Q3$65
M FR?_%8 6.?,3_TF)?$U5$Y#?;WCHX-?PZOW<(B!F=9F0?S:U?.+0'EM\-B\
M+-'Y.IP$8L)(,VV(,<4$.VA&'P9Z?5#.PAMI#-ZC^*%LX>KHV2$N;-Z@NXX&
M'7'0^YL[!G)(Z7&",-8#2JK,Z_1O^A\_CJDXN_A;5M!3T8]^E&O)&=1#X$ #
MR1][TWIXQ.:UJ>#_CO7.\O$A??1#,U[^[-')X>G)8.7'1X?'*S];=]FGAV>/
M3S_HJNL_>W2R^I[?QK,^>O)AL_5EGO5LHZO^0*N65RYL#MQD__G=R7?>\:#S
M\F]'T3%M+KV>^^K3I:\.YN_QRS\NN65+Y73:1Y_:%IW=Y40<Z6G;.6S13CLK
MTWW->XS(\E=[1@3]CY7C\5?ZMG<.EZ1Q23$[_6&E&7X@#[H'LTE/VCDP=A,:
MCM-K=[0^]!G].I;>QYI9_U7Q:"@L Q^)L1WZ<EME@]'5W<#@;O3"W]K '7W:
MD^JK&IOCZ*8^C':#]"&#=(>=&B:C=]?4*7$@CSH:I>EDLN[U[SH9OTQ2XK75
ME>KW%>YZYXW7PU%TWV'YBT>$%L7WW=WRZ=[?OC?1NCZH%Q^<Q$\&CSKB0)]Z
M#/#3>X[%.E-TUS[LFK/=6OXVUO+QD_C1T>EN+>_6\O:OY<?Q8'#\=2]E=XW!
MW=?XN&7]\*;WY/'#F]LO,0[_\7$.^(3^O^USP)5:6;AA[TC7K=L?/2.P)5N
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MR,A TD-*W9]:XOYYF2]F1/:27-, PE?QH[)J//W("'Y =)3$X(!_;J99-3Y
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M8$\:6+B,U9@)^Z),6)9?)5.D=% '\&N$^"U[N 3P"H)DY[.@"#(0';I\Z97
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M$^+)>4JQPUOCB'[E.??OWNTU)>YB[16Z"TD1QAGE>E5))AZD]'G,,2!E2U;
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M/U>_5)QK_-Q%RU"O9]$<W=+CJ#D<X00**N65*MM-6R3E!TMR, =H:S#I5F
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M])?28:K\I4?\=,%].$3Z5IJ+:3]OU:4']_S3#>U>K^M'ICT,!J8;1*XY9/;
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M7M_0 &MQ;]NR^?>5EI%P'E!/>0YU0&+Y5BF,- 4A8W80(N!*@P&ARF?Y(>'
MZG2NET>(5B[*DQ,D5@:>GA6H9++V B5 >/'34I/3BNP2]#M3BL.#X;W[UA+P
MWC5]UJY[ODWZZHE P ]G;,RY8["[8QA_(D9H,A.H)[".\,5(?MY7J-*YL4N
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M7P98P&2!P7^2Q@!<>$F^3FK$HCH152A@77LZXOV7-((OVU<(;Z,:MNR<4^&
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MO?'YSPU=:7 ^SIV]Q[)]?NA]N'COV5M ^?W'#">M059D^6?#F.)P&$L0EM=
MM_/W[Y'?LSA\<62'L1'AOKO_=)X$/U_-9$$^L\.#X8MQ27?^88_/XI=/G_$A
MJ7QX#3Y\.=Y[\A4??@B__H'AW_\Y?LV./[AW SS8_L^[_5_+YWGZ^O EV?OU
M/[U7A[L?)S_[]3_O\OVP_<.W?/\/?;[W^YOLWA,B$D#)'""A#HR6&J)044<M
M:0CQ^T[T&^OHY\1@74=KNHZ09_.JO'K020OH+0$;&(,@N#8QBLA,7D?D46;
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MW=A$V>57G*=:^Q[=]T6!S(1&'3VZ9(DQER*N&R5-L-2[RW-_7GW:WW[YQLN
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MP^$7(]9XYG;,]F)!M"1-+152@/<B 6:'!4X%#T0ZJ:RT4E*[L<G,;<8,U_&
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MHDBRG-M$#0;!M*$QAI@BAN2TX+>!=/7CS>%]?\Z/TVAY8C$"0\X!D]>@>3*
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MTI5)3SGF\2D9.3F!U%6U;N\>$T'SR8Q*!"TG@GF)$QSSS*$"7:H74 <%CM
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M^P #2E,61'8!0F61PRGO,GV;3KV5'^XC/]R=0*K\L!I^6&B+%;1U*BD0DD=
M[A082S-)<(H*B226JLP/3'>E7AP&TCY^N%=3,-754S"+6$K'@[]&G30<G&3)
M]"&.YO32X]O,O_RFD5HSD?+>7>$#JV%\=C;T1Z61=6>09NOW)/9_LN7;VM9
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M-:(IU>K_SX5(,0?GUO08NPPBSVRP[V2Y5G@&5J7>FYW!N.(>G*#=*-5^><Q
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M(?-5$.62J>?!<9 *!O]Q)F+CDFY1PA/C08<GQEPN9=>IX>(4#=<IFC4.K9\
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M?L3R;#U@J^[1F!XK<*OJ@LAEJ$FK-M"*3'DKF*2[=E3JXB7MJ>D;4W5X8'?
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MN?S$LH9KRQ3FDENC+%0LSH.(R90&69KF+*"Y\I*(\D2I],%AI/\"EJW47UH
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M?I[OY^]*916K/AUR*>L\A;$/MXZRB/DLX0')8RD)#=*0,)_Z1/ D5 %-.1/
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MG^,*ZMEASPX?6*_MV>&:L<-Y#=?C*DA"/R>2I3ZP0RH("_P MI=Z-(TX,,L
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M\J]M#(QT=1L2B4+F!2I6,@@%Q1*\@.52 >'0P ^#++LU;%U/(@] (A&0B*?
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M>=FDCAW"^'^,)N++(U^ O=?V IQ]"O8^?HH^??QPN?_QX S,17_O=%1\"G:
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M%2NN1%Q9SG.AL^*B"E?W<JA;-MR;GE5;?C\'H%_/*5K*8IR,%\@+%A'G&(S
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MV=QL%'^OOUMOP)"++GC;[XV.2I/==D^*W^"29XWB:-3/MGIYK'9\V/+5V,>
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M/ O)TF77\%RA&CDKC4,_YI[\L9K7/Z$JSIW'>%)VQ1+<DS<5P(](2BWP;81
MO =[. EM><)$,\J#Q"(%*P'/Y,+HK-H]^?.%CY_3FUT$ <.Y1T0Q@;@C'#FL
M%)(ND9 ,UQ;6'?1FT"U62/0L^[2F9F$E) W&&-ATR5E2UADGC6;*&4% "[T7
M%J[=D[?EWAG5T4K'$HX:$<8#XIA)9"@V2%))O3+$ ?S^PJKCXU C[L\]6=<R
M?$RH.V_>WU%OJMV3*PK4!W-JE@$UBEJA$)7:(AYR/I8T"BG-J4]"<>5 S2(-
M+.83VQ_]*7"-7[\H?MU1::S=DRL)73,Z)FB5AA.P"PD+$71,:9$+P:$D$^9$
M"T^\^X6/P*_#H6'OZ*'TRMB-Q[G:5"Y\<T^%4Z]$WL4YM.76K!IVY35:KO*U
MV7QSP>9MEG6$ME-NI!S]*"<I[^2-V>F]_CZ,W5"BU060@I?T6=$Z[O7#('8?
M?=[ZSP6JK[,ZUFPA(M(\_?,KO.OW7*QH>V,7-S<.V[L[L$YO=T_*W^D'6(M_
M.LVVQOO4)8R]4TC$Z!$GG""M9$):6JZ)"8YZLO9BY[@WGS'OSW:\N$#U>8-1
MZSLZ!%J+W>?UAOZ\#?V^_7[?VN22XAI%9SCBFF%D8@3!Q9Q222M+ EM[D6#;
MQN")RB.=BW!:Y6\_<(3XK431XT;E.ZJ4-2H_.!.?7,G$W_<ZGTZ;;W?%WMOF
MER8\=^MT\V2WLP7OV^QLO?W0:G[>:^V>_O5U]Y^,RM*J&)5 0C&9_9L8:2(P
M<HFE(!*ED9FU%]O=.(_*-1*OQB:R?>MM !RV*%+/0+1F' 9M"_%D"-8Q&>G#
M)3B\ (:O*==\9<T^FDO)5)B*,H ^9W*FR#'Z*77]+JOZK"F54UOIYT_AXMKD
M4@!Y+7+UA@[<>=@^*7)QY2*7URRK0H$A<#BI$=2"21RWVNVR]$.[K(D%TJDJ
MIPL;.2E:6SF];2Z W&_U1H.JD.PWP.[UXD95J>LM_($M_#-OU+B0QJ1N]&0#
M/.Q3UY:%F?,"=KKE7C9 IB8[:N>/S]<>+M4(^"P+TWX^M0BQ++0T*(\TJC++
MN5AS:U!6A?*C 9B*.;DQTTNU^<,^O%V%TN-ZU;EDL!V.^K&F@?NC@8VSR*7S
M##E7\+"12YC;LD[UX"C72\P%4?+N'=F3LBKVJ%\,#O,%,$)O6IERW*=X4 R.
M0!E+K1@FU;K;U:@5W>5+JY+1)9'E(@2Y3'<_VJ)C,Q:4Y>CRU8-1OZQ,5Q6H
M+LN#V^^QAHE[))$WX^+>\[4#&^6VETY5V H0MNUSHJ"LLU[Y^6!M@>/+&NA@
MT P&8Y9WMJP,7B$/H *8+;#99S23=Q=0 X@IUYK+VPS4ULI5_/O1YU+.[J0B
M);@0EB>L%Y]C<6C!WK;P](B&L#(5-&6B3*U^6>,S 1:5)0\S)<,XN8K=Y-'G
MJAGF=X#_#,I(/SN<7X%)H9!;D-Z%O@D/5WGK<SP[5:[V:KSDDSKN\-L9"X\%
M1-Y.F&C?EL?6>=#Q_DT%>K6I5<.F>RO;=59U&![V"D"@+M>U\WK?..NHEA8E
MG3#BDCOD.-@VB3"&98A2L+G2N2%&1PC15FO#G8<1K.;)R^AE"IC-E1O."E]N
M= "<E0MT 4=5&SZFG=P_H^4/LYB8Z!+ 4 LD0?X44".;WKE^25D$]>,0_M.9
MC+L]K1^9I4X_1T>,"X4-BM_N4.CKVC=^7(6^J%%+KYVEUXW^L5%_?ITOLT[U
MY=^NUEQA7<W-YGK7DF1$/,XB7+O9N'\]%S=_F\HGM_&M_D@EI=5;M)LF%5S[
MMD]JR6Y4)J9>LG-+1LR3JT"T?5$!GN@O/]C";IX$9JG@5XMPNO7[_S+A3S]D
MW5P5_G0QM"D;/4\A*A.>=?J);&]\@K]W3_8VWN-FYY_#W<__P/V'[3S&W@[\
M?>I/=T]FCC6^O#YM[GSBS9W\K+^^-C?>T[W/;P[A_YWMM_^ 1?6AW?S\YDOS
MM/D%+*BYJ$R,2324<\0"C8C3 -84PQKY:#A1SCCE]=H+8AI$+"MK_,9LLN(I
MY37</3FX$\QB&F4,E'DNN=34IA !!#DEC!ISZV3T&N[N&>YFBQEY)Z7F$7EC
M N)<1V2Q5 A[S0)+E"GG >YTP^CYSC<UW-5P]Z3@#D=-O"/),9XX!@4O>6*3
MI<11QJ)*&>Z(&<,=,37</33<-6<K+P;M+=4".9YKMQ$?D18Q[Q:6E(K B:0
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MMAJ?L<QR%Q%-. =G!X6LXPZ!^LN5)4('BP%(58/(6_I^:B"M@;0&TH?W*=1
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M[5P$[F JB@K;;D_*R9729S O?K(^,Q4GM2#X4<0I<:%&[!]?/\"^,/)#4%\
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M Y[$*C[@PB;\77FHSE/9&"#BT;#BJ\Q1%&/3R,2>]WKBV6G&K\/LP(*/7@X
MX?9B-WI;O/RS.L[JE)*UD6,[BI<;NTW8N9W7];XM9]]>?_?MT2"S]@>0'19
MHP%("/#2.QK#SGAC2__[W GBQ^H$\:I=+]$4B^FN@S"#FZL];Q1_VN^ %+;X
M]+&* ,E73#Y[VW'_;A0WB9!]PFTY#:[;<J[&7'YB6\YK U=G ET9U31J;[T@
MGMMH+"66FJB\2CRW\ES!0-<+R.^?%1]>_[G9W&W6N+\<W#]W5),A]U+Q/=6*
M:17\*B_!\6;O6P]^]$-K\+5$\IF/7O[^L;QKYL.W5=1F>'9VQ#4]IEPPZP^3
M*."/(]>^;,H3Y9&J<L;J&LD#D^WUCS([9U*[3AX]-L-FYP8& 9@D8 +8$8A
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MGH44-9-)4&2"2(C;&)%Q%",I -"%B8#A.M?E:>B[E^6I.7QU.?Q>S@AJ#G\
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M'H@:?^^.O[-Q #;2R(AAB"43$=?6(VMS.>A$+4AB0[4FM0>B!N :@&L/1 W
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M@UQ\&6!Z(_K8<;%?205&&B6>E^Q:BH1N;PC[8X%+N@>%A_>T( <ZK6ZK,^K
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MC%VF@7H(P_"8210SF<]=*T1J2%&0>]-1)REXD7;N/:-#&IJ#_J-6Y)SG/%5
MUHQ3876IK+!B2S[?C7Q@??JT%)8SF=.$$P'DXU21E(R*1.1,<UU()UA^;_+!
M5J";20@O#VDG"XCBNI/R/0HZ>Q+:N,:61V<QG3U69WEM'III>$4?YPMX+Q=8
M?\/+::SPPA;0_AOOP3K !CK]1331]QGIK5G4H(2VN"^T,46#;C#O-]1I%U&W
M6,,[&**W'SL4W2E?9GF^R5VB+BLVUXJM?M<6J-EC:(&:DF_: _7U=*S?H=\*
M3G3?>[MP*0^Q_>F;*#,NSP_W?C\__/AL<$+AOGMO4&ZPDXO_G+_]#7A_>$)/
MCC4'=?'A:'G$SW"?' SWV<%O_[F >Y/#8Y0;ICK\^\6[D[]A'1=OX;YGZ>''
M_0R@"S_:>W-*"0%BRFQ26F) <+ T@2VV20'PH# B+:U8:2>:B5)DFNC4:IS$
M6@CN7)Z+-"WRTG"FEMN?=L\@%N[TPEGT/J7YZ6U/?WAFW0T.+I!I>N;K/T':
M(&GVTK2/P9Q0><SZ\SY;\XY!WB2*XP^#_1/]N1N5>7TN02HMZ7.3$:'SW&IM
M!)<I+XDFA12, VY-:5GXF5N" %$DS0^W9$?YD\;!C-:$[--7OA/::_]TV$S_
MT1V'-7[_VH5OS9'['P_^/*6\T*D0-*%.*\" 5B:BX JVAQC&,@,,2Y\\Q5GC
MO ]H;$W;#K_9\U27X7",! \'$XU8V?/G,6\M/I_7%/KY'+QN.B#$>^'5L]'$
MGE4UM@,WFVQNE*,)V+>Q-FUDDGH:9SIT.RO*&X6^-EKE!,2^<"#T5:Z(H]RD
M::Y2D@G#UU)E!V!NHL&PW./Q'_#QFTN FZ]QA:]Q@:_:]85K5_N"F-FD[0OR
M@U$EZHF3T[)@)"T+F>0*K%MN<YXH(DU2E"[3*<!.:_63IPZ057)MY619KL>6
MB'>>M?%0LDS^MDV'D;8@<32?>07\80<8!#Z+O3(]I\5F7"C$7V!NQ^N$A<8Y
M/J/PM?_*7]VOO&Z^\C-^!TMXYTW;7N\_;UJ& 7:M)J%76=MFBC>#V&ZY<^<M
M0D@EM!P;XV@6GR^PJDY"LD/KL,)N76W0NOD><';LF??U>SLO^[/"L&#/[3[I
M=C>,W/AHS<O1\3R-Y;&8C-^:K0_XX=[9]='Q+CLX/OEPN/?RM"A33DPJDMP6
M-N&<9TE99"S)<JI #2D"L/O)4T;6V8\!SS1&9!C.TNJ=/I88 <'X:HCP!V/5
M=*$)S3SU)B3NAI8U?H)%0VQU3!2,61Y#58UD+/+MMI1&(TW%;V&=0^550:#K
ML4^PZ2$(I>17.4V "1(0/>^LKRBGZ:]QH$8WXPLY/J!5X_N<J-EBVFB3+7ME
M1[&[OV\?TN_]\<?SP/@1[.YUO]XJW9^QS+Z[%_-.2'Z]\X#V[5P>2^5O?-[.
M"L;^BN;7W- "5D4P\0Q3O'"'P SWJ]^=^/)Q'[9\=CV_)HYPW06J,#^ND?:.
M'QV_H0=[?]+#B[,/A\?[I]3"/H,)E7"<4L%MD28JQ=F\99FYW&F=F6S98#-*
M:Y5*RJDIN<V(XH*0'/Y%,VISQY<-MD>@F!?'$?3FDPCF\'<!^F*6U@0[!2$
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M/#=2F2S7!<LRI<O"<?,0&[U]6B'1E6^M>6D]'INGDJR_T:;T_S;D/VD,> M
M:.A%E9/5I/=>#F;M7>;U!O=R-1.>Y1FS60X_&5G@5#KFB@Q.M62NS$)ER2T!
ML_UF62]@5?_!187ZW6W,;*,6!3O^Y!2@#''&N 3]E E78)3(-)<)S8K2%L0J
MA6/,BY*LB94NFB55+"TY'P/ G=1M' O,6JPN1%3>JM&@)+$8$'7CMT1CRV'6
MN(9=WWAWMUG@\?AX @P;EO,*RR^W5+2!BK@W;7-A+7$DL3EF:S)2)"IC0$JD
M2(W20&$%2/JT3[)R1]Q"1]$#.IT?0"R ;?L%K&V>VW&GMBE*OH-0Z <8[80-
MS74[GL]N4<I]").!!A%ISAFH'>Z ,#G-L])JHTI5:"KOF_>Q)<S/),SKP[V3
MCP<?]?7AQ]T,6]VXG%-+F4J8E3Z,5B;*"9KH5%EK4Z*X44^>WB$M$PWWQHSK
M.!7:%,VZ(=6O4I;2L3+NF?_?X0N?,N>-E, BE'3MDG.)U>5M?],:'E%[UY+W
M5:QUD^ KGP%I3ALN:UPB3:9CK,<?8]P PP'^HO<2EHCP;\5"]UF)RY4'"X7H
MG4H#W)&5?N-PDYB/_<F5!WE:E":WN94YYYD"=F9%YK#)/MB6J1&?W&)_7ARP
M.S*?E&G]XUG][ZX.]O9/#<!ZD6<V<2(C.)&#)<K//')22N)T;JGR5O\M1K\/
MA:_7,_*F=!L3B-BC7;!X*U=IY+G9*&8"^\1<X-_Q !6(3[#5@.BQ1]M-M3*>
M1GT7#(^W$XNXNFD_LF:)T]"Y86)]/B^F]H)I,3;!6U'/E]-#)H]!0L#"857H
M\PS.Q-B6'EO?51,]&]939&MX?ZUGDW]"0^GU<Q)^\G_Z^CVE-RYVO9WG&T>S
M3/0>;>/H4%46FC 7ZYI&SSOA1OTP!W"!66X\L/Y-_9]G9QA%GS_<MX%)&F]\
ML[=]7YH)?^M5P^%L-,8P@>?-R>P,U:RI8M>?$)D#3L8W,#N]-ZUS$'WLK8J7
M"UVD?ZI^[M2 (E*HO/[ZQ!I/ Z"$V+2DMJ"\*'7)-'.JS"T7(LU,Z&U5D#(8
M._##C47R=^C-X5]RN3G'%F%N4$C9X84^5845I+!E(FDF$LZQ3:\ _63@1/+4
MYK+0V)OC;K#RM;V<!H,$SS-(\VY9)H+- &KN1486#&,N<BPEX[9,9:HT()C<
M4.LHM=P[6 HBZ,V=T=;@F,^J<_SQ*&8?(4QZ2E(&P$6;1.<R2[AR:2*4RA/F
MN,PT*:@EF,]Y1TMDWI6CBR_F0+@/4@G$DN\LOD8@!K'KY6O?TU=K+ES9 !I"
M0ZI(?=BE=V ]Y'CE787I9GS38! O6R]##[V5B[!'%4K[MJS)K[=9<,BTF"^Q
M>>BSD/>\+OD"K[UG$](R3XDFK."Y S'K! Y&)843P"Q<2A'%+/!'<B=&6=M"
M$-=]?#7>-B-=8(>+=_R465HPDO*DR''(GLVQ_0A7N-=9)@R3.<V?/%TS8"^V
MD!S731-)-9Z,+%;8S1'$_2@!ZVRY8R*C7/'4I*4!BT\0, "MH"236TKX:I3P
M\2 ]U5E*'7IH<BG+A&-;8HD=15DF;<94;C)M4##>UDRTI8.9ER;OHS!I&PB.
M+Z?1TXBG/ZG4#!TYL8\B_#4(&;8@77SB#0A< Z(.OYVHZV3^6Y@&T<-N CZM
M!*W+^Y%>5J2&I=8PCNVO"U,61&6I,C0'M<!8_AFD]R*\62"\<T!URZ1W--H=
MO6S?Y=EUYV=\K6>XG8LZW54?K$D^VLGX!^[2M7]UN'>6GF8\U6EA>5+Z;C9:
MYTDILBP1*9%&I06SFC]YBGNUFJ@/Q'8_,N'2\3Q--=5$\D(:Z< *PL&RFE&>
MTNS[D\F/+,4.]]Y].$T!7#O'2))34&J\% Q#:FGB3%ZZ3'%5&K%9BJT@FM!>
MZ*<U0@Q]/T@MU]UV+;(=LHCCF:*UX!VRXZO>],H&#U68U>"#PNC372?P?.5X
M*Q\[B8>] 5[E>[J$K.\XJ:9!>-X3NQ-UL%^S6L61TJ/1.OC*-XVZZ3=%[?,W
MQ^S>CO1.0A-4V_C3W^R\WHEY/ WZA%<("!G6M-N+]>_KDG<[ON.AO Z+AA<*
M-?OWXU)J&2#'/&>Y%#RW3EI54E%2!V:[(Z[X#"Y=VZBIL>./Q\_L@BT?FWD\
M;_?@Q^;/H^-=<@IXTE%G;)(KC /EEB2E*4!\ \@ T]A*YPJ, ZWASTV4U6_;
MZT9F<Q4:9*@QT3CN$%QP]%K3<DO#5--J&!-,+R<5,DCT" -^04:[_CE,6QA>
M@O'E?5[Q!M'BD;T:;C"0D][0HENWJH>>0W7@HV#4Z?%L8")5QZ83*WW(ZL=)
M[2_=G,:/T'O]0Q,Z//,@.]4YP&EL1T94622<I0P,*YDECHA"&#BHU&8;#"N@
M.3]R;T[B]XD)D.5D\!1GRGTG=_7Q^:*3V2N>&([$+/!!U%2CL2\, ?[&1NSH
M=5Z:5MQ-"N^-)WW<)"LG@\I.^JUCN!D?M.P>;DHNNZ.+L&.[=R:'WMOS:Z/Z
M:=N\F[E-&WPPZ)6N+-PH:$B\WO<?7/S2HK2*(9]NG*<[NKF=58RYD?K\$1[T
MWX "<!55&ZIN8@P^,(VB.;JYYI!G@_>J$]=N4O0W.K&ZU]8K@<$-104-7I'S
M!G0[O6?- "W?*" FM+61!CPS(P<HJFL[&(1^/I6>7["Q?N%J.?5J&X/XQTAZ
M"B8'_%V3P[T3>K1WP$XEI8!KP/X$Y2L3#KR2"*LR,$0H<UI34Z#Y<9> 1-->
MOI%_0-[WH1QG'$^MM40Q(!9C2J:$A/7 \G29LN)^E!,2H8[<<OY3)S7JU9P!
MCEKZWU+.W2CGY.K4]WL0!"B'9#KA)L,QA)A;P;##>TD+142HDR[OEL,7Y>_]
M&BBIW!96,))91WC&I=(N9SQS7 $Q%89MR>8AD<W9U2G-,FX ,R1&,QP!Y7BB
M!)-)Z8SAG+)"E)B24^SDMU.-3S!;--%O#3/=*Z-+I!1M/)H:P1VJ,%[8@N4T
M=:2D9$M<#XFXT(815#$@(C!:TM0D'&1" LI-)4;E/"<*SI#*)T_S->W;UDJD
M32ANL;7A_5$2SPPK4YY1PRC/"RH%RW&4'DXC*[.B]=XW="5NZYOS5\C.Q()
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MN=5<XJ *)W->T)*4J;HKP:G;"4XM$]S^A\LJ&&.!RK9$MHG(K@^.WY%3:B1
M$DF2E!4BX6FJ$F&S+*%*JR)5*>%,/'GJL=HF&=;D0#2-VSV("S1VB<XM#U_M
M!TP>J6WL?QQ:WD52FXLQ]+MA1H?"29JUM^1B8JFL)K&4NQ>,JD"Q3?G)BH\K
MMI4_W'V]M_MGSX<">Z&2JOEH<;F?UHGZ^R'F-ZV+[GDHK/55\:/I9#SH>.:>
MOWP>''/])D,7DTA"(E!;D>O"*-.QSTL[M.^F<A(3TS&H!++;YSXN#G +>#FF
M_E;3JIG$-@O&, :5L%[-3V0+S7J#<>P/%"73<XF=,W^26&?CO&D?%]@NV=LT
M\,>O%+_WUF[8NY>CN'.OT>A"'T"4*$&$H+7[P>J9S[C:RI--\@2N?4-/.<V%
MD*Q,K*2@M)@FB:"Z2"CE)E-&%X82P$17=O"^&2ZP1G,-!N,KWT%ZE4C[B_;:
M2J8E^EUPG* =V$EWWB#(C]D(#A )%?'(]+KULA]Y+JJLZ[7GW#L*YF._]]J.
M<.;H?U!JO0+CW,_1"[IT^6\_S0-7KR;P<W4I![T7%E^F_CFTUL9)A+>N=OTZ
M,=%N>91B52^RG^?PQLP--82_C<=8U2QKN/POW^XZ?'7+>O\@U@.\>/WU66^G
MMQM3K:6?%;G>J=*[\J-TFZ&;MU([TGJ3H@D?=SR\#0"-Y'\'!=;)O?PTC?Z@
MLFWVF[T-\*6M&'V\F39KBM!0FOMN,C>\;.^G_=>O7F&+_U;L(U*\;*ZY(=;9
M)C-+!*.QQ'ZN$G3'NMA<1-VZ_U&&-T\%$I_>TT7/O$O09:51./RJE+S(E74Y
M_.IDJ;*U,O/V3(5/L9.:_?5#V7SF(NR9W_K8B> !]0WXOL(U/;@XNSZU.5$I
MSVR2:9ZC<.6)),XFJ7$XS-OJPI9/GHIU Z.;65;CJU 2YS/C!^.Z'5.+Y&FK
MB(]Q0/JDGH)YXO/7L;PX_(P3E?5YKZX^)%YXHX<[U*<&WS1(YT_/W[*T$)HQ
M2U-\/T&5E%DA4HPAIIJ:#8.7OF+J3!.: P3P&QIHVPR:NZ1Q'>WMGQ:.2),1
M(%*3ICCD5B2EH2P1128,+YQVG#UYROK99V=QS=-$4#Q_>MZ6SC)7R$QE!<.I
M7^B;S%6FB<XS0)?*5PY30O*T2)H?OC85SH'.-I7K4P*AAQ_W/YPRI;DH@0A-
M66 @5*:)M$".BA$NG;6F4/+)T_365*[5!*XB3J#[!W2WV)2EWML/<V\^(Y+[
M=0L?7NMS:V8#  \-=(ON_0W,%T9 PD]'[J^V-#N8>;Y(XH<NB?AX<*HUA?T7
M)B&%4@D769X(+F@"8C!5<$P@8LKE$H?O%:QO:^MC0:O'VDG V@N0.@YO0N/-
M^RK'HWH\J(SW5[S&_/-0^0C@YN@RVH0UIKX$.]2[5  3C6>P7E/__$O##%.?
MM=/FZTU #R6^^.FRMK\T/_QJJOIR(*]_J4;^)?R7?HUL$Y/\UG1$\8P4/HX)
M;V6Y4Y "<]ZF$_B_:1X<T^%V?#K<OZ9F];.<[E#.-GY,=M*-G]UTVY3LY&SS
MQS?=]N;/,K9=;,[NMJ!_>6((! $DAX3Y?Y^P)_,D2Z]Q?B&]U OCYG[MI6FV
M<BV]_(!7_[J23KK2M<>3YY?F?W%;D9U/_#S!=E3[OHZDVQ^LU5-?8F_FET;F
M]HK\<MKSTJ/7O..CVC?4HPN;]!DO_*-M'-ENW"=M7%K>ARV5U._.)F,PZY*X
M0JVM=>ZFMT9 O?&=;TH1_ZH0Y7GLE'<V'IO:=^Q;RJ9>%.X;7_S.M$!Z]]V;
M;[PMGB#^US(;?;GW[[ZW3Q)Y4"]^CPX)A+!,,4:5+ V8K$Q:EI6ZI&599,+:
MVWRT"5NVDZ+A8\UZNRB:>7=S*[!':AN=_/U[_?9X3 ]_.R%X[<'QV=7;"WC&
M\.75T=Y@ ']C)Q<&GON?P<G?A^<GU_$[_^_W<S4T@Z.+$P)K!COJSP]'>\^&
M^#ZXKJ._W\#?3'5(3[+#O_]S?D)?7( ]-3UX33[\<;P_/3C>OSXZ/CL5/"4Z
MLUE")>$)UT(G@G$&IA;GMF",*4%!7O:+HESQ0H3(Q5?C'/STGAQTD_*Z380O
M*\"M!-Q*P.5"$D<RJIG*!"MX40JE5);F)<6L9"8DB^[8* ')5@(^2 EXO2@!
ME2RT($8D5- \X27Z8@NF$J 6SA2E98K%W;0OZ&H(:RL!MQ+PAY* EG-59GFN
MBDQSSITLJ2UU46@-G&(<\:ULRR@!TW(K 1^B!#Q<PH &%)AC2B42P%[".4T3
M0/4 "4W*3,:I$IEZ\I3W:<D?BP2\MSWO_'\>GSW_5QQJZ-,N.[WXUEOU[5;0
M^VW%6@'^J 49Y215)K=$ER5/#96(X0BEN5,%Y89OC=D'+\@.5HQ9T$Z&&D42
MHYP!*)>11,(1)S)U0LNL--2Z)T\S#E@N_5Q)MEY@?%6XMO3(C1[;'YZYRX+)
M HO*C=/<Y%0XHX51MN1*L#0E6SOM,3#WLIVF2V><$TDI"I9P:DU2.LH2J=/"
M4:JYI3DP=]%/TWS+W/]<YBX,+[DIN.!"<F5SE1>ER@VC5'*92[,U01X!<R^;
M($[P M!8F:29!.;.4Y< +A.)=8635%*2Y^63ISGK4_K9-L@79.X?)FSX6RA$
MC1TVA]6HPCDA6'ST&8;&FLWXYXFKS.56<I<[EV<\-UP6*@=J3PWG+B.:;@V-
M!R^N_EPQ-!@I9"JX2I@5(L%LT40H6B:9M+FQF2IMII\\946?%%_*9?* _,);
MYFY#XK14!6,:SQSPIQ"$L+PH"I*+4E.9;0V-Q\#<RX8&E8;Q4B6I*TG""^82
M98A)%->*\I0P8<#08(!%RB\5$=HR]P-D;DV+W"@EF2XXUYE1V@JK<\"CFAM&
M]-;0> 3,O6QH%'DN4X8]!_UX!9L6V#I()4+J+*..*YE18&[:IT7Q@)C[6\<S
MO@=KOAQ>RFK2CF.J:[O0"GH^_KGI\Q"&+9U-Y'!C$NP/[RW!]K5%04NP/U)>
M4E,2*F6N3%JH4F0R_2;FAZL^6)-\M)/Q5G[=2WZ]6;$\\ !SG(ZDG$(O*%H>
M)<\39V0JRTR)(BVQRX"?\/. /"5;-^B7SD5+)78OD4Q8Q4M+P.046I#4,9YG
M8)]N38_'P-U+IH>SA<H8+1.6YRH,0"MSJQ-2<I*33$@NN:\+_OQ<M"UO/US>
M+@BHZ)(RH_*2*V-ER9@QUA6T2 FWWR;$L57:G\S6RT9';LN\)((GK$S+A!M'
M$J6R(LFE3%V6JE2X!ZFTOU!X(_ G>^#FQ_&-]=J?F.$6BZGAW7MF//O_V7OW
MIC:29'WXJW1PSGEC-T+%U/WBV2 "&]O!Q@)C&X\7_T/4%01"XJ>+,7SZ-ZM;
M B$) T: !+T;@35J=7==,I_*S,IZ,A_-'G7DQA2X5Y0Y^^#1>3&(_UNL$[4U
MMTBPOS?MJQ$<< @:12?SR0)"D1:2(ZU3""X&:0-8<X8WY-QVB>:D6,MQ\* &
MUQI<[[0%SRRF4<9 F><RD[C9%") +J<$G"U3N\K+ *X3KK)DWKH 7C(C+B$N
MP+IVE$DDM!#>>:.8KL"5R@?G^M;@6H-K#:XWI$!$3;PCR3&>. ;C-7EBDZ4$
MM)%%E>I=TB4 UZF A: 1*TZ1-!H#N%*#,@LO<I@'J3!3CF, 5]-0<TN!>&9P
M+4,=?Y1$:&N3W-^W$F4O&)=TKB]R*^]<-YYVNOV*XK[Y^SNON>[OH)4OYV(G
M\;)*0&_$6K]:T5;_NBGY$9D=M7S(7Z.R3R/^U+*R;RY^DCGZFPGFL"RN45("
MEY57BGB-=&NR:G8VZJI:8QF!EJZ@R?HO2X)7-(.#]B7QX,0@5Y,'#_C?>X"Z
MRZA.>729=Y8)Z8CW1!%.0=,  -ALTF,D)K'\3OR7VYUA58>29[97QN'&KV?*
MHNU.?R_VK]@Q[P;_<DGA__<),[?HUL$^2S; 9!&D:!2 WO#):.&0-S9)$X@G
M1J^L$:U6I\,.!0APJZQGE8M!5\4)+JMNW @J]HH_>%AW!%3;]R_K78\))ZCR
M2.\[ !&%+2KACP'9#!D'EQ4E068?F:CUT<3SLD;'\*O\N]E5W3)^O3HIW;S8
M.CK>-X$G$S5#":P-Q"D6R!*%08L5YTY0I7*!+;HJIVIQE*#_$BB.W[; '$)?
M_&&G!:]9[_4&)U5%NN4L8C&["G=P'AP$2SD-AD>!'=<82_B'PKS+Q">K<"L1
MC077 7LON0C)A0!XIIP#Z1 RTU%E ^>J'DM%>=MJYG4NFP37![6JI(9R.8'\
MXY-.B*ULXHQ&NACT*IB")<,/,N9=E56[K*=V6<NE/&4_K.=23!8S[0&4Y3(N
MO6%=RI%54]910V55M:O'OBFE>GRT+NN:SQS%VT>EYOY=-CK=I6ILS?U;<__6
MW+^+-' U]^]2<O\^1T!W?>A:=9N]8Y1RV>UFGA?P:XHNV"6_E3\_%Q:X)8I]
MSRQ<]L#$C:GH]V_7Y_D EN7?V; <\R(^PVQ_@,G>',[U9YCJY:]>-@R.BSUX
M[Q;]^G/OHG6\=;&.=SYN\;VCP^;.QMO6UL<]\$&/\?;'3?[]W61PO-7,E7B^
M[WXXVOGVZ6)KXQ/?NX#[X+=;'[^>?3\ZP#N[T(:CP^-9E+E1" ENJT,V*H*X
M,1JYB!-*X.,$$TR6SY4ULDJ7@"SM.13L_^ZR;#WFL<77C5@/S(:H$6L)$&LR
M5\*&R 7A*)\=0MQ%#]@5-?)4PS]6$J?#RAJ>$0ZN$:M&K&='K >F&-2(M?B(
M-9F P%)P/E?IC)YIQ)GU2$L?D71P@7GKJ?/9QM(U8MT!L5[#Z?&-YH]FB.U0
MG#?C6%&;5WZV;/E\UO?#G>/1?-9X>G\\G6;&]4H9D8) FH: .'<6668P2IIY
M+3SW1.ML 4Z7FGV6TV?/#YGUF=97YGG6N#,7W)G*TN=>VL00%?"':Y&03EP@
MK)CE3$<1-:YQI\:=U^L_UK@S#]R9]!\I)2:28) 5*9=R,@P9K'(6.P],R!"Q
M#S7NO-)-T!^=%FALJ]D_+Y+-F5P/V?Y\\>BYT-[BMV'N\'!J_[Z<V1I&[P^C
MTSS'PGE+A22()&(!1CE%8,)S)*777&E.G+69EGUN<;BEQ]&:A?65^8TU LT7
M@289T0@57A&' O8<\8@%<OFD #:P!&F9P%S/",17YW7(NT:@&H&6RX.L$6BN
M"#3I2F(3H^=1(.T#!012$CFO*(H.1\HHB4%G!*)SR_=:>@1Z#=N-(Z6[/+1X
M>>*QU4PWY],^;!06;^(?^8!F"8+N=IQT]XFT[<;NR8L[C/FT*#G-2TU-CNL'
MCC"1&G'C"'*!)<2D3KFF%\RR65D3JV+V8<Y'C8&_)J7[+5^I5KHE4;K)2C66
M,LL"0UXG@3C18)IHX1%EH'2&):>CSDIWPPGJ6NGFI'2_Y1[42K<<2C?I#SBG
M9";D1L[%A+@R%!FM'?).@C92I3R+=U6ZU[#K,F4ISSP.GT_9#T_25S^(4SE\
M#XY"+-S03+'/_6[012V'F_@K!J*_8K<$N/GN/M&Y15YV*N'\F&6SM]FN&%XF
M0B_EQ0T0[$M0O@R_X!IM[X"VTQS*4E@L!<QN),Z!B8,3<MCFPL I*>I"$H2L
MK.E5/%VMZS&BHC4&O4(,>N#^4XU!RX9!YY,\[DEPFS224<5<$-0CPRU%G(.9
M[Y27A(B5-8)7U70Z40U"-0C-!80>N 55@]"2@="DVYDX<8*8A!CQ O%H.1A"
MQB!JB?(X>FX=&$*$KLXH#3;M<XXSW4YPD)6,<]/?CW'0#469TU65F<)..[V2
MX/!-21G9_!'_'+%&E:(^=N.07@Q?W6)=K],:]&^^98I*YIDH[XR^3LDW_O>P
M>T7A=!"1ZT9[C&R"QKZQK3-[WEOYXSJ'7[.-)L9PLOLW=C*E1^MD!9D &9UN
M.>=O &IC-_\*VF07IBW%83<#XO\T":;,4!F29X[[E SE#LPO%1W6)'&ZKU;6
M=DM*O$XJWF4L!<#ZUQ]V;=9,SN3<D\(S[1R6##,>G+:!B5Q0U2<>N;=B9<E(
MH4<1F!M8@(IFKZC(73L5N?+7U2^KU=U]D.G>H'M>G:XL_*#[(]]<P/H;?;^P
M_?+W?>A('NPR@%,21E=4KKW,%@L+"#PAO^:LV3\L?W]MSS3?V)]@KK9YP5DM
MOL7B$-I>M#.I='%JFYF$L4J7[S6*-KPG=(JST?,RF>.I/;_ZR8@K&AH4>S&6
M(I$&_4$W_IF_!W&""XW\@)(+TE[>.>SM%1'M'=-%E#4<4)IJ$PB/WAEM"8=U
MVE,ON>+AEJ#%YO:'9SAR<$OMOV5=MW^?I?;]S^V+]_O)^Z0<P<AS@1%/L.X:
MX1)R48:<?\9B<"MK>:BFEMW58F?0+4"[8%[[%8_H2.#'4M GE2Y8 (7BL EZ
MT,WV:M'OVFS?PH6^+<.D@VZI3YWVD(%TIO8-R97'GC.D57ZP*HXZ%,K?3+$W
M7W_2M:YE)<F#,X#69";5S*M<,KC&[DGOVDMGLJJ.]<5G:OE6:\@^#8^*/V/7
M-WNQ'*670 W\97 "C3W/HU(2Z!>5W5VL@VS] +E97H;@Q\P7\8<Q#%IQ)\T&
MS'(DAP[,:"!+$V$76O&V!1=?'<IM7FQ=^'WN4HA&$N2]<BC_%S):,22P29YR
M'S6FDSS-&B>,&>,"9H(SX6&ZG S<.1I@[1.P8$18.TZS$=\%![!D;:XHBEUL
M=<Z*T[P:EX3Q1>]*V,?5O[##.2I*\Z]$OOC_!B5JMK,[D"M-G+9 3HM_E&M\
M9P!"FVV"^-/'TZ$) H)6<LH7O2P3)5J, U$)4\UVM?S!2__Y9KK^QR]XF6\?
MA>NCAHU0EH;@B1$@Y<DJL*.3E-X)KJQ63\_CK%=UQ41\7QYG0585^3T.XUO8
MA@FGCT*-;.K&+E=CU9.03D__]+Y!TZ>,6-Q*<UNNP-NE8W*CE; @K>RD16]A
M:4A,U&.X@P"]*EF[3/%8],D<AJ<7O9GOA\[,HK?SKVQ:+7HCL^57*G&MP[4.
M/UTS/\<3VVR#;"QZ0]]=^4*+WM3_C!^M6= V9D<T%P/I_;/&FU^J\<%!-QZ,
MUQY8T G=!/5HMGM-O^@-+</\_R"SY.XUY!GO#/J]OFV7H7+;OU:%I_AEL92:
M?_EJ.ZL,D?4FMK.XCHP;2;1BCBO.G(HB>*VIC=X&*<MJH%-I;].5G1^:<C(V
MP]O#;;>77P3Z]&3[Y-//O6][;._BX.?VR7N\?7$([UKG>R=[9.?;GH#K_/ON
MVZ.=+Q,9)R?0JHT/A]^/PM'.QGNZM_N)[7R$?FT<-K\??17?CX[A^F%KZ^.6
M^._%^QFIMS"CB6%D%..($Z61B9HCI8BHXIO<K*P1UI!L.OEV\6B8GS(#[V%X
ML7#0.I6>-[_^+RE.WIRG]WM@.??TO#&LG,C-&P472N=]Z;?WGQPD)W*#58A8
M)2(0(T0"2$J'-)$&!8MI(D0PP\3*&N6K[,%4@TN&D?=YQMRJU"U6(Y^:"&/,
M)[F>V$!6J7BV7("=&X[US7:+7QEA[4R#^X&'WN9O>5]/]O[8[?1ZM>T]OV5E
MNL:<%ERRP#QRT0<$UK9!AB>&!)5.PR4A18!EI:'-@C#8UN35+^H4;.\AIS]J
M"_-!4#!A86IKN8U,H> 4!2@P"NFD%:+@GGLE4Q*.@QO.5_GTP8^7 P7+_HRG
MCL NMBDXRM9]B#&XO-R3_WAN:S"G6&[V>H,8-@9=&+P*Q:M,E_$4V1&0A]K8
MFQ_"3Q=GBMP([CQ!*4:+>)(866DETCP8(KE,49IL['$]37+[S_N&#Q8Q0O R
MU?PEV'DC!*A-O4<!@@E3+S)C@_$),96!0.B(C$HY*9]CBZEUDO+RC"]>$+[]
MYPK%+?0SZJC?N*D'AD.*S7P>[/^S)Z=_#D]NO=(PX+-;?@^, WZH)G/0O5H0
M:NOO7J _76,E!<GS^75$HR:(6^>1#0DCS3@+U%.O%("^P-/%V>]N^RVP8_\R
M%?TEV'XSE+VV_N8)!)-LOHI@</L",MP $ @BD+'*(JF]IA9'*;E=6>-R%L-+
M'>A;E&?4J9:4U*F6O[OSZS+-%^71*28X$](1[XDBG$+'@U2LS!YZ D.O3K5\
M1.B?KIY %&:&2X&\B2S7F"%(.ZY1"E1%DXE&:"Q3+06?5Y6994DC>G!@<.'0
M\][9E"\[8?+W(*].F%P6J)M,F&0:VYPP:9C+,4Z1D$LX("R-XHQHI91<6:-L
M52Y(/:WGCBTNDY6S<'6@;E7NRV.:8\<@<]D,^C++9CR=WD^5S4@B>AD],B%H
MQ+FP2$M"$&$2)C_9P%T"[W953M7-J"F4:ZOB9JMB\1VHRP.D0R+DVI&:(\I,
ME@NF1%DG):+P 7$;/'(B!A2]4D):'%S(UD5#D06I%SP>,QJ]:R3[U>;=,P2V
MQGQ#!ET*G4$F))O+>8QE".&]I&>\AG#DT$$K6?/F'8ZL(XY/M&".36(=<9SW
M0NFG(HY8,Y>B)"CD<]T@2 RY: V*(CGC(@PSSG65&I3)!5HHZ\3#EQV$&P.!
M.@@W3^V?,).M\!QSJ5%*TB*N.#CC(0J$&77*">VUPF FRU4SG77R<K2_#L(]
M:1#N9N6^*0CW0FO7/IW>3P;AL-/1&\&0CK#@<\,-L@%;)*,0AA'&<*(K:VPL
MO[@.PM5!N.<-PLT'<:X'X4CM7,P59B;,"R),8)I3A,MTAD UTA+<#"^YULG8
M)'QY>IW*>1%'S2T*=UMAM%_5YOH]]9-W2J>?77S@UF("$\4'J,8V>%CQ"?4\
M8&V=\9)ARJDS3#.P^?8?]K]9XW8#:^)8G1(S68F%JA'0-]L!E/H-RM\\TTF&
MV4-_ZU!.##VLM9)J:0!,+<<Q&*(433!QL!P;2=S*6DG=>-/P/7W')VKCB%7&
MRRF8.1JW]^Z2[S/7'*N@>%CYO1LO*X&4]8^:*<5N;/M<)Z1_%F-[6*!H6."G
MJN<Q+!8TJA/2KHH1^5:GEY,20;:.8__JIU,ED^##*$Q8 <XH5K@Z/07%<I;:
MR>56)H<Z#\7D$>PBE&> R_'+IC5< IT+-XQ/Q:59#G@N,UKT.WU8*D/QO_<P
M#QYZK$4\4MCA*L]]-_?J=_;MY)):# ^H'W2V??1IG^&0E(\.4<,$XLPJI/,9
MQK($3J*6T@"+"U&K;&K!+T G6O"A<2\9>F!-[EJ&%DV&P&J,T06?(F(VGWY5
M5"$3%4=6*FZE#BZDG 0K5LV-,E3BTGW$Z(%5E6LQ6C QNOBZ3XB4)!F';'02
MH"@"%%&.P?G /"5ML/-Z98WAU>F-C2LH H,D5S%L_HBM\Q=63?#SEZ_W*B*8
M:]E>L\69'-F!SUC)[W/L@4KD.I,E8<E74/%>J4=U6;_+LG[O]Z6Q2GN%D81%
M$AQQ'9 FQJ-<FI:$B#-)[629OF<Q8M?'2P!F"2W+C5[5_VOV<@'0U&FU.F<3
MQ?ZNU?J[JO)WTAF 1Y&+^54B_K1%]< /6L7XMZKJ*;ZJU-WJGMVSG)HPXE%J
MOSU*"4!A].+4?JO*.CQ-./;68@^E6)6 5U0D3G>(S;_48;BJ6N2Z?UR6!LJ?
M2X;"\M-&#CKD.MCE?Y46U+41>PTI4E_;N=9R+N-<5\:88_*4(II2IB6XNIP;
MQYS#BF.6"$U&<4D?O3+&^[(:[F8;C*%!>:9_)Q>TWSVT[:$_L=T9SOSK2:KJ
MT)V/T(Z/FWQG8[NY?;2%MXZ.\ST8GB2V=^'7&W\?[7S\RKZ_F]CW.-KCWS]N
MGNT='7!H([SYT_E.:6)] L/KF&S1[>/M;UO\^VXXGE4Q(R8=-;@8()HI($Y]
MKI@!_@=5221K/ X)KZRI!IY;6L5+.<59%\QXM04S?@]#YY=Z=G<(G<A:*2V,
M;%QDVV(8F'D1>6E/"*"3QS>$YX+D;#0?33X'[Y!+)B*NM",B.N9]9L*DJWQ>
M6:F/#J!S8H.K8(^6C&X+#7T?)ZH\O'*^IYEFH[4,6QZ\#5KRR+CVVI)HA*3&
M$2/4T_&ZW0I^UXG>:_-Q?N@W7?2!4ANU,QXQ*SSB.G)D,-B0CK!H=."$<;*R
M)AN"/]A\7& "J%<&$#<;1@]$B2>TD'Y9#:(VDQX.%%,E(0P.W$:42&:*PU0@
MZQ5%WFKBL/,,XU"6A) /Y@F>(U#,*<ZV-);0W\.(6SL4W=B*MO>;5M'R'D2Z
M)]WM$IE%U=S69M'\T6ZZ/$*R1)LH,")$),19/JIHC$/>:TPE#HP:DK.))9G.
M)J[+(RPL.+QHB^@Z/M06T=PQ8I)53!D?$I&(\A@0M]XC3;!%"2?&..,\R<S[
M(59GT&@_.^_'JXD-?;BL!9"-HJE* *_#$WRY1M'E]-9VT?PQ;[IP ,Q^-(91
ME&@PF>N((QTE0TIC$7%PV">PBT@#FX>4C:HC1;5=-'>(R#4%:J-H[@ Q810Q
M\)L,3A%AB3WB/DED4J2(46XEL=HED1TGLDJF3V4L?9AHH0VA7Z5CS8,]?YBJ
M.H.\[77G:SD,CH+SGJ60#\@JBP-EU&L,BZ6W*CPZV56=K_5\ #E-NR^2 /L)
M.V2,8HA309$&"4%,4L!&)KDC:67-- Q[<)7UN>OG@B=TO8*<K9>=EO5[4%FG
M9;T(G)R,KEE, O8":<4Q>)J&(\M,0)$SSU,R<%&#IRE7];QP\E'X/*[1&=UR
MXFUA3N[==+S_^8@A5M8RM<#9Z.2%K=2N.,AZAT(^;)% \RK&@=[P/%>ONOQ0
MMH&SV(V_/M^[]![R:\NE^/TCCOGZ >#3.@.<XEM'F_LN>,6( 7L.6XMX" QI
MX0QB6!LK1  IT#?E1=Q"/W"#7$G"@DS)*6PLMSXZ2J,7N61G3$X:<@L-02U7
MBR]7%^O[E@41:"!("L(1!T<!Z2 C<C@HZRTQV@N0*[-*IW>7;J<DN$&TL# A
M$)4$5H)+!F 5&7S 5!*G+'>W4!/4HK4$HG6P;U5>B3A%/&7(2B(@[0F!==MA
M:B4@BA!E.20V70YI@J:@R,ORU=*;5][NY2GY(>]1_]#VBV'LJ=E^0LZ?AVYC
MS8]HXYY[]R7_QICLUM0;-] -;*SO$^^BLY:B%#SX"<)E$@XFD&(@TY9'7/+^
M<3$W%J '+K^U5"V^5'W:QX9A$9U"-G!8?:T6R''!$0["288)T<FNK#'V"ZFZ
M/R_0PQ;?6K 67K!VW^]KY7!*3"(7!"S (@7X)%..<FC,B J:2Q LNCK#JGNQ
M3$$<DW\<_[/X'/O-;BF8Q5\MVUY."L1OL>B=@HITNH4MAAWK7G7L%#I6G($V
M17=>Q%;SH)DC\?'DM-4YC]"Z$YN_ALD%BZ>$AV[3#?JQ&)SF+[+MU(H]:'*V
MM&[$EO9P'V>>#(B;VQ\F\64C)AB6\&[42FA#GK<M^[-Y,CA9;[<'MC5^L0=P
M\7[84_B8F3TN\0#15P<([^%9Q^=;NP=T"YZ[L_L)[S-'D\WK#/$V(F[R6=1
M(K(J6LP#BYB9E34Y'?'\OR$Y*1CBMASW3#UZ"?D%"&,6G5[?]@?]3A>TH<C\
MIQYFIDR,*^]H-4^:_<)FNJ.2MV@ YGFWV,ST*VVX_#G^B&TP\;_$[H],<=J-
M!X-6^?A>Y08,A;V4\-/8/<ED,8->%ML3>QSA3]\?YC"<'Q>)S(KJXJ%MI=P#
M>'EQ:G-\M7F:_;O&4.XMW%T*5?[1$])^SA;ZV.W>N*1^:_8/-]L 5LTP*?UO
MSX?"?\<=UM?GJE[3" [_GN\K,,*2I@(EA1T88N"P.I(L"C90R6CD+#-(RP:
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METC*,<PXHD;CS'FBP/?P$7EGO&0..[!#<U:*G$$94&?NOQ@4F+OO4:/ 0J/
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M;'YH-J-&A=&,82TC8DYJQ+6+2 M,D=$V$.R=D]0"G&G14'S: [M[ =,Z@++
MZOQH]DBMSH^MSA.E$X(RSA-/4#)@HG#J#'*66V2=-%QY'H/&N18Q;A \[98\
MBSJ_AEC*;J=O6W.S,>Y# [A$B+4(]L=VK+/JYXE0/Z<,#O!_M(TN!TX<1]Q0
M@G2D% 4N$E:<.UAQ5M:H;F#SX/*E]U64EQ Z>?G*_VC62JW\<U?^2?-$:(45
MQ2A2$4#Y64*.RX24250(QZFWN70Q:2@]K[ROIZE!\O#PR4+;+]?V@L:X2=[<
M:+_<80 >CVOYKI[?HS3R564S3_+6E/J".@D->G$.)NX2+F3/'$8;*_F2Z2]@
M\-:[7=L^B'52\[R7MXMIVS9$8C 6B'%+$,>6(RT<1B3G2>(HI X$;%O5H'B:
M:>ONSG>=T;S .OT(UFFMTT^ITQ,F*Z%4<$\T4L2 OVH%12X$AZB1DH8DE*'9
M7S4-,&P70Z=?U7[>:\QO7AP38Y@A66/,?3 &3]D-+&)LK=:(,RP1IR2[Q=XC
M0C068$5@[TU9UV Q(O;U!MQR&0UU'O,CJ/"$F4!EPEPXAHP%Q>7<4V2U2J#"
M2<GDI<(YLD4:6DPS:-?;;D^W[?908MT7&GY?').BQJDYXA29,C4D>##2>(VH
M)AAQSP0RQ%"$82*5BUPP1LL0A9(/2?>I=]Y>I.H_KIU2J_Y\57_"1$G1*AYL
M0I8$@SCF$>D$3H>PF,B@#+5<E)MO0CXD-6C)]MTJ)5U58L%MF5S5\@X)1'?<
MSQI6RF;0_] 9Y+K;HQX\#-X6;MCN76%NC@.TV+B_".E68^!?)E_4$'\?B*=3
MUAV6GC/J.&)*2;#NA$'..(-B<,IQ*:R.)A. S8O]:W[*LN"E-6O8K&%S<1+5
M:MA\(&Q.6L;*&^880S ? G'*7$Y+4XCQI*(145H2P2FF#RY^MS"P61K/?_0M
MO'2M[%06W&:[.JP!WX3FC[5_P9]15TYL]Z#9KAI$2^1\8MVC6?>JT9[^^SE"
M'R^J8WV=5'0&,\_S%<T>?'T:VR%S+PY.X<=#>NAHNVT8T5ZC:*;"ML\;)8=T
MOWF2$YMR=5![ K/8S\\^.VSFBJ%PTZ#M881ML[U:O 5]S@E/PW>W8-[SYZ^K
M7U:K!HY>4!PV>_U.%UY0U1OM'\(@-MN^<Q*+;NP-6F4J5>IV3N _?\3V('_M
M.P=M&*10?9];]G;K2_&NTVI9D).JU^L'W5BF S3*]IYV.T?19S[L80];'1@"
MZ-]9+ [MCPA?MUJ9-!LFX@?\*K>Z#0[&58MGC=]9LP]=G\7^L%KL'LZDA<B=
MZ\:RXH@[+_[W'N"I XZ)@[^J2.!:.J.CU00;+(R-@*#[&]GFQ/!_--/X%),H
M.GT6:1)7WQWFI(K-]GHYVW>+1L@EQ=SO_SW$_N3OMOUF!CM''TX 5_/Q9K'U
M\?OAUL:GGSO?_C[<V?TW?+\.;X?G?]P\W]K])'*.Q,[N^_TH# Z9_(WPI!&7
M3" MA4.<!<FD-4ZJ7#.4B-5IT"P &EJEF("HWD<F!+.81AD#99Y++F$E32&"
MI'!*&#6FE D\DHGIE15DH@=8")]JX7@\X3C8]U&2I+!%.N&(N%'PR4>!$B7*
M."*2\W9ES8C5Z:)NE[(1!MV,A1GNS@$^>T7&[5!L1!]/7.Q6*,5(H\C:7TI2
MGO)&QK13@+[FC]@ZKV!I!$'PH7S<3)CJ94GK 3KGM:$$NO[$K1D?.U?IK@"H
MA1^O9CIZ_%4#"OAULQ-ZJY?VP7(MJZ-F/U*;RB>^:?9A[?;76JEFMC('P*[2
MC7-!^W+603^+JK9L<:VX[%W&7"[<D*_WLN$P6\B'JS=8([?)8LEHD"*8D+8U
M,B_R.GXZZ)YVP [([["G8"3\!+CJ@Z+<"X6)EN *,>SRB0V9L/%.NV19HC(R
M;\D-T2!]C4,>9O-R,O-<CL_=ATYWLVPTS.W=@-:\/J!EV[M[^]Q'C1-X*M(I
M@KAW&&EC#<+:$>8-=='!*DQ7IQ.'"E?A;*,X[73S-[TKZ_8,+A4N'F1 ZQ3Q
MYVFS6R(@3"NMS&'X/N^L]_H@/;<*XX.$#0=J2 1KPCK!$RSY)A!K/4W4!^^M
MKH7M*82-[VP<[#/J%?:$H9AR(6FM%*SJQ"!-$QCHW"7'L\FW.GUL\S>%3:X6
MWT;^RA#,NL.2X84O(?^!2&9$,-!H*K1SG*OD7*2!&,^A<S$J<F\?XU*2/H/7
MUO;-5K,T-"[+G]^SY/GKLQ_AWZ.O^Y(;9["G2+F8JIQK:XU$R@?NDR7@!HK,
M[,I6;Z)6.QD)W*U"QDI$JY!LOM)%6!!6V&@H#1S;J'6(5.5L3A$]%JZ6KB>7
MK@MH[W[>"0DP.<AA6E9)\<BR7#1%!N5)2 SG31*N9G@GUX1K*%LE/K6'4E7Y
M%0&$91J[.MW3'.X)W<'!N( ]"V"5R^*'JF$[9;LVH%E#,:K%YR;QV=EXO\^9
M)0D'AK D G$L07P(6%^81:M2I-R6X&1F&%VSQ.?7Z]_7?G,\LMG+ECS\F_W,
MD5A=P==UEV<ZJCOF! V=$4ZKQ ?P"IKY-V_*,GK@NOYYU@S]P]&6Q]B-PY@U
MOKK%NEZG->C??,M89-J#=QV[S^1S@59,C-#8W\/NJ#FG]B B!V[_,;()6OO&
MML[L>6_EC^M>)+B0$X,XV?\;>YG2H_6RV@8 51T&AM\,VB E^5?0)KLP;2D.
MNQG/_J=)8 $V5(;DF8.E/1G* 96QB@YKDCC=5RMKNWF7(DO]NPR%[9SS8M=F
MS>2$P%?P!"Y0=AL4B\YS3X0V7&-,M%$IL:!]A;!P3PSK&?$8UXX1!JZMD=P'
M:Q5W/E 1M#.,1[6R>,&$&0Y8!H5JC9D(4N6=B][ Y=V!C#>V#8/5*EK-DV;?
M5I9Y&,11%<U<NX/B/WT9^LR@U#EKQV[OL'E:7B%_YHV&'\W>R*+/]VQF#6_#
M,S\/-S#>=4(Y>\1H68$5O*QENT/0NGK"W<)D.L-5M0.&\K9Y^<WC#?P]@U1?
MVV/[-3GDXH95?)<S'#4T3;8')_!</X<-FNL&[1=_&,,@EPD<'S>P9T>UC]__
M]*U!GNHJZM[[J]IQ@R]V.^]_PDBTRY]_COU!M]W[W&FU/E2"7F+&+K3U;:OC
MCU^=I?+I;!O<J.A<T"EJQ 4!-THY@0#V,,)<,A]U\H2$2?BCE-E@N7=66JXX
M=N!X$2:QHCP$3-5*$<'^.\W+>G< B\K(R"TMDDZ.IY=[ICG^?5F6MXSC=\"N
MO4$WBG^4H?/. $0X]/[Y9F0W#<7N$NMGXONM#5[[5[G-?67 E%OK/F^?GO;B
MF]&'/T.S=]JRYV^:[5(_RIO^'&KGT.K)J_S$MGJYQE67AP: ,:L*JVP##)-3
MAR\>F@>KI7DPD2E079-TE7)VXV6\2FZ\]JO'$KPJV<V7?_787U\3K&ZL9'=K
MT"W9RK<>3"!BZK<S\L@J^_II\J7TQ,HRM2"6AO!>A)7^_;6MNX*1QK6,F8>.
MS5C>WSWR9A9[W/*2>1=RI7EQ*+VD@</UP/W6P!%S'[6<^PG17[G,CVK]OLW1
MEVQ4%LZVKA6SJ9S+>9]X>6DIP/?N?YWA.^$(W>#^O(8#<:>'VQ=;9&<#WI#O
M^[B)OQ]]A^?[G^7W'[=;VQ=_-[=WOYY]?S>1]GORGFU=?.7;1[EM!QSZ=;)]
M K^]J+[?HU_9]K=-LKW[]OB_%YO3)7R("C: >ZJ$)H@S*Y"-P2+,) &SSL,W
M-%/?-Z1\;4RT-=354#>9CVNL9)E$WAK,I67:TA@4,V UQ)QLDJ&.F!KJ%@/J
M)HH66<<H\9HBD3A'/&J,#'<&&2>3RV?Z;$@ =:K!R4V;GC74U5#W2J!.12V]
MC4H%SKEAU@9*L*#!.FR5=&7.&=$UU"T$U&U/6'5&XQ2D9RAX0A'G3"+GM$ T
M*B$5BU:6]04RU-44XXNAGZ43GO.X1SD%O6K?(&\3= H_Z'9S4GX^!? @OO%%
MH11?Z&?,E;V<KM(%IM4HQ6X=FEV*W"NC*7_"DWAW71<WAX=M<AIC=1+R0[=S
M\JY2_[_*HS3PZ[]&&%$OH_-;1C]-!4>\4DX$:I!D+, R&ABR@6&DB4M,!<T\
MR53F#:;(G%;1!?():MV?UXG+6O>70?<GH@6)<F^B](BK""9T4 H9[2AB'LR&
MX#TC.3!*&X+,J\!QK?L+J/N9],D[DASCB6-8^I,G-EE*'&4LJI1UGYBA[C\@
M]%?K_C/J_J3[#%.LJ50)"6$   #HJ_+F3@C!M25<X+BRQDU#BVE^T.=3_E=5
M\^!S# /_^T[+\E*J+Z#3LA$? %ZI^3,&=!&[G1JW[H5;7Z?\%18$9<X29*GG
MF<*)(N.=09@(Q; BS%B=\YPU)?3/.=$X+1!_7:WX3^VQU(K_3(H_X:QH)Y.@
M."+MM4)<<Y&Y9C!R2@>;DC3"FEKQ7X'B/Y6[4BO^\RC^I*=".%/&<HLL=Q'Q
M& URX*H@[#0U4D6"@UA$Q7_AA5=^O9EW"NK1K0B]?F\O[Z[1F_H9<W:*7_Q>
MWJM8))]W+^^OK/VSELAZ*;S'4NBGG-^$.59*@O-K3$)<4HU,C!$Q9@7!7 22
MV,K:PP-VM?F[N)K]O#MUM6;/2;,GO%OGDG,^.H2U5)E<5R$7N$=")&<(5HS!
M-*X1<Q,/5JW:+T"UGW<CKE;M^:CVI/^JB5)&,HJD\ 06;6>0-A(C 6MVA$7;
M2I^+#JAYU6I9(-_U56RS+6^.P'TJ C[O/EN-3?/ IH,IA\)9)@EW 3%K,.*6
M$*1=2"@RRESR IL<6^-F^K#0O>L$UJD_BZC6S[N+=J-:UYD_<]3Y"5>#2(>%
M"ACYP!/B!HP2%[Q'47%CO%!),YXKF'-1:_T+U?KGW4*K%_/Y*/:DHX%-).!+
M@'O!/"SFY5XYL0$EK96VWO/ ,"@VG^:K?1:U?E6I?%]BO]\J"W?5FQ8+ZF.,
M3=&W9O\0?I_Y* ?]PTYW1M7R>H/_-W'K>'I7([" !5.9M$ @[KE"H  @^HD&
M#<"E885:Q W^.OZYI%L;M?X_K_Y/9O8Q89R.%#GF0/\=J+XS*2#AG-8RFRW)
MU?K_"O3_>=V26O^?2/^GF#RHAOGU#C%N".+1&V2DY(@$:612QGEL%U'_7]4F
MR7\R=W99^S+3^0_Z)=7_6#F!5[9ULH!>S=4VUC58*R=N)ZV?GK9@\%PK?JGF
M;R?]YVKV:FR;"[:]/RMQ;;SDO.5>:<(9D@IPC3NB$"QK =&@L/#.<./HW,"M
M#KHN+@P\E7-3P\!"P,#6=1B(UA$3#$6*8X:XB2;3K,!_2LQM\LY&.S\;IX:!
MQ86!I_)Q:AA8"!CX>AT&E"(J6BP0UU:#JQ,LP(#TB!D)SH[R3"XF##PU,>&S
ME0AXWPZ_7Q]@V.DA3>2PEA X=D7H#')EHE'S7RW5[/P'Z,6L"RXO#)1'IS)-
MLY".>$\4X11Z&Z1B-]0_K[EHGP'7?TYY>8%+;QPVB&$6$6<Q(:=5*A-]O2(T
MD^RMK&G< '-O3A&L^2G1,\>_:SBMX;0NV/*ZX73"6W:8X10U1R)0L)6IT\@D
MHP%=E:0V@96<*[?/IV)+#:<UG-9P6A>%>4EP.A%U,(E:P35#2@.F<ND8TM1@
MI+G5RL&T21[F515F8>"T#%G\45;W72L[-5Y2>.W7M<?IPA7HWDS%62R+NN=J
MZ_V!;;7.B[+<<;]37.I4T1ET08U]53V[K+U\R<[2*"_&E&*NV1S+B]U<F/W$
MGA<NPD/"P,>P6GR+HU(,\(JRYK,MTJ#5*G[8UK @L\WUGW. I+ '\*)>OWSV
MU]4OJT6N41]BBO" JOBS[?7@J[/#IC\LSCJ#5BB:)Z<V5Z4_A$8T3W*X95A2
M?D;CAJ6CB]YA>:MMGP]_W(LW=31W)MD?G2X,SWG1*[,Z0E%6GH8+@_Z@&U>+
M]7 TZ/7+9(\\@OE2;^!Z?0LR8ELP)D<YZZ-\V2_&=-BA;AEAS:\ @;&73Q[=
MG(>D<QJ[58'L5J?7*SK=\D$>!@DZYVVW>YZJ@N:]W._#"-</X6'=4>RV?#C\
ML'<(C^RW[/GJ70K-+Z @@W2E)HAML^T[)\.)KJJZCZ8HBU&C> <Z#4/2;MI&
ML=ZRSI[ A]$D=,H1RHD(T&#;#L5F.S0MS"K\UV@V;A[\? /\*-HNB.2L*6B,
MRT+6,Q#^X>,"-+H'H%,VO*0W@D>=E&TZC>WRT7#O4<SRW2EB6;J^U)E2KX:J
M-OL7N?]E/XK4[9QDU2B5.__;*-R@GP$@=(IVIP_/:#5C68S=]DN=:#6M:[:J
M0NPCB2F?TAM 'V'VQ]]3">U0LV'5A0D&D:^4KX#KN9\)?MSV^?N1L&>9K1[>
M*P>C&E-0@@E)G(;:FV6S@O1F.X"VO&'RV81U=L5YQK5CA D'CB3WP5J5<Q.I
M"-H9QJ-:6=N!D3J%E<N?%\T21T"J6X.0I1M&%02E% @0#-O*&63C!%F#,4NH
M%*8ATH'P-5.>TT9QUNP?#G7BM-OYT>SEEH&,CNE.O-0::'ZYAI;/+S6C K?K
M4U5L#+I9-O(=E?3&:R6[*QUEI%'D:&/Y%Y=]R.9=HWC"[6YQ9RZ#:J1WVIOE
MJ.SF07G_$\:\%V_=Q\)+:E%^_^\A]B=_M^TW,]@Y^G"R!>\'RU!L??Q^N+7Q
MZ>?.M[\/=W;_#=^OP]OA^1\WS[=V/XG_7FQQ^&X?2RI%#!@9(VG.N.7(.AP0
MF/E>*HI#6?3C"7<U[S[;PSG^:Z13]53_>JJIX@HKP1%CN4R:E IL?QV0U*".
M(1CCL'_2=+9:L1]QML&1,S(QBEQDN=2QML@0@9&B7$>LG61&+:ABU[-]_]DV
M*N+D(@Q]D(@;S)#3P2-M.6>6A:B\65#=KF'\?E,=&*B<<!9I%2VLV$P@0_,T
M*&T8=L++O,&XD/99/=7WFVI W"@M<4C0$+-Q)I!.7"'#%644:X858'B[,Q6I
M>Y0OBEX3YC0U/7C#5VX-."%77LT9?%>,>3.EEU-Z&;]P<\!9;_4/.X.#PP+<
M[V;VC6ROTRYC-N!R]IIE;"O[MR.G_\9'@6!GA]8?VO9!O![H:8PYS=F=]\W3
M'%7*+O-XOZI;P5GZ409>8M$&/1EY.]N#$_ J_1R0LE*8]G&_>Y.V5*P((WZV
MT3FESZ.AB=7UG?2N;/ U%0+?U[\)@^Y9IQMZL?WJE.?3V?;1^WTKE:&26)0B
M!7-78(Z,SCY.2+ H6J' @U]9ZY_%UH]8G,",'O9&(C^<Y[75Z1!&,1UL*T>7
M8,K@=2%YYKA/R5#N "Q5=%B3Q.D^R8P+OP[1Z2>(>JB948_M3C]6#C_AHQ!=
MF7CX6)(_6BJ^Q(,<G/@<3SO=#!0;S9YO=7J@K[OPFK>MCC]^;O&]6+\4W^VC
MSR=[1Y_.\L;-]LD6WOFX]7-G=[NU_>T]//.8;'_\RK<VWAY-B^][NOWQ>W,;
MKD$;Z=[%)[YW\5YLT:]D;_?]V<[N5_Q]]^!LZ^,6B.][O'5QL.\D540*,-U3
MIO!0#EQTD"E$C*+)>J:PT]5"#K(9PWI6_:AM($*$"+/*0_#66"4489Q)G!*E
M*T6$%?44QK_?'<1,15&.?G$Y_),*<%W89X;&;G_G]38ZS%U4*O+@ B?$.IY,
MTE1:^,M</MY[@WH\7TSP%P'L*J!6+C4W6ER]:I3G:V!O;G^XMHK C+G8W4D[
MHP#WVT$/.M+K?1F]?7*!: ].+A>(1;&SGES7/O%]Z1*65!,D4CYS:@*L$R"5
M"&9"4VRBBQ2$LM..TP:1&XYQ,9SBX=Y6ZOA!/B&9M\=.3UOGY;[6 ,R)Z _;
M(+,'8-> 790GI P5A_@CMCJG8)K OT7H#@X*L$5"&<$%ZRB'EB_?U$DIYKAM
MKXK:]YH@[[9;@ 71[IPT?;6E46V*@"F36PH_S]L4.9I<AJ1'0=^VS691C@J?
M=COYA$!U+VC+ /"E7T6'X9*'UT:XNW]^&LL@,G2N#X9\%[X+\.ANTPU*@3^)
M8,6%T:;*P0"ZV.F>%[']H]GMM//XE#L?>><2'('3;CP$X[\)73[/+[4'8,O9
M7JU&RZA&T)=/<U4D=UYJS+O#9DS%^Y_1#\K-X)T$9GKLWFG'<_'6BZS(W;QI
M/XC9S0GP]!\@]*==$,8N-*/:I[M4KY'_<@IZ?&)]')09#J5ZN69G#$R:[3#(
M>IC!XO/P^>6COKY[6_Q5WMTHWMJ?X*39XH]BUQ['D/=2X1[['=P-;\N'_I6@
MC]T"FGB:]T3;>?OH1FULEXHRH8PT!(>9 56,FH,5K*VA07.6=,*>>'V+,M))
MZ_!=I^VA'=66U>=F[QB<GOP%8 6YU#9$7YVZ[9UOK>_+X"-35B)N-?QQ5")+
M(T;>.2:8$M0IMK+&Y)2V_=\O=N]F3FNR5D9F3921<);/*7N*=60L294"]_6T
MSFM:M]?WJ18"QI<CPH,!MQ50U"H'H$I)8.!E4NS3RAJ=9O^_][1BG# )@BI+
M"4_"NV D"? 1['@O"*^G=5[3NK.^3VPB6C")2+0><6\=TH$Y^&22!;0$18;%
MD<S0UA*;[S>S,FJ5$K=<"LPE#H8Q%@$@8!6V-IG;C*)Z9N\ZLQ?;G_:C!U-'
M^H2(D%EA943&!(<\PX'IX(TT%&9VAL*.,HF&-D$C)]6<5FEOK?-&F=\QRL[X
M97+&Q*K_=NM+XY:E/XO4^/+_^TM^],P&;#1).G(M$OQ'4-!_;#D6P<5;-@]J
M4;NCJ'FZ=;!OA!4B29 M2@ ZC)"9HUWGC5T/!I9(,=,CLCFL#8)AXJA022G/
M/2$V&N45%8FD)*1R];3.:UJW#_:C%E;!>"-FE4:<4XVT!2S!,N1#GYR"0LUG
MR2<43 OKA)6@K;#B&"&B<$++_[^]=^]J&]GRAK^*5N9]YB$SEJ.ZZ%+I>;(6
M24@W?0*D@3X].?]DE4JE6(FQ?"0YA/[T[]XER3:V 0,&VU!GYN1@6Y>Z[/W;
MU]H;[3;"J-W6%6TK TTN5D0S/V6N'S(,U()E+'VJ7*)(&"=A'(9>B$685R/R
M@5+"2"LPPD$>$1U+7_)(^$3PF&E.[,ZNR-/!#]]_O3@ZW:5'I]_A>7]^20"!
M94 \-_#16Z\]Z48JC5T1AYI1)?PH2I:2_Y<$OGN-P/=N9>:O3M8'/O$9"7W!
MHI@3"FHEP2"7(*E(HE"K&S* +(W=C<9.,4O38QX'[&!!BHV/P7"(_ CT@$3&
M+!":A5@ZC,YW>[RUA !IKT-!2)R&@H<B!? ( Q#XW*=:>I&T>_PP>_SG%QEK
M00)?N2K >#63J2L"&KL>50&H8$G(4[0CQ*(]OKV\D$*).&9>*DG*,1G0C]+0
M\\*(!TSI1-A]?I!]_K;[):6")AY+W$1C@0@L B:U%[N@Y!&J >\%9;#/\SW@
M;B,OG%I4$'&;(QF-$YO3;HA]G]OC'J_K+)X?^I?S+*EZ[9'1J1N;LWW>Y!89
MEWE_5%U]R]0)/B03H,_U^.J)1V=6:.K?7M$.9PAT[,:%EM]=F<)H7\O^N;PH
M7[RZ''W(!N[,(L[._\I9INF#S;(^6P/,F]?L^7H$M%+@53 FN3%C<7H%0M-_
MW)Q+$V*[><P* X9XAZAF>FG(-XMV<F'2PIV3$#;P&%VK"L87SE>=?RWDL)<I
MC+)*##+%L@18R.M(4D_+Y-\C650870+P*'O9<%@?AE/UL: 68H9PT0"NZCYX
M I#JZ634UT=I,P\L3;?W$T8XD/UW;2ALMZK#S#HYS3_D!2S+X%T^&IB8U]N+
M7\?3WH59/^?$H</WNU^B@"4\"1-74*5 OL3$%1Z-W!!,T5 F/$QQ%RXGY20^
M8:D4,J(>:'H!A@(84R&-/);&PI>SB4.GF%:9X]%?DTU@>+'458DBJ>J-!=0"
MDMPQ0<U\!)R0E"]?7Y5PM)!K;QSEF_]IAM**)7.P'!BTC[4.7[=__))DY; O
M+UYG \-FYJ9?&BYO9!EB]\RA<H-<]<\-K O1!1L>D;TIB->\N ']K@']F7/R
M]6\![5+.KOS9ZY(K?[ONL<3K!NSJGZ][[/6_^<P.-F#+#>B&"HDW%D8E_MRU
M"ZJKU%K3XU01B6Y*(C7JS6>,4^S-J:&7ZD7<=VVFJN'<HFK$9J\;BL8K:^;?
M<L+/;>$\NW!W6CAT(RS/ELL6E-W\HJY_#C+T>YZ8>A&WK.G:S/G9%L6Z]?R?
M3,TK[7-*A!<%.@GA+QDS+B/%0B:)%E$L;]VW8\K60?L5AX"-AEI[9^]GDZB[
MBZFWI3D7M"6%L>YH]-2%L7(8S^_]SV?_/#NDO_<.*1@WWWJ]H_?[8/0<?X-[
M^.'?_^H?O.]E!]E,8:QOA]G!V3^S?_WUF7T^VV/_.CT^._IUCQ]\ZWT[_/4
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MF 3$E1&HB)3J4!%%PD0$+][X'2)L;Q,+A\\<#AE3022B((X2Q0.B1*P\7VL
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MC:D;$2Q,"WOL1I&.W"0(8]^+A!]3A&/6"?B]RX)O7H]#"UQ/%+ATP B)E$X
MJWBLE52@=0B/ITF4^HE2-DEQZX!KMHE,2N,@]6.742Y1>_1=$1/AIBH45/L^
M!RL;@"OJ,';O.+0%+@M<CV4!BSA2/DQ->93[&C +E"TA&46MB_K:IA-N&W#-
MIA.F2<@T\U,W(5*[/!+:C0G!>(G/8D48";&K-.4=0>_M$;3 98'KL5JEIBKQ
MJ19A&"K.$M"X"%,T4D$B1$AB;1/_M@ZX9C0N'DFN6"S=,/% XV*)<*7@S-41
MHRE\1T@@ ;C\CN?-%P^VP&6!:S.!*_ 5\6*T#'G"M8H%X2H1H0^&8AP$WFSS
M NOCVGC@FDW1"Q5+DR#PW91$V$&%I:X$P>1JZ<4D49SX E-2O(X?SC=@LL!E
M@6LS@2L)P]27PB>@='$_\64<@I7(/#R&2](XM<ETVP9<<\ET7AH309EPA0"\
MXB' 5TP4<0,2A51["1$)>_&&1YW(>N<M<FT-<BF11@'W D$CP4--HC0(O51&
M4:@\L"MBF_:V?<@UD_:6)@GQ4IZXL>>'+E=!X@HBB1M& %VI$$'$]8LWS.N
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M"8M' $8\#EPJ ^+RB$:N9+!E*>B\?DQADX.F&*D?62>31:9M0*:'2\*RR/2
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MC_6FRTIG@TY]Z:=>][T%U@UCM"<#K(^,J5Z+J:&MEOT$T'25U;*)1QIM];2
M86=UA?P3/91-9VE47G_5 UW(/BBQ?8UI-5.P6Q?LE\8O^;L<C/  O>B8TOB=
MV;K]"_&VSC]<T//5<6Y[UOX)%]=?JR86[1![X/6)8,==H .SG[%1T!@Z7$_,
M'L>8( 8VIA^4HWZ%S32N18\I5:T&D+;O!ZD;?X@Y!+FJ\\<M#>(9X+A-P^CU
MX<;V]Y-'+!%+:B"VI?S3PIT5ZRQB.N_78,G5J-+:@ Z_$ZKD1=53>57=%E4(
MWPI8V3IUA'HVC>+)P,+]TRBNJ_KS=I3U*[?*W9-15M4&_D>C@MS$^6\/CEV
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MT*TRL \NBDR>&=8=%;IZ&B:;%;%/5\3^8YWG"8[WUYMHM[?.R9^<_C91,*R
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M^@4TF.,Q I,XX>4#72%7_69#,Y1R_^FC63R8R.$WX@Z,@!K0A2'ZR'$_[>;
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MTV'7OV3A+'[*+'\Q2&K)R&%T&!6/AJ0&)ZBS(6)L-8U"FOS&7I)X4IV?I(Q
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M44?[1X#U29U69,X:K5I%/+57RJ>9GY5NW+_A+]P#32MJ4;>CMU0NR4F;#0E
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M?/CL)U=[LTD,M*,)@92TIT ]\<:;8E';E"SU.;7)]-B&Z-'KO8JH;U/ U*;
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M7I 8I'$^"\!MO^W]L#F.BARY=H6W^19V@# W+2 _+"YD_CV.NBFD?_PXFUS
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M>K-=2Z_BS@L>F([.4%GZHQDI05/JDI(T0QP<-/(!^9'7QWUQ.>[9W>->A6@
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M@O:$2R6$=M&!;G.:M /()TN=6HIY<+?PKRJ-KIMZLVY;#N+B5OC-*36XHW\
MM./>X*\EP[7[_5P[I@+/%MDE'9->.VLLXRD[X$RQW>[W'P#RF+?_:1!>QAB(
M$ %]" 6<6.X988I3@,2!VW[9@4>]_=]SL/?=:/2ZF_SI)VE (1H532#&E_ +
M6JD$%PI!N#"E":&U6O4[WMU][(>>#[D+!_;)>]M7#;4/?[?!W?8Z_M:-7UU,
M)J7!#RX,+%$%)(>$(@H@2-#.DRAPU\G2>-HSOWI_# ^317OKM@^/*BNF32V
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M?K$J4K]IP?'+9-HD+<Q>7I>0PZ+.@0?CG78$E(4RI3 0[S(M86YE$W?L03U
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M*7'>X[ZT"QJ8X]QU$SRNMH7+E.C>F5^[I^FKKP7NFW%33SP9?4KXDI1I]4O
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M]N X['HQTA8"_G,X__IF'(LRM[Z9E]?+O4P'%LJD#YZ)M^")+,T(K2R]"3T
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M\42<LYYY):P([;HI/?CH"Q:""K3N^@99S5:C"<#:TLQ2>]1,,^XSB4BR5CP
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MP1,@"*69.>J<9U*WDH$="SU=AM>D8.4^?9^'\Z+4W"8/+ ;/HM)JC5.$ZHB
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MML+I/X13B5V3KFA=^X;8"LXYX3V7AKA4"B8=Q:\0++YNCB5!+3YOK=*#SE$
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M(&W *RK*DO&F47: )TN$,SJAI,ILVI7NMUSP%'$9W(9/F4G"0VD<' !5<@E
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M2 Z_\YSRY3SW_N\]:\_Z-+/WS#LS[UKO^K 9?QCS@//WC4R- $Q,3(!G)P^
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M+?%28VHRPPC);@'A*A"1:2_VORMN.7NG7R(.V@6MC-6?_Y[#1=,DF@>U=W3
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MAMHL=(C81M0ZW>@(X&E^_)(2!+MNUY_0Y&0O\.C]M?FP6V(BT<898BV?1AD
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M-A&+0NE*\'X]-FK\O)+>UD K6HR:^!P1>-63\U78%8_D6Q4"@ M&GDQS-]+
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MX%][KIJ+F(J6)=5SE!5=#/\=ONKL<*((<TBWW^AQTO09@';G'@8@WK;$6,1
MQ%A$T>?;N1]Y *;?3*OV0UX!\ !Z]K*.RX#;XK%GU>$JR;@CJ"<.S03'8B5"
M^5/6[:-BFTW!GAS246E&[P"Q"6_POER'7795QV5Z'">SM-WJB5J<VLN?S".!
MH#XTD;%OXX,,P#1]R.5( _;K AQRP_M:@#MZD[0=[LM]MBX7*QA5N%)>XJ2[
MOSI6+H72M.4^6$I_)OKWY@7WOIOK3P=)H%9N(@- O8]KG1.%\&_OZJ.XDB"4
M6?S<+@4RC 9E6"X5;60/78O=WNHJU_5F )CSLGYD3RI8RYLB<(.Z\$5J-NL/
M*/ I"4CCNWITE\QB=:?<DP'@+$ UAEE&14QVAHL&5\XR .^FAO ".N85T'"*
MR7&J'@_5XG9*%_8@IMQW]N'Z[4B*MD;SSZH(N30IM1S%.W_DAF8X_T/)46[!
M>+9FE5)NOG@=ZMN-:L1+!@ 4B' ]TAM;"ISSZ%O<'-J<<;E59L%.U2?0QCR#
M\%%J^IQ]RDD0V<2B-2VG@@;0%1=_4Z472:Q;(TYV]NH73^7S)#GQIF39/0ER
MMDRGG_H[19SJNW&E)_G3\VE3Q/Q]A1T+DKX>3'1!4@!Z]XB") DEZ'#A.95I
M0(*X\?]F9+E;V&8R]'5\RX2#-Y.H:,(-X!UZ%Z+6N+U<DN)"M20<,0#1:*ZJ
MJ>\C8+#KZ);?D<E6\BN7@>L7F%G[F#TO#(9P$H?9H'Q/IVK7<_A>HL71DY!+
MF295F3;(,+-H8K*<9_D+U5._RD7Z[=7GB]\8,57XCU'LJ"I%LP9^(%)4J__4
MM<8^_M]4]SYG3=9+GSY4G[UXWO">>&K&Z B0RJV.V;%)_R&V/P$)U*>Q&3$
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M3%I?"-B8(.6TZ[&3$U*)*KSKSA=_OX@R'O/F#5ZI2\(,ACZDUNUIMRZ?0C,
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M5'T09%BQLELAGE8O8/[ST?#+B4Y.4<OGF\1/C^)GF,OT9['=/2LBLPKWE:O
M_#JR9ABA@ZIO><YHW(2ETD1[G[!#K5.F36H:AT#W%DOE4';878.+_H@026<X
MY03.VC?KK!;#3DHWI=!?C(5J*;#.K:?M;IC7P83LG"-^)\<SKU@+U_]P_THK
M[1_<>^9].M-A;/ MI[KJG#+$MOCR-O_B+%/WCXY%MZZS@@S)(BMT4.,D8.J?
MU(.0_)5%\(ONRV][A2"AA._I>A;#_+_[.+)47I/IS2=P/!];=RYQ@@8]Q49C
M)"_/#3$B9_3A4&KUEE_>5RRD1BUPDX+V9&"394?WHE+0!(U6K1K[SS>:D+R-
M"IZ#Q^M"=/A+$8H@N2GQ*QUZBZF_.F['XSU5GJ5S4+>FXP6^!K5OY TE&5P4
MM'ARJ<91_;/D/'7LH.LJB[K.+T&>Z>+6III0$>INCRIHNJOXCH_"M]IW DYT
M1 MX+ZEQN@V]$2H[SK+EBBIKO!84 >[(&YJ=+!@-K!)R#58<6EC<#MQ+*<,/
MKBO/^&&9]%MJZEU<I#LQ9-#@"G&IR^ AG9)]>E&-%66CEA@5]422X?IO2:VK
M2&*<\8R"J!FXN3]MA;IYHK+R2/#O@>*+&;=J[CKJZ\S,G)59KE9!]#] 02N]
M\PRX_C",_NIYD-(T3.#=MEX38M8'1(P5U3:%OE^G,-]E+!KMH:?W% PDY26)
MWXP@T;IOV1X-]9B0$\,0_+S]<1HN/*W [:A3,G3TME+YK4L9U\*;GB:H^WV8
M8/+=H6%)R9KGS(^ZFI)3^10<0HRYD.8N6\N5Z:G)\YDM%<=5U\AV-;@Y<CSK
M:F\H"((%0C \:SR?@U2!GW#D&/*7D]ZCS_M<Z?O.=1YJ"QZ;M8& E[23::_=
MV8_+/7B(2JMM-*Z3?7@F^])])!-1U^PGW;E<$UM3WMQ?.HM8]+963'XT$(H_
M>JA-':H1Z_$D:OHIJ03B(),'QX$7^^;("L20M:):&Z)6NCOA@HF&S5^0*]FJ
MX=6/8%:&/6[59MPO;1S&3Z@ZB!(4Q+'YR%50WZ/GKJ) (NQ)9YO/A("=;UMJ
MW>#94X][Z$%.OBT^,I@F"2IIS@D@]JYCH*F-YP:0XGP=(H#TV?$"GV@5ZDTL
M!^^Y@P8O,^!L6 X,4[_D97J43P9,Z.W:I@(P85R[9MJ-JS9+7DSWRD6N6<>Y
M3LW.P9N$_8L:#7.K3208=&8S(ZX86[\[YV&VA/67Z-"V;H)#:':/7]9;"2X6
MZ(AXSC\?F!,3R95*4QYYFY,#KK@!)%R.AZ[-;39BFA-AVG;D88V6]JJ8]'";
M7VXV+4T4&?ANP2S+-HT>;;8WF%??^9G)7ES1M6)NNTP38XB37&&,U$4GQ)?N
M7 K75T&<:-M#S_:?VU":$9,,,P:73P]LF0Q0*4P'9\A(!,LB048I?]NUAPU7
M^DB,0YN0N!BSH*]5KBOM#9E#BT$,V$RI;B0IEG 'QN.*0I(L_T'8PD-WM[0[
MM)B8KIQ4ZM0WV,V:D]RZA_3_<?@2<BSQHMU9\9/,)<Z,E5<JP/T,C!D&9P^?
MV)Z$C'@#]P\RYA/%QBYJO[W?]@TQ.XGG.?N)H0\-(BH97#?! 8'1I]84X(B%
MP5,$;7%*R75"U[%&#%-)/<&HD2,J7J[.UO#D\:_#U[N2U@W"9>MY^_XAS-CG
MBK0+2XY&"NP=4@NE4YL)L_N(%):6IYK,4VN/H]63:9B,18/FC1]K+E>YMY^D
MYB*P1/GU5JICF*W81<-CG5Y\@(\]:Q):OS_D#KYO%B<#9YT-4K4)7E,)?*3_
MNJ6A/E >I"L5M6;0G/IY(N/[_:".$N\P<%?M:.UUJL\HD6I'[=1IO,*N-H@<
M:S^NG?4!+7B^H+IQ#D&HZ&]V<L"TC^GY2=%:\5-!@M??879"I_'0F 99\RJ@
M,48!\6.G;2D@)K8X>3)PGCW^@&J)O8>MT;$GU\ESX $HV\<<[7Y@YQ7\?<$%
M+X*.4V#XU2A"M 2> J6-&TN=/W)P8Q/CG,C@,$'24WXE.2:\M_V6H336R4P!
M-+DT:2W/>=!^\JO52WI(R&T9AY3!2:=V*-A;Q\$XUJ $._5!ZM/[E=N8PES!
M2$L0^9^FRX0*6QJG_E?'#V>;1"VHWB!%\LXL!%)?NEYD<W0JW)^#62')-F?_
M=JAK3A_)J5>Z+,21EECTOV^S:([W8];39(>F'<E)WE-]8AISM$P5A))QIPL*
MP.3DIF79E_U8!(OT)NVN,'[M+T'&&RU8RMP ]!/FIT:35X3J4 [JNI%NKY/5
MQHSU3:[+("C&W!N V4R0>"U.+N$&H#?IZK,HKS0>*+'\U0O6N8_[4MMC-KDE
M[B$F)MK_5??"+'[]R-?7^FPW(3;P.M5UI7S.-4E@.D;[$B&!(.+.*^A(XNE!
M?+J]8!R<S<7L('4EF[9H#VM8H!UM2T6^/VKD,ASW\7/0Q, /Z<U/1(Y;V>5!
ME!A5:/3I#8!F1\Q)RJP-.Z9(LR-)G^ZE[.X!/%,)\/ZRI%$K'5UC;V>G">CZ
MX/E3NR3D%RO_5)#2)2@.]Z $Z[.>J-62MM;?PWW)BX*W)L]K<B]PP*5?$PA+
MHHZ9P[<LO=8):\%(8@D=><+L8FRV!2PFT,XN^\"7KP0Y[K8X?T<'KT*%:^&0
M]53SDAO[Q@RU@^(7D/AD!.U2T)B;]K#U*^.+_A.0#KGL] W 7I'5F2[ JM7G
M.M%OK3W8VJ(]_=4DSK#\CV3^(S6332;W]^O4]6IOHK5$WW\12VD([W^;CQ_/
M.HK V:TJ4CC= 'Z_3KSO9'1)F/,.JC#X/E>^N6>0?YA?<O-S3]'&LX\1$*2T
MB1S3E:D%TE$RZP80B^,@CQ 7TNX\9Q6?VJR?&;WN-EV,>CDH;D\\*]7;8W<7
M]NF3]&\U :#)=9&< _K("F-?AB%2F@J2+7*",TP=[?\=#G82%F+=W3H]^#4<
M<(81?V8?;<MERO&Z0_M$DT<[+6OJ-D(V&Z3"SI*;H%:SW)J#DJ>(M4U>Q)CF
MF54;4 T,,D#,XIX6[C(69U_'EUF:]<J/Y6UE*HQR\ JQKI6;.W':EN?*D*56
M6$O=#J[),'7NH[#<JRR%;.B+DCT=U+4JC*-:&/I>>".:=7C_I)*7.\$OC5B;
M-JZ7L^5MHVGDA(QWNK[369VU,FW5GDJ5',6078(T,5.J17D:8(.0O[7O@XRA
M^*DO/@NQ,;?2GA*<?EK0O-T<$A[#FU_X5I5&]\[_3%DY8;Q6A6,Q,2BNZ5-+
M<VWW_6!UY0RG1)+86-GI.*W$K5YN8L=\']N%%T^(/)-+)O\45-T JI%)KU-B
MV^3V>I!W_Y+3.K-RPMO:IW^TSXDO*[YR<MU4=7EA)SZUL*3\5=9>TQZ9MM0:
MKV!QE^P\#$8M$M[ U*%PWI.%C*F&<B6[Q(/,L[AS8GDMRY/4F9_RZ@(TU@W'
M3$)'1@("^!3]Q2^3&QK;0F*&T7+I^M>905P58" *&<&39V B]T R3S(UF+:K
M:"I6+3I9.H-[+G[D:;K.=ZH8M5E#CI#UU95(C]4JGFXKGXT/3LT3SAXK98D'
M5!:"*][)TKP&F;$:G!=JFUE*3W-EV_@++Z"C5<OX !>L2(OB$%((,IJK_3UD
M;%:&JR_E'OX?C%H]:IER^,\*R[1]HXO.L\^.:_/LYE4]^<^6DU1.M/Y1ELTT
M#%>\'S+2E$M=BX:G!J\CZ,#0[I#'5[).9F2UU[EI-7(D=,N_%TV[!8OE[N9K
M/O:[_XZ4O^;,F;?]U0U ,6O^LOHJ;,;T,J@]P/_]ASH<ZX0MVBT1-=,"BQ$2
MQK/H"6PXXB?/^11S.!.T:+F-G.[E\2[5#1"*)759A R:O7!AE.^%)@39E>R8
M,5=P)Z*N7"I>E/R^GR5M>%>^7GRB+)$X_1%_#\/%<]%2XV7'(J#/LA]B'+%*
MOJ*CT!:$*!YS[\^]5X.-+C#;R?HZ]X^R:YG);M1L97F?N7G&(8=^J\:"%=?#
MI\D/.HF^@$]^I@$IQ5TLQ?2RMHB%&@587C/.I)H,NWBQ]#C[\3%I]_R($%5^
M]N181HNO2LCM5DKE)7#T2V)#0>I7,G_:3L^*2A?WLF9C*Y?!$8K4W64FC0W)
MIBM"R:;VG+D/V/G?ZCUEE[X__[5LL<DZ$E&_$HT^,IN2<'&U,9T1V7\W8V,J
M\?@)^XM22U4?SWV.:(#"^R>ENM^)WH;UR:O%:.MT*)*&F-W+3KL!S!Z=0OR[
ML ZK^'C4ZU6,DU<P#X[]\OVE87H..U"4#U8URDUA%YF<(=#@"9:S&8?> &R@
MCY; ;LCGM1CCZ+_!BGC*4AA72%.B[5&9$^;6BU*+&[_TJ>?P+=^)Y6H=F^GO
MF% _O;@!9%_U%<Z.7R)/U+-$?@YK0^ARG+M[0[@FJZKMF]JF_P8R9; WSKB]
MB>?0W/8@SV4HU*VHU.M+)O[I_<9"XA'/V8>)VZQ+OI?+W([AB99()'&6L>R+
M=45=+;:DC;^LSY;-__0N^G%3]8QZ3I&WX1V3NXL=SC&LB+GAXZE!QW#Z83>K
M-)RDW"O0O(,.O'G6=D;.?6W4QFPZ1>M%U?+@.V'7Q5=M@=GJT1R-)LJFG-++
MU(0 6^ID;Z:S#Y/[^^\)(]<@%%@'DUK8].&/.>_9AL".]',A+Q\WE;-CE7=.
M6I17'<.;W$RRL0&;-(OND#T\$!J2;^:(J!*$;S:[148[6]?EQ@:7@<051#!V
MJ>$S6SFE*SO#/JX?FM-]V>^X>PCUG!U;TM]=8/[TCWY#3JL]3['U)YF[6&Y%
MTFNH'GX<1 GI>LEY8G,2,G5==%U0+_MT\P(I_#3GF]OXJ%6BJH)#20IB''1L
M[6G^9,=]SQYA?)[K48A[\$L<@E7KD0I(B2?J84R,%H(-<L@>NBO,;16@I.."
MFRR_OXDO2WLFO7T[K_/6W49M1;#TMNTHB1R2X9?P">_;S(JT4+[.L[/Q+J];
M[*.B3?W*SU^6K&[W^N/OM8[<F(@4Y.4?8S&$Q*T1AR*W%D_EJKM7'[5.,&EA
MB.*#C-<%I%H;LDQ.%[/M-=\VR>8W.:Z%/ANQ0Q\N!@V2E":KOVXJFH'?V6E+
M#,4)H?;<*?:R+'+I8/19PE5NLW7+IK2:[U1(Q:F>[WX9P8AD,OVC2^87?[KS
MU]"R(VCJH@H!/;$]:,ZZD)\[O60U7+6>GWN.9BVR*56N=#'+.:AD;+AK^=R$
M//.ZP(=V9K@F@?,.[/<GW>^\*]U$<;;.R+K<3\&K55+=C)!H' AU)0 A4T5I
M#_YMC[7+TY\J4#-9:W'X]-,.R49.'/\I]:*S-]".5HA//?7@=OG=  85.[X6
M3G7< &ZE73ROO'53D5+109Y@334AS\F_PD7&V[?M_GG$MYUCI4>CJ=,>A;$\
MF:2H3Q$\1CJ%HEZI7*\2H^'W_[#R3\MI!OOXE;WPJW9J"_DVN3@4,QLQY%32
MV!+&ZSN2/(H0:O5B#&JY!U3-K];S7+X!@*Q'F[3.]6+F(3]O %SG'!EHOU [
M=%.87\D*-L4<8SBS4:?C4;;GI3)5:T?:J,>['L%% GC [-PZ3&&:F?B49_\:
M=0/ *LO=1U4$'N@-XLA<F51FJS:BK'^^B5,=9ACZ)UEH8J!(LJ[](1GQWUT^
M:V@)JGF)16@/>W2>*^!^)3+?[PXI7 *?]#;#'R&FJWUDH0]>>I_69I:T!F:R
M.U&-NKU4,WZG/WZ1ON$ZH)4;V9MWW]@"PW78_AT[W)-+,.W#J\>B"9.;=65!
MJRXRR?GY3I6WE?%S1G&D+C#4J"SNB!O,F_)<>U_@^OW\A*%XX,DS<VB8 E,*
M*B1O58 3-NEM*2H _CM8>9AW8"3B-G1VW"]PR+7NK<9T3MC'+)I,)JA8?YVZ
M)'4,CNS-9<?85X%GM7Q<=>=[Y3XL+%6-Z+*;FZL2@\2I1C?3W_P6"=>!EZD:
M+E^T'9T<[4U>-_RVE Z 6%?#VW(A:R*A;<#H @R5I:4S9;R7T51C=AZW"A-W
MG8MOM#[OA\\+_2W,*6F=CQFV#A#V+*Q3O49M#59\&,:=LX 99)20]Y/9=Y-,
MPZF9;D#(//P7JG=D25/L3CO!'0-RV_SBH5E\&R3Y*F;+M_ET)D0'FKG!J+C?
MNKK,TSWUITZSW/KW+?X(=!>"O#F2V*9RC1MS.*-?)W\X3C^AB1-ETVW9[#]S
MG_(I/?58!])AL_NGG!E5^R)27#P7GK\_<*.GKA1P<+]+].7^(PX!!0K 3UN@
M97ZYSFBSD/OE(>>"4W5>4=6%2,O%>!^BSG*L%A7O3*K(O-<&[RB_ ;Q;T(14
M:CHY/ZFOF=;;47D^-,FE2?NRD\EI\ROUIR0DI"M\\A#.A!WO,JONJ';Q!,.E
MUV<E]OJ;S2]P RI,Z</A;#I)_/SA4;R+R0\$026O59>SCBX7<5_4EV\OFU]W
ME=8?MYM7+W&;J3J,^GOA\AB'.+H3C?:)-^FO\6.?*ME:5347*%T<2#(?OR;<
M,=)I#]&5DCP(]EHEC(>".QLS?7+L6237ML9N +KH#=%;12I=7MB_DN^9_SS"
M(E?Z+,% [9B#K/(.T=2?_,.=LQM ).[T=#KW6X?BV!PN:7W\2F+GK&;[-I/'
MR$E#Z$K*G"6S$K+.U (UCC9.W ZH1YM\'%DMM*]Z_6E3?0?N?A2_E;./LV9-
M!0[!)=CZ7@6F-DM)%@[=/"U$W'B%F8I)/TO/B3IGY]=!8>[P]>SSL:"1 X&=
M:3TSLV5%%&+\*'C(M=EO&]N.#[A>3A2KP=Y!'<C,=<]BK)SCLEC;R\"AOV$3
MR>?T^?LOJWT]PP[J#@CNN;ZL?[/%(G7FB<Z)2$%5"=O#IQL.2+N:6<D3%HX-
M!+QL9!8K<WVG]2QB;1_K%6RY23.<\O,>;>-U;I=0QD7.T1S^T2TY@(#UUYE_
M(;5#$GG4V,2>RX)E)_T;P/O=NH7KTA<E%K'9YF\WE1G]W^EN1K_@N*A*YW$R
M<D'6&X676SN?ZR_M,AZF>G"=7D/#? 0R\B?9X6T1&B69ED^D2&RI03GC['PM
M26GRBQ[[WJ\%!L4OD9C&6Q$Z,5YZ'=0.,<)7[13W#S,"]_<PK"?="E*)O695
MN;45X%C-!O02^PW .K#>P8%IQ&P#1)?GS&AP,JC10S(R$7J2/ _RF\/3_5EY
MDM*YN; VJ4BR)#'Z6;(R)E,RQ<SU@\&FBE<KP.8+;)4BD(1O^!:_$'.[R-%H
MQT-$12&",SU?/6TGKS[O\[XX].%.BL1948FC%6T+.LAW+OF'>?;CV67;DZ;\
MY VS[T.I0#&/@;Z7P+K#5,ZLS;[:=1$Z<*+N]-\]5U'9 ZVMW]IOTJ8R#VR;
MCZLF5&JU7D3Z>/8:AUR>Q?"Z-H^<SV%NM5[JO/9O\^D4+GVIG=4P^$INQXKC
MU^HDS'0-1 F>O)^[M>559:$4,B'^*X-VZ,5#)V#J8W>AMR;38O3\XR=SA7_.
M1)T"=%*_-3<S?FU"%^KX^]>/?2O_:!L<4]%:F]*H-/B,H,@B/U%D[WG0K:WX
MD/#F?^F*X?U^]__W);"9F&#=$!D'9PF9RKV'-@#]P+IT7J:8NTW#5.\-$]8<
M-PP+P8R=OH::=*D9,M#Y)7DUBFHT)B<:?W>E%XZZS(W!5N"9AO4;)H,\UF*+
MT!<3XHLL5NN:OZS&+E?P?O5M=)BZY1K)YICMK:2W_+^(E/R.U0:ORV%@N(CB
M0W(<!\<:!8;4Z84%H]WXV=MF1M!94OI^GM,)P?JY;,@OM9"0/"Z0Z,;VC@L.
MZMZ9.G3D+@G?] WV5_4__WD4,X&SP/*A0$"+Q=[":F@QUVD/MT6_VV^%-RM*
M%R\(-]8_6:8E0IURV1M=<@1>-TP?I([8NTC/&CP$<'D6QJTFR/<Z\;9H]A[&
MK5TD.R)4:0R^TKQ6!?R?7K3K0'I%>Q:>=9X$G"+4A95K;GWR[PXJ=Z_[]3+1
M%-2,3H3Z_8>7@D"WK:CJ4UTF.<K]OZ_K037>M:OGD-K$[FN]*WV9KUG%1046
MB\YILP&/>B9(Y46N5'O2H>_UN+[*):9D<G[(9+N;P'<#0 ^$,.%';\'G@6+T
M> RB$=&$0/TCMI"C?P"TNP*"ZJ_S'.81WL:#G<"GP[B9PP:]NF81';@Q8KO,
M8NS\%!)0?W69H4" 5DM!SW4&\(1[,S NJDT<<-0U1"^U$T\H/;89E+--F<ZJ
M0 $O&.3<;P!OHVX ?T/'VF(V<1PW  ZB^!O _E,@_HOIC-8KG>;6![P5'*7Y
M,7P/_V>/"/W_L@32T8FX.%:I&T!-#^12V<%2U1-/>0-("NN[ 9PQ)-X - 3_
M$)3^KWO!\__=@C)@Y@[D"[!2ZU;AZ%ED]VU4\3%'LAT=-F3[I,D+2^,F2 <R
M3YBI2=-X"]GY[)^\ 3I TQ2=W.?[^R#T"I)@HAZ9AU; R0/Q[&P_=]I%'?GB
MYA)UYGC.6JK"JFE1@D8;KKOUM6]^;CS#>8!<]OZ0H])#\@*NR55 "WYJYA#F
MW6:KQYA'B9_E@$*G\!]K%9\<SAYS-SS+>O;:3:<[9UXWZ$O1U[@P4R1Z3H$5
M/_[T!M ELN:.U:8WPO<ID#V=CP<= &VOWE[ I\X\\^RO#U$*3X^O;P!I,*^>
MV]N35K\N_Z*WJ8^<&"O<;]@PNY9MA%Y*3[9RF;(:J5MLQ.D3-"BM^\KMU'E2
MJ)2XND*Z^; 7,/,; *ET7C?1&@^.D\<0W\<8/C")'_.&[F_%'E@[G$@E7:VN
MJ-VYD ;*V[>VBLRE0E:-ZR\D_#:JYH(9$R6SK:Q].I ]EY"?(5*3(5Q@$16,
M49BLQ9^%WD*_IN0V&ANF4@Y^?Z)O% &4AD'_LB5FI7X>A=N@R#M!)& 2\ZF0
M!86,-'TKY3:@!-JO[<WAR]IW_W@^JR*/;'MO]JIH74"#%;66:/)28J8G9<#+
MQM'?_W'&Z2&8@>6^^VM5G5+7X(=L?K3!8WTQO)7#M];W\5\6E M;N^Y.MX.@
ME'N*<G^X9\6,7I):X*ZJ0CJO<$QN(1+$Z[-!4>R5?KZ+=ZZ\GOK:) H^]/IR
M9\_ >,2:[ ;@0B[6G\N-WFJL6L!I--9--5SML=B@$&$^FE7SVVG'TF^_] IM
MO.%MBD][P2[@GT"H)2DO3+[@@EK->M:H8W;55<5Q3PWC%AW\HZ#VV1VK,X;4
M.C ##\^G44! *BUMXXA4&@;DS@^Z5\XJ;?-F:%=-^=X'999=L__MG?^_2@DV
M@B#KT7*B@N(=W#,^UK3.^YB=+"]I UFE$Y[,""UE"CMA+)Y3]?XR[4?J?B!%
M ;JQMSJE^'<38JU#V;32VX23V%3Y3G'62\J')!K+;$2EAL:>I2N&Z\!Y!?=8
M,WST6AXS>,_ G6K'2<;<?(>.T6O'-UK@^0&S[WE3,UN4([N[Q/%F.H?C0O0>
M_#Y:+H2\J2UW:Z<10N$L6+<;T#- IUT&> * 77@\X>1\@U*6-ZF7 BFQ0M!'
M*"8P><_"491[D#44VV\R4UG9L"/L,[!O<^QZ8+6YEB#>T/1)?=3_*5<8]1=1
M0*]?2B?+M.@+<1=!43[U!-6'E85O0LEU5355 ?X^XYW$<B(>PD7H61R87M=>
M5+.XFS)%#?;.4Z7)E.3SMQ1.0KX'FYD1!H=@D34QEZRO<.#<WUDT,O9@_<1V
MBO.K-FV/TD>'QFR #IG&XZXV.Y6H\*^LLZU'C&"FEYB5;-I;C,YQ]W+E61!L
M9)(ZKJYT 'P2%+79?$]%_*2"S^[-T$@AP8_\%A QN/MU[6QZEX*(8WK/G<?[
M/@SZP\VS;%9U:F+'6@6LMM+K1\*ZF.5?_U.;V__+BM9J7;>QL;6I*6N+P4TX
M,XW8]HO D*'V/TK^[VBH/'Y3*]']#R]) M*^E:<U:&#$86..^F@R@V\_2T?;
M4=:6PYLD9:KMK61U.U6KS4BM;JS'ZMZU@LL1-39[*+V/<:ADX;,07(#49S!F
MB*Z?CW5+\#>K;=S11Y)R%-8!+WR>8-Q;AS_I4@!FF4/(^_RU%VL8I4_)O76M
M&$ ?[#U:;>,2#?\%N3X4801+=O>;/<RRNTBC;M%Q]7=>%!;<MK+)I>]<9,]5
MWO"Y1Z'Q+(\<9P?Q"?9!6=,0_\#X9@,S)I^WLTT?U#>Z/[GWC>\9.:MF]-BD
M5L;R5<P&GAW, GM;LC!>LAPOT--F4;RG.2/I=B7WN]/8(AX]T*I)K2B:2_RF
M\CN+'>UPD#RF"[NHE7= %ZDUYWT1GUM1.'"5.[8*T#K\N1179 D$R(@V$6JP
MZ/SO!T8T^<''!8=(R'OK"/P3)%'L*51*ISFR\[S"QRD0<+))ZE-LR4V+=R+0
MIMI6T+KXS$=J#3$,C%>8W=U:V')QM&]IM'?D3OYGG-*.O_?!8SV#+QZ_DU2\
MOSG,(R_Q" K(PP(D;NI:L>C'13;&W "+\,.TKQW^\$%!J9Q"!&<4&)VU2TSZ
M?6S$S5SC_+ZKS6Z11OJ*,%*]DNL6ASU18C!=1D$/9OFS1'!BCS&U%UH\9\2*
MMVNRY9X_NTC3*9[28VX;.L7(3^,*FK^X]5J>+00T+Q#>)#1TXG7B?A2:D.>W
M7)*Y :R+P28A[,DC.7I$/(!18^& U%/.I$VC^:MZ_EHR<[?1GU\"C@6JL8$L
M^V;I<2FZ+:&[:)<'<',31H;%:\(I!C4_CCARF/\]S&0[X[]FS]E3KG$IA?T^
MRLV81)O;7A 0_;]R(6QJ;:O*'VJY@R 7ERUSE;"FX(#_"';KM9UJ:'AB\;)2
M6I-SB2WJE)S-(XF:Y#!(<TU(MHN5=;IQU&KS?4.'S(IV147D#K-C4<85FOQN
MRU$8G&7:IG8ZR')-P+X1 XKAU&[/-@VY#J\+%7H?#"O]?=1/:,KSMEN7R*-P
M1S* +-6AV&FVUM3I3+>HL;&2A.[9.U62J._>  #@+ZW;OV4W@G$%#K"?WJ2/
MB9P?*M"H?:X!JT)_::%"4&E"*/C+Z].VFK:<X"LINN>&=O8LB1$X]1)PNW+M
MK'=L4<>4>[[I]YP[3%\OPT(+O?F5GH02WWO74#'4",36X453#$$I/W/9VX$+
M#W",KPHX ,T<5S5C/8(Y:7IU-E1:/PEF'/\/<-__$;G;5F #+\RAD&$^BA26
MW4*_&U4IYCL3)0_]WC)+8K;CC[5V&+?CQW@)XC$0G,4-('J6E0RT @[LKB*L
MAR8-@;S:@^,S3[M%%BQ\[LI^4#9UF7&)P^JL9D/O835M9HIC3GK:OHZ6[?E]
MV;8]G_RT13.N8 :H?2+/$?-TH5WFWQT ?W59T?Q>@.M*3JFY:N!;/^I.#U<9
MH@23W[2V=G(4RD_"]HQ*OY.+80/+K<! JQM N%_UTK#/9M<4UL^@U?,(8IM!
M^(#Y>(["SC!Z2X6/VQ2V#,^T&.\A)^A<'[UGFITIOJPV:P>;\M&@>?S>+47!
M8H"<J,Q(O[M 1M(PJASQ".>A&"OHMN\3Z/AWG/;/,:FE-2@^6N5+7&4M]; R
M/PY3N_W8J+N@_*/O_U[)LV8+F432*CP)DK@N4F =](?NLE)C#3TD*OE*G2[?
M^YVE2[TZKD1;%ZL,,##02>E1DJ9S9=R_._LZT<]][_*8O&YS\1(/2X0Z0N-#
MY(*<L=E7TN#LOG0I/)\UA=.Y%>V,1 [9V)%&*#%'6PPX[5D5[-N0$7'1HZ>M
MD#Q^&X#[@RPD,YQ#I"<"JQ3TMHP)BM5B K%*,/HD+L*'VH!GB6GZ U>2)R*#
M>3S7UE?6\B#1S>UC!%YG"+^-=?5<>G^PAQ5VN1Z?O?I]Y=D*(;X!#'2N0ZX>
MJM\ "NE\1O!C$&H)8(QU_5$HS+7Z.<?TJ0ZW;'MOXZ>:2<"+.C71#SU4-+;'
M3\T1Y#Z\C:[:?<8?N+I4N6LRS"O\GWQYU_?+,YF_9F?)\Y\ QEF/#RFQ?^SH
M1U)D&7GSOW__+^F.'W8#B$W'U#$]O1HG!Y.[CO9[YYEDB2SU!8>,N[-]">O;
M*V7P8O')HX9]0)#AJ$OWM-^['^ER=43D5D7 8*FS F":,U&M/ZT'[3P?G?)(
M@\B0Y#!JFR(+B_@7AN_. W)_-!,>GQF)6N@D=!;:LT'"?4M1J@"?K_\M\^H*
M>H%.*.#^X;!VF[0X(>@T)X\&:_ND'H_=IL^'@=+FW[>W$E[@JU^%K ]4+4\H
M,<#),+XYZU!RLST9\P'7XJ4JF@&;K >&,8,/2_TU*;L%^#9$D\P-MUGY?C62
MW\6&'O7E/FY(PS-U5*T](ESV/"\OI[%4ZCA\36L Q36J/#A/D_-C)&LOP>:I
MU<TT5+1 _RX.I 4&9ICSL?\S\.37_<M_DY7^!XOO<6@9YRJ9IL2@LR(]C+(0
MVPY"5\W%BH-QH%(5AX8)U0U7?[G Q^>%3]+Y#4U""<G(> FJ\V'T_8J-G&F(
M1VYR+U:A=\'9/6;Q?65DT47SNUE>?]9VMSX8/5:"'7_K1#C:&W+>??7/X\](
M@O_\Y3]K!_E'W N(?RG$S6G=JA8VS7-2>.5+X9RV>9)X.M9,0D1T0'W_SCL
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M@CK'XW;SE1HE[;4'SP<^W.$A_:D7R/BW(5>:,UD\R73]B4S%78.D+\0'G:,
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M>?->1M?>\B4+2PO+>YFVK2(<I.8M;Y-4H)E<+5RPWB?XLOQ*Y_)R6H,W_'$
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M5Y$:IKG9*UGVEF;J>>L81U+$QK:B=T)Q+1R('X.38XW7GE: 31L/A!6Y?LB
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M9R7"&,FN 3!N*Y*RA89%)\KC^',_>WUB ;.A8VJ3+D-*[I>VE[[Q)- ".N7
M@\+4"6+?#@3QNP:E0<;,:PD7=S!NCG^1QDTM#3%#9G$9L"OZNN]BPKNCZ'?A
MJ$QYBRO'$C2 $._WL! TWA)TO^Q??.6IRU8M%G@>LD=T(85CY/Q,&TFQ#T?$
M<]PJ^:50CC.[O[HMDQ9DN/A(S9:W\VU(0_?'55NJMKP8P3B9[I892NWU78(/
MFZ8_T00VOCT$#!.I"2SA,_'F_/;>:8!'?C58UX\&0(DJTP!?&4^C(^HWXH@C
M!<<I0 ,,T]\^)>U+:'+L0[/3<$(08Q-I@#6ZKZ>PO.M#O?O]Y&X/;!\P#,.'
MG)HJ/LQD]F^<Z=3O>?II %?($#52D)/*>>64%VJ ZK1.(>L6.Q,-P)0.VQ4!
M!%ZT5*!\PX*. :X@DE;V::I;HPX3<BD %2!9U)@&^!5 ]^\9Y&MSF;1C/%(N
MNUTWP/VPN;$Q^:HWVN:+3; %7?[EK=BS;Z4$M-UW_N4\7SGRXI=I@'\Q"O@O
M=Q:I$2^3^2]6P?[K?0$VI"O!_]6HD7^Y+?KBO)^P?QDC_?]A>^(GT;VA&4DP
M%X]"UZSPB>[65-V@K/&M8<VKK&) 1X%K!C=^K5O"_A\;[?^UTU]JN8-M*:M0
MLPH8X$)I>D3)CLC7W^1C?I'*X$+ACA28V!N2UO8#:-K\?V[6_F^QIZD8W.N[
MJ6Z95.B:XB'7JJCO&EA"[%D;S7@'K/&STF!SH%HG_\3\_\?5_\6>P.^+ME[F
M4_JLY;\O9D7-/KT__Z#BVB6M04*/P ?#<XEE7[YO#S.V_7>DR?/VT[8;3_Q1
M=AT\$^6$ND>WE9@,+\0(6)LRG#<0.ZC2^DFZB\]M!YX[$&$\[-3A.Q45TY\"
M-0=TCCMYQ[!BGT3=+HQ7\0\:+  8 6?:KI6AUXG-%>^)P0W#\S8F,3>]MB]S
M"L=#KO5!Q(X%38YG_-)KC7.N+IS&3U4G58UD5@@9:L^Y2-!/4+%M,PD7[1S2
M'7MAS7_+[L'J0,:-KU$7T@1=4DHKZ<_7AYJB9A:[JUZK#/'/;Z2M4_GA^!-(
MRLG]#;F2LTT9TF^\OV;L91G>*97VZN:G'],QK8H8@/&5Z]!MY'*2)2M($3W8
MIX2(@E(//IF26>M?Q[H#L[79KE*VUFR/-#2^JV?<2?H[9_\-O[E@M*815,3Q
M[9NKAD4CD2,[STU#+GHVDXB"!KUV,9?,8)[.'OC8^*G6]V_^[C4GJ:W9T<E^
MD\:E%AK@=]9)UIA1JM&7V[C@=>\P!7(&#1!SC#I+J20KAR\"&3VRI&*@%AAK
MLD6^897-6K-VXB/W\W_U'AIJI7Z*%+>QFG+TW%7TO-3 H=TY_]R7P:^TN3R>
M7_:M68S>R\>[G-4K<*E36O@<QC4/E20%Y]$ W0H5D/3;>+O>-Y6@>GD76\VK
M^8JMH5^^,PLDXK4<BZ\*:-( DU?F(_KQ*YGRL8LX!>.<8R^3,$VKBB7X3QK
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MB[/C[K-DJ'1\I@@V,'LD.51>3TTGCP;O%&.WUT5 BUGD[">HWH&(,Y2D?TK
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MT#8_@EL6!3DFV:C)EWR0C:;OJ,SQ "[A/>\]X#?2F,<G1-%:J.MR9N"_5B>
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ML_?^O1'<<X&7#WB?^Q5U@OR@7@9X&=86Y.M]D]HJ&8FW#U?LF!LJ.7[S^T+
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M%\NGUSR[?UB!P N"W=_F?Z9^A%B22.C[,H(H#!G$ @E(8RI2+#PB"3N[_W/
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M4$463(00^T3 . JY[Y$T\LW*<!P>8FH<40L)E)3@,V&:EE\MCN[VP]C-"F[
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M:AV*J/XB-DK;+2Y&?CW,EAS3-?K ,X96Y0SH/T%+HS.P4;;ZI;;[[L^V;JA
M )?K=Z?!X<=R0JZ@V-0"T6" "@UWBY3WL:+3I<O(*HRZH'D?\^PN<]Y)BKZE
M63YG<U$ML&9(XB!)8@^&@C"(./,@B2($HTAX6/@<"6I4H&_?PZ>V_*GD UK
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M *(@PC#U@A@R#V,6QX%(L##> -IY^-2(58EGL56PBY3!+LP)^@],5-_ !?@
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M4'.G?/-VE%')XZ"2NTQP^,)^G_5'(46>EZQ2-3ILE8SY*E8SF4@1>"R&E*,
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M)<[W7S5RD&T=?[1),M0M?^;+XEF]2IO^YPFF.&(I#.- S<H!E3"E(H9$_35
M,1:Q[W;%=(JT4V.2)KX:KM,5;H1VF_3>QL5R4<JL#S>_9++J5_$?@N2V[2J&
MM;^CY=985AV8&!V$Q*Z#7EOY_BVE!R'=4<PSC0!7(XFGM<9S ;ZS<%6K0=]G
MPOKT7>0L*_3)5+-TC(B?"*%K1'&U?L1235(>"2$)4C^-/8P2.NHD]4;"J4U,
ME51E$<:R0](9$!N1^W=.<F_9<::?D^SU!YIR6GJ>.5MM#VZ$24TL;Z7\0TTF
M!T%V/8$<'FAJJ83;*9$S1 /, DQ@' 8,HC 0, VH![TP1(BP4 @4VE5+'TMT
M&](:I^1ZNW+ N!.*K=4'GF<&M.3TIY^>R?X3F)EZFFT:$Y:M\'^,>:RG2=XK
MP_[$6>]"HZGWB?2C;[+BMTT$AC^C(D0DH00&:H*"2!*FRV9RZ#,OQ"SADGA&
M:1@F@TUM =.*%ZK;"-5M89^+U?)1"6 WSW3B;#8WN$)O8#[?$A-H.<_ 1E)W
MG&L"AU.>[!QP5&XS47V7CXSNZ9LI45<!*VO\5Q40XI!$"2.QPE$[N6F20$PD
MAB@049"$8<P\JPV3/6-,CC$:$:MZ%6?@__9^\CS/!T^D+FOQS\#WSM2/:E<5
MD.?5PS+/_B'X/X/%LODI%T5VOR#*K3T#65$\JP<N<[!\7A4KLBCK5Y,5^"A8
M6649A/X9T"^LOD;]W[--F7AK.C,V.M$@ Y/0QA:WE2U* <_ 98FGR[2$@R@X
M3C)X.\[(*0,'%7V; '#XTMZI6$\B7[WJT*#5^:)TD<HPT.OE/&.OFVZ[&'L1
M]T2L",='NOV'5*R#J6[_X1.?ABBPZ_IF.O#4J.C+<G$/OV0ONHQ9C_JAQGB;
M4H5[% ?GCTIDY;IHH<O$I[78ZH>EX.#7^O^#]#"V1<UU4I/9X&/G+5E!LB<U
MR>Y^9]E'^9(_,^UY57D74I (!T3"R!,A1"@.(?$X@2F-/4H(3OS4*-S)>,2I
M$=3^;(RGM=".\HMV8.^FJT' ')JG#F83;:!TDT*T ^7)F4/](7WOA*'=MW38
M/*']./5(#]IYT'MG!>W7RR 9Z,"-[Q,I<+59E=7GR2SQ_#"* ^@)Q'4D:P!3
M$J0P1)RE2#&[C^+94[EU=[LB^6J<>($W<MI\<+O2#O?-M<0\ U3<9XLRDHV2
MN:[F_GYA V_-+''$F=#%P(GGJ>4&22%!B0\Q)DCZC.'4#VHS?UKP/XR1&UE'
M,K&H]C,F:-]QPD).LMCTS^76)V];1I]:6,A!(TSCE.V@E'^,X[1C(+L."SD\
M4(_%7-.$,A/%U:+J8_OY>?6<BYOE*YGK'W]3G] R7^D]W#LE8D%:/C)B0<J\
M-(61B#Q=Q2Q0GPD6,.6(R) CS",R6XA[O=5KL,X[21@C8DDK8FF+-. >E2B*
M/X/GC<A@M9'9>OUWFJ4,%H;#HS]NTUM=;.FJZNFFEXZ5+F"M#&AI UKJ6*\F
M3S.,Q3)S- .-M/YL&VI9]6;3"U%9&2IOE#KK_H1<+4Z=H-NY:CUMA/&6LTZ0
MV%KGNGEBOP7PC=#MW 3_1'*]U"KJ3K\IE1Z6F$&)< A1Y*<0!YQ )I/8%RQ(
M9&A4%:E[F*GM2IXS]64_S_7D!SX*F;%L9;<..8"FV6+B=(P&GCH: 4$CX0"-
ME+M!<.J1'QAJ5+>Z6]U=W_C(U3T<W ^_W%[HAEMT606&G-_GHO2RZS<W9ES0
M"*70XSHO.]1A'"%%D'N,RX@PXONI\4'%D<&FQ@9*7+ E+U@+;.'_'$/8P/5T
MB-O #/$!_ (.@G:<+>S1L_ /':(XD@>H7T"VA25I9';EUAF"TNFX'7O&>*Z9
MH39;SI?I/3W(]7+!EH_BCGP7Q2;'L>H%((-$B)1+R$6H_"N",<2^))!Z >.Z
M&WWJ,V->/3S.U"BUDA24HK9RDGNT7NC UH!1W2 V,)F. I8%@;H!;23NK,%;
ME>#QM;BN>/,X%IV4V7'[>&QY7(<MHC2XO&_W;[K:I#N<?\^*F>!>@$+N01G)
M%"*9*K>3DA0R' GN^QX/_,!F^?EVB*DQ8UE,>R.B;;_O-PB:+3E/PV5@_MN!
M!/RJY7.XU#RLO..&WF^&&;F=]R$UWS;S/GAE#^^G3%NZ)OEJ(?)F5PE1&08)
M5Q\S2R#R$P_26$A(DI"EW(L9QKZQU_/V^5/[IDL)+:;I/8@9^#*GX3#P-URE
M8=;2]5D [L'$PF4Y#9N17)522%>.R6&-.QV2/;>-YX@<EGG+ >FX[/0.+Q]%
MGKTH0[^(#0-^SA9DP;+%_3E3OZC[N82(HIAB*#GUU,(M]"$5)( !CA!'44"E
M--H0.T&&J=%<V>PM%TQD3ZNZ?TB[ECI?:P7F]4'':_^^+J9V,O-_!D9_8'+=
M[MFRD;_E-)V!M0I@H\,P;5DL 1RL"8NI'._6<L42J*X&*[:/ZKM"JQ*ZU.*O
M=5;Y19!"C]*J[SR+ Q_C,(P@"6@$41PI7X\Q#-7/?3\*D2<9;4)>[FS6;X8"
M] ASN1O#$WP2>G=1?81SH;M-Y+IJ(UQ*^*S^07ID:)E;Q'0AZ!+@L=:'=8JG
M$AJTI#X#M=SM2$6'G&>-E>/EI.GH(Z\R+4%YN_BT?4"/->G7Y4)[*U5<Q>M-
M5=>A[""H!E[N#;V8)0*G7-$:I S%$/$40>PKWX]XU%,+6H)]EEI$\?40H0>I
M#<QG2@G(2K>O4F-=(B.O%-&-2I6W7@8M%?NBEBQ6@'UL%@>"!8(PZ-$P43:C
ML?+2(P$%1C+Q44!C+[28AD8TW!BST2'K#6P4@[V,H3 >9T+ZJL,C-:ZU_*!6
M -0:@+OEP7C+@;&WV#,9V 8C;:IH6QQCJ#*D<I>97&W$G !CYTY-G^>.MY5S
M@M9;>SVG/*=O(:S'QZSJ.JL;5"X7VET7:AVU==RUKGS 0H)CYA,H<2H@"CP"
M*0D8#%#$?1P'09)X=J6Q;(:?W!;01OJJ1VQ;?MM"659V,%O>#(?NP%-*)[#;
M00%#U*#HAYOCJEM6(HQ<AZL//&\K<_5Z2C^:^[;(!5O>+\I0<O+]@U@(F>EJ
M@HHF1+&Z6K2.^3]]U_E78A;ZL8=QD,  IU)YTXE:_.@V/2E2O!>05*V&C([M
M3I!A:H375D$'F0!:*W$&LEH-L+G"C@'[F,B,!@<&?F NW,)<[_E\6&/>:* 3
M9;;"IFHMW#'B"1 ZI<4^<HS*C2< M4N0ISRJ'TM^)EE>%BYK;47](H@F8GZU
MN-%MRG4UB@^DR(IOBR4M1/ZB(Z$N%T_/*_5K!9&ZJUSB?,D6XG(E'HN9B'V4
MIG$"?4$P1'X40YI* KT0AU[*(Q0H"2QH= @AI\:S6L>F=E\[(:[14W_P:TU!
MJ>H9:"L+2FW!MKK@5ZTP*#4V#$88],TP8^_WMO? ]/Z>IK:>!H:TA=-Y8A!!
M1YU(AH1Z=Z89=*P>YQ6W>N/C>JE<RO)OG[,741=%NA6+;)G?:HD$_[I<J;7"
ML[ABJR45^=WOR[N'Y7.A%HQJ07'WN[K\M8Z="J1@:AYB,.)8E^7U$,2$!S"D
M"!,L$U_$1ML6@T@WM<DG^2F)_A]0Z0)J94"I#5#J@%H?BZJ[P]C48%_]/2TU
M\+11*@1*W4#U=ZU=4W'\N/64DJ#1$B@U0:5GGUA%YY:UV+5_3PN/M*5?6?>I
MM'11_EUJ2S_5EBXJ2Q>UI1>EI7G+TJO?]:%D;6G]WZK4U]6&_U 6Z#P-<#[H
M>$<%0^&U=8XPV"#]UI5JH9KK *"/HOK_Y>*<L>7S8E7<Z/C)TI>8Q2(-/!T6
M'T12S=$ZV#2-/0'] ,>Q1V.BV]0;!1S8##N]((-&QBJVM!32;JUFA+;9VLL9
M@J.E#I9B@A\:@7_4E4O7B-X<1]1Z260#D=,ECM' HRY9;*#878)8W=MG25&>
MG6Y*\Y^O>U!<+EJU910+25_Z@80A$02B"/D0(TY@Y/E!FH8^1MABI6 VZ-06
M .?W]WE)=6 II:A+5&?,)E#&%&X3)]X]B$/[YG6P2RESM;<#-E+K,M4MN0<
MU<9_=@_N6&ZQ$Y M?5T[M+I=6,-GC>B9VFFW[7!:WMNS:I>.'[^2WPI1MO>X
MHE5=H,O%I^_L04?*?E[FZYAS'4.[WM!ZG05AD&+. BA\X4/%X@DD,0]@PGV&
M>8 #%ELU=3M!EJGQO4&8?NM45WM4HM812+7TK&Z:;[8.+8N'G6!4,R]V)%,-
M/*O<-%91>E3M;4"CB3;)I[9)-A8MU5D?+!S.0+.O6'8ZJ&[+FIT@S[BUSTX'
M[DV!- >/[-E(@#T(_JRYOY7(4/5>.E_PUG%"63%C$[\F2)+2-$YAB)5SC8A0
M;!S2"$912$,A&?5BJTH7/>68&A,W:NC<@=M,\:W,F.[#I&M"+Q=E.)SZS58&
M4*5DN;'WI2\%][6B&?V.8)NA'?J660S KTL5#=,?ZT0TW19W[RG+N"7<3P/L
M3:'V$Q_78^_BLU 7DOE5_J3(_&/^?'^A1LU6Q2SBGI?HC%,>I3%$$0XA26,*
MXT @+&F (L:--RL.C3(UCJSE5/!I00%7D@)6B6JQECZ(J<&.A NDAHXJJ4&J
M9 1:2'#A#B2+'0878(VTI=#Q9KDZ+3N&1N>6P<&;Q]LC.";_UJ; T8O[IN6_
M3?[7W/OO@M]OI?]OPLC/J;J0L)5Q6GCO$2;$ 7LK8U3.2JU(JS;&5E)%HXS3
MJF,G0^HXG[R_/"-GF)\,W-N<\],?Z;BC\9=6N+ GJ* <>I1AW2/4@UA7C$T8
M366,9.QQHQZAYD-.S<'I;,)[0@RO ?AF].@6TH%9T &:[GH8OP%HG.[%7]XG
MA-4<!N..Q6_OM",B+K+9I\4J6[W^3<SG_W.Q_'UQ*TBQU+ME1?$L\ED2\#CB
M2/$/]@E$OF*B%*L_?"]&3 0$1=*(?XZ.-#7:J80%6EKXFQ87-/*"2F SMCF.
M<#?).,5M8&[I#YDQI1C#L8=)"L%^NE^^_*R>49+(WY'^*ZS^6C+'\:>/0AC&
M2C8\87[#B8E0=12\IIZ_9:N'-\'OQ7;T^W:H_'J3_2\D6WQ9%L7E@LV?N=Z8
M+XLZZEW=7#R(15&Z8CJ9:Q;YA(=$T4_$O1BBA!'E_J0A#.)$)(('B#/9HY+8
MNRG4([YNC%HP%]596;8HZ_5(G8/S4H80+*7C*H[O]RJ9.7/3?C/&S\%JP0!^
M5SCLR;4J=I*MSMXF:*WQ. ,:$?"#QN1'T*"B7[RJ1O 6,$T2;W7U &E;[V7C
M87*[1M?F?1+ WLMH![/$WDV@ 4O<K'<(@R@,8AS'$$>Z[AV)(D@]'88>1T(2
MWV>& :"]1I_:FL"\#LOQ+4,'MC&;T09#?.!9R"78PY2\&71'UDZ"Z16\.;;K
MVN\AIX;EW(I[/>2->-*-5!?WEPNYS!]+7O[P6O^R:HF4H#AD:9*4]6T@HG$(
M4Z:6'SX6'B:>8'XD^H7D&,LP-?K;"L>IY 1K+4!+C3- 7]=76#6J.L5BMN$W
M@]AAQ- ;=R8X(>K&&L2!(F[,Y7BG:!MKH Y'VM@_ZMWKWU1?*(D\YDGJP1 '
M3#F320IQ@F,HXY1B'X>QEUKUDW8MX-0(=ZAB*'T8V?G+8+D?\PXF'G&;943K
MOF>5F^%F N="_E&KVW3.(8.-TR.,4U?V59[_Y>)%%-4ZX'+Q"\E_$RO]Y#(E
MORK^OSZ.3Q,9,8^E, @P@L@/*4SCB,$H%G&"I? 3WSR^TWKXJ4T.98UQO3!N
MJ: W4C=*@(T6/>(D>AJIF]:'AW[H70F-^OD.ZI?OCKI%!.J@Z(\4FCK NV\7
MN-H;Q,Z(5ONGCA?JVEOCK1C8_D_I,<.<YX)<R3+!B]_J-^FCF&<O0LUU,TH3
ME 8I@M)#0DTEQ(<D\0B,I$1QXC&?^])X*CD\SM3FC$I&4/X:\$9*\(/Z=(J_
M [DZ?,AFA:[!'. &LX')7@NID^IKV$HYP5I0-UA9,+<;S$:BZ!*[I:S2H=^\
M<JX2"(Y#TDFX';>/QZS'==BB4(/+>W#EASPK5LOY+Z^*A6[__IQ1>K&<J]\N
M\_(].;_/17G"6=>DHU(2C^ 0QBGR($H3"BDF".(X\*CTTC *(F/^M!M[:IQ:
M2P]*\4$E/]A2 *PUL* ,2X,84.YP, ],PS8(]ZG8: FU!6,/!_E(++X7>K8%
M/6F4<,7I_4#KY'G+1X['_?UTW9H/>CZBQQS1A*A<?;T1.CRP?+Z:BC9[2>O>
M3'</8F][IK_DZOY9PG L_41"D00((D8B2,/8@R%/HP"E?ARDOD4S15=R]0C.
M'-I?5U+I;>!\HU?I4S5!0_LZ+9[8:-&9D0UFI%$--\Y<U0YOO/H*6GJ5"XG6
M-G^K':!2[F!+P#-0JO@>%K28Z-[#DB--@:-;U&ZV=(U\YSSJ;+#Q9EC7^&S-
MO<X?WK^;<=,'IVY]L],E<=,#-)!I2!B-($EI E&4<DBDIQ9RB$=IE!!",;5O
M9&PX^O1FV'47W'7#+E&IH*?=5A&W 7L:FUJ.BL27J5#V\H7RFF3B0Q(QO00/
M!9.<B9 ;%8D:RFXCKKG[6.T=+!;Y:9+$7,( 1QY$!/O:SZ703S"*<" 0BZ+9
MB\CI\IUMUI;A':PVG 4,G-#A4!W8U5PWFE[WO:MEW]=I^H06TZ98VW>7'@#S
M\1I+'R"@W<[2BG"&ZBIM"9])0VG31X[>2]I2UWUMI&T?T2]H\M/CTWSY*L2M
MR%\R)FX?2"X^Z+UZG<FCQJTV9>:EA4MG\69=2O9:Y-E275>L6B?[<1+P)/0%
M%"P-(8I]#M-8=V$-_5@DS*.ACVQB)AW+-S7/H-0'TO+,J:T1.,]SG>-:[A'K
MT.C6==?DM?SQ^>\DYV?;MVEM3R@RXOIMZ)[/)F#C@>>\O6;;6/:LF0*KUCX7
MY"E;D;G6ZPR</^K^"0.5.!D(<:<ADJYE'#5"<B" =P,DAQJFQ[K^>KE2;W1&
MYA\W"?B_9&H-LUHNE+>5!*$7>7$,!4(I1.I/F)((0<(Y#3DFE ?F$2S=8TV-
MX]?2-DLYI7.FS:%^\E210E'6_6Z7+GA<JV/A 1^Q@<'JPAVR S/K!M26I."7
M 5"S6">X0V^D=<$&Q?WOGJL5@!DPG1[_D4>,Y^&;Z;+ET1O>TH-U?WF>__TY
M6YR7_3G.%_PC><PHJ?Y9G__C($Q%BA(8!YA A#P"<8 9I"QDJ1>+,$J,,D,-
MQYL:^]82@TK&,A:Z$KK^B051&(!M0+%N(1R89H^AUR=^Q0!&"\YU"^=(O-O[
MI;2C77-L.JG7X#'CT:^Y3EL4;'%;SXT4DB^RQ7VA_.K&#<_83# 4"^I)Z!&?
M041E#$E"4IA(]8Y0(1.!C'* .D>9&N660H$?=(8#U[$]>:'[W8)""VP8LMV-
MJN&VPJE8#<RMC7RZ[7.UP7-6IDTRA^O\+@C<KM;WCC3NFKM+V3<KY\Z+^U&
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M8VF#?P41N[%3'9&8EQ>0!&8^R;=>OUME.VSU=$S4APQ<96ZG,C5D2E6:7[\
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MQPV.4PIRO-O]".-7^4!7==CLW9]YN4R1$%% ,DB8-(>V"$.2,4T^:2(2$>.
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M#A7*3=3%#X]8.1RX^<%LHD.V[O?,U_E:/R2=9VH=MT]WCM:OP]'9F<7EXX7
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M.M8XCMY8IU^2-^^W8PV631L>^X=Y.>"Z_RDO^C^_Z^7RTZ8P37J7,N-*1C2
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MWV7^R)[U9KRN 29(A,)$24A%I"#".(.$XP#&B0PX%4DL>;!;[>ZMV\L,%VC
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M4G=F( S'U"F]S3NVDZ6WG6-\Y<W5"O@ZRG?$JR?;S>Y94V:[.6EWDNWF=N\
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MZVVMV[^J!S4E-85N_R:*Q^^*ENY_B)(\BOJ7;Q5/[7Q3%VF64A@JPR7)PQQ
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MD000PAB@,"(Z&3&"$N6*EZQ8R;#?N1%3*^Q=4(N[B\8/?M<2![7(EB6_30?
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M=8W)H.I+FU;Q]I*FIN56=9V)IE.^?JU5/]#Z!RT 7LN\3CUNGNY\/ O_2M=
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M!)C;YO=K5R2BV)<+M<YW8S<$9ISE$UC/['7HG/RU/2NM?0OW,M\%.WV 7)=
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M "9$ *3^#X09)P02'%&1V!#2]2[GQD<]B8-:Y+KN;2UT7177CH4,(#<C(;=
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MTM;XQ+T$QR3*8,!C#)%'4I@BFL D)1GS*<US7VNWVM?XW'B^$0\*^0S.E,>
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M&5?_^*DL%R<__7VQ_,?T:P#XM\U?>K'X<K:<?OJ\_DDP(6[_Z?*?(]<J65N
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MI=.3T\TC\(=2'!<[A3M1'*,HUE@!BAB!J)*M'>F5"XZ"W-3F-GAG$L?-#S0
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M?6RU=V".#V)V.\+E;F58FIW6^0C7Q;H5]81D@-+S*I-09XR3^?$8##!E@J0
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M149<EU!'8/+Z[!K!YZ*M5#9F;(6J>\@9]XU/<S0=JH .4/3[A[\MON)ROIE
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M ,FR]:BC<]O]@(_5G>*XC];'!%Q/XAA!%L7#I>]6"R9C(MM%D"6LG%#@HRB
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MEF1P)Z!K;@#\H7S^1H?JM[#$_&K^O;:@VIS3F];+O_VZ^9W-#*JS6B%^ _Z
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M.QE# F($Y^%&,3Q,_-H(^/!C'<PX2ZOIS^GJU]H$N&69N2)(!10PJC9_(6%
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M3!=@RI,CZE@!EY,!YG7VB='=W:B<H!U-P\:-ASY P\-D+ ?F@#+ =8NAZQK
M+5VR_N'OMYWFB35%^VPL<%<O[" Y>.,4!..*<IQQTVCX]9$)';8+XM!':Z2
M.N'D\DONG*456;^K7W_."#]7!8&WQM6U#/GMLXUCI9X?PIUQ!.<DBT67'"%'
M.FTJ\5)K)$*->G.KL^39M-&+)QJ<VVB+#Q>KY2K,\G3V]=/\_/S-?%%_.$D.
MN:YM45R0NCX:&'#1(: 2]-?)1AW'><L\3,])A^%V07;?ETD/\'@!-MHM+ERV
MO9LD[HR)QH"/IH!2/D -.$+.3FH2B^2I3=U+[Z2<Z#B7'O'9[LCL 9:]3\N/
MM;GWF:[^U2C.S%TS]!^+^7(Y"4DR[T4!=$G5*?818BH9+":?B^$LL7'>*@\0
M<Z)S9<9[;@X%S!CNF6I*OUTN+S#_?K$@WE[2<MD8]?8C]U7OGSPIR'/FCH.P
M]$75B8!!>@F%:U%D\41X:7,D=M[KB8Z1:8CXMN+>'=#^$M S_%KMRE%< \3G
M@M,5V;[71WM")FQ"JV*-B0@ZU8F!$RC .*T\TTX;-;*VZX\3<Z+39,9[#1P*
MF!=Q:N[;D$Y&'K .G,JU,XGA&EP.'KRW+":-@O$VM67#.!SCZU(SWA-S&%@.
M=#A>ST9W8K9"WE>7[WH<2I59V<A,89!&!0,IU6$.6A;P5N6:2I0#2]+9/,[>
MG+O3>M()-".)?[6 U1A\EN-P:((Z98P^0%;6DX;4%FI3+0C)FXR,:2].^K2]
MF#A:$YP/<RQW MWI1-X>'?7>Y07X+H.D)S&I.M (2ZGU)[7SO560/"8FM5*H
MVQ3[')'(%Q.I&\7)' A\IW!3/L>:>QV_G^2.XR)*EP(PD:ON,AYB# J,B)[^
M1\QK]*!]7#I?3%3Q)$YG.PB^A /Z0.SI:07&)8G29TBB#@;,AD3)C $NO$7G
MM!.-"L*.3>F+B7*>Q"%M"<-3.*8]&?\\%H<J2K B$EO0UYYE-H/E(1==@N>A
M31N',7F<IQ!('<6A' !T+R3T>C,!]";0=Q.]\X5IHYD',O7K7$,;:G-U [&^
MX">1$76;[N--R3KIRJDA ZK]@64L-]D^53#/*I5/6'L_T=^O.\,3:R[">2V/
M$1,O4K&&$^*+8J1@M(! 9C@DAB8IB9[KAK?:<8D][9AJCU#OJ_KJ2+@;R]'L
MY[[?&LFFBTLVTY6>/1I04@3P*3O0Q7## P84(QLV]AQ)IQT@;7S,!L?0"SA,
M&Q.Y-G#;9"@PS8Q.GA2)EQX4,Q$<YP&R4Y$EYXTIXSQ$]T@YZ1+@(2W!PT#Q
MLD[%TX^82J0ZZ!-<4H+<7E9'LI':L-$XQU16MK3I!WTD D^ZTG<D)Z@W (WE
M7!U@W3[.EL>L6SXIR7@6A0)3:EZVU!R<U1%L<9YX93&VK$PY+K&=SENS@6M#
MG[<1 ^MEG;V[)B^?1))<0:%!1A9 E2HYSB241->^8LZYW##5I E-G4Z2_=^3
MU HFI]F.XA.2!*:UX<WZ-_^<32]Y<]5]H6$+BJY+'Z'MQ%Y<&$>K"5%R$8@6
M5%CG+9%BIY.3P$J/+&A1#+[(5A/7#=WW?^&^;.*N@@X!I:Q#HXB!)GF(@AD@
MMCIC1!'TGS9705\DG'1#B5WP^_APPV."8 26T>7.Z9?74]!L5E&4HL%H54>B
M6P071 8M65+)Q\ :=>&ZLXVQ#"T\*A2VN^#O+9<1@&I_QMV0/<NU-=/[\!TW
M V.*,E8+$2 %78OFB0=1.6)N$"D(XVR4C4K*&U S+,0/ %=O26$]27H$:'_
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M^K)FE?]*RMKRNVF<>%\B$U.,2\E;R+4#NY+1D5=N$Y00T)1H5+!M;AK[H7_
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MZ&!T*-HN)(;<AV 2U$3#.FHMD<=-=C &$XURA2327^K*+BJ&VU7ZT.RS0#E
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M9=VIU=;^51[WR1BF:]O)<'.XR$>!F+>XF!'HEQ_SXN(KWKNSY=HYU&0Z>2V
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MH=)LI5LIY]@4-)7PJXZ5H[[:O5*3]3Z)*]N\X=Y!@3]7>5ID.?^Z.DGB9)H
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M", &  HF>%/8;EDDT4OBB,,\M>(;RA',AUR3E!JATU=-U@N*S<EH:<YYT5H
MG+4=J0Y-TO55=-7:N,#VUGB6.BT(7>4@>HU$D,'!Z?;8,@(2G"8Q5GA-8:9:
M(C)51,(5O\S(JUD8*Z4G2=4Y!ACY'G83P=NUI]$8F:N<&NK&5DX\L!L$PCPM
MKM=KGAC,+%J%U5:8(5D;SX8SFVPG!>:]I.QPQ)R-+L*NHPUU2]J<$;^"CW,L
M6!WKPJT$ 6G1R'JIPBP00E%%C]!(;"3WG-+*1K0U?R3IA>_]?KKG8Z,B;6Y$
M0 _&B6*B!>]JT9\L 8@6NA:VY>2RR^&8CPGN8^7]"8I"!IH)ETM$FOI[3,6
MC[5+9I^H) ^!RCQ7'*^Z5!WR,K2YX51$-*]?DR2T&_MR\]M&!A*ZYA,JQMRY
MYZRZ<,4L3O'AVEI#P 3A2&'&4L+9L%4'[%N8$YX8VKU^*FCG"LF]F^7N%9N"
MDDQ'=8_Y;*FR".*"+=15^9M-8[,)%-6!4(RWIM"DMFQI=R8F:I4!5%G92"))
M.7I5YW QW HS9]^;)"'6#!<<=',E%)4=QS 'P5FA6&IO#- E*R1H)RYU70+H
MRE#Q<BFNUX5TRC $ H/S,N:_L !4D]]D4&AK@Z[__1^J1.:6#P34L#UM2X,9
MVT\!,[!F'(FE<"9  ^%XRBYT92"$:=6>IT"CJ06:82NF\J*=PMDG<@HG7$S8
MQLH5W/1+0<4(G-G8_<G;1FWMF24F0W5>8.:=]A5=)1REIVLFE@)RSS16:]D!
ME5HAV*4(5=8^=/O!DQC/L"QU$ ?- =NXVU^[*Q _JGF6;(DHSHH<W81H- 46
M&T7)54;FQ6<+^/TMX#L/:@''T57X\PL5! ,1#EYOCC:%W-I:E\/!]GJ(:PT'
MHYWMS:U_;[VXO]6<(@+JY_;DJY"WD_?#8^_KX=GQP>FI]_5?!U\.3CX^9BR;
M[[!DE"WRQ"?IGKDV4*ZASG^),*X%\_/QJ>',UX41!5DO6@DDOVPS<XZ#(1Y_
M#5\7E>6J-N*!*6/G?0!5HTDK?WF7<PD_0R6PY,8J;&8DIIG<-;^\!8%F&HG9
MKHII2^BEMRX8O8+]HTC.0$0:D@B"^'8%K?UUAM@<P#0/S9?U[3[=6LO#YKVM
M-_V=]>[;Z_V-SGO?:=@UFC)/&W8FFXKXYQ>;+RHD)D%@=S#]YFVX*(6R06-S
MDNE-GBY7MACTMU]9UT@]TA<?"36U)YGC-V0!J\MNPXWU)=@([I^X,*MM1_WW
M,^X2277IN#J=]ZN*O*.^]TD,0>"";5#RSE%>B[?@8U!Y>,G-9=X]FFWQUGFF
M\D@O=/_DA,3Q_8\G2[1 I/V\OM]$7&"1BHV![PW6!X.:H* IX#-Q0W1/598G
MT>K1#%.R3O\JU'!(-7= W_F;4;D##.892E +C^"#2X08%85;VB5:Q.W@?S_[
M54;Y3R\WX=K[(E-4XM@*&%VBU7=3/J^%])& MT;"[3SZWX+IY>60(K@X3U'S
M6-7;/*+_WG['3:=/[:H<IA',<0RGI:GCLV"C:%/UN;-%81'7RTBF F 8H$$-
M=;VARMP[OY%A7@/$VC )9_!CG$^B7_X?4$L#!!0    ( (:67%3.9Q" X (
M .T)   7    ;FMT<C(P,C$Q,C,Q+65X>#(Q,2YH=&W-5EU/VS 4?=^O,)DF
M7DB<I.E7&OI BS0F!@B*T)XF)W;;*YPXLMV6\NOG? VZ4L80&^M#FN3<>WW/
MT7%\H[WQ^6CR[>(8S77*T<7UT>G)"%DVQC>M$<;CR1A]GGP]18'C>F@B2:9
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M<BTR,#(Q,3(S,2YH=&U02P$"% ,4    " "&EEQ49A/,C(H;  !D.@$ $0
M            @ %,"00 ;FMT<BTR,#(Q,3(S,2YX<V102P$"% ,4    " "&
MEEQ4J(TB=WLF  #K@0$ %0              @ $%)00 ;FMT<BTR,#(Q,3(S
M,5]C86PN>&UL4$L! A0#%     @ AI9<5,=^,(;W?@  X6,% !4
M     ( !LTL$ &YK='(M,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( (:6
M7%2C'FDLDOT  / 3 0 4              "  =W*! !N:W1R+3(P,C$Q,C,Q
M7V<Q+FIP9U!+ 0(4 Q0    ( (:67%35_-P*2SP! /<L#0 5
M  "  :'(!0!N:W1R+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "&EEQ4
M_?:F!N.S  "M* @ %0              @ $?!0< ;FMT<BTR,#(Q,3(S,5]P
M<F4N>&UL4$L! A0#%     @ AI9<5(Y5.MNX!P  )Q\  !@
M ( !-;D' &YK='(M,C R,3$R,S%X97AX,S$Q+FAT;5!+ 0(4 Q0    ( (:6
M7%0O#XF<RP<  %(?   8              "  2/!!P!N:W1R+3(P,C$Q,C,Q
M>&5X>#,Q,BYH=&U02P$"% ,4    " "&EEQ4C5POFOH%  !-&   &
M        @ $DR0< ;FMT<BTR,#(Q,3(S,7AE>'@S,C$N:'1M4$L! A0#%
M  @ AI9<5#%,-)E')   S_@  !@              ( !5,\' &YK='(R,#(Q
M,3(S,2UE>'@Q,#0P+FAT;5!+ 0(4 Q0    ( (:67%3.9Q" X (  .T)   7
M              "  ='S!P!N:W1R,C R,3$R,S$M97AX,C$Q+FAT;5!+ 0(4
M Q0    ( (:67%3Z4@@P*00  /85   7              "  >;V!P!N:W1R
I,C R,3$R,S$M97AX,C,Q+FAT;5!+!08     #0 - &X#  !$^P<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
